<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004525.pub2" GROUP_ID="MUSKEL" ID="507403031110494468" MERGED_FROM="" MODIFIED="2014-01-24 15:42:42 +0000" MODIFIED_BY="Jordi Pardo Pardo" REVIEW_NO="C032-R" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2014-01-24 10:34:15 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<TITLE MODIFIED="2012-04-27 15:46:20 -0400" MODIFIED_BY="[Empty name]">Etanercept for the treatment of rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Medicine &amp; Epidemiology and Community Medicine, Canada Research Chair in Health Equity</POSITION>
<EMAIL_1>tugwell.bb@uottawa.ca</EMAIL_1>
<EMAIL_2>kerry.obrien@uottawa.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, University of Ottawa</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1H 8M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-01-24 10:24:05 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<PERSON ID="4773" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lethaby</LAST_NAME>
<SUFFIX/>
<POSITION>Systematic reviewer</POSITION>
<EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT>
<ORGANISATION>University of Auckland</ORGANISATION>
<ADDRESS_1>Private Bag 92019</ADDRESS_1>
<ADDRESS_2/>
<CITY>Auckland</CITY>
<ZIP>1142</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 9 373 7599 ext 86333</PHONE_1>
<PHONE_2/>
<FAX_1>+64 9 373 7503</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>Joint first author</FOOTNOTE>
</PERSON>
<PERSON ID="3BB5F5F082E26AA200E154977C3B33AA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria Angeles</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lopez-Olivo</LAST_NAME>
<SUFFIX/>
<POSITION>Instructor</POSITION>
<EMAIL_1>amlopezo@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Internal Medicine</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1-713-792-9175</PHONE_1>
<PHONE_2>1-713-606-2601</PHONE_2>
<FAX_1>1-713-563-4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE>Joint first author</FOOTNOTE>
</PERSON>
<PERSON ID="17387" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Lara</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Maxwell</LAST_NAME>
<SUFFIX/>
<POSITION>Managing Editor, Cochrane Musculoskeletal Group</POSITION>
<EMAIL_1>lmaxwell@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613 562 5800 ext: 1977</PHONE_1>
<PHONE_2/>
<FAX_1>613 562 5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7244" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Amanda</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Burls</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Public Health</POSITION>
<EMAIL_1>Amanda.Burls.1@city.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>07970 271743</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>School of Health Sciences</DEPARTMENT>
<ORGANISATION>City University London</ORGANISATION>
<ADDRESS_1>Myddleton Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>EC1V 0HB</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 2070405409</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Medicine &amp; Epidemiology and Community Medicine, Canada Research Chair in Health Equity</POSITION>
<EMAIL_1>tugwell.bb@uottawa.ca</EMAIL_1>
<EMAIL_2>kerry.obrien@uottawa.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, University of Ottawa</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1H 8M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>MSc, PhD</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology and Community Medicine</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>Room H1281</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-01-24 10:18:15 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<UP_TO_DATE>
<DATE DAY="13" MONTH="6" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2014-01-24 10:34:15 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-24 10:33:20 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<DATE DAY="24" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Minor correction on the summary of findings</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-01-24 10:34:15 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-24 10:34:15 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<DATE DAY="14" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>New search with six new studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-01-24 10:33:38 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<DATE DAY="13" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>New authors added. Updated risk of bias methods and added summary of findings table.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-04-02 09:35:10 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment. New author (AL) added as an updating officer for a pilot update scheme.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-03 11:36:05 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: C032-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-02-21 14:52:57 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-02-21 14:51:45 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-02-21 14:51:45 -0500" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-02-21 14:52:57 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-02-21 14:52:57 -0500" MODIFIED_BY="[Empty name]">
<NAME>MD Anderson Cancer Center. Research Library</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-03-21 09:23:30 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-03-20 14:00:56 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-09-24 18:10:44 -0400" MODIFIED_BY="[Empty name]">Etanercept for the treatment of rheumatoid arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2013-03-20 14:00:56 -0400" MODIFIED_BY="[Empty name]">
<P>Researchers in The Cochrane Collaboration conducted a review of the effect of etanercept (Enbrel) for people with rheumatoid arthritis. After searching for all relevant studies, they found nine studies with over 2800 people.  Their findings are summarised below.</P>
<P>In people with rheumatoid arthritis who have NOT improved with a traditional disease-modifying anti-rheumatic drug (DMARD):</P>
<P>- Etanercept plus DMARDs probably improves pain, function and other symptoms of rheumatoid arthritis;</P>
<P>- Etanercept plus DMARDs reduces disease activity and disability;</P>
<P>- Showing a small difference needs a larger number of participants &#8211; when all the data from the different types of participants are combined, etanercept reduces permanent joint damage as seen on x-ray.</P>
<P>We often do not have precise information about side effects and complications. This is particularly true for rare, but serious, side effects. Side effects such as injection site reactions, headache, common colds, nausea, dizziness and infections may occur with etanercept on its own or combined with a DMARD. Another Cochrane Review (Singh 2011) has shown that there is a small risk of tuberculosis reactivation and serious infections.  Rare complications may include certain types of cancer.<BR/>
</P>
<P>
<B>What is etanercept and why is it prescribed?</B>
<BR/>When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints. This makes your joints swollen, stiff and painful. The small joints of your hands and feet are usually affected first. Etanercept is a "biologic" that is prescribed to decrease pain and swelling and slow the progress of rheumatoid arthritis. A biologic is a medical product not chemically synthesized, that is derived from living material.<B> </B>This medical product<B> </B>is injected beneath the skin in the same way as insulin in treating diabetes. It is usually prescribed when other DMARDs do not work well, but it can be expensive.</P>
<P>
<B>What happens to people with rheumatoid arthritis who take etanercept plus traditional DMARDs (methotrexate or sulphasalazine) after they have NOT improved with traditional DMARDs alone</B>
</P>
<P>
<B>ACR 50 (number of tender or swollen joints and other outcomes such as pain and disability)</B>
</P>
<P>38 more people out of 100 had a 50% improvement in symptoms after six months to three years compared with people taking a DMARD alone (38% absolute improvement).<BR/>79 people out of 100 on etanercept plus DMARDs had a 50% improvement in symptoms.<BR/>41 people out of 100 on DMARDs alone had a 50% improvement in symptoms</P>
<P>
<B>Disease activity</B>
</P>
<P>22 more people out of 100 were considered to have low disease activity of their rheumatoid arthritis from six months to three years on etanercept with DMARDs (22% absolute improvement).<BR/>46 people out of 100 on etanercept plus DMARDs were considered to have low disease activity of their rheumatoid arthritis.<BR/>24 people out of 100 on DMARDs alone were considered to have low disease activity of their rheumatoid arthritis.<BR/>
</P>
<P>
<B>Disability</B>
</P>
<P>People who took etanercept plus a DMARD rated the change in their disability to be 0.36 points lower on a scale of 0 to 3 after six months to three years compared with people who took a DMARD alone (12% absolute improvement).<BR/>People who took etanercept plus a DMARD rated the change in their disability to be between 0.51 and 1.08 on a scale of 0 to 3 after six months to three years.<BR/>People who took a DMARD alone rated the change in their disability to be between 0.15 and 0.72 on a scale of 0 to 3 after six months to three years.</P>
<P>
<B>X-rays of the joints</B>
</P>
<P>When all people in all the studies were considered, joint damage improved slightly in those who received combined treatment with etanercept plus DMARD compared with DMARD or etanercept alone after 12 to 36 months. Joint damage in people whom DMARDs were not working and received combined treatment with etanercept plus DMARD was similar to those given a DMARD alone, but this result might be due to low numbers of people in this group.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-03-14 10:40:07 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-02-12 03:58:29 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept is a soluble tumour necrosis factor alpha-receptor disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-03-14 10:05:37 -0400" MODIFIED_BY="[Empty name]">
<P>The purpose of this review was to update the previous Cochrane systematic review published in 2003 assessing the benefits and harms of etanercept for the treatment of RA. In addition, we also evaluated the benefits and harms of etanercept plus DMARD compared with DMARD monotherapy in those people with RA who are partial responders to methotrexate (MTX) or any other traditional DMARD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-09-22 20:48:18 -0400" MODIFIED_BY="[Empty name]">
<P>Five electronic databases were searched from 1966 to February 2003 with no language restriction. The search was updated to January 2012. Attempts were made to identify other studies by contact with experts, searching reference lists and searching trial registers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-03-14 10:34:23 -0400" MODIFIED_BY="[Empty name]">
<P>All controlled trials (minimum 24 weeks' duration) comparing four possible combinations: 1) etanercept (10 mg or 25 mg twice weekly) plus a traditional DMARD (either MTX or sulphasalazine) versus a DMARD, 2) etanercept plus DMARD versus etanercept alone, 3) etanercept alone versus a DMARD or 4) etanercept versus placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-09-18 07:00:32 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and assessed the risk of bias of the trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-03-14 10:38:20 -0400" MODIFIED_BY="[Empty name]">
<P>Three trials were included in the original version of the review. An additional six trials, giving a total of 2842 participants, were added to the 2012 update of the review. The trials were generally of moderate to low risk of bias, the majority funded by pharmaceutical companies. Follow-up ranged from six months to 36 months.</P>
<P>Benefit</P>
<P>At six to 36 months the American College of Rheumatology (ACR) 50 response rate was statistically significantly improved with etanercept plus DMARD treatment when compared with a DMARD in those people who had an inadequate response to any traditional DMARD (risk ratio (RR) 2.0; 95% confidence interval (CI) 1.3 to 2.9, absolute treatment benefit (ATB) 38%; 95% CI 13% to 59%) and in those people who were partial responders to MTX (RR 11.7; 95% CI 1.7 to 82.5, ATB 36%). Similar results were observed when pooling data from all participants (responders or not) (ACR 50 response rates at 24 months: RR 1.9; 95% CI 1.3 to 2.8, ATB 29%; 36 months: RR 1.6; 95% CI 1.3 to 1.9, ATB 24%). Statistically significant improvement in physical function and a higher proportion of disease remission were observed in combination-treated participants compared with DMARDs alone ((mean difference (MD) -0.36; 95% CI -0.43 to -0.28 in a 0-3 scale) and (RR 1.92; 95% CI 1.60 to 2.31), respectively) in those people who had an inadequate response to any traditional DMARD. All changes in radiographic scores were statistically significantly less with combination treatment (etanercept plus DMARD) compared with MTX alone for all participants (responders or not) (Total Sharp Score (TSS) (scale = 0 to 448): MD -2.2, 95% CI -3.0 to -1.4; Erosion Score (ES) (scale = 0 to 280): MD -1.6; 95% CI -2.4 to -0.9; Joint Space Narrowing Score (JSNS) (scale = 0 to 168): MD -0.7; 95% CI -1.1 to -0.2), and with combination treatment compared with etanercept alone (TSS: MD -1.1; 95% CI -1.8 to -0.5; ES: MD -0.7; 95% CI -1.1 to -0.2; JSNS: MD -0.5, 95% CI -0.7 to -0.2). The estimate of irreversible physical disability over 10 years given the radiographic findings was 0.45 out of 3.0.</P>
<P>When etanercept monotherapy was compared with DMARD monotherapy, there was generally no evidence of a difference in ACR50 response rates when etanercept 10 mg or 25 mg was used; at six months etanercept 25 mg was significantly more likely to achieve ACR50 than DMARD monotherapy but this difference was not found at 12, 24 or 36 months. TSS and ES radiographic scores were statistically significantly improved with etanercept 25 mg monotherapy compared with DMARD (TSS: MD -0.7; 95% CI -1.4 to 0.1; ES: MD -0.7; 95% CI -1.0 to -0.3) but there was no evidence of a statistically significant difference between etanercept 10 mg monotherapy and MTX.</P>
<P>Harms</P>
<P>There was no evidence of statistically significant differences in infections or serious infections between etanercept plus DMARD and DMARD alone at any point in time. Infection rates were higher in people receiving etanercept monotherapy compared with DMARD; however, there were no differences regarding serious infections. For those participants who had an inadequate response to DMARDs, the rate of total withdrawals was lower for the etanercept plus DMARD group compared with DMARD alone (RR 0.53; 95% CI 0.36 to 0.77, ATB 18%). No other statistically significant differences were observed in any of the assessed comparisons.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-03-14 10:40:07 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept 25 mg administered subcutaneously twice weekly together with MTX was more efficacious than either etanercept or MTX monotherapy for ACR50 and it slowed joint radiographic progression after up to three years of treatment for all participants (responders or not). There was no evidence of a difference in the rates of infections between groups.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-03-21 09:23:30 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-03-14 11:44:15 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-12-03 14:57:51 -0500" MODIFIED_BY="[Empty name]">
<P>Rheumatoid arthritis (RA) is chronic progressive systemic inflammatory condition, affecting mainly the joint synovium, but can also affect other tissues and organs. RA is associated with significant morbidity, mortality, joint deformity and impaired quality of life (<LINK REF="REF-Pincus-1993" TYPE="REFERENCE">Pincus 1993</LINK>; <LINK REF="REF-Puolakka-2005" TYPE="REFERENCE">Puolakka 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-03-14 11:08:00 -0400" MODIFIED_BY="[Empty name]">
<P>Disease modifying anti-rheumatic drugs (DMARDs) are drugs that have been shown to reduce disease activity, slow down joint damage and improve quality of life. DMARDs are the mainstay of treatment of RA (<LINK REF="REF-Saag-2008" TYPE="REFERENCE">Saag 2008</LINK>; <LINK REF="REF-Singh-2012" TYPE="REFERENCE">Singh 2012</LINK>). However, often people do not respond to or are unable to tolerate traditional DMARDS (<LINK REF="REF-Yee-2003" TYPE="REFERENCE">Yee 2003</LINK>). Newer biological drugs have been introduced and approved for the treatment of RA since 1998 (<LINK REF="REF-Fernandez_x002d_Cruz-2008" TYPE="REFERENCE">Fernandez-Cruz 2008</LINK>). These biologic DMARDs have been associated with clinical outcome improvement (<LINK REF="REF-Singh-2009" TYPE="REFERENCE">Singh 2009</LINK>), but also with higher rates of adverse events and tuberculosis (TB) (<LINK REF="REF-Singh-2011" TYPE="REFERENCE">Singh 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-03-14 11:44:15 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumour necrosis alpha receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept is produced by recombinant deoxyribonucleic acid (DNA) technology (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>). Etanercept inhibits the action of tumour necrosis factor (TNF), thus suppressing inflammation. It is usually prescribed when the DMARD methotrexate (MTX) does not work well, but it is significantly more expensive (<LINK REF="REF-Jarvis-1999" TYPE="REFERENCE">Jarvis 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-03-14 11:12:58 -0400" MODIFIED_BY="[Empty name]">
<P>This review summarises the current data available on the benefits and harms of etanercept on its own and in combination with MTX for the treatment of RA. This information will enable clinicians to choose appropriate treatment for people with RA using the best medical evidence available.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-04-27 17:26:42 -0400" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of etanercept monotherapy or combined with DMARD for the treatment of RA.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-03-14 12:01:24 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-03-14 11:51:08 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-03-14 11:15:03 -0400" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing etanercept to placebo, etanercept to DMARD (either MTX or sulphasalazine), or etanercept plus MTX to DMARD alone or etanercept alone that were at least six months' duration were eligible for inclusion. Participants could be on other DMARDS, non-steroidal anti-inflammatory drugs or corticosteroids provided they were on stable doses and were randomly allocated to treatment with or without etanercept.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-03-14 11:15:41 -0400" MODIFIED_BY="Anne Lawson">
<P>People 16 years of age or older meeting the American College of Rheumatology (ACR) 1987 revised criteria (<LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>) for RA. Participants had to have evidence of active disease as demonstrated by at least two of:</P>
<OL>
<LI>tender joint count;</LI>
<LI>swollen joint count;</LI>
<LI>duration of early morning stiffness (EMS) lasting more than 30 minutes;</LI>
<LI>acute phase reactants such as Westergren erythrocyte sedimentation rate (ESR) or C reactive protein (CRP).</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-03-14 11:38:11 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment trials with etanercept and DMARD (either MTX or sulphasalazine) versus DMARD, etanercept versus DMARD, etanercept plus DMARD versus etanercept and etanercept versus placebo were eligible for inclusion. Doses of etanercept eligible for inclusion were 10 or 25 mg subcutaneous (SC) injections twice weekly, with a minimum trial duration of six months. SC injections are given by a needle injection into the fatty layer of tissue just below the skin because there is little blood flow to fatty tissue so the injected medication is absorbed slowly.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-03-14 11:51:08 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Major outcomes</HEADING>
<P>The response of RA to treatment with etanercept has been defined by the World Health Organization (WHO), the International League of Associations for Rheumatology (ILAR) core set of disease activity measures and the ACR outcome measures for RA clinical trials (<LINK REF="REF-Boers-1994" TYPE="REFERENCE">Boers 1994</LINK>; <LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>; <LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>). The set of efficacy measures includes: 1) tender joint count; 2) swollen joint count; 3) patient assessment of pain using 10-cm visual analogue scale or Likert scale; 4) patient global assessment of disease activity; 5) physician global assessment of disease activity using 10-cm visual analogue scale or Likert scale; 6) patient assessment of functional ability as measured by a validated scale such as the Health Assessment Questionnaire (HAQ), which is a standardised, validated scale used in people with arthritis; 7) acute phase reactants such as ESR or CRP; 8) Radiographic bone changes are accepted as part of the core set of disease activity measures in studies of a minimum of 12 months' duration. Radiographic progression as measured by Total Sharp Score (TSS) or Larsen scale was included as a primary outcome measure of studies with a minimum duration of 12 months.</P>
<SUBSECTION>
<HEADING LEVEL="5">Definition of improvement</HEADING>
<P>Statistical versus clinical significance is relevant to clinical care. Based on the set of efficacy measures outlined above, a definition of clinical improvement has been established (<LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>; <LINK REF="REF-Pincus-1999" TYPE="REFERENCE">Pincus 1999</LINK>). An ACR20 response represents a 20% improvement in tender and swollen joint counts plus a 20% improvement in three of the five following remaining core measures: patient and physician global assessments, pain, functional status and an acute phase reactant.</P>
<P>Based on these definitions, the following primary efficacy outcomes have been recorded in this review:</P>
<UL>
<LI>ACR response:</LI>
<UL>
<LI>ACR 20 response;</LI>
<LI>ACR 50 response;</LI>
<LI>ACR 70 response;</LI>
</UL>
<LI>Radiographic scores:</LI>
<UL>
<LI>TSS (change in this score from baseline, range of score 0 to 448);</LI>
<LI>Erosion Score (ES) (change in this score from baseline);</LI>
<LI>Joint Space Narrowing Score (JSNS) (change in this score from baseline) (scores for ES and JSNS are summed to yield the TSS);</LI>
</UL>
<LI>Remission (considered a useful measure of disease activity (<LINK REF="REF-van-der-Heijde-2005a" TYPE="REFERENCE">van der Heijde 2005a</LINK>)).</LI>
<UL>
<LI>disease activity score (DAS) &lt; 1.6;</LI>
<LI>DAS28 &lt; 2.6.</LI>
</UL>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minor outcomes</HEADING>
<P>Secondary outcome measures included:</P>
<UL>
<LI>health-related quality of life (HRQoL) such as the Short Form (SF)-36, when available;</LI>
<LI>adverse events;</LI>
<LI>withdrawals from the study (total, due to lack of efficacy, due to adverse events and death).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-03-14 11:53:49 -0400" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-03-14 11:52:29 -0400" MODIFIED_BY="[Empty name]">
<P>Electronic databases including Biological Abstracts, Current Contents, Dissertation Abstracts, EBM Reviews and all Cochrane electronic databases were searched from 1966 to February 2003. A further search was performed from 2003 to January 2012 of the following databases:<BR/>
</P>
<UL>
<LI>MEDLINE;</LI>
<LI>EMBASE;</LI>
<LI>CINAHL;</LI>
<LI>Web of Science;</LI>
<LI>Controlled Clinical Trials;</LI>
<LI>
<I>The Cochrane Library</I> (CENTRAL, DARE, NEED).</LI>
</UL>
<P>We searched RA as an exploded MESH heading. Etanercept was searched as a text word as it is not currently indexed. The search was not limited by language, year or publication or type of publication. The MEDLINE search strategy used is located in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. This strategy was modified for other databases.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-03-14 11:53:39 -0400" MODIFIED_BY="[Empty name]">
<P>The proceedings of major rheumatology conferences including the ACR (1990 to 2003), the European League of Rheumatology (1990 to 2002) and the Canadian Rheumatology Association were handsearched. The reference lists from standard rheumatology textbooks, comprehensive reviews and identified clinical trials were searched. Content experts and the pharmaceutical companies that manufacture etanercept were contacted. The Current Controlled Trials register was also searched for ongoing trials. Additional unpublished data were sought through the US Food and Drug Administration (FDA) website. The only unpublished data used in this review were additional information from published trials from manufacturers.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-03-14 12:01:24 -0400" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-03-14 11:54:10 -0400" MODIFIED_BY="[Empty name]">
<P>Each study was independently reviewed by two review authors (either BB and MJ or AL and MLO) to determine if the study met the inclusion criteria outlined in the a priori protocol developed for the review. Disagreements on study eligibility were resolved by discussion. The reason(s) for exclusion of any study were noted.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-03-14 11:55:17 -0400" MODIFIED_BY="[Empty name]">
<P>Data were extracted by one review author for the 2003 publication of the review (BB) and the extraction forms were then double-checked independently by another individual against the original data source. For the 2012 update of the review, data were extracted independently by two review authors (AL and MLO). Any discrepancies were resolved through consensus by both review authors returning to the original data source to confirm which value was correct.</P>
<P>The following data were extracted from each study:</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<OL>
<LI>Study design.</LI>
<LI>Number of people randomised, excluded or lost to follow-up.</LI>
<LI>Whether an intention-to-treat analysis was done.</LI>
<LI>Whether a power calculation was done.</LI>
<LI>Duration, timing and location of the study.</LI>
<LI>Number of centres.</LI>
<LI>Source of funding.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of the study participants</HEADING>
<OL>
<LI>Age and any other recorded characteristics of participants in the study.</LI>
<LI>Other inclusion criteria.</LI>
<LI>Exclusion criteria.</LI>
<LI>Time since diagnosis of RA.</LI>
<LI>Source of participants.</LI>
<LI>Proportion of those eligible.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions used</HEADING>
<OL>
<LI>Dose/regimen of etanercept.</LI>
<LI>Dose/regimen of MTX.</LI>
<LI>Other concomitant medications allowed during the trial.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<OL>
<LI>Methods used to measure efficacy.</LI>
<LI>Methods used to measure quality of life.</LI>
<LI>Methods used to determine/collect adverse events.</LI>
</OL>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-03-14 11:59:08 -0400" MODIFIED_BY="[Empty name]">
<P>Two independent review authors (AL and MLO) assessed risk of bias of each study, using the 'Risk of bias' tool developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The following domains were assessed:</P>
<OL>
<LI>sequence generation (whether the allocation sequence was adequately generated, for example, random number table, computer random number generator, coin tossing, throwing dice);</LI>
<LI>allocation concealment (whether the allocation was adequately concealed, for example, sequentially numbered containers of identical appearance, central allocation, sequentially numbered, opaque sealed envelopes);</LI>
<LI>blinding of participants, personnel and outcome assessors (whether knowledge of the allocated intervention was adequately prevented during the study, for example, by ensuring blinding or participants and key personnel or, where there is no blinding, knowledge of the intervention is not likely to influence the outcomes);</LI>
<LI>incomplete outcome data (whether incomplete outcome data were adequately addressed, for example, missing data balanced in numbers across intervention groups, proportion of missing outcomes insufficient to affect estimates, reasons for missing data unlikely to be related to the outcomes);</LI>
<LI>selective outcome reporting (whether the reports of the study were free of suggestion of selective outcome reporting, for example, previous publication of a study protocol, other evidence that the study contains all of the prespecified outcomes);</LI>
<LI>other sources of bias (whether the study was apparently free of other problems that could put it at a high risk of bias, for example, baseline imbalance, bias related to study design, early termination of study).</LI>
</OL>
<P>These domains were judged as either 'low risk', 'high risk' or 'unclear risk' of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-03-14 12:00:25 -0400" MODIFIED_BY="[Empty name]">
<P>The data were analysed using an intention-to-treat model, where data were available. Dichotomous data were reported as a Mantel Haenszel risk ratio (RR) with 95% confidence intervals (CI). Continuous data were analysed as a mean difference (MD) with 95% CIs. The mean and standard deviation (SD) were used when available. When only the median and interquartile ranges were reported, the distribution of the data was checked. If the data appeared to be roughly normal, the median was used as the mean, and one half of the difference between the 1st and 3rd quartile range was used as the SD. When only the baseline SD was available, it was used as the end of study SD as well. For some of the trials, measures of variation were missing in the publication of results and contact with the authors was unsuccessful. Where possible, SDs were imputed from the measures of variation from other trials measuring the same outcome. It was not always possible to impute these missing values. Outcome variables that were reported only graphically were not included in the study. Results have been calculated to provide an indication of the number needed to treat for an additional beneficial outcome (NNTB) for major statistically significant outcomes. The NNTB reflects the effort required (or number of people needing to be treated) to obtain a beneficial outcome with an intervention.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-03-14 12:01:12 -0400" MODIFIED_BY="[Empty name]">
<P>The included studies were carefully inspected for evidence of clinical heterogeneity in the characteristics of the participants, interventions and outcomes of the trial duration. Where pooling the studies was appropriate, statistical heterogeneity was assessed by the results of the Chi<SUP>2</SUP> using n - 1 degrees of freedom and a P value of less than 0.10 and the I<SUP>2</SUP> statistics (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The I<SUP>2</SUP> statistic represents the proportion of variation between studies that is not due to chance and it takes values from 0% to 100%. We considered an I<SUP>2</SUP> of 25% to represent mild heterogeneity, 50% to represent moderate heterogeneity and 75% or more to be evidence of extreme heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-03-14 12:01:24 -0400" MODIFIED_BY="[Empty name]">
<P>A fixed-effect model was used to calculate a pooled estimate of effect in meta-analyses. If significant statistical heterogeneity was confirmed by the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic (&gt; 50%), the random-effects model was used to display the results.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-04-26 15:28:41 -0400" MODIFIED_BY="[Empty name]">
<P>A priori, subgroup analysis was planned to determine differential effects according to duration and severity of disease and type of control group.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-04-26 15:29:07 -0400" MODIFIED_BY="[Empty name]">
<P>A priori, sensitivity analysis was planned to determine the effects of previous DMARD treatment and quality of the trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-03-20 15:17:55 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-03-20 14:02:30 -0400" MODIFIED_BY="[Empty name]">
<P>Methods of included studies are summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2013-03-14 12:02:35 -0400" MODIFIED_BY="[Empty name]">
<P>The original search strategy was run from inception to 2003. Updated search strategies were run from: 2003 to 2008, 2008 to 2010, and 2010 to January 2012. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the number of citations retrieved from 2008 to 2012. There were 2363 original citations: 1211 from MEDLINE, 128 from EMBASE, 74 from CINAHL, 814 from Web of Science, 104 from <I>The Cochrane Library</I> and 32 from web links. After de-duplication there were 1604 titles and abstracts to screen; 1527 were excluded. We retrieved 77 full texts for the final review, 69 were excluded and four trials (eight publications) met the inclusion criteria and were added to the three trials included in the original review plus two more trials found in the first updating search from 2003 to 2008.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-03-14 12:25:44 -0400" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK> was a 24-week randomised double-blind trial comparing etanercept 25 mg SC twice weekly plus stable doses of MTX (15 to 25 mg once weekly, or as low as 10 mg if participant was unable to tolerate higher doses) was compared with placebo injections plus MTX. All drugs were administered for a 24-week period. All participants received either folic acid or folinic acid. Participants had to have had an incomplete response to at least six months of MTX at a stable dose for at least four weeks prior to randomisation. Participants had to be at least 18 years of age, and meet 1987 American Rheumatology Association criteria for RA; be in functional class I, II or III according to the revised criteria of the ACR and have active disease with at least six tender and six swollen joints. Sulphasalazine and hydroxychlorquine were discontinued two weeks prior to starting study drug and all other DMARDs (except MTX) were discontinued four weeks prior. Prednisone at 10 mg daily or less and non-steroidal anti-inflammatory drugs (NSAIDs) were permitted as long as the dose had been stable for at least four weeks prior to the study, and remained stable throughout the study.</P>
<P>
<LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK> was a six-month double-blind randomised study with three arms: etanercept 25 mg SC twice weekly, etanercept 10 mg SC twice weekly and injectable placebo twice weekly. Participants had to have had an inadequate response to one to four DMARDs, with an inadequate response being defined as discontinuation of the drug due to lack of efficacy. DMARDs had to be washed out at least one month prior to starting study drug and no DMARDs aside from etanercept were permitted during the trial. Participants had to have evidence of active disease at enrolment, with at least 12 tender joints, at least 10 swollen joints and one of: an ESR of at least 28, CRP concentration of at least 20 mg/L or early morning stiffness (EMS) of at least 45 minutes. Intra-articular steroids were not allowed during the study, or within four weeks of enrolment. Eight people taking placebo from an earlier three-month study were enrolled in this trial. Stable doses of steroids at prednisone 10 mg daily or less and stable doses of NSAIDs that did not exceed the manufacturer's recommended doses were allowed. Ninety per cent of participants had used MTX previously, and 22% were on MTX prior to the DMARD washout period.</P>
<P>
<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK> was a 12-month randomised study with three treatment arms: etanercept 10 mg SC twice weekly, etanercept 25 mg SC twice weekly, escalating weekly MTX (7.5 mg at week 0, 15 mg at week four and 20 mg at week eight). One 5-mg dose reduction was allowed for preset laboratory abnormalities. The etanercept/placebo dose was not adjusted. All participants received 1 mg of folic acid daily. Partipants were at least 18 years old with RA for three years or less and no other significant concurrent illnesses. Participants had never received MTX. Participants had to be either rheumatoid factor positive, or have three bony erosions visible on x-rays of the hands, wrists or feet. Participants also had to have at least 10 swollen joints, and at least 12 tender joints. Participants also had to have one of either an ESR of at least 28 mm/hour, a CRP of at least 2.0 mg/day or a minimum of 45 minutes of EMS. DMARDs were discontinued at least four weeks before starting the study. Stable dose of NSAIDs and prednisone (10 mg daily or less) were allowed.</P>
<P>
<LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> was a three-year double-blind randomised study with three treatment arms: etanercept only (25 mg SC twice weekly plus oral placebo once weekly), etanercept plus MTX (combination of etanercept injections 25 mg SC twice weekly and oral MTX (escalating up to 20 mg) once weekly) and MTX only (7.5 mg escalating to 20 mg oral capsules once weekly within eight weeks if participants had any painful or swollen joints and placebo SC injections twice weekly). All participants had folic acid 5 mg supplement twice a week. Participants were at least 18 years old with a disease duration of six months to 20 years, had active adult-onset RA (class I to III), defined as 10 or more swollen and 12 or more painful joints and at least one of the following: ESR 28 mm/hour or greater; plasma CRP 20 mg/L or greater; or morning stiffness for 45 minutes or more. Participants also had to have a less than satisfactory response to at least one DMARD other than MTX. Those who had previously been treated with MTX were eligible if they had not had important toxic effects or lack of response and had not been treated with MTX in previous six months. Participants were ineligible if they had previously received etanercept or other TNF antagonists. Other exclusion criteria included: previous treatment with immunosuppressive drugs within six months of screening; use of any investigational drug or biological agent within three months of screening; any other DMARD or corticosteroid injection within previous four weeks and presence of comorbidity.</P>
<P>
<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK> was a two-year double-blind randomised study with three treatment arms (randomisation ratio: 2:2:1): etanercept only (25 mg SC twice weekly plus oral placebo once daily); etanercept plus sulphasalazine (combination of 25 mg SC etanercept injections twice weekly and oral sulphasalazine (2, 2.5 or 3 mg) once daily) and sulphasalazine only (2, 2.5 or 3 mg tablets plus placebo SC injections twice weekly). Participants were permitted stable doses of oral steroids, one NSAID and analgesics. Participants were at least 18 years old with a disease duration of six months to 20 years, had active adult onset RA (class I to III), defined as 10 or more swollen and 12 or more painful joints and at least one of the following: ESR 28 mm/hour or greater; plasma CRP 20 mg/L or greater; or morning stiffness for 45 minutes or more. Participants had active disease despite receiving sulphasalazine.</P>
<P>
<LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK> was a six-month unblinded randomised study with two treatment arms: etanercept 25 mg SC twice weekly versus MTX 7.5 mg once a week (escalating, if necessary, to 20 mg per week). The study was primarily designed to assess the effects of etanercept and MTX on cachexia in people with early RA (&lt; six months' history of RA) but function, adverse events and disability were also measured (by blinded assessors). Participants were excluded if they had previously used DMARDs, steroids or biologics, or they had concurrent disease but NSAIDs and analgesics were allowed during the study and all participants took folic acid supplements.</P>
<P>
<LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> was a two-year double-blind randomised study with two treatment arms for the first year: etanercept (25 mg SC twice weekly) plus oral MTX (starting at 7.5 mg/week and escalating up to 20 mg/week) versus MTX alone (with placebo injection). Those participants who completed the first year of treatment were eligible to enter the second year of the study. In year two, participants in the combination therapy group either continued combination treatment or received etanercept monotherapy. Participants in the original MTX monotherapy group either continued with MTX monotherapy or etanercept plus MTX. Randomisation to these four groups was undertaken at baseline. In sum, the first year of the study compared etanercept plus MTX with MTX alone; the second year of the study compared four groups: (1) etanercept plus MTX in year one and etanercept plus MTX in year two; (2) etanercept plus MTX in year one and etanercept monotherapy in year two; (3) MTX monotherapy in year one and etanercept plus MTX in year two; (4) MTX monotherapy in year one and MTX monotherapy in year two. This review has reported results of two of the four groups in the second year of the study: those who continued with their year one treatment. Participants were at least 18 years old, had a disease duration between three months and two years and had not had previous treatment with etanercept, MTX or other TNF antagonists. Participants were required to have DAS28 greater than 3.2; 92% of participants had severe disease (DAS28 &gt; 5.1). All participants received folic acid supplementation and stable doses of corticosteroids or NSAIDs were permitted. The study was designed to assess rates of clinical remission, radiographic non-progression and restoration of function.</P>
<P>
<LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK> was a six-month double-blind randomised study with two treatment arms: Yisaipu (25 mg SC twice weekly plus oral placebo) and oral MTX (three x 2.5 mg (increasing to 5 mg) per week plus placebo injection). Yisaipu is a rhTNFR:Fc available in China that has the same structure as etanercept and for the purposes of this review is considered identical to etanercept. Stable doses of NSAIDs and prednisone (&#8804; 10 mg/day) were allowed. Participants were 18 to 65 years old, had active RA (as defined by ACR 1987 criteria: swelling in six joints or more, six or more tender joints, morning stiffness &#8805; 45 minutes, ESR &#8805; 28 mm/h, CRP &#8805; 20 &#956;g/mL). Participants were ineligible if they had any serious illness (affecting heart, liver, renal, blood or other vital organs). Other exclusion criteria included: pregnancy or breastfeeding; previous treatment with Yisaipu or other biological agents; no efficacy to treatment with MTX; joint injection of corticosteroids within past four weeks; any acute or chronic infection or past history of active TB; any tumour or family history of tumour; any other DMARD for at least four weeks prior to the study entry. The study outcome measures included: ACR20, ACR50, ACR70; withdrawals and adverse events.</P>
<P>
<LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK> was a two-year unblinded randomised study with two treatment arms: etanercept (25 mg SC twice weekly) plus oral MTX (6-8 mg once weekly) versus etanercept alone. Participants were allowed stable doses of corticosteroids (&lt; 10 mg/day). The publication provides data on the first six months of the study. Randomisation was stratified by age (&lt; 55 years or &#8805; 55 years), disease duration (&lt; 10 years or &#8805; 10 years), disease activity (DAS28 &lt; 5.1 or &#8805; 5.1) and institution. Participants were at least 18 years old, met 1987 American Rheumatology Association criteria for RA and had active disease despite receiving MTX defined as six or more swollen and painful joints and at least one of the following: ESR 28 mm/h or greater; plasma CRP 2 mg/dL or greater and adequate safety profile. Participants had not received DMARDs other than MTX before and were biologic-naive.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>
<LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK> and <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK> studies included participants with long-standing RA (11 to 13 years), whereas the <LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK> and <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> studies included participants who had only had RA for three years or less. Participants in the <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK> study had very early RA (&lt; six months). <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>, <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK> and <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> included participants with a wide range of disease duration (from six months to 20 years). <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK> only reported the mean disease duration (in months; which was 90.78 ± 98.75 months) for the etanercept and 93.74 ± 94.29 months for the MTX group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Two trials assessed the effects of two different doses of etanercept (10 and 25 mg), one against placebo and one against MTX (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>). The other trials used the 25 mg dose of etanercept in their comparisons. Four trials compared combination etanercept plus DMARD (either MTX or sulphasalazine) versus DMARD plus placebo (<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>); <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK> and <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> also included an etanercept plus placebo arm in the comparisons. Two trials compared etanercept 25 mg versus MTX (<LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>) and one trial compared etanercept plus MTX versus etanercept (<LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>). Etanercept was invariably delivered SC and MTX was usually given orally but all arms were placebo controlled, except for the <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK> and <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK> trials. In trials where participants received MTX, folic acid supplementation was required. In all the trials except one, analgesics, NSAIDs and corticosteroids were permitted; the <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK> study did not allow corticosteroids. The dose of MTX was escalated to a maximum dose of 20 mg, dependent on participant response.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Eight of the nine studies reported on ACR20, ACR50 and ACR70 response rates, quality of life outcomes, and withdrawal rates and three trials also measured radiographic scores (TSS, ES and JSNS). Adverse events were measured by all studies. For some outcomes, no measure of variability was included in the summary effect estimates and, where possible, SDs were imputed from the results of other trials where values were similar. Some of the reported data could not be used because it was not in a form suitable for entering in the meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration</HEADING>
<P>Six of the nine studies evaluated outcomes at the end of six months. One study evaluated outcomes at six and 12 months. Two ongoing studies had a trial duration of two years and reported overall results at six months and one year (<LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> and <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>, respectively). At two years the groups in <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> were modified and participants were re-randomised to one of four groups. One other study evaluated outcomes at one, two and three years (<LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-03-20 14:02:30 -0400" MODIFIED_BY="[Empty name]">
<P>Thirty-nine studies were excluded (<LINK REF="STD-ACP-2001" TYPE="STUDY">ACP 2001</LINK>; <LINK REF="STD-Angel-2010" TYPE="STUDY">Angel 2010</LINK>; <LINK REF="STD-Anis-2009" TYPE="STUDY">Anis 2009</LINK>; <LINK REF="STD-Benucci-2011" TYPE="STUDY">Benucci 2011</LINK>; <LINK REF="STD-Blank-2009" TYPE="STUDY">Blank 2009</LINK>; <LINK REF="STD-Bliddal-2006" TYPE="STUDY">Bliddal 2006</LINK>; <LINK REF="STD-Boesen-2008" TYPE="STUDY">Boesen 2008</LINK>; <LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Cuomo-2006" TYPE="STUDY">Cuomo 2006</LINK>; <LINK REF="STD-De-Filippis-2006" TYPE="STUDY">De Filippis 2006</LINK>; <LINK REF="STD-De-Stefano-2010" TYPE="STUDY">De Stefano 2010</LINK>; <LINK REF="STD-Garnero-2002" TYPE="STUDY">Garnero 2002</LINK>; <LINK REF="STD-Genovese-2002" TYPE="STUDY">Genovese 2002</LINK>; <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK>; <LINK REF="STD-Gerlag-2010" TYPE="STUDY">Gerlag 2010</LINK>; <LINK REF="STD-Holman-2008" TYPE="STUDY">Holman 2008</LINK>; <LINK REF="STD-Iwamoto-2009" TYPE="STUDY">Iwamoto 2009</LINK>; <LINK REF="STD-Johnsen-2006" TYPE="STUDY">Johnsen 2006</LINK>; <LINK REF="STD-Kavanaugh-2008" TYPE="STUDY">Kavanaugh 2008</LINK>; <LINK REF="STD-Keystone-2004" TYPE="STUDY">Keystone 2004</LINK>; <LINK REF="STD-Keystone-2009" TYPE="STUDY">Keystone 2009</LINK>; <LINK REF="STD-Koumakis-2009" TYPE="STUDY">Koumakis 2009</LINK>; <LINK REF="STD-Lan-2004" TYPE="STUDY">Lan 2004</LINK>; <LINK REF="STD-Lisbona-2008" TYPE="STUDY">Lisbona 2008</LINK>; <LINK REF="STD-Lukas-2009" TYPE="STUDY">Lukas 2009</LINK>; <LINK REF="STD-Lukas-2010" TYPE="STUDY">Lukas 2010</LINK>; <LINK REF="STD-Lukina-2001" TYPE="STUDY">Lukina 2001</LINK>; <LINK REF="STD-Luzi-2009" TYPE="STUDY">Luzi 2009</LINK>; <LINK REF="STD-Machado-2009" TYPE="STUDY">Machado 2009</LINK>; <LINK REF="STD-Moreland-1997" TYPE="STUDY">Moreland 1997</LINK>; <LINK REF="STD-Moreland-2001" TYPE="STUDY">Moreland 2001</LINK>; <LINK REF="STD-Paleolog-1998" TYPE="STUDY">Paleolog 1998</LINK>; <LINK REF="STD-Roux-2011" TYPE="STUDY">Roux 2011</LINK>; <LINK REF="STD-Saleem-2009" TYPE="STUDY">Saleem 2009</LINK>; <LINK REF="STD-Sennels-2008" TYPE="STUDY">Sennels 2008</LINK>; <LINK REF="STD-van-Riel-2006" TYPE="STUDY">van Riel 2006</LINK>; <LINK REF="STD-Weinblatt-2007" TYPE="STUDY">Weinblatt 2007</LINK>; <LINK REF="STD-Weinblatt-2008" TYPE="STUDY">Weinblatt 2008</LINK>; <LINK REF="STD-Weisman-2007" TYPE="STUDY">Weisman 2007</LINK>) as they did not meet the inclusion criteria. Owing to the inclusion criteria listed a priori in the 2003 review, we have excluded seven potentially relevant studies (<LINK REF="STD-Bliddal-2006" TYPE="STUDY">Bliddal 2006</LINK>; <LINK REF="STD-Genovese-2002" TYPE="STUDY">Genovese 2002</LINK>; <LINK REF="STD-Johnsen-2006" TYPE="STUDY">Johnsen 2006</LINK>; <LINK REF="STD-Keystone-2004" TYPE="STUDY">Keystone 2004</LINK>; <LINK REF="STD-Weinblatt-2007" TYPE="STUDY">Weinblatt 2007</LINK>; <LINK REF="STD-Weinblatt-2008" TYPE="STUDY">Weinblatt 2008</LINK>; <LINK REF="STD-Weisman-2007" TYPE="STUDY">Weisman 2007</LINK>) that were analysed in a separate Cochrane network meta-analysis to evaluate the adverse effects of biologics for the treatment of rheumatic conditions (<LINK REF="REF-Singh-2011" TYPE="REFERENCE">Singh 2011</LINK>). Specific reasons for exclusion are provided in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table in this review.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-03-14 12:33:01 -0400" MODIFIED_BY="[Empty name]">
<P>Each study was assessed separately for risk of bias independently by two review authors (AL and MLO). The results of this assessment are contained in a table attached to the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and in summary form (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).<BR/>
</P>
<ALLOCATION MODIFIED="2013-03-14 12:31:17 -0400" MODIFIED_BY="[Empty name]">
<P>Five of the nine included studies described the randomisation method clearly and were at low risk of bias (<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>; <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>). Three of the nine included studies provided details that indicated that allocation had been adequately concealed and were considered at low risk of bias (<LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-14 12:32:00 -0400" MODIFIED_BY="[Empty name]">
<P>Seven of the nine included studies reported at least double blinding and were considered at low risk of bias (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>), and Bathon was placebo controlled so blinding was likely. The Emery study reported that blinding was removed for the analyst who undertook the primary analysis for the publication of results (<LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>). Another study blinded only the outcome assessors (<LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>). <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK> was an open-label study.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-03-14 12:33:01 -0400" MODIFIED_BY="[Empty name]">
<P>All of the nine included studies described methods to deal with withdrawals and loss to follow-up and were considered at low risk of bias (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>). The first six of these studies mostly counted withdrawals as non-responders and used the last observation carried forward (LOCF) or linear extrapolation, or both, to calculate outcomes where there were missing data. <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> and <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK> used a modified intention-to-treat analysis, including only participants who had baseline assessments and at least one assessment after treatment; measures for missing values included LOCF and imputation by linear extrapolation. One study reported the total number of withdrawals, but did not specify reasons (<LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>), and in the other small study one person dropped out because of knowledge of treatment assignment (<LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-05-07 15:18:44 -0400" MODIFIED_BY="[Empty name]">
<P>None of the protocols for the published studies was identified to determine whether selective reporting had occurred. However, a wide range of outcomes were reported in most studies and it is probably unlikely that selective reporting occurred for eight of the nine included studies; these were considered at low risk of bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-04-25 21:39:04 -0400" MODIFIED_BY="[Empty name]">
<P>Eight studies were supported by pharmaceutical companies engaged in the promotion of etanercept (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>) and one study did not specify the funding source. Thus, all studies were considered to have unclear risk of bias for this domain. In some cases, the authors of the publications were staff of the pharmaceutical company that provided funding. There was no evidence of any other biases that had the potential to affect the results.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-03-20 15:17:55 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>Nine trials (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>), representing 2842 participants, met the inclusion criteria, although not all the participants provided data for all of the outcomes. Study details for the included studies are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparisons</HEADING>
<P>Comparisons have been structured in the meta-analyses to show the effects of etanercept plus a DMARD (either MTX or sulphasalazine) compared with DMARD monotherapy, etanercept monotherapy compared with DMARD monotherapy, etanercept plus DMARD compared with etanercept monotherapy and etanercept monotherapy compared with placebo. For the comparison of etanercept plus DMARD versus DMARD, four studies compared a dose of 25 mg of etanercept with either MTX (<LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>) or sulphasalazine (<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>). Similarly, for the comparison of etanercept alone versus DMARD alone, five studies compared a dose of 25 mg of etanercept versus either MTX (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>) or sulphasalazine (<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>) and one of these trials also compared a lower dose of etanercept (10 mg) versus MTX (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>). For the comparison of etanercept plus DMARD versus etanercept alone, three studies reported results from this arm using a dose of 25 mg of etanercept (<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>). For the comparison of etanercept versus placebo, one study compared two different doses of etanercept (10 and 25 mg SC twice weekly) (<LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Follow-up and measurement of outcomes</HEADING>
<P>
<LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>, <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>, <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>, <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK> and <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK> followed participants for six months; <LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK> for 12 months; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK> for two years and overall results from the two-year <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> trial were reported at the end of the first and in modified groups at the end of the second year. <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> followed participants for three years, with follow-up at the end of every year. Participants from five included studies were invited to participate in open-label extensions to the original randomised trials to assess longer-term effects and adverse effects of treatment (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>). Results from these unblinded extensions have not been reported in this review and the publications of results from these extensions have been excluded.</P>
<P>Efficacy outcomes have been extracted at multiple follow-up times in the <LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>, <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>, <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> and <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> trials to show patterns as follow-up time increases. Quality of life outcomes and withdrawal have also been extracted at multiple follow-up times in the <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> and <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK> trials to show longitudinal results. Adverse effects have mostly been extracted at the end of the trials (except for <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK> and <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>, where data were extracted at the end of two years because more specific information on effects at this time was available).</P>
<P>A summary of the ACR50 response rates, radiographic progression and serious infections is provided in <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>. Subgroup analyses are shown in <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">A. Benefits</HEADING>
<P>(see "definition of improvement" in methods section for description of measures presented below)</P>
<P>For this update, first, we sought to answer two clinically relevant question since most people will have used at least one traditional DMARD before starting treatment with etanercept: 1) what are the benefits and harms of etanercept plus DMARD compared with DMARD monotherapy in those people with RA who are partial responders to traditional DMARDs? and 2) what are the benefits and harms of etanercept plus DMARD compared with DMARD monotherapy in those people with RA who are partial responders to MTX? Second, we provide evidence on the benefits and harms of using: 1) etanercept plus DMARDs versus DMARD; 2) etanercept monotherapy versus DMARD monotherapy; 3) etanercept plus DMARDs versus etanercept monotherapy and 4) etanercept monotherapy versus placebo at 24, 52, 104 and 156 weeks. Third, we report the ACR response rates by group of studies including DMARD-naive; MTX-inadequate response; and non-MTX-inadequate response participants. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> shows study characteristics.</P>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus DMARD (inadequate responders to DMARDs or MTX)</HEADING>
<P>
<I>
<U>ACR response.</U> </I>The benefits and harms of etanercept plus DMARDs versus DMARDs in people who are partial responders to DMARDs is shown in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. We found that people who had an inadequate response to traditional DMARDs and received the combination therapy were 2.0 (95% CI 1.3 to 2.9) and 2.2 (95% CI 1.5 to 3.3) times more likely to achieve an ACR50 and ACR70 response than those people who had an inadequate response to traditional DMARDs and continue with DMARD monotherapy at 24, 52, 104 and 156 weeks (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> show the benefits and harms of etanercept plus DMARD versus DMARD in people who are partial responders to MTX. A higher proportion of people on etanercept plus DMARD achieved an ACR50 compared with DMARD monotherapy (RR 11.7; 95% CI 1.7 to 82.5) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). No other statistically significant differences were observed between groups at 24 weeks (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). However, the analysis was based only in one small study (<LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>).</P>
<P>
<I>
<U>Remission score.</U>
</I> Remission measured by DAS less than 2.6 was significantly more likely with etanercept 25 mg plus DMARD compared with DMARD alone (RR 1.9; 95% CI 1.6 to 2.3) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The absolute treatment benefit (ATB) was 22%, with a NNTB of five people.</P>
<P>
<I>
<U>Disability score.</U>
</I> People taking etanercept plus DMARD had significantly improved HAQ scores after treatment when compared with those taking DMARD alone (MD -0.36; 95% CI -0.43 to -0.28) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>No other differences were observed in radiographic score, discontinuation rates or serious adverse events (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>
<I>
<U>ACR response.</U> </I>ACR20 response rates were significantly improved with etanercept plus DMARD compared with DMARD alone (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The RR of achieving an ACR20 was 2.7 (95% CI 1.8 to 3.8) and the RR of achieving an ACR50 was 4.7 (95% CI 2.4 to 9.3). About 47.5% achieved an ACR50 response in the etanercept plus DMARD group compared with 10% of DMARD alone group with an ATB of 37.5% and an NNTB of three people (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). ACR70 response rates were also significantly improved with etanercept plus DMARD (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The RR of achieving an ACR70 was 11.5 (95% CI 2.3 to 57.9). About 21.3% achieved an ACR70 in the etanercept plus DMARD group compared with 1% in the DMARD only group with an ATB of 20% and an NNTB of five people.</P>
<P>
<I>
<U>DAS.</U>
</I> Final DAS44 score was significantly lower with etanercept plus DMARD than with DMARD alone (MD -1.4; 95 CI -1.8 to -1.0) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12 months</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> All ACR response rates were significantly improved with etanercept 25 mg plus DMARD compared with DMARD alone (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) (ACR 20: RR 1.2; 95% CI 1.1 to 1.3; ACR50: RR 1.5; 95% CI 1.4 to 1.7; ACR70: RR 1.9, 95% CI 1.6 to 2.3). The ATB was 15% with an NNTB of seven people for ACR20. The ATB was 24% and 22% for ACR50 (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>) and ACR70, respectively, with an NNTB of four people.</P>
<P>
<I>
<U>Remission scores.</U>
</I> Remission (DAS &lt; 1.6 and &lt; 2.6) was significantly more likely with etanercept 25 mg plus DMARD compared with DMARD alone (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>) (DAS: RR 2.7; 95% CI 1.9 to 3.8); DAS28: RR 2.0; 95% CI 1.6 to 2.4, respectively). The ATB was 23% and 21%, with an NNTB of four and five people, respectively.</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> All changes in radiographic scores were significantly less with etanercept 25 mg plus DMARD compared with DMARD alone (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>; <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>; <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>) (TSS: MD -2.2; 95% CI -3.0 to -1.4; ES: MD -1.6; 95% CI -2.4 to -0.9; JSNS: MD -0.7; 95% CI -1.1 to -0.2). The proportion of participants with no evidence of joint damage (as measured by modified TSS &#8804; 0.5) was significantly higher with etanercept plus DMARD treatment when compared with DMARD alone (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>) (RR 1.4; 95% CI 1.3 to 1.5) with an NNTB of five people (<LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Two and three years</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> At two years, all ACR response rates were significantly improved with etanercept 25 mg plus DMARD compared with DMARD alone (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) (ACR 20: RR 1.5; 95% CI 1.2 to 1.9; ACR50: RR 1.9; 95% CI 1.3 to 2.8; ACR70: RR 2.2; 95% CI 1.5 to 3.3). The ATB was 21.5% for ACR20, 28.8% for ACR50 and 24.1% for ACR70, resulting in NNTBs of four, three and four people respectively.</P>
<P>At three years, all ACR response rates were significantly improved with etanercept plus DMARD when compared with DMARD alone (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>) (ACR20: RR 1.2, 95% CI 1.1 to 1.4); ACR50: RR 1.6; 95% CI 1.3 to 1.9 (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>); ACR70: RR 2.3; 95% CI 1.7 to 3.0). The ATB was 15%, 24% and 28% and the NNTBs were six, four and four people, respectively.</P>
<P>
<I>
<U>Remission scores.</U>
</I> At two years, remission rates, as measured by DAS less than 1.6 and DAS28 less than 2.6, were significantly improved with etanercept 25 mg plus DMARD compared with DMARD alone (RR 2.6; 95% CI 1.8 to 3.6 and RR 2.2; 95% CI 1.7 to 2.7, respectively) (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). The ATB was 25% and 23%, resulting in NNTBs of four and four people, respectively. Final DAS44 score was significantly lower with etanercept plus DMARD than with DMARD alone (MD -2.0; 95 CI -2.4 to -1.6) (<LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>).</P>
<P>At three years, remission, as measured by either DAS less than 1.6 or DAS28 less than 2.6, was significantly<B> </B>more likely with etanercept plus DMARD when compared with DMARD alone (RR 2.3; 95% CI 1.7 to 3.2 and RR 2.1; 95% CI 1.6 to 2.9, respectively) (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>; <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>). The ATBs were 23% and 19% resulting in NNTBs of four and five people, respectively.</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> At two years, all changes in radiographic scores were significantly less with etanercept 25 mg plus DMARD when compared with DMARD alone (TSS: MD -3.9; 95% CI -6.1 to -1.7; ES: MD -2.9; 95% CI -4.4 to -1.4; JSNS: MD -1.0; 95% CI -1.9 to -0.2) (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>; <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>; <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>). The proportion of participants with no evidence of joint damage (as measured by modified TSS &#8804; 0.5) was significantly higher with etanercept plus DMARD treatment when compared with DMARD alone (RR 1.3; 95% CI 1.2 to 1.5) (<LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>) with an NNTB of five people (<LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
<P>At three years, changes from baseline in all radiographic scores (TSS, ES, JSNS) were significantly less with etanercept plus DMARD when compared with DMARD alone (TSS: MD -6.1; 95% CI -9.2 to -3.0; ES: MD -3.9; 95% CI -5.7 to -2.1; JSNS: MD -2.2; 95% CI -3.8 to -0.6) (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>; <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>; <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>). Participants taking etanercept plus DMARD were more likely to have no progression of their joint damage (as assessed by modified TSS &#8804; 0.5) when compared with those taking DMARD alone (RR 1.5; 95% CI 1.3 to 1.7) (<LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> There was no evidence of a statistical difference in ACR20, ACR50 or ACR70 response rates between those who received etanercept 10 mg compared with those who received DMARD after six months (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>; <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>). There was a trend towards a significant improvement in ACR20 in those receiving etanercept 25 mg monotherapy compared with those who received DMARD monotherapy after six months (RR 1.4; 95% CI 0.97 to 1.9) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>); ACR50 and ACR70 response rates were significantly improved in those receiving etanercept 25 mg monotherapy compared with those who received DMARD monotherapy after six months (ACR50: RR 1.6; 95% CI 1.0 to 2.4; ACR70: RR 2.0; 95% CI 1.1 to 3.5) (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>, and <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>, respectively). About 41% of participants taking etanercept achieved an ACR50 (compared with 28.7% of those taking DMARD with an ATB of 12.3% and an NNTB of eight people (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). About 20.6% of participants taking etanercept achieved an ACR70 (compared with 10.9% of those taking MTX) with an ATB of 9.8% and an NNTB of 10 people.</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> There was no difference from baseline in any of the radiographic scores (TSS, ES and JSNS) between etanercept 10 mg monotherapy and DMARD monotherapy (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>; <LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>; <LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK>). However, there were significant differences between etanercept 25 mg and DMARD for TSS and ES. The difference from baseline in the TSS was significantly less in those who received etanercept 25 mg compared with those who received DMARD (MD -0.5; 95% CI -0.9 to -0.1) (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>). The difference from baseline in ES was significantly less in those who received etanercept 25 mg compared with those who received DMARD (MD -0.4; 95% CI -0.7 to -0.1) (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>). There was no evidence of a statistical difference between changes from baseline in the JSNS between those who received etanercept 25 mg compared with those who received MTX (<LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK>).</P>
<P>
<I>
<U>DAS28.</U>
</I> There was no evidence of a significant difference in the final values of the DAS scores between etanercept 25 mg monotherapy and the DMARD monotherapy groups (<LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12 months</HEADING>
<P>
<I>
<U>ACR response.</U> </I>There was no significant difference in most ACR response rates between either dose of etanercept alone (10 or 25 mg) compared with DMARD alone (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>). However, ACR50 response rates were significantly lower for those receiving etanercept 10 mg compared with those receiving MTX (RR 0.8; 95% CI 0.6 to 1.0).</P>
<P>
<I>
<U>Remission scores.</U>
</I> There was no evidence of a significant difference in proportions achieving remission (as measured by DAS &lt; 1.6 and DAS28 &lt; 2.6) with etanercept 25 mg when compared with DMARD (<LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>; <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>).</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> There was no evidence of a difference from baseline in any of the radiographic scores (TSS, ES and JSNS) between etanercept 10 mg and DMARD (<LINK REF="CMP-008.06" TYPE="ANALYSIS">Analysis 8.6</LINK>; <LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>; <LINK REF="CMP-008.08" TYPE="ANALYSIS">Analysis 8.8</LINK>). Changes in the TSS and ES from baseline were significantly less for those receiving etanercept 25 mg compared with those receiving DMARD (<LINK REF="CMP-008.06" TYPE="ANALYSIS">Analysis 8.6</LINK>; <LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>) (MD -0.7; 95% CI -1.4 to -0.1 and MD -0.7; 95% CI -1.0 to -0.3, respectively). However, there was no evidence of a significant difference in the changes from baseline in the JSNS between etanercept 25 mg and DMARD (<LINK REF="CMP-008.08" TYPE="ANALYSIS">Analysis 8.8</LINK>). The proportion of participants with no evidence of joint damage (as measured by modified TSS &#8804; 0.5) was significantly higher with etanercept treatment when compared with DMARD (RR 1.2; 95% CI 1.0 to 1.4) (<LINK REF="CMP-008.09" TYPE="ANALYSIS">Analysis 8.9</LINK>) with an NNTB of nine people (<LINK REF="SOF-05" TYPE="SOF">Summary of results table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Two and three years</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> At two years, there was no evidence of a difference in ACR20, ACR50 and ACR70 response rates between etanercept monotherapy and DMARD monotherapy (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>; <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
<P>At three years, there was no evidence of a difference in any of the ACR response rates between those receiving etanercept 25 mg alone when compared with DMARD alone (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>; <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>; <LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>).</P>
<P>
<I>
<U>Remission scores.</U>
</I> At two years, remission (as measured by DAS &lt; 1.6) was significantly more likely with etanercept 25 mg when compared with MTX (RR 1.5; 95% CI 1.01 to 2.2) (<LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>). However, there was no evidence of a difference in remission rates (as measured by DAS28 &lt; 2.6) between etanercept 25 mg and MTX (<LINK REF="CMP-009.05" TYPE="ANALYSIS">Analysis 9.5</LINK>). Final DAS44 score was significantly lower with etanercept alone than with DMARD alone (MD -1.7; 95 CI -2.1 to -1.3) (<LINK REF="CMP-009.10" TYPE="ANALYSIS">Analysis 9.10</LINK>).</P>
<P>At three years, there was no evidence of a difference in remission, as measured by either DAS less than 1.6 or DAS28 less than 2.6, between those receiving etanercept 25 mg monotherapy when compared with DMARD monotherapy (<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>; <LINK REF="CMP-010.05" TYPE="ANALYSIS">Analysis 10.5</LINK>).</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> At two years, the change from baseline in ES was significantly less with etanercept 25 mg monotherapy compared with DMARD monotherapy (MD -1.8, 95% CI -3.3 to -0.2) (<LINK REF="CMP-009.07" TYPE="ANALYSIS">Analysis 9.7</LINK>). However, there was no evidence of a difference in the changes from baseline for either TSS or JSNS between groups (<LINK REF="CMP-009.06" TYPE="ANALYSIS">Analysis 9.6</LINK>; <LINK REF="CMP-009.08" TYPE="ANALYSIS">Analysis 9.8</LINK>). The change in TSS was just outside the 0.05 level of significance. There was also no evidence of a difference in the proportion of participants with no evidence of joint damage (as measured by modified TSS &#8804; 0.5) between groups (<LINK REF="CMP-009.09" TYPE="ANALYSIS">Analysis 9.9</LINK>).</P>
<P>At three years, the change from baseline in the TSS and ES was significantly reduced with etanercept 25 mg monotherapy when compared with DMARD monotherapy (TSS: MD -4.3; 95% CI -7.6 to -1.1; ES: MD -2.9; 95% CI -4.8 to -0.9) (<LINK REF="CMP-010.06" TYPE="ANALYSIS">Analysis 10.6</LINK>; <LINK REF="CMP-010.07" TYPE="ANALYSIS">Analysis 10.7</LINK>). There was no evidence of a statistical difference in the change from baseline in the JSNS between groups but the summary estimate was just outside the 0.05 level of significance in favour of etanercept monotherapy (<LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>). Participants taking etanercept alone were more likely to have no progression of their joint damage (as assessed by modified TSS &#8804; 0.5) when compared with those taking DMARD alone (RR 1.2, 95% CI 1.0 to 1.4) (<LINK REF="CMP-010.09" TYPE="ANALYSIS">Analysis 10.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus etanercept alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> ACR20 and ACR70 response rates were not significantly different between etanercept plus DMARD treatment and etanercept alone (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>). There was a trend favouring the etanercept plus DMARD group in improvement of ACR50 response rates when compared with etanercept monotherapy. The ATB was 10%, resulting in NNTBs of 10 people (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<I>
<U>Remission scores.</U>
</I> Significantly more people receiving etanercept plus DMARD were reported as having achieved remission (DAS &lt; 1.6 and DAS28 &lt; 2.6) when compared with those receiving etanercept alone (RR 1.6; 95% CI 1.1 to 2.3 and RR 2.7; 95% CI 1.2 to 6.0, respectively) (<LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>; <LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>). The ATBs were 19% and 17%, resulting in NNTBs of five and six people, respectively. People assigned to etanercept plus DMARD were more likely to have a good European League Against Rheumatism (EULAR) response than those assigned to etanercept alone (<LINK REF="CMP-011.06" TYPE="ANALYSIS">Analysis 11.6</LINK>). Similarly, the etanercept plus DMARD group were less likely to have no EULAR response (<LINK REF="CMP-011.08" TYPE="ANALYSIS">Analysis 11.8</LINK>). There were no statistically significant differences in moderate EULAR response rates between groups or the DAS final values (<LINK REF="CMP-011.07" TYPE="ANALYSIS">Analysis 11.7</LINK>; <LINK REF="CMP-011.09" TYPE="ANALYSIS">Analysis 11.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12 months</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> All ACR response rates (ACR20, ACR50 and ACR70) were significantly improved with etanercept plus DMARD when compared with etanercept alone (RR 1.1; 95% CI 1.02 to 1.2; RR 1.4; 95% CI 1.2 to 1.7; RR 1.8; 95% CI 1.3 to 2.3, respectively) (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>; <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>; <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>). The ATB was 9% for ACR20, 21% for ACR50 and 24% for ACR70, resulting in NNTBs of 11, five and five people, respectively.</P>
<P>
<I>
<U>Remission scores.</U>
</I> Significantly more people receiving etanercept plus DMARD were reported as having achieved remission (DAS &lt; 1.6 and DAS28 &lt; 2.6) when compared with those receiving etanercept alone (RR 2.1; 95% CI 1.5 to 3.0 and RR 2.2; 95% CI 1.6 to 3.0, respectively) (<LINK REF="CMP-012.04" TYPE="ANALYSIS">Analysis 12.4</LINK>; <LINK REF="CMP-012.05" TYPE="ANALYSIS">Analysis 12.5</LINK>). The ATBs for both scores was approximately 20%, resulting in NNTBs of five people.</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> All changes from baseline in TSS, ES and JSNS were significantly reduced with etanercept plus DMARD when compared with etanercept alone (TSS: RR -1.1; 95% CI -1.8 to -0.5; ES: RR -0.7; 95% CI -1.1 to -0.2; JSNS: RR -0.5; 95% CI -0.7 to -0.2) (<LINK REF="CMP-012.06" TYPE="ANALYSIS">Analysis 12.6</LINK>; <LINK REF="CMP-012.07" TYPE="ANALYSIS">Analysis 12.7</LINK>; <LINK REF="CMP-012.08" TYPE="ANALYSIS">Analysis 12.8</LINK>). The proportion of participants with no evidence of joint damage (as measured by modified TSS &#8804; 0.5) was significantly higher with etanercept plus DMARD when compared with etanercept alone (RR 1.2; 95% CI 1.1 to 1.3) (<LINK REF="CMP-012.09" TYPE="ANALYSIS">Analysis 12.9</LINK>) with an NNTB of eight people.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Two and three years</HEADING>
<P>
<I>
<U>ACR response</U>
</I>
<U>.</U> At two years, ACR20 and ACR50 response rates were significantly improved with etanercept plus DMARD when compared with etanercept alone (RR 1.2; 95% CI 1.1 to 1.2; RR 1.5; 95% CI 1.1 to 2.0, respectively) (<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>; <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>) . The ATB was 11% and 24%, resulting in NNTBs of nine and four people, respectively. ACR70 response rates were not different between groups (<LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
<P>At three years, all ACR response rates (ACR20, ACR50 and ACR70) were significantly improved with etanercept plus DMARD when compared with etanercept alone (RR 1.2; 95% CI 1.1 to 1.3; RR 1.4; 95% CI 1.2 to 1.7; RR 2.0; 95% CI 1.6 to 2.7, respectively) (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>; <LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>; <LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK>). The ATBs were 13%, 21% and 25%, resulting in NNTBs of eight, five and four people, respectively.</P>
<P>
<I>
<U>Remission scores</U>
</I>
<U>.</U> At two years, remission rates, as measured by DAS less than 1.6 and DAS28 less than 2.6, were significantly increased with etanercept plus DMARD compared with etanercept alone (RR 1.8; 95% CI 1.3 to 2.3; RR 1.9; 95% CI 1.4 to 2.5, respectively) (<LINK REF="CMP-013.04" TYPE="ANALYSIS">Analysis 13.4</LINK>; <LINK REF="CMP-013.05" TYPE="ANALYSIS">Analysis 13.5</LINK>). The ATB was 17% and 20%, resulting in NNTBs of six and five people, respectively. Final DAS values were not different between groups (<LINK REF="CMP-013.10" TYPE="ANALYSIS">Analysis 13.10</LINK>).</P>
<P>At three years, people receiving etanercept plus DMARD were significantly more likely to go into remission (DAS &lt; 1.6 or DAS28 &lt; 2.6) when compared with those taking etanercept alone (RR 1.9; 95% CI 1.4 to 2.5 and RR 2.0; 95% CI 1.4 to 2.6 respectively) (<LINK REF="CMP-014.04" TYPE="ANALYSIS">Analysis 14.4</LINK>; <LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>). The ATBs were 19% and 20% resulting in NNTBs of five people.</P>
<P>
<I>
<U>Radiographic scores.</U>
</I> At two years, all radiographic scores were significantly improved with etanercept plus DMARD when compared with etanercept alone (TSS: RR -1.7; 95% CI -2.8 to -0.6; ES: RR -1.1; 95% CI -1.8 to -0.4; JSNS: RR -0.5; 95% CI -1.1 to 0.01) (<LINK REF="CMP-013.06" TYPE="ANALYSIS">Analysis 13.6</LINK>; <LINK REF="CMP-013.07" TYPE="ANALYSIS">Analysis 13.7</LINK>; <LINK REF="CMP-013.08" TYPE="ANALYSIS">Analysis 13.8</LINK>). The proportion of participants with no evidence of joint damage (as measured by modified TSS &#8804; 0.5) was significantly higher with etanercept plus DMARD treatment when compared with etanercept alone (RR 1.2, 95% CI 1.0 to 1.3) (<LINK REF="CMP-013.09" TYPE="ANALYSIS">Analysis 13.9</LINK>) with NNTBs of 10 people.</P>
<P>At three years, both TSS and ES scores were significantly improved with etanercept plus DMARD when compared with etanercept alone (TSS: RR -1.8; 95% CI -3.3 to -0.2; RR -1.1; 95% CI -2.0 to -0.1, respectively) (<LINK REF="CMP-014.06" TYPE="ANALYSIS">Analysis 14.6</LINK>; <LINK REF="CMP-014.07" TYPE="ANALYSIS">Analysis 14.7</LINK>). There was no evidence of a difference in JSNS between groups (<LINK REF="CMP-014.08" TYPE="ANALYSIS">Analysis 14.8</LINK>). Participants taking etanercept plus DMARD were more likely to have no progression of their joint damage (as assessed by modified TSS &#8804; 0.5) when compared with those taking etanercept monotherapy (RR 1.2; 95% CI 1.1 to 1.4) (<LINK REF="CMP-014.09" TYPE="ANALYSIS">Analysis 14.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>
<I>
<U>ACR response.</U>
</I> After six months of therapy, ACR20 and ACR50 response rates were significantly improved with both etanercept doses compared with the placebo group (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>; <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>). For etanercept 10 mg SC twice weekly compared with placebo, the RR of achieving an ACR20 and ACR50 were 4.6 (95% CI 2.4 to 8.8) and 5.9 (95% CI 1.9 to 18.4), respectively, and there was a trend favouring etanercept 10 mg in improvement of ACR70 when compared with placebo. For etanercept 25 mg SC twice weekly compared with placebo, the RR of achieving an ACR20, ACR50 and ACR70 were 5.2 (95% CI 2.8 to 10.0), 12.5 (95% CI 4.2 to 37.8) and 12.3 (95% CI 1.6 to 92.4), respectively (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>; <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>; <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">B. Quality of life</HEADING>
<P>A large number of different scales and questionnaires were used in the included trials to evaluate quality of life. For the purposes of this review, data were extracted from those measures that were most frequently used: HAQ, Medical Outcome Study (MOS) SF-36, EQ-5D VAS, and Arthritis-Specific Health Index (ASHI).</P>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>There was evidence of a significant difference in the final value for the HAQ score between groups (MD -0.49; 95% CI -0.77 to -0.21) (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>). Significantly higher values were found in the final EQ-5D scores for those receiving etanercept 25 mg plus DMARD when compared with DMARD alone (MD 18.6; 95% CI 11.8 to 25.4) (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12 months</HEADING>
<P>Participants taking etanercept plus DMARD were more likely to be satisfied with their treatment when compared with those taking DMARD alone (RR 1.2; 95% CI 1.1 to 1.3) (<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>). Participants taking etanercept plus DMARD had significantly improved HAQ scores after treatment when compared with those taking DMARD alone (MD -0.2; 95% CI -0.33 to -0.15) (<LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). Participants taking etanercept plus DMARD had significantly higher EQ-5D scores after treatment when compared with those taking DMARD alone (MD 7.6; 95% CI 4.7 to 10.5) (<LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>). Participants taking etanercept plus DMARD were more likely to have HAQ scores equivalent to population norms (HAQ &#8804; 0.5) after treatment when compared with those taking DMARD alone (RR 1.4; 95% CI 1.2 to 1.6) (<LINK REF="CMP-017.04" TYPE="ANALYSIS">Analysis 17.4</LINK>). Participants taking etanercept plus DMARD were less likely to have stopped work during treatment than those taking DMARD alone (RR 0.4; 95% CI 0.2 to 0.7) (<LINK REF="CMP-017.05" TYPE="ANALYSIS">Analysis 17.5</LINK>). Nearly 9% of those taking etanercept plus DMARD stopped work compared with 24% of those taking DMARD alone. Participants taking etanercept plus DMARD had significantly improved scores on the physical domain component of the SF-36 (MD 2.8; 95% CI 1.0 to 4.6) (<LINK REF="CMP-017.06" TYPE="ANALYSIS">Analysis 17.6</LINK>), but there was no evidence of a difference in the mental domain component of the SF-36 (<LINK REF="CMP-017.07" TYPE="ANALYSIS">Analysis 17.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Two years</HEADING>
<P>Participants taking etanercept plus DMARD were more likely to have improvements in their HAQ scores compared with those taking DMARD alone (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>). There was a 20% difference in the rate of improvement of the final HAQ score for those having etanercept plus DMARD (MD 20.0; 95% CI 17.5 to 22.6). There was also a reduction of 0.49 points in the final value of the 3-point HAQ score for those having etanercept plus DMARD (MD -0.49; 95% CI -0.69 to -0.30) (<LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>There was no evidence of significant differences in the final value HAQ scores between etanercept 25 mg and DMARD groups (<LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>). However, significantly higher values were found in the final EQ-5D scores for those receiving etanercept 25 mg monotherapy when compared with DMARD alone (MD 21.3; 95% CI 14.6 to 28.0) (<LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12 months</HEADING>
<P>There was no evidence of a significant difference between groups on any of the scales used to measure quality of life (HAQ, SF-36 summary scores, ASHI and EQ-5D VAS) (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>; <LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>; <LINK REF="CMP-020.03" TYPE="ANALYSIS">Analysis 20.3</LINK>; <LINK REF="CMP-020.04" TYPE="ANALYSIS">Analysis 20.4</LINK>; <LINK REF="CMP-020.05" TYPE="ANALYSIS">Analysis 20.5</LINK>; <LINK REF="CMP-020.06" TYPE="ANALYSIS">Analysis 20.6</LINK>; <LINK REF="CMP-020.07" TYPE="ANALYSIS">Analysis 20.7</LINK>; <LINK REF="CMP-020.08" TYPE="ANALYSIS">Analysis 20.8</LINK>; <LINK REF="CMP-020.09" TYPE="ANALYSIS">Analysis 20.9</LINK>; <LINK REF="CMP-020.10" TYPE="ANALYSIS">Analysis 20.10</LINK>). However, participants taking etanercept 25 mg were more likely to be satisfied with their treatment (RR 1.2; 95% CI 1.1 to 1.3) (<LINK REF="CMP-020.11" TYPE="ANALYSIS">Analysis 20.11</LINK>). Reduction to normal health assessment (HAQ &#8804; 0.5) was not significantly different between etanercept 25 mg and DMARD alone (<LINK REF="CMP-020.12" TYPE="ANALYSIS">Analysis 20.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Two years</HEADING>
<P>There was a small but significantly higher percentage improvement in the HAQ score for participants taking etanercept compared with those taking DMARD (MD 3.0; 95% CI 0.1 to 5.9) (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>). However, there was no evidence of a significant difference in the final HAQ score after treatment between groups (<LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus etanercept alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>There was no evidence of a difference in final HAQ score values between groups (<LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12 months</HEADING>
<P>There was no evidence of a difference in satisfaction rates and EQ-5D VAS scores between groups (<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>; <LINK REF="CMP-023.03" TYPE="ANALYSIS">Analysis 23.3</LINK>). However, HAQ scores were significantly improved after treatment with etanercept plus DMARD when compared with etanercept alone (RR -0.20; 95% CI -0.30 to -0.10) (<LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>). Reduction to normal health assessment (HAQ &#8804; 0.5) was also significantly higher in the etanercept 25 mg plus DMARD group than in the etanercept alone group (RR 1.3; 95% CI 1.0 to 1.6) (<LINK REF="CMP-023.04" TYPE="ANALYSIS">Analysis 23.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Two years</HEADING>
<P>There were highly significant improvements in HAQ scores (either percentage improvement or absolute scores) were reported for participants taking etanercept plus DMARD when compared with etanercept alone (RR 17.0; 95% CI 14.6 to 19.4 and RR -0.26; 95% CI -0.36 to -0.15, respectively) (<LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>; <LINK REF="CMP-024.02" TYPE="ANALYSIS">Analysis 24.2</LINK>). However, there was no evidence of a difference in satisfaction rates between groups (<LINK REF="CMP-024.03" TYPE="ANALYSIS">Analysis 24.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Six months</HEADING>
<P>Significantly higher changes were found from baseline in the MOS mental health scores and MOS energy/vitality scores both for those receiving etanercept 10 mg and etanercept 25 mg when compared with placebo (mental health: etanercept 10 mg: MD 8.5; 95% CI 3.2 to 13.8; etanercept 25 mg: MD 9.5; 95% CI 4.3 to 14.7; energy/vitality: etanercept 10 mg: MD 12.6; 95% CI 6.4 to 18.9; etanercept 25 mg: MD 11.6; 95% CI 5.5 to 17.7) (<LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>; <LINK REF="CMP-025.02" TYPE="ANALYSIS">Analysis 25.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">C. Harms</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Study withdrawals</HEADING>
<P>Withdrawals are reported in four ways in this meta-analysis, that is, total withdrawals, withdrawal because of lack of efficacy, withdrawal because of adverse events and deaths; they are reported at different follow-up times.</P>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept plus DMARD versus DMARD group</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a) Total withdrawals</HEADING>
<P>At six months, significantly more people withdrew from the DMARD group than from the etanercept plus DMARD group (RR 0.17; 95% CI 0.04 to 0.79) (<LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>). About 3.4% in total withdrew from the etanercept plus DMARD group and 20% in total withdrew from the DMARD alone group.</P>
<P>At 12 months, significantly more people withdrew from the DMARD group than from the etanercept plus DMARD group (RR 0.6; 95% CI 0.5 to 0.8) (<LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>). About 18% of people withdrew from the etanercept plus DMARD group and 30% withdrew from the DMARD control group.</P>
<P>At two years, significantly more people withdrew from the DMARD group than from the etanercept 25 mg group (RR 0.47; 95% CI 0.28 to 0.80) (<LINK REF="CMP-028.01" TYPE="ANALYSIS">Analysis 28.1</LINK>). About 49% withdrew from the DMARD group and 26% withdrew from the etanercept plus DMARD group.</P>
<P>At three years, significantly more people withdrew from the DMARD group than from the etanercept 25 mg plus DMARD group (RR 0.7; 95% CI 0.6 to 0.8) (<LINK REF="CMP-029.01" TYPE="ANALYSIS">Analysis 29.1</LINK>). About 61% had withdrawn from the DMARD group and 43% had withdrawn from the etanercept plus DMARD group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b) Lack of efficacy</HEADING>
<P>At six months, withdrawals were reduced in the etanercept plus DMARD group compared with the DMARD alone group (RR 0.14; 95% CI 0.05 to 0.37) (<LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>). About 2.5% of people withdrew from the etanercept plus DMARD group and 20% withdrew from the DMARD group.</P>
<P>At 12 months, withdrawals were reduced in the etanercept 25 mg plus DMARD group compared with the DMARD group (RR 0.33; 95% CI 0.2 to 0.6) (<LINK REF="CMP-027.02" TYPE="ANALYSIS">Analysis 27.2</LINK>). About 3% of people withdrew from the etanercept 25 mg group and 9.1% withdrew from the control group.</P>
<P>At two years, withdrawals were reduced in the etanercept 25 mg group compared with the DMARD group (RR 0.19; 95% CI 0.07 to 0.48) (<LINK REF="CMP-028.02" TYPE="ANALYSIS">Analysis 28.2</LINK>). About 4.5% of people withdrew from the etanercept 25 mg group and 20% withdrew from the control group.</P>
<P>At three years, withdrawals were reduced in the etanercept 25 mg group compared with the DMARD group (RR 0.3, 95% CI 0.2 to 0.6) (<LINK REF="CMP-029.02" TYPE="ANALYSIS">Analysis 29.2</LINK>). About 5% withdrew from the etanercept 25 mg group and 17% withdrew from the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c) Adverse effects</HEADING>
<P>At six months, 12 months and two years, there was no evidence of a statistically significant difference in the rate of withdrawal because of adverse events in either etanercept plus DMARD group and the DMARD alone group (<LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>; <LINK REF="CMP-027.03" TYPE="ANALYSIS">Analysis 27.3</LINK>; <LINK REF="CMP-028.03" TYPE="ANALYSIS">Analysis 28.3</LINK>).</P>
<P>At three years, withdrawals were significantly reduced in the etanercept 25 mg plus DMARD group compared with the DMARD alone group (RR 0.7; 95% CI 0.5 to 1.0) (<LINK REF="CMP-029.03" TYPE="ANALYSIS">Analysis 29.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d) Deaths</HEADING>
<P>At six months, there were no deaths in either group (<LINK REF="CMP-026.04" TYPE="ANALYSIS">Analysis 26.4</LINK>).</P>
<P>At 12 months, there was no statistically significant difference in the death rates between groups (<LINK REF="CMP-027.04" TYPE="ANALYSIS">Analysis 27.4</LINK>). There were two deaths in the etanercept plus DMARD group and one death in the DMARD group.</P>
<P>At two years, there was no statistically significant difference in the death rates between groups (<LINK REF="CMP-028.04" TYPE="ANALYSIS">Analysis 28.4</LINK>). There was one death in each group.</P>
<P>At three years, there was no statistically significant difference in the death rates between groups (<LINK REF="CMP-029.04" TYPE="ANALYSIS">Analysis 29.4</LINK>). Two people had died by three years in the etanercept 25 mg plus DMARD group compared with one person in the DMARD group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a) Total withdrawals</HEADING>
<P>There was no significant difference in the total number of withdrawals between the etanercept and DMARD groups at six months (25 mg) or 12 months (10 mg) (<LINK REF="CMP-030.01" TYPE="ANALYSIS">Analysis 30.1</LINK>; <LINK REF="CMP-031.01" TYPE="ANALYSIS">Analysis 31.1</LINK>). Total withdrawals were significantly reduced in the etanercept 25 mg group compared with the DMARD group at 12 months (RR 0.8; 95% CI 0.6 to 1.0) (<LINK REF="CMP-031.01" TYPE="ANALYSIS">Analysis 31.1</LINK>) and two years (RR 0.67; 95% CI 0.46 to 0.97) (<LINK REF="CMP-032.01" TYPE="ANALYSIS">Analysis 32.1</LINK>). The estimate at three years was just outside the 0.05 level of significance (P value = 0.06) (<LINK REF="CMP-033.01" TYPE="ANALYSIS">Analysis 33.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b) Lack of efficacy</HEADING>
<P>Withdrawals due to lack of efficacy were significantly reduced in the etanercept 25 mg group compared with the DMARD group at six months (RR 0.04; 95% CI 0.01 to 0.30) (<LINK REF="CMP-030.02" TYPE="ANALYSIS">Analysis 30.2</LINK>). However, there was no significant difference in the rate of withdrawals because of lack of efficacy between either etanercept group (10 and 25 mg) and the DMARD groups at 12 months (<LINK REF="CMP-031.02" TYPE="ANALYSIS">Analysis 31.2</LINK>;) and between the etanercept 25 mg group and the DMARD group at two and three years (<LINK REF="CMP-032.02" TYPE="ANALYSIS">Analysis 32.2</LINK>; <LINK REF="CMP-033.02" TYPE="ANALYSIS">Analysis 33.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c) Adverse events</HEADING>
<P>There was no significant difference in the rate of withdrawals because of adverse events between the etanercept group and the DMARD group at six months (25 mg) and 12 months (10 mg) (<LINK REF="CMP-030.03" TYPE="ANALYSIS">Analysis 30.3</LINK>; <LINK REF="CMP-031.03" TYPE="ANALYSIS">Analysis 31.3</LINK>) and between etanercept 25 mg and the DMARD groups at two and three years (<LINK REF="CMP-032.03" TYPE="ANALYSIS">Analysis 32.3</LINK>; <LINK REF="CMP-033.03" TYPE="ANALYSIS">Analysis 33.3</LINK>). However, significantly fewer people withdrew for this reason from the etanercept 25 mg group at 12 months compared with the DMARD group (RR 0.7; 95% CI 0.5 to 1.0) (<LINK REF="CMP-031.03" TYPE="ANALYSIS">Analysis 31.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d) Deaths</HEADING>
<P>There was no significant difference in the death rates at any follow-up time between groups (<LINK REF="CMP-031.04" TYPE="ANALYSIS">Analysis 31.4</LINK>; <LINK REF="CMP-032.04" TYPE="ANALYSIS">Analysis 32.4</LINK>; <LINK REF="CMP-033.04" TYPE="ANALYSIS">Analysis 33.4</LINK>). By three years' follow-up, two people had died in the etanercept 25 mg group compared with one in the DMARD group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept plus DMARD versus etanercept alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a) Total withdrawals</HEADING>
<P>Overall, significantly fewer people taking etanercept plus DMARD treatment withdrew by six and 12 months' follow-up when compared with those taking etanercept alone (RR 0.31; 95% CI 0.11 to 0.92 and RR 0.5; 95% CI 0.4 to 0.8, respectively) (<LINK REF="CMP-034.01" TYPE="ANALYSIS">Analysis 34.1</LINK>; <LINK REF="CMP-035.01" TYPE="ANALYSIS">Analysis 35.1</LINK>). Also, significantly fewer people taking etanercept plus DMARD treatment withdrew by the two- and three-year follow-up when compared with those taking etanercept alone (RR 0.8; 95% CI 0.6 to 1.0 and RR 0.8; 95% CI 0.7 to 1.0, respectively) (<LINK REF="CMP-036.01" TYPE="ANALYSIS">Analysis 36.1</LINK>; <LINK REF="CMP-037.01" TYPE="ANALYSIS">Analysis 37.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b) Lack of efficacy</HEADING>
<P>There was no significant difference in the rate of withdrawals because of lack of efficacy between the etanercept plus DMARD group and the etanercept alone group at six months and two years (<LINK REF="CMP-034.02" TYPE="ANALYSIS">Analysis 34.2</LINK>; <LINK REF="CMP-036.02" TYPE="ANALYSIS">Analysis 36.2</LINK>). At 12 months and three-year follow-up, significantly fewer people taking etanercept plus DMARD treatment withdrew from the trial because of lack of efficacy by all follow-up periods when compared with etanercept alone (<LINK REF="CMP-035.02" TYPE="ANALYSIS">Analysis 35.2</LINK>; <LINK REF="CMP-037.02" TYPE="ANALYSIS">Analysis 37.2</LINK>) ( RR 0.4; 95% CI 0.1 to 0.9 and RR 0.3; 95% CI 0.2 to 0.6, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c) Adverse events</HEADING>
<P>Significantly fewer people taking etanercept plus DMARD treatment withdrew by six months' follow-up when compared with those taking etanercept alone (RR 0.16; 95% CI 0.03 to 0.86) (<LINK REF="CMP-034.03" TYPE="ANALYSIS">Analysis 34.3</LINK>). At 12 months', two years' and three years' follow-up, there was no evidence of a difference between groups in the rates of withdrawal from the trial because of adverse events (<LINK REF="CMP-035.03" TYPE="ANALYSIS">Analysis 35.3</LINK>; <LINK REF="CMP-036.03" TYPE="ANALYSIS">Analysis 36.3</LINK>; <LINK REF="CMP-037.03" TYPE="ANALYSIS">Analysis 37.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d) Deaths</HEADING>
<P>At 12 months', two years' and three years' follow-up, there was no evidence of a difference between groups in the death rates before the completion of the trial (<LINK REF="CMP-035.04" TYPE="ANALYSIS">Analysis 35.4</LINK>; <LINK REF="CMP-036.04" TYPE="ANALYSIS">Analysis 36.4</LINK>; <LINK REF="CMP-037.04" TYPE="ANALYSIS">Analysis 37.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a) Total withdrawals</HEADING>
<P>At six months, significantly more people withdrew from the placebo group than from either etanercept group (10 or 25 mg) (10 mg: RR 0.5; 95% CI 0.3 to 0.7; 25 mg: RR 0.4; 95% CI 0.2 to 0.5) (<LINK REF="CMP-038.01" TYPE="ANALYSIS">Analysis 38.1</LINK>). About 32% of people in total withdrew from the etanercept 10 mg group, 24% in total withdrew from the etanercept 25 mg group and 68% in total withdrew from the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b) Lack of efficacy</HEADING>
<P>At six months, significantly more people withdrew because of lack of efficacy from the placebo group than from either etanercept group (10 or 25 mg) (10 mg: RR 0.4; 95% CI 0.3 to 0.7; 25 mg: RR 0.3; 95% CI 0.2 to 0.5) (<LINK REF="CMP-038.02" TYPE="ANALYSIS">Analysis 38.2</LINK>). About 21% of people withdrew from the etanercept 10 mg group, 15% withdrew from the etanercept 25 mg group and 53% withdrew from the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c) Adverse events</HEADING>
<P>There were no significant differences between groups in the rate of withdrawal due to adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept plus DMARD versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Injection site reaction</HEADING>
<P>A greater proportion of people receiving either etanercept plus DMARD developed injection site reactions at six months than those taking DMARD (RR 6.9; 95% CI 2.2 to 21.3) (<LINK REF="CMP-039.15" TYPE="ANALYSIS">Analysis 39.15</LINK>). About 25.6% of those taking etanercept plus DMARD experienced reactions compared with 3.8% of those taking DMARD alone. A greater proportion of people receiving etanercept plus DMARD developed injection site reactions at two years than those taking DMARD alone (RR 5.0; 95% CI 2.3 to 11.0) (<LINK REF="CMP-041.17" TYPE="ANALYSIS">Analysis 41.17</LINK>). About 14% of those taking etanercept plus DMARD reported reactions compared with 3% of those taking DMARD alone.</P>
<P>There was no evidence of statistically significant differences in the rates of all other adverse effects in the included studies:<BR/>
</P>
<UL>
<LI>total adverse reactions at six and 12 months (<LINK REF="CMP-039.01" TYPE="ANALYSIS">Analysis 39.1</LINK>; <LINK REF="CMP-041.01" TYPE="ANALYSIS">Analysis 41.1</LINK>);</LI>
<LI>abdominal pain at six months and two years (<LINK REF="CMP-039.02" TYPE="ANALYSIS">Analysis 39.2</LINK>; <LINK REF="CMP-041.03" TYPE="ANALYSIS">Analysis 41.3</LINK>);</LI>
<LI>asthenia at six months and two years (<LINK REF="CMP-039.03" TYPE="ANALYSIS">Analysis 39.3</LINK>; <LINK REF="CMP-041.04" TYPE="ANALYSIS">Analysis 41.4</LINK>);</LI>
<LI>arthralgia/Bone pain at six months and two years (<LINK REF="CMP-039.04" TYPE="ANALYSIS">Analysis 39.4</LINK>; <LINK REF="CMP-041.05" TYPE="ANALYSIS">Analysis 41.5</LINK>);</LI>
<LI>back pain at two years (<LINK REF="CMP-041.06" TYPE="ANALYSIS">Analysis 41.6</LINK>);</LI>
<LI>bronchitis at six months and two years (<LINK REF="CMP-039.05" TYPE="ANALYSIS">Analysis 39.5</LINK>; <LINK REF="CMP-041.07" TYPE="ANALYSIS">Analysis 41.7</LINK>);</LI>
<LI>breast cancer at 12 months (<LINK REF="CMP-040.05" TYPE="ANALYSIS">Analysis 40.5</LINK>);</LI>
<LI>chest pain at 12 months (<LINK REF="CMP-040.06" TYPE="ANALYSIS">Analysis 40.6</LINK>);</LI>
<LI>cholelithiasis at 12 months (<LINK REF="CMP-040.08" TYPE="ANALYSIS">Analysis 40.8</LINK>);</LI>
<LI>diarrhoea at six months and two years (<LINK REF="CMP-039.06" TYPE="ANALYSIS">Analysis 39.6</LINK>; <LINK REF="CMP-041.08" TYPE="ANALYSIS">Analysis 41.8</LINK>);</LI>
<LI>dizziness at six months (<LINK REF="CMP-039.07" TYPE="ANALYSIS">Analysis 39.7</LINK>);</LI>
<LI>dyspepsia at six months and two years (<LINK REF="CMP-039.08" TYPE="ANALYSIS">Analysis 39.8</LINK>; <LINK REF="CMP-041.09" TYPE="ANALYSIS">Analysis 41.9</LINK>);</LI>
<LI>fever at six months (<LINK REF="CMP-039.09" TYPE="ANALYSIS">Analysis 39.9</LINK>);</LI>
<LI>flu-syndrome six months and two years (<LINK REF="CMP-039.10" TYPE="ANALYSIS">Analysis 39.10</LINK>; <LINK REF="CMP-041.10" TYPE="ANALYSIS">Analysis 41.10</LINK>);</LI>
<LI>gingival/dental infection at two years (<LINK REF="CMP-041.11" TYPE="ANALYSIS">Analysis 41.11</LINK>);</LI>
<LI>headache at six months and two years (<LINK REF="CMP-039.11" TYPE="ANALYSIS">Analysis 39.11</LINK>; <LINK REF="CMP-041.12" TYPE="ANALYSIS">Analysis 41.12</LINK>);</LI>
<LI>hip arthroplasty at 12 months (<LINK REF="CMP-040.12" TYPE="ANALYSIS">Analysis 40.12</LINK>);</LI>
<LI>hypertension at six months and two years (<LINK REF="CMP-039.12" TYPE="ANALYSIS">Analysis 39.12</LINK>; <LINK REF="CMP-041.13" TYPE="ANALYSIS">Analysis 41.13</LINK>);</LI>
<LI>increased cough at six and two years (<LINK REF="CMP-039.13" TYPE="ANALYSIS">Analysis 39.13</LINK>; <LINK REF="CMP-041.14" TYPE="ANALYSIS">Analysis 41.14</LINK>);</LI>
<LI>infection at six months and two years (<LINK REF="CMP-039.14" TYPE="ANALYSIS">Analysis 39.14</LINK>; <LINK REF="CMP-041.15" TYPE="ANALYSIS">Analysis 41.15</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>);</LI>
<LI>injection site haemorrhage at six months and two years (<LINK REF="CMP-039.16" TYPE="ANALYSIS">Analysis 39.16</LINK>; <LINK REF="CMP-041.16" TYPE="ANALYSIS">Analysis 41.16</LINK>);</LI>
<LI>interstitial lung disease at 12 months (<LINK REF="CMP-040.11" TYPE="ANALYSIS">Analysis 40.11</LINK>);</LI>
<LI>invertebral disc protrusion at 12 months (<LINK REF="CMP-040.09" TYPE="ANALYSIS">Analysis 40.9</LINK>);</LI>
<LI>leukopenia at six months (<LINK REF="CMP-039.17" TYPE="ANALYSIS">Analysis 39.17</LINK>);</LI>
<LI>malignancy at 12 months and two years (<LINK REF="CMP-040.13" TYPE="ANALYSIS">Analysis 40.13</LINK>; <LINK REF="CMP-041.18" TYPE="ANALYSIS">Analysis 41.18</LINK>);</LI>
<LI>miscellaneous skin infections at six months and two years (<LINK REF="CMP-039.18" TYPE="ANALYSIS">Analysis 39.18</LINK>; <LINK REF="CMP-041.19" TYPE="ANALYSIS">Analysis 41.19</LINK>);</LI>
<LI>mouth ulcers at six months (<LINK REF="CMP-039.19" TYPE="ANALYSIS">Analysis 39.19</LINK>);</LI>
<LI>nausea at six and 12 months and two years (<LINK REF="CMP-039.20" TYPE="ANALYSIS">Analysis 39.20</LINK>; <LINK REF="CMP-040.01" TYPE="ANALYSIS">Analysis 40.1</LINK>; <LINK REF="CMP-041.20" TYPE="ANALYSIS">Analysis 41.20</LINK>);</LI>
<LI>osteoarthritis at 12 months (<LINK REF="CMP-040.10" TYPE="ANALYSIS">Analysis 40.10</LINK>);</LI>
<LI>pain at six months and two years (<LINK REF="CMP-039.21" TYPE="ANALYSIS">Analysis 39.21</LINK>; <LINK REF="CMP-041.21" TYPE="ANALYSIS">Analysis 41.21</LINK>);</LI>
<LI>paraesthesia at six months and two years (<LINK REF="CMP-039.22" TYPE="ANALYSIS">Analysis 39.22</LINK>; <LINK REF="CMP-041.22" TYPE="ANALYSIS">Analysis 41.22</LINK>);</LI>
<LI>pharyngitis (non-infectious) at six months (<LINK REF="CMP-039.23" TYPE="ANALYSIS">Analysis 39.23</LINK>);</LI>
<LI>pharyngitis or laryngitis at six and 12 months and two years (<LINK REF="CMP-039.24" TYPE="ANALYSIS">Analysis 39.24</LINK>; <LINK REF="CMP-040.02" TYPE="ANALYSIS">Analysis 40.2</LINK>; <LINK REF="CMP-041.23" TYPE="ANALYSIS">Analysis 41.23</LINK>);</LI>
<LI>pneumonia at 12 months (<LINK REF="CMP-040.07" TYPE="ANALYSIS">Analysis 40.7</LINK>);</LI>
<LI>pruritus at six months (<LINK REF="CMP-039.25" TYPE="ANALYSIS">Analysis 39.25</LINK>);</LI>
<LI>rash at six months and two years (<LINK REF="CMP-039.26" TYPE="ANALYSIS">Analysis 39.26</LINK>; <LINK REF="CMP-041.24" TYPE="ANALYSIS">Analysis 41.24</LINK>);</LI>
<LI>rhinitis at six months (<LINK REF="CMP-039.27" TYPE="ANALYSIS">Analysis 39.27</LINK>);</LI>
<LI>serious infections at 12 months and two years (<LINK REF="CMP-040.03" TYPE="ANALYSIS">Analysis 40.3</LINK>; <LINK REF="CMP-041.25" TYPE="ANALYSIS">Analysis 41.25</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>);</LI>
<LI>sinusitis at two years (<LINK REF="CMP-041.26" TYPE="ANALYSIS">Analysis 41.26</LINK>);</LI>
<LI>trauma/accidental injury at six months and two years (<LINK REF="CMP-039.28" TYPE="ANALYSIS">Analysis 39.28</LINK>; <LINK REF="CMP-041.02" TYPE="ANALYSIS">Analysis 41.2</LINK>);</LI>
<LI>upper respiratory tract infection (URTI) at six months and two years (<LINK REF="CMP-039.29" TYPE="ANALYSIS">Analysis 39.29</LINK>; <LINK REF="CMP-041.27" TYPE="ANALYSIS">Analysis 41.27</LINK>);</LI>
<LI>vomiting at six months and two years (<LINK REF="CMP-039.30" TYPE="ANALYSIS">Analysis 39.30</LINK>; <LINK REF="CMP-041.28" TYPE="ANALYSIS">Analysis 41.28</LINK>);</LI>
<LI>worsening of RA at 12 months and two years (<LINK REF="CMP-040.04" TYPE="ANALYSIS">Analysis 40.4</LINK>; <LINK REF="CMP-041.29" TYPE="ANALYSIS">Analysis 41.29</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept versus DMARD</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Total adverse events</HEADING>
<P>Significantly more people had adverse events in the etanercept monotherapy group when compared with the DMARD alone group at two years (RR 1.4; 95% CI 1.1 to 1.7) (<LINK REF="CMP-044.01" TYPE="ANALYSIS">Analysis 44.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Alopecia</HEADING>
<P>People taking etanercept 25 mg were less likely to experience alopecia compared with those taking DMARD at 12 months (RR 0.5; 95% CI 0.3 to 0.97) (<LINK REF="CMP-043.01" TYPE="ANALYSIS">Analysis 43.1</LINK>). However, there was no evidence of a significant difference in alopecia rates between those taking etanercept 10 mg and those taking DMARD at 12 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Dizziness</HEADING>
<P>People taking etanercept 10 mg alone were less likely to experience dizziness than those taking DMARD at 12 months (RR 0.5; 95% CI 0.2 to 0.9) (<LINK REF="CMP-043.06" TYPE="ANALYSIS">Analysis 43.6</LINK>). However, there was no evidence of a significant difference in dizziness rates between etanercept 25 mg and DMARD at 12 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Elevation in alanine transaminase (ALT)</HEADING>
<P>Significantly more people had ALT elevation in the DMARD group when compared with the etanercept group at six months in one small trial (RR 0.3; 95% CI 0.1 to 0.7) (<LINK REF="CMP-042.11" TYPE="ANALYSIS">Analysis 42.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Flu syndrome</HEADING>
<P>More people in the etanercept alone group had flu syndrome than in the DMARD alone group (RR 4.4; 95% CI 1.1 to 18.1) (<LINK REF="CMP-044.10" TYPE="ANALYSIS">Analysis 44.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Hypertension</HEADING>
<P>People taking etanercept were more likely to have hypertension at two years than those taking DMARD (RR 2.5; 95% CI 1.3 to 4.7) (<LINK REF="CMP-044.13" TYPE="ANALYSIS">Analysis 44.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Infections (total)</HEADING>
<P>People assigned to etanercept alone were more likely to experience an infection than those assigned to DMARD alone at six months (RR 1.8; 95% CI 1.1 to 2.9) (<LINK REF="CMP-042.30" TYPE="ANALYSIS">Analysis 42.30</LINK>). However, this difference was not observed at two years (<LINK REF="CMP-044.15" TYPE="ANALYSIS">Analysis 44.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Injection site reaction</HEADING>
<P>There was a significant difference in the rates of injection site reaction at six months in three trials (RR 18.2; 95% CI 4.5 to 73.7) (<LINK REF="CMP-042.20" TYPE="ANALYSIS">Analysis 42.20</LINK>), although CIs were wide. At 12 months' follow-up, significantly more people receiving etanercept 10 or 25 mg had a reaction compared with those having DMARD (RR 4.1; 95% CI 2.5 to 6.9 and RR 5.0; 95% CI 3.1 to 8.4) (<LINK REF="CMP-043.12" TYPE="ANALYSIS">Analysis 43.12</LINK>) and at two years significantly more people receiving etanercept 25 mg had a reaction compared with those receiving DMARD (RR 9.0; 95% CI 4.2 to 19.2) (<LINK REF="CMP-044.17" TYPE="ANALYSIS">Analysis 44.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Miscellaneous skin infections</HEADING>
<P>At two years, there was a significant increase in the rate of miscellaneous skin infections in the etanercept monotherapy group compared with the DMARD alone group (RR 19.1; 95% CI 1.2 to 310.5) (<LINK REF="CMP-044.19" TYPE="ANALYSIS">Analysis 44.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Mouth ulcers</HEADING>
<P>People taking etanercept 10 mg or 25 mg were less likely to develop mouth ulcers than DMARD at 12 months (RR 0.5; 95% CI 0.2 to 0.8 and RR 0.4; 95% CI 0.2 to 0.7, respectively) (<LINK REF="CMP-043.13" TYPE="ANALYSIS">Analysis 43.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Nausea</HEADING>
<P>People taking etanercept 10 mg or 25 mg were less likely to experience nausea than those taking DMARD at 12 months (RR 0.5; 95% CI 0.3 to 0.7 and RR 0.6; 95% CI 0.4 to 0.9, respectively) (<LINK REF="CMP-043.14" TYPE="ANALYSIS">Analysis 43.14</LINK>). This finding was also apparent at two years; people taking etanercept were significantly less likely to experience nausea than those taking DMARD (RR 0.3; 95% CI 0.2 to 0.5) (<LINK REF="CMP-044.20" TYPE="ANALYSIS">Analysis 44.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Pharyngitis or laryngitis</HEADING>
<P>People taking etanercept 25 mg were more likely to experience pharyngitis or laryngitis compared with those taking DMARD at two years (RR 3.9; 95% CI 1.2 to 12.3) (<LINK REF="CMP-044.23" TYPE="ANALYSIS">Analysis 44.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rash</HEADING>
<P>People taking etanercept 25 mg were more likely to experience rash compared with those taking DMARD at six months (RR 2.4; 95% CI 1.1 to 5.6) (<LINK REF="CMP-042.29" TYPE="ANALYSIS">Analysis 42.29</LINK>) and less likely at 12 months (RR 0.5; 95% CI 0.3 to 0.8) (<LINK REF="CMP-043.15" TYPE="ANALYSIS">Analysis 43.15</LINK>). However, there was no evidence of a significant difference in rash rates between those taking etanercept 10 mg and DMARD at 12 months (the P value was just outside the 0.06 level of significance). At two years' follow-up, there was no significant difference between groups (etanercept vs. DMARD) (<LINK REF="CMP-044.24" TYPE="ANALYSIS">Analysis 44.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Sinusitis</HEADING>
<P>There was no significant difference between people taking etanercept 10 mg and people taking DMARD alone at 12 months (<LINK REF="CMP-043.17" TYPE="ANALYSIS">Analysis 43.17</LINK>). However, people taking etanercept 25 mg were less likely to report sinusitis than those taking DMARD at 12 months (RR 0.6; 95% CI 0.4 to 1.0) (<LINK REF="CMP-043.17" TYPE="ANALYSIS">Analysis 43.17</LINK>). The difference was not observed at two years between groups (<LINK REF="CMP-044.27" TYPE="ANALYSIS">Analysis 44.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Upper respiratory tract infection (URTI)</HEADING>
<P>Fewer people taking etanercept 10 mg reported URTI when compared with people taking DMARD at 12 months (RR 0.7; 95% CI 0.5 to 0.9) (<LINK REF="CMP-043.19" TYPE="ANALYSIS">Analysis 43.19</LINK>). However, there was no significant difference in URTI rates between the etanercept 25 mg and DMARD groups at 12 months and two years (<LINK REF="CMP-043.19" TYPE="ANALYSIS">Analysis 43.19</LINK>; <LINK REF="CMP-044.28" TYPE="ANALYSIS">Analysis 44.28</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Vomiting</HEADING>
<P>People taking etanercept were less likely to experience vomiting at two years than those taking DMARD (RR 0.3 95% CI 0.2 to 0.6) (<LINK REF="CMP-044.29" TYPE="ANALYSIS">Analysis 44.29</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Worsening of rheumatoid arthritis</HEADING>
<P>In one study, people in the etanercept monotherapy group were more likely to experience worsening of the RA at two years than those taking DMARD alone (RR 8.3; 95% CI 2.1 to 33.0) (<LINK REF="CMP-044.25" TYPE="ANALYSIS">Analysis 44.25</LINK>).</P>
<P>There was no evidence of statistically significant differences in the rates of all other adverse effects in the included studies at various different time points:<BR/>
</P>
<UL>
<LI>total at six months (<LINK REF="CMP-042.01" TYPE="ANALYSIS">Analysis 42.1</LINK>);</LI>
<LI>alopecia at six months (<LINK REF="CMP-042.02" TYPE="ANALYSIS">Analysis 42.2</LINK>);</LI>
<LI>accidental injury at six months and two years (<LINK REF="CMP-042.03" TYPE="ANALYSIS">Analysis 42.3</LINK>; <LINK REF="CMP-044.04" TYPE="ANALYSIS">Analysis 44.4</LINK>);</LI>
<LI>asthenia at six months, 12 months and two years (<LINK REF="CMP-042.04" TYPE="ANALYSIS">Analysis 42.4</LINK>; <LINK REF="CMP-043.03" TYPE="ANALYSIS">Analysis 43.3</LINK>;; <LINK REF="CMP-044.03" TYPE="ANALYSIS">Analysis 44.3</LINK>);</LI>
<LI>arthralgia at six months and two years (<LINK REF="CMP-042.05" TYPE="ANALYSIS">Analysis 42.5</LINK>; <LINK REF="CMP-044.05" TYPE="ANALYSIS">Analysis 44.5</LINK>);</LI>
<LI>back pain at 12 months and two years (<LINK REF="CMP-043.04" TYPE="ANALYSIS">Analysis 43.4</LINK>; <LINK REF="CMP-044.06" TYPE="ANALYSIS">Analysis 44.6</LINK>);</LI>
<LI>bronchitis at six months and two years (<LINK REF="CMP-042.06" TYPE="ANALYSIS">Analysis 42.6</LINK>; <LINK REF="CMP-044.07" TYPE="ANALYSIS">Analysis 44.7</LINK>);</LI>
<LI>chest discomfort at six months (<LINK REF="CMP-042.07" TYPE="ANALYSIS">Analysis 42.7</LINK>);</LI>
<LI>diarrhoea at 12 months and two years (<LINK REF="CMP-043.05" TYPE="ANALYSIS">Analysis 43.5</LINK>; <LINK REF="CMP-044.08" TYPE="ANALYSIS">Analysis 44.8</LINK>);</LI>
<LI>dyspepsia at six months, 12 months and two years (<LINK REF="CMP-042.08" TYPE="ANALYSIS">Analysis 42.8</LINK>; <LINK REF="CMP-043.07" TYPE="ANALYSIS">Analysis 43.7</LINK>; <LINK REF="CMP-044.09" TYPE="ANALYSIS">Analysis 44.9</LINK>);</LI>
<LI>dizziness at six months (<LINK REF="CMP-042.09" TYPE="ANALYSIS">Analysis 42.9</LINK>);</LI>
<LI>ecchymosis at 12 months (<LINK REF="CMP-043.08" TYPE="ANALYSIS">Analysis 43.8</LINK>);</LI>
<LI>enlargement of lymph nodes at six months (<LINK REF="CMP-042.12" TYPE="ANALYSIS">Analysis 42.12</LINK>);</LI>
<LI>fever at six months (<LINK REF="CMP-042.13" TYPE="ANALYSIS">Analysis 42.13</LINK>);</LI>
<LI>gastrointestinal (GI) symptoms/abdominal pain at six months, 12 months and two years (<LINK REF="CMP-042.14" TYPE="ANALYSIS">Analysis 42.14</LINK>; <LINK REF="CMP-043.02" TYPE="ANALYSIS">Analysis 43.2</LINK>; <LINK REF="CMP-044.02" TYPE="ANALYSIS">Analysis 44.2</LINK>);</LI>
<LI>gingival/dental infection at two years (<LINK REF="CMP-044.11" TYPE="ANALYSIS">Analysis 44.11</LINK>);</LI>
<LI>headache at six months, 12 months and two years (<LINK REF="CMP-042.15" TYPE="ANALYSIS">Analysis 42.15</LINK>; <LINK REF="CMP-043.09" TYPE="ANALYSIS">Analysis 43.9</LINK>; <LINK REF="CMP-044.12" TYPE="ANALYSIS">Analysis 44.12</LINK>);</LI>
<LI>increased blood pressure at six months (<LINK REF="CMP-042.16" TYPE="ANALYSIS">Analysis 42.16</LINK>);</LI>
<LI>increase in cough at six months and two years (<LINK REF="CMP-042.17" TYPE="ANALYSIS">Analysis 42.17</LINK>; <LINK REF="CMP-044.14" TYPE="ANALYSIS">Analysis 44.14</LINK>);</LI>
<LI>infection at another site/pharyngitis or laryngitis, flu syndrome or miscellaneous skin infections at six months (<LINK REF="CMP-042.18" TYPE="ANALYSIS">Analysis 42.18</LINK>);</LI>
<LI>influenza-like syndrome at 12 months (<LINK REF="CMP-043.10" TYPE="ANALYSIS">Analysis 43.10</LINK>);</LI>
<LI>injection site haemorrhage at six months, 12 months and two years (<LINK REF="CMP-042.19" TYPE="ANALYSIS">Analysis 42.19</LINK>; <LINK REF="CMP-043.11" TYPE="ANALYSIS">Analysis 43.11</LINK>; <LINK REF="CMP-044.16" TYPE="ANALYSIS">Analysis 44.16</LINK>);</LI>
<LI>insomnia at six months (<LINK REF="CMP-042.21" TYPE="ANALYSIS">Analysis 42.21</LINK>);</LI>
<LI>leukopenia at six months (<LINK REF="CMP-042.22" TYPE="ANALYSIS">Analysis 42.22</LINK>);</LI>
<LI>malignancy at two years (<LINK REF="CMP-044.18" TYPE="ANALYSIS">Analysis 44.18</LINK>);</LI>
<LI>nausea at six months (<LINK REF="CMP-042.23" TYPE="ANALYSIS">Analysis 42.23</LINK>);</LI>
<LI>oedema at six months (<LINK REF="CMP-042.10" TYPE="ANALYSIS">Analysis 42.10</LINK>);</LI>
<LI>pain at six months and two years (<LINK REF="CMP-042.24" TYPE="ANALYSIS">Analysis 42.24</LINK>; <LINK REF="CMP-044.21" TYPE="ANALYSIS">Analysis 44.21</LINK>);</LI>
<LI>paraesthesia at six months (<LINK REF="CMP-042.25" TYPE="ANALYSIS">Analysis 42.25</LINK>);</LI>
<LI>pharyngitis (non-infectious) at six months (<LINK REF="CMP-042.26" TYPE="ANALYSIS">Analysis 42.26</LINK>);</LI>
<LI>pruritus at six months and two years (<LINK REF="CMP-042.27" TYPE="ANALYSIS">Analysis 42.27</LINK>; <LINK REF="CMP-044.22" TYPE="ANALYSIS">Analysis 44.22</LINK>);</LI>
<LI>rhinitis at six and 12 months (<LINK REF="CMP-042.28" TYPE="ANALYSIS">Analysis 42.28</LINK>; <LINK REF="CMP-043.16" TYPE="ANALYSIS">Analysis 43.16</LINK>);</LI>
<LI>serious infections at two years (<LINK REF="CMP-044.26" TYPE="ANALYSIS">Analysis 44.26</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>);</LI>
<LI>skin infection at 12 months (<LINK REF="CMP-043.18" TYPE="ANALYSIS">Analysis 43.18</LINK>);</LI>
<LI>URTI at six months (<LINK REF="CMP-042.31" TYPE="ANALYSIS">Analysis 42.31</LINK>);</LI>
<LI>vision disorder at six months (<LINK REF="CMP-042.32" TYPE="ANALYSIS">Analysis 42.32</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept plus DMARD versus etanercept</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Headache</HEADING>
<P>At six months, more people reported headache in the etanercept plus DMARD group than in the etanercept group (RR 3.1; 95% CI 1.2 to 8.1) (<LINK REF="CMP-045.08" TYPE="ANALYSIS">Analysis 45.8</LINK>). However, this difference was not observed at two years (<LINK REF="CMP-046.12" TYPE="ANALYSIS">Analysis 46.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Increased cough</HEADING>
<P>At six months, there were no differences observed between the group receiving etanercept plus DMARD and the etanercept alone (<LINK REF="CMP-045.11" TYPE="ANALYSIS">Analysis 45.11</LINK>). However, at two years people in the etanercept plus DMARD group were more likely to have an increase in cough than people in the etanercept alone group (RR 1.7; 95% CI 1.1 to 2.6) (<LINK REF="CMP-046.14" TYPE="ANALYSIS">Analysis 46.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Injection site reaction</HEADING>
<P>At the end of six months' and two years' follow-up, significantly fewer people receiving etanercept plus DMARD had injection site reactions when compared with people receiving etanercept alone (RR 0.6; 95% CI 0.43 to 0.8 and RR 0.6; 95% CI 0.4 to 0.8) (<LINK REF="CMP-045.13" TYPE="ANALYSIS">Analysis 45.13</LINK>; <LINK REF="CMP-046.17" TYPE="ANALYSIS">Analysis 46.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Nausea</HEADING>
<P>At six months and two years, significantly more people receiving etanercept plus MTX reported nausea when compared with people receiving etanercept alone (RR 4.1; 95% CI 1.2 to 14.0 and RR 2.4; 95% CI 1.7 to 3.4) (<LINK REF="CMP-045.19" TYPE="ANALYSIS">Analysis 45.19;</LINK> <LINK REF="CMP-046.20" TYPE="ANALYSIS">Analysis 46.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Pharyngitis or laryngitis (infectious)</HEADING>
<P>At six months, there was no statistically significant difference between etanercept plus DMARD and the etanercept alone groups in the rates of pharyngitis or laryngitis (<LINK REF="CMP-045.23" TYPE="ANALYSIS">Analysis 45.23</LINK>) but, at two years, significantly fewer people having etanercept plus DMARD reported pharyngitis or laryngitis than those having etanercept monotherapy (RR 0.4; 95% CI 0.2 to 0.8) (<LINK REF="CMP-046.23" TYPE="ANALYSIS">Analysis 46.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Sinusitis</HEADING>
<P>At two years, there were significantly fewer cases of sinusitis in people having etanercept plus DMARD compared with those having etanercept monotherapy (RR 0.3; 95% CI 0.1 to 0.9) (<LINK REF="CMP-046.27" TYPE="ANALYSIS">Analysis 46.27</LINK>).</P>
<P>There was no evidence of statistically significant differences in the rates of all other adverse effects:</P>
<UL>
<LI>total at six months and two years (<LINK REF="CMP-045.01" TYPE="ANALYSIS">Analysis 45.1</LINK>; <LINK REF="CMP-046.01" TYPE="ANALYSIS">Analysis 46.1</LINK>);</LI>
<LI>arthralgia at two years (<LINK REF="CMP-046.04" TYPE="ANALYSIS">Analysis 46.4</LINK>);</LI>
<LI>asthenia at six months and two years (<LINK REF="CMP-045.02" TYPE="ANALYSIS">Analysis 45.2</LINK>; <LINK REF="CMP-046.05" TYPE="ANALYSIS">Analysis 46.5</LINK>);</LI>
<LI>back pain at two years (<LINK REF="CMP-046.06" TYPE="ANALYSIS">Analysis 46.6</LINK>);</LI>
<LI>blood and lymphatic system disorders/leukopenia at six months (<LINK REF="CMP-045.03" TYPE="ANALYSIS">Analysis 45.3</LINK>);</LI>
<LI>dyspepsia at two years (<LINK REF="CMP-046.09" TYPE="ANALYSIS">Analysis 46.9</LINK>);</LI>
<LI>diarrhoea at two years (<LINK REF="CMP-046.08" TYPE="ANALYSIS">Analysis 46.8</LINK>);</LI>
<LI>dizziness at six months (<LINK REF="CMP-045.04" TYPE="ANALYSIS">Analysis 45.4</LINK>);</LI>
<LI>fever at six months (<LINK REF="CMP-045.05" TYPE="ANALYSIS">Analysis 45.5</LINK>);</LI>
<LI>flu syndrome at six months and two years (<LINK REF="CMP-045.06" TYPE="ANALYSIS">Analysis 45.6</LINK>; <LINK REF="CMP-046.10" TYPE="ANALYSIS">Analysis 46.10</LINK>);</LI>
<LI>GI disorders/abdominal pain at six months and two years (<LINK REF="CMP-045.07" TYPE="ANALYSIS">Analysis 45.7</LINK>; <LINK REF="CMP-046.02" TYPE="ANALYSIS">Analysis 46.2</LINK>);</LI>
<LI>gingival/dental infection at two years (<LINK REF="CMP-046.11" TYPE="ANALYSIS">Analysis 46.11</LINK>);</LI>
<LI>hepatobiliary disorders at six months (<LINK REF="CMP-045.09" TYPE="ANALYSIS">Analysis 45.9</LINK>);</LI>
<LI>hypertension at six months and two years (<LINK REF="CMP-045.10" TYPE="ANALYSIS">Analysis 45.10</LINK>; <LINK REF="CMP-046.13" TYPE="ANALYSIS">Analysis 46.13</LINK>);</LI>
<LI>infections (total) at six months and two years (<LINK REF="CMP-045.12" TYPE="ANALYSIS">Analysis 45.12</LINK>; <LINK REF="CMP-046.15" TYPE="ANALYSIS">Analysis 46.15</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>);</LI>
<LI>injection site haemorrhage at two years (<LINK REF="CMP-046.16" TYPE="ANALYSIS">Analysis 46.16</LINK>);</LI>
<LI>injury, poisoning and procedural complications/accidental injury at six months and two years (<LINK REF="CMP-045.14" TYPE="ANALYSIS">Analysis 45.14</LINK>; <LINK REF="CMP-046.03" TYPE="ANALYSIS">Analysis 46.3</LINK>);</LI>
<LI>malignancy at six months and two years (<LINK REF="CMP-045.15" TYPE="ANALYSIS">Analysis 45.15</LINK>; <LINK REF="CMP-046.18" TYPE="ANALYSIS">Analysis 46.18</LINK>);</LI>
<LI>metabolism and nutrition disorders at six months (<LINK REF="CMP-045.16" TYPE="ANALYSIS">Analysis 45.16</LINK>);</LI>
<LI>miscellaneous skin infections at six months and two years (<LINK REF="CMP-045.17" TYPE="ANALYSIS">Analysis 45.17</LINK>; <LINK REF="CMP-046.19" TYPE="ANALYSIS">Analysis 46.19</LINK>);</LI>
<LI>musculoskeletal and connective tissue disorders/arthralgia at six months (<LINK REF="CMP-045.18" TYPE="ANALYSIS">Analysis 45.18</LINK>);</LI>
<LI>nervous system disorders/paraesthesia at six months and two years (<LINK REF="CMP-045.20" TYPE="ANALYSIS">Analysis 45.20</LINK>; <LINK REF="CMP-046.22" TYPE="ANALYSIS">Analysis 46.22</LINK>);</LI>
<LI>pain at six months and two years (<LINK REF="CMP-045.21" TYPE="ANALYSIS">Analysis 45.21</LINK>; <LINK REF="CMP-046.21" TYPE="ANALYSIS">Analysis 46.21</LINK>);</LI>
<LI>pharyngitis (non-infectious) at six months (<LINK REF="CMP-045.22" TYPE="ANALYSIS">Analysis 45.22</LINK>);</LI>
<LI>reproductive system and breast disorders at six months (<LINK REF="CMP-045.24" TYPE="ANALYSIS">Analysis 45.24</LINK>);</LI>
<LI>respiratory, thoracic and mediastinal disorders/bronchitis at six months and two years (<LINK REF="CMP-045.25" TYPE="ANALYSIS">Analysis 45.25</LINK>; <LINK REF="CMP-046.07" TYPE="ANALYSIS">Analysis 46.7</LINK>);</LI>
<LI>rhinitis at six months (<LINK REF="CMP-045.26" TYPE="ANALYSIS">Analysis 45.26</LINK>);</LI>
<LI>serious adverse events (total) at six months (<LINK REF="CMP-045.28" TYPE="ANALYSIS">Analysis 45.28</LINK>);</LI>
<LI>serious infections at two years (<LINK REF="CMP-046.26" TYPE="ANALYSIS">Analysis 46.26</LINK>);</LI>
<LI>skin and subcutaneous tissue disorders/rash/pruritus at six months and two years (<LINK REF="CMP-045.27" TYPE="ANALYSIS">Analysis 45.27</LINK>; <LINK REF="CMP-046.24" TYPE="ANALYSIS">Analysis 46.24</LINK>);</LI>
<LI>URTI at six months and two years (<LINK REF="CMP-045.29" TYPE="ANALYSIS">Analysis 45.29</LINK>; <LINK REF="CMP-046.28" TYPE="ANALYSIS">Analysis 46.28</LINK>);</LI>
<LI>vomiting at two years (<LINK REF="CMP-046.29" TYPE="ANALYSIS">Analysis 46.29</LINK>);</LI>
<LI>worsening of RA at two years (<LINK REF="CMP-046.25" TYPE="ANALYSIS">Analysis 46.25</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Injection site reaction</HEADING>
<P>A greater proportion of people receiving either etanercept 10 or 25 mg developed injection site reactions at six months than those taking placebo (RR 3.5; 95% CI 1.8 to 6.6 and RR 3.9 95% CI 2.1 to 7.3) (<LINK REF="CMP-047.03" TYPE="ANALYSIS">Analysis 47.3</LINK>). About 43% and 49%, respectively, of those taking etanercept 10 and 25 mg experienced reactions compared with 13% of those taking placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Upper respiratory tract infection</HEADING>
<P>People taking etanercept 25 mg were more likely to develop URTI in comparison to those taking placebo at six months (RR 2.1; 95% CI 1.1 to 3.7) (<LINK REF="CMP-047.06" TYPE="ANALYSIS">Analysis 47.6</LINK>). However, there was no evidence of a difference in URTI rates between those taking etanercept 10 mg and control (P value just outside the 0.05 level of significance).</P>
<P>There was no statistically significant differences in the rates of all other adverse effects in the included studies:<BR/>
</P>
<UL>
<LI>diarrhoea at six months (<LINK REF="CMP-047.01" TYPE="ANALYSIS">Analysis 47.1</LINK>);</LI>
<LI>headache at six months (<LINK REF="CMP-047.02" TYPE="ANALYSIS">Analysis 47.2</LINK>);</LI>
<LI>rhinitis at six months (<LINK REF="CMP-047.04" TYPE="ANALYSIS">Analysis 47.4</LINK>);</LI>
<LI>sinusitis at six months (<LINK REF="CMP-047.05" TYPE="ANALYSIS">Analysis 47.5</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">D. Subgroup analyses</HEADING>
<P>Results on the subgroup analyses are summarised in <LINK REF="SOF-04" TYPE="SOF">Summary of results table 4</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus DMARD</HEADING>
<P>There was a greater proportion of people significantly achieving an ACR20 and ACR50 response in people who previously had an inadequate response with MTX compared with people who had never been treated with a DMARD or had failed treatment with DMARDs other than MTX (<LINK REF="CMP-048.01" TYPE="ANALYSIS">Analysis 48.1</LINK>; <LINK REF="CMP-048.02" TYPE="ANALYSIS">Analysis 48.2</LINK>). However, a greater proportion of DMARD-naïve people achieved an ACR70 response compared with the groups who have not benefited from DMARDs alone (<LINK REF="CMP-048.03" TYPE="ANALYSIS">Analysis 48.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept versus DMARD</HEADING>
<P>The indirect comparisons showed no difference across groups (<LINK REF="CMP-049.01" TYPE="ANALYSIS">Analysis 49.1</LINK>; <LINK REF="CMP-049.02" TYPE="ANALYSIS">Analysis 49.2</LINK>; <LINK REF="CMP-049.03" TYPE="ANALYSIS">Analysis 49.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept plus DMARD versus etanercept</HEADING>
<P>The indirect comparisons showed no difference across groups (<LINK REF="CMP-050.01" TYPE="ANALYSIS">Analysis 50.1</LINK>; <LINK REF="CMP-050.02" TYPE="ANALYSIS">Analysis 50.2</LINK>; <LINK REF="CMP-050.03" TYPE="ANALYSIS">Analysis 50.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-03-21 09:23:30 -0400" MODIFIED_BY="[Empty name]">
<P>RA is a common systemic inflammatory arthritis associated with significant morbidity, mortality, joint deformity and impaired quality of life. DMARDS have been shown to reduce disease activity, slow down joint damage and improve quality of life. While DMARDS are the mainstay of treatment of RA, many people do not respond to or are unable to tolerate traditional DMARDS. Biological drugs have been introduced and approved since 1998 for the treatment of RA. Etanercept is one biological agent (a soluble TNF alpha receptor) that inhibits the action of TNF. The benefits of six biologics for the treatment of RA and the adverse effects of nine biologics used in various rheumatic conditions have been compared in two separate Cochrane network meta-analyses (<LINK REF="REF-Singh-2009" TYPE="REFERENCE">Singh 2009</LINK>; <LINK REF="REF-Singh-2011" TYPE="REFERENCE">Singh 2011</LINK>).</P>
<SUMMARY_OF_RESULTS MODIFIED="2013-03-21 09:23:30 -0400" MODIFIED_BY="[Empty name]">
<P>The ACR20, ACR50 and ACR70 response rates were improved with etanercept plus DMARD at all follow-up time points (6 months, one year, two years and three years). These findings were consistent when etanercept was directly compared with placebo. However, there was mostly no evidence of significant differences in ACR response rates when etanercept monotherapy was compared with DMARD alone at six months, 12 months, two years and three years. The exceptions to this finding may have been due to chance as no patterns could be determined. For example, people receiving etanercept 25 mg had improved response to ACR70 at six months and improved response to ACR50 at two years when compared with people receiving DMARD and, by contrast, one trial reported that etanercept at the lower dosage of 10 mg had lower response rates to ACR50 at 12 months compared with DMARD. Results were consistent for the comparison of etanercept plus DMARD versus etanercept alone at all time points (as well as DMARD alone) in the improvement of ACR response rates. The superior efficacy of etanercept plus DMARD treatment over monotherapy has been highlighted by others (<LINK REF="REF-Furst-2007" TYPE="REFERENCE">Furst 2007</LINK>).</P>
<P>Remission rates (as defined by DAS &lt; 1.6 and DAS28 &lt; 2.6) and joint damage (as assessed by radiographic scores) were other outcomes that provided an assessment of response to treatment. These outcomes were measured in five trials (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>; <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>; <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>). When etanercept monotherapy was compared with DMARD alone, there was mostly no evidence of a difference in remission rates (as defined by DAS &lt; 1.6 and DAS28 &lt; 2.6) at 12 months, two years and three years although at two years, people receiving etanercept were more likely to be in remission (DAS &lt; 1.6) than those receiving DMARD (not confirmed by results from the DAS28 definition of remission at this time point).</P>
<P>We found no statistically significant differences in the radiographic score in people with inadequate response to DMARDs. However, when all participants were combined, there was some evidence of an improvement in some of the radiographic scores for people receiving etanercept when compared with those receiving DMARD. At 12 months and two years, people receiving etanercept had smaller changes from baseline in the TSS and ES scores and at one year they had a smaller change in the ES score (with a trend of P value = 0.06 for the TSS score) when compared with those receiving DMARD. There were also more participants in the etanercept group that had no progression of their joint damage (as measured by TSS &#8804; 0.5 when compared with those in the DMARD group at one and three years', but not at two years' follow-up. There was no evidence of any differences in the JSNS at any time period between groups. The effects of etanercept plus DMARD treatment on remission rates and radiographic scores paralleled the improvements in ACR response rates when compared with monotherapy with either etanercept or DMARD. People receiving etanercept plus DMARD were significantly more likely to experience remission at 12 months, two years and three years when compared with those receiving DMARD or etanercept alone. There was also a significantly smaller change from baseline in radiographic scores at 12 months, two years and three years for people taking combination treatment compared with DMARD and etanercept alone (although at three years, there was no evidence of a difference between etanercept plus DMARD and etanercept alone). For many people taking etanercept plus DMARD, radiographic damage appeared to be arrested, as evidenced by the negative mean scores in the change from baseline, particularly for TSS and ES. This was further confirmed by the publication of cumulative probability plots published by one of the TEMPO authors (<LINK REF="REF-van-der-Heijde-2005b" TYPE="REFERENCE">van der Heijde 2005b</LINK>). The MD in TSS score and the absolute reduction observed at 12 months in radiographic progression were -2.12% and 0.49%, respectively. To transform the radiographic findings in terms of disability, we have used a previously published formula (<LINK REF="REF-Smolen-2010b" TYPE="REFERENCE">Smolen 2010b</LINK>; <LINK REF="REF-Tugwell-2011" TYPE="REFERENCE">Tugwell 2011</LINK>). In our review, the radiographic score expressed as estimate of irreversible physical disability over 10 years is 0.45 out of 3.0. That is, etanercept would prevent an increase in disability of 0.45 irreversible HAQ units (15%), which surpasses the minimal clinically important difference of 0.22 HAQ units.</P>
<P>Quality of life was measured by scores on MOS SF-36, HAQ, EQ-5D VAS and ASHI and people were also asked to indicate their satisfaction with treatment. Quality of life of people taking either etanercept alone or etanercept plus DMARD was mostly significantly improved when compared with DMARD alone at six months, 12 months and two years. People taking etanercept 25 mg had higher scores on the MOS mental health and energy/vitality domains at six months compared with placebo. When etanercept monotherapy was compared with DMARD alone, there was mostly no evidence of a benefit for etanercept in perceived quality of life, although at one year, people taking etanercept were more satisfied with their treatment than those taking DMARD. A small improvement of three percentage points in the HAQ was also found for those taking etanercept at two years but this was not confirmed when HAQ was measured as an absolute score after treatment. There was no evidence of a difference in the HAQ at other time points, SF-36, ASHI and EQ-5D VAS between etanercept and DMARD monotherapy groups. Treatment with etanercept plus DMARD appeared to mostly improve quality of life when compared with either DMARD or etanercept alone. Those taking etanercept plus DMARD had higher scores on the HAQ at one and two years and higher scores on the EQ-5D VAS at one year than those taking DMARD or etanercept alone. Satisfaction rates with etanercept plus DMARD treatment were also improved at one year when compared with DMARD monotherapy but not when compared with etanercept monotherapy. Overall, it appears as though combination therapy is associated with less disability, as perceived by people through their HAQ assessments than either monotherapy with etanercept or MTX.</P>
<P>Withdrawals before the end of the study were measured in four ways: total withdrawals, withdrawal because of lack of efficacy, withdrawal because of adverse events and deaths before the completion of the trial. Withdrawals were measured at six months, one year, two years and three years cumulatively to enable a comparison of the pattern of withdrawals over time. People taking etanercept plus DMARD were less likely to withdraw from the study overall and also less likely to withdraw from the study because of lack of efficacy of the treatment at all time periods when compared with those taking DMARD alone. However, there was mostly no evidence of a difference in the withdrawal rates because of adverse events between groups except at three years when people taking etanercept plus DMARD were less likely to have withdrawn from the study because of adverse events compared with those taking DMARD alone. There was mostly no evidence of a difference in withdrawals when etanercept alone was compared with DMARD alone. At two follow-up times, people on etanercept were less likely to have withdrawn: at two years, significantly fewer people taking etanercept 25 mg had withdrawn overall and at 12 months, significantly fewer people taking etanercept 25 mg had withdrawn because of adverse events than people taking DMARD. At all other time points, there was no evidence of a difference in the withdrawal rates between groups taking either etanercept or DMARD monotherapy. Participants were also less likely to withdraw at any time of follow-up, either overall or because of lack of efficacy, when taking etanercept plus DMARD treatment when compared with etanercept monotherapy, confirming the clinical efficacy seen with this treatment. By contrast, withdrawal because of adverse events did not differ between the etanercept plus DMARD group or etanercept monotherapy group at any time point. There was also no evidence of a difference in the death rates between groups (whether etanercept plus DMARD was compared with DMARD or etanercept monotherapy or etanercept was compared with DMARD or with control).</P>
<P>Adverse events were reported only at the end of the included studies. However, in the <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> study, adverse events were reported at the end of the first two years of the three-year trial because more detailed information on effects was available at this follow-up time. There was a greater risk of injection site reactions when etanercept alone was compared with placebo at six months, when etanercept plus DMARD treatment was compared with DMARD alone and when etanercept monotherapy was compared with DMARD alone at six months, 12 months and two years. Injection site reactions were also more likely for people taking etanercept monotherapy compared with those taking etanercept plus DMARD. The significantly greater likelihood of this particular adverse effect in people taking etanercept (compared with either placebo or DMARD) may have affected the blinding of the studies as participants may have become aware of the nature of their treatment. People taking etanercept 25 mg were more likely to report URTI at six months than people taking placebo. Those people taking etanercept monotherapy were less likely to report nausea compared with DMARD alone or etanercept plus DMARD. When etanercept monotherapy was compared with placebo or etanercept plus DMARD, there was no evidence of a difference in the rates of other adverse events at any time period. When etanercept monotherapy was compared with DMARD, a number of adverse events were significantly more likely with DMARD alone. At six months, there was a higher proportion of people with elevation in ALT in the control group. At 12 months, the rate of URTI and dizziness were more likely with DMARD compared with etanercept 10 mg (but not etanercept 25 mg) and rates of sinusitis, rash, and alopecia were significantly more likely with DMARD compared with etanercept 25 mg (but not etanercept 10 mg). At 12 months, people taking DMARD were also significantly more likely to experience mouth ulcers and at both 12 months and two years, people taking DMARD were more likely to experience nausea when compared with those taking either dose of etanercept (25 mg or 10 mg). At two years, vomiting and hypertension were more common among people taking DMARD in comparison to those taking etanercept. Also at two years, there were more reports of worsening RA in the etanercept monotherapy group than in the DMARD group.<BR/>
<BR/>The participant groups in the trials differed in the previous response or exposure to DMARDs. Three of the studies recruited participants with 'early' RA and no prior treatment; in the <LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK> and <LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK> trials, participants had been diagnosed for less than three years with no previous DMARD treatment and in the <LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK> trial participants had RA for less than six months with no previous DMARD treatment. In the <LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>, <LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>, <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>, and <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>, trials, participants had RA for more than five years and were required to have had no response to previous MTX treatment. In the <LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK> and <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> trials, the duration of RA varied and participants were required to have no response to previous DMARDs (including MTX). ACR20 and ACR50 results from the trials where participants were inadequate responders to MTX appear significantly different between etanercept plus DMARD and DMARD even at the short time period of six months in comparison to a more limited response in the trials where participants were DMARD-naive or have had an inadequate response to DMARDs. However, for ACR70 the difference was observed from trials where participants were DMARD-naive. For the other comparisons (etanercept monotherapy versus DMARD alone or etanercept plus DMARD versus etanercept monotherapy) we did not observed any differences. In contrast, ACR70 and remission rates (evaluated by DAS &lt; 2.6) were higher for people receiving etanercept plus DMARD who had an inadequate response to DMARDs compared with people who maintain DMARD monotherapy despite inadequate response.<BR/>
</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-03-20 14:35:38 -0400" MODIFIED_BY="[Empty name]">
<P>This review has assessed the effects of etanercept in RA through the evaluation of results from a wide variety of outcomes measuring both benefits and harms. There has been much discussion on the identification of appropriate outcomes for assessment of interventions in rheumatology. OMERACT (Outcome Measures for Arthritis Clinical Trials) is an international initiative with the aim of determining the applicability of various outcome measures (<LINK REF="REF-Molenaar-2000" TYPE="REFERENCE">Molenaar 2000</LINK>), and these are specified in 'Types of Outcome Measures' in the review. Benefit includes both clinical measures and patient and physician assessment of pain, disability and function. There is strong evidence that etanercept is more efficacious than placebo and that combination etanercept plus DMARD treatment is more efficacious than DMARD or etanercept monotherapy in people with RA. Etanercept monotherapy does not appear to be more efficacious than DMARD alone in terms of ACR response, rate of remission or quality of life, but there is good evidence that etanercept alone causes less joint damage as assessed by the TSS and the ES. Withdrawal from the study before completion can be due to a variety of reasons and may, to some extent, reflect the acceptability of treatment. There is good evidence that etanercept is associated with less overall withdrawal and less withdrawal because of lack of efficacy than control, either when compared with placebo or when etanercept plus DMARD treatment is compared with DMARD. These benefits were not found when etanercept alone was compared with DMARD alone, suggesting that both of these monotherapies have similar acceptability and benefit (confirmed by efficacy outcomes previously discussed). However, etanercept plus DMARD treatment is associated with fewer withdrawals when compared with etanercept monotherapy, either overall or as a result of lack of efficacy.</P>
<P>Although there appear to be clear benefits of etanercept therapy in the studies included in this review, it is important to consider results in the light of characteristics of participants with RA who enter randomised studies. Some authors have suggested that comparable benefit is hardly ever achieved in clinical practice (<LINK REF="REF-Kievit-2007" TYPE="REFERENCE">Kievit 2007</LINK>). Participants often differ from patients in clinical practice in various ways: participant selection, a washout period before inclusion that artificially increases the disease activity, differences in doses, co-medication, occurrence of co-morbidity and adherence. A study that compared the efficacy of anti-TNF drugs in RA from RCTs with their efficacy in a large Dutch cohort of people with RA found that the effects of anti-TNF treatment were much smaller in the large Dutch cohort of patients than in those observed in the RCTs (<LINK REF="REF-Kievit-2007" TYPE="REFERENCE">Kievit 2007</LINK>). The authors also found that response rates were up to 44% higher in people with RA in clinical practice who were eligible for RCTs compared with those in clinical practice who were ineligible. The authors concluded that selection towards high disease activity and the continued use of co-medication in RCTs are probable explanations for the difference in effects of anti-TNF in clinical practice and RCTs. These findings limit the applicability of the results of this review to people with RA in the wider community.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-03-14 15:44:40 -0400" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>, <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> and <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK> show the overall quality of evidence. Evidence quality ranged from moderate to high. Regarding individual trials quality assessment, only two studies were rated with high risk of bias in one item (blinding) and one study included relatively few participants and few events providing wider CIs (<LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>). Also, significant heterogeneity was noted in 20 out of the 59 analyses ranging from 38% to 98%.</P>
<P>A funnel plot was not created due to the limited number of studies included in this review. Nonetheless, we concluded that the evidence provided in this review for ACR50 response rates is unlikely to have an important impact on our confidence of the estimate. Further studies are needed to assess long-term safety.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-03-14 15:45:22 -0400" MODIFIED_BY="[Empty name]">
<P>Our methods and reporting are based on the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> recommendations (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We have followed a pre-established and published protocol. All analyses were specified a priori. We have made every attempt to minimise errors. Nonetheless, we are constrained by the information reported in the included studies. Also, most studies are designed to measure benefit and analyses on harms is somewhat limited. Non-statistically significant results in safety outcomes may be due to inadequate power to detect differences.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-03-14 15:50:58 -0400" MODIFIED_BY="[Empty name]">
<P>Our benefit findings are similar to those reported in the 2009 Cochrane network meta-analysis evaluating the efficacy of biologics in RA (<LINK REF="REF-Singh-2009" TYPE="REFERENCE">Singh 2009</LINK>). However, in <LINK REF="REF-Singh-2009" TYPE="REFERENCE">Singh 2009</LINK>, the results reported include data from six of the nine studies included in this review; therefore, effect estimates are not identical. In addition, our main findings (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>) are based on subgroup analyses evaluating the efficacy and safety of etanercept in people who have not responded to DMARDs or MTX only. Our safety results suggest that there are no major issues with etanercept or combined etanercept with MTX in the short term. There were very few serious adverse events and no evidence that these differed according to treatments used. Injection site reactions were more common with etanercept monotherapy and a number of minor adverse events, including nausea, were more common with DMARD. Infection and death rates did not differ between groups over three years of follow-up. Open-label extensions of four of the included studies (<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>; <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>; <LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>; <LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>) indicated that the rates of serious adverse events (up to seven years of follow-up) were similar to those reported for people with RA in general (<LINK REF="REF-Klareskog-2006" TYPE="REFERENCE">Klareskog 2006</LINK>; <LINK REF="REF-Moreland-2006" TYPE="REFERENCE">Moreland 2006</LINK>). However, the findings that adverse events did not differ in frequency between randomised groups should be treated with caution.</P>
<P>Some of the included studies claimed to be assessing both benefit and safety of treatment but invariably power calculations were based solely on efficacy considerations. Thus, these studies may not have been sufficiently powered to assess the harms of treatment adequately and type 2 error could not be ruled out, that is, the conclusion of no association between treatment and adverse effects, when an association actually exists. In fact, an analysis of trials of TNF inhibitors suggested that trials would need to have much larger sample sizes to adequately assess safety, particularly the risk of rare and serious events (<LINK REF="REF-Yazici-2008" TYPE="REFERENCE">Yazici 2008</LINK>). These authors also suggested that phase 4 trials of TNF inhibitors are needed to assess safety adequately.</P>
<P>There are concerns about the risk of serious infection and malignancies with etanercept that has caused the US FDA to announce black box warnings on etanercept. The risk of serious infection warning is based on monitoring from the FDA's safety information and adverse event reporting programme, which evaluated data from clinical studies of over 20,000 participants during 28,300 patient-years. Reported infections included bacterial sepsis and TB. Also the Cochrane network meta-analysis of adverse events has shown that there is a small risk of TB (<LINK REF="REF-Singh-2011" TYPE="REFERENCE">Singh 2011</LINK>). The authors included studies with less than 24 weeks of follow-up, and open-label trials, which may explain the discrepancy with our results. Nonetheless, the FDA advised that people should be screened for latent TB and treated before the initiation of therapy with etanercept and monitored for TB and other infections during treatment. The ACR guidelines (<LINK REF="REF-Saag-2008" TYPE="REFERENCE">Saag 2008</LINK> and <LINK REF="REF-Singh-2012" TYPE="REFERENCE">Singh 2012</LINK>) has also recommended against the use of any biological agents in the presence of active bacterial infection or active TB and another large systematic review commissioned by the Agency of Healthcare Research and Quality has concluded that there is insufficient evidence to draw conclusions about differences in risk for rare but serious events (<LINK REF="REF-Donahue-2008" TYPE="REFERENCE">Donahue 2008</LINK>). Similarly, the FDA warning on the risk of malignancy development is based on an analysis of US reports of cancer in children and adolescents treated with TNF-blockers, which showed an increased risk of cancer, half of them lymphomas. However, in one meta-analysis of RCTs, no association was found between any type of malignancy and etanercept in the short term (<LINK REF="REF-Lopez_x002d_Olivo-2012" TYPE="REFERENCE">Lopez-Olivo 2012</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-03-14 15:54:51 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-03-14 15:53:51 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept is approved for the treatment of RA at a dose of 25 mg SC twice weekly. In this review, while some outcome variables were significantly improved with etanercept 10 mg SC twice weekly, etanercept 25 mg SC twice weekly was a more efficacious treatment than 10 mg SC twice weekly compared with control.</P>
<P>This review has been able to assess etanercept monotherapy and also etanercept combined with a DMARD (either MTX or sulphasalazine) for clinical benefit, effects on quality of life and safety of people with RA. Etanercept monotherapy is more effective than control in improving ACR response rates, remission rates and lessening joint damage. These clinical benefits were also paralleled by patients' feelings of satisfaction and assessment of their disability after treatment and the rate in which they discontinued therapy. Etanercept monotherapy does not appear to offer an advantage over DMARD monotherapy, other than lessening joint damage as assessed by radiographic scores. However, combined treatment with both etanercept and a DMARD is more effective than etanercept monotherapy for all efficacy outcomes up until three years in people with RA who are judged to be appropriate candidates for MTX. Quality of life is also improved and participants were more compliant with their treatment. It is not known whether longer-term treatment would maintain these improvements, or whether effects are reduced with ongoing treatment.</P>
<P>This review has found no evidence of a difference in the rates of serious adverse events with either etanercept monotherapy or combined treatment with etanercept and DMARD in the short term. The most common side effect was a reaction to the injection site with etanercept alone but this ceased after a few injections. However, there are concerns with increased incidence of infections (particularly TB) and possibly increased malignancy risks, so the long-term benefit and safety need to be evaluated further.</P>
<P>The availability of etanercept varies within and between countries. In most countries the cost of etanercept is significantly more than that of other traditional DMARDS. A 'stepped care' approach is commonly recommended for the treatment of RA by most rheumatology societies. The ACR and EULAR guidelines, and Canadian treatment recommendations emphasise the early use of traditional DMARDs, MTX being the first option, to avert joint deformity and dysfunction. In those people who have an inadequate response, a change to either other DMARDs alone or in combination with other traditional DMARDs is suggested. Current guidelines recommend initiation of biologic therapy (including etanercept) in people with a moderate to high disease activity despite treatment with at least two DMARDs for three months (<LINK REF="REF-Bykerk-2012" TYPE="REFERENCE">Bykerk 2012</LINK>; <LINK REF="REF-Saag-2008" TYPE="REFERENCE">Saag 2008</LINK>; <LINK REF="REF-Singh-2012" TYPE="REFERENCE">Singh 2012</LINK>; <LINK REF="REF-Smolen-2010a" TYPE="REFERENCE">Smolen 2010a</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-14 15:54:51 -0400" MODIFIED_BY="[Empty name]">
<P>Further long-term studies are required to confirm the safety of etanercept plus DMARD therapy for both clinical and radiographic outcome variables at three years and beyond. In addition, because of the high cost of etanercept, cost-effectiveness studies should be undertaken that include quality of life and adverse events as well as disease progression over the long term since RA is a chronic progressive disease (<LINK REF="REF-Kobelt-2005" TYPE="REFERENCE">Kobelt 2005</LINK>). Finally, head-to-head comparison of etanercept monotherapy and combination therapy with the other licensed biological agents would be useful to allow physicians to select the best treatment for each participant. Studies should incorporate measures to determine how therapy can be individualised. Information on which group of participants are most likely to respond to biological treatment is important so people most likely to benefit could be offered this expensive treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-03-20 13:59:06 -0400" MODIFIED_BY="[Empty name]">
<P>The Arthritis Society provided support for the first publication of this review as the third and fourth authors were supported by Arthritis Society Scholarships.</P>
<P>The authors of the update would like to thank Ann Cranney, Barb Blumenauer, and Marc Hochberg for their contributions as co-authors to the original review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-03-14 17:27:27 -0400" MODIFIED_BY="Anne Lawson">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-03-14 17:27:27 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="6">For the first publication of the review in 2003</HEADING>
<P>BB and AC extracted and analysed the data and selected trials of the initial review and preparation of the initial manuscript.</P>
<P>AB and MH contributed data, updated of the selection of the reference list, updated the analyses and updated the interpretation of results.</P>
<P>BB and MJ wrote the manuscript, contributed data extraction, updated the analyses and interpretation of results.</P>
<P>AC, DC, GW and PT contributed methodological expertise and commented on drafts.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">For the update</HEADING>
<P>AL undertook searches, selected studies for inclusion, extracted data and assessed all included studies for risk of bias. She also entered data, re-ordered the comparisons, updated the analyses and prepared the final manuscript.</P>
<P>MLO extracted data, selected studies for inclusion, assessed new studies for risk of bias, extracted data, provided comment on methodological issues and prepared the final manuscript.</P>
<P>LM made substantial contributions to the interpretation of data, revised the manuscript critically, provided comment on methodological issues, and reviewed the final version</P>
<P>AB, PT, MH, and GW provided comment on methodological issues and reviewed the final draft.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-03-20 15:23:02 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-03-20 14:59:02 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-03-14 17:12:32 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Bathon-2000-_x0028_ERA_x0029_" MODIFIED="2013-03-14 17:08:46 -0400" MODIFIED_BY="[Empty name]" NAME="Bathon 2000 (ERA)" YEAR="2000">
<REFERENCE MODIFIED="2013-03-14 17:08:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al</AU>
<TI>A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<PG>1586-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:08:46 -0400" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, et al</AU>
<TI>Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response</TI>
<SO>The American Journal of Managed Care</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>231-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Combe-2006" MODIFIED="2013-03-14 17:10:02 -0400" MODIFIED_BY="[Empty name]" NAME="Combe 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-14 17:08:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al</AU>
<TI>Efficacy, safety and patient-reported outcomes of combination etanercept and sulphasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<NO>7</NO>
<PG>1146-52</PG>
<IDENTIFIERS MODIFIED="2012-01-31 05:41:45 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-31 05:41:45 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18794178"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:10:02 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al; Etanercept European Investigators Network (Etanercept Study 309 Investigators)</AU>
<TI>Etanercept and sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulphasalazine: a double-blind comparison</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>10</NO>
<PG>1357-62</PG>
<IDENTIFIERS MODIFIED="2012-01-31 05:38:55 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-31 05:38:55 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16606651"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-01-31 05:36:20 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emery-2008-_x0028_COMET_x0029_" MODIFIED="2013-03-14 17:10:30 -0400" MODIFIED_BY="[Empty name]" NAME="Emery 2008 (COMET)" YEAR="2008">
<REFERENCE MODIFIED="2013-03-14 17:10:15 -0400" MODIFIED_BY="Anne Lethaby" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al</AU>
<TI>Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<PG>375-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:10:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emery P, Breedveld FC, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, et al</AU>
<TI>Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>3</NO>
<PG>674-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:10:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al</AU>
<TI>Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<PG>222-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2009" MODIFIED="2013-03-14 17:10:40 -0400" MODIFIED_BY="[Empty name]" NAME="Hu 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-14 17:10:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu D, Bao C, Chen S, Gu J, Li Z, Sun L, et al</AU>
<TI>A comparison study of a recombinant tumour necrosis factor receptor: Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China</TI>
<SO>Rheumatology International</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>297-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kameda-2010" MODIFIED="2013-03-14 17:11:31 -0400" MODIFIED_BY="[Empty name]" NAME="Kameda 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-14 17:11:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al; Japan Biological Agent Study Integrated Consortium</AU>
<TI>Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomised trial</TI>
<SO>Modern Rheumatology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>6</NO>
<PG>531-8</PG>
<IDENTIFIERS MODIFIED="2012-01-31 05:45:13 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-31 05:45:13 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20574649"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" MODIFIED="2013-03-14 17:12:10 -0400" MODIFIED_BY="Anne Lethaby" NAME="Klareskog 2004 (TEMPO)" YEAR="2004">
<REFERENCE MODIFIED="2013-03-14 17:11:46 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;First publication - 1 year data&lt;/p&gt;" NOTES_MODIFIED="2013-03-14 17:11:46 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al</AU>
<TI>Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>675-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:11:52 -0400" MODIFIED_BY="Anne Lethaby" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Klareskog L, Landewe R, Bruyn GAW, Cantagrel A, Durez P, et al</AU>
<TI>Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>12</NO>
<PG>3928-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:12:00 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Report of 2 year data&lt;/p&gt;" NOTES_MODIFIED="2013-03-14 17:12:00 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al</AU>
<TI>Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>4</NO>
<PG>1063-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:12:10 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Patient reported outcomes at 1 year&lt;/p&gt;" NOTES_MODIFIED="2013-03-14 17:12:10 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al</AU>
<TI>Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>65</VL>
<PG>328-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcora-2006" MODIFIED="2012-05-07 12:55:05 -0400" MODIFIED_BY="[Empty name]" NAME="Marcora 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-07 12:55:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ</AU>
<TI>Randomized phase 2 trial of anti-tumour necrosis factor therapy for cachexia in patients with early rheumatoid arthritis</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<PG>1463-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreland-1999" MODIFIED="2013-03-14 17:12:19 -0400" MODIFIED_BY="[Empty name]" NAME="Moreland 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-05-07 12:55:45 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Quality of life outcomes for the Moreland study&lt;/p&gt;" NOTES_MODIFIED="2012-05-07 12:55:45 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L</AU>
<TI>Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>1</NO>
<PG>128-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-14 17:12:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann, Bulpitt KJ, et al</AU>
<TI>Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>130</VL>
<PG>478-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Weinblatt-1999" MODIFIED="2013-03-14 17:12:32 -0400" MODIFIED_BY="[Empty name]" NAME="Weinblatt 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-14 17:12:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al</AU>
<TI>A trial of etanercept, a recombinant tumour necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>253-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-03-14 17:16:12 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACP-2001" NAME="ACP 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Summary of Bathon 2000 with no new data&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Etanercept was more effective and safer than methotrexate in disease progression in early rheumatoid arthritis</TI>
<SO>ACP Journal club</SO>
<YR>July/August 2001</YR>
<VL>135</VL>
<NO>1</NO>
<PG>22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angel-2010" MODIFIED="2012-04-27 15:49:53 -0400" MODIFIED_BY="[Empty name]" NAME="Angel 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-27 15:49:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D</AU>
<TI>Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study</TI>
<SO>Hypertension</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>2</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anis-2009" MODIFIED="2013-03-14 17:12:41 -0400" MODIFIED_BY="[Empty name]" NAME="Anis 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-14 17:12:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al</AU>
<TI>The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>10</NO>
<PG>1283-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benucci-2011" MODIFIED="2012-05-07 12:58:38 -0400" MODIFIED_BY="[Empty name]" NAME="Benucci 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-05-07 12:58:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F</AU>
<TI>Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis</TI>
<SO>International Journal of Immunopathology and Pharmacology</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>1</NO>
<PG>269-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blank-2009" MODIFIED="2012-09-22 22:13:14 -0400" MODIFIED_BY="[Empty name]" NAME="Blank 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-09-22 22:13:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blank N, Max R, Schiller M, Briem S, Lorenz HM</AU>
<TI>Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>4</NO>
<PG>440-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bliddal-2006" MODIFIED="2013-03-14 17:12:51 -0400" MODIFIED_BY="[Empty name]" NAME="Bliddal 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-14 17:12:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, et al</AU>
<TI>A randomised, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>5</NO>
<PG>341-5</PG>
<IDENTIFIERS MODIFIED="2012-02-22 12:06:02 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 12:06:02 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17062431"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boesen-2008" MODIFIED="2013-03-14 17:12:58 -0400" MODIFIED_BY="[Empty name]" NAME="Boesen 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-03-14 17:12:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boesen M, Boesen L, Jensen KE, Cimmino MA, Torp-Pedersen S, Terslev L, et al</AU>
<TI>Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>4</NO>
<PG>584-91</PG>
<IDENTIFIERS MODIFIED="2012-02-22 12:09:15 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 12:09:15 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18322991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2013-03-14 17:13:05 -0400" MODIFIED_BY="[Empty name]" NAME="Chen 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-14 17:13:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, et al</AU>
<TI>Theeffect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS MODIFIED="2012-02-22 11:47:19 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 11:47:19 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15975966"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuomo-2006" MODIFIED="2013-03-13 05:37:26 -0400" MODIFIED_BY="[Empty name]" NAME="Cuomo 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-13 05:37:26 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuomo G, Molinaro G, La Montagna G, Migliaresi S, Valentini G</AU>
<TI>A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens</TI>
<SO>Reumatismo</SO>
<YR>2006</YR>
<VL>58</VL>
<NO>1</NO>
<PG>22-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Filippis-2006" MODIFIED="2012-05-07 13:00:10 -0400" MODIFIED_BY="[Empty name]" NAME="De Filippis 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-07 13:00:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G</AU>
<TI>Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis</TI>
<SO>Panminerva Medica</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>2</NO>
<PG>129-35</PG>
<IDENTIFIERS MODIFIED="2012-02-22 11:53:25 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 11:53:25 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16953150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Stefano-2010" MODIFIED="2013-03-14 17:13:14 -0400" MODIFIED_BY="[Empty name]" NAME="De Stefano 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-14 17:13:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, et al</AU>
<TI>Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha</TI>
<SO>Clinical Rheumatology</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>5</NO>
<PG>517-24</PG>
<IDENTIFIERS MODIFIED="2012-02-22 11:43:22 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 11:43:22 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20082236"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garnero-2002" MODIFIED="2013-03-14 17:13:22 -0400" MODIFIED_BY="Anne Lawson" NAME="Garnero 2002" YEAR="">
<REFERENCE MODIFIED="2013-03-14 17:13:22 -0400" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Study subset looking at collagen markers and joint destruction&lt;/p&gt;" NOTES_MODIFIED="2013-03-14 17:13:22 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD</AU>
<TI>Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>1</NO>
<PG>21-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genovese-2002" MODIFIED="2013-03-14 17:13:30 -0400" MODIFIED_BY="[Empty name]" NAME="Genovese 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-14 17:13:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al</AU>
<TI>Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>6</NO>
<PG>1443-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genovese-2004" MODIFIED="2013-03-14 17:13:37 -0400" MODIFIED_BY="[Empty name]" NAME="Genovese 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-14 17:13:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al</AU>
<TI>Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>5</NO>
<PG>1412-9</PG>
<IDENTIFIERS MODIFIED="2012-02-22 12:04:20 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 12:04:20 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15146410"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlag-2010" MODIFIED="2013-03-14 17:13:45 -0400" MODIFIED_BY="[Empty name]" NAME="Gerlag 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-14 17:13:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlag DM, Hollis S, Layton M, Vencovský J, Szekanecz Z, Braddock M, et al</AU>
<TI>Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>11</NO>
<PG>3154-60</PG>
<IDENTIFIERS MODIFIED="2012-02-22 11:39:53 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 11:39:53 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20662070"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-22 11:38:31 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holman-2008" MODIFIED="2012-05-07 16:50:45 -0400" MODIFIED_BY="[Empty name]" NAME="Holman 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-07 16:50:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holman AJ, Ng E</AU>
<TI>Heart rate variability predicts anti-tumour necrosis factor therapy response for inflammatory arthritis</TI>
<SO>Autonomic Neuroscience</SO>
<YR>2008</YR>
<VL>143</VL>
<NO>1-2</NO>
<PG>58-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwamoto-2009" MODIFIED="2013-03-14 17:13:54 -0400" MODIFIED_BY="[Empty name]" NAME="Iwamoto 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-14 17:13:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al</AU>
<TI>Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population</TI>
<SO>Modern Rheumatology</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>5</NO>
<PG>488-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsen-2006" MODIFIED="2013-03-14 17:14:06 -0400" MODIFIED_BY="[Empty name]" NAME="Johnsen 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-14 17:14:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al</AU>
<TI>Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomised double blind study</TI>
<SO>Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>4</NO>
<PG>659-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavanaugh-2008" MODIFIED="2012-05-07 16:50:54 -0400" MODIFIED_BY="[Empty name]" NAME="Kavanaugh 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-07 16:50:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M</AU>
<TI>Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<NO>10</NO>
<PG>1444-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keystone-2004" MODIFIED="2013-03-14 17:14:14 -0400" MODIFIED_BY="[Empty name]" NAME="Keystone 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-14 17:14:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al</AU>
<TI>Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomised, double-blind, placebo-controlled trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>2</NO>
<PG>353-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keystone-2009" MODIFIED="2012-05-07 16:51:04 -0400" MODIFIED_BY="[Empty name]" NAME="Keystone 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-07 16:51:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keystone E, Freundlich B, Schiff M, Li J, Hooper M</AU>
<TI>Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA</TI>
<SO>Journal of Rheumatology</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>3</NO>
<PG>522-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koumakis-2009" MODIFIED="2012-05-07 16:51:13 -0400" MODIFIED_BY="[Empty name]" NAME="Koumakis 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-07 16:51:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koumakis E, Wipff J, Avouac J, Kahan A, Allanore Y</AU>
<TI>Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumour necrosis factor-alpha-blocking agents</TI>
<SO>Journal of Rheumatology</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>9</NO>
<PG>2125-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lan-2004" MODIFIED="2013-03-14 17:14:24 -0400" MODIFIED_BY="[Empty name]" NAME="Lan 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-14 17:14:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M Jr</AU>
<TI>A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomised, placebo-controlled study</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>2004</YR>
<VL>103</VL>
<NO>8</NO>
<PG>618-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lisbona-2008" MODIFIED="2012-05-07 16:51:24 -0400" MODIFIED_BY="[Empty name]" NAME="Lisbona 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-07 13:05:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lisbona MP, Maymó J, Perich J, Almirall M, Carbonell J</AU>
<TI>Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>6</NO>
<PG>1117-22</PG>
<IDENTIFIERS MODIFIED="2012-02-22 11:41:31 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 11:41:31 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20448287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-07 16:51:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J</AU>
<TI>Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>3</NO>
<PG>394-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukas-2009" MODIFIED="2012-05-07 16:51:37 -0400" MODIFIED_BY="[Empty name]" NAME="Lukas 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-07 16:51:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukas C, Landewé R, Fatenejad S, van der Heijde D</AU>
<TI>Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<NO>11</NO>
<PG>1691-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukas-2010" MODIFIED="2012-05-07 16:51:44 -0400" MODIFIED_BY="[Empty name]" NAME="Lukas 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-07 16:51:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukas C, van der Heijde D, Fatenajad S, Landewé R</AU>
<TI>Repair of erosions occurs almost exclusively in damaged joints without swelling</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>5</NO>
<PG>851-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukina-2001" MODIFIED="2013-03-14 17:14:42 -0400" MODIFIED_BY="[Empty name]" NAME="Lukina 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-03-14 17:14:42 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Compared anti-TNF mAbs(?which drug) to interferon gamma to PBO given IM daily X5 with outcomes at day 7 and 28. Doesn't meet inclusion criteria even if E was used&lt;/p&gt;" NOTES_MODIFIED="2013-03-14 17:14:42 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lukina GV</AU>
<TI>Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumour necrosis factor-alpha in rheumatoid arthritis (preliminary results)</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2001</YR>
<VL>73</VL>
<NO>5</NO>
<PG>12-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luzi-2009" MODIFIED="2012-05-07 16:51:50 -0400" MODIFIED_BY="[Empty name]" NAME="Luzi 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-07 16:51:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luzi G, Laganà B, Salemi S, Di Rosa R</AU>
<TI>Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?</TI>
<SO>Clinica Terapeutica</SO>
<YR>2009</YR>
<VL>160</VL>
<NO>2</NO>
<PG>121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Machado-2009" MODIFIED="2013-03-14 17:14:54 -0400" MODIFIED_BY="[Empty name]" NAME="Machado 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-14 17:14:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Machado P, Santos A, Pereira C, Loureiro C, Silva J, Chieira C, et al</AU>
<TI>Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha</TI>
<SO>Bone Spine</SO>
<YR>2009</YR>
<VL>76</VL>
<NO>5</NO>
<PG>508-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreland-1997" MODIFIED="2013-03-14 17:15:01 -0400" MODIFIED_BY="[Empty name]" NAME="Moreland 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-14 17:15:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al</AU>
<TI>Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>3</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreland-2001" MODIFIED="2013-03-14 17:15:12 -0400" MODIFIED_BY="Anne Lawson" NAME="Moreland 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-03-14 17:15:12 -0400" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Examined all pts who had received at least 1 dose of E in controlled or open label trials for clinical and safety benefit at a later date. Duplicates patients from previous studies and doesn't meet inclusion criteria.&lt;/p&gt;" NOTES_MODIFIED="2013-03-14 17:15:12 -0400" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al</AU>
<TI>Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>6</NO>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paleolog-1998" MODIFIED="2012-05-07 13:07:34 -0400" MODIFIED_BY="[Empty name]" NAME="Paleolog 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-05-07 13:07:34 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Looked at synovial cells from patients treated with anti-TNF agents&lt;/p&gt;" NOTES_MODIFIED="2012-05-07 13:07:34 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Paleolog EM</AU>
<TI>Modulation of angiogenic vascular endothelial growth factor by tumour necrosis factor alpha and interleukin-1 in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>7</NO>
<PG>1258-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roux-2011" MODIFIED="2013-03-14 17:15:20 -0400" MODIFIED_BY="[Empty name]" NAME="Roux 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-03-14 17:15:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, Albert C, et al</AU>
<TI>Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomised pilot study</TI>
<SO>Journal of Rheumatology</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1009-11</PG>
<IDENTIFIERS MODIFIED="2012-02-22 12:07:39 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 12:07:39 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21406499"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saleem-2009" MODIFIED="2013-03-14 17:15:27 -0400" MODIFIED_BY="[Empty name]" NAME="Saleem 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-14 17:15:27 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al</AU>
<TI>Disease remission state in patients treated with the combination of tumour necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2009</YR>
<VL>60</VL>
<NO>7</NO>
<PG>1915-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sennels-2008" MODIFIED="2013-03-14 17:15:34 -0400" MODIFIED_BY="[Empty name]" NAME="Sennels 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-03-14 17:15:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sennels H, Sørensen S, Ostergaard M, Knudsen L, Hansen M, Skjødt H, et al</AU>
<TI>Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomised to etanercept alone or in combination with methotrexate</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>4</NO>
<PG>241-7</PG>
<IDENTIFIERS MODIFIED="2012-02-22 11:45:40 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 11:45:40 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18612923"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Riel-2006" MODIFIED="2013-03-14 17:15:42 -0400" MODIFIED_BY="[Empty name]" NAME="van Riel 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-14 17:15:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Riel PLC, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al</AU>
<TI>Efficacy and safety of combination etanercept and methotrexate versus methotrexate alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>11</NO>
<PG>1478-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinblatt-2007" MODIFIED="2013-03-14 17:15:54 -0400" MODIFIED_BY="[Empty name]" NAME="Weinblatt 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-14 17:15:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, et al</AU>
<TI>Selective co stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>2</NO>
<PG>228-34</PG>
<IDENTIFIERS MODIFIED="2012-02-22 12:00:41 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-02-22 12:00:41 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16935912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinblatt-2008" MODIFIED="2013-03-14 17:16:03 -0400" MODIFIED_BY="Anne Lethaby" NAME="Weinblatt 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-03-14 17:16:03 -0400" MODIFIED_BY="Anne Lethaby" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, et al</AU>
<TI>Efficacy and safety of etanercept 50mg twice a week in patients with rheumatoid arthritis who had a sub-optimal response to etanercept 50mg once a week</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>7</NO>
<PG>1921-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisman-2007" MODIFIED="2013-03-14 17:16:12 -0400" MODIFIED_BY="[Empty name]" NAME="Weisman 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-14 17:16:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al</AU>
<TI>A placebo-controlled, randomised, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases</TI>
<SO>Rheumatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>7</NO>
<PG>1122-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-03-20 14:59:02 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-EMPIRE-2006" MODIFIED="2013-03-20 14:56:41 -0400" MODIFIED_BY="Anne Lethaby" NAME="EMPIRE 2006" YEAR="2006">
<IDENTIFIERS MODIFIED="2013-03-20 14:56:41 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-20 14:56:41 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01303874"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-France-2008" MODIFIED="2013-03-20 14:57:31 -0400" MODIFIED_BY="[Empty name]" NAME="France 2008" YEAR="2008">
<IDENTIFIERS MODIFIED="2013-03-20 14:57:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-20 14:57:31 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00706797"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Japanese-2006" MODIFIED="2013-03-20 14:58:01 -0400" MODIFIED_BY="Anne Lethaby" NAME="Japanese 2006" YEAR="2006">
<IDENTIFIERS MODIFIED="2013-03-20 14:58:01 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-20 14:58:01 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00445770"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Jobanputra-2005" MODIFIED="2013-03-20 14:58:26 -0400" MODIFIED_BY="Anne Lethaby" NAME="Jobanputra 2005" YEAR="2005">
<IDENTIFIERS MODIFIED="2013-03-20 14:58:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-20 14:58:26 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00523692"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Takeuchi-2005" MODIFIED="2013-03-20 14:59:02 -0400" MODIFIED_BY="Anne Lethaby" NAME="Takeuchi 2005" YEAR="2005">
<IDENTIFIERS MODIFIED="2013-03-20 14:59:02 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-20 14:59:02 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00688103"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-03-20 15:23:02 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-03-20 15:23:02 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arnett-1988" MODIFIED="2013-03-20 15:23:02 -0400" MODIFIED_BY="Anne Lawson" NAME="Arnett 1988" TYPE="JOURNAL_ARTICLE">
<AU>Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al</AU>
<TI>The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>315-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boers-1994" MODIFIED="2013-03-14 17:16:22 -0400" MODIFIED_BY="[Empty name]" NAME="Boers 1994" TYPE="JOURNAL_ARTICLE">
<AU>Boers M, Tugwell P, Felson DT</AU>
<TI>World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials</TI>
<SO>Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>86-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bykerk-2012" MODIFIED="2013-03-14 17:16:34 -0400" MODIFIED_BY="[Empty name]" NAME="Bykerk 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al</AU>
<TI>Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs</TI>
<SO>Journal of Rheumatology</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>8</NO>
<PG>1559-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donahue-2008" MODIFIED="2013-03-14 17:16:41 -0400" MODIFIED_BY="[Empty name]" NAME="Donahue 2008" TYPE="JOURNAL_ARTICLE">
<AU>Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al</AU>
<TI>Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>148</VL>
<PG>124-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1993" MODIFIED="2013-03-12 14:38:50 -0400" MODIFIED_BY="Anne Lawson" NAME="Felson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al</AU>
<TI>The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>729-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1995" MODIFIED="2013-03-20 15:21:55 -0400" MODIFIED_BY="Anne Lawson" NAME="Felson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al</AU>
<TI>American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandez_x002d_Cruz-2008" MODIFIED="2013-03-14 17:17:04 -0400" MODIFIED_BY="[Empty name]" NAME="Fernandez-Cruz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Fernández-Cruz E, Alecsandru D, Rodríguez-Sainz C</AU>
<TI>Introduction to biological drugs</TI>
<SO>Actas Dermo-Sifiliograficas</SO>
<YR>2008</YR>
<VL>99 Suppl 4</VL>
<PG>2-6</PG>
<IDENTIFIERS MODIFIED="2013-03-12 14:39:37 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-12 14:39:37 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19080985"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furst-2007" MODIFIED="2013-03-14 17:17:13 -0400" MODIFIED_BY="[Empty name]" NAME="Furst 2007" TYPE="JOURNAL_ARTICLE">
<AU>Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al</AU>
<TI>Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66 Suppl III</VL>
<PG>iii2-iii22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-05-07 13:11:24 -0400" MODIFIED_BY="Anne E Lethaby" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-03-14 17:17:24 -0400" MODIFIED_BY="Anne E Lethaby" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jarvis-1999" MODIFIED="2012-04-26 14:27:01 -0400" MODIFIED_BY="[Empty name]" NAME="Jarvis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jarvis B, Faulds D</AU>
<TI>Etanercept: a review of its use in rheumatoid arthritis</TI>
<SO>Drugs</SO>
<YR>1999</YR>
<VL>57</VL>
<NO>6</NO>
<PG>945-66</PG>
<IDENTIFIERS MODIFIED="2012-04-26 14:27:01 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 14:27:01 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10400407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kievit-2007" MODIFIED="2013-03-14 17:17:41 -0400" MODIFIED_BY="[Empty name]" NAME="Kievit 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kievit W, Fransen J, Oerlemans AJM, Kuper HH, van der Laar MAFJ, de Rooij DJRAM, et al</AU>
<TI>The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<PG>1473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klareskog-2006" MODIFIED="2012-05-07 13:16:21 -0400" MODIFIED_BY="[Empty name]" NAME="Klareskog 2006" TYPE="JOURNAL_ARTICLE">
<AU>Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J</AU>
<TI>A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with disease-modifying antirheumatic drugs</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<PG>1578-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kobelt-2005" MODIFIED="2012-05-07 13:16:45 -0400" MODIFIED_BY="[Empty name]" NAME="Kobelt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kobelt G, Lindgren P, Singh A, Klareskog L</AU>
<TI>Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>1174-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopez_x002d_Olivo-2012" MODIFIED="2013-02-12 04:13:11 -0500" MODIFIED_BY="[Empty name]" NAME="Lopez-Olivo 2012" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al</AU>
<TI>Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy - a meta-analysis</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>308</VL>
<NO>9</NO>
<PG>898-908</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molenaar-2000" MODIFIED="2012-05-07 13:16:57 -0400" MODIFIED_BY="[Empty name]" NAME="Molenaar 2000" TYPE="JOURNAL_ARTICLE">
<AU>Molenaar E, van der Heijde D, Boers M</AU>
<TI>Update on outcome assessment in rheumatic disorders</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moreland-2006" MODIFIED="2013-03-14 17:17:50 -0400" MODIFIED_BY="[Empty name]" NAME="Moreland 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al</AU>
<TI>Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience</TI>
<SO>Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>33</VL>
<PG>854-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" MODIFIED="2012-05-07 13:17:29 -0400" MODIFIED_BY="[Empty name]" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray KM, Dahl SL</AU>
<TI>Recombinant human tumour necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1997</YR>
<VL>31</VL>
<NO>11</NO>
<PG>1335-8</PG>
<IDENTIFIERS MODIFIED="2012-04-26 14:23:27 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 14:23:27 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9391689"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-OMERACT-1993" MODIFIED="2012-05-07 13:17:41 -0400" MODIFIED_BY="[Empty name]" NAME="OMERACT 1993" TYPE="JOURNAL_ARTICLE">
<AU>OMERACT</AU>
<TI>Conference on outcome measures in rheumatoid arthritis clinical trials</TI>
<SO>Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>526-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1993" MODIFIED="2012-05-07 13:18:08 -0400" MODIFIED_BY="[Empty name]" NAME="Pincus 1993" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Callahan LF</AU>
<TI>What is the natural history of rheumatoid arthritis?</TI>
<SO>Rheumatic Diseases Clinics of North America</SO>
<YR>1993</YR>
<VL>19</VL>
<PG>123-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1999" MODIFIED="2012-05-07 13:18:21 -0400" MODIFIED_BY="[Empty name]" NAME="Pincus 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Stein CM</AU>
<TI>ACR 20: clinical or statistical significance?</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1572-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puolakka-2005" MODIFIED="2013-03-14 17:18:04 -0400" MODIFIED_BY="[Empty name]" NAME="Puolakka 2005" TYPE="BOOK">
<AU>Puolakka K</AU>
<SO>Work Capacity and Productivity Costs in Early Rheumatoid Arthritis: A Five-Year Prospective Study [dissertation]. Available from: ethesis.helsinki.fi/julkaisut/laa/kliin/vk/puolakka2/workcapa.pdf (accessed 12 March 2013)</SO>
<YR>2005</YR>
<PB>Academic Dissertation University of Helsinki</PB>
<CY>Helsinki</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saag-2008" MODIFIED="2013-03-14 17:18:22 -0400" MODIFIED_BY="Anne Lethaby" NAME="Saag 2008" TYPE="JOURNAL_ARTICLE">
<AU>Saag KG, Teng GG, Patkar NM, Anuntiy J, Finney C, Curtis JR, et al</AU>
<TI>American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis</TI>
<SO>Arthritis Care and Research</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>6</NO>
<PG>762-84</PG>
<IDENTIFIERS MODIFIED="2008-07-14 17:11:40 -0400" MODIFIED_BY="Anne Lethaby"/>
</REFERENCE>
<REFERENCE ID="REF-Singh-2009" MODIFIED="2013-03-14 12:47:51 -0400" MODIFIED_BY="[Empty name]" NAME="Singh 2009" TYPE="COCHRANE_REVIEW">
<AU>Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al</AU>
<TI>Biologics for rheumatoid arthritis: an overview of Cochrane reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-03-12 14:54:28 -0400" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2013-03-12 14:54:28 -0400" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD007848.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2011" MODIFIED="2013-03-14 17:18:33 -0400" MODIFIED_BY="[Empty name]" NAME="Singh 2011" TYPE="COCHRANE_REVIEW">
<AU>Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al</AU>
<TI>Adverse effects of biologics: a network meta-analysis and Cochrane overview</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-05-07 13:22:19 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-07 13:22:19 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008794.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2012" MODIFIED="2013-03-14 17:19:20 -0400" MODIFIED_BY="[Empty name]" NAME="Singh 2012" TYPE="JOURNAL_ARTICLE">
<AU>Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al</AU>
<TI>2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis</TI>
<SO>Arthritis Care and Research (Hoboken)</SO>
<YR>2012</YR>
<VL>64</VL>
<NO>5</NO>
<PG>625-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smolen-2010a" MODIFIED="2013-03-14 17:19:42 -0400" MODIFIED_BY="[Empty name]" NAME="Smolen 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al</AU>
<TI>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs</TI>
<SO>Annals of the Rheumatic Disease</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>6</NO>
<PG>964-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smolen-2010b" MODIFIED="2013-03-14 17:19:56 -0400" MODIFIED_BY="[Empty name]" NAME="Smolen 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT</AU>
<TI>Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials</TI>
<SO>Annals of the Rheumatic Disease</SO>
<YR>2010</YR>
<VL>69</VL>
<PG>1058-64</PG>
<IDENTIFIERS MODIFIED="2012-12-03 16:25:07 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-03 16:25:07 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/ard.2009.114652"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2011" MODIFIED="2012-12-03 15:20:17 -0500" MODIFIED_BY="[Empty name]" NAME="Tugwell 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Singh JA, Wells GA</AU>
<TI>Biologicals for rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4027</PG>
<IDENTIFIERS MODIFIED="2012-12-03 15:20:17 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-03 15:20:17 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.d4027"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-2005a" MODIFIED="2013-03-14 17:20:06 -0400" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2005a" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al</AU>
<TI>Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>1582-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-2005b" MODIFIED="2013-03-14 17:20:12 -0400" MODIFIED_BY="Anne Lawson" NAME="van der Heijde 2005b" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Landewe R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, et al</AU>
<TI>Presentation and analysis of data on radiographic outcome in clinical trials</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>1</NO>
<PG>49-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yazici-2008" MODIFIED="2012-05-07 13:23:07 -0400" MODIFIED_BY="Anne Lethaby" NAME="Yazici 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yazici Y, Adler NM, Yazici H</AU>
<TI>Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations</TI>
<SO>Rheumatology</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>7</NO>
<PG>1054-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yee-2003" MODIFIED="2012-04-26 13:34:05 -0400" MODIFIED_BY="[Empty name]" NAME="Yee 2003" TYPE="JOURNAL_ARTICLE">
<AU>Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF; West Midlands Rheumatology Services and Training Committee</AU>
<TI>The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>7</NO>
<PG>856-9</PG>
<IDENTIFIERS MODIFIED="2012-04-26 13:34:05 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-26 13:34:05 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 12730544"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-03-14 17:20:23 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Blumenauer-2003a" MODIFIED="2013-03-14 17:20:23 -0400" MODIFIED_BY="[Empty name]" NAME="Blumenauer 2003a" TYPE="COCHRANE_REVIEW">
<AU>Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al</AU>
<TI>Etanercept for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-05-01 15:21:58 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-01 15:21:57 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004525"/>
<IDENTIFIER MODIFIED="2012-05-01 15:21:58 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14584021"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-03-20 15:11:38 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-03-20 14:37:37 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-03-14 15:55:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<CHAR_METHODS MODIFIED="2013-03-14 15:55:36 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not reported<BR/>Allocation concealment not reported<BR/>Blinding not reported, but treatments provided in identical containers<BR/>Multicentre parallel group study<BR/>Power calculation not reported<BR/>No of participants randomised = 632<BR/>No of participants analysed = 632<BR/>Intention-to-treat analysis<BR/>Source of funding: Immunex (pharmaceutical company)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:55:38 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:<BR/>At least 18 years; RA max 3 years; no other illnesses; no treatment with MTX; at high risk for radiographic progression<BR/>No exclusion criteria reported<BR/>Location: centres in the USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:55:40 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 10 mg SC twice weekly</LI>
<LI>Etanercept 25 mg SC twice weekly</LI>
<LI>MTX (initially 7.5 mg increasing to 20 mg at week 8)</LI>
</OL>
<P>(PBO controlled)<BR/>Duration: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:55:46 -0400" MODIFIED_BY="Anne Lawson">
<P>ACR20, ACR50, ACR70<BR/>Radiographic: TSS, Erosion Score, Joint Space Narrowing Score; withdrawals; adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-14 15:55:46 -0400" MODIFIED_BY="[Empty name]">
<P>Early RA; MTX naive; most erosions and RF+</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:56:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Combe-2006">
<CHAR_METHODS MODIFIED="2013-03-14 15:55:50 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was computer generated</P>
<P>Allocation concealment not described</P>
<P>Double blinding</P>
<P>Multicentre, parallel group study</P>
<P>Power calculation not reported</P>
<P>No of participants randomised = 260</P>
<P>No of participants analysed = 254</P>
<P>Authors stated that they used a modified intention to treat analysis: "all randomly assigned patients who received any test article and provided efficacy data at baseline"</P>
<P>Measures to deal with missing data included LOCF</P>
<P>Source of funding: Wyeth (some authors either paid consultants or employees of Wyeth)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:55:57 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:</P>
<P>At least 18 years; diagnosis of adult onset RA; disease duration &#8804; 20 years; swelling in &#8805; 6 joints, &#8805; 6 tender joints, morning stiffness &#8805; 45 minutes, ESR &#8805; 28 mm/h or CRP &#8805; 20 mg/L</P>
<P>Previous stable doses of SSZ at least 4 weeks prior to the study, without signs of toxicity</P>
<P>Exclusion:</P>
<P>Previous treatment with etanercept or other TNF antagonist; treatment with DMARDs other than SSZ in 3 months before baseline; treatment with other biological agents or immunosuppressants within 6 months prior to the study entrance; or steroid injection in 4 weeks before study start; relevant co-morbidities; pregnancy or lactation</P>
<P>Stable doses of NSAIDs, analgesics or prednisone were allowed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:55:58 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 25 mg SC twice weekly + oral PBO once daily</LI>
<LI>SSZ tablets (2, 2.5 or 3 g daily) + SC PBO twice weekly</LI>
<LI>Etanercept 25 mg SC twice weekly + SSZ tablets (2, 2.5 or 3 g daily)</LI>
</OL>
<P>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:56:01 -0400" MODIFIED_BY="[Empty name]">
<P>ACR20, ACR50, ACR70</P>
<P>DAS44-ESR</P>
<P>SJC, TJC, morning stiffness, physician and participant global assessment, pain-VAS, general health-VAS, ESR, CRP</P>
<P>Functional status (HAQ)</P>
<P>EuroQoL</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-31 05:51:52 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:56:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<CHAR_METHODS MODIFIED="2013-03-14 15:56:11 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation was computer generated</P>
<P>Allocation concealment not described</P>
<P>Double blinding reported but masking removed for primary analysis of data at 1 year for publication. Data also unblinded for medical management of participants if needed</P>
<P>Multicentre, parallel group study (22 countries, 70 centres)</P>
<P>Power calculation reported (90% power to show a significant difference in remission; 94% power to show significant difference in radiographic progression)</P>
<P>No of participants randomised = 542</P>
<P>No of participants analysed = 542 (for safety outcomes). n = 528 for clinical efficacy. n = 476 for radiographic progression at end of first year</P>
<P>Authors stated that they used a modified intention-to-treat analysis: remission - all participants who received at least 1 dose of the drug and reported both baseline and at least 1 on-treatment DAS28 result; radiographic progression - all participants with valid baseline and follow-up radiographs. Measures to deal with missing data included LOCF and imputation by linear extrapolation</P>
<P>Source of funding: Wyeth (many authors either paid consultants or employees of Wyeth)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:56:14 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:</P>
<P>At least 18 years; diagnosis of adult onset RA; disease duration between 3 months and 2 years; DAS28 &#8805; 3.2; either Westergren ESR &#8805; 28 mm/h or CRP &#8805; 20 mg/L</P>
<P>Exclusion:</P>
<P>Previous treatment with MTX, etanercept or other TNF antagonist; treatment with other DMARDs or steroid injection in 4 weeks before baseline; important concurrent medical diseases; other relevant co-morbidities</P>
<P>Location: 22 countries, 70 centres in Europe, Latin America, Asia and Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:56:17 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 25 mg SC twice weekly + MTX oral 7.5 mg/week (titration up to a maximum of 20 mg/week over 8 weeks if necessary)</LI>
<LI>MTX oral 7.5 mg/week (with titration if necessary) + PBO SC injection</LI>
</OL>
<P>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:56:18 -0400" MODIFIED_BY="[Empty name]">
<P>Remission (DAS28 &lt; 2.6)</P>
<P>Change in modified TSS (from baseline to end of year 1)</P>
<P>Functional status (HAQ Disability Index)</P>
<P>Employment status</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:56:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2009">
<CHAR_METHODS MODIFIED="2013-03-14 15:56:21 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not described</P>
<P>Method of allocation concealment not described</P>
<P>Blinding not described but treatments appeared identical</P>
<P>Multicentre, parallel group study (6 centres)</P>
<P>Power calculation not reported</P>
<P>No of participants randomised = 238</P>
<P>No of participants analysed = 238</P>
<P>Drop-outs: 17 in treatment group (reasons given) and 12 in control group (reasons given)</P>
<P>Intention-to-treat analysis (LOCF for drop-outs)</P>
<P>Source of funding: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:56:27 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:</P>
<P>18-65 years of age; active RA (as defined by ACR 1987 criteria: swelling in &#8805; 6 joints, &#8805; 6 tender joints, morning stiffness &#8805; 45 minutes, ESR &#8805; 28 mm/h, CRP &#8805; 20 &#956;g/mL)</P>
<P>Exclusion criteria:</P>
<P>Any serious illness (heart, liver, renal, blood or other vital organs); pregnant or breastfeeding; previous treatment with Yisaipu or other biological agents; no efficacy to treatment with MTX; joint injection of corticosteroids within past 4 weeks; any acute or chronic infection or past history of active TB; any tumour or family history of tumour</P>
<P>Stable doses of NSAIDs or prednisone were allowed but all DMARDS were discontinued at least 4 weeks prior to the study</P>
<P>Location: 6 hospitals in China</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:56:30 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Yisaipu 25 mg SC twice weekly + oral PBO</LI>
<LI>MTX 3 x 2.5 mg (increasing to 5 mg) per week + PBO injection</LI>
</OL>
<P>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-20 22:40:15 -0400" MODIFIED_BY="[Empty name]">
<P>ACR20, ACR50, ACR70</P>
<P>Withdrawals</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-27 17:15:44 -0400" MODIFIED_BY="[Empty name]">
<P>Yisaipu is a rhTNFR:Fc available in China. The authors claim it has the same structure as etanercept</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-20 14:37:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kameda-2010">
<CHAR_METHODS MODIFIED="2013-03-14 15:56:35 -0400" MODIFIED_BY="[Empty name]">
<P>Randomisation was computer generated and stratified by baseline age, disease duration, disease activity and institution</P>
<P>Method of allocation concealment not described</P>
<P>No blinding</P>
<P>Multicentre, parallel group study (34 centres in Japan)</P>
<P>Power calculation not reported</P>
<P>No of participants randomised = 151</P>
<P>No of participants analysed = 147 (safety), 142 (efficacy)</P>
<P>Dropouts: 4 in treatment group (reasons given) and 12 in control group (reasons given)</P>
<P>Modified intention-to-treat analysis: all participants who took the study drugs and had a valid baseline and at least 1 on-therapy value for each end point (LOCF for drop-outs)</P>
<P>Source of funding: not reported, however, many authors were paid consultants of Wyeth</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-20 14:37:37 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:</P>
<P>&#8805; 18 years of age; RA (as defined by ACR 1987 criteria); active disease; swelling in &#8805; 6 joints, &#8805; 6 tender joints, ESR &#8805; 28 mm/h, adequate safety profiles; RA functional class I-III. Treatment with MTX at least 6 mg/week in 3 months before baseline (stable dose)</P>
<P>Exclusion criteria:</P>
<P>Treatment with &gt; 10 mg/day prednisolone; treatment with DMARDs other than MTX; previously treated with any biological agent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:56:44 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept SC twice weekly + oral MTX (6-8 mg/week)</LI>
<LI>Etanercept SC twice weekly</LI>
</OL>
<P>Duration: 2 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:56:46 -0400" MODIFIED_BY="[Empty name]">
<P>EULAR criteria</P>
<P>DAS28 and remission rate</P>
<P>ACR20, ACR50, ACR70)</P>
<P>van der Heijde-modified Sharp Score</P>
<P>Withdrawals</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-31 07:26:16 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:57:08 -0400" MODIFIED_BY="Anne Lethaby" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<CHAR_METHODS MODIFIED="2013-03-14 15:56:53 -0400" MODIFIED_BY="Anne Lethaby">
<P>Randomisation method not described<BR/>Allocation concealment<BR/>Triple blinding<BR/>Multicentre (N = 19), parallel group study<BR/>Power calculation for sample size<BR/>No of participants randomised = 686<BR/>No of participants analysed = 682 (4 did not receive treatment)<BR/>Modified intention-to-treat analysis (those who received the study drug). Other missing data estimated by LOCF or linear extrapolation<BR/>Source of funding: Wyeth Research (pharmaceutical company)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:56:59 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:<BR/>&#8805; 18 years of age; disease duration 6 months to 20 years; active RA; less than satisfactory response to at least 1 DMARD (except MTX); treatment with MTX in last 6 months; toxic effects from previous MTX treatment<BR/>Exclusion:<BR/>Previous treatment with etanercept or other TNF antagonist; previous treatment with immunosuppressive drugs in past 6 months; use or any investigative drug or biological agent in past 3 months; use of any other DMARD or steroid injection in past 4 weeks; presence of co-morbidity<BR/>Location: 17 centres in Europe, Australia and Israel</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:57:02 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 25 mg SC twice weekly + MTX</LI>
<LI>Etanercept 25 mg SC twice weekly</LI>
<LI>MTX (7.5 mg escalating to 20 mg) oral/week</LI>
</OL>
<P>PBO controlled<BR/>Duration: 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:57:08 -0400" MODIFIED_BY="Anne Lawson">
<P>ACR20, ACR50, ACR70<BR/>Radiographic: TSS; Erosion Score; Joint Space Narrowing Score<BR/>HAQ; DAS<BR/>Satisfaction<BR/>Adverse events<BR/>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-27 17:16:54 -0400" MODIFIED_BY="[Empty name]">
<P>Trial has continued open label</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:57:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcora-2006">
<CHAR_METHODS MODIFIED="2013-03-14 15:57:15 -0400" MODIFIED_BY="[Empty name]">
<P>Computer-generated list of random numbers<BR/>Allocation concealment not reported<BR/>Only investigators measuring outcomes were blinded<BR/>Single centre, parallel group study<BR/>Power calculation not reported<BR/>No of participants randomised = 26<BR/>No of participants analysed = 24 (2 in MTX group dropped out: 1 lost to follow-up and 1 started physical training)<BR/>Not intention-to-treat analysis<BR/>Source of funding: Wyeth provided the etanercept treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:57:19 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:<BR/>&#8805; 18 years of age; diagnosis of RA; &lt; 6 months history of RA; active disease<BR/>Exclusion:<BR/>Previous treatment with DMARD or corticosteroid treatment; recent history of important infection; concurrent disease; cognitive impairment; any other cachectic disease; taking drugs or supplements affecting muscle mass; participating in physical training<BR/>Location: Clinic in Welsh Hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:57:28 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 25 mg SC twice weekly</LI>
<LI>MTX 7.5 mg/week escalating to 20 mg/week if necessary</LI>
</OL>
<P>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physical function (handgrip strength; arm-curl test; walking velocity; sit to stand test)<BR/>HAQ<BR/>Adverse events<BR/>DAS28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-14 15:57:28 -0400" MODIFIED_BY="[Empty name]">
<P>Primary objective to assess effects of treatment on cachexia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:57:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moreland-1999">
<CHAR_METHODS MODIFIED="2013-03-14 15:57:32 -0400" MODIFIED_BY="[Empty name]">
<P>Blocked randomisation with stratification by study site<BR/>Allocation concealed<BR/>Double blinding<BR/>Multicentre (n = 13), parallel group study<BR/>Power calculation not reported<BR/>No of participants randomised = 246<BR/>No of participants analysed = 234 (12 not eligible after randomisation)<BR/>Intention-to-treat analysis by counting withdrawals as non-responders and using last available observation for drop-outs<BR/>Source of funding: Immunex (pharmaceutical company)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:57:35 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:<BR/>&#8805; 18 years of age; active RA; inadequate response to a DMARD<BR/>90% of participants had used MTX previously<BR/>Location: 13 centres in North America</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:57:38 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 10 mg SC twice weekly</LI>
<LI>Etanercept 25 mg SC twice weekly</LI>
<LI>PBO SC twice weekly</LI>
</OL>
<P>Concomitant treatment with oral steroids, analgesics and NSAIDs allowed<BR/>Washout period for previous DMARDs<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:57:40 -0400" MODIFIED_BY="[Empty name]">
<P>ACR20, ACR50, ACR70<BR/>Radiographic: TJC; SJC<BR/>HAQ<BR/>Adverse events<BR/>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-14 15:57:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinblatt-1999">
<CHAR_METHODS MODIFIED="2013-03-14 15:57:45 -0400" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not reported<BR/>Allocation concealment not reported<BR/>Double blinding<BR/>Multicentre, parallel group study<BR/>Power calculation for sample size<BR/>No of participants randomised = 89<BR/>No of participants analysed = 89 (2 withdrew in etanercept group because of adverse events; 4 withdrew in MTX group because of lack of efficacy, 1 because of myocardial infarction, 1 lost to follow-up)<BR/>Intention-to-treat analysis (participants who withdrew were considered not to have a response and for individual measures, last observation was used in the analysis)<BR/>Source of funding: Immunex (pharmaceutical company)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:57:46 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion:<BR/>&#8805; 18 years of age; diagnosis of RA; active disease<BR/>Exclusion not reported<BR/>Location: centres in North America</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:57:51 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Etanercept 25 mg SC twice weekly + MTX</LI>
<LI>MTX + etanercept PBO</LI>
</OL>
<P>All participants had been taking MTX prior to study for at least 6 months<BR/>All participants received folic acid and were allowed to use NSAIDs or steroids during study<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:57:54 -0400" MODIFIED_BY="Anne Lawson">
<P>ACR20, ACR50, ACR70<BR/>Radiographic: TJC; SJC<BR/>HAQ<BR/>Adverse events<BR/>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACR: American College of Rheumatology; CRP: C reactive protein; DAS: disease activity score; DMARD: disease-modifying anti-rheumatic drug; ESR: erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; h: hour; HAQ: Health Assessment Questionnaire; LOCF: last observation carried forward; MTX: methotrexate; NSAID: non-steroidal anti-inflammatory drug; PBO: placebo; RA: rheumatoid arthritis; RF+: rheumatoid factor positive; SC: subcutaneous; SJC: swollen joint count; SSZ: sulphasalazine; TB: tuberculosis; TJC: tender joint count; TNF: tumour necrosis factor; TSS: Total Sharp Score; VAS: visual analogue scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-03-14 15:58:42 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACP-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:08 -0400" MODIFIED_BY="[Empty name]">
<P>Summary of Bathon 2000 with no new information provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-07 16:49:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angel-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-07 16:49:48 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome is arterial stiffness. Participants are a mixed group of RA and other diseases. Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anis-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:10 -0400" MODIFIED_BY="[Empty name]">
<P>Data is from the COMET trial. Outcome not listed as an eligible outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benucci-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:19 -0400" MODIFIED_BY="[Empty name]">
<P>Three arms were included: adalimumab + leflunomide or MTX</P>
<P>Etanercept + leflunomide or MTX</P>
<P>Infliximab + leflunomide or MTX</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blank-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:20 -0400" MODIFIED_BY="[Empty name]">
<P>Intervention is etanercept + rituximab. Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-22 12:17:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bliddal-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-22 12:17:05 -0500" MODIFIED_BY="[Empty name]">
<P>Trial of intra-articular injection of etanercept</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-22 12:17:32 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boesen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-22 12:17:32 -0500" MODIFIED_BY="[Empty name]">
<P>Trial of intra-articular injection of etanercept</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:15 -0400" MODIFIED_BY="[Empty name]">
<P>Study duration only 12 weeks. Does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cuomo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:26 -0400" MODIFIED_BY="[Empty name]">
<P>Four arms were included: MTX + sulphasalazine</P>
<P>MTX + adalimumab</P>
<P>MTX + etanercept</P>
<P>MTX + infliximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Filippis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:27 -0400" MODIFIED_BY="[Empty name]">
<P>CCT compares etanercept vs. infliximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Stefano-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:27 -0400" MODIFIED_BY="[Empty name]">
<P>CCT compares etanercept + MTX versus etanercept + leflunomide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garnero-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:19 -0400" MODIFIED_BY="[Empty name]">
<P>Patient subset from published studies looking at collagen markers and joint destruction. The relationship of collagen markers to joint destruction was not an outcome of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genovese-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:28 -0400" MODIFIED_BY="[Empty name]">
<P>Study was an extension of the Bathon study at 24 months. All participants who completed the Bathon study were eligible and were given etanercept 25 mg and were followed forward for 5 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genovese-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:28 -0400" MODIFIED_BY="[Empty name]">
<P>Compares etanercept monotherapy vs. etanercept (half dose) + anakinra versus etanercept + anakinra</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlag-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:29 -0400" MODIFIED_BY="[Empty name]">
<P>12-week RCT with an open-label etanercept arm. Does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-03 12:13:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-03 12:13:24 -0400" MODIFIED_BY="[Empty name]">
<P>Participants are a mixed group of RA + psoriatic arthritis. Intervention is mixed: etanercept or adalimumab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-15 12:39:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwamoto-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-15 12:39:17 -0400" MODIFIED_BY="[Empty name]">
<P>Observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnsen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:30 -0400" MODIFIED_BY="[Empty name]">
<P>Comparison of doses of etanercept. 1 arm had a dose of 50 mg of etanercept twice weekly - this dose does not meet the inclusion criteria for this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kavanaugh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:30 -0400" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis of TEMPO trial. Analysis of changes in responders and non-responders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keystone-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:37 -0400" MODIFIED_BY="[Empty name]">
<P>Study was less than 6 months in duration and included a dose of etanercept (50 mg) which does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keystone-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:39 -0400" MODIFIED_BY="[Empty name]">
<P>Results of TEMPO and other earlier trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-15 12:39:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koumakis-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-15 12:39:19 -0400" MODIFIED_BY="[Empty name]">
<P>intervention is a combination of therapies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:41 -0400" MODIFIED_BY="[Empty name]">
<P>Study duration only 12 weeks - this does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lisbona-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:42 -0400" MODIFIED_BY="[Empty name]">
<P>Study duration only 6 weeks. Does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lukas-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:43 -0400" MODIFIED_BY="[Empty name]">
<P>Subgroup from TEMPO. Agreement between readings of joint scores</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lukas-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:44 -0400" MODIFIED_BY="[Empty name]">
<P>Subgroup from TEMPO. Relationship between inflammation and repair</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lukina-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:31 -0400" MODIFIED_BY="[Empty name]">
<P>Compared TNF alpha (?drug) to interferon gamma to placebo. Drugs given intramuscularly daily for 5 days with outcome determination at days 7 and 28. Even if etanercept used, study duration too short to meet inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luzi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:33 -0400" MODIFIED_BY="[Empty name]">
<P>Not randomised. Interventions are etanercept + MTX vs. etanercept + MTX + steroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:18:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Machado-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:18:48 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome not listed as an eligible outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moreland-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:33 -0400" MODIFIED_BY="[Empty name]">
<P>3-month study only so does not meet inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:35 -0400" MODIFIED_BY="Anne Lethaby" STUDY_ID="STD-Moreland-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:35 -0400" MODIFIED_BY="Anne Lethaby">
<P>Examined all participants who had received at least 1 dose of etanercept in controlled or open-label trials for efficacy and safety at a date removed from trial. Doesn't meet inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paleolog-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:35 -0400" MODIFIED_BY="[Empty name]">
<P>Looked at synovial cells from participants treated with anti-TNF alpha</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-03 12:13:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roux-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-03 12:13:29 -0400" MODIFIED_BY="[Empty name]">
<P>Trial of intra-articular injection of etanercept</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saleem-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:37 -0400" MODIFIED_BY="[Empty name]">
<P>Interventions are: combination therapy of a TNF agent (any) + MTX vs. DMARDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:19:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sennels-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:19:25 -0400" MODIFIED_BY="[Empty name]">
<P>Study duration only 16 weeks. Does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:19:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Riel-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:19:26 -0400" MODIFIED_BY="[Empty name]">
<P>Study duration only 16 weeks. Does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-14 15:58:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinblatt-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-14 15:58:38 -0400" MODIFIED_BY="[Empty name]">
<P>Compares etanercept + abatacept vs. etanercept + placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:19:29 -0400" MODIFIED_BY="Anne Lethaby" STUDY_ID="STD-Weinblatt-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:19:29 -0400" MODIFIED_BY="Anne Lethaby">
<P>Dose of etanercept did not meet the inclusion criteria of the review and study duration too short (12 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-27 17:19:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-27 17:19:29 -0400" MODIFIED_BY="[Empty name]">
<P>Study duration only 16 weeks. Does not meet the inclusion criteria of this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CCT: controlled clinical trial; DMARD: disease-modifying anti-rheumatic drug; MTX: methotrexate; RA: rheumatoid arthritis; RCT: randomised controlled trial; TNF: tumour necrosis factor.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-07-17 15:56:48 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-03-20 15:11:38 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-03-20 15:10:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EMPIRE-2006">
<CHAR_STUDY_NAME MODIFIED="2013-03-12 08:20:33 -0400" MODIFIED_BY="[Empty name]">
<P>EMPIRE (Etanercept and Methotrexate in Patients to Induce Remission in Early arthritis)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-03-14 15:58:43 -0400" MODIFIED_BY="Anne Lethaby">
<P>Multicentre, double-blind, placebo-controlled RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-20 15:10:15 -0400" MODIFIED_BY="Anne Lethaby">
<P>Inclusion: aged 18-80 years; articular synovitis within 3 months of diagnosis; either rheumatoid factor antibody positive or anti-cyclic citrullinated peptide positive; not pregnant; negative TB screening test</P>
<P>Exclusion: previous treatment with DMARDs, etanercept or TNF drugs; HIV; significant concurrent medical diseases; cancer or history of cancer; chronic infection of upper respiratory tract; ongoing or active infection; liver function abnormality; renal disease; leukopenia; thrombocytopenia, etc. (large list of exclusions)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:58:49 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept + MTX vs. placebo + MTX</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-20 15:10:31 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: proportion in clinical remission at 12 months (defined as absence of symptoms and signs of inflammatory arthritis: i.e. SJC = 0; TJC = 0)</P>
<P>Secondary: number of participants in clinical remission at 18 months (see above for definition of remission); disease activity measures (VAS; EMS, TJC, SJC, CRP, ESR); functional, work and quality of life assessments (HAQ; WIS, WDA, EuroQol; SF-36); proportion of participants achieving 26 weeks of remission; DAS28; radiographic change</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-24 13:38:57 -0400" MODIFIED_BY="[Empty name]">
<P>October 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-24 13:39:23 -0400" MODIFIED_BY="[Empty name]">
<P>A.Keenan@Leeds.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-24 13:38:23 -0400" MODIFIED_BY="[Empty name]">
<P>Funded by Wyeth</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-03-14 15:59:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-France-2008">
<CHAR_STUDY_NAME MODIFIED="2013-03-14 15:59:05 -0400" MODIFIED_BY="[Empty name]">
<P>An Open-Label, Randomised Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) Added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-03-14 15:59:06 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised open-label parallel group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:59:08 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion: meet the ACR 1987 revised criteria for RA; documented evidence confirmed by a blinded 3rd party assessor of at least 1 erosion observed by x-ray; received MTX as stable dose for 28 days prior to the screening visit</P>
<P>Exclusion: previous treatment with etanercept, infliximab, adalimumab, other TNF-alpha inhibitors, anakinra or other biological agents; previous combination DMARD therapy; receipt of any DMARD, other than MTX, within 28 days of screening</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:59:09 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept + MTX vs. usual treatment (not defined)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:59:10 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: radiographic disease progression (not defined) at week 52</P>
<P>Secondary: clinical outcomes, QoL and safety (not defined)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-27 12:12:04 -0400" MODIFIED_BY="[Empty name]">
<P>June 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-27 12:12:51 -0400" MODIFIED_BY="[Empty name]">
<P>clintrialparticipation@wyeth.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-27 12:13:09 -0400" MODIFIED_BY="[Empty name]">
<P>Estimated completion June 2010. Funded by Wyeth</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-03-14 15:59:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Japanese-2006">
<CHAR_STUDY_NAME MODIFIED="2013-03-14 15:59:20 -0400" MODIFIED_BY="[Empty name]">
<P>A Randomised, Double-Blind, Multi-Centre, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects with Active Rheumatoid Arthritis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-03-14 15:59:22 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre, double-blind (subjects, carers, investigators, outcome assessors), parallel group RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:59:23 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion: Japanese citizen living in Japan; 20 to 75 years; diagnosed &#8804;5 years from time of first visit</P>
<P>Exclusion: Etanercept or TNF inhibitors such as infliximab, or adalimumab in the past; other rheumatic diseases or conditions that could predispose the person to infection, pregnant or lactating women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:59:24 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept 10 or 25 mg SC twice weekly for 52 weeks vs. MTX (up to 8 mg/week) oral for 52 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:59:26 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: radiographic scores (change in modified TSS from baseline) at 52 weeks</P>
<P>Secondary: adverse events incidence at 52 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-27 11:26:18 -0400" MODIFIED_BY="[Empty name]">
<P>June 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-27 11:26:37 -0400" MODIFIED_BY="[Empty name]">
<P>clinicaltrialparticipation@wyeth.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-04-27 17:20:15 -0400" MODIFIED_BY="[Empty name]">
<P>Estimated completion: October 2010. Funded by Wyeth</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-03-14 15:59:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jobanputra-2005">
<CHAR_STUDY_NAME MODIFIED="2013-03-14 15:59:33 -0400" MODIFIED_BY="[Empty name]">
<P>Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept plus Methotrexate plus Steroid with Standard Therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-03-14 15:59:34 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised single-blind pilot study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 15:59:40 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion: aged &gt; 18 years; synovial swelling of at least 1 joint confirmed by clinical assessment; seropositivity for RF and anti-CCP antibody; adequate birth control measures if fertile; if female, not pregnant; informed consent</P>
<P>Exclusion: duration of symptoms attributable to inflammatory joint disease of &gt; 12 weeks; previous history of inflammatory arthritis; previous use of DMARDs or anti-TNF agents; current inflammatory condition; history of other evidence of latent or active infection; virus or bacterial vaccination within 3 months before treatment; history of joint prosthesis infection of administration of antibiotics for a suspicion of this; serious and uncontrolled existing disease; bleeding disorder or use of anticoagulants; malignancy or history of malignancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 15:59:41 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept + MTX + parenteral steroid vs. conventional therapy (parental steroid plus MTX if necessary)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-14 15:59:46 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: percentage of participants in drug-free clinical remission at week 48 (having withdrawn therapy at week 24) (defined as DAS28 &lt; 2.6 plus no clinical evidence of joint swelling)</P>
<P>Secondary: percentage of participants in clinical remission (see above) at week 24 (when drugs are withdrawn if remission achieved); percentage of participants in clinical remission at weeks 24 and 48 according to ARA criteria; percentage of participants with radiological remission at week 24 (no MRI or radiological remission at week 24); clinical disease activity measures (ACR rates; DAS28; HAQ, EuroQol) at 24 and 48 weeks; rate of progression of radiological change according to van Heijde modification of the TSS from baseline to week 48 and 96; biological predictors of response to therapy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-27 11:44:12 -0400" MODIFIED_BY="[Empty name]">
<P>December 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-27 11:52:14 -0400" MODIFIED_BY="[Empty name]">
<P>Dr P. Jobanputra, Selly Oak Hospital, Birmingham</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-04-27 17:20:20 -0400" MODIFIED_BY="[Empty name]">
<P>Estimated completion: December 2008. Funded by University Hospital of Birmingham NHS Trust and NHS R &amp; D support funding</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-03-14 16:00:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takeuchi-2005">
<CHAR_STUDY_NAME MODIFIED="2013-03-14 15:59:52 -0400" MODIFIED_BY="[Empty name]">
<P>Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-03-14 15:59:53 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised, open-label, parallel group study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-14 16:00:14 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion: aged &#8805; 18 years; meet the ACR 1987 criteria for RA; at least 6 tender joints and 6 swollen joints; either CRP &gt; 2 mg/dL or ESR no less than 28 mm at 1 hour; ACR functional class I-III; receiving MTX 6 mg/week for a minimum of 3 months at stable dose for at least 4 weeks at the time of enrolment</P>
<P>Exclusion: those requiring concurrent use of prednisone &gt; 10 mg/day or its equivalent; the start of dose increments of prednisone equivalents within 3 months of enrolment; anti-RA therapy except for MTX or prednisone equivalents; previous treatment with etanercept or any other biological treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-14 16:00:15 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept (25 mg SC twice a week) + MTX (oral, 6-8 mg/week) vs. etanercept (25 mg SC twice a week) alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-27 17:20:25 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: ACR50 and DAS28 "good response" at 24 weeks; TSS at 52 weeks</P>
<P>Secondary: ACR20 and ACR70 at 24 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-27 12:00:56 -0400" MODIFIED_BY="[Empty name]">
<P>June 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-27 12:02:54 -0400" MODIFIED_BY="[Empty name]">
<P>Dr T. Takeuchi, Saitama Medical Center, Kawagoe, Saitama, Japan</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-04-27 17:20:28 -0400" MODIFIED_BY="[Empty name]">
<P>Estimate completion: October 2010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ACR: American College of Rheumatology; ARA: American Rheumatology Association; CRP: C reactive protein; DMARD: disease-modifying anti-rheumatic drug; EMS: early morning stiffness; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; HIV: human immunodeficiency virus; MRI: magnetic resonance imaging; MTX: methotrexate; QoL: quality of life; RA: rheumatoid arthritis; RF: rheumatoid factor; RCT: randomized controlled trial; SC: subcutaneous; SF-36: short form-36; SJC: swollen joint count; TB: tuberculosis; TNF: anti-tumour necrosis factor; TJC: tender joint count; TNF: tumour necrosis factor; TSS: Total Sharp Score; VAS: visual analogue scale; WDA: work disability appointments; WIS: Work Instability Scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-03-14 15:57:29 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-03-14 15:57:29 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:26:40 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:14:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Combe-2006">
<DESCRIPTION>
<P>Method of randomisation was computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-15 12:39:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:15:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009">
<DESCRIPTION>
<P>Described only as "randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-01 13:59:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kameda-2010">
<DESCRIPTION>
<P>"Randomization was performed on the University Hospital Medical Information Network's web site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 19:34:01 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-14 15:57:29 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Marcora-2006">
<DESCRIPTION>
<P>Computer-generated list of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:53:42 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Moreland-1999">
<DESCRIPTION>
<P>Blocked randomisation with stratification according to study site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 14:56:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinblatt-1999">
<DESCRIPTION>
<P>No method of randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-03-14 15:56:46 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:26:51 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:14:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Combe-2006">
<DESCRIPTION>
<P>Allocation concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-15 12:39:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<DESCRIPTION>
<P>Central control by computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:15:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-14 15:56:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kameda-2010">
<DESCRIPTION>
<P>Method of allocation concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 14:50:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<DESCRIPTION>
<P>Centralised telephone randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:39:28 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Marcora-2006">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:54:04 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Moreland-1999">
<DESCRIPTION>
<P>Randomisation code housed with the sponsor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 17:45:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinblatt-1999">
<DESCRIPTION>
<P>No description of method used to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-03-14 15:57:08 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Clinical outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-14 15:55:47 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<DESCRIPTION>
<P>Not explicitly described but PBO controlled; assessors of radiographic scores unaware of assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-27 17:14:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Combe-2006">
<DESCRIPTION>
<P>Stated double blind and treatments were identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-15 12:39:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<DESCRIPTION>
<P>Stated as double blind, but masking removed for primary analysis of data for the publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-27 17:15:47 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hu-2009">
<DESCRIPTION>
<P>Stated double blind and treatments were identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-14 15:56:46 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kameda-2010">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-14 15:57:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<DESCRIPTION>
<P>Triple blinding (participants, investigators and assessors)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-26 15:50:05 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marcora-2006">
<DESCRIPTION>
<P>"Patients and clinician. . . . . aware of treatment allocation" but assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-10 18:54:45 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Moreland-1999">
<DESCRIPTION>
<P>Double blind, participants and key personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-30 21:50:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinblatt-1999">
<DESCRIPTION>
<P>Stated as "double blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-03-14 15:57:29 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Clinical outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-14 15:55:49 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<DESCRIPTION>
<P>Analyses were intention to treat: inclusion of all participants who received at least 1 dose of the study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-14 15:56:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Combe-2006">
<DESCRIPTION>
<P>Analyses were based on a modified intention to treat: inclusion of all participants who received at least 1 dose of the study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-12 17:45:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<DESCRIPTION>
<P>Reasons documented for dropouts. Methods employed to deal with missing data: LOCF or imputation by linear extrapolation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-14 15:56:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hu-2009">
<DESCRIPTION>
<P>Analysis by intention to treat (LOCF for drop-outs)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-14 15:56:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kameda-2010">
<DESCRIPTION>
<P>Modified intention-to-treat analysis: all participants who took the study drugs and had a valid baseline and at least 1 on-therapy value for each end point (LOCF for drop-outs)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-14 15:57:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<DESCRIPTION>
<P>Clear descriptions of methods for dealing with missing data (LOCF, linear extrapolation and assumption that participants withdrawing from the study had no response to treatment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-14 15:57:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcora-2006">
<DESCRIPTION>
<P>Minimal drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-12 17:45:31 -0400" MODIFIED_BY="Anne Lethaby" RESULT="YES" STUDY_ID="STD-Moreland-1999">
<DESCRIPTION>
<P>Reasons for withdrawal clearly specified with methods stated to deal with missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-23 14:58:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinblatt-1999">
<DESCRIPTION>
<P>Clear descriptions of reasons for withdrawal of dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-03-14 15:56:49 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:14:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<DESCRIPTION>
<P>No evidence of a prior published protocol but wide range of outcomes assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:15:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Combe-2006">
<DESCRIPTION>
<P>No evidence of a prior published protocol but wide range of outcomes assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:13:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<DESCRIPTION>
<P>No protocol for study identified but wide range of outcomes assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:15:48 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hu-2009">
<DESCRIPTION>
<P>No protocol sighted but all important outcomes measured</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-14 15:56:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kameda-2010">
<DESCRIPTION>
<P>No protocol sighted but all important outcomes measured</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-15 12:42:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<DESCRIPTION>
<P>No access to prior protocol to check for selective reporting but wide range of outcomes measured</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-10 18:46:39 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Marcora-2006">
<DESCRIPTION>
<P>No prior published protocol identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-15 12:42:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moreland-1999">
<DESCRIPTION>
<P>No prior published protocol identified but wide range of outcomes measured</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-15 12:39:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinblatt-1999">
<DESCRIPTION>
<P>No prior published protocol identified but wide range of outcomes measured</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-03-12 17:45:32 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 17:45:32 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_">
<DESCRIPTION>
<P>Drug company funding with no guarantees described to ensure that the results were not influenced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-31 06:30:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Combe-2006">
<DESCRIPTION>
<P>Source of funding: Wyeth (some authors either paid consultants or employees of Wyeth)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:15:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_">
<DESCRIPTION>
<P>Good baseline comparability. Drug company funding with no guarantees to ensure results not influenced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 17:15:49 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2009">
<DESCRIPTION>
<P>Funding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-31 07:28:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kameda-2010">
<DESCRIPTION>
<P>Source of funding: not reported, however, many authors were paid consultants of Wyeth</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 17:45:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_">
<DESCRIPTION>
<P>Drug company funding with no guarantees described to prevent influence on results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 17:45:31 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Marcora-2006">
<DESCRIPTION>
<P>Drug company funding with no guarantees described to prevent influence on the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 17:45:31 -0400" MODIFIED_BY="Anne Lethaby" RESULT="UNKNOWN" STUDY_ID="STD-Moreland-1999">
<DESCRIPTION>
<P>Drug company funding with no guarantees described to prevent influence on results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-12 17:45:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinblatt-1999">
<DESCRIPTION>
<P>Drug company funding with no guarantees described to prevent influence on results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-01-24 10:21:09 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-03-28 16:14:17 -0400" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-12-17 16:34:46 -0500" MODIFIED_BY="Grade Profiler">Inadequate responders to traditional disease-modifying anti-rheumatic drugs (DMARDs)</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>E</B>tanercept<B> 25 mg + DMARD for the treatment of rheumatoid arthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with rheumatoid arthritis and with a partial response to DMARDs<BR/>
<B>Settings:</B> international hospital or clinic settings<BR/>
<B>Intervention:</B> etanercept 25 mg + DMARD<BR/>
<B>Comparison</B>: DMARD<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DMARD</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ET 25 mg + DMARD</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>ACR50</B>
<BR/>American College of Rheumatology 50% improvement criteria<BR/>Follow-up: 24 to 156 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>405 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>793 per 1000</B>
<BR/>(538 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.96 </B>
<BR/>(1.33 to 2.89)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1198<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 38% (95% CI 13% to 59%); Relative percent change 96% (95% CI 33% to 189%);<BR/>NNTB 3 (95% CI 2 to 8)</P>
<P>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>
</P>
<P/>
<P/>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Remission</B>
<BR/>Achievement of disease activity score &lt; 2.6<BR/>Follow-up: 52 and 156 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>236 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>454 per 1000</B>
<BR/>(378 to 546)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.92 </B>
<BR/>(1.6 to 2.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>987<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 22% (95% CI 17% to 27%);</P>
<P>Relative percent change 122% (95% CI 50% to 229%);</P>
<P>NNTB 5 (95% CI 4 to 8)</P>
<P>
<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>
</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Reduction in disability score</B>
<BR/>Health Assessment Questionnaire. Scale from: 0 to 3<BR/>Follow-up: mean 24 to 156 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean reduction in disability score ranged across control groups from<BR/>
<B>-0.15 to -0.72 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean reduction in disability score in the intervention groups was<BR/>
<B>0.36 lower</B>
<BR/>(0.43 lower to 0.28 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1227<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -12% (95% CI -16% to -2%);</P>
<P>Relative percent change 57% (95% CI 5% to 76%);</P>
<P>NNTB 5 (95% CI 4 to 6).<SUP>3 </SUP>
</P>
<P>
<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>
</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Radiographic progression</B>
<BR/>Total Sharp Score Scale from: 0 to 448<BR/>Follow-up: 52 and 156 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean radiographic progression ranged across control groups from<BR/>
<B>2.4 to 5.96 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean radiographic progression in the intervention groups was<BR/>
<B>3.83 lower</B>
<BR/>(7.67 lower to 0.01 higher)<SUP>1,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>903<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Statistically significant for all participants (MD -2.2; 95% CI -3.0 to -1.4);</P>
<P>Absolute treatment benefit -0.49% (95% CI -0.67% to -0.32%);</P>
<P>Relative percent change -92% (95% CI -125% to -59.6%);</P>
<P>NNTB 6 (95% CI 5 to 9)<BR/>
<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>
</P>
<P/>
<P>Smaller sample size in inadequate responders did not achieve statistical significance. However, the point estimate is very similar (MD -3.83; 95% CI -7.67 to 0.01);</P>
<P>Absolute treatment benefit -0.85% (95% CI -1.7% to 0.002%);</P>
<P>Relative percent change -64% (95% CI -128.9% to 0.17%); NNTB N/A.<SUP>3</SUP>
</P>
<P>
<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>
</P>
<P>
<BR/>When we transform the x-ray score to an estimate of irreversible physical disability, etanercept + DMARD treatment would prevent an increase in irreversible disability of 0.45 irreversible HAQ units over 10 years (15%) in addition to the reversible change noted in the disability row above</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawals</B>
</P>
<P>
<B>due to adverse events</B>
</P>
<P>Follow-up: 24 to 156 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>158 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
<P>(90 to 158)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.75</B> (0.57 to 1.0)<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>1241<BR/>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Not statistically significant;</P>
<P>Absolute risk difference -4% (95% CI -8% to 0%);</P>
<P>Relative percent change -25% (95% CI -43% to 0%);</P>
<P>NNTH N/A</P>
<P>
<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>
</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>Follow-up: 24 to 156 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>141 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
<BR/>(104 to 297)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.25 </B>
<BR/>(0.74 to 2.11)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1241<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not statistically significant;</P>
<P>Absolute risk difference 5% (95% CI -4% to 13%);</P>
<P>Relative percent change 25% (95% CI -26% to 111%);</P>
<P>NNTH N/A</P>
<P>
<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>
</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious infections</B>
<BR/>Follow-up: 52 to 156 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>49 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>45 per 1000</B>
<BR/>(27 to 77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.91 </B>
<BR/>(0.54 to 1.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1152<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not statistically significant;</P>
<P>Absolute risk difference -0.49% (95% CI -3% to 2%);</P>
<P>Relative percent change -9% (95% CI -46% to 55%);</P>
<P>NNTH N/A</P>
<P>
<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>
</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>N/A</B>: not applicable; <B>NNTB</B>: number needed to treat for an additional beneficial outcome; <B>NNTH</B>: number needed to treat for an additional harmful outcome; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Random-effects model was used.<BR/>
<SUP>2</SUP> Inconsistency across studies (I<SUP>2 </SUP>statistic) was greater than 50% which may represent moderate heterogeneity.</P>
<P>
<SUP>3 </SUP>
<LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> was identified as the most representative study (to calculate baseline mean).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-01-24 10:21:09 -0500" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-09-22 21:21:03 -0400" MODIFIED_BY="Grade Profiler">Inadequate responders to methotrexate (MTX)</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>E</B>tanercept<B> 25 mg + DMARD for the treatment of rheumatoid arthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with rheumatoid arthritis and with partial response to MTX<BR/>
<B>Settings:</B> international hospital or clinic setting<BR/>
<B>Intervention:</B> etanercept 25 mg + DMARD (disease-modifying anti-rheumatic drug)<BR/>
<B>Comparison</B>: DMARD<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>DMARD</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ET 25 mg + DMARD</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>ACR50 </B>
<BR/>American College of Rheumatology improvement criteria<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>390 per 1000</B>
<BR/>(55 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 11.69 </B>
<BR/>(1.66 to 82.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>89<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 36% (95% CI 22% to 50%);</P>
<P>Relative percent change 1069% (95% CI 66% to 8147%);</P>
<P>NNTB 3 (95% CI 2 to 6)</P>
<P>
<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Remission</B>
<BR/>Disease activity score &lt; 2.6</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Reduction in disability score</B>
<BR/>Health Assessment Questionnaire (mean improvement from baseline). Scale from: 0 to 3<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean reduction in disability score in the control groups was<BR/>
<B>-0.4 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean reduction in disability score in the intervention groups was<BR/>
<B>0.3 lower</B>
<BR/>(0.62 lower to 0.02 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>89<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -10% (95% CI -21% to 0.6%);<BR/>Relative percent change 75% (95% CI 5% to 155%)<SUP>2</SUP>
</P>
<P>
<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Radiographic progression</B>
<BR/>Total Sharp Score<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Withdrawals due to adverse events</B>
<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
<BR/>(3 to 359)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.02 </B>
<BR/>(0.1 to 10.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>89<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not statistically significant;</P>
<P>Absolute risk difference 0.06% (95% CI -8% to 8%);</P>
<P>Relative percent change 2% (95% CI -90% to 977%);</P>
<P>NNTH N/A</P>
<P>
<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 1000</B>
<BR/>(7 to 175)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.25 </B>
<BR/>(0.05 to 1.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>89<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not statistically significant;<BR/>Absolute treatment benefit -10% (95% CI -23% to 3%);</P>
<P>Relative percent change -75% (95% CI -95% to 31%); NNTH N/A</P>
<P>
<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious infections</B>
<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>DMARD</B>: disease-modifying anti-rheumatic drug; <B>N/A</B>: not available; <B>NNTB</B>: number needed to treat for an additional beneficial outcome; <B>NNTH</B>: number needed to treat for an additional harmful outcome; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Evidence derived from 1 study only.<BR/>
</P>
<P>
<SUP>2</SUP> <LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK> was identified as the most representative study (to calculate baseline mean).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-03-28 16:15:27 -0400" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-03-20 15:12:11 -0400" MODIFIED_BY="Grade Profiler">ACR50, radiographic progression and serious infections</TITLE>
<TABLE COLS="10" ROWS="17">
<TR>
<TD COLSPAN="10">
<P>
<B>Etanercept for the treatment of rheumatoid arthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Patient or population:</B> participants with rheumatoid arthritis<BR/>
<B>Intervention:</B> etanercept<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Intervention</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Follow-up</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Etanercept </B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>ACR50 - </B>American College of Rheumatology Improvement Criteria</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD>
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>461 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>700 per 1000</B>
<BR/>(627 to 783)</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>RR 1.52 </B>
<BR/>(1.36 to 1.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>958<BR/>(2 studies)</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
<P>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute treatment benefit 24% (95% CI 18% to 30%);</P>
<P>Relative percent change 52% (95% CI 36% to 70%);</P>
<P>NNTB 5 (95% CI 4 to 7)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Etanercept (10 mg)</B>
</P>
</TD>
<TD>
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>392 per 1000</B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>298 per 1000</B>
<BR/>(227 to 388)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>RR 0.76 </B>
<BR/>(0.58 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>423<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute treatment benefit -10% (95% CI -19% to -1%;</P>
<P>Relative percent change 24% (95% CI -42% TO -1%);</P>
<P>NNTB not statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<BR/>
</P>
<P>
<B>Etanercept </B>
<BR/>
</P>
<P>
<BR/>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>480 per 1000</B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>686 per 1000</B>
<BR/>(585 to 811)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>RR 1.43 </B>
<BR/>(1.22 to 1.69)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>454<BR/>(1 study)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute treatment benefit 21% (95% CI 12% to 30%);</P>
<P>Relative percent change 43% (95% CI 22% to 69%);</P>
<P>NNTB 5 (95% CI 4 to 10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2">
<P>
<B>Etanercept (25 mg)</B>
</P>
</TD>
<TD>
<P>
<B>PBO</B>
<BR/>
</P>
</TD>
<TD>
<P>6 months</P>
<P/>
</TD>
<TD>
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>398 per 1000</B>
<BR/>(147 to 1000)</P>
</TD>
<TD>
<P>
<B>RR 7.95 </B>
<BR/>(2.94 to 21.47)</P>
</TD>
<TD>
<P>158<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 35% (95% CI 23% to 47%);</P>
<P>Relative percent change 695% (95% CI 194% to 2047%);</P>
<P>NNTB 3 (95% CI 2 to 8)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Radiographic progression -</B> mean change in Total Sharp Score (from baseline). Scale from: 0 to 448</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD>
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>2.4</B>
</P>
<P/>
</TD>
<TD>
<P>
<B>MD -2.21 </B>
</P>
<P>(-2.99 to -1.43)</P>
</TD>
<TD>
<P>
<BR/>
</P>
</TD>
<TD>
<P>894<BR/>(2 studies)<BR/>
</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.49% (95% CI -0.67% to -0.32%);</P>
<P>Relative percent change -92% (95% CI -125% to -59.6%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>Serious infections</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P/>
<P>
<B>Etanercept (25 mg) + DMARD </B>
</P>
</TD>
<TD>
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>18 per 1000</B>
<BR/>(6 to 55)</P>
</TD>
<TD>
<P>
<B>RR 0.61 </B>
<BR/>(0.2 to 1.84)</P>
</TD>
<TD>
<P>542<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute risk difference -1% (95% CI -4% to 1%);</P>
<P>Relative percent change -39% (95% CI -80% to 84%);</P>
<P>NNTH not statistically significant.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P/>
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD>
<P>
<B>Etanercept</B>
</P>
</TD>
<TD>
<P>2 years</P>
<P/>
</TD>
<TD>
<P>
<B>63 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>57 per 1000</B>
<BR/>(27 to 117)</P>
</TD>
<TD>
<P>
<B>RR 0.9 </B>
<BR/>(0.43 to 1.86)</P>
</TD>
<TD>
<P>454<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute risk difference -1% (95% CI -5% to 4%); Relative percent change -10% (95% CI -57% to 86%);</P>
<P>NNH not statistically significant</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>DMARD</B>: disease-modifying anti-rheumatic drugs; <B>N/A</B>: not available; <B>NNTB</B>: number needed to treat for an additional beneficial outcome; <B>NNTH</B>: number needed to treat for an additional harmful outcome; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>One study was not blinded.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-03-28 16:16:03 -0400" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-03-14 16:19:15 -0400" MODIFIED_BY="Grade Profiler">Subgroup analyses: ACR50</TITLE>
<TABLE COLS="8" ROWS="19">
<TR>
<TD COLSPAN="8">
<P>
<B>Etanercept for rheumatoid arthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="8">
<P>
<B>Patient or population:</B> participants with rheumatoid arthritis<BR/>
<B>Intervention:</B> etanercept<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcome:</P>
<P>
<B>ACR50 - </B>American College of Rheumatology Improvement Criteria</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Subgroup</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Etanercept</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Etanercept + DMARD vs. DMARD </B>
<BR/>Follow-up: 6-36 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>All combined</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>319 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>615 per 1000</B>
<BR/>(561 to 742)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.82 </B>
<BR/>(1.71 to 4.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1118<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 34% (95% CI 26% to 42%);</P>
<P>Relative percent change 182% (95% CI 71% to 368%);</P>
<P>NNTB 4 (95% CI 3 to 5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>DMARD naive</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>462 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>702 per 1000</B>
<BR/>(568 to 872)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.52 </B>
<BR/>(1.23 to 1.89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>261<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 24% (95% CI 12% to 36%);</P>
<P>Relative percent change 52% (95% CI 23% to 89%);</P>
<P>NNTB 5 (95% CI 3 to 10)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Methotrexate-inadequate response</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>394 per 1000</B>
<BR/>(164 to 995)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 8.61 </B>
<BR/>(3.55 to 20.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>247<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 35% (95% CI 26% to 44%);</P>
<P>Relative percent change 761% (95% CI 255% to 1986%;</P>
<P>NNTB 3 (95% CI 2 to 9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Non-methotrexate inadequate response</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>360 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>672 per 1000</B>
<BR/>(594 to 849)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.96 </B>
<BR/>(0.81 to 10.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>610<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 38% (95% CI 19% to 57%);</P>
<P>Relative percent change 196% (95% CI 19% to 981%);</P>
<P>NNTB 3 (95% CI 3 to 5)<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Etanercept vs. DMARD</B>
<BR/>Follow-up: 3 to 36 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>All combined</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>389 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>457 per 1000</B>
<BR/>(397 to 526)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.17 </B>
<BR/>(1.02 to 1.35)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1112<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 7% (95% CI 1% to 13%);</P>
<P>Relative percent change 17% (95% CI 2% to 35%);</P>
<P>NNTB 16 (95% CI 3 to 129)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>DMARD naive</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>392 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>461 per 1000</B>
<BR/>(368 to 576)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.18 </B>
<BR/>(0.94 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>423<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 7% (95% CI -2% to 16%);</P>
<P>Relative percent change 18% (95% CI -6% to 47%);</P>
<P>NNTB not statistically significant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Methotrexate-inadequate response</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>308 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>407 per 1000</B>
<BR/>(287 to 574)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.32 </B>
<BR/>(0.93 to 1.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>238<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit 10% (95% CI -2% to 22%);</P>
<P>Relative percent change 32% (95% CI -7% to 86%); </P>
<P>NNTB 11 not statistically significant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Non-methotrexate inadequate response</B>
</P>
</TD>
<TD>
<P>
<B>430 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>480 per 1000</B>
<BR/>(391 to 589)</P>
</TD>
<TD>
<P>
<B>RR 1.12 </B>
<BR/>(0.91 to 1.37)</P>
</TD>
<TD>
<P>451<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 5% (95% CI -4% to 14%);</P>
<P>Relative percent change 12% (95% CI -9% to 37%);</P>
<P>NNTB not statistically significant</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Etanercept + DMARD vs. Etanercept</B>
<BR/>Follow-up: 6 to 36 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>All combined</B>
</P>
</TD>
<TD>
<P>
<B>442 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>667 per 1000</B>
<BR/>(584 to 761)</P>
</TD>
<TD>
<P>
<B>RR 1.44 </B>
<BR/>(1.16 to 1.79)</P>
</TD>
<TD>
<P>805<BR/>(3 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 20% (95% CI 8% to 32%);</P>
<P>Relative percent change 44% (95% CI 16% to 79%);</P>
<P>NNTB 5 (95% CI 4 to 8)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>DMARD naive</B>
</P>
</TD>
<TD>
<P>No data</P>
</TD>
<TD>
<P>No data</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>No data</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Methotrexate-inadequate response</B>
</P>
</TD>
<TD>
<P>
<B>478 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>644 per 1000</B>
<BR/>(478 to 870)</P>
</TD>
<TD>
<P>
<B>RR 1.35 </B>
<BR/>(1 to 1.82)</P>
</TD>
<TD>
<P>142<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 17% (95% CI 0% to 33%);</P>
<P>Relative percent change 35% (95% CI 0% to 82%);</P>
<P>NNTB not statistically significant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Non-methotrexate inadequate response</B>
</P>
</TD>
<TD>
<P>
<B>435 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>672 per 1000</B>
<BR/>(583 to 774)</P>
</TD>
<TD>
<P>
<B>RR 1.47 </B>
<BR/>(1.07 to 2.02)</P>
</TD>
<TD>
<P>663<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 21% (95% CI 3% to 39%);</P>
<P>Relative percent change 47% (95% CI 7% to 102%);</P>
<P>NNTB 5 (95% CI 3 to 7)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="8">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>DMARD</B>: disease-modifying anti-rheumatic drug; <B>N/A</B>: not available; <B>NNTB</B>: number needed to treat for an additional beneficial outcome; <B>NNTH</B>: number needed to treat for an additional harmful outcome; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="8">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-03-28 16:16:46 -0400" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-05-01 10:36:26 -0400" MODIFIED_BY="[Empty name]">Radiographic outcomes</TITLE>
<TABLE COLS="10" ROWS="58">
<TR>
<TD COLSPAN="10">
<P>
<B>Etanercept for rheumatoid arthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Patient or population:</B> participants with rheumatoid arthritis<BR/>
<B>Intervention:</B> etanercept<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Intervention</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Comparison</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<B>Follow-up</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Etanercept </B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Radiographic progression - </B>mean change in Total Sharp Score (from baseline). Scale from: 0 to 448<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>
<B>DMARD</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>12 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>2.4 </B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>MD -2.21 </B>
</P>
<P>(-2.99 to -1.43)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>894<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -0.49% (95% CI -0.67% to 0.32%);</P>
<P>Relative percent change -92% (95% CI -125% to -59.6%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>3.34 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>MD -3.9</B>
<BR/>(-6.11 to -1.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>419<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -0.87% (95% CI -1.36 to -0.38);</P>
<P>Relative percent change -114.7% (95% CI -180% to -50%)<SUP> </SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5.95 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>MD -6.09</B>
<BR/>(-9.22 to -2.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>427<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -1.36% (95% CI -2.06 to -0.66%);</P>
<P>Relative percent change -102% (95% CI -155% to -49.7%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Etanercept (10 mg)</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1.06 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>MD</B> <B>-0.25 </B>
<BR/>(-0.72 to 0.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>425<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -0.06% (95% CI -0.16% to 0.05%);</P>
<P>Relative percent change -24% (95% CI -68% to 21%)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1.59 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>MD -0.04 </B>
<BR/>(-0.93 to 0.85)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>425<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -0.009% (95% CI -0.21 to 0.19%);</P>
<P>Relative percent change -2.5% (95% CI -58.5% to 53.5%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Etanercept (25 mg)</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>DMARD</B>
<BR/>
</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1.06 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>MD -0.49</B>
<BR/>(-0.92 to -0.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>424<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute treatment benefit -0.11% (95% CI -0.21% to -0.01%);</P>
<P>Relative percent change -46% (95% CI -87% to -5.7%)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>1.54 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.74</B>
<BR/>(-1.35 to -0.13)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>832<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.17% (95% CI -0.30 to -0.03%);</P>
<P>Relative percent change -46.5% (95% CI -85% to -8.2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>3.34 </B>
</P>
</TD>
<TD>
<P>
<B>MD -2.24</B>
<BR/>(-4.61 to 0.13)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>409<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.50% (95% CI -1.03% to 0.03%);</P>
<P>Relative percent change -67.1% (95% CI -138% to 3.89%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>5.95 </B>
</P>
</TD>
<TD>
<P>
<B>MD -4.34 </B>
</P>
<P>(-7.56 to -1.12)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>421<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.97% (95% CI -1.69% to -0.25%);</P>
<P>Relative percent change -72.9% (95% CI -127.0% to -18.8%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="4">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>
<B>Etanercept </B>
<BR/>
</P>
</TD>
<TD ROWSPAN="2">
<P>12 months</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>0.33 </B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>MD -1.13 </B>
<BR/>(-1.76 to -0.5)</P>
</TD>
<TD ROWSPAN="2">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P>414<BR/>(1 study)</P>
</TD>
<TD ROWSPAN="2">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.25% (95% CI-0.39% to -0.11%);</P>
<P>Relative percent change -342.4% (95% CI -533.3% to -151.5%)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>1.1 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.66 </B>
<BR/>(-2.76 to -0.56)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>416<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.37% (95% CI -0.62% to -0.13%);<BR/>Relative percent change -150.9% (95% CI -250.91% to -50.91%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>1.61 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.75</B>
<BR/>(-3.27 to -0.23)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>428<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.39% (95% CI -0.73% to -0.05%)<BR/>Relative percent change -108.7% (95% CI -203.11% to -14.29%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="10">
<P>
<B>No progression of joint damage - </B>Total Sharp Score &#8804; 0.5 at final visit<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>579 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>799 per 1000</B>
<BR/>(730 to 875)</P>
</TD>
<TD>
<P>
<B>RR 1.38 </B>
<BR/>(1.26 to 1.51)</P>
</TD>
<TD>
<P>906<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 22% (95% CI 16% to 28%);</P>
<P>Relative percent change 38% (95% CI 26% to 51%);</P>
<P>NNTB 5 (95% CI 4 to 7)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>623 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>816 per 1000</B>
<BR/>(735 to 903)</P>
</TD>
<TD>
<P>
<B>RR 1.31 </B>
<BR/>(1.18 to 1.45)</P>
</TD>
<TD>
<P>601<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 19% (95% CI 12% to 26%);</P>
<P>Relative percent change 31% (95% CI 18% to 45%);</P>
<P>NNTB 6 (95% CI 4 to 9)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>510 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>759 per 1000</B>
<BR/>(652 to 887)</P>
</TD>
<TD>
<P>
<B>RR 1.49 </B>
<BR/>(1.28 to 1.74)</P>
</TD>
<TD>
<P>427<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 25% (95% CI 16% to 34%);</P>
<P>Relative percent change 49% (95% CI 28% to 74%);</P>
<P>NNTB 5 (95% CI 3 to 8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg)</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>571 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>679 per 1000</B>
<BR/>(588 to 788)</P>
</TD>
<TD>
<P>
<B>RR 1.19 </B>
<BR/>(1.03 to 1.38)</P>
</TD>
<TD>
<P>424<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 11% (95% CI 2% to 20%);</P>
<P>Relative percent change 19% (95% CI 3% to 38%);</P>
<P>NNTB 10 (95% CI 59 to 5)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>602 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>680 per 1000</B>
<BR/>(590 to 789)</P>
</TD>
<TD>
<P>
<B>RR 1.13 </B>
<BR/>(0.98 to 1.31)</P>
</TD>
<TD>
<P>409<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 8% (95% CI -1% to 17%);</P>
<P>Relative percent change 13% (95% CI -2% to 31%);</P>
<P>NNTB 13 (95% CI 6 to 84)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>510 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>611 per 1000</B>
<BR/>(515 to 724)</P>
</TD>
<TD>
<P>
<B>RR 1.2 </B>
<BR/>(1.01 to 1.42)</P>
</TD>
<TD>
<P>421<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 10% (95% CI 1% to 20%);</P>
<P>Relative percent change 20% (95% CI 1% to 42%); NNTB 10 (95% CI 5 to 197)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>Etanercept </B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>679 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>802 per 1000</B>
<BR/>(713 to 897)</P>
</TD>
<TD>
<P>
<B>RR 1.18 </B>
<BR/>(1.05 to 1.32)</P>
</TD>
<TD>
<P>430<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 12% (95% CI 4% to 20%);</P>
<P>Relative percent change 18% (95% CI 5% to 32%);</P>
<P>NNTB 9 (95% CI 5 to 30)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>680 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>782 per 1000</B>
<BR/>(693 to 877)</P>
</TD>
<TD>
<P>
<B>RR 1.15 </B>
<BR/>(1.02 to 1.29)</P>
</TD>
<TD>
<P>416<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 10% (95% CI 1% to 18%);</P>
<P>Relative percent change 15% (95% CI 2% to 29%);</P>
<P>NNTB 10 (95% CI 6 to 74)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>611 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>758 per 1000</B>
<BR/>(666 to 868)</P>
</TD>
<TD>
<P>
<B>RR 1.24 </B>
<BR/>(1.09 to 1.42)</P>
</TD>
<TD>
<P>428<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 15% (95% CI 6% to 24%);</P>
<P>Relative percent change 24% (95% CI 9% to 42%);</P>
<P>NNTB 7 (95% CI 4 to 19)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Erosions - </B>Change in Sharp Score (from baseline). Scale from: 0 to 280.</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>0.99 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.63 </B>
<BR/>(-2.41 to -0.85)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>418<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.58% (95% CI -0.86% to -0.30%);</P>
<P>Relative percent change -164.65% (95% CI -243.43% to -85.86%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>2.12 </B>
</P>
</TD>
<TD>
<P>
<B>MD -2.88 </B>
<BR/>(-4.39 to -1.37)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>419<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -1.03% (95% CI -1.57% to -0.49%);</P>
<P>Relative percent change -86.23% (95% CI -131.44% to -41.02%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>3.25 </B>
</P>
</TD>
<TD>
<P>
<B>MD -3.92 </B>
<BR/>(-5.72 to -2.12)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>427<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -1.40% (95% CI -2.04% to -0.76%);</P>
<P>Relative percent change -120.62% (95% CI -176.00% to -65.23%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="2">
<P>
<B>Etanercept (10 mg)</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>
<B>0.68 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.18 </B>
<BR/>(-0.49 to 0.13)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>425<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.06% (95% CI -0.18% to 0.05%);</P>
<P>Relative percent change -26.47% (95% CI -72.06% to 19.1%);</P>
<P>NNTB not statistically significant</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>1.03 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.13</B>
<BR/>(-0.66 to 0.4)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>425<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.05% (95% CI -0.24% to 0.14%);</P>
<P>Relative percent change -12.62% (95% CI -64.08% to 38.8%);</P>
<P>NNTB not statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="4">
<P>
<B>Etanercept (25 mg)</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>
<B>0.68 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.38 </B>
<BR/>(-0.66 to -0.1)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>424<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.14% (95% CI -0.24% to -0.04%);</P>
<P>Relative percent change -55.88% (95% CI -97.06% to -14.7%)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>1.0 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.65 </B>
<BR/>(-1.04 to 0.27)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>832<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.23% (95% CI -0.37% to 0.10%);</P>
<P>Relative percent change -65.00% (95% CI -104% to 27%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>2.12 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.76 </B>
<BR/>(-3.34 to -0.18)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>409<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.63% (95% CI -1.19% to -0.06%);</P>
<P>Relative percent change -83.02% (95% CI -157.55% to -8.49%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>3.25 </B>
</P>
</TD>
<TD>
<P>
<B>MD -2.86</B>
<BR/>(-4.81 to -0.91)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>421<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -1.02% (95% CI -1.72% to -0.33%);</P>
<P>Relative percent change -88.00% (95% CI -148% to -28%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>Etanercept </B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>0.03 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.67</B>
<BR/>(-1.12 to -0.22)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>414<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.24% (95% CI -0.40% to -0.08%);</P>
<P>Relative percent change -2233.33% (95% CI -3733.3% to -733.3%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>0.36 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.12 </B>
<BR/>(-1.83 to -0.41)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>416<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.40% (95% CI -0.65% to -0.15%);</P>
<P>Relative percent change -311.11% (95% CI -508.3% to -113.89%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>0.39 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.06 </B>
<BR/>(-1.98 to -0.14)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>428<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.38% (95% CI -0.71% to -0.05%);</P>
<P>Relative percent change -271.79% (95% CI -507.69% to -35.9%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Joint space narrowing Score - </B>change in Total Sharp Score (from baseline). Scale from: 0 to 168<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>0.51 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.67 </B>
<BR/>(-1.12 to -0.22)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>418<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.40% (95% CI -0.67% to -0.13%);</P>
<P>Relative percent change -131.37% (95% CI -219.61% to -43.14%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>1.23 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.03</B>
<BR/>(-1.89 to 0.17)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>419<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.61% (95% CI -1.13% to 0.10%);</P>
<P>Relative percent change -83.74% (95% CI -153.66% to 13.82%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>2.7 </B>
</P>
</TD>
<TD>
<P>
<B>MD -2.17 </B>
<BR/>(-3.78 to -0.56)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>427<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -1.29% (95% CI -2.25 to -0.33%);</P>
<P>Relative percent change -80.37% (95% CI -140.00% to -20.7%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="2">
<P>
<B>Etanercept (10 mg)</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>
<B>0.38 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.07 </B>
<BR/>(-0.35 to 0.21)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>425<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.04% (95% CI -0.21% to 0.13%);</P>
<P>Relative percent change -18.42% (95% CI -92.11% to 55.26%)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>0.56 </B>
</P>
</TD>
<TD>
<P>
<B>MD 0.09 </B>
<BR/>(-0.42 to 0.6)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>425<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit 0.05% (95% CI -0.25% to 0.36%);</P>
<P>Relative percent change 16.07% (95% CI -75.00% to 107.1%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="4">
<P>
<B>Etanercept (25 mg)</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>
<B>DMARD</B>
</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>
<B>0.38 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.11 </B>
<BR/>(-0.35 to 0.13)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>424<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.07% (95% CI -0.21% to 0.08%);</P>
<P>Relative percent change -28.95% (95% CI -92.11% to 34.2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>0.53 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.11 </B>
<BR/>(-0.43 to 0.2)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>832<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.07% (95% CI -0.26% to 0.12%);</P>
<P>Relative percent change -20.75% (95% CI -81.13% to 37.7%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>1.23 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.49</B>
<BR/>(-1.46 to 0.48)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>409<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.29% (95% CI -0.87% to 0.29%);</P>
<P>Relative percent change -39.84% (95% CI -118.70% to 39%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>2.7 </B>
</P>
</TD>
<TD>
<P>
<B>MD -1.48 </B>
<BR/>(-3.04 to 0.08)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>421<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.88% (95% CI -1.81% to 0.05%);</P>
<P>Relative percent change -54.81% (95% CI -112.59% to 2.96%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="2" ROWSPAN="3">
<P>
<B>Etanercept (25 mg) + DMARD</B>
</P>
</TD>
<TD ROWSPAN="3">
<P>
<B>Etanercept </B>
</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>
<B>0.3 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.46 </B>
<BR/>(-0.74 to -0.18)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>414<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.27% (95% CI -0.44% to -0.11%);</P>
<P>Relative percent change -153.33% (95% CI -246.67% to -60%)</P>
</TD>
</TR>
<TR>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>
<B>0.74 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.54</B>
<BR/>(-1.09 to 0.01)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>416<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.32% (95% CI -0.65% to 0.01%);</P>
<P>Relative percent change -72.97% (95% CI -147.30% to 1.35%)</P>
</TD>
</TR>
<TR>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>
<B>1.22 </B>
</P>
</TD>
<TD>
<P>
<B>MD -0.69</B>
<BR/>(-1.65 to 0.27)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>428<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD>
<P>Absolute treatment benefit -0.41% (95% CI -0.98% to 0.16%);</P>
<P>Relative percent change -56.56% (95% CI -135.25% to 22%)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>DMARD</B>: disease-modifying anti-rheumatic drug; <B>MD</B>: mean difference; <B>N/A</B>: not available; <B>NNTB</B>: number needed to treat for an additional beneficial outcome; <B>NNTH</B>: number needed to treat for an additional harmful outcome; <B>RR</B>: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-03-14 17:08:26 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-03-14 17:08:26 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-14 17:08:04 -0400" MODIFIED_BY="[Empty name]">Subgroups - study characteristics</TITLE>
<TABLE COLS="11" ROWS="10">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Follow-up (weeks)</B>
</P>
</TD>
<TD>
<P>
<B>n</B>
</P>
</TD>
<TD>
<P>
<B>Group 1</B>
</P>
</TD>
<TD>
<P>
<B>Group 2</B>
</P>
</TD>
<TD>
<P>
<B>Group 3</B>
</P>
</TD>
<TD>
<P>
<B>Group 4</B>
</P>
</TD>
<TD>
<P>
<B>Group 5</B>
</P>
</TD>
<TD>
<P>
<B>Disease duration</B>
</P>
</TD>
<TD>
<P>
<B>Eligibility</B>
</P>
</TD>
<TD>
<P>
<B>Previously treated with</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bathon-2000-_x0028_ERA_x0029_" TYPE="STUDY">Bathon 2000 (ERA)</LINK>
</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>632</P>
</TD>
<TD>
<P>ET 10 mg</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>PBO</P>
</TD>
<TD>
<P>&lt; 3 years</P>
</TD>
<TD>
<P>MTX-naive</P>
</TD>
<TD>
<P>DMARDs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Combe-2006" TYPE="STUDY">Combe 2006</LINK>
</P>
</TD>
<TD>
<P>104</P>
</TD>
<TD>
<P>254</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>ET 25 mg + SSZ</P>
</TD>
<TD>
<P>SSZ</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>&lt; 20 years</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SSZ</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Emery-2008-_x0028_COMET_x0029_" TYPE="STUDY">Emery 2008 (COMET)</LINK>
</P>
</TD>
<TD>
<P>104</P>
</TD>
<TD>
<P>542</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg + MTX</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>&lt; 2 years</P>
</TD>
<TD>
<P>MTX-naive</P>
</TD>
<TD>
<P>DMARDs (4 weeks prior enrolment)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hu-2009" TYPE="STUDY">Hu 2009</LINK>
</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>238</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS (mean 7.7 years)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>DMARDs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kameda-2010" TYPE="STUDY">Kameda 2010</LINK>
</P>
</TD>
<TD>
<P>104</P>
</TD>
<TD>
<P>151</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>ET 25 mg + MTX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS (but subgroups by &lt; 10 and &gt; 10 years)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MTX</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TYPE="STUDY">Klareskog 2004 (TEMPO)</LINK>
</P>
</TD>
<TD>
<P>156</P>
</TD>
<TD>
<P>686</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>ET 25 mg + MTX</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>&lt; 20 years</P>
</TD>
<TD>
<P>no MTX 6 months prior enrolment</P>
</TD>
<TD>
<P>DMARDs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marcora-2006" TYPE="STUDY">Marcora 2006</LINK>
</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>&lt; 6 months</P>
</TD>
<TD>
<P>DMARDs-naive</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Moreland-1999" TYPE="STUDY">Moreland 1999</LINK>
</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>234</P>
</TD>
<TD>
<P>ET 10 mg</P>
</TD>
<TD>
<P>ET 25 mg</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>PBO</P>
</TD>
<TD>
<P>NS (mean 12 years)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>DMARDs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Weinblatt-1999" TYPE="STUDY">Weinblatt 1999</LINK>
</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ET 25 mg + MTX</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>NS (mean 13 years)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>MTX</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DMARD: disease-modifying anti-rheumatic drug; ET: etanercept; MTX: methotrexate; NS: not stated; PBO: placebo; SSZ: sulphasalazine.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-03-20 15:21:03 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-03-20 15:21:03 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs)</NAME>
<DICH_OUTCOME CHI2="16.717337760994255" CI_END="2.8927208737861365" CI_START="1.3269586425618562" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.959214374178997" ESTIMABLE="YES" EVENTS_1="417" EVENTS_2="223" I2="82.05455890829847" I2_Q="79.09396838040335" ID="CMP-001.01" LOG_CI_END="0.4613065294575894" LOG_CI_START="0.12285738738058517" LOG_EFFECT_SIZE="0.2920819584190873" METHOD="MH" MODIFIED="2013-03-12 15:22:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="8.079249581453007E-4" P_Q="0.0024655507628384976" P_Z="7.172425349104849E-4" Q="14.34992567976361" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08940529079298483" TOTALS="YES" TOTAL_1="647" TOTAL_2="551" WEIGHT="100.0" Z="3.3829018772048647">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="82.47034208424034" CI_START="1.6584270096040779" DF="0" EFFECT_SIZE="11.69491525423729" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.2196963621842661" LOG_EFFECT_SIZE="1.0679970790951112" MODIFIED="2012-09-15 17:37:30 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.013603612466877283" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="3.6508466297628615" Z="2.4675634110543716">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="82.47034208424034" CI_START="1.6584270096040779" EFFECT_SIZE="11.694915254237289" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.2196963621842661" LOG_EFFECT_SIZE="1.0679970790951112" MODIFIED="2012-09-15 17:37:30 -0400" MODIFIED_BY="[Empty name]" ORDER="7534" O_E="0.0" SE="0.9965920805394045" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.993195774993859" WEIGHT="3.6508466297628615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6784844636880316" CI_START="1.2418768111277236" DF="0" EFFECT_SIZE="1.4437696953781514" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="119" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.224917325705697" LOG_CI_START="0.09407851782053583" LOG_EFFECT_SIZE="0.15949792176311642" MODIFIED="2012-09-15 17:41:01 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.765599731424206E-6" STUDIES="1" TAU2="0.0" TOTAL_1="256" TOTAL_2="243" WEIGHT="41.46811408792303" Z="4.778554426131383">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="1.6784844636880316" CI_START="1.2418768111277236" EFFECT_SIZE="1.4437696953781514" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="119" LOG_CI_END="0.224917325705697" LOG_CI_START="0.09407851782053583" LOG_EFFECT_SIZE="0.15949792176311642" MODIFIED="2012-09-15 17:41:01 -0400" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.0768553634142881" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="256" TOTAL_2="243" VAR="0.005906746885542293" WEIGHT="41.46811408792303"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.635383171399639" CI_START="2.5026143417392626" DF="0" EFFECT_SIZE="5.841584158415841" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="5" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="1.1346673466697506" LOG_CI_START="0.3983939290492527" LOG_EFFECT_SIZE="0.7665306378595016" MODIFIED="2012-09-15 17:43:02 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="4.4838930232656516E-5" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="14.2968387847431" Z="4.081017750461597">
<NAME>104 weeks</NAME>
<DICH_DATA CI_END="13.635383171399639" CI_START="2.5026143417392626" EFFECT_SIZE="5.841584158415841" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="5" LOG_CI_END="1.1346673466697506" LOG_CI_START="0.3983939290492527" LOG_EFFECT_SIZE="0.7665306378595016" MODIFIED="2012-09-15 17:43:02 -0400" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.4324906501224772" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.187048162443363" WEIGHT="14.2968387847431"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8478577774453655" CI_START="1.3018665916295435" DF="0" EFFECT_SIZE="1.5510204081632653" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="98" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.2666685421830145" LOG_CI_START="0.11456648232154079" LOG_EFFECT_SIZE="0.1906175122522777" MODIFIED="2012-09-15 17:43:44 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="8.990564885382587E-7" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="40.58420049757102" Z="4.912536479484163">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="1.8478577774453655" CI_START="1.3018665916295435" EFFECT_SIZE="1.5510204081632653" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="98" LOG_CI_END="0.2666685421830145" LOG_CI_START="0.11456648232154079" LOG_EFFECT_SIZE="0.1906175122522777" MODIFIED="2012-09-15 17:43:44 -0400" MODIFIED_BY="[Empty name]" ORDER="7595" O_E="0.0" SE="0.08934550287996887" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.007982618884874525" WEIGHT="40.58420049757102"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.3272778410715285" CI_END="3.28653225708772" CI_START="1.4955295341525847" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2170038465054227" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="120" I2="59.05710053487906" I2_Q="56.83864991861963" ID="CMP-001.02" LOG_CI_END="0.5167378992077298" LOG_CI_START="0.1747949940258749" LOG_EFFECT_SIZE="0.34576644661680234" METHOD="MH" MODIFIED="2013-03-12 15:22:31 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.062166675106895886" P_Q="0.07348712051565642" P_Z="7.377846806326178E-5" Q="6.950663022225961" RANDOM="YES" SCALE="26.31" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07115923662755681" TOTALS="YES" TOTAL_1="647" TOTAL_2="551" WEIGHT="100.0" Z="3.9637598684547015">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="163.14803287586722" CI_START="0.5906718134797626" DF="0" EFFECT_SIZE="9.816666666666668" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.9919640444034581" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11120253297582895" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="1.896327340732288" Z="1.5928112839535284">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="163.14803287586722" CI_START="0.5906718134797626" EFFECT_SIZE="9.816666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.991964044403458" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" ORDER="7537" O_E="0.0" SE="1.4339938726200825" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.056338426711941" WEIGHT="1.896327340732288"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1605462755024623" CI_START="1.346834500591385" DF="0" EFFECT_SIZE="1.705842391304348" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="69" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.3345635726514794" LOG_CI_START="0.12931423277140536" LOG_EFFECT_SIZE="0.2319389027114424" MODIFIED="2012-08-02 12:43:38 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.438389858207224E-6" STUDIES="1" TAU2="0.0" TOTAL_1="256" TOTAL_2="243" WEIGHT="47.07894943664697" Z="4.429655132569799">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="2.1605462755024623" CI_START="1.346834500591385" EFFECT_SIZE="1.705842391304348" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="69" LOG_CI_END="0.3345635726514794" LOG_CI_START="0.12931423277140536" LOG_EFFECT_SIZE="0.2319389027114424" MODIFIED="2012-08-02 12:43:38 -0400" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.12056447824617376" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="256" TOTAL_2="243" VAR="0.014535793414772106" WEIGHT="47.07894943664697"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.935464996518842" CI_START="1.719481183754231" DF="0" EFFECT_SIZE="6.93069306930693" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="2" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.4461559047544077" LOG_CI_START="0.2353974277088207" LOG_EFFECT_SIZE="0.8407766662316142" MODIFIED="2012-08-02 13:53:41 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0064872025105654095" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="6.992416035217358" Z="2.7220820933282996">
<NAME>104 weeks</NAME>
<DICH_DATA CI_END="27.935464996518842" CI_START="1.719481183754231" EFFECT_SIZE="6.930693069306931" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="2" LOG_CI_END="1.4461559047544077" LOG_CI_START="0.2353974277088207" LOG_EFFECT_SIZE="0.8407766662316143" MODIFIED="2012-08-02 13:53:41 -0400" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.7112055227676988" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5058132956152758" WEIGHT="6.992416035217358"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0394950322389747" CI_START="1.734849634464588" DF="0" EFFECT_SIZE="2.29631592896899" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="49" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.48280143790866065" LOG_CI_START="0.23926183892387617" LOG_EFFECT_SIZE="0.3610316384162684" MODIFIED="2012-08-02 13:54:05 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="6.208643427819702E-9" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="44.032307187403376" Z="5.811038628010411">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="3.0394950322389747" CI_START="1.734849634464588" EFFECT_SIZE="2.29631592896899" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="49" LOG_CI_END="0.48280143790866065" LOG_CI_START="0.23926183892387617" LOG_EFFECT_SIZE="0.3610316384162684" MODIFIED="2012-08-02 13:54:05 -0400" MODIFIED_BY="[Empty name]" ORDER="7596" O_E="0.0" SE="0.14305636598412003" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.020465123848582494" WEIGHT="44.032307187403376"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7781236272247664" CI_END="2.3118164416747162" CI_START="1.596039041454465" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.920872014890421" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="116" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.36395334811678065" LOG_CI_START="0.20304351062427195" LOG_EFFECT_SIZE="0.2834984293705263" METHOD="MH" MODIFIED="2013-03-20 15:21:03 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3777156588349163" P_Q="0.3794295962974228" P_Z="4.974179640331604E-12" Q="0.7725493120061286" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="496" TOTAL_2="491" WEIGHT="100.0" Z="6.9063112597546725">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>24 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.998016099496631E-31" CI_END="2.2572837517937883" CI_START="1.4267101002302331" DF="0" EFFECT_SIZE="1.7945722408891185" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="73" I2="100.0" ID="CMP-001.03.02" LOG_CI_END="0.35358615548561334" LOG_CI_START="0.1543357357910746" LOG_EFFECT_SIZE="0.2539609456383439" MODIFIED="2012-08-02 14:34:29 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="5.845023795017913E-7" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="263" WEIGHT="62.86723450948206" Z="4.99626859199566">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="2.2572837517937887" CI_START="1.4267101002302334" EFFECT_SIZE="1.7945722408891187" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="73" LOG_CI_END="0.3535861554856134" LOG_CI_START="0.15433573579107465" LOG_EFFECT_SIZE="0.253960945638344" MODIFIED="2012-08-02 14:34:29 -0400" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.1170406828340565" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" VAR="0.013698521438262208" WEIGHT="62.86723450948206"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-02 14:25:57 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>104 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9154926339156324" CI_START="1.5630136531674002" DF="0" EFFECT_SIZE="2.13470250679553" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="43" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.46471194849970243" LOG_CI_START="0.19396277166561351" LOG_EFFECT_SIZE="0.329337360082658" MODIFIED="2012-08-02 14:34:56 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.8590474796760023E-6" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="37.13276549051793" Z="4.768172314119759">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="2.9154926339156324" CI_START="1.5630136531674002" EFFECT_SIZE="2.13470250679553" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="43" LOG_CI_END="0.46471194849970243" LOG_CI_START="0.19396277166561351" LOG_EFFECT_SIZE="0.329337360082658" MODIFIED="2012-08-02 14:34:56 -0400" MODIFIED_BY="[Empty name]" ORDER="7597" O_E="0.0" SE="0.15903940670238417" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.025293532884246357" WEIGHT="37.13276549051793"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.006365306148986" CI_END="-0.28180858691732497" CI_START="-0.4327114863819091" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35726003664961703" ESTIMABLE="YES" I2="0.21172763456146834" I2_Q="0.21172763456146834" ID="CMP-001.04" MODIFIED="2013-03-14 17:21:52 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3906450123450709" P_Q="0.3906450123450709" P_Z="1.6890292727616057E-20" Q="3.006365306148986" RANDOM="NO" SCALE="1.66" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="656" TOTAL_2="571" UNITS="" WEIGHT="99.99999999999999" Z="9.280362503744273">
<NAME>HAQ (mean improvement from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ET + DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARDs</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.020844374958172263" CI_START="-0.6208443749581721" DF="0" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2012-11-12 14:10:53 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06685753547631378" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="5.530269786276306" Z="1.8326305251219415">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="0.020844374958172318" CI_START="-0.6208443749581722" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.4" MODIFIED="2012-11-12 14:10:53 -0500" MODIFIED_BY="[Empty name]" ORDER="7608" SD_1="0.71" SD_2="0.74" SE="0.1636991176822389" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" WEIGHT="5.530269786276306"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.17628305176304584" CI_START="-0.42371694823695427" DF="0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2012-08-02 14:54:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.0072082507060465E-6" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="263" WEIGHT="37.19433346095921" Z="4.752697215225878">
<NAME>52 weeks</NAME>
<CONT_DATA CI_END="-0.17628305176304584" CI_START="-0.42371694823695427" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="-0.72" MODIFIED="2012-08-02 14:54:42 -0400" MODIFIED_BY="[Empty name]" ORDER="442" SD_1="0.71" SD_2="0.74" SE="0.06312205184014487" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" WEIGHT="37.19433346095921"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.30861746894126907" CI_START="-0.6713825310587309" DF="0" EFFECT_SIZE="-0.49" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" MODIFIED="2012-08-02 15:00:17 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.1915347129100441E-7" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="17.303910566225387" Z="5.294789673618894">
<NAME>104 weeks</NAME>
<CONT_DATA CI_END="-0.30861746894126907" CI_START="-0.6713825310587309" EFFECT_SIZE="-0.49" ESTIMABLE="YES" MEAN_1="-0.64" MEAN_2="-0.15" MODIFIED="2012-08-02 14:56:50 -0400" MODIFIED_BY="[Empty name]" ORDER="449" SD_1="0.6" SD_2="0.5" SE="0.0925438081972185" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" WEIGHT="17.303910566225387"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.24165823935024214" CI_START="-0.48034176064975787" DF="0" EFFECT_SIZE="-0.361" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.04" MODIFIED="2012-08-02 15:08:28 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="3.052566487485805E-9" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="39.971486186539096" Z="5.928746103348152">
<NAME>156 weeks</NAME>
<CONT_DATA CI_END="-0.24165823935024214" CI_START="-0.48034176064975787" EFFECT_SIZE="-0.361" ESTIMABLE="YES" MEAN_1="-0.99" MEAN_2="-0.629" MODIFIED="2012-08-02 15:08:28 -0400" MODIFIED_BY="[Empty name]" ORDER="7630" SD_1="0.6" SD_2="0.7" SE="0.06088977225658758" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" WEIGHT="39.971486186539096"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.500430239419541" CI_END="0.014861563429873659" CI_START="-7.666134358526085" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.825636397548106" ESTIMABLE="YES" I2="81.8196039860051" I2_Q="81.8196039860051" ID="CMP-001.05" MODIFIED="2013-03-20 15:20:49 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.01901189077235077" P_Q="0.01901189077235077" P_Z="0.05089316295984599" Q="5.500430239419541" RANDOM="YES" SCALE="12.31" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="6.415311509334684" TOTALS="YES" TOTAL_1="463" TOTAL_2="440" UNITS="" WEIGHT="100.0" Z="1.952379517793171">
<NAME>Total Sharp Score</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2012-08-02 15:18:58 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>24 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.0575421204875155" CI_START="-3.202457879512484" DF="0" EFFECT_SIZE="-2.13" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2013-03-20 15:20:49 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.914748269003077E-5" STUDIES="1" TAU2="0.0" TOTAL_1="246" TOTAL_2="230" WEIGHT="57.18089905181549" Z="3.8926687628683863">
<NAME>52 weeks</NAME>
<CONT_DATA CI_END="-1.0575421204875155" CI_START="-3.202457879512484" EFFECT_SIZE="-2.13" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="2.4" MODIFIED="2012-08-02 15:17:10 -0400" MODIFIED_BY="[Empty name]" ORDER="440" SD_1="3.2" SD_2="7.7" SE="0.5471824421121486" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="246" TOTAL_2="230" WEIGHT="57.18089905181549"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.03" MODIFIED="2012-08-02 15:19:12 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>104 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.9592261708644583" CI_START="-9.220773829135542" DF="0" EFFECT_SIZE="-6.09" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.04" MODIFIED="2012-08-02 15:19:19 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.375494790865523E-4" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="210" WEIGHT="42.819100948184506" Z="3.8125336792995705">
<NAME>156 weeks</NAME>
<CONT_DATA CI_END="-2.9592261708644583" CI_START="-9.220773829135542" EFFECT_SIZE="-6.09" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="5.95" MODIFIED="2012-08-02 15:18:52 -0400" MODIFIED_BY="[Empty name]" ORDER="7598" SD_1="7.0" SD_2="22.1" SE="1.5973629382124803" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="210" WEIGHT="42.819100948184506"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.713029072572493" CI_END="0.7730404092370355" CI_START="0.35735882205226144" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.52559757423693" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="258" I2="76.40216204277941" I2_Q="76.34018754752735" ID="CMP-001.06" LOG_CI_END="-0.111797803559074" LOG_CI_START="-0.446895492081567" LOG_EFFECT_SIZE="-0.2793466478203205" METHOD="MH" MODIFIED="2012-09-22 22:58:09 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.005300151329561853" P_Q="0.005382987310288523" P_Z="0.0010840234387838115" Q="12.67972857361545" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09967586038585854" TOTALS="YES" TOTAL_1="665" TOTAL_2="576" WEIGHT="100.0" Z="3.267759746979405">
<NAME>Total withdrawals</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7896370124580337" CI_START="0.0363804846242428" DF="0" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02377202768570906" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="5.41088905344032" Z="2.260793816561138">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="0.7896370124580337" CI_START="0.0363804846242428" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" ORDER="7635" O_E="0.0" SE="0.7851013824920705" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.6163841807909605" WEIGHT="5.41088905344032"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8898131351986112" CI_START="0.4839129078902977" DF="0" EFFECT_SIZE="0.6561951399796729" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="79" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-0.050701187594300715" LOG_CI_START="-0.3152327933682023" LOG_EFFECT_SIZE="-0.1829669904812515" MODIFIED="2012-08-02 15:25:13 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.006702539915628211" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="31.291302450060172" Z="2.711273087038553">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="0.8898131351986112" CI_START="0.4839129078902977" EFFECT_SIZE="0.6561951399796729" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="79" LOG_CI_END="-0.050701187594300715" LOG_CI_START="-0.3152327933682023" LOG_EFFECT_SIZE="-0.1829669904812515" MODIFIED="2012-08-02 15:25:13 -0400" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.15538717468415697" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.024145174056324714" WEIGHT="31.291302450060172"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5201261526018915" CI_START="0.23477574062259074" DF="0" EFFECT_SIZE="0.3494467093768201" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="-0.2838913087994064" LOG_CI_START="-0.6293467807551393" LOG_EFFECT_SIZE="-0.4566190447772728" MODIFIED="2012-08-02 15:25:25 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.203265452569376E-7" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="27.507494625712017" Z="5.18131542309579">
<NAME>104 weeks</NAME>
<DICH_DATA CI_END="0.5201261526018915" CI_START="0.23477574062259074" EFFECT_SIZE="0.34944670937682004" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="-0.2838913087994064" LOG_CI_START="-0.6293467807551393" LOG_EFFECT_SIZE="-0.4566190447772729" MODIFIED="2012-08-02 15:25:25 -0400" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.20292225425896274" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.04117744127353912" WEIGHT="27.507494625712017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8429269047228327" CI_START="0.5862685629317989" DF="0" EFFECT_SIZE="0.7029804727646455" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="139" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="-0.0742100840370394" LOG_CI_START="-0.23190339305943192" LOG_EFFECT_SIZE="-0.15305673854823565" MODIFIED="2012-08-02 15:25:41 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.4199195333377962E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="35.790313870787486" Z="3.80467246207773">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="0.8429269047228327" CI_START="0.5862685629317989" EFFECT_SIZE="0.7029804727646455" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="139" LOG_CI_END="-0.0742100840370394" LOG_CI_START="-0.23190339305943192" LOG_EFFECT_SIZE="-0.15305673854823565" MODIFIED="2012-08-02 15:25:41 -0400" MODIFIED_BY="[Empty name]" ORDER="7664" O_E="0.0" SE="0.09262983031422231" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.008580285464041618" WEIGHT="35.790313870787486"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3147223684742328" CI_END="1.0038135619581514" CI_START="0.5665768909370898" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7541469134159041" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.0016530588931604202" LOG_CI_START="-0.24674114309333284" LOG_EFFECT_SIZE="-0.12254404210008624" METHOD="MH" MODIFIED="2013-03-14 17:22:11 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7256402404006446" P_Q="0.7262603203714266" P_Z="0.05312826058525049" Q="1.3121069417563844" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="665" TOTAL_2="576" WEIGHT="100.0" Z="1.9338769352530167">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.769158781101229" CI_START="0.09603215997442066" DF="0" EFFECT_SIZE="1.0169491525423728" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="1.0321817802715805" LOG_CI_START="-1.0175833027885817" LOG_EFFECT_SIZE="0.007299238741499423" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9888627614380081" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="1.419636837303777" Z="0.013958911844219803">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="10.769158781101229" CI_START="0.09603215997442066" EFFECT_SIZE="1.0169491525423728" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0321817802715805" LOG_CI_START="-1.0175833027885817" LOG_EFFECT_SIZE="0.007299238741499423" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" ORDER="7641" O_E="0.0" SE="1.204042156290341" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.4497175141242937" WEIGHT="1.419636837303777"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2900567508484102" CI_START="0.5029419661690943" DF="0" EFFECT_SIZE="0.8054959209961357" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.11060881575520744" LOG_CI_START="-0.29848212473847757" LOG_EFFECT_SIZE="-0.09393665449163506" MODIFIED="2012-08-02 15:28:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.36806423162677127" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="36.808273597243634" Z="0.9001052891056606">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="1.29005675084841" CI_START="0.5029419661690944" EFFECT_SIZE="0.8054959209961357" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.11060881575520737" LOG_CI_START="-0.29848212473847746" LOG_EFFECT_SIZE="-0.09393665449163506" MODIFIED="2012-08-02 15:28:18 -0400" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.24030204347880527" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.05774507210008962" WEIGHT="36.808273597243634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7512450170431086" CI_START="0.40832112278436955" DF="0" EFFECT_SIZE="1.2376237623762376" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.5741754315393086" LOG_CI_START="-0.38899815308848096" LOG_EFFECT_SIZE="0.09258863922541384" MODIFIED="2012-08-02 15:28:32 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.706309131850173" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="5.72953890695865" Z="0.37681763942791563">
<NAME>104 weeks</NAME>
<DICH_DATA CI_END="3.751245017043108" CI_START="0.40832112278436966" EFFECT_SIZE="1.2376237623762376" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5741754315393085" LOG_CI_START="-0.38899815308848085" LOG_EFFECT_SIZE="0.09258863922541384" MODIFIED="2012-08-02 15:28:32 -0400" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5657729313965012" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.32009900990099005" WEIGHT="5.72953890695865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.095256486644231E-31" CI_END="0.9787556590733335" CI_START="0.4509214029231386" DF="0" EFFECT_SIZE="0.6643356643356645" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="52" I2="100.0" ID="CMP-001.07.04" LOG_CI_END="-0.009325713876818775" LOG_CI_START="-0.3458991504756091" LOG_EFFECT_SIZE="-0.17761243217621395" MODIFIED="2012-08-02 15:28:48 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.038585834143672594" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="56.042550658493944" Z="2.068576616085772">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="0.9787556590733333" CI_START="0.45092140292313854" EFFECT_SIZE="0.6643356643356644" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="52" LOG_CI_END="-0.009325713876818874" LOG_CI_START="-0.34589915047560915" LOG_EFFECT_SIZE="-0.177612432176214" MODIFIED="2012-08-02 15:28:48 -0400" MODIFIED_BY="[Empty name]" ORDER="7666" O_E="0.0" SE="0.19770490272351054" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03908722856091277" WEIGHT="56.042550658493944"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.720871396027791" CI_END="2.114577296618996" CI_START="0.7370992671550622" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2484604021275945" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="81" I2="55.36293103639689" I2_Q="54.13689349360205" ID="CMP-001.08" LOG_CI_END="0.3252235650476105" LOG_CI_START="-0.13247402058789845" LOG_EFFECT_SIZE="0.09637477222985605" METHOD="MH" MODIFIED="2013-03-14 17:22:23 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.08134729512377858" P_Q="0.08805172159107433" P_Z="0.4091463060944244" Q="6.541205401298966" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1337784499649765" TOTALS="YES" TOTAL_1="665" TOTAL_2="576" WEIGHT="100.0" Z="0.8253968931319365">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4339543951769103" CI_START="0.07529115560687076" DF="0" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.5357945231910793" LOG_CI_START="-1.123256037036043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2012-08-02 15:45:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4876737765171083" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="6.6712182533054944" Z="0.6940134538647702">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="3.4339543951769103" CI_START="0.07529115560687076" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5357945231910793" LOG_CI_START="-1.123256037036043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2012-08-02 15:45:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7690" O_E="0.0" SE="0.9745345115101332" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.9497175141242938" WEIGHT="6.6712182533054944"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4864321954248818" CI_START="0.6063081481248207" DF="0" EFFECT_SIZE="0.9493344783168742" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.17214510336642783" LOG_CI_START="-0.2173065952783614" LOG_EFFECT_SIZE="-0.022580745955966767" MODIFIED="2012-08-02 15:40:08 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8202053940275251" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="38.83805287515246" Z="0.22728081028661595">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="1.4864321954248818" CI_START="0.6063081481248207" EFFECT_SIZE="0.9493344783168742" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="34" LOG_CI_END="0.17214510336642783" LOG_CI_START="-0.2173065952783614" LOG_EFFECT_SIZE="-0.022580745955966767" MODIFIED="2012-08-02 15:40:08 -0400" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="0.22876585560094892" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.05233381668883422" WEIGHT="38.83805287515246"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.192851470799035" CI_START="1.397458099290786" DF="0" EFFECT_SIZE="5.693069306930694" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="1.3653541467364492" LOG_CI_START="0.14533879507752673" LOG_EFFECT_SIZE="0.7553464709069879" MODIFIED="2012-08-02 15:43:15 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.015226784162352326" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="11.165790030869552" Z="2.4269397541827256">
<NAME>104 weeks</NAME>
<DICH_DATA CI_END="23.192851470799035" CI_START="1.397458099290786" EFFECT_SIZE="5.693069306930693" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" LOG_CI_END="1.3653541467364492" LOG_CI_START="0.14533879507752673" LOG_EFFECT_SIZE="0.7553464709069879" MODIFIED="2012-08-02 15:43:15 -0400" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.7166430567378402" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5135772707705553" WEIGHT="11.165790030869552"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7701726545824785" CI_START="0.8679220363894331" DF="0" EFFECT_SIZE="1.2395046813651465" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.24801562753445064" LOG_CI_START="-0.06151928483106771" LOG_EFFECT_SIZE="0.09324817135169146" MODIFIED="2012-08-02 15:54:51 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2376471740400612" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="43.324938840672495" Z="1.1808881659056076">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="1.7701726545824785" CI_START="0.8679220363894331" EFFECT_SIZE="1.2395046813651465" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" LOG_CI_END="0.24801562753445064" LOG_CI_START="-0.06151928483106771" LOG_EFFECT_SIZE="0.09324817135169146" MODIFIED="2012-08-02 15:54:51 -0400" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.181822339746033" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03305936323072186" WEIGHT="43.324938840672495"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.01836631069802" CI_END="1.5473017729462781" CI_START="0.5406860262906082" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9146608371887014" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" I2="0.9099592378584829" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.1895750231655984" LOG_CI_START="-0.2670548543624203" LOG_EFFECT_SIZE="-0.03873991559841095" METHOD="MH" MODIFIED="2013-03-12 15:23:50 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.3645167325241374" P_Q="0.3728502420108798" P_Z="0.7394650424467866" Q="1.9731574003283971" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="606" TOTAL_2="546" WEIGHT="100.0" Z="0.33256185402519106">
<NAME>Serious Infections</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-02 12:04:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>24 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8449383168903932" CI_START="0.20255671560262972" DF="0" EFFECT_SIZE="0.6113138686131386" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.2659818506674665" LOG_CI_START="-0.6934533535625144" LOG_EFFECT_SIZE="-0.21373575144752396" MODIFIED="2012-08-02 15:38:04 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3825257242233181" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="29.012668214581076" Z="0.8732520407815598">
<NAME>52 weeks</NAME>
<DICH_DATA CI_END="1.8449383168903932" CI_START="0.20255671560262972" EFFECT_SIZE="0.6113138686131386" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2659818506674665" LOG_CI_START="-0.6934533535625144" LOG_EFFECT_SIZE="-0.21373575144752396" MODIFIED="2012-08-02 15:38:04 -0400" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.5635769882455471" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.31761902167992156" WEIGHT="29.012668214581076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.53656077231553" CI_START="0.31014011320958995" DF="0" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="1.9891674379078073" LOG_CI_START="-0.5084420589193198" LOG_EFFECT_SIZE="0.7403626894942439" MODIFIED="2012-08-02 15:46:24 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2452442383506972" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="2.3912509386105447" Z="1.1619784507941167">
<NAME>104 weeks</NAME>
<DICH_DATA CI_END="97.53656077231553" CI_START="0.3101401132095901" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9891674379078073" LOG_CI_START="-0.5084420589193196" LOG_EFFECT_SIZE="0.7403626894942439" MODIFIED="2012-08-02 15:46:24 -0400" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="1.4671081818026575" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.1524064171122994" WEIGHT="2.3912509386105447"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5183970630643776E-31" CI_END="1.6552160625635812" CI_START="0.47117439643389203" DF="0" EFFECT_SIZE="0.8831168831168832" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="100.0" ID="CMP-001.09.04" LOG_CI_END="0.21885469216280187" LOG_CI_START="-0.3268183170952929" LOG_EFFECT_SIZE="-0.05398181246624552" MODIFIED="2012-08-02 15:49:10 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.6981737797911571" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="68.59608084680838" Z="0.38778684838338284">
<NAME>156 weeks</NAME>
<DICH_DATA CI_END="1.6552160625635812" CI_START="0.471174396433892" EFFECT_SIZE="0.8831168831168831" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.21885469216280187" LOG_CI_START="-0.32681831709529297" LOG_EFFECT_SIZE="-0.053981812466245574" MODIFIED="2012-08-02 15:49:10 -0400" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.3205310267631639" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.10274013911784809" WEIGHT="68.59608084680838"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-03-14 17:22:59 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX))</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="82.47034208424034" CI_START="1.6584270096040774" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="11.694915254237289" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.219696362184266" LOG_EFFECT_SIZE="1.0679970790951112" METHOD="MH" MODIFIED="2013-03-12 15:24:54 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.013603612466877302" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="2.467563411054371">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="82.47034208424034" CI_START="1.6584270096040774" DF="0" EFFECT_SIZE="11.694915254237289" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.219696362184266" LOG_EFFECT_SIZE="1.0679970790951112" MODIFIED="2012-09-15 17:54:05 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.013603612466877302" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="2.467563411054371">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="82.47034208424034" CI_START="1.6584270096040779" EFFECT_SIZE="11.694915254237289" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.2196963621842661" LOG_EFFECT_SIZE="1.0679970790951112" MODIFIED="2012-09-15 17:54:05 -0400" MODIFIED_BY="[Empty name]" ORDER="7534" O_E="0.0" SE="0.9965920805394045" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.993195774993859" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="163.14803287586722" CI_START="0.5906718134797626" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.816666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.991964044403458" METHOD="MH" MODIFIED="2013-03-12 15:25:02 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.11120253297582895" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.5928112839535284">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="163.14803287586722" CI_START="0.5906718134797626" DF="0" EFFECT_SIZE="9.816666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.991964044403458" MODIFIED="2012-08-02 11:40:37 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11120253297582895" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.5928112839535284">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="163.14803287586722" CI_START="0.5906718134797626" EFFECT_SIZE="9.816666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.991964044403458" MODIFIED="2012-08-02 11:40:37 -0400" MODIFIED_BY="[Empty name]" ORDER="7537" O_E="0.0" SE="1.4339938726200825" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.056338426711941" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.020844374958172263" CI_START="-0.6208443749581721" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-03-14 17:22:45 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.06685753547631378" Q="0.0" RANDOM="NO" SCALE="0.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.8326305251219415">
<NAME>HAQ (mean reduction from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.020844374958172263" CI_START="-0.6208443749581721" DF="0" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2012-10-19 09:54:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06685753547631378" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="1.8326305251219415">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="0.020844374958172318" CI_START="-0.6208443749581722" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.4" MODIFIED="2012-10-19 09:54:53 -0400" MODIFIED_BY="[Empty name]" ORDER="7608" SD_1="0.71" SD_2="0.74" SE="0.1636991176822389" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7896370124580337" CI_START="0.0363804846242428" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" METHOD="MH" MODIFIED="2013-03-12 15:25:17 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.02377202768570906" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="2.260793816561138">
<NAME>Total withdrawals</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7896370124580337" CI_START="0.0363804846242428" DF="0" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" MODIFIED="2012-08-02 11:56:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02377202768570906" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="2.260793816561138">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="0.7896370124580337" CI_START="0.0363804846242428" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" MODIFIED="2012-08-02 11:56:50 -0400" MODIFIED_BY="[Empty name]" ORDER="7635" O_E="0.0" SE="0.7851013824920705" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.6163841807909605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.769158781101229" CI_START="0.09603215997442066" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0169491525423728" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.0321817802715805" LOG_CI_START="-1.0175833027885817" LOG_EFFECT_SIZE="0.007299238741499423" METHOD="MH" MODIFIED="2013-03-14 17:22:51 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9888627614380081" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.013958911844219803">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.769158781101229" CI_START="0.09603215997442066" DF="0" EFFECT_SIZE="1.0169491525423728" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="1.0321817802715805" LOG_CI_START="-1.0175833027885817" LOG_EFFECT_SIZE="0.007299238741499423" MODIFIED="2012-08-02 11:56:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9888627614380081" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.013958911844219803">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="10.769158781101229" CI_START="0.09603215997442066" EFFECT_SIZE="1.0169491525423728" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0321817802715805" LOG_CI_START="-1.0175833027885817" LOG_EFFECT_SIZE="0.007299238741499423" MODIFIED="2012-08-02 11:56:38 -0400" MODIFIED_BY="[Empty name]" ORDER="7641" O_E="0.0" SE="1.204042156290341" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.4497175141242937" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3099714809424476" CI_START="0.049341989210359295" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2542372881355932" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.11726184084343928" LOG_CI_START="-1.3067833460163651" LOG_EFFECT_SIZE="-0.594760752586463" METHOD="MH" MODIFIED="2013-03-14 17:22:59 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.10159271654532381" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.6371807092132225">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Etanercept 25 mg + DMARD</GROUP_LABEL_1>
<GROUP_LABEL_2>DMARD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARDs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ET 25 mg + DMARDs</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3099714809424476" CI_START="0.049341989210359295" DF="0" EFFECT_SIZE="0.2542372881355932" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.11726184084343928" LOG_CI_START="-1.3067833460163651" LOG_EFFECT_SIZE="-0.594760752586463" MODIFIED="2012-08-02 12:04:05 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10159271654532381" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.6371807092132225">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="1.309971480942448" CI_START="0.049341989210359274" EFFECT_SIZE="0.2542372881355932" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.11726184084343942" LOG_CI_START="-1.3067833460163654" LOG_EFFECT_SIZE="-0.594760752586463" MODIFIED="2012-08-02 12:04:05 -0400" MODIFIED_BY="[Empty name]" ORDER="7690" O_E="0.0" SE="0.8364911918988113" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.6997175141242938" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-03-14 17:23:52 -0400" MODIFIED_BY="Anne Lethaby" NO="3">
<NAME>Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="2.801309470952517E-4" CI_END="3.8406907965657555" CI_START="1.839997517578323" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6583569232642374" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.5844093447203429" LOG_CI_START="0.2648172370841216" LOG_EFFECT_SIZE="0.42461329090223227" METHOD="MH" MODIFIED="2013-03-14 17:23:30 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.9866463395866869" P_Q="1.0" P_Z="1.9082959154918977E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="5.208055753821643">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.801309470952517E-4" CI_END="3.8406907965657555" CI_START="1.839997517578323" DF="1" EFFECT_SIZE="2.6583569232642374" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="22" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.5844093447203429" LOG_CI_START="0.2648172370841216" LOG_EFFECT_SIZE="0.42461329090223227" MODIFIED="2012-02-21 14:47:37 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9866463395866869" P_Z="1.9082959154918977E-7" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="5.208055753821643">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.197142819603702" CI_START="1.675752858854574" EFFECT_SIZE="2.6520509193776522" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="14" LOG_CI_END="0.6229537475556604" LOG_CI_START="0.22420996897801626" LOG_EFFECT_SIZE="0.4235818582668383" MODIFIED="2012-01-31 09:06:50 -0500" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.23422406935004536" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.05486091466289486" WEIGHT="63.842977302935296"/>
<DICH_DATA CI_END="4.9386965489029695" CI_START="1.4429282977290927" EFFECT_SIZE="2.669491525423729" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="8" LOG_CI_END="0.6936123423823175" LOG_CI_START="0.15924475058463272" LOG_EFFECT_SIZE="0.4264285464834751" ORDER="7531" O_E="0.0" SE="0.31389016858420016" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.09852703793381759" WEIGHT="36.1570226970647"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2369988201931572" CI_END="9.276969760734344" CI_START="2.415560709472375" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.733823365630917" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="8" I2="19.15917916204236" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.9674061409709109" LOG_CI_START="0.38301795693639806" LOG_EFFECT_SIZE="0.6752120489536545" METHOD="MH" MODIFIED="2013-03-14 17:23:35 -0400" MODIFIED_BY="Anne Lethaby" NO="2" P_CHI2="0.26605032058461" P_Q="1.0" P_Z="5.922103769267325E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.00000000000001" Z="4.529151457992181">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2369988201931572" CI_END="9.276969760734344" CI_START="2.415560709472375" DF="1" EFFECT_SIZE="4.733823365630917" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="8" I2="19.15917916204236" ID="CMP-003.02.01" LOG_CI_END="0.9674061409709109" LOG_CI_START="0.38301795693639806" LOG_EFFECT_SIZE="0.6752120489536545" MODIFIED="2012-02-21 14:47:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.26605032058461" P_Z="5.922103769267325E-6" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.00000000000001" Z="4.529151457992181">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.6361981479298295" CI_START="1.8398216755488328" EFFECT_SIZE="3.748231966053748" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="7" LOG_CI_END="0.8828771891606054" LOG_CI_START="0.2647757311192117" LOG_EFFECT_SIZE="0.5738264601399085" MODIFIED="2012-01-31 09:07:33 -0500" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.36307585610507737" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.13182407728643483" WEIGHT="87.59744960463304"/>
<DICH_DATA CI_END="82.47034208424034" CI_START="1.6584270096040779" EFFECT_SIZE="11.694915254237289" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.2196963621842661" LOG_EFFECT_SIZE="1.0679970790951112" ORDER="7534" O_E="0.0" SE="0.9965920805394045" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.993195774993859" WEIGHT="12.402550395366967"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01755303937061236" CI_END="57.85966073998811" CI_START="2.298119479553" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="11.531193061730194" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.7623758828345522" LOG_CI_START="0.36137260397005516" LOG_EFFECT_SIZE="1.0618742434023036" METHOD="MH" MODIFIED="2013-03-14 17:23:44 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8945984112294372" P_Q="1.0" P_Z="0.0029676983164335854" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="2.971064100386775">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01755303937061236" CI_END="57.85966073998811" CI_START="2.298119479553" DF="1" EFFECT_SIZE="11.531193061730194" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="1" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="1.7623758828345522" LOG_CI_START="0.36137260397005516" LOG_EFFECT_SIZE="1.0618742434023036" MODIFIED="2012-02-21 14:47:41 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8945984112294372" P_Z="0.0029676983164335854" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="2.971064100386775">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="88.7314403907299" CI_START="1.7262343206121757" EFFECT_SIZE="12.376237623762377" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="1" LOG_CI_END="1.9480775315433794" LOG_CI_START="0.23709974690744842" LOG_EFFECT_SIZE="1.0925886392254138" MODIFIED="2012-01-31 09:08:58 -0500" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="1.0050368201717736" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.01009900990099" WEIGHT="66.98491363603236"/>
<DICH_DATA CI_END="163.14803287586722" CI_START="0.5906718134797626" EFFECT_SIZE="9.816666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.991964044403458" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7537" O_E="0.0" SE="1.4339938726200825" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.056338426711941" WEIGHT="33.01508636396764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.2820360599885787E-30" CI_END="-1.0356399899313122" CI_START="-1.8043600100686863" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4199999999999993" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2013-03-14 17:23:52 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="4.454052804951112E-13" Q="0.0" RANDOM="NO" SCALE="3.71" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="7.240994861951203">
<NAME>DAS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2820360599885787E-30" CI_END="-1.0356399899313122" CI_START="-1.8043600100686863" DF="0" EFFECT_SIZE="-1.4199999999999993" ESTIMABLE="YES" I2="100.0" ID="CMP-003.04.01" MODIFIED="2013-03-14 17:23:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="4.454052804951112E-13" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="7.240994861951203">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-1.0356399899313125" CI_START="-1.8043600100686865" EFFECT_SIZE="-1.4199999999999995" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="4.02" MODIFIED="2012-01-31 10:48:46 -0500" MODIFIED_BY="[Empty name]" ORDER="453" SD_1="1.2" SD_2="1.1" SE="0.1961056494407396" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-03-20 15:20:22 -0400" MODIFIED_BY="Anne Lethaby" NO="4">
<NAME>Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="2.9576136031834666" CI_END="1.3549750075387985" CI_START="1.0711356515516295" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2047248804338047" ESTIMABLE="YES" EVENTS_1="417" EVENTS_2="334" I2="66.18895724162086" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.1319312847395094" LOG_CI_START="0.029844474557105597" LOG_EFFECT_SIZE="0.08088787964830749" METHOD="MH" MODIFIED="2013-03-14 17:25:05 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.08547417640516075" P_Q="1.0" P_Z="0.0018968051003035162" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.004764903589704882" TOTALS="SUB" TOTAL_1="487" TOTAL_2="471" WEIGHT="100.0" Z="3.1059317185682693">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9576136031834666" CI_END="1.3549750075387985" CI_START="1.0711356515516295" DF="1" EFFECT_SIZE="1.2047248804338047" ESTIMABLE="YES" EVENTS_1="417" EVENTS_2="334" I2="66.18895724162086" ID="CMP-004.01.01" LOG_CI_END="0.1319312847395094" LOG_CI_START="0.029844474557105597" LOG_EFFECT_SIZE="0.08088787964830749" MODIFIED="2008-10-08 16:30:07 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.08547417640516075" P_Z="0.0018968051003035162" STUDIES="2" TAU2="0.004764903589704882" TOTAL_1="487" TOTAL_2="471" WEIGHT="100.0" Z="3.1059317185682693">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.417403752886547" CI_START="1.1580016843655563" EFFECT_SIZE="1.2811541411042944" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="163" LOG_CI_END="0.15149357831667942" LOG_CI_START="0.0637091910927426" LOG_EFFECT_SIZE="0.10760138470471102" MODIFIED="2008-10-08 16:30:07 -0400" MODIFIED_BY="Anne Lethaby" ORDER="436" O_E="0.0" SE="0.05156498359506537" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="256" TOTAL_2="243" VAR="0.0026589475331593605" WEIGHT="48.43789015992933"/>
<DICH_DATA CI_END="1.2468109200346738" CI_START="1.0370157882030484" EFFECT_SIZE="1.1370851370851371" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="171" LOG_CI_END="0.09580059733437603" LOG_CI_START="0.015785368421121167" LOG_EFFECT_SIZE="0.055792982877748594" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7550" O_E="0.0" SE="0.04700134154541691" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.002209126107068933" WEIGHT="51.56210984007067"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8874801214472929" CI_END="1.7013603930405903" CI_START="1.3556493162016419" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5186994611963334" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="217" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.23079631839239786" LOG_CI_START="0.13214735934258034" LOG_EFFECT_SIZE="0.18147183886748916" METHOD="MH" MODIFIED="2013-03-14 17:25:15 -0400" MODIFIED_BY="Anne Lethaby" NO="2" P_CHI2="0.34616119460482897" P_Q="1.0" P_Z="5.554703251631539E-13" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="487" TOTAL_2="471" WEIGHT="100.0" Z="7.210988779089255">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8874801214472929" CI_END="1.7013603930405903" CI_START="1.3556493162016419" DF="1" EFFECT_SIZE="1.5186994611963334" ESTIMABLE="YES" EVENTS_1="341" EVENTS_2="217" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.23079631839239786" LOG_CI_START="0.13214735934258034" LOG_EFFECT_SIZE="0.18147183886748916" MODIFIED="2012-02-21 10:46:14 -0500" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.34616119460482897" P_Z="5.554703251631539E-13" STUDIES="2" TAU2="0.0" TOTAL_1="487" TOTAL_2="471" WEIGHT="100.0" Z="7.210988779089255">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6784844636880316" CI_START="1.2418768111277236" EFFECT_SIZE="1.4437696953781514" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="119" LOG_CI_END="0.224917325705697" LOG_CI_START="0.09407851782053583" LOG_EFFECT_SIZE="0.15949792176311642" MODIFIED="2008-10-08 16:31:58 -0400" MODIFIED_BY="Anne Lethaby" ORDER="437" O_E="0.0" SE="0.0768553634142881" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="256" TOTAL_2="243" VAR="0.005906746885542293" WEIGHT="55.31385355107004"/>
<DICH_DATA CI_END="1.914691758116164" CI_START="1.3562341642835545" EFFECT_SIZE="1.6114497747150809" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="98" LOG_CI_END="0.28209886784814237" LOG_CI_START="0.13233468029533652" LOG_EFFECT_SIZE="0.2072167740717394" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7551" O_E="0.0" SE="0.08797222511320281" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.007739112391368031" WEIGHT="44.686146448929954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.115842944616581" CI_END="2.317319070789248" CI_START="1.5921330479499098" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9208019875167088" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="112" I2="52.737512841189954" I2_Q="100.00000000000001" ID="CMP-004.03" LOG_CI_END="0.36498583575061283" LOG_CI_START="0.20197935710523476" LOG_EFFECT_SIZE="0.28348259642792384" METHOD="MH" MODIFIED="2013-03-14 17:25:22 -0400" MODIFIED_BY="Anne Lethaby" NO="3" P_CHI2="0.1457818234321181" P_Q="0.0" P_Z="9.289702912310272E-12" Q="1.3444217327368811E-30" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="487" TOTAL_2="471" WEIGHT="100.0" Z="6.817099343043662">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.115842944616581" CI_END="2.317319070789248" CI_START="1.5921330479499098" DF="1" EFFECT_SIZE="1.9208019875167088" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="112" I2="52.737512841189954" ID="CMP-004.03.01" LOG_CI_END="0.36498583575061283" LOG_CI_START="0.20197935710523476" LOG_EFFECT_SIZE="0.28348259642792384" MODIFIED="2008-10-08 16:33:49 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.1457818234321181" P_Z="9.289702912310272E-12" STUDIES="2" TAU2="0.0" TOTAL_1="487" TOTAL_2="471" WEIGHT="100.0" Z="6.817099343043662">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.1605462755024623" CI_START="1.346834500591385" EFFECT_SIZE="1.705842391304348" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="69" LOG_CI_END="0.3345635726514794" LOG_CI_START="0.12931423277140536" LOG_EFFECT_SIZE="0.2319389027114424" MODIFIED="2008-10-08 16:33:49 -0400" MODIFIED_BY="Anne Lethaby" ORDER="438" O_E="0.0" SE="0.12056447824617376" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="256" TOTAL_2="243" VAR="0.014535793414772106" WEIGHT="62.060342414463555"/>
<DICH_DATA CI_END="3.091070266506304" CI_START="1.670591758788877" EFFECT_SIZE="2.272425249169435" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="43" LOG_CI_END="0.4901088775994089" LOG_CI_START="0.22287033465313677" LOG_EFFECT_SIZE="0.35648960612627284" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7552" O_E="0.0" SE="0.1569772429787625" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.024641854813213446" WEIGHT="37.93965758553645"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8106651106501257" CI_START="1.846468470976724" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6525974025974026" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.5810007837269492" LOG_CI_START="0.26634189633699323" LOG_EFFECT_SIZE="0.4236713400319712" METHOD="MH" MODIFIED="2013-03-14 17:25:27 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.3062065169447418E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="5.277973075112276">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8106651106501257" CI_START="1.846468470976724" DF="0" EFFECT_SIZE="2.6525974025974026" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="32" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.5810007837269492" LOG_CI_START="0.26634189633699323" LOG_EFFECT_SIZE="0.4236713400319712" MODIFIED="2008-07-28 11:18:31 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.3062065169447418E-7" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="5.277973075112276">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.8106651106501257" CI_START="1.846468470976724" EFFECT_SIZE="2.6525974025974026" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="32" LOG_CI_END="0.5810007837269492" LOG_CI_START="0.26634189633699323" LOG_EFFECT_SIZE="0.4236713400319712" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7553" O_E="0.0" SE="0.18483218803947313" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.034162937735459156" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1219665459208623" CI_END="2.3501880180032537" CI_START="1.6104227041636183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9454552534678702" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="112" I2="10.870782766589299" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.3711026077674664" LOG_CI_START="0.2069398847217983" LOG_EFFECT_SIZE="0.2890212462446324" METHOD="MH" MODIFIED="2013-03-14 17:25:36 -0400" MODIFIED_BY="Anne Lethaby" NO="5" P_CHI2="0.2894954368364828" P_Q="1.0" P_Z="5.151493454062419E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="496" TOTAL_2="491" WEIGHT="100.0" Z="6.9013381710143324">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1219665459208623" CI_END="2.3501880180032537" CI_START="1.6104227041636183" DF="1" EFFECT_SIZE="1.9454552534678702" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="112" I2="10.870782766589299" ID="CMP-004.05.01" LOG_CI_END="0.3711026077674664" LOG_CI_START="0.2069398847217983" LOG_EFFECT_SIZE="0.2890212462446324" MODIFIED="2008-10-08 16:35:30 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.2894954368364828" P_Z="5.151493454062419E-12" STUDIES="2" TAU2="0.0" TOTAL_1="496" TOTAL_2="491" WEIGHT="100.0" Z="6.9013381710143324">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.2572837517937887" CI_START="1.4267101002302334" EFFECT_SIZE="1.7945722408891187" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="73" LOG_CI_END="0.3535861554856134" LOG_CI_START="0.15433573579107465" LOG_EFFECT_SIZE="0.253960945638344" MODIFIED="2008-10-08 16:35:30 -0400" MODIFIED_BY="Anne Lethaby" ORDER="439" O_E="0.0" SE="0.1170406828340565" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" VAR="0.013698521438262208" WEIGHT="65.11649549244517"/>
<DICH_DATA CI_END="3.0967711810868956" CI_START="1.6016689179710355" EFFECT_SIZE="2.227106227106227" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="39" LOG_CI_END="0.4909091167346998" LOG_CI_START="0.20457274772925801" LOG_EFFECT_SIZE="0.34774093223197894" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7554" O_E="0.0" SE="0.1681954005416824" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.02828969276337697" WEIGHT="34.88350450755483"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.04538626030134996" CI_END="-1.4293282937402496" CI_START="-2.9905427390681485" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.209935516404199" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2013-03-20 15:20:22 -0400" MODIFIED_BY="Anne Lethaby" NO="6" P_CHI2="0.8312955116179747" P_Q="1.0" P_Z="2.87719892381653E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="458" TOTAL_2="436" UNITS="" WEIGHT="100.0" Z="5.5487496074230105">
<NAME>Change in Total Sharp Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04538626030134996" CI_END="-1.4293282937402496" CI_START="-2.9905427390681485" DF="1" EFFECT_SIZE="-2.209935516404199" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" MODIFIED="2013-03-20 15:20:22 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.8312955116179747" P_Z="2.87719892381653E-8" STUDIES="2" TAU2="0.0" TOTAL_1="458" TOTAL_2="436" WEIGHT="100.0" Z="5.5487496074230105">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-1.0575421204875155" CI_START="-3.202457879512484" EFFECT_SIZE="-2.13" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="2.4" MODIFIED="2008-10-08 16:38:46 -0400" MODIFIED_BY="Anne Lethaby" ORDER="440" SD_1="3.2" SD_2="7.7" SE="0.5471824421121486" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="246" TOTAL_2="230" WEIGHT="52.9791079975298"/>
<CONT_DATA CI_END="-1.1616203238871488" CI_START="-3.438379676112851" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="1.5" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7555" SD_1="2.7" SD_2="7.9" SE="0.5808166298423056" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="206" WEIGHT="47.0208920024702"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8530006868481393" CI_START="-2.4069993131518603" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.63" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2013-03-14 17:26:09 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="3.9285889038543915E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="4.11163979262861">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8530006868481393" CI_START="-2.4069993131518603" DF="0" EFFECT_SIZE="-1.63" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" MODIFIED="2013-03-14 17:26:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.9285889038543915E-5" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="206" WEIGHT="100.0" Z="4.11163979262861">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.8530006868481393" CI_START="-2.4069993131518603" EFFECT_SIZE="-1.63" ESTIMABLE="YES" MEAN_1="-0.64" MEAN_2="0.99" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7556" SD_1="2.1" SD_2="5.3" SE="0.3964355055912925" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="206" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2169008424087578" CI_START="-1.1230991575912423" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.67" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2013-03-20 15:20:07 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0037530089616611816" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="2.898208587768997">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2169008424087578" CI_START="-1.1230991575912423" DF="0" EFFECT_SIZE="-0.67" ESTIMABLE="YES" I2="0.0" ID="CMP-004.08.01" MODIFIED="2013-03-20 15:20:07 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0037530089616611816" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="206" WEIGHT="100.0" Z="2.898208587768997">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.2169008424087578" CI_START="-1.1230991575912423" EFFECT_SIZE="-0.67" ESTIMABLE="YES" MEAN_1="-0.16" MEAN_2="0.51" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7557" SD_1="1.2" SD_2="3.1" SE="0.23117728752427624" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="206" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.10066891726080657" CI_END="1.5088691120471807" CI_START="1.255948624746696" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.376612540331674" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="256" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.1786515682175585" LOG_CI_START="0.09897187471538749" LOG_EFFECT_SIZE="0.138811721466473" METHOD="MH" MODIFIED="2013-03-14 17:26:30 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="0.7510284055330282" P_Q="1.0" P_Z="8.551364234697465E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="464" TOTAL_2="442" WEIGHT="100.0" Z="6.828991497033804">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10066891726080657" CI_END="1.5088691120471807" CI_START="1.255948624746696" DF="1" EFFECT_SIZE="1.376612540331674" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="256" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="0.1786515682175585" LOG_CI_START="0.09897187471538749" LOG_EFFECT_SIZE="0.138811721466473" MODIFIED="2012-05-07 16:52:54 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.7510284055330282" P_Z="8.551364234697465E-12" STUDIES="2" TAU2="0.0" TOTAL_1="464" TOTAL_2="442" WEIGHT="100.0" Z="6.828991497033804">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5388482581832044" CI_START="1.1973862488173992" EFFECT_SIZE="1.35742246311352" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="135" LOG_CI_END="0.1871957972955811" LOG_CI_START="0.07823426625578628" LOG_EFFECT_SIZE="0.13271503177568372" MODIFIED="2008-10-08 16:44:41 -0400" MODIFIED_BY="Anne Lethaby" ORDER="441" O_E="0.0" SE="0.06400454270105295" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="246" TOTAL_2="230" VAR="0.00409658148637091" WEIGHT="53.21276894800565"/>
<DICH_DATA CI_END="1.599723511829202" CI_START="1.2224794370237548" EFFECT_SIZE="1.3984380923496853" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="121" LOG_CI_END="0.20404492786650683" LOG_CI_START="0.08724156271408558" LOG_EFFECT_SIZE="0.14564324529029624" MODIFIED="2008-10-11 10:51:50 -0400" MODIFIED_BY="Anne Lethaby" ORDER="471" O_E="0.0" SE="0.06861087487651459" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="218" TOTAL_2="212" VAR="0.004707452151320741" WEIGHT="46.78723105199434"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-03-20 15:19:47 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="12.121028600658745" CI_END="1.9011031498699518" CI_START="1.145591143187509" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4757665570058471" ESTIMABLE="YES" EVENTS_1="391" EVENTS_2="257" I2="83.4997501788643" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.2790056814125237" LOG_CI_START="0.05902964735234442" LOG_EFFECT_SIZE="0.16901766438243404" METHOD="MH" MODIFIED="2013-03-14 17:29:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002333207756175404" P_Q="1.0" P_Z="0.00259652116106684" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03798842699482051" TOTALS="SUB" TOTAL_1="463" TOTAL_2="408" WEIGHT="100.0" Z="3.011860236102113">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.121028600658745" CI_END="1.9011031498699518" CI_START="1.145591143187509" DF="2" EFFECT_SIZE="1.4757665570058471" ESTIMABLE="YES" EVENTS_1="391" EVENTS_2="257" I2="83.4997501788643" ID="CMP-005.01.01" LOG_CI_END="0.2790056814125237" LOG_CI_START="0.05902964735234442" LOG_EFFECT_SIZE="0.16901766438243404" MODIFIED="2012-01-31 13:52:21 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002333207756175404" P_Z="0.00259652116106684" STUDIES="3" TAU2="0.03798842699482051" TOTAL_1="463" TOTAL_2="408" WEIGHT="100.0" Z="3.011860236102113">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.430823642361403" CI_START="1.5426066766306414" EFFECT_SIZE="2.3005241700640653" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="17" LOG_CI_END="0.5353983942095422" LOG_CI_START="0.18825520672154525" LOG_EFFECT_SIZE="0.3618268004655437" MODIFIED="2012-01-31 13:52:21 -0500" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.20391362671694127" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.04158076716085607" WEIGHT="20.98364740770395"/>
<DICH_DATA CI_END="1.6559572702546386" CI_START="1.21673973629983" EFFECT_SIZE="1.419460817470287" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="79" LOG_CI_END="0.21904912620970404" LOG_CI_START="0.08519769147839755" LOG_EFFECT_SIZE="0.1521234088440508" MODIFIED="2010-05-21 00:25:49 -0400" MODIFIED_BY="[Empty name]" ORDER="712" O_E="0.0" SE="0.07862499533645725" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.006181889891657924" WEIGHT="37.80031551435336"/>
<DICH_DATA CI_END="1.346143552672601" CI_START="1.1056273146955957" EFFECT_SIZE="1.219972574009841" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="161" LOG_CI_END="0.12909137549662633" LOG_CI_START="0.04360875947570651" LOG_EFFECT_SIZE="0.0863500674861664" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7578" O_E="0.0" SE="0.05021291179646201" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.0025213365110792743" WEIGHT="41.21603707794269"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.043515651695098" CI_END="3.269685717995521" CI_START="1.5082900449038008" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2207283531347954" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="91" I2="60.34512157550634" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.5145060103055927" LOG_CI_START="0.17848486460331278" LOG_EFFECT_SIZE="0.34649543745445277" METHOD="MH" MODIFIED="2013-03-14 17:30:01 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08031837418700027" P_Q="1.0" P_Z="5.297053941000256E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06200478470061575" TOTALS="SUB" TOTAL_1="463" TOTAL_2="408" WEIGHT="100.0" Z="4.042118104197455">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.043515651695098" CI_END="3.269685717995521" CI_START="1.5082900449038008" DF="2" EFFECT_SIZE="2.2207283531347954" ESTIMABLE="YES" EVENTS_1="215" EVENTS_2="91" I2="60.34512157550634" ID="CMP-005.02.01" LOG_CI_END="0.5145060103055927" LOG_CI_START="0.17848486460331278" LOG_EFFECT_SIZE="0.34649543745445277" MODIFIED="2012-01-31 13:54:30 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08031837418700027" P_Z="5.297053941000256E-5" STUDIES="3" TAU2="0.06200478470061575" TOTAL_1="463" TOTAL_2="408" WEIGHT="100.0" Z="4.042118104197455">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="27.935464996518842" CI_START="1.719481183754231" EFFECT_SIZE="6.930693069306931" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="2" LOG_CI_END="1.4461559047544077" LOG_CI_START="0.2353974277088207" LOG_EFFECT_SIZE="0.8407766662316143" MODIFIED="2012-01-31 13:54:30 -0500" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.7112055227676988" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5058132956152758" WEIGHT="6.861186168560541"/>
<DICH_DATA CI_END="2.3670711618173215" CI_START="1.3266511715126401" EFFECT_SIZE="1.772082878953108" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="42" LOG_CI_END="0.37421131442254507" LOG_CI_START="0.12275674486719913" LOG_EFFECT_SIZE="0.2484840296448721" MODIFIED="2010-05-21 00:27:26 -0400" MODIFIED_BY="[Empty name]" ORDER="714" O_E="0.0" SE="0.14770565887700413" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.02181696166428991" WEIGHT="46.478458489301104"/>
<DICH_DATA CI_END="3.1349110577369492" CI_START="1.7646591808852898" EFFECT_SIZE="2.3520309477756287" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="47" LOG_CI_END="0.49622522373706973" LOG_CI_START="0.2466608399484776" LOG_EFFECT_SIZE="0.37144303184277366" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7580" O_E="0.0" SE="0.1465953544010425" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.02149019793196725" WEIGHT="46.66035534213835"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.210040282868272" CI_END="2.820667459181828" CI_START="1.3250482524382816" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.93326679159872" ESTIMABLE="YES" EVENTS_1="315" EVENTS_2="160" I2="80.41143869573307" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.4503518882981541" LOG_CI_START="0.1222316936585783" LOG_EFFECT_SIZE="0.28629179097836616" METHOD="MH" MODIFIED="2013-03-14 17:30:09 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.006066242774700137" P_Q="1.0" P_Z="6.257054888492716E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0764826529704537" TOTALS="SUB" TOTAL_1="463" TOTAL_2="408" WEIGHT="100.0" Z="3.4202198374497006">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.210040282868272" CI_END="2.820667459181828" CI_START="1.3250482524382816" DF="2" EFFECT_SIZE="1.93326679159872" ESTIMABLE="YES" EVENTS_1="315" EVENTS_2="160" I2="80.41143869573307" ID="CMP-005.03.01" LOG_CI_END="0.4503518882981541" LOG_CI_START="0.1222316936585783" LOG_EFFECT_SIZE="0.28629179097836616" MODIFIED="2012-01-31 13:54:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006066242774700137" P_Z="6.257054888492716E-4" STUDIES="3" TAU2="0.0764826529704537" TOTAL_1="463" TOTAL_2="408" WEIGHT="100.0" Z="3.4202198374497006">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="13.635383171399639" CI_START="2.5026143417392626" EFFECT_SIZE="5.841584158415841" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="5" LOG_CI_END="1.1346673466697506" LOG_CI_START="0.3983939290492527" LOG_EFFECT_SIZE="0.7665306378595016" MODIFIED="2012-01-31 13:54:25 -0500" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.4324906501224772" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.187048162443363" WEIGHT="14.096448830635618"/>
<DICH_DATA CI_END="1.8895863235173307" CI_START="1.2253228441188946" EFFECT_SIZE="1.5216284987277353" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="60" LOG_CI_END="0.2763667369362209" LOG_CI_START="0.0882505302897473" LOG_EFFECT_SIZE="0.18230863361298413" MODIFIED="2010-05-21 00:26:53 -0400" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.11050039097437953" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.012210336405490737" WEIGHT="41.88435501965502"/>
<DICH_DATA CI_END="2.0283467406407505" CI_START="1.431343997898105" EFFECT_SIZE="1.7038961038961038" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="95" LOG_CI_END="0.3071421985286158" LOG_CI_START="0.1557440212057034" LOG_EFFECT_SIZE="0.23144310986715957" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7579" O_E="0.0" SE="0.08893203879254322" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.00790890752379841" WEIGHT="44.019196149709366"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.612803741266218" CI_START="1.8384510454462462" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.577200577200577" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.5578443699820397" LOG_CI_START="0.2644520698994021" LOG_EFFECT_SIZE="0.41114821994072087" METHOD="MH" MODIFIED="2013-03-14 17:30:22 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="3.9464810701145924E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="5.493230075667237">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.612803741266218" CI_START="1.8384510454462462" DF="0" EFFECT_SIZE="2.577200577200577" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="36" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.5578443699820397" LOG_CI_START="0.2644520698994021" LOG_EFFECT_SIZE="0.41114821994072087" MODIFIED="2008-07-28 11:19:54 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.9464810701145924E-8" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="5.493230075667237">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.612803741266218" CI_START="1.8384510454462462" EFFECT_SIZE="2.577200577200577" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="36" LOG_CI_END="0.5578443699820397" LOG_CI_START="0.2644520698994021" LOG_EFFECT_SIZE="0.41114821994072087" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7581" O_E="0.0" SE="0.17234008938384932" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.029701106408833174" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19233691413366769" CI_END="2.7351087607801428" CI_START="1.7007251411708557" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1567726429309726" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.43697460060273075" LOG_CI_START="0.23063413176770753" LOG_EFFECT_SIZE="0.33380436618521914" METHOD="MH" MODIFIED="2013-03-14 17:30:46 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6609787080631078" P_Q="1.0" P_Z="2.276749065770896E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="362" TOTAL_2="358" WEIGHT="100.0" Z="6.3414078614732805">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19233691413366769" CI_END="2.7351087607801428" CI_START="1.7007251411708557" DF="1" EFFECT_SIZE="2.1567726429309726" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="72" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.43697460060273075" LOG_CI_START="0.23063413176770753" LOG_EFFECT_SIZE="0.33380436618521914" MODIFIED="2010-05-21 00:28:15 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6609787080631078" P_Z="2.276749065770896E-10" STUDIES="2" TAU2="0.0" TOTAL_1="362" TOTAL_2="358" WEIGHT="100.0" Z="6.3414078614732805">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.9300014697236865" CI_START="1.391183129921922" EFFECT_SIZE="2.018952355883127" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="29" LOG_CI_END="0.4668678382014565" LOG_CI_START="0.14338430258706475" LOG_EFFECT_SIZE="0.3051260703942606" MODIFIED="2010-05-21 00:28:15 -0400" MODIFIED_BY="[Empty name]" ORDER="715" O_E="0.0" SE="0.19001583008921993" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.0361060156844953" WEIGHT="40.213073311664864"/>
<DICH_DATA CI_END="3.0618147951218173" CI_START="1.6526544492174406" EFFECT_SIZE="2.2494714587737845" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="43" LOG_CI_END="0.4859789172932609" LOG_CI_START="0.2181820571491747" LOG_EFFECT_SIZE="0.3520804872212178" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7582" O_E="0.0" SE="0.15730520126447314" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.0247449263448564" WEIGHT="59.78692668833514"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.6859198851941266" CI_START="-6.114080114805873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2013-03-20 15:19:47 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="5.556518927060114E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="3.4523861573890753">
<NAME>Change in Total Sharp Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.6859198851941266" CI_START="-6.114080114805873" DF="0" EFFECT_SIZE="-3.9" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.01" MODIFIED="2013-03-20 15:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.556518927060114E-4" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="206" WEIGHT="100.0" Z="3.4523861573890753">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-1.6859198851941266" CI_START="-6.114080114805873" EFFECT_SIZE="-3.9" ESTIMABLE="YES" MEAN_1="-0.56" MEAN_2="3.34" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7583" SD_1="3.7" SD_2="15.8" SE="1.1296534692832392" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="206" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3280540170021132E-31" CI_END="-1.371229691619051" CI_START="-4.38877030838095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8800000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2013-03-14 17:31:03 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="1.831027439049769E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="3.7412562032272763">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.3280540170021132E-31" CI_END="-1.371229691619051" CI_START="-4.38877030838095" DF="0" EFFECT_SIZE="-2.8800000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-005.07.01" MODIFIED="2013-03-14 17:31:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="1.831027439049769E-4" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="206" WEIGHT="100.0" Z="3.7412562032272763">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-1.3712296916190505" CI_START="-4.388770308380949" EFFECT_SIZE="-2.88" ESTIMABLE="YES" MEAN_1="-0.76" MEAN_2="2.12" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7584" SD_1="2.8" SD_2="10.7" SE="0.7697949147443203" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="206" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.16628244712158224" CI_START="-1.8937175528784178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.03" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2013-03-14 17:31:33 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.019423839144864632" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="206" UNITS="" WEIGHT="100.00000000000001" Z="2.3372952157201667">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16628244712158224" CI_START="-1.8937175528784178" DF="0" EFFECT_SIZE="-1.03" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.01" MODIFIED="2013-03-14 17:31:33 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.019423839144864632" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="206" WEIGHT="100.00000000000001" Z="2.3372952157201667">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.16628244712158224" CI_START="-1.8937175528784178" EFFECT_SIZE="-1.03" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="1.23" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7585" SD_1="1.7" SD_2="6.1" SE="0.4406803184606001" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="206" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0731274303377217" CI_END="1.449708237669169" CI_START="1.1783448053796424" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3070027433687894" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="180" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.16128060670387376" LOG_CI_START="0.07127239160744686" LOG_EFFECT_SIZE="0.11627649915566035" METHOD="MH" MODIFIED="2013-03-14 17:31:46 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7868365159993289" P_Q="1.0" P_Z="4.106957030716327E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="312" TOTAL_2="289" WEIGHT="99.99999999999999" Z="5.06393222772714">
<NAME>No progression of joint damage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0731274303377217" CI_END="1.449708237669169" CI_START="1.1783448053796424" DF="1" EFFECT_SIZE="1.3070027433687894" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="180" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="0.16128060670387376" LOG_CI_START="0.07127239160744686" LOG_EFFECT_SIZE="0.11627649915566035" MODIFIED="2013-03-14 17:31:46 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7868365159993289" P_Z="4.106957030716327E-7" STUDIES="2" TAU2="0.0" TOTAL_1="312" TOTAL_2="289" WEIGHT="99.99999999999999" Z="5.06393222772714">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5688287278354376" CI_START="1.1316554555974105" EFFECT_SIZE="1.3324314574314575" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="56" LOG_CI_END="0.1955755333791155" LOG_CI_START="0.053714221455357286" LOG_EFFECT_SIZE="0.12464487741723639" MODIFIED="2010-05-21 00:30:44 -0400" MODIFIED_BY="[Empty name]" ORDER="716" O_E="0.0" SE="0.08333003684883494" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="99" TOTAL_2="83" VAR="0.0069438950412281895" WEIGHT="32.58011310084825"/>
<DICH_DATA CI_END="1.4774875599245783" CI_START="1.1345514800603653" EFFECT_SIZE="1.2947145237013478" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="124" LOG_CI_END="0.1695238329178584" LOG_CI_START="0.05482420669861297" LOG_EFFECT_SIZE="0.11217401980823567" MODIFIED="2008-10-11 11:04:31 -0400" MODIFIED_BY="Anne Lethaby" ORDER="474" O_E="0.0" SE="0.0673751282134915" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="206" VAR="0.0045394079017844185" WEIGHT="67.41988689915173"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.6156399899313134" CI_START="-2.3843600100686877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2012-02-22 15:08:32 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="2.0118353936673963E-24" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="10.198584312607336">
<NAME>DAS 28</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.6156399899313134" CI_START="-2.3843600100686877" EFFECT_SIZE="-2.0000000000000004" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.4" MODIFIED="2012-01-31 13:33:08 -0500" MODIFIED_BY="[Empty name]" ORDER="511" SD_1="1.2" SD_2="1.1" SE="0.1961056494407396" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-03-20 15:19:22 -0400" MODIFIED_BY="Anne Lethaby" NO="6">
<NAME>Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3755430777016326" CI_START="1.117981158899423" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.24009324009324" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="156" I2="0.0" I2_Q="99.99999999999999" ID="CMP-006.01" LOG_CI_END="0.13847419568183805" LOG_CI_START="0.04843448453880981" LOG_EFFECT_SIZE="0.09345434011032393" METHOD="MH" MODIFIED="2013-03-14 17:32:14 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="4.7299363129140326E-5" Q="2.753956567852558E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="4.068585704905928">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3755430777016326" CI_START="1.117981158899423" DF="0" EFFECT_SIZE="1.24009324009324" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="156" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.13847419568183805" LOG_CI_START="0.04843448453880981" LOG_EFFECT_SIZE="0.09345434011032393" MODIFIED="2008-07-28 11:05:45 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.7299363129140326E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="4.068585704905928">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3755430777016326" CI_START="1.117981158899423" EFFECT_SIZE="1.24009324009324" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="156" LOG_CI_END="0.13847419568183805" LOG_CI_START="0.04843448453880981" LOG_EFFECT_SIZE="0.09345434011032393" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7594" O_E="0.0" SE="0.052889772029173186" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.0027973279852979106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8478577774453655" CI_START="1.3018665916295435" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5510204081632653" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.2666685421830145" LOG_CI_START="0.11456648232154079" LOG_EFFECT_SIZE="0.1906175122522777" METHOD="MH" MODIFIED="2013-03-14 17:32:07 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="8.990564885382587E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="4.912536479484163">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8478577774453655" CI_START="1.3018665916295435" DF="0" EFFECT_SIZE="1.5510204081632653" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="98" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.2666685421830145" LOG_CI_START="0.11456648232154079" LOG_EFFECT_SIZE="0.1906175122522777" MODIFIED="2008-07-28 11:05:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="8.990564885382587E-7" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="4.912536479484163">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8478577774453655" CI_START="1.3018665916295435" EFFECT_SIZE="1.5510204081632653" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="98" LOG_CI_END="0.2666685421830145" LOG_CI_START="0.11456648232154079" LOG_EFFECT_SIZE="0.1906175122522777" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7595" O_E="0.0" SE="0.08934550287996887" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.007982618884874525" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.0394950322389747" CI_START="1.734849634464588" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.29631592896899" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.48280143790866065" LOG_CI_START="0.23926183892387617" LOG_EFFECT_SIZE="0.3610316384162684" METHOD="MH" MODIFIED="2013-03-14 17:32:20 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="6.208643427819702E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="5.811038628010411">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0394950322389747" CI_START="1.734849634464588" DF="0" EFFECT_SIZE="2.29631592896899" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="49" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.48280143790866065" LOG_CI_START="0.23926183892387617" LOG_EFFECT_SIZE="0.3610316384162684" MODIFIED="2008-07-28 11:05:59 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="6.208643427819702E-9" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="5.811038628010411">
<NAME>Etancercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.0394950322389747" CI_START="1.734849634464588" EFFECT_SIZE="2.29631592896899" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="49" LOG_CI_END="0.48280143790866065" LOG_CI_START="0.23926183892387617" LOG_EFFECT_SIZE="0.3610316384162684" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7596" O_E="0.0" SE="0.14305636598412003" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.020465123848582494" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.19932740195954" CI_START="1.6816002879087828" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3194805194805195" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.505058685719844" LOG_CI_START="0.2257227730402475" LOG_EFFECT_SIZE="0.36539072938004574" METHOD="MH" MODIFIED="2013-03-20 15:19:22 -0400" MODIFIED_BY="Anne Lethaby" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="2.935566750155916E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="5.127537401115707">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.19932740195954" CI_START="1.6816002879087828" DF="0" EFFECT_SIZE="2.3194805194805195" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="40" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.505058685719844" LOG_CI_START="0.2257227730402475" LOG_EFFECT_SIZE="0.36539072938004574" MODIFIED="2013-03-20 15:19:22 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="2.935566750155916E-7" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="5.127537401115707">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.19932740195954" CI_START="1.6816002879087828" EFFECT_SIZE="2.3194805194805195" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="40" LOG_CI_END="0.505058685719844" LOG_CI_START="0.2257227730402475" LOG_EFFECT_SIZE="0.36539072938004574" MODIFIED="2008-10-10 15:22:30 -0400" MODIFIED_BY="Anne Lethaby" ORDER="465" O_E="0.0" SE="0.16408329784306322" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.0269233286310554" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9154926339156324" CI_START="1.5630136531674002" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.13470250679553" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.46471194849970243" LOG_CI_START="0.19396277166561351" LOG_EFFECT_SIZE="0.329337360082658" METHOD="MH" MODIFIED="2013-03-14 17:32:32 -0400" MODIFIED_BY="Anne Lethaby" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.8590474796760023E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="4.768172314119759">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9154926339156324" CI_START="1.5630136531674002" DF="0" EFFECT_SIZE="2.13470250679553" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="43" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.46471194849970243" LOG_CI_START="0.19396277166561351" LOG_EFFECT_SIZE="0.329337360082658" MODIFIED="2008-07-17 16:01:49 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.8590474796760023E-6" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="4.768172314119759">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.9154926339156324" CI_START="1.5630136531674002" EFFECT_SIZE="2.13470250679553" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="43" LOG_CI_END="0.46471194849970243" LOG_CI_START="0.19396277166561351" LOG_EFFECT_SIZE="0.329337360082658" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7597" O_E="0.0" SE="0.15903940670238417" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.025293532884246357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.9592261708644583" CI_START="-9.220773829135542" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.09" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2013-03-20 15:19:01 -0400" MODIFIED_BY="Anne Lethaby" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.375494790865523E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="210" UNITS="" WEIGHT="100.0" Z="3.8125336792995705">
<NAME>Change in Total Sharp Score (TSS) (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.9592261708644583" CI_START="-9.220773829135542" DF="0" EFFECT_SIZE="-6.09" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" MODIFIED="2013-03-20 15:18:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.375494790865523E-4" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.0" Z="3.8125336792995705">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-2.9592261708644583" CI_START="-9.220773829135542" EFFECT_SIZE="-6.09" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="5.95" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7598" SD_1="7.0" SD_2="22.1" SE="1.5973629382124803" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.3380094390166203E-31" CI_END="-2.119906009363085" CI_START="-5.720093990636916" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.9200000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.07" MODIFIED="2013-03-20 15:18:32 -0400" MODIFIED_BY="Anne Lethaby" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="1.971068380156801E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="210" UNITS="" WEIGHT="100.00000000000001" Z="4.2681431410581885">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.3380094390166203E-31" CI_END="-2.119906009363085" CI_START="-5.720093990636916" DF="0" EFFECT_SIZE="-3.9200000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-006.07.01" MODIFIED="2013-03-20 15:18:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="1.971068380156801E-5" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.00000000000001" Z="4.2681431410581885">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-2.1199060093630844" CI_START="-5.720093990636915" EFFECT_SIZE="-3.92" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="3.25" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7599" SD_1="2.9" SD_2="13.0" SE="0.9184321777521562" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5603831835490565" CI_START="-3.779616816450943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.17" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.08" MODIFIED="2013-03-14 17:32:51 -0400" MODIFIED_BY="Anne Lethaby" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.008234034930559003" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="210" UNITS="" WEIGHT="100.00000000000001" Z="2.6423194657158584">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5603831835490565" CI_START="-3.779616816450943" DF="0" EFFECT_SIZE="-2.17" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.01" MODIFIED="2013-03-14 17:32:51 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.008234034930559003" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.00000000000001" Z="2.6423194657158584">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.5603831835490565" CI_START="-3.779616816450943" EFFECT_SIZE="-2.17" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="2.7" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7600" SD_1="5.5" SD_2="10.6" SE="0.821248160245492" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.737769300759418" CI_START="1.2815257413901444" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4923123304190533" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="107" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.2399921207562764" LOG_CI_START="0.1077273340718964" LOG_EFFECT_SIZE="0.1738597274140864" METHOD="MH" MODIFIED="2013-03-20 15:18:14 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="2.567952509375567E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.0" Z="5.152676122431654">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.737769300759418" CI_START="1.2815257413901444" DF="0" EFFECT_SIZE="1.4923123304190533" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="107" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.2399921207562764" LOG_CI_START="0.1077273340718964" LOG_EFFECT_SIZE="0.1738597274140864" MODIFIED="2013-03-14 17:33:06 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="2.567952509375567E-7" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="210" WEIGHT="100.0" Z="5.152676122431654">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.737769300759418" CI_START="1.2815257413901444" EFFECT_SIZE="1.4923123304190533" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="107" LOG_CI_END="0.2399921207562764" LOG_CI_START="0.1077273340718964" LOG_EFFECT_SIZE="0.1738597274140864" MODIFIED="2008-10-10 15:49:35 -0400" MODIFIED_BY="Anne Lethaby" ORDER="468" O_E="0.0" SE="0.07769299041965809" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="210" VAR="0.006036200760349084" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-03-14 17:37:05 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="16.003956535158913" CI_END="1.2387348650910135" CI_START="0.9150219936726779" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0646453145942243" ESTIMABLE="YES" EVENTS_1="410" EVENTS_2="340" I2="81.25463541837712" I2_Q="59.61002174461321" ID="CMP-007.01" LOG_CI_END="0.09297836129949812" LOG_CI_START="-0.03856846700908603" LOG_EFFECT_SIZE="0.027204947145206035" METHOD="MH" MODIFIED="2013-03-14 17:34:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0011318723701385647" P_Q="0.11560632655407244" P_Z="0.41755361560541804" Q="2.475861694396012" RANDOM="YES" SCALE="12.52" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0407085744598868" TOTALS="SUB" TOTAL_1="633" TOTAL_2="604" WEIGHT="200.0" Z="0.810672781571582">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1863386298083851" CI_START="0.8448921884560171" DF="0" EFFECT_SIZE="1.0011634437936292" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="121" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.07420867222047492" LOG_CI_START="-0.0731987051873995" LOG_EFFECT_SIZE="5.04983516537739E-4" MODIFIED="2013-03-14 17:34:37 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9892857178652142" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="100.0" Z="0.013428764863806378">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1863386298083851" CI_START="0.8448921884560171" EFFECT_SIZE="1.0011634437936292" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="121" LOG_CI_END="0.07420867222047492" LOG_CI_START="-0.0731987051873995" LOG_EFFECT_SIZE="5.04983516537739E-4" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7538" O_E="0.0" SE="0.08658782316767172" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.007497451120915987" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.757994840208726" CI_END="1.8940683908171738" CI_START="0.9679921692582403" DF="2" EFFECT_SIZE="1.354047034024513" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="219" I2="86.44802344996813" ID="CMP-007.01.02" LOG_CI_END="0.277395656408686" LOG_CI_START="-0.014128155978477507" LOG_EFFECT_SIZE="0.1316337502151043" MODIFIED="2013-03-14 17:34:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.242319178887401E-4" P_Z="0.07672847147908347" STUDIES="3" TAU2="0.07019598979132746" TOTAL_1="427" TOTAL_2="387" WEIGHT="100.0" Z="1.7699920116913663">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3253953426013454" CI_START="0.9663969503481664" EFFECT_SIZE="1.1317499799406243" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="121" LOG_CI_END="0.12234544016024716" LOG_CI_START="-0.014844449220721562" LOG_EFFECT_SIZE="0.05375049546976282" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7539" O_E="0.0" SE="0.08058602012328589" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.006494106639310638" WEIGHT="38.23701573471851"/>
<DICH_DATA CI_END="4.170813539366155" CI_START="1.6650063638937553" EFFECT_SIZE="2.635228848821082" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="14" LOG_CI_END="0.6202207746853264" LOG_CI_START="0.22141589778147353" LOG_EFFECT_SIZE="0.4208183362333999" MODIFIED="2012-01-31 09:14:41 -0500" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.23425995880930198" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.05487772830133586" WEIGHT="23.445376603763087"/>
<DICH_DATA CI_END="1.259353559642424" CI_START="0.921875439234755" EFFECT_SIZE="1.0774818401937045" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="84" LOG_CI_END="0.100147674067756" LOG_CI_START="-0.035327755418694935" LOG_EFFECT_SIZE="0.032409959324530536" MODIFIED="2010-05-20 22:49:59 -0400" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.07957893789453278" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.006332807356421905" WEIGHT="38.3176076615184"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.661440691040957" CI_END="1.4597528651380767" CI_START="0.9106895051945888" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1529881241621607" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="178" I2="68.94873036086744" I2_Q="64.39229254687389" ID="CMP-007.02" LOG_CI_END="0.16427933633807776" LOG_CI_START="-0.04062966821425347" LOG_EFFECT_SIZE="0.06182483406191209" METHOD="MH" MODIFIED="2013-03-14 17:35:32 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.021674516874529925" P_Q="0.09377308359930525" P_Z="0.23692224884882007" Q="2.8083807454225957" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06840575330521956" TOTALS="SUB" TOTAL_1="633" TOTAL_2="604" WEIGHT="200.0" Z="1.1827147213588316">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3375370914347826" CI_START="0.7569889415723121" DF="0" EFFECT_SIZE="1.0062309810172438" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="67" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.12630583434343043" LOG_CI_START="-0.12091046481855677" LOG_EFFECT_SIZE="0.0026976847624368317" MODIFIED="2013-03-14 17:35:24 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.965880722740759" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="100.0" Z="0.04277521339767458">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3375370914347826" CI_START="0.7569889415723121" EFFECT_SIZE="1.0062309810172438" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="67" LOG_CI_END="0.12630583434343043" LOG_CI_START="-0.12091046481855677" LOG_EFFECT_SIZE="0.0026976847624368317" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7540" O_E="0.0" SE="0.1452160778681684" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.02108770927141395" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.721608115711932" CI_END="2.369997341988422" CI_START="1.0197132439791137" DF="2" EFFECT_SIZE="1.5545795823375819" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="111" I2="70.24521564527173" ID="CMP-007.02.02" LOG_CI_END="0.37474785893820156" LOG_CI_START="0.008478059932020348" LOG_EFFECT_SIZE="0.19161295943511095" MODIFIED="2013-03-14 17:35:32 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03470744754812649" P_Z="0.040296298121718824" STUDIES="3" TAU2="0.09217428943087211" TOTAL_1="427" TOTAL_2="387" WEIGHT="100.0" Z="2.0506986952403023">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6170687048555878" CI_START="0.9540280235960588" EFFECT_SIZE="1.2420663671931604" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="67" LOG_CI_END="0.2087284722909293" LOG_CI_START="-0.020438868152947053" LOG_EFFECT_SIZE="0.09414480206899112" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7541" O_E="0.0" SE="0.13461403017336349" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.018120937119515214" WEIGHT="41.96823520633674"/>
<DICH_DATA CI_END="6.820962627666077" CI_START="1.624449758774687" EFFECT_SIZE="3.3287101248266295" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="7" LOG_CI_END="0.8338456700203927" LOG_CI_START="0.21070628396396113" LOG_EFFECT_SIZE="0.522275976992177" MODIFIED="2012-01-31 09:15:13 -0500" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.36603515995925656" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.13398173832639854" WEIGHT="20.467710084521674"/>
<DICH_DATA CI_END="1.8635239637917635" CI_START="0.9339906362280546" EFFECT_SIZE="1.3192853870819972" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="37" LOG_CI_END="0.2703349818902942" LOG_CI_START="-0.029657477790110888" LOG_EFFECT_SIZE="0.12033875205009163" MODIFIED="2010-05-20 22:50:40 -0400" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.17621705580289493" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.031052450755840587" WEIGHT="37.56405470914159"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.417846782979334" CI_END="1.9172158070167589" CI_START="0.8961988790144888" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.310803820972947" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="70" I2="59.55699695922989" I2_Q="68.40087483430258" ID="CMP-007.03" LOG_CI_END="0.28267100099565984" LOG_CI_START="-0.04759560364784309" LOG_EFFECT_SIZE="0.11753769867390834" METHOD="MH" MODIFIED="2013-03-14 17:35:53 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.059707357629036895" P_Q="0.07524885566579953" P_Z="0.16299995376458254" Q="3.1646445740388884" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14563530000787633" TOTALS="SUB" TOTAL_1="633" TOTAL_2="604" WEIGHT="200.0" Z="1.3950526816070175">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.61043474047939" CI_START="0.5941177526422681" DF="0" EFFECT_SIZE="0.9781553398058253" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="0.20694313063107056" LOG_CI_START="-0.2261274704151209" LOG_EFFECT_SIZE="-0.009592169892025142" MODIFIED="2013-03-14 17:35:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9308119735787839" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="100.0" Z="0.0868232915212524">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.61043474047939" CI_START="0.5941177526422681" EFFECT_SIZE="0.9781553398058253" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="0.20694313063107056" LOG_CI_START="-0.2261274704151209" LOG_EFFECT_SIZE="-0.009592169892025142" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7542" O_E="0.0" SE="0.25438781478858175" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.06471316031290977" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.799412653297979" CI_END="3.544306138255757" CI_START="1.0938443218742282" DF="2" EFFECT_SIZE="1.9689893713057551" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="42" I2="47.36028479917934" ID="CMP-007.03.02" LOG_CI_END="0.5495312268755871" LOG_CI_START="0.03895551673054369" LOG_EFFECT_SIZE="0.29424337180306537" MODIFIED="2013-03-14 17:35:53 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14961266647264815" P_Z="0.02388066894143662" STUDIES="3" TAU2="0.12277394020497921" TOTAL_1="427" TOTAL_2="387" WEIGHT="100.0" Z="2.259043663709764">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.4498222208836133" CI_START="1.0191379538724" EFFECT_SIZE="1.5800970873786409" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="28" LOG_CI_END="0.3891345695520361" LOG_CI_START="0.008232975518078618" LOG_EFFECT_SIZE="0.19868377253505737" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7543" O_E="0.0" SE="0.22374348182884593" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.05006114566089511" WEIGHT="52.04315231677463"/>
<DICH_DATA CI_END="76.98963440718654" CI_START="1.4814215690643409" EFFECT_SIZE="10.679611650485437" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="1" LOG_CI_END="1.8864322573439858" LOG_CI_START="0.1706786635621197" LOG_EFFECT_SIZE="1.028555460453053" MODIFIED="2012-01-31 09:15:35 -0500" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="1.0078421541047327" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.0157458075904677" WEIGHT="7.900506527723919"/>
<DICH_DATA CI_END="3.508554403930611" CI_START="1.0046297648902969" EFFECT_SIZE="1.8774445893089962" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5451282151226863" LOG_CI_START="0.0020060411698511874" LOG_EFFECT_SIZE="0.2735671281462687" MODIFIED="2010-05-20 22:51:10 -0400" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.31903265347801596" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.10178183398522381" WEIGHT="40.05634115550144"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5547020391192556" CI_END="-0.06623661915485946" CI_START="-0.6952758584044932" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.38075623877967635" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2013-03-14 17:36:16 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.45640288358532166" P_Q="0.45640288358532166" P_Z="0.017657412514763382" Q="0.5547020391192556" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" UNITS="" WEIGHT="200.0" Z="2.372724842371694">
<NAME>Change in Total Sharp Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21618150593480934" CI_START="-0.7161815059348093" DF="0" EFFECT_SIZE="-0.25" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" MODIFIED="2013-03-14 17:36:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.29322487976758527" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.0510734336242282">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.21618150593480934" CI_START="-0.7161815059348093" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="1.06" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7544" SD_1="2.49" SD_2="2.41" SE="0.23785207769734013" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06388958158481872" CI_START="-0.9161104184151815" DF="0" EFFECT_SIZE="-0.4900000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" MODIFIED="2013-03-14 17:36:16 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.024206582920197114" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.2538344779189994">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.06388958158481872" CI_START="-0.9161104184151815" EFFECT_SIZE="-0.4900000000000001" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="1.06" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7545" SD_1="2.06" SD_2="2.41" SE="0.2174072696112204" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8835089374878182" CI_END="-0.08002619368094588" CI_START="-0.49576015711796506" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.28789317539945547" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2013-03-14 17:36:41 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3472425129466481" P_Q="0.3472425129466481" P_Z="0.006637075890467873" Q="0.8835089374878182" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" UNITS="" WEIGHT="200.0" Z="2.7145256572874974">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12630536439737344" CI_START="-0.48630536439737354" DF="0" EFFECT_SIZE="-0.18000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2013-03-14 17:36:35 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24941536647549234" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.1517706126737197">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.1263053643973735" CI_START="-0.4863053643973736" EFFECT_SIZE="-0.18000000000000005" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.68" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7546" SD_1="1.63" SD_2="1.59" SE="0.15628111884374976" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09698886675568219" CI_START="-0.6630111332443179" DF="0" EFFECT_SIZE="-0.38000000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.02" MODIFIED="2013-03-14 17:36:41 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.008497129086817023" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.6316502308135754">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.09698886675568219" CI_START="-0.6630111332443179" EFFECT_SIZE="-0.38000000000000006" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.68" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7547" SD_1="1.38" SD_2="1.59" SE="0.14439608864074727" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.045644609183956714" CI_END="0.08907028965526882" CI_START="-0.27449497325028815" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09271234179750966" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2013-03-14 17:36:52 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8308232838995125" P_Q="0.8308232838995125" P_Z="0.3174963267310297" Q="0.045644609183956714" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" UNITS="" WEIGHT="200.0" Z="0.9996161316032541">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20651220016909172" CI_START="-0.34651220016909173" DF="0" EFFECT_SIZE="-0.07" ESTIMABLE="YES" I2="0.0" ID="CMP-007.06.01" MODIFIED="2013-03-14 17:36:46 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6197734039417111" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.4961715209452071">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.20651220016909172" CI_START="-0.34651220016909173" EFFECT_SIZE="-0.07" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="0.38" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7548" SD_1="1.53" SD_2="1.37" SE="0.14108024553011417" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13124116880093767" CI_START="-0.35124116880093764" DF="0" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-007.06.02" MODIFIED="2013-03-14 17:36:52 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3714850846574519" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.893695049526588">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.13124116880093767" CI_START="-0.35124116880093764" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="0.38" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7549" SD_1="1.16" SD_2="1.37" SE="0.12308449068647036" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.9734075888191684" CI_END="0.7120924407226316" CI_START="-2.2392541252738147" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7635808422755915" ESTIMABLE="YES" I2="83.25913667984472" I2_Q="0.0" ID="CMP-007.07" MODIFIED="2013-03-14 17:37:05 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.014523238808489825" P_Q="1.0" P_Z="0.31049926997958965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.9618095469255663" TOTALS="YES" TOTAL_1="115" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="1.0141749988887758">
<NAME>DAS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.9734075888191684" CI_END="0.7120924407226316" CI_START="-2.2392541252738147" DF="1" EFFECT_SIZE="-0.7635808422755915" ESTIMABLE="YES" I2="83.25913667984472" ID="CMP-007.07.01" MODIFIED="2013-03-14 17:37:05 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.014523238808489825" P_Z="0.31049926997958965" STUDIES="2" TAU2="0.9618095469255663" TOTAL_1="115" TOTAL_2="62" WEIGHT="100.0" Z="1.0141749988887758">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-1.048393863513023" CI_START="-1.791606136486976" EFFECT_SIZE="-1.4199999999999995" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="4.02" MODIFIED="2012-01-31 10:49:26 -0500" MODIFIED_BY="[Empty name]" ORDER="454" SD_1="1.1" SD_2="1.1" SE="0.18959845151143503" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" WEIGHT="56.81452909707841"/>
<CONT_DATA CI_END="1.2609099030186866" CI_START="-1.0609099030186864" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.1" MODIFIED="2008-10-24 08:10:14 -0400" MODIFIED_BY="[Empty name]" ORDER="2809" SD_1="1.5" SD_2="1.4" SE="0.5923118547972287" STUDY_ID="STD-Marcora-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="43.18547090292158"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-03-20 15:17:55 -0400" MODIFIED_BY="Anne Lethaby" NO="8">
<NAME>Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="2.7412768069442186" CI_END="1.1092697179714153" CI_START="0.9495912325950312" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.026329770964878" ESTIMABLE="YES" EVENTS_1="423" EVENTS_2="429" I2="27.041297145418213" I2_Q="42.20691064612787" ID="CMP-008.01" LOG_CI_END="0.04503715731653439" LOG_CI_START="-0.022463303797753437" LOG_EFFECT_SIZE="0.011286926759390487" METHOD="MH" MODIFIED="2013-03-14 17:37:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2539450186361608" P_Q="0.18837132731853068" P_Z="0.5121708002635668" Q="1.7303106845126632" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="635" TOTAL_2="662" WEIGHT="200.0" Z="0.6554612984670165">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1062175757473214" CI_START="0.7971879634047372" DF="0" EFFECT_SIZE="0.9390757883645668" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="129" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.043840554322478874" LOG_CI_START="-0.09843926725500124" LOG_EFFECT_SIZE="-0.027299356466261183" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45197885479580946" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="100.0" Z="0.7521200811438377">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1062175757473214" CI_START="0.7971879634047372" EFFECT_SIZE="0.9390757883645668" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="129" LOG_CI_END="0.043840554322478874" LOG_CI_START="-0.09843926725500124" LOG_EFFECT_SIZE="-0.027299356466261183" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7558" O_E="0.0" SE="0.0835758714910874" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.006984926295494755" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3219194159424184" CI_END="1.1600724145010466" CI_START="0.9750114183051584" DF="1" EFFECT_SIZE="1.0635242593374892" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="300" I2="24.352423609189266" ID="CMP-008.01.02" LOG_CI_END="0.06448509977573408" LOG_CI_START="-0.010990298272862048" LOG_EFFECT_SIZE="0.026747400751436" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2502480035756831" P_Z="0.1647821671857295" STUDIES="2" TAU2="0.0" TOTAL_1="429" TOTAL_2="445" WEIGHT="100.0" Z="1.3891663643594199">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.30380591998439" CI_START="0.9739817750455153" EFFECT_SIZE="1.1268909460374803" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="129" LOG_CI_END="0.11521294864059758" LOG_CI_START="-0.01144916947787021" LOG_EFFECT_SIZE="0.05188188958136368" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7559" O_E="0.0" SE="0.07440195517038459" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.005535650933175917" WEIGHT="42.62784031645876"/>
<DICH_DATA CI_END="1.12876741514234" CI_START="0.9152950760174777" EFFECT_SIZE="1.0164424514200299" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="171" LOG_CI_END="0.052604463868073346" LOG_CI_START="-0.03843887399124692" LOG_EFFECT_SIZE="0.007082794938413197" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7560" O_E="0.0" SE="0.05347930733035546" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0028600363125346117" WEIGHT="57.37215968354125"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.15350498422071" CI_END="1.1644083929011377" CI_START="0.896843995471062" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0219063927040943" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="268" I2="72.04167740972258" I2_Q="85.73565440107645" ID="CMP-008.02" LOG_CI_END="0.06610532711503403" LOG_CI_START="-0.047283095192690555" LOG_EFFECT_SIZE="0.009411115961171765" METHOD="MH" MODIFIED="2013-03-14 17:37:34 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.027966421224751015" P_Q="0.008103382192314434" P_Z="0.744916370410925" Q="7.010486342082629" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="635" TOTAL_2="662" WEIGHT="200.0" Z="0.32534976610165106">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.988301442278771" CI_START="0.5782523633045968" DF="0" EFFECT_SIZE="0.7559680182752713" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="85" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="-0.005110570846508391" LOG_CI_START="-0.23788258360179074" LOG_EFFECT_SIZE="-0.1214965772241496" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04075371081336745" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="100.0" Z="2.0460270355145496">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.988301442278771" CI_START="0.5782523633045968" EFFECT_SIZE="0.7559680182752713" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="85" LOG_CI_END="-0.005110570846508391" LOG_CI_START="-0.23788258360179074" LOG_EFFECT_SIZE="-0.1214965772241496" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7561" O_E="0.0" SE="0.1367314325324991" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.01869548464238935" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12052988778036416" CI_END="1.3291836183166474" CI_START="0.9853476868953488" DF="1" EFFECT_SIZE="1.1444247479705683" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="183" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="0.12358498012508622" LOG_CI_START="-0.0064104985820815615" LOG_EFFECT_SIZE="0.05858724077150232" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7284605515522222" P_Z="0.07728524882771774" STUDIES="2" TAU2="0.0" TOTAL_1="429" TOTAL_2="445" WEIGHT="100.0" Z="1.7666596255149563">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4699625559664824" CI_START="0.9429488037851276" EFFECT_SIZE="1.1773272415762421" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="85" LOG_CI_END="0.16730627220106659" LOG_CI_START="-0.025511886093204317" LOG_EFFECT_SIZE="0.07089719305393113" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7562" O_E="0.0" SE="0.11326234064733173" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.012828357808912214" WEIGHT="46.07020537356315"/>
<DICH_DATA CI_END="1.366950251060561" CI_START="0.9116385103426713" EFFECT_SIZE="1.116317378969525" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="98" LOG_CI_END="0.1357527090937666" LOG_CI_START="-0.04017733720375077" LOG_EFFECT_SIZE="0.04778768594500793" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7563" O_E="0.0" SE="0.10334218006293605" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.010679606180160298" WEIGHT="53.92979462643685"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.204439976232739" CI_END="1.3215654305298152" CI_START="0.8596130070514989" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0658493485258802" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="131" I2="52.43123908758856" I2_Q="75.51369129539759" ID="CMP-008.03" LOG_CI_END="0.12108866986242914" LOG_CI_START="-0.06569702169623634" LOG_EFFECT_SIZE="0.0276958240830964" METHOD="MH" MODIFIED="2013-03-14 17:37:40 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.12218493154628851" P_Q="0.043293342137701085" P_Z="0.5610847759671936" Q="4.083914860601435" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="635" TOTAL_2="662" WEIGHT="200.0" Z="0.5812310062088124">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1274940499549606" CI_START="0.4885272605045406" DF="0" EFFECT_SIZE="0.7421668137687555" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="0.05211425868432538" LOG_CI_START="-0.3111111970294027" LOG_EFFECT_SIZE="-0.12949846917253865" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16224912250752868" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="100.0" Z="1.3975470696706098">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1274940499549606" CI_START="0.48852726050454065" EFFECT_SIZE="0.7421668137687555" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.05211425868432538" LOG_CI_START="-0.3111111970294027" LOG_EFFECT_SIZE="-0.12949846917253865" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7564" O_E="0.0" SE="0.21336043068124733" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.04552267338048735" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12249872511618076" CI_END="1.5815937284203982" CI_START="0.9539569043908995" DF="1" EFFECT_SIZE="1.2283209096844294" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="87" I2="0.0" ID="CMP-008.03.02" LOG_CI_END="0.19909493417750884" LOG_CI_START="-0.02047124438183571" LOG_EFFECT_SIZE="0.08931184489783657" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7263401277680983" P_Z="0.11082640750069782" STUDIES="2" TAU2="0.0" TOTAL_1="429" TOTAL_2="445" WEIGHT="100.0" Z="1.5944896480973725">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6808641371582018" CI_START="0.8187272074548835" EFFECT_SIZE="1.1731023830538394" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" LOG_CI_END="0.2255326111985038" LOG_CI_START="-0.08686077715509911" LOG_EFFECT_SIZE="0.06933591702170236" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7565" O_E="0.0" SE="0.18350142269111824" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.03367277212966444" WEIGHT="50.19472591576804"/>
<DICH_DATA CI_END="1.8321405903863246" CI_START="0.8998119984814703" EFFECT_SIZE="1.2839712170195015" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" LOG_CI_END="0.26295879645316506" LOG_CI_START="-0.04584822006181494" LOG_EFFECT_SIZE="0.10855528819567507" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7566" O_E="0.0" SE="0.18139477012028424" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.03290406262699076" WEIGHT="49.805274084231954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9145814325361676" CI_START="0.8109897821629151" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2460762331838564" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" I2="0.0" I2_Q="100.0" ID="CMP-008.04" LOG_CI_END="0.28207384284301323" LOG_CI_START="-0.09098461752524063" LOG_EFFECT_SIZE="0.09554461265888631" METHOD="MH" MODIFIED="2013-03-14 17:37:46 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.31540795050880743" Q="1.604247923600802E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.0039391656921257">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9145814325361676" CI_START="0.8109897821629151" DF="0" EFFECT_SIZE="1.2460762331838564" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.28207384284301323" LOG_CI_START="-0.09098461752524063" LOG_EFFECT_SIZE="0.09554461265888631" MODIFIED="2008-07-28 11:10:06 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.31540795050880743" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.0039391656921257">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.9145814325361676" CI_START="0.8109897821629151" EFFECT_SIZE="1.2460762331838564" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.28207384284301323" LOG_CI_START="-0.09098461752524063" LOG_EFFECT_SIZE="0.09554461265888631" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7567" O_E="0.0" SE="0.21913638628947388" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.048020755796009514" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5308317413010797" CI_START="0.6828613138156786" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.18492745860145035" LOG_CI_START="-0.16566749069686407" LOG_EFFECT_SIZE="0.009629983952293144" METHOD="MH" MODIFIED="2013-03-14 17:37:51 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9142568222699987" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.10767081360395396">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5308317413010797" CI_START="0.6828613138156786" DF="0" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.18492745860145035" LOG_CI_START="-0.16566749069686407" LOG_EFFECT_SIZE="0.009629983952293144" MODIFIED="2008-07-28 11:10:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9142568222699987" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.10767081360395396">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5308317413010797" CI_START="0.6828613138156786" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" LOG_CI_END="0.18492745860145035" LOG_CI_START="-0.16566749069686407" LOG_EFFECT_SIZE="0.009629983952293144" MODIFIED="2008-07-17 15:41:42 -0400" MODIFIED_BY="[Empty name]" ORDER="7568" O_E="0.0" SE="0.20594120869081825" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.042411781437035154" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.3072971545359735" CI_END="-0.015726965816910465" CI_START="-1.0165624607080255" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5161447132624679" ESTIMABLE="YES" I2="13.318490595450625" I2_Q="38.81701616772769" ID="CMP-008.06" MODIFIED="2013-03-14 17:38:33 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.31548400577574254" P_Q="0.20108990546965988" P_Z="0.043221714846711744" Q="1.6344413713809884" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="617" TOTAL_2="640" UNITS="" WEIGHT="200.0" Z="2.021561093644564">
<NAME>Change in Total Sharp Score (TSS) (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8450241096546627" CI_START="-0.9250241096546628" DF="0" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-008.06.01" MODIFIED="2013-03-14 17:38:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9294128981286922" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.08858352956304595">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.8450241096546627" CI_START="-0.9250241096546628" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.55" MEAN_2="1.59" MODIFIED="2012-04-30 16:10:35 -0400" MODIFIED_BY="[Empty name]" ORDER="7569" SD_1="5.05" SD_2="4.2" SE="0.45155121044856944" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6728557831549847" CI_END="-0.13319758816427862" CI_START="-1.346629513061443" DF="1" EFFECT_SIZE="-0.7399135506128608" ESTIMABLE="YES" I2="0.0" ID="CMP-008.06.02" MODIFIED="2013-03-14 17:38:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.41205805544035035" P_Z="0.016836825812340507" STUDIES="2" TAU2="0.0" TOTAL_1="409" TOTAL_2="423" WEIGHT="100.0" Z="2.390251782764432">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.11456576711100541" CI_START="-1.2945657671110056" EFFECT_SIZE="-0.5900000000000001" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.59" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7570" SD_1="3.15" SD_2="4.2" SE="0.3594789356684767" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="74.1528361012309"/>
<CONT_DATA CI_END="0.02338059811547999" CI_START="-2.36338059811548" EFFECT_SIZE="-1.17" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="1.5" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7571" SD_1="3.7" SD_2="7.9" SE="0.6088788403913101" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="202" TOTAL_2="206" WEIGHT="25.8471638987691"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2007310140949388" CI_END="-0.15732894164530908" CI_START="-0.7810894444984181" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4692091930718636" ESTIMABLE="YES" I2="37.5142743581802" I2_Q="59.47668937093027" ID="CMP-008.07" MODIFIED="2013-03-14 17:39:00 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.20182287231305862" P_Q="0.11620696683216702" P_Z="0.0031914065634210073" Q="2.4677154567984427" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="617" TOTAL_2="640" UNITS="" WEIGHT="200.0" Z="2.948673779213366">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.39572435162373343" CI_START="-0.6557243516237334" DF="0" EFFECT_SIZE="-0.13" ESTIMABLE="YES" I2="0.0" ID="CMP-008.07.01" MODIFIED="2013-03-14 17:38:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6279205780266425" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.48465572728989126">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.39572435162373343" CI_START="-0.6557243516237334" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.03" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7572" SD_1="2.93" SD_2="2.58" SE="0.2682316388314173" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7330155572964961" CI_END="-0.2660003523339323" CI_START="-1.0408328033759744" DF="1" EFFECT_SIZE="-0.6534165778549533" ESTIMABLE="YES" I2="0.0" ID="CMP-008.07.02" MODIFIED="2013-03-14 17:39:00 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.39190749970998773" P_Z="9.474719374194132E-4" STUDIES="2" TAU2="0.0" TOTAL_1="409" TOTAL_2="423" WEIGHT="99.99999999999999" Z="3.3056771377471184">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.11747942556241014" CI_START="-1.00252057443759" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="0.47" MEAN_2="1.03" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7573" SD_1="2.05" SD_2="2.58" SE="0.22577995204408638" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="76.64585553626166"/>
<CONT_DATA CI_END="-0.15832964436775154" CI_START="-1.7616703556322484" EFFECT_SIZE="-0.96" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.99" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7574" SD_1="2.5" SD_2="5.3" SE="0.4090230034611462" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="202" TOTAL_2="206" WEIGHT="23.354144463738322"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7096921179118993" CI_END="0.21338539881800928" CI_START="-0.32624754397611083" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05643107257905078" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.08" MODIFIED="2013-03-20 15:17:55 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7012814940091756" P_Q="0.5069519332959647" P_Z="0.6818654450783976" Q="0.4403534494712571" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="617" TOTAL_2="640" UNITS="" WEIGHT="200.0" Z="0.40991889520763525">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5997572548485237" CI_START="-0.4197572548485238" DF="0" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-008.08.01" MODIFIED="2013-03-14 17:39:07 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7293121265407695" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.3460407025713087">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.5997572548485237" CI_START="-0.4197572548485238" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="0.56" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7575" SD_1="2.9" SD_2="2.43" SE="0.2600850111886871" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2693386684406422" CI_END="0.20459524617606303" CI_START="-0.43144007803457796" DF="1" EFFECT_SIZE="-0.11342241592925748" ESTIMABLE="YES" I2="0.0" ID="CMP-008.08.02" MODIFIED="2013-03-14 17:39:15 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6037757947809845" P_Z="0.48453335850267476" STUDIES="2" TAU2="0.0" TOTAL_1="409" TOTAL_2="423" WEIGHT="100.0" Z="0.6990298865452467">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.38192720886129233" CI_START="-0.4619272088612924" EFFECT_SIZE="-0.040000000000000036" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.56" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7576" SD_1="1.99" SD_2="2.43" SE="0.21527293980369044" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="56.81034357102502"/>
<CONT_DATA CI_END="0.2739063999154866" CI_START="-0.6939063999154866" EFFECT_SIZE="-0.21000000000000002" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.51" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7577" SD_1="1.7" SD_2="3.1" SE="0.24689555712884448" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="202" TOTAL_2="206" WEIGHT="43.18965642897497"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.381218958240606" CI_START="1.0253962216454706" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1900826446280992" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="121" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.14026253072779052" LOG_CI_START="0.010891712829808603" LOG_EFFECT_SIZE="0.07557712177879959" METHOD="MH" MODIFIED="2013-03-20 15:17:53 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.022022347045925053" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="212" WEIGHT="100.0" Z="2.289982225488514">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.381218958240606" CI_START="1.0253962216454706" DF="0" EFFECT_SIZE="1.1900826446280992" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="121" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.14026253072779052" LOG_CI_START="0.010891712829808603" LOG_EFFECT_SIZE="0.07557712177879959" MODIFIED="2013-03-14 17:39:33 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.022022347045925053" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="212" WEIGHT="100.0" Z="2.289982225488514">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.381218958240606" CI_START="1.0253962216454706" EFFECT_SIZE="1.1900826446280992" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="121" LOG_CI_END="0.14026253072779052" LOG_CI_START="0.010891712829808603" LOG_EFFECT_SIZE="0.07557712177879959" MODIFIED="2008-10-11 10:56:42 -0400" MODIFIED_BY="Anne Lethaby" ORDER="472" O_E="0.0" SE="0.07599305882915135" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="212" VAR="0.0057749449902108575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-03-14 17:42:45 -0400" MODIFIED_BY="Anne Lethaby" NO="9">
<NAME>Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="9.614016589637888" CI_END="2.7307635472744565" CI_START="0.7383296098106197" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4199308378735258" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="178" I2="89.59852013280471" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.43628409685899444" LOG_CI_START="-0.13174971437652727" LOG_EFFECT_SIZE="0.15226719124123358" METHOD="MH" MODIFIED="2013-03-14 17:39:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0019309982732703679" P_Q="1.0" P_Z="0.2933613946952981" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2011105712755035" TOTALS="SUB" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.0507762212631753">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.614016589637888" CI_END="2.7307635472744565" CI_START="0.7383296098106197" DF="1" EFFECT_SIZE="1.4199308378735258" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="178" I2="89.59852013280471" ID="CMP-009.01.01" LOG_CI_END="0.43628409685899444" LOG_CI_START="-0.13174971437652727" LOG_EFFECT_SIZE="0.15226719124123358" MODIFIED="2012-01-31 16:43:18 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0019309982732703679" P_Z="0.2933613946952981" STUDIES="2" TAU2="0.2011105712755035" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.0507762212631753">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.0068441035040685" CI_START="1.3287793943678334" EFFECT_SIZE="1.9988577955454025" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="17" LOG_CI_END="0.47811091172437575" LOG_CI_START="0.12345288480928332" LOG_EFFECT_SIZE="0.3007818982668295" MODIFIED="2012-01-31 14:09:16 -0500" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.20832788059547222" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.043400505833401326" WEIGHT="45.532871479380844"/>
<DICH_DATA CI_END="1.1938821708939495" CI_START="0.9533784098152855" EFFECT_SIZE="1.066874634431663" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="161" LOG_CI_END="0.07696146661270102" LOG_CI_START="-0.020734687320088558" LOG_EFFECT_SIZE="0.028113389646306258" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7586" O_E="0.0" SE="0.057387204423882045" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0032932912315884267" WEIGHT="54.46712852061916"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.527887482625754" CI_END="8.981572588296004" CI_START="0.6047525091206559" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.330585454048255" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="100" I2="89.50449402531763" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.953352384175689" LOG_CI_START="-0.2184223210727471" LOG_EFFECT_SIZE="0.3674650315514709" METHOD="MH" MODIFIED="2013-03-14 17:39:59 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0020237463872647687" P_Q="1.0" P_Z="0.21896774765244897" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8557257726626657" TOTALS="SUB" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.2292776490102835">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.527887482625754" CI_END="8.981572588296004" CI_START="0.6047525091206559" DF="1" EFFECT_SIZE="2.330585454048255" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="100" I2="89.50449402531763" ID="CMP-009.02.01" LOG_CI_END="0.953352384175689" LOG_CI_START="-0.2184223210727471" LOG_EFFECT_SIZE="0.3674650315514709" MODIFIED="2012-01-31 14:10:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0020237463872647687" P_Z="0.21896774765244897" STUDIES="2" TAU2="0.8557257726626657" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.2292776490102835">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="11.196216668007736" CI_START="2.0213727948807683" EFFECT_SIZE="4.757281553398058" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="5" LOG_CI_END="1.0490712942965965" LOG_CI_START="0.3056464163500863" LOG_EFFECT_SIZE="0.6773588553233414" MODIFIED="2012-01-31 14:10:31 -0500" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="0.4366914533182765" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.19069942540122847" WEIGHT="45.27466573980758"/>
<DICH_DATA CI_END="1.5709507327061643" CI_START="1.0617265661893895" EFFECT_SIZE="1.2914798206278026" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="95" LOG_CI_END="0.1961625651485917" LOG_CI_START="0.026012684273548612" LOG_EFFECT_SIZE="0.11108762471107016" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7587" O_E="0.0" SE="0.09994688228149436" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.00998937927779089" WEIGHT="54.72533426019241"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.916358144014245" CI_END="12.032509118859272" CI_START="0.5243177711317327" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5117440877451154" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="49" I2="79.659740590349" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="1.0803561994803965" LOG_CI_START="-0.28040542213816955" LOG_EFFECT_SIZE="0.3999753886711135" METHOD="MH" MODIFIED="2013-03-14 17:40:05 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.026603679345183262" P_Q="1.0" P_Z="0.24923735564858485" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.0526241909545957" TOTALS="SUB" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.00000000000001" Z="1.1522038012290992">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.916358144014245" CI_END="12.032509118859272" CI_START="0.5243177711317327" DF="1" EFFECT_SIZE="2.5117440877451154" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="49" I2="79.659740590349" ID="CMP-009.03.01" LOG_CI_END="1.0803561994803965" LOG_CI_START="-0.28040542213816955" LOG_EFFECT_SIZE="0.3999753886711135" MODIFIED="2012-01-31 14:10:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.026603679345183262" P_Z="0.24923735564858485" STUDIES="2" TAU2="1.0526241909545957" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.00000000000001" Z="1.1522038012290992">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="25.539470300174695" CI_START="1.5593384159039787" EFFECT_SIZE="6.310679611650485" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="2" LOG_CI_END="1.407211885562604" LOG_CI_START="0.19294037831276284" LOG_EFFECT_SIZE="0.8000761319376833" MODIFIED="2012-01-31 14:10:39 -0500" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.7132690940994575" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5087528005974608" WEIGHT="40.919614436192745"/>
<DICH_DATA CI_END="1.850610715517424" CI_START="0.9515001246954207" EFFECT_SIZE="1.3269726171166873" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="47" LOG_CI_END="0.2673150725167438" LOG_CI_START="-0.021591150462058412" LOG_EFFECT_SIZE="0.12286196102734269" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7588" O_E="0.0" SE="0.1697049454866167" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.028799768522615544" WEIGHT="59.08038556380727"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1655198999286256" CI_START="1.0071623317570786" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4768310911808669" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.33556217900997687" LOG_CI_START="0.003099474629633106" LOG_EFFECT_SIZE="0.169330826819805" METHOD="MH" MODIFIED="2013-03-14 17:40:14 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.045878592042227585" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.9965085867768615">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1655198999286256" CI_START="1.0071623317570786" DF="0" EFFECT_SIZE="1.4768310911808669" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.33556217900997687" LOG_CI_START="0.003099474629633106" LOG_EFFECT_SIZE="0.169330826819805" MODIFIED="2008-07-28 11:08:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.045878592042227585" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.9965085867768615">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.1655198999286256" CI_START="1.0071623317570786" EFFECT_SIZE="1.4768310911808669" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="36" LOG_CI_END="0.33556217900997687" LOG_CI_START="0.003099474629633106" LOG_EFFECT_SIZE="0.169330826819805" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7589" O_E="0.0" SE="0.1952902382699424" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.03813827716353088" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7099079243104551" CI_START="0.8265903682896905" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1888622379810199" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.2329727249883468" LOG_CI_START="-0.082709659570896" LOG_EFFECT_SIZE="0.07513153270872537" METHOD="MH" MODIFIED="2013-03-14 17:40:22 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.3508550932644642" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.9329319937695799">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7099079243104551" CI_START="0.8265903682896905" DF="0" EFFECT_SIZE="1.1888622379810199" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" I2="0.0" ID="CMP-009.05.01" LOG_CI_END="0.2329727249883468" LOG_CI_START="-0.082709659570896" LOG_EFFECT_SIZE="0.07513153270872537" MODIFIED="2008-07-28 11:08:34 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3508550932644642" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.9329319937695799">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7099079243104551" CI_START="0.8265903682896905" EFFECT_SIZE="1.1888622379810199" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" LOG_CI_END="0.2329727249883468" LOG_CI_START="-0.082709659570896" LOG_EFFECT_SIZE="0.07513153270872537" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7590" O_E="0.0" SE="0.18543339534310493" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.03438554410847225" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.12837119006901476" CI_START="-4.608371190069015" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2399999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.06" MODIFIED="2013-03-14 17:40:53 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0637778821397796" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="206" UNITS="" WEIGHT="100.00000000000001" Z="1.8537294085399625">
<NAME>Change in Total Sharp Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12837119006901476" CI_START="-4.608371190069015" DF="0" EFFECT_SIZE="-2.2399999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.01" MODIFIED="2013-03-14 17:40:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0637778821397796" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="206" WEIGHT="100.00000000000001" Z="1.8537294085399625">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.12837119006901476" CI_START="-4.608371190069015" EFFECT_SIZE="-2.2399999999999998" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="3.34" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7591" SD_1="7.1" SD_2="15.8" SE="1.2083748521658684" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="203" TOTAL_2="206" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.1784339568096982" CI_START="-3.3415660431903023" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7600000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.07" MODIFIED="2013-03-14 17:40:59 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.029176819647840063" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="206" UNITS="" WEIGHT="99.99999999999999" Z="2.181089198040799">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1784339568096982" CI_START="-3.3415660431903023" DF="0" EFFECT_SIZE="-1.7600000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-009.07.01" MODIFIED="2013-03-14 17:40:59 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.029176819647840063" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="206" WEIGHT="99.99999999999999" Z="2.181089198040799">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.1784339568096982" CI_START="-3.3415660431903023" EFFECT_SIZE="-1.7600000000000002" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="2.12" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7592" SD_1="4.4" SD_2="10.7" SE="0.8069362782507705" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="203" TOTAL_2="206" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.47908958495915865" CI_START="-1.4590895849591585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.49" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.08" MODIFIED="2013-03-14 17:41:07 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.32167825010546913" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="0.9910150385788131">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47908958495915865" CI_START="-1.4590895849591585" DF="0" EFFECT_SIZE="-0.49" ESTIMABLE="YES" I2="0.0" ID="CMP-009.08.01" MODIFIED="2013-03-14 17:41:07 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32167825010546913" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="206" WEIGHT="100.0" Z="0.9910150385788131">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.47908958495915865" CI_START="-1.4590895849591585" EFFECT_SIZE="-0.49" ESTIMABLE="YES" MEAN_1="0.74" MEAN_2="1.23" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7593" SD_1="3.6" SD_2="6.1" SE="0.4944425472116904" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="203" TOTAL_2="206" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3065609927883588" CI_START="0.9761745460449233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1293500715080247" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="124" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="0.11612968824102192" LOG_CI_START="-0.01047252085113817" LOG_EFFECT_SIZE="0.05282858369494189" METHOD="MH" MODIFIED="2013-03-14 17:41:19 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.10190072005500411" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="206" WEIGHT="100.0" Z="1.6357079728517614">
<NAME>No progression of joint damage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3065609927883588" CI_START="0.9761745460449233" DF="0" EFFECT_SIZE="1.1293500715080247" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="124" I2="0.0" ID="CMP-009.09.01" LOG_CI_END="0.11612968824102192" LOG_CI_START="-0.01047252085113817" LOG_EFFECT_SIZE="0.05282858369494189" MODIFIED="2013-03-14 17:41:19 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.10190072005500411" STUDIES="1" TAU2="0.0" TOTAL_1="203" TOTAL_2="206" WEIGHT="100.0" Z="1.6357079728517614">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3065609927883588" CI_START="0.9761745460449233" EFFECT_SIZE="1.1293500715080247" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="124" LOG_CI_END="0.11612968824102192" LOG_CI_START="-0.01047252085113817" LOG_EFFECT_SIZE="0.05282858369494189" MODIFIED="2008-10-11 11:08:06 -0400" MODIFIED_BY="Anne Lethaby" ORDER="475" O_E="0.0" SE="0.07436676431177701" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="203" TOTAL_2="206" VAR="0.00553041563420339" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.3283938635130237" CI_START="-2.0716061364869764" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.10" MODIFIED="2012-02-22 15:14:06 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="3.065920428883606E-19" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="8.966317954856661">
<NAME>DAS 28</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.3283938635130237" CI_START="-2.0716061364869764" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="4.4" MODIFIED="2012-01-31 13:32:43 -0500" MODIFIED_BY="[Empty name]" ORDER="511" SD_1="1.1" SD_2="1.1" SE="0.18959845151143503" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-03-14 18:51:18 -0400" MODIFIED_BY="Anne Lethaby" NO="10">
<NAME>Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1831172199803452" CI_START="0.9294434282992251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.048637461193515" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.07302777545518145" LOG_CI_START="-0.03177703894766891" LOG_EFFECT_SIZE="0.02062536825375629" METHOD="MH" MODIFIED="2013-03-14 17:43:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.44044995739176973" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.7714336249831417">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1831172199803452" CI_START="0.9294434282992251" DF="0" EFFECT_SIZE="1.048637461193515" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.07302777545518145" LOG_CI_START="-0.03177703894766891" LOG_EFFECT_SIZE="0.02062536825375629" MODIFIED="2012-02-21 14:47:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44044995739176973" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.7714336249831417">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1831172199803452" CI_START="0.9294434282992251" EFFECT_SIZE="1.048637461193515" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="156" LOG_CI_END="0.07302777545518145" LOG_CI_START="-0.03177703894766891" LOG_EFFECT_SIZE="0.02062536825375629" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7601" O_E="0.0" SE="0.061562866772432584" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.003789986565240284" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3203479680786931" CI_START="0.874568567502562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.074585888166926" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.12068840143413556" LOG_CI_START="-0.058206135504194643" LOG_EFFECT_SIZE="0.03124113296497044" METHOD="MH" MODIFIED="2013-03-14 17:43:55 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4936253366425417" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.684554112109944">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3203479680786931" CI_START="0.874568567502562" DF="0" EFFECT_SIZE="1.074585888166926" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="98" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="0.12068840143413556" LOG_CI_START="-0.058206135504194643" LOG_EFFECT_SIZE="0.03124113296497044" MODIFIED="2012-02-21 14:47:27 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4936253366425417" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.684554112109944">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3203479680786931" CI_START="0.8745685675025618" EFFECT_SIZE="1.074585888166926" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="98" LOG_CI_END="0.12068840143413556" LOG_CI_START="-0.0582061355041947" LOG_EFFECT_SIZE="0.03124113296497044" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7602" O_E="0.0" SE="0.10508353653981486" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.011042549651714605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5827001608603928" CI_START="0.8021520190840421" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1267502516701748" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="0.1993986464998689" LOG_CI_START="-0.09574331900637296" LOG_EFFECT_SIZE="0.05182766374674798" METHOD="MH" MODIFIED="2013-03-14 17:44:05 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.49123296851555454" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.6883491080114122">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5827001608603928" CI_START="0.8021520190840421" DF="0" EFFECT_SIZE="1.1267502516701748" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="49" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.1993986464998689" LOG_CI_START="-0.09574331900637296" LOG_EFFECT_SIZE="0.05182766374674798" MODIFIED="2012-02-21 14:47:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49123296851555454" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.6883491080114122">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5827001608603926" CI_START="0.8021520190840422" EFFECT_SIZE="1.1267502516701748" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="49" LOG_CI_END="0.19939864649986883" LOG_CI_START="-0.0957433190063729" LOG_EFFECT_SIZE="0.05182766374674798" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7603" O_E="0.0" SE="0.173367851514658" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.030056411938808508" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.788386447507081" CI_START="0.8417072925127393" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2269058295964126" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.25246137010049424" LOG_CI_START="-0.07483891010065837" LOG_EFFECT_SIZE="0.08881122999991796" METHOD="MH" MODIFIED="2013-03-14 17:46:01 -0400" MODIFIED_BY="Anne Lethaby" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.28748635519991206" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="99.99999999999999" Z="1.0636520819081743">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.788386447507081" CI_START="0.8417072925127393" DF="0" EFFECT_SIZE="1.2269058295964126" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="0.25246137010049424" LOG_CI_START="-0.07483891010065837" LOG_EFFECT_SIZE="0.08881122999991796" MODIFIED="2013-03-14 17:46:01 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.28748635519991206" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="99.99999999999999" Z="1.0636520819081743">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7883864475070812" CI_START="0.8417072925127393" EFFECT_SIZE="1.2269058295964126" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" LOG_CI_END="0.2524613701004943" LOG_CI_START="-0.07483891010065837" LOG_EFFECT_SIZE="0.08881122999991796" MODIFIED="2008-10-10 15:25:26 -0400" MODIFIED_BY="Anne Lethaby" ORDER="466" O_E="0.0" SE="0.19225780475267373" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.03696306348831721" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5874604529887772" CI_START="0.7535911771503392" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0937532589425383" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="0.20070291490090683" LOG_CI_START="-0.12286419479234548" LOG_EFFECT_SIZE="0.03891936005428064" METHOD="MH" MODIFIED="2013-03-14 17:45:27 -0400" MODIFIED_BY="Anne Lethaby" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6372854957078076" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.47149751456538525">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5874604529887772" CI_START="0.7535911771503392" DF="0" EFFECT_SIZE="1.0937532589425383" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" I2="0.0" ID="CMP-010.05.01" LOG_CI_END="0.20070291490090683" LOG_CI_START="-0.12286419479234548" LOG_EFFECT_SIZE="0.03891936005428064" MODIFIED="2012-02-21 14:47:30 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6372854957078076" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.47149751456538525">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.587460452988777" CI_START="0.7535911771503392" EFFECT_SIZE="1.0937532589425383" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" LOG_CI_END="0.20070291490090675" LOG_CI_START="-0.12286419479234548" LOG_EFFECT_SIZE="0.03891936005428064" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7604" O_E="0.0" SE="0.19006492191684096" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.03612467454325485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.118755962558851" CI_START="-7.561244037441149" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.34" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.06" MODIFIED="2013-03-14 18:49:52 -0400" MODIFIED_BY="Anne Lethaby" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.008274217863412786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="210" UNITS="" WEIGHT="99.99999999999999" Z="2.6406703726989025">
<NAME>Change in Total Sharp Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.118755962558851" CI_START="-7.561244037441149" DF="0" EFFECT_SIZE="-4.34" ESTIMABLE="YES" I2="0.0" ID="CMP-010.06.01" MODIFIED="2013-03-14 18:49:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.008274217863412786" STUDIES="1" TAU2="0.0" TOTAL_1="211" TOTAL_2="210" WEIGHT="99.99999999999999" Z="2.6406703726989025">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-1.118755962558851" CI_START="-7.561244037441149" EFFECT_SIZE="-4.34" ESTIMABLE="YES" MEAN_1="1.61" MEAN_2="5.95" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7605" SD_1="8.9" SD_2="22.1" SE="1.6435220559407777" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="211" TOTAL_2="210" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.9128746702691166" CI_START="-4.807125329730884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.86" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.07" MODIFIED="2013-03-14 18:50:06 -0400" MODIFIED_BY="Anne Lethaby" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.00399118217208289" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="210" UNITS="" WEIGHT="100.0" Z="2.8788578270713083">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9128746702691166" CI_START="-4.807125329730884" DF="0" EFFECT_SIZE="-2.86" ESTIMABLE="YES" I2="0.0" ID="CMP-010.07.01" MODIFIED="2013-03-14 18:50:06 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.00399118217208289" STUDIES="1" TAU2="0.0" TOTAL_1="211" TOTAL_2="210" WEIGHT="100.0" Z="2.8788578270713083">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.9128746702691166" CI_START="-4.807125329730884" EFFECT_SIZE="-2.86" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="3.25" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7606" SD_1="6.2" SD_2="13.0" SE="0.9934495455475505" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="211" TOTAL_2="210" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.08224250220949036" CI_START="-3.0422425022094908" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4800000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.08" MODIFIED="2013-03-14 18:50:18 -0400" MODIFIED_BY="Anne Lethaby" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.06334190782463238" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="210" UNITS="" WEIGHT="100.0" Z="1.8567838815143833">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.08224250220949036" CI_START="-3.0422425022094908" DF="0" EFFECT_SIZE="-1.4800000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-010.08.01" MODIFIED="2013-03-14 18:50:18 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06334190782463238" STUDIES="1" TAU2="0.0" TOTAL_1="211" TOTAL_2="210" WEIGHT="100.0" Z="1.8567838815143833">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.08224250220949036" CI_START="-3.0422425022094908" EFFECT_SIZE="-1.4800000000000002" ESTIMABLE="YES" MEAN_1="1.22" MEAN_2="2.7" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7607" SD_1="4.6" SD_2="10.6" SE="0.7970771476069255" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="211" TOTAL_2="210" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.423415432108457" CI_START="1.0114720213961708" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.199893697125393" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="107" I2="0.0" I2_Q="0.0" ID="CMP-010.09" LOG_CI_END="0.1533316699658372" LOG_CI_START="0.00495387413469471" LOG_EFFECT_SIZE="0.07914277205026592" METHOD="MH" MODIFIED="2013-03-14 18:51:18 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.036542569200455566" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="210" WEIGHT="100.0" Z="2.090838214522492">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.423415432108457" CI_START="1.0114720213961708" DF="0" EFFECT_SIZE="1.199893697125393" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="107" I2="0.0" ID="CMP-010.09.01" LOG_CI_END="0.1533316699658372" LOG_CI_START="0.00495387413469471" LOG_EFFECT_SIZE="0.07914277205026592" MODIFIED="2013-03-14 18:50:45 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.036542569200455566" STUDIES="1" TAU2="0.0" TOTAL_1="211" TOTAL_2="210" WEIGHT="100.0" Z="2.090838214522492">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.423415432108457" CI_START="1.0114720213961708" EFFECT_SIZE="1.199893697125393" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="107" LOG_CI_END="0.1533316699658372" LOG_CI_START="0.00495387413469471" LOG_EFFECT_SIZE="0.07914277205026592" MODIFIED="2008-10-10 15:51:27 -0400" MODIFIED_BY="Anne Lethaby" ORDER="469" O_E="0.0" SE="0.08715785175314804" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="211" TOTAL_2="210" VAR="0.0075964911222237315" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2013-03-14 18:58:14 -0400" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="7.090246754654489" CI_END="1.6643548787303777" CI_START="0.8503148491645769" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1896325767496234" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="120" I2="85.89611850471162" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.22124593339822446" LOG_CI_START="-0.07042023671325695" LOG_EFFECT_SIZE="0.07541284834248374" METHOD="MH" MODIFIED="2013-03-14 18:56:33 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.007750476216396351" P_Q="1.0" P_Z="0.31080623677324837" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05045435759437841" TOTALS="YES" TOTAL_1="174" TOTAL_2="172" WEIGHT="100.00000000000001" Z="1.0135317830405515">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.090246754654489" CI_END="1.6643548787303777" CI_START="0.8503148491645769" DF="1" EFFECT_SIZE="1.1896325767496234" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="120" I2="85.89611850471162" ID="CMP-011.01.01" LOG_CI_END="0.22124593339822446" LOG_CI_START="-0.07042023671325695" LOG_EFFECT_SIZE="0.07541284834248374" MODIFIED="2013-03-14 18:56:33 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.007750476216396351" P_Z="0.31080623677324837" STUDIES="2" TAU2="0.05045435759437841" TOTAL_1="174" TOTAL_2="172" WEIGHT="100.00000000000001" Z="1.0135317830405515">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1840629235215372" CI_START="0.8553665481415551" EFFECT_SIZE="1.0063835330901512" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="76" LOG_CI_END="0.07337478229573323" LOG_CI_START="-0.06784773822885652" LOG_EFFECT_SIZE="0.0027635220334383433" MODIFIED="2012-01-31 09:16:26 -0500" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.08295480761889493" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.0068815001070878686" WEIGHT="51.19422917552754"/>
<DICH_DATA CI_END="1.7194781867288078" CI_START="1.1690640578541782" EFFECT_SIZE="1.417808219178082" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="44" LOG_CI_END="0.23539667074052698" LOG_CI_START="0.06783830860443427" LOG_EFFECT_SIZE="0.15161748967248062" MODIFIED="2012-01-31 07:51:34 -0500" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.09842461134601027" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.009687404118613173" WEIGHT="48.805770824472475"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7351809845583122" CI_END="1.4929897466117577" CI_START="0.9932315817812368" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2177374789380362" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.17405682513612702" LOG_CI_START="-0.002949479637754211" LOG_EFFECT_SIZE="0.08555367274918642" METHOD="MH" MODIFIED="2013-03-14 18:56:39 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3912089955787499" P_Q="1.0" P_Z="0.05813935568247365" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="172" WEIGHT="100.0" Z="1.894645702566795">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7351809845583122" CI_END="1.4929897466117577" CI_START="0.9932315817812368" DF="1" EFFECT_SIZE="1.2177374789380362" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="81" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="0.17405682513612702" LOG_CI_START="-0.002949479637754211" LOG_EFFECT_SIZE="0.08555367274918642" MODIFIED="2013-03-14 18:56:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3912089955787499" P_Z="0.05813935568247365" STUDIES="2" TAU2="0.0" TOTAL_1="174" TOTAL_2="172" WEIGHT="100.0" Z="1.894645702566795">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4866327646706912" CI_START="0.8528983339907834" EFFECT_SIZE="1.1260313531353134" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" LOG_CI_END="0.17220370021378623" LOG_CI_START="-0.0691027339183234" LOG_EFFECT_SIZE="0.051550483147731425" MODIFIED="2012-01-31 09:16:49 -0500" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14174459389531457" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.020091529898547646" WEIGHT="58.34765716377986"/>
<DICH_DATA CI_END="1.8167126078027573" CI_START="0.9975486085782341" EFFECT_SIZE="1.3462017434620175" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="33" LOG_CI_END="0.2592862301604411" LOG_CI_START="-0.001065932811182198" LOG_EFFECT_SIZE="0.12911014867462942" MODIFIED="2012-01-31 07:52:29 -0500" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.15293214929352314" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.02338824228753645" WEIGHT="41.652342836220136"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4403319605557452" CI_END="1.8502947591153915" CI_START="0.9160764317766922" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3019260427019432" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.26724091870590017" LOG_CI_START="-0.03806828996307353" LOG_EFFECT_SIZE="0.11458631437141333" METHOD="MH" MODIFIED="2013-03-14 18:56:46 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5069622992589373" P_Q="1.0" P_Z="0.14123775377669387" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="172" WEIGHT="99.99999999999999" Z="1.4711973495215278">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4403319605557452" CI_END="1.8502947591153915" CI_START="0.9160764317766922" DF="1" EFFECT_SIZE="1.3019260427019432" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="40" I2="0.0" ID="CMP-011.03.01" LOG_CI_END="0.26724091870590017" LOG_CI_START="-0.03806828996307353" LOG_EFFECT_SIZE="0.11458631437141333" MODIFIED="2013-03-14 18:56:46 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5069622992589373" P_Z="0.14123775377669387" STUDIES="2" TAU2="0.0" TOTAL_1="174" TOTAL_2="172" WEIGHT="99.99999999999999" Z="1.4711973495215278">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.916256232794574" CI_START="0.70083015001621" EFFECT_SIZE="1.158865886588659" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.28245358044632624" LOG_CI_START="-0.15438722290160414" LOG_EFFECT_SIZE="0.06403317877236105" MODIFIED="2012-01-31 09:17:18 -0500" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.25660245028342554" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.06584481749145789" WEIGHT="54.066965968676094"/>
<DICH_DATA CI_END="2.4054406305387426" CI_START="0.8987292393533559" EFFECT_SIZE="1.4703196347031964" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" LOG_CI_END="0.3811946424077351" LOG_CI_START="-0.04637112869630991" LOG_EFFECT_SIZE="0.16741175685571258" MODIFIED="2012-01-31 07:53:07 -0500" MODIFIED_BY="[Empty name]" ORDER="386" O_E="0.0" SE="0.2511542504312172" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.06307845750966656" WEIGHT="45.93303403132389"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.329159804103462" CI_START="1.0470434295759006" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5616438356164384" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.36719928658509754" LOG_CI_START="0.01996469584693582" LOG_EFFECT_SIZE="0.1935819912160167" METHOD="MH" MODIFIED="2013-03-14 18:57:09 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.02886354233709805" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="2.1853452447371255">
<NAME>DAS &lt; 3.2</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.329159804103462" CI_START="1.0470434295759006" DF="0" EFFECT_SIZE="1.5616438356164384" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" I2="0.0" ID="CMP-011.04.01" LOG_CI_END="0.36719928658509754" LOG_CI_START="0.01996469584693582" LOG_EFFECT_SIZE="0.1935819912160167" MODIFIED="2013-03-14 18:57:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02886354233709805" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="2.1853452447371255">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.329159804103462" CI_START="1.0470434295759006" EFFECT_SIZE="1.5616438356164384" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" LOG_CI_END="0.36719928658509754" LOG_CI_START="0.01996469584693582" LOG_EFFECT_SIZE="0.1935819912160167" MODIFIED="2012-01-31 08:00:59 -0500" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.2039673174385414" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.04160266658307472" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.9822906158689655" CI_START="1.2191267638727963" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.700587084148728" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="0.7768675069571725" LOG_CI_START="0.08604886557587509" LOG_EFFECT_SIZE="0.43145818626652377" METHOD="MH" MODIFIED="2013-03-14 18:57:26 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.014355877631094185" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="2.448233024593812">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.9822906158689655" CI_START="1.2191267638727963" DF="0" EFFECT_SIZE="2.700587084148728" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="0.0" ID="CMP-011.05.01" LOG_CI_END="0.7768675069571725" LOG_CI_START="0.08604886557587509" LOG_EFFECT_SIZE="0.43145818626652377" MODIFIED="2013-03-14 18:57:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.014355877631094185" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="2.448233024593812">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="5.9822906158689655" CI_START="1.2191267638727965" EFFECT_SIZE="2.700587084148728" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.7768675069571725" LOG_CI_START="0.08604886557587517" LOG_EFFECT_SIZE="0.43145818626652377" MODIFIED="2012-01-31 08:01:32 -0500" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.4057902895547996" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.16466575909696812" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.329159804103462" CI_START="1.0470434295759006" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5616438356164384" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-011.06" LOG_CI_END="0.36719928658509754" LOG_CI_START="0.01996469584693582" LOG_EFFECT_SIZE="0.1935819912160167" METHOD="MH" MODIFIED="2013-03-14 18:57:38 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.02886354233709805" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="2.1853452447371255">
<NAME>EULAR - good response</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.329159804103462" CI_START="1.0470434295759006" DF="0" EFFECT_SIZE="1.5616438356164384" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" I2="0.0" ID="CMP-011.06.01" LOG_CI_END="0.36719928658509754" LOG_CI_START="0.01996469584693582" LOG_EFFECT_SIZE="0.1935819912160167" MODIFIED="2013-03-14 18:57:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02886354233709805" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="2.1853452447371255">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.329159804103462" CI_START="1.0470434295759006" EFFECT_SIZE="1.5616438356164384" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" LOG_CI_END="0.36719928658509754" LOG_CI_START="0.01996469584693582" LOG_EFFECT_SIZE="0.1935819912160167" MODIFIED="2012-01-31 08:28:32 -0500" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.2039673174385414" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.04160266658307472" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.734394551508693" CI_START="0.7802931985310957" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1633298208640674" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-011.07" LOG_CI_END="0.23914790055165885" LOG_CI_START="-0.10774217861988403" LOG_EFFECT_SIZE="0.06570286096588743" METHOD="MH" MODIFIED="2013-03-14 18:57:47 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.45781134832509773" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="0.7424556013935492">
<NAME>EULAR - moderate response</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.734394551508693" CI_START="0.7802931985310957" DF="0" EFFECT_SIZE="1.1633298208640674" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" I2="0.0" ID="CMP-011.07.01" LOG_CI_END="0.23914790055165885" LOG_CI_START="-0.10774217861988403" LOG_EFFECT_SIZE="0.06570286096588743" MODIFIED="2013-03-14 18:57:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45781134832509773" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="0.7424556013935492">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.734394551508693" CI_START="0.7802931985310957" EFFECT_SIZE="1.1633298208640674" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.23914790055165885" LOG_CI_START="-0.10774217861988403" LOG_EFFECT_SIZE="0.06570286096588743" MODIFIED="2012-01-31 08:28:48 -0500" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.2037649496389498" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.041520154701363755" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.45591168953241745" CI_START="0.04409143684011619" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14178082191780822" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-011.08" LOG_CI_END="-0.3411192723860146" LOG_CI_START="-1.355645748269024" LOG_EFFECT_SIZE="-0.8483825103275193" METHOD="MH" MODIFIED="2013-03-14 18:58:03 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0010455249897156692" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="3.277980821364715">
<NAME>EULAR - no response</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.45591168953241745" CI_START="0.04409143684011619" DF="0" EFFECT_SIZE="0.14178082191780822" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" I2="0.0" ID="CMP-011.08.01" LOG_CI_END="-0.3411192723860146" LOG_CI_START="-1.355645748269024" LOG_EFFECT_SIZE="-0.8483825103275193" MODIFIED="2013-03-14 18:58:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0010455249897156692" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="3.277980821364715">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.45591168953241745" CI_START="0.04409143684011619" EFFECT_SIZE="0.14178082191780822" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" LOG_CI_END="-0.3411192723860146" LOG_CI_START="-1.355645748269024" LOG_EFFECT_SIZE="-0.8483825103275193" MODIFIED="2012-01-31 08:29:12 -0500" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.5959378739207289" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.3551419495731586" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.31606507414325763" CI_START="-0.31606507414325763" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.09" MODIFIED="2013-03-14 18:58:14 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" UNITS="" WEIGHT="99.99999999999999" Z="0.0">
<NAME>DAS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.31606507414325763" CI_START="-0.31606507414325763" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.09.01" MODIFIED="2013-03-14 18:58:14 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="99.99999999999999" Z="0.0">
<NAME>ET 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.31606507414325763" CI_START="-0.31606507414325763" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.6" MODIFIED="2012-01-31 10:50:43 -0500" MODIFIED_BY="[Empty name]" ORDER="454" SD_1="1.2" SD_2="1.1" SE="0.1612606540917785" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2013-03-20 15:17:24 -0400" MODIFIED_BY="Anne Lethaby" NO="12">
<NAME>Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2275538772306964" CI_START="1.0211368229096769" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.119598350367581" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="169" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.08904056235957088" LOG_CI_START="0.009083937438066856" LOG_EFFECT_SIZE="0.04906224989881884" METHOD="MH" MODIFIED="2013-03-14 18:59:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.016158743166678678" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="2.4053102015397085">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2275538772306964" CI_START="1.0211368229096769" DF="0" EFFECT_SIZE="1.119598350367581" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="169" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="0.08904056235957088" LOG_CI_START="0.009083937438066856" LOG_EFFECT_SIZE="0.04906224989881884" MODIFIED="2013-03-14 18:59:03 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.016158743166678678" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="2.4053102015397085">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2275538772306964" CI_START="1.0211368229096769" EFFECT_SIZE="1.119598350367581" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="169" LOG_CI_END="0.08904056235957088" LOG_CI_START="0.009083937438066856" LOG_EFFECT_SIZE="0.04906224989881884" MODIFIED="2008-07-11 14:16:23 -0400" MODIFIED_BY="Anne Lethaby" ORDER="757" O_E="0.0" SE="0.046966917270568065" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.0022058913179003846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6865937869571492" CI_START="1.2201183631438879" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4345187522757616" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="107" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.22701049614808905" LOG_CI_START="0.08640196343442741" LOG_EFFECT_SIZE="0.1567062297912582" METHOD="MH" MODIFIED="2013-03-14 18:59:17 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.2498573287347286E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.368704524772869">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6865937869571492" CI_START="1.2201183631438879" DF="0" EFFECT_SIZE="1.4345187522757616" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="107" I2="0.0" ID="CMP-012.02.01" LOG_CI_END="0.22701049614808905" LOG_CI_START="0.08640196343442741" LOG_EFFECT_SIZE="0.1567062297912582" MODIFIED="2013-03-14 18:59:17 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="1.2498573287347286E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.368704524772869">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6865937869571492" CI_START="1.2201183631438879" EFFECT_SIZE="1.4345187522757616" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="107" LOG_CI_END="0.22701049614808905" LOG_CI_START="0.08640196343442741" LOG_EFFECT_SIZE="0.1567062297912582" MODIFIED="2008-07-11 14:17:21 -0400" MODIFIED_BY="Anne Lethaby" ORDER="758" O_E="0.0" SE="0.08259414813946711" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.006821793306884239" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3319960023654653" CI_START="1.3432004674347917" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7698412698412698" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.3677278015963645" LOG_CI_START="0.12814083426483108" LOG_EFFECT_SIZE="0.24793431793059775" METHOD="MH" MODIFIED="2013-03-14 18:59:33 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="4.98134429391303E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.05650056084263">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3319960023654653" CI_START="1.3432004674347917" DF="0" EFFECT_SIZE="1.7698412698412698" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="54" I2="0.0" ID="CMP-012.03.01" LOG_CI_END="0.3677278015963645" LOG_CI_START="0.12814083426483108" LOG_EFFECT_SIZE="0.24793431793059775" MODIFIED="2013-03-14 18:59:33 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="4.98134429391303E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.05650056084263">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.3319960023654653" CI_START="1.3432004674347917" EFFECT_SIZE="1.7698412698412698" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="54" LOG_CI_END="0.3677278015963645" LOG_CI_START="0.12814083426483108" LOG_EFFECT_SIZE="0.24793431793059775" MODIFIED="2008-07-11 14:18:19 -0400" MODIFIED_BY="Anne Lethaby" ORDER="759" O_E="0.0" SE="0.14073457058515818" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.019806219357788868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9628807197096334" CI_START="1.5294640974419467" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1287601287601285" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.47171416791115617" LOG_CI_START="0.18453928683501356" LOG_EFFECT_SIZE="0.32812672737308485" METHOD="MH" MODIFIED="2013-03-14 18:59:55 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="7.502186422776694E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.478919365135708">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9628807197096334" CI_START="1.5294640974419467" DF="0" EFFECT_SIZE="2.1287601287601285" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="39" I2="0.0" ID="CMP-012.04.01" LOG_CI_END="0.47171416791115617" LOG_CI_START="0.18453928683501356" LOG_EFFECT_SIZE="0.32812672737308485" MODIFIED="2013-03-14 18:59:55 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="7.502186422776694E-6" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.478919365135708">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.9628807197096325" CI_START="1.5294640974419467" EFFECT_SIZE="2.1287601287601285" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="39" LOG_CI_END="0.47171416791115606" LOG_CI_START="0.18453928683501356" LOG_EFFECT_SIZE="0.32812672737308485" MODIFIED="2008-07-11 14:19:33 -0400" MODIFIED_BY="Anne Lethaby" ORDER="760" O_E="0.0" SE="0.16868794668271372" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.028455623356030073" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.02712306431944" CI_START="1.5674432266416893" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.178266178266178" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-012.05" LOG_CI_END="0.4810300770743266" LOG_CI_START="0.19519181948504488" LOG_EFFECT_SIZE="0.33811094827968574" METHOD="MH" MODIFIED="2013-03-14 19:00:08 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="3.538700502573002E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.636785061564958">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.02712306431944" CI_START="1.5674432266416893" DF="0" EFFECT_SIZE="2.178266178266178" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="39" I2="0.0" ID="CMP-012.05.01" LOG_CI_END="0.4810300770743266" LOG_CI_START="0.19519181948504488" LOG_EFFECT_SIZE="0.33811094827968574" MODIFIED="2013-03-14 19:00:08 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="3.538700502573002E-6" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.636785061564958">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.02712306431944" CI_START="1.5674432266416893" EFFECT_SIZE="2.178266178266178" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="39" LOG_CI_END="0.4810300770743266" LOG_CI_START="0.19519181948504488" LOG_EFFECT_SIZE="0.33811094827968574" MODIFIED="2008-07-11 14:20:14 -0400" MODIFIED_BY="Anne Lethaby" ORDER="761" O_E="0.0" SE="0.16790280743013872" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.028191352742922247" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5035497950050092" CI_START="-1.756450204994991" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1300000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.06" MODIFIED="2013-03-14 19:00:25 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="4.07140490336615E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="202" UNITS="" WEIGHT="100.0" Z="3.5354115696202397">
<NAME>Change in Total Sharp Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5035497950050092" CI_START="-1.756450204994991" DF="0" EFFECT_SIZE="-1.1300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-012.06.01" MODIFIED="2013-03-14 19:00:25 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="4.07140490336615E-4" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="202" WEIGHT="100.0" Z="3.5354115696202397">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.5035497950050092" CI_START="-1.756450204994991" EFFECT_SIZE="-1.1300000000000001" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.33" MODIFIED="2008-07-11 14:23:59 -0400" MODIFIED_BY="Anne Lethaby" ORDER="762" SD_1="2.7" SD_2="3.7" SE="0.3196233246816524" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="202" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2241675096261268" CI_START="-1.1158324903738732" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.67" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.07" MODIFIED="2013-03-14 19:00:33 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.0032248862961664873" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="202" UNITS="" WEIGHT="100.0" Z="2.9454467720390065">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2241675096261268" CI_START="-1.1158324903738732" DF="0" EFFECT_SIZE="-0.67" ESTIMABLE="YES" I2="0.0" ID="CMP-012.07.01" MODIFIED="2013-03-14 19:00:33 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.0032248862961664873" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="202" WEIGHT="100.0" Z="2.9454467720390065">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.2241675096261268" CI_START="-1.1158324903738732" EFFECT_SIZE="-0.67" ESTIMABLE="YES" MEAN_1="-0.64" MEAN_2="0.03" MODIFIED="2008-07-11 14:26:24 -0400" MODIFIED_BY="Anne Lethaby" ORDER="763" SD_1="2.1" SD_2="2.5" SE="0.22746973612298135" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="202" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.1753029453144488" CI_START="-0.7446970546855511" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.08" MODIFIED="2013-03-14 19:00:41 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.001541173438283475" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="202" UNITS="" WEIGHT="100.0" Z="3.1668168604140523">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1753029453144488" CI_START="-0.7446970546855511" DF="0" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-012.08.01" MODIFIED="2013-03-14 19:00:41 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.001541173438283475" STUDIES="1" TAU2="0.0" TOTAL_1="212" TOTAL_2="202" WEIGHT="100.0" Z="3.1668168604140523">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.1753029453144488" CI_START="-0.7446970546855511" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" MEAN_1="-0.16" MEAN_2="0.3" MODIFIED="2008-07-11 14:27:48 -0400" MODIFIED_BY="Anne Lethaby" ORDER="764" SD_1="1.2" SD_2="1.7" SE="0.1452562684473823" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="212" TOTAL_2="202" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3170657931877567" CI_START="1.0483946030604407" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1750764525993884" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-012.09" LOG_CI_END="0.11960747040953566" LOG_CI_START="0.020524776613457724" LOG_EFFECT_SIZE="0.07006612351149669" METHOD="MH" MODIFIED="2013-03-20 15:17:24 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.005571833975940837" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="218" TOTAL_2="212" WEIGHT="100.0" Z="2.771969016133158">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3170657931877567" CI_START="1.0483946030604407" DF="0" EFFECT_SIZE="1.1750764525993884" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="144" I2="0.0" ID="CMP-012.09.01" LOG_CI_END="0.11960747040953566" LOG_CI_START="0.020524776613457724" LOG_EFFECT_SIZE="0.07006612351149669" MODIFIED="2013-03-14 19:01:07 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.005571833975940837" STUDIES="1" TAU2="0.0" TOTAL_1="218" TOTAL_2="212" WEIGHT="100.0" Z="2.771969016133158">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3170657931877567" CI_START="1.0483946030604407" EFFECT_SIZE="1.1750764525993884" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="144" LOG_CI_END="0.11960747040953566" LOG_CI_START="0.020524776613457724" LOG_EFFECT_SIZE="0.07006612351149669" MODIFIED="2008-10-11 11:00:07 -0400" MODIFIED_BY="Anne Lethaby" ORDER="473" O_E="0.0" SE="0.05820166480306065" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="218" TOTAL_2="212" VAR="0.003387433785847829" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2013-03-14 19:04:23 -0400" MODIFIED_BY="Anne Lethaby" NO="13">
<NAME>Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.006850272527623793" CI_END="1.2436267222423132" CI_START="1.0563357624137149" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1461620224897975" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="237" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.09469004530883192" LOG_CI_START="0.023801983146869876" LOG_EFFECT_SIZE="0.059246014227850884" METHOD="MH" MODIFIED="2013-03-14 19:02:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9340373078821188" P_Q="1.0" P_Z="0.0010523169048197456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="3.2761525868440087">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.006850272527623793" CI_END="1.2436267222423132" CI_START="1.0563357624137149" DF="1" EFFECT_SIZE="1.1461620224897975" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="237" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="0.09469004530883192" LOG_CI_START="0.023801983146869876" LOG_EFFECT_SIZE="0.059246014227850884" MODIFIED="2013-03-14 19:02:12 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.9340373078821188" P_Z="0.0010523169048197456" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="3.2761525868440087">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3692134461923118" CI_START="0.9706252173631782" EFFECT_SIZE="1.1528196297890658" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="69" LOG_CI_END="0.1364711554223469" LOG_CI_START="-0.012948429670837433" LOG_EFFECT_SIZE="0.061761362875754705" MODIFIED="2012-02-16 17:20:28 -0500" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.08776980392261141" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.007703538480613652" WEIGHT="28.55333543066278"/>
<DICH_DATA CI_END="1.2526662275999534" CI_START="1.043849738750274" EFFECT_SIZE="1.1435013399299114" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="168" LOG_CI_END="0.09783536882215875" LOG_CI_START="0.018637986857561586" LOG_EFFECT_SIZE="0.05823667783986019" MODIFIED="2008-07-11 14:29:09 -0400" MODIFIED_BY="Anne Lethaby" ORDER="765" O_E="0.0" SE="0.046520934199367724" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.0021641973187819016" WEIGHT="71.44666456933722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.183728948645247" CI_END="2.021525633810603" CI_START="1.0665374584506546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4683435605052413" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="144" I2="76.09787793915726" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.3056792527445937" LOG_CI_START="0.02797611314947748" LOG_EFFECT_SIZE="0.16682768294703557" METHOD="MH" MODIFIED="2013-03-14 19:02:49 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.040813939101780106" P_Q="1.0" P_Z="0.01852959827766238" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04084166351256272" TOTALS="YES" TOTAL_1="332" TOTAL_2="331" WEIGHT="100.0" Z="2.3548617468076114">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.183728948645247" CI_END="2.021525633810603" CI_START="1.0665374584506546" DF="1" EFFECT_SIZE="1.4683435605052413" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="144" I2="76.09787793915726" ID="CMP-013.02.01" LOG_CI_END="0.3056792527445937" LOG_CI_START="0.02797611314947748" LOG_EFFECT_SIZE="0.16682768294703557" MODIFIED="2013-03-14 19:02:49 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.040813939101780106" P_Z="0.01852959827766238" STUDIES="2" TAU2="0.04084166351256272" TOTAL_1="332" TOTAL_2="331" WEIGHT="100.0" Z="2.3548617468076114">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5942958449557016" CI_START="0.9457462998505676" EFFECT_SIZE="1.2279248332996564" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="49" LOG_CI_END="0.20256891424327664" LOG_CI_START="-0.02422534917095637" LOG_EFFECT_SIZE="0.08917178253616012" MODIFIED="2012-01-31 14:11:40 -0500" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.13322007297923025" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.01774758784459143" WEIGHT="45.41704089805378"/>
<DICH_DATA CI_END="2.0283467406407505" CI_START="1.431343997898105" EFFECT_SIZE="1.7038961038961038" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="95" LOG_CI_END="0.3071421985286158" LOG_CI_START="0.1557440212057034" LOG_EFFECT_SIZE="0.23144310986715957" MODIFIED="2008-07-11 14:30:13 -0400" MODIFIED_BY="Anne Lethaby" ORDER="766" O_E="0.0" SE="0.08893203879254322" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.00790890752379841" WEIGHT="54.582959101946216"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.227544936346395" CI_END="2.3062328178433136" CI_START="0.9138316804089385" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.451726079997186" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="87" I2="69.01669783931786" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.36290314788529987" LOG_CI_START="-0.03913379004449201" LOG_EFFECT_SIZE="0.1618846789204039" METHOD="MH" MODIFIED="2013-03-14 19:03:03 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07240921736708972" P_Q="1.0" P_Z="0.11447307259536403" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07916115653749457" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="1.5784029296742408">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.227544936346395" CI_END="2.3062328178433136" CI_START="0.9138316804089385" DF="1" EFFECT_SIZE="1.451726079997186" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="87" I2="69.01669783931786" ID="CMP-013.03.01" LOG_CI_END="0.36290314788529987" LOG_CI_START="-0.03913379004449201" LOG_EFFECT_SIZE="0.1618846789204039" MODIFIED="2013-03-14 19:03:03 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.07240921736708972" P_Z="0.11447307259536403" STUDIES="2" TAU2="0.07916115653749457" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="1.5784029296742408">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7359451432313495" CI_START="0.6948084178876175" EFFECT_SIZE="1.0982482863670981" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.2395359971259908" LOG_CI_START="-0.15813492853812916" LOG_EFFECT_SIZE="0.04070053429393085" MODIFIED="2012-01-31 14:11:54 -0500" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.2335938702379337" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.054566096212736614" WEIGHT="41.704910592272014"/>
<DICH_DATA CI_END="2.2800728671182866" CI_START="1.3778864048574713" EFFECT_SIZE="1.7724788872329855" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="61" LOG_CI_END="0.35794872650997434" LOG_CI_START="0.13921341512088753" LOG_EFFECT_SIZE="0.24858107081543093" MODIFIED="2008-07-11 14:30:56 -0400" MODIFIED_BY="Anne Lethaby" ORDER="767" O_E="0.0" SE="0.12848620466720345" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.016508704789782495" WEIGHT="58.29508940772798"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.319166150484062" CI_START="1.3131154844207868" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.745088245088245" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="0.365331863624421" LOG_CI_START="0.11830292261741072" LOG_EFFECT_SIZE="0.24181739312091585" METHOD="MH" MODIFIED="2013-03-14 19:03:15 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.244301287031042E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="3.8372295927780287">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.319166150484062" CI_START="1.3131154844207868" DF="0" EFFECT_SIZE="1.745088245088245" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="52" I2="0.0" ID="CMP-013.04.01" LOG_CI_END="0.365331863624421" LOG_CI_START="0.11830292261741072" LOG_EFFECT_SIZE="0.24181739312091585" MODIFIED="2013-03-14 19:03:15 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="1.244301287031042E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="3.8372295927780287">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.319166150484062" CI_START="1.3131154844207868" EFFECT_SIZE="1.745088245088245" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="52" LOG_CI_END="0.365331863624421" LOG_CI_START="0.11830292261741072" LOG_EFFECT_SIZE="0.24181739312091585" MODIFIED="2008-07-11 14:34:22 -0400" MODIFIED_BY="Anne Lethaby" ORDER="768" O_E="0.0" SE="0.1451060227604971" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.021055757841369906" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.7622751672299875E-31" CI_END="2.5202414844043166" CI_START="1.4205474767054875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8921212121212119" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="50" I2="99.99999999999999" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="0.4014421559877461" LOG_CI_START="0.15245575303723866" LOG_EFFECT_SIZE="0.27694895451249235" METHOD="MH" MODIFIED="2013-03-14 19:03:31 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="1.2996881357476232E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.3601575826484344">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.7622751672299875E-31" CI_END="2.5202414844043166" CI_START="1.4205474767054875" DF="0" EFFECT_SIZE="1.8921212121212119" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="50" I2="99.99999999999999" ID="CMP-013.05.01" LOG_CI_END="0.4014421559877461" LOG_CI_START="0.15245575303723866" LOG_EFFECT_SIZE="0.27694895451249235" MODIFIED="2013-03-14 19:03:31 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.0" P_Z="1.2996881357476232E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.3601575826484344">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.520241484404317" CI_START="1.4205474767054875" EFFECT_SIZE="1.892121212121212" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="50" LOG_CI_END="0.4014421559877462" LOG_CI_START="0.15245575303723866" LOG_EFFECT_SIZE="0.2769489545124924" MODIFIED="2008-07-11 14:35:04 -0400" MODIFIED_BY="Anne Lethaby" ORDER="769" O_E="0.0" SE="0.14625584559570023" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.02139077237091331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5641760495865538" CI_START="-2.7558239504134465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.06" MODIFIED="2013-03-14 19:03:46 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0029873607862180083" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="203" UNITS="" WEIGHT="100.0" Z="2.9690355034756752">
<NAME>Change in Total Sharp Score (TSS) (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5641760495865538" CI_START="-2.7558239504134465" DF="0" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-013.06.01" MODIFIED="2013-03-14 19:03:46 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.0029873607862180083" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="203" WEIGHT="100.0" Z="2.9690355034756752">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.5641760495865538" CI_START="-2.7558239504134465" EFFECT_SIZE="-1.6600000000000001" ESTIMABLE="YES" MEAN_1="-0.56" MEAN_2="1.1" MODIFIED="2008-07-11 14:36:19 -0400" MODIFIED_BY="Anne Lethaby" ORDER="770" SD_1="3.7" SD_2="7.1" SE="0.559104125921275" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="203" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.4074325387858556" CI_START="-1.8325674612141447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.12" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.07" MODIFIED="2013-03-14 19:03:56 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.002065602737832231" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="203" UNITS="" WEIGHT="100.0" Z="3.080634160510958">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4074325387858556" CI_START="-1.8325674612141447" DF="0" EFFECT_SIZE="-1.12" ESTIMABLE="YES" I2="0.0" ID="CMP-013.07.01" MODIFIED="2013-03-14 19:03:56 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.002065602737832231" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="203" WEIGHT="100.0" Z="3.080634160510958">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.4074325387858556" CI_START="-1.8325674612141447" EFFECT_SIZE="-1.12" ESTIMABLE="YES" MEAN_1="-0.76" MEAN_2="0.36" MODIFIED="2008-07-11 14:37:15 -0400" MODIFIED_BY="Anne Lethaby" ORDER="771" SD_1="2.8" SD_2="4.4" SE="0.3635615076780929" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="203" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.005315519864382612" CI_START="-1.0853155198643827" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.54" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.08" MODIFIED="2013-03-14 19:04:05 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.052275378470965785" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="203" UNITS="" WEIGHT="100.0" Z="1.940859031327118">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.005315519864382612" CI_START="-1.0853155198643827" DF="0" EFFECT_SIZE="-0.54" ESTIMABLE="YES" I2="0.0" ID="CMP-013.08.01" MODIFIED="2013-03-14 19:04:05 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.052275378470965785" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="203" WEIGHT="100.0" Z="1.940859031327118">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.005315519864382612" CI_START="-1.0853155198643827" EFFECT_SIZE="-0.54" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.74" MODIFIED="2008-07-11 14:38:04 -0400" MODIFIED_BY="Anne Lethaby" ORDER="772" SD_1="1.7" SD_2="3.6" SE="0.2782273165046714" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="203" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2905286663045787" CI_START="1.0184113160560273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1464244403619785" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-013.09" LOG_CI_END="0.11076765590013053" LOG_CI_START="0.007923216326456975" LOG_EFFECT_SIZE="0.05934543611329375" METHOD="MH" MODIFIED="2013-03-14 19:04:23 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.023699979110846956" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="203" WEIGHT="99.99999999999999" Z="2.2619583112328616">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2905286663045787" CI_START="1.0184113160560273" DF="0" EFFECT_SIZE="1.1464244403619785" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="138" I2="0.0" ID="CMP-013.09.01" LOG_CI_END="0.11076765590013053" LOG_CI_START="0.007923216326456975" LOG_EFFECT_SIZE="0.05934543611329375" MODIFIED="2013-03-14 19:04:23 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.023699979110846956" STUDIES="1" TAU2="0.0" TOTAL_1="213" TOTAL_2="203" WEIGHT="99.99999999999999" Z="2.2619583112328616">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2905286663045787" CI_START="1.0184113160560273" EFFECT_SIZE="1.1464244403619785" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="138" LOG_CI_END="0.11076765590013053" LOG_CI_START="0.007923216326456975" LOG_EFFECT_SIZE="0.05934543611329375" MODIFIED="2008-10-11 11:28:26 -0400" MODIFIED_BY="Anne Lethaby" ORDER="476" O_E="0.0" SE="0.06041133289376225" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="213" TOTAL_2="203" VAR="0.003649529142000961" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.016065074143257363" CI_START="-0.6160650741432578" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.10" MODIFIED="2012-02-22 15:17:46 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.06283712664926613" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" UNITS="" WEIGHT="99.99999999999999" Z="1.8603421999594572">
<NAME>DAS</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.016065074143257363" CI_START="-0.6160650741432578" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.7" MODIFIED="2012-01-31 13:31:39 -0500" MODIFIED_BY="[Empty name]" ORDER="511" SD_1="1.2" SD_2="1.1" SE="0.1612606540917785" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2013-03-14 19:06:42 -0400" MODIFIED_BY="Anne Lethaby" NO="14">
<NAME>Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3053214222637286" CI_START="1.0713724593445964" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1825757575757576" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="160" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.11571746548850295" LOG_CI_START="0.029940478224632416" LOG_EFFECT_SIZE="0.07282897185656766" METHOD="MH" MODIFIED="2013-03-14 19:05:07 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="8.740413504397017E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="99.99999999999999" Z="3.3282157936101147">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3053214222637286" CI_START="1.0713724593445964" DF="0" EFFECT_SIZE="1.1825757575757576" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="160" I2="0.0" ID="CMP-014.01.01" LOG_CI_END="0.11571746548850295" LOG_CI_START="0.029940478224632416" LOG_EFFECT_SIZE="0.07282897185656766" MODIFIED="2013-03-14 19:05:07 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="8.740413504397017E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="99.99999999999999" Z="3.3282157936101147">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3053214222637286" CI_START="1.0713724593445964" EFFECT_SIZE="1.1825757575757576" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="160" LOG_CI_END="0.11571746548850295" LOG_CI_START="0.029940478224632416" LOG_EFFECT_SIZE="0.07282897185656766" MODIFIED="2008-07-11 14:41:00 -0400" MODIFIED_BY="Anne Lethaby" ORDER="773" O_E="0.0" SE="0.05038582692173243" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.0025387315545867765" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6681634747354214E-30" CI_END="1.7082236902680736" CI_START="1.2195736095105492" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.44336569579288" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="103" I2="100.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.23254474052635812" LOG_CI_START="0.08620801804825624" LOG_EFFECT_SIZE="0.15937637928730713" METHOD="MH" MODIFIED="2013-03-14 19:05:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="1.9615613169212203E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.26922180707254">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6681634747354214E-30" CI_END="1.7082236902680736" CI_START="1.2195736095105492" DF="0" EFFECT_SIZE="1.44336569579288" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="103" I2="100.0" ID="CMP-014.02.01" LOG_CI_END="0.23254474052635812" LOG_CI_START="0.08620801804825624" LOG_EFFECT_SIZE="0.15937637928730713" MODIFIED="2013-03-14 19:05:18 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.0" P_Z="1.9615613169212203E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.26922180707254">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7082236902680736" CI_START="1.2195736095105492" EFFECT_SIZE="1.4433656957928802" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="103" LOG_CI_END="0.23254474052635812" LOG_CI_START="0.08620801804825624" LOG_EFFECT_SIZE="0.15937637928730722" MODIFIED="2008-07-11 14:42:03 -0400" MODIFIED_BY="Anne Lethaby" ORDER="774" O_E="0.0" SE="0.08595891516209594" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.007388935095844407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6601635954136507" CI_START="1.5613476126227308" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.037999037999038" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.4249083458042574" LOG_CI_START="0.19349960353478343" LOG_EFFECT_SIZE="0.30920397466952043" METHOD="MH" MODIFIED="2013-03-14 19:05:29 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.625606158721119E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="5.23773344330422">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6601635954136507" CI_START="1.5613476126227308" DF="0" EFFECT_SIZE="2.037999037999038" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="54" I2="0.0" ID="CMP-014.03.01" LOG_CI_END="0.4249083458042574" LOG_CI_START="0.19349960353478343" LOG_EFFECT_SIZE="0.30920397466952043" MODIFIED="2013-03-14 19:05:29 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="1.625606158721119E-7" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="5.23773344330422">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.6601635954136507" CI_START="1.5613476126227308" EFFECT_SIZE="2.037999037999038" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="54" LOG_CI_END="0.4249083458042574" LOG_CI_START="0.19349960353478343" LOG_EFFECT_SIZE="0.30920397466952043" MODIFIED="2008-07-11 14:42:39 -0400" MODIFIED_BY="Anne Lethaby" ORDER="775" O_E="0.0" SE="0.13593064070083746" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.018477139081340167" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5392657585933627" CI_START="1.4075079041873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8905122655122655" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="0.4047081563485665" LOG_CI_START="0.14845084241168907" LOG_EFFECT_SIZE="0.2765794993801278" METHOD="MH" MODIFIED="2013-03-14 19:05:41 -0400" MODIFIED_BY="Anne Lethaby" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="2.3286863286945253E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.230793254788411">
<NAME>Remission (DAS &lt; 1.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5392657585933627" CI_START="1.4075079041873" DF="0" EFFECT_SIZE="1.8905122655122655" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="48" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="0.4047081563485665" LOG_CI_START="0.14845084241168907" LOG_EFFECT_SIZE="0.2765794993801278" MODIFIED="2013-03-14 19:05:41 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="2.3286863286945253E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.230793254788411">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.5392657585933627" CI_START="1.4075079041873" EFFECT_SIZE="1.8905122655122655" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="48" LOG_CI_END="0.4047081563485665" LOG_CI_START="0.14845084241168907" LOG_EFFECT_SIZE="0.2765794993801278" MODIFIED="2008-10-10 15:28:12 -0400" MODIFIED_BY="Anne Lethaby" ORDER="467" O_E="0.0" SE="0.15052681470068383" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.022658321943934003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.63875692453977" CI_START="1.4435658983371291" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9517221908526257" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="0.4213993859786085" LOG_CI_START="0.15943661407814635" LOG_EFFECT_SIZE="0.2904180000283774" METHOD="MH" MODIFIED="2013-03-14 19:05:56 -0400" MODIFIED_BY="Anne Lethaby" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.3881766505217811E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.3457229925331085">
<NAME>Remission (DAS &lt; 2.6)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.63875692453977" CI_START="1.4435658983371291" DF="0" EFFECT_SIZE="1.9517221908526257" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="46" I2="0.0" ID="CMP-014.05.01" LOG_CI_END="0.4213993859786085" LOG_CI_START="0.15943661407814635" LOG_EFFECT_SIZE="0.2904180000283774" MODIFIED="2013-03-14 19:05:56 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="1.3881766505217811E-5" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="4.3457229925331085">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.63875692453977" CI_START="1.4435658983371291" EFFECT_SIZE="1.9517221908526257" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="46" LOG_CI_END="0.4213993859786085" LOG_CI_START="0.15943661407814635" LOG_EFFECT_SIZE="0.2904180000283774" MODIFIED="2008-07-11 14:45:29 -0400" MODIFIED_BY="Anne Lethaby" ORDER="776" O_E="0.0" SE="0.15387822895096587" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.02367850934508587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2302892544348485" CI_START="-3.2697107455651517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.75" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.06" MODIFIED="2013-03-14 19:06:10 -0400" MODIFIED_BY="Anne Lethaby" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.02401013808286602" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="211" UNITS="" WEIGHT="100.0" Z="2.2569669806931363">
<NAME>Change in Total Sharp Score (TSS) (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2302892544348485" CI_START="-3.2697107455651517" DF="0" EFFECT_SIZE="-1.75" ESTIMABLE="YES" I2="0.0" ID="CMP-014.06.01" MODIFIED="2013-03-14 19:06:10 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.02401013808286602" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0" Z="2.2569669806931363">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.2302892544348485" CI_START="-3.2697107455651517" EFFECT_SIZE="-1.75" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="1.61" MODIFIED="2008-07-11 14:46:47 -0400" MODIFIED_BY="Anne Lethaby" ORDER="777" SD_1="7.0" SD_2="8.9" SE="0.7753768730203391" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.13874216985998644" CI_START="-1.9812578301400137" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.06" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.07" MODIFIED="2013-03-14 19:06:21 -0400" MODIFIED_BY="Anne Lethaby" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.024124785037792345" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="211" UNITS="" WEIGHT="100.0" Z="2.255136136315615">
<NAME>Change in Erosion Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.13874216985998644" CI_START="-1.9812578301400137" DF="0" EFFECT_SIZE="-1.06" ESTIMABLE="YES" I2="0.0" ID="CMP-014.07.01" MODIFIED="2013-03-14 19:06:21 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.024124785037792345" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0" Z="2.255136136315615">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.13874216985998644" CI_START="-1.9812578301400137" EFFECT_SIZE="-1.06" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="0.39" MODIFIED="2008-07-11 14:47:43 -0400" MODIFIED_BY="Anne Lethaby" ORDER="778" SD_1="2.9" SD_2="6.2" SE="0.47003814223464196" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2695525728941105" CI_START="-1.6495525728941103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.69" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.08" MODIFIED="2013-03-14 19:06:28 -0400" MODIFIED_BY="Anne Lethaby" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.15872254389664217" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="211" UNITS="" WEIGHT="100.0" Z="1.4093809839451872">
<NAME>Change in Joint Space Narrowing Score (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2695525728941105" CI_START="-1.6495525728941103" DF="0" EFFECT_SIZE="-0.69" ESTIMABLE="YES" I2="0.0" ID="CMP-014.08.01" MODIFIED="2013-03-14 19:06:28 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.15872254389664217" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0" Z="1.4093809839451872">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.2695525728941105" CI_START="-1.6495525728941103" EFFECT_SIZE="-0.69" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="1.22" MODIFIED="2008-07-11 14:48:34 -0400" MODIFIED_BY="Anne Lethaby" ORDER="779" SD_1="5.5" SD_2="4.6" SE="0.48957663531725004" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.23589197532292494" CI_START="0.06209653670013847" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.1489942560115317" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="129" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="-0.6272868328840122" LOG_CI_START="-1.2069326209822282" LOG_EFFECT_SIZE="-0.8268304740748436" METHOD="MH" MODIFIED="2013-03-14 19:06:42 -0400" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="7.778989606682977E-4" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0" Z="3.3605413122465593">
<NAME>No progression of joint damage (TSS &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.23589197532292494" CI_START="0.06209653670013847" DF="0" EFFECT_SIZE="0.1489942560115317" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="129" I2="0.0" ID="CMP-014.09.01" LOG_CI_END="-0.6272868328840122" LOG_CI_START="-1.2069326209822282" LOG_EFFECT_SIZE="-0.8268304740748436" MODIFIED="2013-03-14 19:06:42 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="7.778989606682977E-4" STUDIES="1" TAU2="0.0" TOTAL_1="217" TOTAL_2="211" WEIGHT="100.0" Z="3.3605413122465593">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.23589197532292494" CI_START="0.06209653670013847" EFFECT_SIZE="0.1489942560115317" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="129" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-10 15:53:09 -0400" MODIFIED_BY="Anne Lethaby" ORDER="470" O_E="0.0" SE="0.0443363857687342" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="217" TOTAL_2="211" VAR="0.0019657151030340165" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2013-03-14 19:07:57 -0400" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Efficacy at six months: etanercept vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.08856367081200306" CI_END="7.752984297526178" CI_START="3.1019770682002283" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.904037061548643" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.8894689043739136" LOG_CI_START="0.49163858290669216" LOG_EFFECT_SIZE="0.6905537436403028" METHOD="MH" MODIFIED="2013-03-14 19:07:45 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7660111688092442" P_Q="0.7660824260548927" P_Z="1.0160544619306216E-11" Q="0.08850811823258448" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="6.8042097039393985">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.766188411867304" CI_START="2.373483319348923" DF="0" EFFECT_SIZE="4.56140350877193" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="9" I2="0.0" ID="CMP-015.01.01" LOG_CI_END="0.9428108007184586" LOG_CI_START="0.37538618387819456" LOG_EFFECT_SIZE="0.6590984922983265" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.28267669041569E-6" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="4.553236743103898">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.766188411867304" CI_START="2.373483319348923" EFFECT_SIZE="4.56140350877193" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="9" LOG_CI_END="0.9428108007184586" LOG_CI_START="0.37538618387819456" LOG_EFFECT_SIZE="0.6590984922983265" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" ORDER="7529" O_E="0.0" SE="0.33330802872912413" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.11109424201529464" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.968604902184852" CI_START="2.7566842798777613" DF="0" EFFECT_SIZE="5.2421652421652425" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="9" I2="0.0" ID="CMP-015.01.02" LOG_CI_END="0.9986343834192503" LOG_CI_START="0.4403870296681745" LOG_EFFECT_SIZE="0.7195107065437124" MODIFIED="2012-02-20 08:47:16 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.3653348109420836E-7" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="5.052294692812691">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="9.968604902184852" CI_START="2.7566842798777613" EFFECT_SIZE="5.2421652421652425" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="9" LOG_CI_END="0.9986343834192503" LOG_CI_START="0.4403870296681745" LOG_EFFECT_SIZE="0.7195107065437124" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" ORDER="7530" O_E="0.0" SE="0.32791725896234997" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.10752972872538089" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5033349615040897" CI_END="12.981670692960531" CI_START="3.109445500110999" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="6.353408338848445" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="1.113330588153291" LOG_CI_START="0.49268294924779515" LOG_EFFECT_SIZE="0.8030067687005431" METHOD="MH" MODIFIED="2013-03-14 19:07:49 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4780384776159571" P_Q="0.47988222809529235" P_Z="3.943107838064772E-7" Q="0.4991310594662647" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="5.071683987295724">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.360419921388742" CI_START="1.6794137656012864" DF="0" EFFECT_SIZE="4.7368421052631575" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" I2="0.0" ID="CMP-015.02.01" LOG_CI_END="1.1258201083398243" LOG_CI_START="0.22515770863316764" LOG_EFFECT_SIZE="0.6754889084864959" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0032830586471339325" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="2.9399116317523784">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="13.360419921388742" CI_START="1.679413765601286" EFFECT_SIZE="4.7368421052631575" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="1.1258201083398243" LOG_CI_START="0.22515770863316753" LOG_EFFECT_SIZE="0.6754889084864959" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" ORDER="7532" O_E="0.0" SE="0.529053551938472" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.2798976608187135" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.466572319046385" CI_START="2.943279257127233" DF="0" EFFECT_SIZE="7.94871794871795" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" I2="0.0" ID="CMP-015.02.02" LOG_CI_END="1.331762703878927" LOG_CI_START="0.4688314697366198" LOG_EFFECT_SIZE="0.9002970868077735" MODIFIED="2012-02-20 08:47:28 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.319965266119743E-5" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="4.089665075765637">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="21.466572319046385" CI_START="2.943279257127233" EFFECT_SIZE="7.948717948717949" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" LOG_CI_END="1.331762703878927" LOG_CI_START="0.4688314697366198" LOG_EFFECT_SIZE="0.9002970868077734" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" ORDER="7533" O_E="0.0" SE="0.5068900785136913" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.25693755169561616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12235933071455281" CI_END="41.64957807509787" CI_START="2.331577526537731" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="9.85440105890139" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="1.619610606208955" LOG_CI_START="0.3676498606173464" LOG_EFFECT_SIZE="0.9936302334131508" METHOD="MH" MODIFIED="2013-03-14 19:07:57 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.726489622938101" P_Q="0.727957501748518" P_Z="0.001863999411071281" Q="0.12099535716026973" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="3.1110871140286913">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="58.48903190552811" CI_START="0.9282702592267162" DF="0" EFFECT_SIZE="7.368421052631579" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-015.03.01" LOG_CI_END="1.7670744330992332" LOG_CI_START="-0.03232556364841511" LOG_EFFECT_SIZE="0.8673744347254091" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.058818984788109874" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="1.8895439104649554">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="58.48903190552811" CI_START="0.9282702592267162" EFFECT_SIZE="7.368421052631579" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7670744330992332" LOG_CI_START="-0.03232556364841511" LOG_EFFECT_SIZE="0.8673744347254091" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" ORDER="7535" O_E="0.0" SE="1.0569764652632057" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="1.1171992481203008" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="92.41030659850975" CI_START="1.63920341265561" DF="0" EFFECT_SIZE="12.307692307692308" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="0.0" ID="CMP-015.03.02" LOG_CI_END="1.9657204111469375" LOG_CI_START="0.21463284955123846" LOG_EFFECT_SIZE="1.090176630349088" MODIFIED="2012-02-20 08:47:42 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.014669620618820375" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="2.4404341383412596">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="92.41030659850975" CI_START="1.63920341265561" EFFECT_SIZE="12.307692307692308" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9657204111469375" LOG_CI_START="0.21463284955123846" LOG_EFFECT_SIZE="1.090176630349088" MODIFIED="2012-02-17 16:14:17 -0500" MODIFIED_BY="[Empty name]" ORDER="7536" O_E="0.0" SE="1.0285975017045397" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="1.0580128205128205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2013-03-14 19:08:23 -0400" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Quality of life at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<CONT_OUTCOME CHI2="2.2088519922405365" CI_END="-0.2056683211015201" CI_START="-0.773053127314508" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4893607242080141" ESTIMABLE="YES" I2="54.72761400433826" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2012-02-23 08:48:19 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13722083926615647" P_Q="1.0" P_Z="7.225462507185073E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.024627426301952197" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" UNITS="" WEIGHT="100.0" Z="3.380877966394126">
<NAME>HAQ: final value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.41861746894126906" CI_START="-0.7813825310587309" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.5" MODIFIED="2012-01-31 09:57:52 -0500" MODIFIED_BY="[Empty name]" ORDER="449" SD_1="0.6" SD_2="0.5" SE="0.0925438081972185" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" WEIGHT="63.12024140267135"/>
<CONT_DATA CI_END="0.051598042218585216" CI_START="-0.6515980422185853" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.1" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7608" SD_1="0.8" SD_2="0.8" SE="0.1793900525682848" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" WEIGHT="36.87975859732865"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="25.442470009627666" CI_START="11.757529990372337" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="18.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.02" MODIFIED="2012-02-22 15:00:23 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="9.940802765905424E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="5.327802688378717">
<NAME>EuroQoL VAS</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_DATA CI_END="25.442470009627666" CI_START="11.757529990372337" EFFECT_SIZE="18.6" ESTIMABLE="YES" MEAN_1="72.2" MEAN_2="53.6" MODIFIED="2012-01-31 11:36:04 -0500" MODIFIED_BY="[Empty name]" ORDER="457" SD_1="22.4" SD_2="19.0" SE="3.4911202775154004" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2013-03-18 11:19:29 -0400" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.341723795397682" CI_START="1.11113273559059" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.220996818663839" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="164" I2="0.0" I2_Q="100.0" ID="CMP-017.01" LOG_CI_END="0.1276631220322459" LOG_CI_START="0.04576594273132773" LOG_EFFECT_SIZE="0.08671453238178684" METHOD="MH" MODIFIED="2013-03-18 11:18:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="3.317413060848955E-5" Q="3.3287975626853628E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="230" TOTAL_2="228" WEIGHT="100.0" Z="4.150505838059528">
<NAME>Satisfaction with treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.341723795397682" CI_START="1.11113273559059" DF="0" EFFECT_SIZE="1.220996818663839" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="164" I2="0.0" ID="CMP-017.01.01" LOG_CI_END="0.1276631220322459" LOG_CI_START="0.04576594273132773" LOG_EFFECT_SIZE="0.08671453238178684" MODIFIED="2013-03-18 11:18:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.317413060848955E-5" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="228" WEIGHT="100.0" Z="4.150505838059528">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.341723795397682" CI_START="1.11113273559059" EFFECT_SIZE="1.220996818663839" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="164" LOG_CI_END="0.1276631220322459" LOG_CI_START="0.04576594273132773" LOG_EFFECT_SIZE="0.08671453238178684" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7615" O_E="0.0" SE="0.048106808518935056" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="230" TOTAL_2="228" VAR="0.0023142650258774827" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.157353271730206" CI_END="-0.15277664108805353" CI_START="-0.333149304377773" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24296297273291328" ESTIMABLE="YES" I2="13.595958604322073" I2_Q="0.0" ID="CMP-017.02" MODIFIED="2013-03-18 11:18:13 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28201517347276006" P_Q="1.0" P_Z="1.290678820771765E-7" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="496" TOTAL_2="491" UNITS="" WEIGHT="100.0" Z="5.280164604194084">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.157353271730206" CI_END="-0.15277664108805353" CI_START="-0.333149304377773" DF="1" EFFECT_SIZE="-0.24296297273291328" ESTIMABLE="YES" I2="13.595958604322073" ID="CMP-017.02.01" MODIFIED="2013-03-18 11:18:13 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28201517347276006" P_Z="1.290678820771765E-7" STUDIES="2" TAU2="0.0" TOTAL_1="496" TOTAL_2="491" WEIGHT="100.0" Z="5.280164604194084">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.08058406564026602" CI_START="-0.31941593435973414" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.9" MODIFIED="2010-05-21 00:45:37 -0400" MODIFIED_BY="[Empty name]" ORDER="442" SD_1="0.7" SD_2="0.7" SE="0.060927616681567466" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" WEIGHT="57.037027267086735"/>
<CONT_DATA CI_END="-0.16240788061339995" CI_START="-0.43759211938660014" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.1" MODIFIED="2008-07-15 15:03:12 -0400" MODIFIED_BY="Anne Lethaby" ORDER="7616" SD_1="0.7" SD_2="0.8" SE="0.07020135087782693" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" WEIGHT="42.96297273291326"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7107728267952689" CI_END="10.540889779725925" CI_START="4.66645479792019" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="7.6036722888230575" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.03" MODIFIED="2013-03-18 11:18:28 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3991878435740148" P_Q="1.0" P_Z="3.8990023760737316E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="496" TOTAL_2="491" UNITS="" WEIGHT="100.0" Z="5.073823740494424">
<NAME>EQ-5D VAS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7107728267952689" CI_END="10.540889779725925" CI_START="4.66645479792019" DF="1" EFFECT_SIZE="7.6036722888230575" ESTIMABLE="YES" I2="0.0" ID="CMP-017.03.01" MODIFIED="2013-03-18 11:18:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3991878435740148" P_Z="3.8990023760737316E-7" STUDIES="2" TAU2="0.0" TOTAL_1="496" TOTAL_2="491" WEIGHT="100.0" Z="5.073823740494424">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="10.400073954468338" CI_START="2.5999260455316624" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="72.8" MEAN_2="66.3" MODIFIED="2010-05-21 00:47:34 -0400" MODIFIED_BY="[Empty name]" ORDER="720" SD_1="22.2" SD_2="23.5" SE="1.9898702145710958" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" WEIGHT="56.71873377164477"/>
<CONT_DATA CI_END="13.514636719227681" CI_START="4.585363280772313" EFFECT_SIZE="9.049999999999997" ESTIMABLE="YES" MEAN_1="72.71" MEAN_2="63.66" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7617" SD_1="24.3" SD_2="24.5" SE="2.277917734429902" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" WEIGHT="43.28126622835523"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3687846803710504" CI_END="1.57865957392069" CI_START="1.1719960308918995" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.360214231202036" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="171" I2="0.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="0.19828848776165423" LOG_CI_START="0.06892614089310856" LOG_EFFECT_SIZE="0.1336073143273814" METHOD="MH" MODIFIED="2013-03-18 11:18:37 -0400" MODIFIED_BY="Anne Lethaby" NO="4" P_CHI2="0.543667739906988" P_Q="1.0" P_Z="5.153402106892364E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="487" TOTAL_2="469" WEIGHT="100.0" Z="4.04855864927822">
<NAME>Reduction to normal health assessment (HAQ &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3687846803710504" CI_END="1.57865957392069" CI_START="1.1719960308918995" DF="1" EFFECT_SIZE="1.360214231202036" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="171" I2="0.0" ID="CMP-017.04.01" LOG_CI_END="0.19828848776165423" LOG_CI_START="0.06892614089310856" LOG_EFFECT_SIZE="0.1336073143273814" MODIFIED="2008-10-08 17:06:03 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.543667739906988" P_Z="5.153402106892364E-5" STUDIES="2" TAU2="0.0" TOTAL_1="487" TOTAL_2="469" WEIGHT="100.0" Z="4.04855864927822">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7213066976363585" CI_START="1.1667721926886374" EFFECT_SIZE="1.4171706989247312" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="93" LOG_CI_END="0.23585825860416396" LOG_CI_START="0.06698607017047958" LOG_EFFECT_SIZE="0.15142216438732176" MODIFIED="2008-10-08 17:02:23 -0400" MODIFIED_BY="Anne Lethaby" ORDER="443" O_E="0.0" SE="0.09919635941676065" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="256" TOTAL_2="241" VAR="0.009839917721539158" WEIGHT="54.96138424643831"/>
<DICH_DATA CI_END="1.6263641047596766" CI_START="1.0243281121661563" EFFECT_SIZE="1.2907092907092907" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="78" LOG_CI_END="0.2112177804868254" LOG_CI_START="0.010439091872667876" LOG_EFFECT_SIZE="0.11082843617974665" MODIFIED="2008-10-08 17:06:03 -0400" MODIFIED_BY="Anne Lethaby" ORDER="444" O_E="0.0" SE="0.11793839556249373" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.013909465147855241" WEIGHT="45.03861575356169"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.730405959356814" CI_START="0.1746303117796069" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-017.05" LOG_CI_END="-0.136435692065732" LOG_CI_START="-0.7578803706187063" LOG_EFFECT_SIZE="-0.4471580313422192" METHOD="MH" MODIFIED="2012-02-22 15:22:17 -0500" MODIFIED_BY="Anne Lethaby" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.004793864007287581" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="100" WEIGHT="100.0" Z="2.8205684820386585">
<NAME>Proportion stopping work</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.730405959356814" CI_START="0.1746303117796069" DF="0" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" I2="0.0" ID="CMP-017.05.01" LOG_CI_END="-0.136435692065732" LOG_CI_START="-0.7578803706187063" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2008-10-08 17:16:28 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.004793864007287581" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="100" WEIGHT="100.0" Z="2.8205684820386585">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.730405959356814" CI_START="0.1746303117796069" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.136435692065732" LOG_CI_START="-0.7578803706187063" LOG_EFFECT_SIZE="-0.4471580313422192" MODIFIED="2008-10-08 17:16:28 -0400" MODIFIED_BY="Anne Lethaby" ORDER="447" O_E="0.0" SE="0.3650396803827883" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="105" TOTAL_2="100" VAR="0.13325396825396824" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.59982124631482" CI_START="1.0001787536851745" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.06" MODIFIED="2013-03-18 11:19:13 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0022950081543913845" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="265" TOTAL_2="263" UNITS="" WEIGHT="100.0" Z="3.049135667194035">
<NAME>SF-36 Physical domain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.59982124631482" CI_START="1.0001787536851745" DF="0" EFFECT_SIZE="2.799999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-017.06.01" MODIFIED="2013-03-18 11:19:13 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0022950081543913845" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="263" WEIGHT="100.0" Z="3.049135667194035">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="4.59982124631482" CI_START="1.0001787536851747" EFFECT_SIZE="2.799999999999997" ESTIMABLE="YES" MEAN_1="43.0" MEAN_2="40.2" MODIFIED="2010-05-21 00:57:58 -0400" MODIFIED_BY="[Empty name]" ORDER="722" SD_1="10.5" SD_2="10.6" SE="0.9182930199287246" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.553607522053025" CI_START="-1.3536075220530226" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.07" MODIFIED="2013-03-18 11:19:29 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5472059437561496" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="265" TOTAL_2="263" UNITS="" WEIGHT="100.0" Z="0.6019522229768102">
<NAME>SF-36 Mental domain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.553607522053025" CI_START="-1.3536075220530226" DF="0" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-017.07.01" MODIFIED="2013-03-18 11:19:29 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5472059437561496" STUDIES="1" TAU2="0.0" TOTAL_1="265" TOTAL_2="263" WEIGHT="100.0" Z="0.6019522229768102">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="2.553607522053025" CI_START="-1.3536075220530226" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="48.9" MEAN_2="48.3" MODIFIED="2010-05-21 00:59:58 -0400" MODIFIED_BY="[Empty name]" ORDER="723" SD_1="11.7" SD_2="11.2" SE="0.9967568473006804" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="265" TOTAL_2="263" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2013-03-18 11:20:37 -0400" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.55172213020553" CI_START="17.44827786979447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="20.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-018.01" MODIFIED="2013-03-18 11:20:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.9484298344057815E-53" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" UNITS="" WEIGHT="100.0" Z="15.361891965738351">
<NAME>Percentage improvement in HAQ (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.55172213020553" CI_START="17.44827786979447" DF="0" EFFECT_SIZE="20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-018.01.01" MODIFIED="2013-03-18 11:20:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.9484298344057815E-53" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="15.361891965738351">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="22.55172213020553" CI_START="17.44827786979447" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="36.0" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7629" SD_1="10.6" SD_2="16.6" SE="1.3019229691633054" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.964591050330915" CI_END="-0.2957247614490929" CI_START="-0.6860946046980483" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4909096830735706" ESTIMABLE="YES" I2="66.26853474821165" I2_Q="0.0" ID="CMP-018.02" MODIFIED="2013-03-18 11:20:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08510614887242363" P_Q="1.0" P_Z="8.243768238498526E-7" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.01325370694964232" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" UNITS="" WEIGHT="100.0" Z="4.929506288079517">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.964591050330915" CI_END="-0.2957247614490929" CI_START="-0.6860946046980483" DF="1" EFFECT_SIZE="-0.4909096830735706" ESTIMABLE="YES" I2="66.26853474821165" ID="CMP-018.02.01" MODIFIED="2013-03-18 11:20:37 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08510614887242363" P_Z="8.243768238498526E-7" STUDIES="2" TAU2="0.01325370694964232" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="4.929506288079517">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.41861746894126917" CI_START="-0.781382531058731" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.6" MODIFIED="2012-01-31 14:13:21 -0500" MODIFIED_BY="[Empty name]" ORDER="529" SD_1="0.6" SD_2="0.5" SE="0.0925438081972185" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" WEIGHT="45.45484153678525"/>
<CONT_DATA CI_END="-0.26240788061340004" CI_START="-0.5375921193866002" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.1" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7630" SD_1="0.7" SD_2="0.8" SE="0.07020135087782693" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" WEIGHT="54.54515846321475"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2013-03-18 11:20:53 -0400" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Quality of life at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<CONT_OUTCOME CHI2="6.038012365468284" CI_END="0.7207392121538899" CI_START="-0.8319952801150549" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.055628033980582456" ESTIMABLE="YES" I2="83.43825849514563" I2_Q="0.0" ID="CMP-019.01" MODIFIED="2012-02-23 09:04:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.014001095857588353" P_Q="1.0" P_Z="0.8883165003317052" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.2670024271844662" TOTALS="SUB" TOTAL_1="115" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.14043475388170526">
<NAME>HAQ score: final value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.038012365468284" CI_END="0.7207392121538899" CI_START="-0.8319952801150549" DF="1" EFFECT_SIZE="-0.055628033980582456" ESTIMABLE="YES" I2="83.43825849514563" ID="CMP-019.01.01" MODIFIED="2012-01-31 10:02:22 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.014001095857588353" P_Z="0.8883165003317052" STUDIES="2" TAU2="0.2670024271844662" TOTAL_1="115" TOTAL_2="62" WEIGHT="100.0" Z="0.14043475388170526">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.21935185548268918" CI_START="-0.5806481445173106" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.5" MODIFIED="2012-01-31 10:02:22 -0500" MODIFIED_BY="[Empty name]" ORDER="450" SD_1="0.6" SD_2="0.5" SE="0.09216911430120157" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" WEIGHT="56.95350424757281"/>
<CONT_DATA CI_END="1.0119985580192794" CI_START="-0.21199855801927936" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.6" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7613" SD_1="0.9" SD_2="0.6" SE="0.3122498999199199" STUDY_ID="STD-Marcora-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="43.046495752427184"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="27.982516471932684" CI_START="14.617483528067325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="21.300000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-019.02" MODIFIED="2012-02-22 15:27:06 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="4.177894259916566E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="6.247232318251102">
<NAME>EuroQoL VAS</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.982516471932684" CI_START="14.617483528067325" DF="0" EFFECT_SIZE="21.300000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-019.02.01" MODIFIED="2012-02-22 15:27:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.177894259916566E-10" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="6.247232318251102">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="27.982516471932684" CI_START="14.617483528067325" EFFECT_SIZE="21.300000000000004" ESTIMABLE="YES" MEAN_1="74.9" MEAN_2="53.6" MODIFIED="2012-01-31 11:36:46 -0500" MODIFIED_BY="[Empty name]" ORDER="457" SD_1="21.3" SD_2="19.0" SE="3.409509830100714" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2013-03-18 11:25:03 -0400" MODIFIED_BY="Anne Lethaby" NO="20">
<NAME>Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<CONT_OUTCOME CHI2="3.392529867392759E-32" CI_END="0.04767483487841641" CI_START="-0.24767483487841657" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10000000000000007" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-020.01" MODIFIED="2013-03-18 11:21:45 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.1844372527812033" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" UNITS="" WEIGHT="100.0" Z="1.3272159648282198">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.392529867392759E-32" CI_END="0.04767483487841641" CI_START="-0.24767483487841657" DF="0" EFFECT_SIZE="-0.10000000000000007" ESTIMABLE="YES" I2="100.0" ID="CMP-020.01.01" MODIFIED="2013-03-18 11:21:45 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.1844372527812033" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.3272159648282198">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.047674834878416394" CI_START="-0.24767483487841657" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.1" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7618" SD_1="0.8" SD_2="0.8" SE="0.07534568800409433" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16897582247253348" CI_START="-0.10897582247253343" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.02" MODIFIED="2013-03-18 11:21:58 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.672231495398492" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" UNITS="" WEIGHT="100.00000000000001" Z="0.4230874010320927">
<NAME>HAQ score: change from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16897582247253348" CI_START="-0.10897582247253343" DF="0" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" I2="0.0" ID="CMP-020.02.01" MODIFIED="2013-03-18 11:21:58 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.672231495398492" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.00000000000001" Z="0.4230874010320927">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.16897582247253348" CI_START="-0.10897582247253343" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-0.76" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7619" SD_1="0.72" SD_2="0.74" SE="0.07090733481265829" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2456792607496947" CI_START="0.9588904360502205" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0929180799671085" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="141" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.09540623396201782" LOG_CI_START="-0.018231012993201984" LOG_EFFECT_SIZE="0.03858761048440792" METHOD="MH" MODIFIED="2013-03-18 11:22:21 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.18316156880830242" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="1.3310834048752131">
<NAME>Proportion of participants whose HAQ scores improved from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2456792607496947" CI_START="0.9588904360502205" DF="0" EFFECT_SIZE="1.0929180799671085" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="141" I2="0.0" ID="CMP-020.03.01" LOG_CI_END="0.09540623396201782" LOG_CI_START="-0.018231012993201984" LOG_EFFECT_SIZE="0.03858761048440792" MODIFIED="2013-03-18 11:22:21 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18316156880830242" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="1.3310834048752131">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2456792607496947" CI_START="0.9588904360502205" EFFECT_SIZE="1.0929180799671085" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="141" LOG_CI_END="0.09540623396201782" LOG_CI_START="-0.018231012993201984" LOG_EFFECT_SIZE="0.03858761048440792" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7620" O_E="0.0" SE="0.06675108137494064" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.004455706864723946" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.3170010236515877" CI_START="-1.1170010236515884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.04" MODIFIED="2013-03-18 11:22:42 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3308182758099487" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" UNITS="" WEIGHT="100.0" Z="0.9724670218884293">
<NAME>SF-36 score - physical domain: change from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3170010236515877" CI_START="-1.1170010236515884" DF="0" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-020.04.01" MODIFIED="2013-03-18 11:22:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3308182758099487" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.9724670218884293">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="3.3170010236515877" CI_START="-1.1170010236515884" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="9.6" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7621" SD_1="11.51" SD_2="11.78" SE="1.131143756282773" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2303356693492626" CI_START="0.9202787984257524" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0640732265446224" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="133" I2="0.0" I2_Q="0.0" ID="CMP-020.05" LOG_CI_END="0.09002361506380124" LOG_CI_START="-0.03608058322473712" LOG_EFFECT_SIZE="0.026971515919532087" METHOD="MH" MODIFIED="2013-03-18 11:23:01 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4018032492804592" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.8384050733945527">
<NAME>Proportion of participants whose SF-36 (physical) scores improved from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2303356693492626" CI_START="0.9202787984257524" DF="0" EFFECT_SIZE="1.0640732265446224" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="133" I2="0.0" ID="CMP-020.05.01" LOG_CI_END="0.09002361506380124" LOG_CI_START="-0.03608058322473712" LOG_EFFECT_SIZE="0.026971515919532087" MODIFIED="2013-03-18 11:23:01 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4018032492804592" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.8384050733945527">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2303356693492626" CI_START="0.9202787984257524" EFFECT_SIZE="1.0640732265446224" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="133" LOG_CI_END="0.09002361506380124" LOG_CI_START="-0.03608058322473712" LOG_EFFECT_SIZE="0.026971515919532087" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7622" O_E="0.0" SE="0.07407423030053635" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.005486991594616898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.7170010236515885" CI_START="-2.7170010236515876" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.49999999999999956" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.06" MODIFIED="2013-03-18 11:23:16 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6584671623170757" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" UNITS="" WEIGHT="100.0" Z="0.44203046449474037">
<NAME>SF-36 score - mental domain: change from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7170010236515885" CI_START="-2.7170010236515876" DF="0" EFFECT_SIZE="-0.49999999999999956" ESTIMABLE="YES" I2="0.0" ID="CMP-020.06.01" MODIFIED="2013-03-18 11:23:16 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6584671623170757" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.44203046449474037">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="1.7170010236515885" CI_START="-2.7170010236515876" EFFECT_SIZE="-0.49999999999999956" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="4.1" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7623" SD_1="11.51" SD_2="11.78" SE="1.131143756282773" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2332808383820364" CI_START="0.699043323047253" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9285024154589372" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-020.07" LOG_CI_END="0.09106198387202726" LOG_CI_START="-0.1554959081208096" LOG_EFFECT_SIZE="-0.0322169621243912" METHOD="MH" MODIFIED="2013-03-18 11:23:31 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6085075863151128" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.5122049425773992">
<NAME>Proportion of participants whose SF-36 (mental) scores improved from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2332808383820364" CI_START="0.699043323047253" DF="0" EFFECT_SIZE="0.9285024154589372" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="70" I2="0.0" ID="CMP-020.07.01" LOG_CI_END="0.09106198387202726" LOG_CI_START="-0.1554959081208096" LOG_EFFECT_SIZE="-0.0322169621243912" MODIFIED="2013-03-18 11:23:31 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6085075863151128" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.5122049425773992">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2332808383820362" CI_START="0.699043323047253" EFFECT_SIZE="0.9285024154589372" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="70" LOG_CI_END="0.09106198387202717" LOG_CI_START="-0.1554959081208096" LOG_EFFECT_SIZE="-0.0322169621243912" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7624" O_E="0.0" SE="0.14482932623784137" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.020975533738507086" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8719624667312975" CI_START="-2.6719624667312982" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.08" MODIFIED="2013-03-18 11:24:01 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.943631165414357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" UNITS="" WEIGHT="100.0" Z="0.07070672882707679">
<NAME>ASHI: change from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.8719624667312975" CI_START="-2.6719624667312982" DF="0" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-020.08.01" MODIFIED="2013-03-18 11:24:01 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.943631165414357" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.07070672882707679">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="2.8719624667312975" CI_START="-2.6719624667312982" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="8.1" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7625" SD_1="14.39" SD_2="14.73" SE="1.4142925526163663" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2383796455332226" CI_START="0.8874113348056936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0483091787439613" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="120" I2="0.0" I2_Q="0.0" ID="CMP-020.09" LOG_CI_END="0.09285380517243291" LOG_CI_START="-0.05187502838920942" LOG_EFFECT_SIZE="0.020489388391611754" METHOD="MH" MODIFIED="2013-03-18 11:24:18 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.5789304680413371" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.5549476538233545">
<NAME>Proportion of participants whose ASHI scores improved from baseline</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2383796455332226" CI_START="0.8874113348056936" DF="0" EFFECT_SIZE="1.0483091787439613" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="120" I2="0.0" ID="CMP-020.09.01" LOG_CI_END="0.09285380517243291" LOG_CI_START="-0.05187502838920942" LOG_EFFECT_SIZE="0.020489388391611754" MODIFIED="2013-03-18 11:24:18 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5789304680413371" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.5549476538233545">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2383796455332226" CI_START="0.8874113348056936" EFFECT_SIZE="1.0483091787439613" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="120" LOG_CI_END="0.09285380517243291" LOG_CI_START="-0.05187502838920942" LOG_EFFECT_SIZE="0.020489388391611754" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7626" O_E="0.0" SE="0.08501443325338913" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.0072274538613949545" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.6312433342286745" CI_START="-1.4512433342286677" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0900000000000034" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-020.10" MODIFIED="2013-03-18 11:24:35 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.18232872991365012" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" UNITS="" WEIGHT="100.00000000000001" Z="1.3336190700420667">
<NAME>EQ-5D VAS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.6312433342286745" CI_START="-1.4512433342286677" DF="0" EFFECT_SIZE="3.0900000000000034" ESTIMABLE="YES" I2="0.0" ID="CMP-020.10.01" MODIFIED="2013-03-18 11:24:35 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18232872991365012" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.00000000000001" Z="1.3336190700420667">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="7.6312433342286745" CI_START="-1.4512433342286677" EFFECT_SIZE="3.0900000000000034" ESTIMABLE="YES" MEAN_1="66.75" MEAN_2="63.66" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7627" SD_1="24.7" SD_2="24.5" SE="2.3170034602928515" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3107820553416536" CI_START="1.0784265508279585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1889416179229666" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="164" I2="0.0" I2_Q="0.0" ID="CMP-020.11" LOG_CI_END="0.11753048724234591" LOG_CI_START="0.03279057163943287" LOG_EFFECT_SIZE="0.07516052944088936" METHOD="MH" MODIFIED="2013-03-18 11:24:48 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="5.074334386238997E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="228" WEIGHT="100.0" Z="3.47680145100455">
<NAME>Satisfaction with treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3107820553416536" CI_START="1.0784265508279585" DF="0" EFFECT_SIZE="1.1889416179229666" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="164" I2="0.0" ID="CMP-020.11.01" LOG_CI_END="0.11753048724234591" LOG_CI_START="0.03279057163943287" LOG_EFFECT_SIZE="0.07516052944088936" MODIFIED="2013-03-18 11:24:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.074334386238997E-4" STUDIES="1" TAU2="0.0" TOTAL_1="221" TOTAL_2="228" WEIGHT="100.0" Z="3.47680145100455">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3107820553416536" CI_START="1.0784265508279585" EFFECT_SIZE="1.1889416179229666" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="164" LOG_CI_END="0.11753048724234591" LOG_CI_START="0.03279057163943287" LOG_EFFECT_SIZE="0.07516052944088936" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7628" O_E="0.0" SE="0.04977664589449846" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="221" TOTAL_2="228" VAR="0.002477714476506291" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.2611270900832445E-31" CI_END="1.2873140256085063" CI_START="0.7709273371429126" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9962055881338394" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="78" I2="100.0" I2_Q="0.0" ID="CMP-020.12" LOG_CI_END="0.10968450102518965" LOG_CI_START="-0.11298655393998133" LOG_EFFECT_SIZE="-0.0016510264573958643" METHOD="MH" MODIFIED="2013-03-18 11:25:03 -0400" MODIFIED_BY="Anne Lethaby" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="0.976812855340072" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.029064867856532128">
<NAME>Reduction to normal health assessment (HAQ &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.2611270900832445E-31" CI_END="1.2873140256085063" CI_START="0.7709273371429126" DF="0" EFFECT_SIZE="0.9962055881338394" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="78" I2="100.0" ID="CMP-020.12.01" LOG_CI_END="0.10968450102518965" LOG_CI_START="-0.11298655393998133" LOG_EFFECT_SIZE="-0.0016510264573958643" MODIFIED="2008-10-08 17:10:44 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.0" P_Z="0.976812855340072" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.029064867856532128">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.287314025608506" CI_START="0.7709273371429125" EFFECT_SIZE="0.9962055881338393" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="78" LOG_CI_END="0.10968450102518956" LOG_CI_START="-0.1129865539399814" LOG_EFFECT_SIZE="-0.0016510264573959127" MODIFIED="2008-10-08 17:10:44 -0400" MODIFIED_BY="Anne Lethaby" ORDER="445" O_E="0.0" SE="0.1307980799260402" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.017108137712338798" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2013-03-18 11:25:59 -0400" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Quality of life at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.90984165592752" CI_START="0.09015834407247914" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-021.01" MODIFIED="2013-03-18 11:25:46 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.04331172263533383" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" UNITS="" WEIGHT="100.0" Z="2.020691380798152">
<NAME>Percentage improvement in HAQ (from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.90984165592752" CI_START="0.09015834407247914" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-021.01.01" MODIFIED="2013-03-18 11:25:46 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04331172263533383" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="2.020691380798152">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="5.90984165592752" CI_START="0.09015834407247914" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="36.0" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7631" SD_1="14.9" SD_2="16.6" SE="1.4846403703741398" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.350497356316668" CI_END="0.04854738548225784" CI_START="-0.5391534757147325" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24530304511623735" ESTIMABLE="YES" I2="84.25320185346858" I2_Q="0.0" ID="CMP-021.02" MODIFIED="2013-03-18 11:25:59 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011734859715575086" P_Q="1.0" P_Z="0.10180695059736268" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.037913940834060876" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" UNITS="" WEIGHT="99.99999999999999" Z="1.636155961203112">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.350497356316668" CI_END="0.04854738548225784" CI_START="-0.5391534757147325" DF="1" EFFECT_SIZE="-0.24530304511623735" ESTIMABLE="YES" I2="84.25320185346858" ID="CMP-021.02.01" MODIFIED="2013-03-18 11:25:59 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.011734859715575086" P_Z="0.10180695059736268" STUDIES="2" TAU2="0.037913940834060876" TOTAL_1="326" TOTAL_2="278" WEIGHT="99.99999999999999" Z="1.636155961203112">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.2193518554826894" CI_START="-0.5806481445173108" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.6" MODIFIED="2012-01-31 14:14:03 -0500" MODIFIED_BY="[Empty name]" ORDER="530" SD_1="0.6" SD_2="0.5" SE="0.09216911430120157" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" WEIGHT="48.43434837207908"/>
<CONT_DATA CI_END="0.047674834878416394" CI_START="-0.24767483487841657" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.1" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7632" SD_1="0.8" SD_2="0.8" SE="0.07534568800409433" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" WEIGHT="51.56565162792091"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2013-03-18 11:26:31 -0400" MODIFIED_BY="Anne Lethaby" NO="22">
<NAME>Quality of life at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.03361314791864542" CI_START="-0.4336131479186456" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.01" MODIFIED="2013-03-18 11:26:31 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09335551039073724" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="1.6779569146704034">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.03361314791864542" CI_START="-0.4336131479186456" DF="0" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-022.01.01" MODIFIED="2013-03-18 11:26:31 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.09335551039073724" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0" Z="1.6779569146704034">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="0.03361314791864542" CI_START="-0.4336131479186456" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.9" MODIFIED="2012-01-31 08:08:54 -0500" MODIFIED_BY="[Empty name]" ORDER="393" SD_1="0.6" SD_2="0.8" SE="0.11919257178262263" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2013-03-18 11:27:42 -0400" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1041956049737736" CI_START="0.9551289124939161" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0269611226132964" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.043046014186625695" LOG_CI_START="-0.019938008304830872" LOG_EFFECT_SIZE="0.0115540029408974" METHOD="MH" MODIFIED="2013-03-18 11:26:58 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4720886181084222" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="230" TOTAL_2="221" WEIGHT="100.0" Z="0.7190848963163798">
<NAME>Satisfaction with treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1041956049737736" CI_START="0.9551289124939161" DF="0" EFFECT_SIZE="1.0269611226132964" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" I2="0.0" ID="CMP-023.01.01" LOG_CI_END="0.043046014186625695" LOG_CI_START="-0.019938008304830872" LOG_EFFECT_SIZE="0.0115540029408974" MODIFIED="2013-03-18 11:26:58 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4720886181084222" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="221" WEIGHT="100.0" Z="0.7190848963163798">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1041956049737736" CI_START="0.9551289124939161" EFFECT_SIZE="1.0269611226132964" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" LOG_CI_END="0.043046014186625695" LOG_CI_START="-0.019938008304830872" LOG_EFFECT_SIZE="0.0115540029408974" MODIFIED="2012-01-31 08:04:40 -0500" MODIFIED_BY="[Empty name]" ORDER="780" O_E="0.0" SE="0.03699712658742116" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="230" TOTAL_2="221" VAR="0.0013687873757256656" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1997163639114568E-30" CI_END="-0.10066803339124172" CI_START="-0.29933196660875827" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-023.02" MODIFIED="2013-03-18 11:27:10 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="7.937130430164245E-5" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="395" UNITS="" WEIGHT="100.0" Z="3.9462905073848416">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1997163639114568E-30" CI_END="-0.10066803339124172" CI_START="-0.29933196660875827" DF="2" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-023.02.01" MODIFIED="2013-03-18 11:27:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.937130430164245E-5" STUDIES="3" TAU2="0.0" TOTAL_1="405" TOTAL_2="395" WEIGHT="100.0" Z="3.9462905073848416">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.03532217367272125" CI_START="-0.36467782632727885" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.1" MODIFIED="2012-01-31 10:20:41 -0500" MODIFIED_BY="[Empty name]" ORDER="451" SD_1="0.6" SD_2="0.6" SE="0.0840208430492787" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" WEIGHT="36.38377991666213"/>
<CONT_DATA CI_END="0.03361314791864542" CI_START="-0.4336131479186456" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.9" MODIFIED="2012-02-16 16:56:34 -0500" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="0.6" SD_2="0.8" SE="0.11919257178262263" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" WEIGHT="18.07937881853517"/>
<CONT_DATA CI_END="-0.052800076949986535" CI_START="-0.34719992305001335" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.0" MODIFIED="2012-01-31 08:04:40 -0500" MODIFIED_BY="[Empty name]" ORDER="781" SD_1="0.8" SD_2="0.8" SE="0.07510338159839039" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" WEIGHT="45.536841264802696"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.114007657473539" CI_END="10.33967327650091" CI_START="-6.608470653985183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8656013112578642" ESTIMABLE="YES" I2="80.4458642423303" I2_Q="0.0" ID="CMP-023.03" MODIFIED="2013-03-18 11:27:27 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.023733472819757684" P_Q="1.0" P_Z="0.6661092009087561" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="30.165429281860497" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" UNITS="" WEIGHT="100.0" Z="0.43149402017985344">
<NAME>EQ-5D VAS</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.114007657473539" CI_END="10.33967327650091" CI_START="-6.608470653985183" DF="1" EFFECT_SIZE="1.8656013112578642" ESTIMABLE="YES" I2="80.4458642423303" ID="CMP-023.03.01" MODIFIED="2013-03-18 11:27:27 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.023733472819757684" P_Z="0.6661092009087561" STUDIES="2" TAU2="30.165429281860497" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.43149402017985344">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="3.3003963918629884" CI_START="-8.700396391862995" EFFECT_SIZE="-2.700000000000003" ESTIMABLE="YES" MEAN_1="72.2" MEAN_2="74.9" MODIFIED="2012-01-31 11:37:45 -0500" MODIFIED_BY="[Empty name]" ORDER="459" SD_1="22.4" SD_2="21.3" SE="3.061482986010637" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" WEIGHT="47.27943058593685"/>
<CONT_DATA CI_END="10.468796234485417" CI_START="1.4512037655145704" EFFECT_SIZE="5.959999999999994" ESTIMABLE="YES" MEAN_1="72.71" MEAN_2="66.75" MODIFIED="2012-01-31 08:04:40 -0500" MODIFIED_BY="[Empty name]" ORDER="782" SD_1="24.3" SD_2="24.7" SE="2.3004485133656702" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" WEIGHT="52.72056941406315"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6357907786914685" CI_START="1.0261980135144975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2956254272043746" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-023.04" LOG_CI_END="0.21372775564925467" LOG_CI_START="0.011231169625030415" LOG_EFFECT_SIZE="0.11247946263714258" METHOD="MH" MODIFIED="2013-03-18 11:27:42 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.029452456735492502" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="2.1773769138295047">
<NAME>Reduction to normal health assessment (HAQ &#8804; 0.5)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6357907786914685" CI_START="1.0261980135144975" DF="0" EFFECT_SIZE="1.2956254272043746" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="76" I2="0.0" ID="CMP-023.04.01" LOG_CI_END="0.21372775564925467" LOG_CI_START="0.011231169625030415" LOG_EFFECT_SIZE="0.11247946263714258" MODIFIED="2012-01-31 08:04:40 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.029452456735492502" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="2.1773769138295047">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6357907786914687" CI_START="1.0261980135144975" EFFECT_SIZE="1.2956254272043746" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="76" LOG_CI_END="0.21372775564925475" LOG_CI_START="0.011231169625030415" LOG_EFFECT_SIZE="0.11247946263714258" MODIFIED="2012-01-31 08:04:40 -0500" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.11894749700489625" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.014148507043729802" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2013-03-18 11:28:47 -0400" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="19.385983442644893" CI_START="14.614016557355106" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="17.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.01" MODIFIED="2013-03-18 11:28:23 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.5621492787546964E-44" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" UNITS="" WEIGHT="99.99999999999999" Z="13.96463493487027">
<NAME>Percentage improvement in HAQ (from baseline)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.385983442644893" CI_START="14.614016557355106" DF="0" EFFECT_SIZE="17.0" ESTIMABLE="YES" I2="0.0" ID="CMP-024.01.01" MODIFIED="2013-03-18 11:28:23 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="2.5621492787546964E-44" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="99.99999999999999" Z="13.96463493487027">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="19.385983442644893" CI_START="14.614016557355106" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="55.8" MEAN_2="38.8" MODIFIED="2008-07-11 18:58:31 -0400" MODIFIED_BY="Anne Lethaby" ORDER="783" SD_1="10.6" SD_2="14.9" SE="1.217360860436838" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8298294238944874" CI_END="-0.15260019317484264" CI_START="-0.3645634574851806" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2585818253300116" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-024.02" MODIFIED="2013-03-18 11:28:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36232192493675786" P_Q="1.0" P_Z="1.735034638501208E-6" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" UNITS="" WEIGHT="100.0" Z="4.782065103143737">
<NAME>HAQ score after treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8298294238944874" CI_END="-0.15260019317484264" CI_START="-0.3645634574851806" DF="1" EFFECT_SIZE="-0.2585818253300116" ESTIMABLE="YES" I2="0.0" ID="CMP-024.02.01" MODIFIED="2013-03-18 11:28:37 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.36232192493675786" P_Z="1.735034638501208E-6" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="4.782065103143737">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="-0.03532217367272114" CI_START="-0.36467782632727874" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.2" MODIFIED="2012-01-31 14:14:32 -0500" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="0.6" SD_2="0.6" SE="0.0840208430492787" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" WEIGHT="41.41817466998842"/>
<CONT_DATA CI_END="-0.16153208470458455" CI_START="-0.4384679152954155" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.0" MODIFIED="2008-07-11 18:59:39 -0400" MODIFIED_BY="Anne Lethaby" ORDER="784" SD_1="0.7" SD_2="0.8" SE="0.0706481937360241" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" WEIGHT="58.58182533001159"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1041956049737736" CI_START="0.9551289124939161" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0269611226132964" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="0.043046014186625695" LOG_CI_START="-0.019938008304830872" LOG_EFFECT_SIZE="0.0115540029408974" METHOD="MH" MODIFIED="2013-03-18 11:28:47 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4720886181084222" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="230" TOTAL_2="221" WEIGHT="100.0" Z="0.7190848963163798">
<NAME>Satisfaction with treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1041956049737736" CI_START="0.9551289124939161" DF="0" EFFECT_SIZE="1.0269611226132964" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" I2="0.0" ID="CMP-024.03.01" LOG_CI_END="0.043046014186625695" LOG_CI_START="-0.019938008304830872" LOG_EFFECT_SIZE="0.0115540029408974" MODIFIED="2013-03-18 11:28:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4720886181084222" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="221" WEIGHT="100.0" Z="0.7190848963163798">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1041956049737736" CI_START="0.9551289124939161" EFFECT_SIZE="1.0269611226132964" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" LOG_CI_END="0.043046014186625695" LOG_CI_START="-0.019938008304830872" LOG_EFFECT_SIZE="0.0115540029408974" MODIFIED="2008-07-23 13:36:48 -0400" MODIFIED_BY="[Empty name]" ORDER="1686" O_E="0.0" SE="0.03699712658742116" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="230" TOTAL_2="221" VAR="0.0013687873757256656" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2013-03-18 11:29:11 -0400" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Quality of life at six months: etanercept vs. placebo</NAME>
<CONT_OUTCOME CHI2="0.0604875706860868" CI_END="12.71972311354043" CI_START="5.310034878052628" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="9.01487899579653" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.01" MODIFIED="2012-02-22 15:35:15 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8057269709463994" P_Q="0.8057269709463994" P_Z="1.8503440907915001E-6" Q="0.0604875706860868" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" UNITS="" WEIGHT="200.0" Z="4.769117834708633">
<NAME>MOS: mental health (change from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.835999975474945" CI_START="3.244000024525053" DF="0" EFFECT_SIZE="8.54" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.01" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0015748997859774128" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="3.160515956473543">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="13.835999975474945" CI_START="3.244000024525053" EFFECT_SIZE="8.54" ESTIMABLE="YES" MEAN_1="12.95" MEAN_2="4.41" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" ORDER="7609" SD_1="17.0" SD_2="16.73" SE="2.7020904553599547" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="14.654655845778588" CI_START="4.285344154221413" DF="0" EFFECT_SIZE="9.47" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.02" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.436472153305119E-4" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="99.99999999999999" Z="3.5799596898426342">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="14.654655845778588" CI_START="4.285344154221413" EFFECT_SIZE="9.47" ESTIMABLE="YES" MEAN_1="13.88" MEAN_2="4.41" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="16.52" SD_2="16.73" SE="2.6452811820393087" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.05355459488096225" CI_END="16.476718608773474" CI_START="7.754712963532852" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="12.115715786153164" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-025.02" MODIFIED="2013-03-12 16:26:51 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8169895737690807" P_Q="0.8169895737690803" P_Z="5.175827546917354E-8" Q="0.05355459488096244" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" UNITS="" WEIGHT="200.0" Z="5.445161939499863">
<NAME>MOS: energy/vitality (change from baseline)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.863744060807154" CI_START="6.416255939192843" DF="0" EFFECT_SIZE="12.639999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-025.02.01" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="6.875505481303824E-5" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="3.980553268665961">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<CONT_DATA CI_END="18.863744060807154" CI_START="6.416255939192843" EFFECT_SIZE="12.639999999999999" ESTIMABLE="YES" MEAN_1="17.38" MEAN_2="4.74" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" ORDER="7611" SD_1="19.96" SD_2="19.68" SE="3.175437972278702" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.2442433871629134E-31" CI_END="17.722538245142495" CI_START="5.497461754857505" DF="0" EFFECT_SIZE="11.61" ESTIMABLE="YES" I2="100.0" ID="CMP-025.02.02" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="1.9709910151060144E-4" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="3.7227058462322247">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<CONT_DATA CI_END="17.722538245142495" CI_START="5.497461754857507" EFFECT_SIZE="11.610000000000001" ESTIMABLE="YES" MEAN_1="16.35" MEAN_2="4.74" MODIFIED="2012-02-20 08:49:09 -0500" MODIFIED_BY="[Empty name]" ORDER="7612" SD_1="19.52" SD_2="19.68" SE="3.1186992686383097" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2013-03-18 11:30:10 -0400" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARDs</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7896370124580337" CI_START="0.0363804846242428" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" METHOD="MH" MODIFIED="2012-02-22 15:36:08 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02377202768570906" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="2.260793816561138">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7896370124580337" CI_START="0.0363804846242428" DF="0" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-026.01.01" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" MODIFIED="2012-02-21 14:48:00 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02377202768570906" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="2.260793816561138">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.7896370124580337" CI_START="0.0363804846242428" EFFECT_SIZE="0.1694915254237288" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.10257250328477685" LOG_CI_START="-1.4391315199995114" LOG_EFFECT_SIZE="-0.7708520116421442" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7635" O_E="0.0" SE="0.7851013824920705" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.6163841807909605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.46562756033998626" CI_END="0.3716124674905825" CI_START="0.049753230566765255" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13597397095232422" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="-0.42990972397997373" LOG_CI_START="-1.3031787144807006" LOG_EFFECT_SIZE="-0.8665442192303372" METHOD="MH" MODIFIED="2013-03-18 11:29:48 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.49500563612760873" P_Q="1.0" P_Z="1.0035092330454729E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="3.889741830244065">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.46562756033998626" CI_END="0.3716124674905825" CI_START="0.049753230566765255" DF="1" EFFECT_SIZE="0.13597397095232422" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" I2="0.0" ID="CMP-026.02.01" LOG_CI_END="-0.42990972397997373" LOG_CI_START="-1.3031787144807006" LOG_EFFECT_SIZE="-0.8665442192303372" MODIFIED="2012-02-21 14:48:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49500563612760873" P_Z="1.0035092330454729E-4" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="3.889741830244065">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.4857458904145891" CI_START="0.056059034886774745" EFFECT_SIZE="0.16501650165016502" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.31359086500057665" LOG_CI_START="-1.2513543833319958" LOG_EFFECT_SIZE="-0.7824726241662862" MODIFIED="2012-01-31 11:42:35 -0500" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="0.5508469326721566" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.3034323432343234" WEIGHT="73.01108154267784"/>
<DICH_DATA CI_END="1.0323297528737432" CI_START="0.0031924008932861956" EFFECT_SIZE="0.05740740740740741" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.01381844436343438" LOG_CI_START="-2.495882576340826" LOG_EFFECT_SIZE="-1.2410320659886958" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7638" O_E="0.0" SE="1.4742108027820942" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.1732974910394267" WEIGHT="26.988918457322164"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2030461538568138" CI_END="1.6412820907033314" CI_START="0.08640113284638119" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37657486899319875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="16.877669506350486" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="0.21518323060043204" LOG_CI_START="-1.0634805632420925" LOG_EFFECT_SIZE="-0.4241486663208302" METHOD="MH" MODIFIED="2013-03-18 11:29:57 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.27271376439883455" P_Q="1.0" P_Z="0.1935020025578084" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.3002888078676702">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2030461538568138" CI_END="1.6412820907033314" CI_START="0.08640113284638119" DF="1" EFFECT_SIZE="0.37657486899319875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="16.877669506350486" ID="CMP-026.03.01" LOG_CI_END="0.21518323060043204" LOG_CI_START="-1.0634805632420925" LOG_EFFECT_SIZE="-0.4241486663208302" MODIFIED="2012-02-21 14:48:03 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27271376439883455" P_Z="0.1935020025578084" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.3002888078676702">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5464177500341934" CI_START="0.01760872559582093" EFFECT_SIZE="0.16501650165016502" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.18932682595173206" LOG_CI_START="-1.7542720742843045" LOG_EFFECT_SIZE="-0.7824726241662862" MODIFIED="2012-01-31 11:43:04 -0500" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="1.141679614968369" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.3034323432343233" WEIGHT="75.16724272494146"/>
<DICH_DATA CI_END="10.769158781101229" CI_START="0.09603215997442066" EFFECT_SIZE="1.0169491525423728" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0321817802715805" LOG_CI_START="-1.0175833027885817" LOG_EFFECT_SIZE="0.007299238741499423" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7641" O_E="0.0" SE="1.204042156290341" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.4497175141242937" WEIGHT="24.832757275058533"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-03-18 11:30:10 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-026.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-03-18 11:30:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-24 15:30:26 -0400" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.0" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2013-03-18 11:31:02 -0400" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.6308404418761282" CI_END="0.7598761495220889" CI_START="0.479804487327527" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6038145297637852" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-0.11925718661691531" LOG_CI_START="-0.31893569464982563" LOG_EFFECT_SIZE="-0.2190964406333705" METHOD="MH" MODIFIED="2013-03-18 11:30:36 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.4270474268536941" P_Q="1.0" P_Z="1.699329974327724E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="4.301125213851742">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6308404418761282" CI_END="0.7598761495220889" CI_START="0.479804487327527" DF="1" EFFECT_SIZE="0.6038145297637852" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="148" I2="0.0" ID="CMP-027.01.01" LOG_CI_END="-0.11925718661691531" LOG_CI_START="-0.31893569464982563" LOG_EFFECT_SIZE="-0.2190964406333705" MODIFIED="2013-03-18 11:30:36 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.4270474268536941" P_Z="1.699329974327724E-5" STUDIES="2" TAU2="0.0" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="4.301125213851742">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8898131351986112" CI_START="0.4839129078902977" EFFECT_SIZE="0.6561951399796729" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="79" LOG_CI_END="-0.050701187594300715" LOG_CI_START="-0.3152327933682023" LOG_EFFECT_SIZE="-0.1829669904812515" MODIFIED="2008-10-08 17:18:45 -0400" MODIFIED_BY="Anne Lethaby" ORDER="448" O_E="0.0" SE="0.15538717468415697" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.024145174056324714" WEIGHT="53.49021333173113"/>
<DICH_DATA CI_END="0.7722313003722011" CI_START="0.3826197162879097" EFFECT_SIZE="0.5435723696593262" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="69" LOG_CI_END="-0.11225259936641842" LOG_CI_START="-0.4172326546578529" LOG_EFFECT_SIZE="-0.26474262701213563" MODIFIED="2008-07-11 14:12:47 -0400" MODIFIED_BY="Anne Lethaby" ORDER="755" O_E="0.0" SE="0.17914679415381005" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03209357385558759" WEIGHT="46.509786668268866"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19716674742731927" CI_END="0.5794628789324637" CI_START="0.1848891834987867" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.32731700009880255" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="-0.23697438022007902" LOG_CI_START="-0.7330884954616878" LOG_EFFECT_SIZE="-0.4850314378408834" METHOD="MH" MODIFIED="2013-03-18 11:30:45 -0400" MODIFIED_BY="Anne Lethaby" NO="2" P_CHI2="0.6570175605337074" P_Q="1.0" P_Z="1.269194038863141E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="3.832360823174094">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19716674742731927" CI_END="0.5794628789324637" CI_START="0.1848891834987867" DF="1" EFFECT_SIZE="0.32731700009880255" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="45" I2="0.0" ID="CMP-027.02.01" LOG_CI_END="-0.23697438022007902" LOG_CI_START="-0.7330884954616878" LOG_EFFECT_SIZE="-0.4850314378408834" MODIFIED="2013-03-18 11:30:45 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.6570175605337074" P_Z="1.269194038863141E-4" STUDIES="2" TAU2="0.0" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="3.832360823174094">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.7744378716285154" CI_START="0.1737178377682539" EFFECT_SIZE="0.36678832116788324" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.11101341727362798" LOG_CI_START="-0.7601555848541325" LOG_EFFECT_SIZE="-0.43558450106388025" MODIFIED="2008-10-08 17:20:26 -0400" MODIFIED_BY="Anne Lethaby" ORDER="449" O_E="0.0" SE="0.38130932254234134" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.14539679945769932" WEIGHT="53.44518209952288"/>
<DICH_DATA CI_END="0.6857863513637841" CI_START="0.11596336471263657" EFFECT_SIZE="0.2820037105751391" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="21" LOG_CI_END="-0.1638111625374628" LOG_CI_START="-0.9356791919464696" LOG_EFFECT_SIZE="-0.5497451772419661" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7642" O_E="0.0" SE="0.4533991012832174" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.20557074504442924" WEIGHT="46.55481790047712"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05849265531684751" CI_END="1.0891535673344226" CI_START="0.5499521361234196" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7739394878942465" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="0.03708911827178321" LOG_CI_START="-0.2596751067276313" LOG_EFFECT_SIZE="-0.11129299422792402" METHOD="MH" MODIFIED="2013-03-18 11:30:54 -0400" MODIFIED_BY="Anne Lethaby" NO="3" P_CHI2="0.8088944216587582" P_Q="1.0" P_Z="0.14154613945276226" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="1.4700576554925755">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05849265531684751" CI_END="1.0891535673344226" CI_START="0.5499521361234196" DF="1" EFFECT_SIZE="0.7739394878942465" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="66" I2="0.0" ID="CMP-027.03.01" LOG_CI_END="0.03708911827178321" LOG_CI_START="-0.2596751067276313" LOG_EFFECT_SIZE="-0.11129299422792402" MODIFIED="2013-03-18 11:30:54 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.8088944216587582" P_Z="0.14154613945276226" STUDIES="2" TAU2="0.0" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="1.4700576554925755">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.29005675084841" CI_START="0.5029419661690944" EFFECT_SIZE="0.8054959209961357" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.11060881575520737" LOG_CI_START="-0.29848212473847746" LOG_EFFECT_SIZE="-0.09393665449163506" MODIFIED="2008-10-08 17:21:36 -0400" MODIFIED_BY="Anne Lethaby" ORDER="450" O_E="0.0" SE="0.24030204347880527" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.05774507210008962" WEIGHT="51.62740561192334"/>
<DICH_DATA CI_END="1.2163597372481305" CI_START="0.45051185621218276" EFFECT_SIZE="0.7402597402597403" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.08506203611829613" LOG_CI_START="-0.346293775118277" LOG_EFFECT_SIZE="-0.13061586949999046" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7643" O_E="0.0" SE="0.2533805387660655" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.06420169742538162" WEIGHT="48.37259438807665"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2567065206913345" CI_END="12.371443786556128" CI_START="0.21690565274884518" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6381196812103203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="1.0924203861242576" LOG_CI_START="-0.6637291297486393" LOG_EFFECT_SIZE="0.21434562818780908" METHOD="MH" MODIFIED="2013-03-18 11:31:02 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.612391940723044" P_Q="1.0" P_Z="0.6323341339681583" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="0.47844412755812893">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2567065206913345" CI_END="12.371443786556128" CI_START="0.21690565274884518" DF="1" EFFECT_SIZE="1.6381196812103203" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-027.04.01" LOG_CI_END="1.0924203861242576" LOG_CI_START="-0.6637291297486393" LOG_EFFECT_SIZE="0.21434562818780908" MODIFIED="2013-03-18 11:31:02 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.612391940723044" P_Z="0.6323341339681583" STUDIES="2" TAU2="0.0" TOTAL_1="505" TOTAL_2="496" WEIGHT="100.0" Z="0.47844412755812893">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="71.71817258993904" CI_START="0.12007496445888895" EFFECT_SIZE="2.9345454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8556292150198632" LOG_CI_START="-0.9205475332362473" LOG_EFFECT_SIZE="0.46754084089180775" MODIFIED="2010-05-21 00:35:02 -0400" MODIFIED_BY="[Empty name]" ORDER="719" O_E="0.0" SE="1.630739964222176" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.659312830911344" WEIGHT="33.43239227340268"/>
<DICH_DATA CI_END="15.684765946170021" CI_START="0.062110881340258856" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1954780423805766" LOG_CI_START="-1.2068323081639576" LOG_EFFECT_SIZE="-0.005677132891690521" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7644" O_E="0.0" SE="1.4111289915378804" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="1.991285030758715" WEIGHT="66.56760772659733"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2013-03-18 11:37:51 -0400" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="5.04320850971316" CI_END="0.7952342763820981" CI_START="0.2754845792901068" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46805424906328413" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="136" I2="80.17135325509521" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="-0.09950490914043468" LOG_CI_START="-0.5599027064915125" LOG_EFFECT_SIZE="-0.3297038078159736" METHOD="MH" MODIFIED="2012-04-26 16:15:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02472268976714831" P_Q="1.0" P_Z="0.004997875971702063" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11805244138060732" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="2.807170636362781">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.04320850971316" CI_END="0.7952342763820981" CI_START="0.2754845792901068" DF="1" EFFECT_SIZE="0.46805424906328413" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="136" I2="80.17135325509521" ID="CMP-028.01.01" LOG_CI_END="-0.09950490914043468" LOG_CI_START="-0.5599027064915125" LOG_EFFECT_SIZE="-0.3297038078159736" MODIFIED="2012-01-31 12:35:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02472268976714831" P_Z="0.004997875971702063" STUDIES="2" TAU2="0.11805244138060732" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="2.807170636362781">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.5201261526018915" CI_START="0.23477574062259074" EFFECT_SIZE="0.34944670937682004" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="-0.2838913087994064" LOG_CI_START="-0.6293467807551393" LOG_EFFECT_SIZE="-0.4566190447772729" MODIFIED="2012-01-31 12:35:24 -0500" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.20292225425896274" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.04117744127353912" WEIGHT="45.93218479118225"/>
<DICH_DATA CI_END="0.7759018163991618" CI_START="0.46389746696173095" EFFECT_SIZE="0.5999490705373058" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="102" LOG_CI_END="-0.11019323144006056" LOG_CI_START="-0.3335779988706478" LOG_EFFECT_SIZE="-0.2218856151553542" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7656" O_E="0.0" SE="0.13121731816115942" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.017217984585406937" WEIGHT="54.067815208817755"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.92076607337478" CI_END="0.4773622142074011" CI_START="0.07386016458650668" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18777127498299068" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="56" I2="65.76240702342326" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="-0.3211519607182028" LOG_CI_START="-1.1315897289226247" LOG_EFFECT_SIZE="-0.7263708448204137" METHOD="MH" MODIFIED="2012-04-26 16:15:00 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08744648854543557" P_Q="1.0" P_Z="4.425561290771762E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.29863753044360875" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="3.513312807279842">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.92076607337478" CI_END="0.4773622142074011" CI_START="0.07386016458650668" DF="1" EFFECT_SIZE="0.18777127498299068" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="56" I2="65.76240702342326" ID="CMP-028.02.01" LOG_CI_END="-0.3211519607182028" LOG_CI_START="-1.1315897289226247" LOG_EFFECT_SIZE="-0.7263708448204137" MODIFIED="2012-01-31 12:38:57 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08744648854543557" P_Z="4.425561290771762E-4" STUDIES="2" TAU2="0.29863753044360875" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="3.513312807279842">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.25950203921981563" CI_START="0.05029354992173305" EFFECT_SIZE="0.11424219345011424" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="26" LOG_CI_END="-0.5858592250277253" LOG_CI_START="-1.298487709039871" LOG_EFFECT_SIZE="-0.9421734670337981" MODIFIED="2012-01-31 12:38:57 -0500" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.4186014990766221" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.17522721502919522" WEIGHT="47.8255693121636"/>
<DICH_DATA CI_END="0.609592170106031" CI_START="0.14382979570202892" EFFECT_SIZE="0.2961038961038961" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="30" LOG_CI_END="-0.2149606199190846" LOG_CI_START="-0.8421511364249716" LOG_EFFECT_SIZE="-0.5285558781720281" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7657" O_E="0.0" SE="0.36841481403868576" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.13572947520315942" WEIGHT="52.174430687836406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.603923208752079" CI_END="1.1893441896645467" CI_START="0.5706286172216746" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8238166242246592" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="0.07530755524161561" LOG_CI_START="-0.24364645211495076" LOG_EFFECT_SIZE="-0.08416944843666757" METHOD="MH" MODIFIED="2012-02-22 15:36:48 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.437085218666612" P_Q="1.0" P_Z="0.30093141866202056" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.0344380928253818">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.603923208752079" CI_END="1.1893441896645467" CI_START="0.5706286172216746" DF="1" EFFECT_SIZE="0.8238166242246592" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="51" I2="0.0" ID="CMP-028.03.01" LOG_CI_END="0.07530755524161561" LOG_CI_START="-0.24364645211495076" LOG_EFFECT_SIZE="-0.08416944843666757" MODIFIED="2012-01-31 12:45:21 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.437085218666612" P_Z="0.30093141866202056" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.0344380928253818">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.751245017043108" CI_START="0.40832112278436966" EFFECT_SIZE="1.2376237623762376" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5741754315393085" LOG_CI_START="-0.38899815308848085" LOG_EFFECT_SIZE="0.09258863922541384" MODIFIED="2012-01-31 12:45:21 -0500" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.5657729313965012" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.32009900990099005" WEIGHT="10.161750901310413"/>
<DICH_DATA CI_END="1.147597075727583" CI_START="0.5260948295254778" EFFECT_SIZE="0.7770102238187344" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="47" LOG_CI_END="0.05978943291920971" LOG_CI_START="-0.27893596644003577" LOG_EFFECT_SIZE="-0.10957326676041301" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7658" O_E="0.0" SE="0.19896897630138938" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03958865353042285" WEIGHT="89.83824909868959"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.684765946170021" CI_START="0.062110881340258856" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-028.04" LOG_CI_END="1.1954780423805766" LOG_CI_START="-1.2068323081639576" LOG_EFFECT_SIZE="-0.005677132891690521" METHOD="MH" MODIFIED="2012-02-22 15:36:48 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9926088522361107" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="0.009263562470718233">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.684765946170021" CI_START="0.062110881340258856" DF="0" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-028.04.01" LOG_CI_END="1.1954780423805766" LOG_CI_START="-1.2068323081639576" LOG_EFFECT_SIZE="-0.005677132891690521" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9926088522361107" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="0.009263562470718233">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="15.684765946170021" CI_START="0.062110881340258856" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1954780423805766" LOG_CI_START="-1.2068323081639576" LOG_EFFECT_SIZE="-0.005677132891690521" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7659" O_E="0.0" SE="1.4111289915378804" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="1.991285030758715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2013-03-18 11:38:09 -0400" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8429269047228327" CI_START="0.5862685629317989" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7029804727646455" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="139" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="-0.0742100840370394" LOG_CI_START="-0.23190339305943192" LOG_EFFECT_SIZE="-0.15305673854823565" METHOD="MH" MODIFIED="2012-02-22 15:37:03 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.4199195333377935E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="3.8046724620777304">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8429269047228327" CI_START="0.5862685629317989" DF="0" EFFECT_SIZE="0.7029804727646455" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="139" I2="0.0" ID="CMP-029.01.01" LOG_CI_END="-0.0742100840370394" LOG_CI_START="-0.23190339305943192" LOG_EFFECT_SIZE="-0.15305673854823565" MODIFIED="2008-07-28 08:53:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.4199195333377935E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="99.99999999999999" Z="3.8046724620777304">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8429269047228327" CI_START="0.5862685629317989" EFFECT_SIZE="0.7029804727646455" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="139" LOG_CI_END="-0.0742100840370394" LOG_CI_START="-0.23190339305943192" LOG_EFFECT_SIZE="-0.15305673854823565" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7664" O_E="0.0" SE="0.09262983031422231" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.008580285464041618" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5648874767522428" CI_START="0.16327401239105505" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3036963036963037" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-029.02" LOG_CI_END="-0.24803805322912392" LOG_CI_START="-0.787082934512006" LOG_EFFECT_SIZE="-0.5175604938705649" METHOD="MH" MODIFIED="2012-02-22 15:37:03 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.6742189391307045E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="3.7636937592019546">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5648874767522428" CI_START="0.16327401239105505" DF="0" EFFECT_SIZE="0.3036963036963037" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="39" I2="0.0" ID="CMP-029.02.01" LOG_CI_END="-0.24803805322912392" LOG_CI_START="-0.787082934512006" LOG_EFFECT_SIZE="-0.5175604938705649" MODIFIED="2008-07-28 08:53:33 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.6742189391307045E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="3.7636937592019546">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.5648874767522428" CI_START="0.16327401239105505" EFFECT_SIZE="0.3036963036963037" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="39" LOG_CI_END="-0.24803805322912392" LOG_CI_START="-0.787082934512006" LOG_EFFECT_SIZE="-0.5175604938705649" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7665" O_E="0.0" SE="0.3166376315807613" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.10025938973307394" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.095256486644231E-31" CI_END="0.9787556590733335" CI_START="0.4509214029231386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6643356643356645" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="52" I2="100.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="-0.009325713876818775" LOG_CI_START="-0.3458991504756091" LOG_EFFECT_SIZE="-0.17761243217621395" METHOD="MH" MODIFIED="2012-02-22 15:37:03 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.038585834143672594" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="2.068576616085772">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.095256486644231E-31" CI_END="0.9787556590733335" CI_START="0.4509214029231386" DF="0" EFFECT_SIZE="0.6643356643356645" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="52" I2="100.0" ID="CMP-029.03.01" LOG_CI_END="-0.009325713876818775" LOG_CI_START="-0.3458991504756091" LOG_EFFECT_SIZE="-0.17761243217621395" MODIFIED="2008-07-28 08:53:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.038585834143672594" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="2.068576616085772">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9787556590733333" CI_START="0.45092140292313854" EFFECT_SIZE="0.6643356643356644" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="52" LOG_CI_END="-0.009325713876818874" LOG_CI_START="-0.34589915047560915" LOG_EFFECT_SIZE="-0.177612432176214" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7666" O_E="0.0" SE="0.19770490272351054" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03908722856091277" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.618457838743986" CI_START="0.18025238318088993" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.974025974025974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-029.04" LOG_CI_END="1.3348247101532933" LOG_CI_START="-0.7441189846087122" LOG_EFFECT_SIZE="0.29535286277229067" METHOD="MH" MODIFIED="2012-02-22 15:37:03 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5775963474887091" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="0.556899136059344">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.618457838743986" CI_START="0.18025238318088993" DF="0" EFFECT_SIZE="1.974025974025974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-029.04.01" LOG_CI_END="1.3348247101532933" LOG_CI_START="-0.7441189846087122" LOG_EFFECT_SIZE="0.29535286277229067" MODIFIED="2008-07-28 08:53:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5775963474887091" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="0.556899136059344">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="21.618457838743986" CI_START="0.18025238318088993" EFFECT_SIZE="1.974025974025974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3348247101532933" LOG_CI_START="-0.7441189846087122" LOG_EFFECT_SIZE="0.29535286277229067" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7667" O_E="0.0" SE="1.2211818172404612" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="1.491285030758715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2013-03-18 11:38:43 -0400" MODIFIED_BY="[Empty name]" NO="30">
<NAME>Withdrawals six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8835791461663938" CI_START="0.7197836080796614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4406779661016949" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="0.45993187607693403" LOG_CI_START="-0.142798047932637" LOG_EFFECT_SIZE="0.1585669140721485" METHOD="MH" MODIFIED="2012-02-22 15:37:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3024192208266069" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.00000000000001" Z="1.0312593695485195">
<NAME>Total</NAME>
<GROUP_LABEL_1>Yisaipu</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8835791461663938" CI_START="0.7197836080796614" EFFECT_SIZE="1.4406779661016949" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.45993187607693403" LOG_CI_START="-0.142798047932637" LOG_EFFECT_SIZE="0.1585669140721485" MODIFIED="2010-05-20 22:57:29 -0400" MODIFIED_BY="[Empty name]" ORDER="696" O_E="0.0" SE="0.35404654092446414" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.12534895314057826" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.3024668061471026" CI_START="0.005410349823111209" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.040453074433656956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-030.02" LOG_CI_END="-0.5193222795177789" LOG_CI_START="-2.2667746533157778" LOG_EFFECT_SIZE="-1.3930484664167782" METHOD="MH" MODIFIED="2013-03-18 11:38:35 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.00177853154248153" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="3.124920442851806">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3024668061471026" CI_START="0.005410349823111209" DF="0" EFFECT_SIZE="0.040453074433656956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-030.02.01" LOG_CI_END="-0.5193222795177789" LOG_CI_START="-2.2667746533157778" LOG_EFFECT_SIZE="-1.3930484664167782" MODIFIED="2012-02-21 14:48:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.00177853154248153" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="3.124920442851806">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.3024668061471026" CI_START="0.005410349823111209" EFFECT_SIZE="0.040453074433656956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5193222795177789" LOG_CI_START="-2.2667746533157778" LOG_EFFECT_SIZE="-1.3930484664167782" MODIFIED="2012-01-31 11:44:04 -0500" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="1.0264621743977007" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.0536245954692556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7230420476415906" CI_START="0.2531789587847534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="0.5708979411218573" LOG_CI_START="-0.5965723905322018" LOG_EFFECT_SIZE="-0.0128372247051722" METHOD="MH" MODIFIED="2013-03-18 11:38:43 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.965619753928156" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.043102590963383564">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7230420476415906" CI_START="0.2531789587847534" DF="0" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-030.03.01" LOG_CI_END="0.5708979411218573" LOG_CI_START="-0.5965723905322018" LOG_EFFECT_SIZE="-0.0128372247051722" MODIFIED="2012-02-21 14:48:10 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.965619753928156" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.043102590963383564">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.7230420476415906" CI_START="0.2531789587847534" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5708979411218573" LOG_CI_START="-0.5965723905322018" LOG_EFFECT_SIZE="-0.0128372247051722" MODIFIED="2012-01-31 11:44:17 -0500" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="0.6857778518849397" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.4702912621359223" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2013-03-18 11:39:15 -0400" MODIFIED_BY="[Empty name]" NO="31">
<NAME>Withdrawals 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="1.2406456890991497" CI_END="1.0085447126912759" CI_START="0.6678184275405533" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8206855330355391" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="159" I2="0.0" I2_Q="13.905865062411998" ID="CMP-031.01" LOG_CI_END="0.003695156931171659" LOG_CI_START="-0.1753416013511888" LOG_EFFECT_SIZE="-0.08582322221000857" METHOD="MH" MODIFIED="2012-02-22 15:38:05 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5377711071047162" P_Q="0.2811507213943809" P_Z="0.060236272005519176" Q="1.161519307586896" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="638" TOTAL_2="662" WEIGHT="200.0" Z="1.8790602129145872">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4168134574238913" CI_START="0.6691965259699133" DF="0" EFFECT_SIZE="0.9737179487179487" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" I2="0.0" ID="CMP-031.01.01" LOG_CI_END="0.15131267329295847" LOG_CI_START="-0.17444632227630902" LOG_EFFECT_SIZE="-0.011566824491675263" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8893031050570805" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.1391860837461282">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4168134574238913" CI_START="0.6691965259699133" EFFECT_SIZE="0.9737179487179487" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.15131267329295847" LOG_CI_START="-0.17444632227630902" LOG_EFFECT_SIZE="-0.011566824491675263" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7645" O_E="0.0" SE="0.19135244653042238" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.03661575879317815" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10151871905667884" CI_END="0.9739751740672977" CI_START="0.5939618342229872" DF="1" EFFECT_SIZE="0.7605945574855669" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="114" I2="0.0" ID="CMP-031.01.02" LOG_CI_END="-0.011452112836979228" LOG_CI_START="-0.2262414602694339" LOG_EFFECT_SIZE="-0.11884678655320657" MODIFIED="2012-01-31 12:35:38 -0500" MODIFIED_BY="Anne Lethaby" NO="2" P_CHI2="0.750014695460451" P_Z="0.030085247297918435" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="445" WEIGHT="100.00000000000001" Z="2.1689662369858067">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0946822378603593" CI_START="0.47641899161745815" EFFECT_SIZE="0.7221685453569512" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" LOG_CI_END="0.039288071348387216" LOG_CI_START="-0.32201093444730566" LOG_EFFECT_SIZE="-0.1413614315494592" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7646" O_E="0.0" SE="0.2122288244633126" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.045041073933079545" WEIGHT="39.17021043895598"/>
<DICH_DATA CI_END="1.0672466389354927" CI_START="0.5778947244798766" EFFECT_SIZE="0.785338272567752" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="69" LOG_CI_END="0.028264795760765498" LOG_CI_START="-0.23815127012911175" LOG_EFFECT_SIZE="-0.10494323718417314" MODIFIED="2008-07-11 14:14:02 -0400" MODIFIED_BY="Anne Lethaby" ORDER="756" O_E="0.0" SE="0.1564941158845091" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.024490408306474164" WEIGHT="60.82978956104403"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1239824257237503" CI_END="1.761843327068078" CI_START="0.7456380688294066" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.146166417225273" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" I2="35.979153290638344" I2_Q="55.50088396931712" ID="CMP-031.02" LOG_CI_END="0.24596728590630546" LOG_CI_START="-0.12747192702144994" LOG_EFFECT_SIZE="0.0592476794424278" METHOD="MH" MODIFIED="2013-03-18 11:39:15 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20971816669207244" P_Q="0.1338534317094895" P_Z="0.533999195285503" Q="2.2472356514014424" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="638" TOTAL_2="662" WEIGHT="200.0" Z="0.6219128246566736">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5162986991848175" CI_START="0.8472521592145821" DF="0" EFFECT_SIZE="1.9561298076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-031.02.01" LOG_CI_END="0.6547826575925658" LOG_CI_START="-0.07198731569355453" LOG_EFFECT_SIZE="0.29139767094950564" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11602221305874878" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.5716910748458737">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.516298699184817" CI_START="0.8472521592145821" EFFECT_SIZE="1.9561298076923077" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6547826575925657" LOG_CI_START="-0.07198731569355453" LOG_EFFECT_SIZE="0.29139767094950564" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7647" O_E="0.0" SE="0.4269082798776556" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.18225067942809875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8541072725451253" CI_END="1.5401996427529303" CI_START="0.5546092248420984" DF="1" EFFECT_SIZE="0.9242342397732729" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-031.02.02" LOG_CI_END="0.1875770183211245" LOG_CI_START="-0.256012911056929" LOG_EFFECT_SIZE="-0.034217946367902236" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.35539308387294977" P_Z="0.7623638393663089" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="445" WEIGHT="100.0" Z="0.3023781112436121">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.2553652036646525" CI_START="0.5274716052795506" EFFECT_SIZE="1.3103864734299517" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.5125997170330527" LOG_CI_START="-0.2778009142337164" LOG_EFFECT_SIZE="0.11739940139966819" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7648" O_E="0.0" SE="0.4642852433523257" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.2155607871947283" WEIGHT="27.33285317780979"/>
<DICH_DATA CI_END="1.4533817738409849" CI_START="0.41752418227971877" EFFECT_SIZE="0.7789878283151825" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.1623797096140056" LOG_CI_START="-0.37931836586540835" LOG_EFFECT_SIZE="-0.1084693281257014" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7649" O_E="0.0" SE="0.3181961309853272" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.10124877777403149" WEIGHT="72.6671468221902"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8135120329052545" CI_END="0.8728240712318098" CI_START="0.4417977565523098" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6209764218833651" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-031.03" LOG_CI_END="-0.059073285037733424" LOG_CI_START="-0.3547764938050684" LOG_EFFECT_SIZE="-0.20692488942140091" METHOD="MH" MODIFIED="2012-02-22 15:38:05 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.40383217179634945" P_Q="0.5435455494795485" P_Z="0.00608701780893711" Q="0.369008391404906" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="638" TOTAL_2="662" WEIGHT="200.0" Z="2.7430566780895895">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0156753558100586" CI_START="0.26790319407763746" DF="0" EFFECT_SIZE="0.5216346153846154" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" I2="0.0" ID="CMP-031.03.01" LOG_CI_END="0.006754914925609484" LOG_CI_START="-0.5720221084820359" LOG_EFFECT_SIZE="-0.2826335967782132" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05559276027904225" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.00000000000001" Z="1.9142144490976225">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0156753558100586" CI_START="0.26790319407763746" EFFECT_SIZE="0.5216346153846154" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="0.006754914925609484" LOG_CI_START="-0.5720221084820359" LOG_EFFECT_SIZE="-0.2826335967782132" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7650" O_E="0.0" SE="0.33997648854212276" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.11558401276143213" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3979996907153582" CI_END="0.9862095445351616" CI_START="0.44618173793793614" DF="1" EFFECT_SIZE="0.663346582528077" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="56" I2="28.469225948948623" ID="CMP-031.03.02" LOG_CI_END="-0.006030798682903139" LOG_CI_START="-0.35048820920926116" LOG_EFFECT_SIZE="-0.17825950394608214" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23705898906863465" P_Z="0.04249960722011112" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="445" WEIGHT="100.0" Z="2.0285945197254613">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9557942398225496" CI_START="0.24153343333963762" EFFECT_SIZE="0.480475040257649" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.01963559112095782" LOG_CI_START="-0.6170227452025806" LOG_EFFECT_SIZE="-0.3183291681617692" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7651" O_E="0.0" SE="0.35090817142164965" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.12313654477048587" WEIGHT="42.545941766333115"/>
<DICH_DATA CI_END="1.3032134507091946" CI_START="0.4895809095776384" EFFECT_SIZE="0.7987668161434978" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" LOG_CI_END="0.11501555375796896" LOG_CI_START="-0.3101755251491195" LOG_EFFECT_SIZE="-0.09757998569557524" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7652" O_E="0.0" SE="0.24975934447980896" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.06237973015498388" WEIGHT="57.45405823366688"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.38004899006723863" CI_END="11.256933014152327" CI_START="0.3819506120600631" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0735458651003147" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-031.04" LOG_CI_END="1.0514200817707822" LOG_CI_START="-0.41799278969679354" LOG_EFFECT_SIZE="0.3167136460369943" METHOD="MH" MODIFIED="2012-02-22 15:38:05 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.826938933378465" P_Q="0.7570866859760197" P_Z="0.3981713401168816" Q="0.09567191147966525" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="638" TOTAL_2="662" WEIGHT="200.0" Z="0.8448916593808036">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.38235840519039" CI_START="0.12819463813414808" DF="0" EFFECT_SIZE="3.1291866028708135" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-031.04.01" LOG_CI_END="1.8829930636543153" LOG_CI_START="-0.8921301392278886" LOG_EFFECT_SIZE="0.49543146221321327" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4840467216868629" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.6998088025334651">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="76.38235840519039" CI_START="0.12819463813414808" EFFECT_SIZE="3.1291866028708135" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8829930636543153" LOG_CI_START="-0.8921301392278886" LOG_EFFECT_SIZE="0.49543146221321327" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7653" O_E="0.0" SE="1.6301211064544097" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="2.6572948217081485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2729811783704883" CI_END="12.953078782124292" CI_START="0.22939324261061553" DF="1" EFFECT_SIZE="1.7237600597595522" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-031.04.02" LOG_CI_END="1.1123730069631674" LOG_CI_START="-0.6394193795478548" LOG_EFFECT_SIZE="0.23647681370765639" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6013390013925517" P_Z="0.5966969918452607" STUDIES="2" TAU2="0.0" TOTAL_1="430" TOTAL_2="445" WEIGHT="100.0" Z="0.5291563562151353">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="76.74851992253109" CI_START="0.12881273984379757" EFFECT_SIZE="3.144230769230769" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8850700089612695" LOG_CI_START="-0.8900411822382581" LOG_EFFECT_SIZE="0.4975144133615057" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7654" O_E="0.0" SE="1.6301140507325467" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="2.6572718183956714" WEIGHT="33.053797691364466"/>
<DICH_DATA CI_END="16.245695887971742" CI_START="0.06434601394142611" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2107383191795071" LOG_CI_START="-1.1914783512749207" LOG_EFFECT_SIZE="0.009629983952293144" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7655" O_E="0.0" SE="1.4110739633892277" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="1.991129730154984" WEIGHT="66.94620230863553"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" MODIFIED="2013-03-18 11:39:52 -0400" MODIFIED_BY="[Empty name]" NO="32">
<NAME>Withdrawals two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="3.687095212204001" CI_END="0.9673700716716114" CI_START="0.4586430171550563" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6660912312716412" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="136" I2="72.87837871151042" I2_Q="0.0" ID="CMP-032.01" LOG_CI_END="-0.014407352867483058" LOG_CI_START="-0.3385252142442785" LOG_EFFECT_SIZE="-0.17646628355588076" METHOD="MH" MODIFIED="2012-04-26 16:19:08 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05483525996762584" P_Q="1.0" P_Z="0.03282571072200668" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0532188556352839" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="2.134208579471522">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.687095212204001" CI_END="0.9673700716716114" CI_START="0.4586430171550563" DF="1" EFFECT_SIZE="0.6660912312716412" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="136" I2="72.87837871151042" ID="CMP-032.01.01" LOG_CI_END="-0.014407352867483058" LOG_CI_START="-0.3385252142442785" LOG_EFFECT_SIZE="-0.17646628355588076" MODIFIED="2012-01-31 12:35:38 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05483525996762584" P_Z="0.03282571072200668" STUDIES="2" TAU2="0.0532188556352839" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="2.134208579471522">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.7442849545100221" CI_START="0.39549015632300893" EFFECT_SIZE="0.5425471159337522" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="-0.12826076004792106" LOG_CI_START="-0.40286432154127577" LOG_EFFECT_SIZE="-0.26556254079459835" MODIFIED="2012-01-31 12:35:38 -0500" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="0.1613034913307486" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.02601881631548889" WEIGHT="45.745610313177856"/>
<DICH_DATA CI_END="0.9951615058836061" CI_START="0.630115609605772" EFFECT_SIZE="0.7918754945924558" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="102" LOG_CI_END="-0.002106431392870691" LOG_CI_START="-0.20057976164549537" LOG_EFFECT_SIZE="-0.10134309651918305" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7660" O_E="0.0" SE="0.11658421664922138" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.013591879571712588" WEIGHT="54.254389686822144"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.136958746872544" CI_END="2.4812378240724207" CI_START="0.04221801711374543" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3236555899717506" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="56" I2="94.48639645733088" I2_Q="0.0" ID="CMP-032.02" LOG_CI_END="0.3946683929430052" LOG_CI_START="-1.3745021683941034" LOG_EFFECT_SIZE="-0.4899168877255491" METHOD="MH" MODIFIED="2013-03-18 11:39:52 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.055761381736243E-5" P_Q="1.0" P_Z="0.27769921293062916" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.0422462408408824" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.0855024115191159">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.136958746872544" CI_END="2.4812378240724207" CI_START="0.04221801711374543" DF="1" EFFECT_SIZE="0.3236555899717506" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="56" I2="94.48639645733088" ID="CMP-032.02.01" LOG_CI_END="0.3946683929430052" LOG_CI_START="-1.3745021683941034" LOG_EFFECT_SIZE="-0.4899168877255491" MODIFIED="2012-01-31 12:39:15 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.055761381736243E-5" P_Z="0.27769921293062916" STUDIES="2" TAU2="2.0422462408408824" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.0855024115191159">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.254577687555264" CI_START="0.04929479067997216" EFFECT_SIZE="0.11202389843166542" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="26" LOG_CI_END="-0.5941796627258098" LOG_CI_START="-1.3071989731868456" LOG_EFFECT_SIZE="-0.9506893179563277" MODIFIED="2012-01-31 12:39:15 -0500" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.4188310724673224" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.17541946726412747" WEIGHT="48.69883045553779"/>
<DICH_DATA CI_END="1.448785474660347" CI_START="0.5419510614988218" EFFECT_SIZE="0.8860986547085202" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.1610040831463651" LOG_CI_START="-0.26603992873946775" LOG_EFFECT_SIZE="-0.05251792279655133" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7661" O_E="0.0" SE="0.2508477664836896" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.06292460194985566" WEIGHT="51.301169544462205"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9100496036528165" CI_END="1.1256426366022338" CI_START="0.5520612010097723" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7883042723913374" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-032.03" LOG_CI_END="0.05140053475574616" LOG_CI_START="-0.25801277410504014" LOG_EFFECT_SIZE="-0.103306119674647" METHOD="MH" MODIFIED="2012-02-22 15:38:20 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34010138783139854" P_Q="1.0" P_Z="0.1906104194092215" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.00000000000001" Z="1.3087754672892402">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9100496036528165" CI_END="1.1256426366022338" CI_START="0.5520612010097723" DF="1" EFFECT_SIZE="0.7883042723913374" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="55" I2="0.0" ID="CMP-032.03.01" LOG_CI_END="0.05140053475574616" LOG_CI_START="-0.25801277410504014" LOG_EFFECT_SIZE="-0.103306119674647" MODIFIED="2012-01-31 13:13:05 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34010138783139854" P_Z="0.1906104194092215" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.00000000000001" Z="1.3087754672892402">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.3383714135331712" CI_START="0.5101725673659688" EFFECT_SIZE="1.0922330097087378" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.3689134931547655" LOG_CI_START="-0.29228289767034743" LOG_EFFECT_SIZE="0.03831529774220907" MODIFIED="2012-01-31 13:13:05 -0500" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.3883900329455918" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.1508468176914779" WEIGHT="18.814337867687453"/>
<DICH_DATA CI_END="1.0763597210655338" CI_START="0.4787785601380318" EFFECT_SIZE="0.7178704322106669" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="47" LOG_CI_END="0.0319574374693863" LOG_CI_START="-0.31986530568046" LOG_EFFECT_SIZE="-0.14395393410553686" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7662" O_E="0.0" SE="0.20666242087688566" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.04270935620269503" WEIGHT="81.18566213231256"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.245695887971742" CI_START="0.06434601394142611" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-032.04" LOG_CI_END="1.2107383191795071" LOG_CI_START="-1.1914783512749207" LOG_EFFECT_SIZE="0.009629983952293144" METHOD="MH" MODIFIED="2012-02-22 15:38:20 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9874624216029161" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.015714170957462196">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.245695887971742" CI_START="0.06434601394142611" DF="0" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-032.04.01" LOG_CI_END="1.2107383191795071" LOG_CI_START="-1.1914783512749207" LOG_EFFECT_SIZE="0.009629983952293144" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9874624216029161" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.015714170957462196">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="16.245695887971742" CI_START="0.06434601394142611" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2107383191795071" LOG_CI_START="-1.1914783512749207" LOG_EFFECT_SIZE="0.009629983952293144" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7663" O_E="0.0" SE="1.4110739633892277" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="1.991129730154984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" MODIFIED="2013-03-18 11:40:08 -0400" MODIFIED_BY="[Empty name]" NO="33">
<NAME>Withdrawals three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.004633737004201" CI_START="0.7246671714801987" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8532438623092558" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" I2="0.0" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="0.0020077582837573302" LOG_CI_START="-0.13986141243352426" LOG_EFFECT_SIZE="-0.06892682707488348" METHOD="MH" MODIFIED="2012-02-22 15:38:36 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.05684659928291001" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.9044884516116445">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.004633737004201" CI_START="0.7246671714801987" DF="0" EFFECT_SIZE="0.8532438623092558" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" I2="0.0" ID="CMP-033.01.01" LOG_CI_END="0.0020077582837573302" LOG_CI_START="-0.13986141243352426" LOG_EFFECT_SIZE="-0.06892682707488348" MODIFIED="2008-07-28 11:20:27 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05684659928291001" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.9044884516116445">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.004633737004201" CI_START="0.7246671714801987" EFFECT_SIZE="0.8532438623092558" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="139" LOG_CI_END="0.0020077582837573302" LOG_CI_START="-0.13986141243352426" LOG_EFFECT_SIZE="-0.06892682707488348" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7668" O_E="0.0" SE="0.08333465314305229" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.006944664414472834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.766859120887202E-31" CI_END="1.4273383404244528" CI_START="0.6240348206438673" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9437737150741636" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" I2="100.0" I2_Q="100.0" ID="CMP-033.02" LOG_CI_END="0.15452693174288792" LOG_CI_START="-0.20479117635672547" LOG_EFFECT_SIZE="-0.025132122306918768" METHOD="MH" MODIFIED="2012-02-22 15:38:36 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.7839499966639564" Q="1.0808043440965632E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.27417518608864944">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.766859120887202E-31" CI_END="1.4273383404244528" CI_START="0.6240348206438673" DF="0" EFFECT_SIZE="0.9437737150741636" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" I2="100.0" ID="CMP-033.02.01" LOG_CI_END="0.15452693174288792" LOG_CI_START="-0.20479117635672547" LOG_EFFECT_SIZE="-0.025132122306918768" MODIFIED="2008-07-28 11:20:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.7839499966639564" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.27417518608864944">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4273383404244528" CI_START="0.6240348206438672" EFFECT_SIZE="0.9437737150741635" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="39" LOG_CI_END="0.15452693174288792" LOG_CI_START="-0.20479117635672553" LOG_EFFECT_SIZE="-0.025132122306918817" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7669" O_E="0.0" SE="0.2110652353510338" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.04454853357378729" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.112240757616872" CI_START="0.5286688101492157" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7668161434977578" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-033.03" LOG_CI_END="0.04619880557974107" LOG_CI_START="-0.27681631089175474" LOG_EFFECT_SIZE="-0.11530875265600685" METHOD="MH" MODIFIED="2012-02-22 15:38:36 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.16171658837200775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.3993215226381146">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.112240757616872" CI_START="0.5286688101492157" DF="0" EFFECT_SIZE="0.7668161434977578" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="52" I2="0.0" ID="CMP-033.03.01" LOG_CI_END="0.04619880557974107" LOG_CI_START="-0.27681631089175474" LOG_EFFECT_SIZE="-0.11530875265600685" MODIFIED="2008-07-28 11:20:36 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16171658837200775" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="1.3993215226381146">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.112240757616872" CI_START="0.5286688101492157" EFFECT_SIZE="0.7668161434977578" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="52" LOG_CI_END="0.04619880557974107" LOG_CI_START="-0.27681631089175474" LOG_EFFECT_SIZE="-0.11530875265600685" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7670" O_E="0.0" SE="0.18974067836597072" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.036001525026778745" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.391217106874" CI_START="0.1867421085876894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0448430493273544" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-033.04" LOG_CI_END="1.3500777009230707" LOG_CI_START="-0.728757741690522" LOG_EFFECT_SIZE="0.31065997961627434" METHOD="MH" MODIFIED="2012-02-22 15:38:36 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5580154419479955" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.5857917938134963">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.391217106874" CI_START="0.1867421085876894" DF="0" EFFECT_SIZE="2.0448430493273544" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-033.04.01" LOG_CI_END="1.3500777009230707" LOG_CI_START="-0.728757741690522" LOG_EFFECT_SIZE="0.31065997961627434" MODIFIED="2008-07-28 11:20:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5580154419479955" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.5857917938134963">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="22.391217106874" CI_START="0.1867421085876894" EFFECT_SIZE="2.0448430493273544" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3500777009230707" LOG_CI_START="-0.728757741690522" LOG_EFFECT_SIZE="0.31065997961627434" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7671" O_E="0.0" SE="1.2211182293926268" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="1.491129730154984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" MODIFIED="2013-03-18 11:40:57 -0400" MODIFIED_BY="[Empty name]" NO="34">
<NAME>Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9209899386127424" CI_START="0.10529121026179225" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31140350877192985" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-034.01" LOG_CI_END="-0.035745114242710416" LOG_CI_START="-0.9776078823200465" LOG_EFFECT_SIZE="-0.5066764982813785" METHOD="MH" MODIFIED="2013-03-18 11:40:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03496779274072461" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="2.108731169980449">
<NAME>Total</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9209899386127424" CI_START="0.10529121026179225" DF="0" EFFECT_SIZE="0.31140350877192985" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-034.01.01" LOG_CI_END="-0.035745114242710416" LOG_CI_START="-0.9776078823200465" LOG_EFFECT_SIZE="-0.5066764982813785" MODIFIED="2013-03-18 11:40:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03496779274072461" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="2.108731169980449">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9209899386127424" CI_START="0.10529121026179225" EFFECT_SIZE="0.31140350877192985" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.035745114242710416" LOG_CI_START="-0.9776078823200465" LOG_EFFECT_SIZE="-0.5066764982813785" MODIFIED="2012-01-31 08:15:33 -0500" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.5532548522645216" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.3060909315542377" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4102821429348427" CI_END="24.82876950214898" CI_START="0.029491568007153735" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8557098482000609" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="70.67691299173816" I2_Q="0.0" ID="CMP-034.02" LOG_CI_END="1.3949551967326275" LOG_CI_START="-1.530302136273192" LOG_EFFECT_SIZE="-0.06767346977028221" METHOD="MH" MODIFIED="2013-03-18 11:40:48 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06479146356920729" P_Q="1.0" P_Z="0.9277433880593547" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.205012760936384" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.09068437293502847">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4102821429348427" CI_END="24.82876950214898" CI_START="0.029491568007153735" DF="1" EFFECT_SIZE="0.8557098482000609" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="70.67691299173816" ID="CMP-034.02.01" LOG_CI_END="1.3949551967326275" LOG_CI_START="-1.530302136273192" LOG_EFFECT_SIZE="-0.06767346977028221" MODIFIED="2013-03-18 11:40:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06479146356920729" P_Z="0.9277433880593547" STUDIES="2" TAU2="4.205012760936384" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.09068437293502847">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="35.871850149554575" CI_START="0.46387173205950344" EFFECT_SIZE="4.079207920792079" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5547537767044228" LOG_CI_START="-0.3336020922034388" LOG_EFFECT_SIZE="0.610575842250492" MODIFIED="2012-01-31 11:45:59 -0500" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="1.1092295849087837" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="1.2303902720369124" WEIGHT="54.321481398912795"/>
<DICH_DATA CI_END="2.541273085129446" CI_START="0.00702160065173256" EFFECT_SIZE="0.13358070500927643" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4050513368300773" LOG_CI_START="-2.153563874341018" LOG_EFFECT_SIZE="-0.8742562687554702" MODIFIED="2012-01-31 08:16:18 -0500" MODIFIED_BY="[Empty name]" ORDER="399" O_E="0.0" SE="1.5029432403914607" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="2.2588383838383836" WEIGHT="45.678518601087205"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.017053527242216742" CI_END="0.861361579760763" CI_START="0.02832421901111945" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1561966517980065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" I2_Q="100.0" ID="CMP-034.03" LOG_CI_END="-0.06481450344643193" LOG_CI_START="-1.5478420561807993" LOG_EFFECT_SIZE="-0.8063282798136157" METHOD="MH" MODIFIED="2013-03-18 11:40:57 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8961003276882272" P_Q="0.0" P_Z="0.03306598103214919" Q="6.496909353889645E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="2.131281222977913">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.017053527242216742" CI_END="0.861361579760763" CI_START="0.02832421901111945" DF="1" EFFECT_SIZE="0.1561966517980065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-034.03.01" LOG_CI_END="-0.06481450344643193" LOG_CI_START="-1.5478420561807993" LOG_EFFECT_SIZE="-0.8063282798136157" MODIFIED="2013-03-18 11:40:57 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8961003276882272" P_Z="0.03306598103214919" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="2.131281222977913">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3867806943390033" CI_START="0.02083154177515805" EFFECT_SIZE="0.16996699669966997" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1420077871230956" LOG_CI_START="-1.6812785860453234" LOG_EFFECT_SIZE="-0.769635399461114" MODIFIED="2012-01-31 11:46:17 -0500" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="1.0710074410122365" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="1.1470569387035792" WEIGHT="62.15512968775814"/>
<DICH_DATA CI_END="2.541273085129446" CI_START="0.00702160065173256" EFFECT_SIZE="0.13358070500927643" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4050513368300773" LOG_CI_START="-2.153563874341018" LOG_EFFECT_SIZE="-0.8742562687554702" MODIFIED="2012-01-31 08:16:51 -0500" MODIFIED_BY="[Empty name]" ORDER="400" O_E="0.0" SE="1.5029432403914607" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="2.2588383838383836" WEIGHT="37.844870312241866"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-035" MODIFIED="2013-03-18 11:41:53 -0400" MODIFIED_BY="[Empty name]" NO="35">
<NAME>Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7722313003722011" CI_START="0.3826197162879097" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5435723696593262" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-035.01" LOG_CI_END="-0.11225259936641842" LOG_CI_START="-0.4172326546578529" LOG_EFFECT_SIZE="-0.26474262701213563" METHOD="MH" MODIFIED="2013-03-18 11:41:23 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="6.671037524841742E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="3.402753754637935">
<NAME>Total</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7722313003722011" CI_START="0.3826197162879097" DF="0" EFFECT_SIZE="0.5435723696593262" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="69" I2="0.0" ID="CMP-035.01.01" LOG_CI_END="-0.11225259936641842" LOG_CI_START="-0.4172326546578529" LOG_EFFECT_SIZE="-0.26474262701213563" MODIFIED="2013-03-18 11:41:23 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="6.671037524841742E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="3.402753754637935">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.7722313003722011" CI_START="0.3826197162879097" EFFECT_SIZE="0.5435723696593262" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="69" LOG_CI_END="-0.11225259936641842" LOG_CI_START="-0.4172326546578529" LOG_EFFECT_SIZE="-0.26474262701213563" MODIFIED="2008-07-11 14:09:20 -0400" MODIFIED_BY="Anne Lethaby" ORDER="751" O_E="0.0" SE="0.17914679415381005" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03209357385558759" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9084343893898653" CI_START="0.14426292564076632" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.362012987012987" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-035.02" LOG_CI_END="-0.04170643363376273" LOG_CI_START="-0.8408452645987669" LOG_EFFECT_SIZE="-0.4412758491162648" METHOD="MH" MODIFIED="2013-03-18 11:41:31 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.030422778808391907" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="2.1645419744421983">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9084343893898653" CI_START="0.14426292564076632" DF="0" EFFECT_SIZE="0.362012987012987" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" ID="CMP-035.02.01" LOG_CI_END="-0.04170643363376273" LOG_CI_START="-0.8408452645987669" LOG_EFFECT_SIZE="-0.4412758491162648" MODIFIED="2013-03-18 11:41:31 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.030422778808391907" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="2.1645419744421983">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9084343893898653" CI_START="0.14426292564076632" EFFECT_SIZE="0.362012987012987" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.04170643363376273" LOG_CI_START="-0.8408452645987669" LOG_EFFECT_SIZE="-0.4412758491162648" MODIFIED="2008-07-11 14:10:00 -0400" MODIFIED_BY="Anne Lethaby" ORDER="752" O_E="0.0" SE="0.46941810510985504" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.2203533574049269" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5729502921699612" CI_START="0.546025888194362" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9267532467532468" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" I2_Q="100.0" ID="CMP-035.03" LOG_CI_END="0.19671499841642398" LOG_CI_START="-0.26278676602525436" LOG_EFFECT_SIZE="-0.03303588380441521" METHOD="MH" MODIFIED="2013-03-18 11:41:43 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7780790355244906" Q="2.6435706094953274E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.281823259298157">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5729502921699612" CI_START="0.546025888194362" DF="0" EFFECT_SIZE="0.9267532467532468" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-035.03.01" LOG_CI_END="0.19671499841642398" LOG_CI_START="-0.26278676602525436" LOG_EFFECT_SIZE="-0.03303588380441521" MODIFIED="2013-03-18 11:41:43 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.7780790355244906" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.281823259298157">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5729502921699612" CI_START="0.546025888194362" EFFECT_SIZE="0.9267532467532468" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.19671499841642398" LOG_CI_START="-0.26278676602525436" LOG_EFFECT_SIZE="-0.03303588380441521" MODIFIED="2008-07-11 14:10:38 -0400" MODIFIED_BY="Anne Lethaby" ORDER="753" O_E="0.0" SE="0.2699136110034596" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.0728533574049269" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.339754120917931" CI_START="0.060752949572239826" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-035.04" LOG_CI_END="1.1858183984145028" LOG_CI_START="-1.21643263210247" LOG_EFFECT_SIZE="-0.015307116843983656" METHOD="MH" MODIFIED="2013-03-18 11:41:53 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9800727210362137" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.02497773741397707">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.339754120917931" CI_START="0.060752949572239826" DF="0" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-035.04.01" LOG_CI_END="1.1858183984145028" LOG_CI_START="-1.21643263210247" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2013-03-18 11:41:53 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.9800727210362137" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.02497773741397707">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="15.339754120917931" CI_START="0.060752949572239826" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1858183984145028" LOG_CI_START="-1.21643263210247" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2008-07-11 14:11:15 -0400" MODIFIED_BY="Anne Lethaby" ORDER="754" O_E="0.0" SE="1.411094146660052" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="1.9911866907382603" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-036" MODIFIED="2013-03-18 11:42:52 -0400" MODIFIED_BY="[Empty name]" NO="36">
<NAME>Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.26333930414125845" CI_END="0.9998828759300986" CI_START="0.620231866845833" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7875018874677733" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="107" I2="0.0" I2_Q="100.0" ID="CMP-036.01" LOG_CI_END="-5.086931632505915E-5" LOG_CI_START="-0.20744592394235079" LOG_EFFECT_SIZE="-0.10374839662933792" METHOD="MH" MODIFIED="2013-03-18 11:42:25 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6078352785460281" P_Q="0.0" P_Z="0.04988771952111103" Q="5.190730489509158E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="1.960925454215356">
<NAME>Total</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.26333930414125845" CI_END="0.9998828759300986" CI_START="0.620231866845833" DF="1" EFFECT_SIZE="0.7875018874677733" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="107" I2="0.0" ID="CMP-036.01.01" LOG_CI_END="-5.086931632505915E-5" LOG_CI_START="-0.20744592394235079" LOG_EFFECT_SIZE="-0.10374839662933792" MODIFIED="2013-03-18 11:42:25 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.6078352785460281" P_Z="0.04988771952111103" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="1.960925454215356">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4001057683138631" CI_START="0.5457293077959481" EFFECT_SIZE="0.8741159830268741" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.14616084486395708" LOG_CI_START="-0.2630227222801242" LOG_EFFECT_SIZE="-0.05843093870808357" MODIFIED="2012-02-16 17:08:28 -0500" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.2403564528317574" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.05777122441786482" WEIGHT="25.643836229314754"/>
<DICH_DATA CI_END="0.9994409477782756" CI_START="0.574325135762622" EFFECT_SIZE="0.7576305550989095" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="79" LOG_CI_END="-2.4286118736090344E-4" LOG_CI_START="-0.24084217608498149" LOG_EFFECT_SIZE="-0.12054251863617119" MODIFIED="2008-07-11 13:53:25 -0400" MODIFIED_BY="Anne Lethaby" ORDER="747" O_E="0.0" SE="0.14132922855667907" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.019973950844426026" WEIGHT="74.35616377068526"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7461000526525456" CI_END="1.5978658275506632" CI_START="0.18271943214432573" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.540334282322416" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="32" I2="63.58472084678531" I2_Q="0.0" ID="CMP-036.02" LOG_CI_END="0.20354030889488342" LOG_CI_START="-0.7382152631330697" LOG_EFFECT_SIZE="-0.2673374771190931" METHOD="MH" MODIFIED="2013-03-18 11:42:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09749204169892689" P_Q="1.0" P_Z="0.2658134876066385" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.39678634769177484" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="1.1127554589200157">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7461000526525456" CI_END="1.5978658275506632" CI_START="0.18271943214432573" DF="1" EFFECT_SIZE="0.540334282322416" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="32" I2="63.58472084678531" ID="CMP-036.02.01" LOG_CI_END="0.20354030889488342" LOG_CI_START="-0.7382152631330697" LOG_EFFECT_SIZE="-0.2673374771190931" MODIFIED="2013-03-18 11:42:33 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.09749204169892689" P_Z="0.2658134876066385" STUDIES="2" TAU2="0.39678634769177484" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="1.1127554589200157">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.056909954136476" CI_START="0.3402115516711657" EFFECT_SIZE="1.0198019801980198" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4852826461197394" LOG_CI_START="-0.4682509442746801" LOG_EFFECT_SIZE="0.008515850922529638" MODIFIED="2012-01-31 12:42:55 -0500" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.5601103510650788" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.31372360537024574" WEIGHT="43.07065088413119"/>
<DICH_DATA CI_END="0.6971320580669635" CI_START="0.16018027493009301" EFFECT_SIZE="0.3341658341658342" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="26" LOG_CI_END="-0.1566849454926465" LOG_CI_START="-0.7953909652583069" LOG_EFFECT_SIZE="-0.4760379553754767" MODIFIED="2008-07-11 13:54:14 -0400" MODIFIED_BY="Anne Lethaby" ORDER="748" O_E="0.0" SE="0.37517907765613717" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.1407593403109098" WEIGHT="56.92934911586881"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.172570251044589" CI_END="1.628544302312549" CI_START="0.37776379350221984" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7843500962759006" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="68.47981539035287" I2_Q="0.0" ID="CMP-036.03" LOG_CI_END="0.211799577446898" LOG_CI_START="-0.4227796690603264" LOG_EFFECT_SIZE="-0.10549004580671416" METHOD="MH" MODIFIED="2013-03-18 11:42:43 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07488455748463174" P_Q="1.0" P_Z="0.5146373449704684" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19434403479182946" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.6516339500437366">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.172570251044589" CI_END="1.628544302312549" CI_START="0.37776379350221984" DF="1" EFFECT_SIZE="0.7843500962759006" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="68.47981539035287" ID="CMP-036.03.01" LOG_CI_END="0.211799577446898" LOG_CI_START="-0.4227796690603264" LOG_EFFECT_SIZE="-0.10549004580671416" MODIFIED="2013-03-18 11:42:43 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.07488455748463174" P_Z="0.5146373449704684" STUDIES="2" TAU2="0.19434403479182946" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.6516339500437366">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.034787728371852" CI_START="0.25125831373458235" EFFECT_SIZE="0.5099009900990099" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.014851269743007964" LOG_CI_START="-0.5998795592259111" LOG_EFFECT_SIZE="-0.29251414474145154" MODIFIED="2012-02-16 17:09:26 -0500" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.36109593190302275" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.13039027203691245" WEIGHT="42.787682147367455"/>
<DICH_DATA CI_END="1.6667510050299919" CI_START="0.7028952508923807" EFFECT_SIZE="1.082382264200446" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="33" LOG_CI_END="0.22187072567181662" LOG_CI_START="-0.15310939098156898" LOG_EFFECT_SIZE="0.03438066734512384" MODIFIED="2008-07-11 13:54:56 -0400" MODIFIED_BY="Anne Lethaby" ORDER="749" O_E="0.0" SE="0.22026517670371223" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.04851674806831758" WEIGHT="57.212317852632545"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2361739869340268" CI_END="4.50380715925346" CI_START="0.07838564402160696" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5941664957965962" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-036.04" LOG_CI_END="0.6535797869354193" LOG_CI_START="-1.105763469115233" LOG_EFFECT_SIZE="-0.22609184108990693" METHOD="MH" MODIFIED="2013-03-18 11:42:52 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6269832482326866" P_Q="1.0" P_Z="0.6144392401337873" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.5037469114802606">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2361739869340268" CI_END="4.50380715925346" CI_START="0.07838564402160696" DF="1" EFFECT_SIZE="0.5941664957965962" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-036.04.01" LOG_CI_END="0.6535797869354193" LOG_CI_START="-1.105763469115233" LOG_EFFECT_SIZE="-0.22609184108990693" MODIFIED="2013-03-18 11:42:52 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.6269832482326866" P_Z="0.6144392401337873" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.5037469114802606">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.246084574500596" CI_START="0.014007997026340448" EFFECT_SIZE="0.33986928104575165" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9162477847523345" LOG_CI_START="-1.8536239591179335" LOG_EFFECT_SIZE="-0.46868808718279964" MODIFIED="2012-02-16 17:14:20 -0500" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="1.627036373435657" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="2.6472473604826545" WEIGHT="59.34488415009227"/>
<DICH_DATA CI_END="15.339754120917931" CI_START="0.060752949572239826" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1858183984145028" LOG_CI_START="-1.21643263210247" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2008-07-11 13:56:03 -0400" MODIFIED_BY="Anne Lethaby" ORDER="750" O_E="0.0" SE="1.411094146660052" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="1.9911866907382603" WEIGHT="40.65511584990772"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-037" MODIFIED="2013-03-18 11:43:56 -0400" MODIFIED_BY="[Empty name]" NO="37">
<NAME>Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0013812492619887" CI_START="0.6778611155941403" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8238916256157636" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="116" I2="0.0" I2_Q="100.0" ID="CMP-037.01" LOG_CI_END="5.994550294461842E-4" LOG_CI_START="-0.16885927797615055" LOG_EFFECT_SIZE="-0.08412991147335219" METHOD="MH" MODIFIED="2013-03-18 11:43:30 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.05164304560306311" Q="7.774945670408999E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="1.9460973605280945">
<NAME>Total</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0013812492619887" CI_START="0.6778611155941403" DF="0" EFFECT_SIZE="0.8238916256157636" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="116" I2="0.0" ID="CMP-037.01.01" LOG_CI_END="5.994550294461842E-4" LOG_CI_START="-0.16885927797615055" LOG_EFFECT_SIZE="-0.08412991147335219" MODIFIED="2013-03-18 11:43:30 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.05164304560306311" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="1.9460973605280945">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0013812492619887" CI_START="0.6778611155941403" EFFECT_SIZE="0.8238916256157636" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="116" LOG_CI_END="5.994550294461842E-4" LOG_CI_START="-0.16885927797615055" LOG_EFFECT_SIZE="-0.08412991147335219" MODIFIED="2008-07-11 13:49:39 -0400" MODIFIED_BY="Anne Lethaby" ORDER="743" O_E="0.0" SE="0.09954089860174441" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.00990839049444276" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6023101259777318" CI_START="0.17191868964437765" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3217893217893218" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-037.02" LOG_CI_END="-0.220179835452554" LOG_CI_START="-0.7646769076747382" LOG_EFFECT_SIZE="-0.49242837156364605" METHOD="MH" MODIFIED="2013-03-18 11:43:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="3.924992318020183E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="3.5450764474877623">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6023101259777318" CI_START="0.17191868964437765" DF="0" EFFECT_SIZE="0.3217893217893218" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="36" I2="0.0" ID="CMP-037.02.01" LOG_CI_END="-0.220179835452554" LOG_CI_START="-0.7646769076747382" LOG_EFFECT_SIZE="-0.49242837156364605" MODIFIED="2013-03-18 11:43:37 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="3.924992318020183E-4" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="3.5450764474877623">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.6023101259777318" CI_START="0.17191868964437765" EFFECT_SIZE="0.3217893217893218" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="36" LOG_CI_END="-0.220179835452554" LOG_CI_START="-0.7646769076747382" LOG_EFFECT_SIZE="-0.49242837156364605" MODIFIED="2008-07-11 13:50:21 -0400" MODIFIED_BY="Anne Lethaby" ORDER="744" O_E="0.0" SE="0.3198402755272878" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.10229780184937134" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3154140388383637" CI_START="0.5705978992227049" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8663558663558664" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-037.03" LOG_CI_END="0.1190624725829138" LOG_CI_START="-0.24366983162332817" LOG_EFFECT_SIZE="-0.062303679520207204" METHOD="MH" MODIFIED="2013-03-18 11:43:45 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5007594811502971" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.6732952458212875">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3154140388383637" CI_START="0.5705978992227049" DF="0" EFFECT_SIZE="0.8663558663558664" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" I2="0.0" ID="CMP-037.03.01" LOG_CI_END="0.1190624725829138" LOG_CI_START="-0.24366983162332817" LOG_EFFECT_SIZE="-0.062303679520207204" MODIFIED="2013-03-18 11:43:45 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.5007594811502971" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.6732952458212875">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3154140388383637" CI_START="0.5705978992227049" EFFECT_SIZE="0.8663558663558664" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.1190624725829138" LOG_CI_START="-0.24366983162332817" LOG_EFFECT_SIZE="-0.062303679520207204" MODIFIED="2008-07-11 13:51:03 -0400" MODIFIED_BY="Anne Lethaby" ORDER="745" O_E="0.0" SE="0.21307075104461068" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.04539914495071446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.794150673329871" CI_START="0.13716730072192168" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-037.04" LOG_CI_END="0.8321351739544002" LOG_CI_START="-0.8627494076423675" LOG_EFFECT_SIZE="-0.015307116843983656" METHOD="MH" MODIFIED="2013-03-18 11:43:56 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9717589587147294" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.035402289981409554">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.794150673329871" CI_START="0.13716730072192168" DF="0" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-037.04.01" LOG_CI_END="0.8321351739544002" LOG_CI_START="-0.8627494076423675" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2013-03-18 11:43:56 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.9717589587147294" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.035402289981409554">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.794150673329869" CI_START="0.1371673007219217" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8321351739544001" LOG_CI_START="-0.8627494076423674" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2008-07-11 13:51:39 -0400" MODIFIED_BY="Anne Lethaby" ORDER="746" O_E="0.0" SE="0.9955835930439293" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.9911866907382603" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-038" MODIFIED="2013-03-18 11:44:43 -0400" MODIFIED_BY="[Empty name]" NO="38">
<NAME>Withdrawals six months: etanercept vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.844423954772109" CI_END="0.5452687652450257" CI_START="0.3143346242098768" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41400102948746237" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-038.01" LOG_CI_END="-0.2633893793904708" LOG_CI_START="-0.5026077784635372" LOG_EFFECT_SIZE="-0.38299857892700395" METHOD="MH" MODIFIED="2012-02-22 15:40:07 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3581346514697923" P_Q="0.3597980222221322" P_Z="3.474672899079975E-10" Q="0.8385983562549139" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="6.275967264521893">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6733797715111259" CI_START="0.32503317282995847" DF="0" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="54" I2="0.0" ID="CMP-038.01.01" LOG_CI_END="-0.17173993406175184" LOG_CI_START="-0.4880723127386688" LOG_EFFECT_SIZE="-0.32990612340021025" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.3486235994443954E-5" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="4.0881311160628435">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.6733797715111258" CI_START="0.3250331728299586" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="54" LOG_CI_END="-0.17173993406175192" LOG_CI_START="-0.48807231273866863" LOG_EFFECT_SIZE="-0.32990612340021025" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7633" O_E="0.0" SE="0.1858152051053494" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.03452729044834307" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5490085856483651" CI_START="0.2372090830179443" DF="0" EFFECT_SIZE="0.36087369420702753" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="54" I2="0.0" ID="CMP-038.01.02" LOG_CI_END="-0.2604208638002673" LOG_CI_START="-0.6248686853370855" LOG_EFFECT_SIZE="-0.4426447745686764" MODIFIED="2012-02-20 08:59:35 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.9263721702640963E-6" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="4.760998775852534">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.5490085856483651" CI_START="0.2372090830179443" EFFECT_SIZE="0.36087369420702753" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="54" LOG_CI_END="-0.2604208638002673" LOG_CI_START="-0.6248686853370855" LOG_EFFECT_SIZE="-0.4426447745686764" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7634" O_E="0.0" SE="0.2140784544165389" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.04582958464537412" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6947132937054429" CI_END="0.49976439858720273" CI_START="0.24046536747349734" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34666414547288144" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-038.02" LOG_CI_END="-0.30123468467980363" LOG_CI_START="-0.6189474631496356" LOG_EFFECT_SIZE="-0.46009107391471954" METHOD="MH" MODIFIED="2013-03-18 11:44:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4045662364415772" P_Q="0.4059881128220988" P_Z="1.3740959246249801E-8" Q="0.6905195516245668" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="5.676585869943737">
<NAME>Lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6497962265614751" CI_START="0.24746682645768026" DF="0" EFFECT_SIZE="0.40100250626566414" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="42" I2="0.0" ID="CMP-038.02.01" LOG_CI_END="-0.1872228149797825" LOG_CI_START="-0.6064830110818644" LOG_EFFECT_SIZE="-0.3968529130308235" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.069090169609801E-4" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="3.7104281490668223">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.649796226561475" CI_START="0.24746682645768026" EFFECT_SIZE="0.40100250626566414" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="42" LOG_CI_END="-0.18722281497978258" LOG_CI_START="-0.6064830110818644" LOG_EFFECT_SIZE="-0.3968529130308235" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7636" O_E="0.0" SE="0.24627551456180474" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.060651629072681706" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5133459990342393" CI_START="0.16728018433316605" DF="0" EFFECT_SIZE="0.29304029304029305" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="42" I2="0.0" ID="CMP-038.02.02" LOG_CI_END="-0.289589818475107" LOG_CI_START="-0.7765555016225179" LOG_EFFECT_SIZE="-0.5330726600488125" MODIFIED="2012-02-20 08:59:48 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.7780997875880745E-5" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="4.291075330342571">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.5133459990342393" CI_START="0.16728018433316605" EFFECT_SIZE="0.29304029304029305" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="42" LOG_CI_END="-0.289589818475107" LOG_CI_START="-0.7765555016225179" LOG_EFFECT_SIZE="-0.5330726600488125" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7637" O_E="0.0" SE="0.2860460527997971" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.08182234432234432" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6748658360227082" CI_END="3.530176110458246" CI_START="0.41853847535901345" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.215530553717185" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-038.03" LOG_CI_END="0.5477963716462957" LOG_CI_START="-0.37826461206010126" LOG_EFFECT_SIZE="0.0847658797930972" METHOD="MH" MODIFIED="2013-03-18 11:44:43 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4113606236939128" P_Q="0.4113731167736513" P_Z="0.7197403006894985" Q="0.6748297858247103" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="0.3588058981761299">
<NAME>Adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.089534263244365" CI_START="0.43414277999027207" DF="0" EFFECT_SIZE="1.7543859649122806" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-038.03.01" LOG_CI_END="0.8506177057688686" LOG_CI_START="-0.3623674171138515" LOG_EFFECT_SIZE="0.24412514432750856" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4301564796680485" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="99.99999999999999" Z="0.7889239226041556">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.089534263244365" CI_START="0.43414277999027207" EFFECT_SIZE="1.7543859649122806" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8506177057688686" LOG_CI_START="-0.3623674171138515" LOG_EFFECT_SIZE="0.24412514432750856" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7639" O_E="0.0" SE="0.7125134655545053" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.5076754385964912" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4322959357964986E-32" CI_END="3.981486250350817" CI_START="0.11742566550761857" DF="0" EFFECT_SIZE="0.6837606837606837" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="100.0" ID="CMP-038.03.02" LOG_CI_END="0.600045220273983" LOG_CI_START="-0.9302369697824194" LOG_EFFECT_SIZE="-0.1650958747542181" MODIFIED="2012-02-20 08:59:59 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.6723646008603118" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.42290496565535624">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.9814862503508177" CI_START="0.11742566550761863" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6000452202739831" LOG_CI_START="-0.9302369697824192" LOG_EFFECT_SIZE="-0.16509587475421805" MODIFIED="2012-02-20 08:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7640" O_E="0.0" SE="0.8988953334581399" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.8080128205128205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-039" MODIFIED="2013-03-20 15:16:38 -0400" MODIFIED_BY="[Empty name]" NO="39">
<NAME>Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6042321077517314" CI_START="0.9416706920613517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2290884260839876" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-039.01" LOG_CI_END="0.20526720423686087" LOG_CI_START="-0.026100946065483743" LOG_EFFECT_SIZE="0.08958312908568856" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12907699469502198" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.517751742414936">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6042321077517314" CI_START="0.9416706920613517" DF="0" EFFECT_SIZE="1.2290884260839876" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="29" I2="0.0" ID="CMP-039.01.01" LOG_CI_END="0.20526720423686087" LOG_CI_START="-0.026100946065483743" LOG_EFFECT_SIZE="0.08958312908568856" MODIFIED="2012-02-17 12:39:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12907699469502198" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.517751742414936">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6042321077517314" CI_START="0.9416706920613517" EFFECT_SIZE="1.2290884260839876" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="29" LOG_CI_END="0.20526720423686087" LOG_CI_START="-0.026100946065483743" LOG_EFFECT_SIZE="0.08958312908568856" MODIFIED="2012-02-17 12:39:16 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.13590679677841222" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.01847065741056864" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.970006926676868" CI_END="20.818628599550436" CI_START="0.7153235391814392" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.859022556390977" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-039.02" LOG_CI_END="1.3184521175249395" LOG_CI_START="-0.14549748337385227" LOG_EFFECT_SIZE="0.5864773170755436" METHOD="MH" MODIFIED="2013-03-18 11:45:52 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3246786558722212" P_Q="1.0" P_Z="0.1163280564311969" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.5703743059351547">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.970006926676868" CI_END="20.818628599550436" CI_START="0.7153235391814392" DF="1" EFFECT_SIZE="3.859022556390977" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-039.02.01" LOG_CI_END="1.3184521175249395" LOG_CI_START="-0.14549748337385227" LOG_EFFECT_SIZE="0.5864773170755436" MODIFIED="2012-02-17 12:47:27 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3246786558722212" P_Z="0.1163280564311969" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.5703743059351547">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="144.36672109418475" CI_START="0.5004615984376631" EFFECT_SIZE="8.5" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.1594670927430335" LOG_CI_START="-0.3006292413144481" LOG_EFFECT_SIZE="0.9294189257142927" MODIFIED="2012-02-17 12:47:27 -0500" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="1.4450727642986174" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.088235294117647" WEIGHT="33.45864661654135"/>
<DICH_DATA CI_END="14.046305196138265" CI_START="0.16566047226904912" EFFECT_SIZE="1.5254237288135593" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1475621004720362" LOG_CI_START="-0.7807811048776748" LOG_EFFECT_SIZE="0.18339049779718067" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7691" O_E="0.0" SE="1.1327183442752338" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.283050847457627" WEIGHT="66.54135338345864"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2035429522458041" CI_END="16.034212191152047" CI_START="0.8778804951300095" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.751815845345849" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-039.03" LOG_CI_END="1.2050476266005659" LOG_CI_START="-0.05656460008250999" LOG_EFFECT_SIZE="0.5742415132590278" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6518761591430774" P_Q="1.0" P_Z="0.07438900494052547" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.7842133432307088">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2035429522458041" CI_END="16.034212191152047" CI_START="0.8778804951300095" DF="1" EFFECT_SIZE="3.751815845345849" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" I2="0.0" ID="CMP-039.03.01" LOG_CI_END="1.2050476266005659" LOG_CI_START="-0.05656460008250999" LOG_EFFECT_SIZE="0.5742415132590278" MODIFIED="2012-01-31 12:23:54 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6518761591430774" P_Z="0.07438900494052547" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.7842133432307088">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="37.59924197626813" CI_START="0.6518057265793173" EFFECT_SIZE="4.9504950495049505" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.5751790893733426" LOG_CI_START="-0.18588182826659028" LOG_EFFECT_SIZE="0.6946486305533762" MODIFIED="2012-01-31 12:23:54 -0500" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="1.0344559004138312" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.0700990099009902" WEIGHT="50.223488657950604"/>
<DICH_DATA CI_END="20.79405032093144" CI_START="0.3108417921518492" EFFECT_SIZE="2.542372881355932" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3179390906159736" LOG_CI_START="-0.5074605957888996" LOG_EFFECT_SIZE="0.405239247413537" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7690" O_E="0.0" SE="1.072248811668399" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.1497175141242937" WEIGHT="49.77651134204939"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1904358544028426" CI_END="1.2782352117206555" CI_START="0.13951800938183975" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4222994580401926" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="15.997153790228436" I2_Q="0.0" ID="CMP-039.04" LOG_CI_END="0.10661077694696673" LOG_CI_START="-0.8553697288037809" LOG_EFFECT_SIZE="-0.37437947592840704" METHOD="MH" MODIFIED="2013-03-18 11:46:01 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2752417168422864" P_Q="1.0" P_Z="0.12712424742651782" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.525540871117778">
<NAME>Bone pain/arthralgia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1904358544028426" CI_END="1.2782352117206555" CI_START="0.13951800938183975" DF="1" EFFECT_SIZE="0.4222994580401926" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="15.997153790228436" ID="CMP-039.04.01" LOG_CI_END="0.10661077694696673" LOG_CI_START="-0.8553697288037809" LOG_EFFECT_SIZE="-0.37437947592840704" MODIFIED="2012-02-17 12:46:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2752417168422864" P_Z="0.12712424742651782" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.525540871117778">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.2042726369412478" CI_START="0.17372086278353824" EFFECT_SIZE="0.6188118811881188" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.3432653095065902" LOG_CI_START="-0.7601480223837248" LOG_EFFECT_SIZE="-0.20844135643856737" MODIFIED="2012-02-17 12:46:11 -0500" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.6481504531364536" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.4200990099009901" WEIGHT="61.877671929174944"/>
<DICH_DATA CI_END="2.086441392791408" CI_START="0.00511769840009366" EFFECT_SIZE="0.10333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3194061900806696" LOG_CI_START="-2.290925311851449" LOG_EFFECT_SIZE="-0.9857595608853897" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7699" O_E="0.0" SE="1.533321645584254" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.3510752688172043" WEIGHT="38.122328070825056"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.255581767633817" CI_START="0.2272414949800546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-039.05" LOG_CI_END="1.2369296060044346" LOG_CI_START="-0.6435123622417576" LOG_EFFECT_SIZE="0.2967086218813386" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5362377172905244" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.6185122674456288">
<NAME>Bronchitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.255581767633817" CI_START="0.2272414949800546" DF="0" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-039.05.01" LOG_CI_END="1.2369296060044346" LOG_CI_START="-0.6435123622417576" LOG_EFFECT_SIZE="0.2967086218813386" MODIFIED="2012-02-17 12:48:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5362377172905244" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.6185122674456288">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="17.255581767633817" CI_START="0.2272414949800546" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2369296060044346" LOG_CI_START="-0.6435123622417576" LOG_EFFECT_SIZE="0.2967086218813386" MODIFIED="2012-02-17 12:48:09 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.1045809204856791" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.22009900990099" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6092060334727303" CI_START="0.2186857141119022" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5932203389830508" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-039.06" LOG_CI_END="0.20661165222323646" LOG_CI_START="-0.6601795868069738" LOG_EFFECT_SIZE="-0.2267839672918686" METHOD="MH" MODIFIED="2013-03-18 11:46:14 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3050825093920203" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="1.0255950640675093">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6092060334727303" CI_START="0.2186857141119022" DF="0" EFFECT_SIZE="0.5932203389830508" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-039.06.01" LOG_CI_END="0.20661165222323646" LOG_CI_START="-0.6601795868069738" LOG_EFFECT_SIZE="-0.2267839672918686" MODIFIED="2012-02-21 14:48:56 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3050825093920203" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="100.0" Z="1.0255950640675093">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.60920603347273" CI_START="0.2186857141119023" EFFECT_SIZE="0.5932203389830508" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.20661165222323638" LOG_CI_START="-0.6601795868069735" LOG_EFFECT_SIZE="-0.2267839672918686" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7687" O_E="0.0" SE="0.5091574644921778" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.2592413236481033" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2887395608292846" CI_END="3.286756285740625" CI_START="0.44353838795039857" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.207394957983193" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="22.40480308088665" I2_Q="0.0" ID="CMP-039.07" LOG_CI_END="0.5167675021704322" LOG_CI_START="-0.3530687863090356" LOG_EFFECT_SIZE="0.08184935793069832" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.25628047610267723" P_Q="1.0" P_Z="0.7122357017775864" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="99.99999999999999" Z="0.3688551416550455">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2887395608292846" CI_END="3.286756285740625" CI_START="0.44353838795039857" DF="1" EFFECT_SIZE="1.207394957983193" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="22.40480308088665" ID="CMP-039.07.01" LOG_CI_END="0.5167675021704322" LOG_CI_START="-0.3530687863090356" LOG_EFFECT_SIZE="0.08184935793069832" MODIFIED="2012-02-17 12:55:07 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.25628047610267723" P_Z="0.7122357017775864" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="99.99999999999999" Z="0.3688551416550455">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="24.007352802866873" CI_START="0.3674984292149328" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3803442747388461" LOG_CI_START="-0.4347445128648063" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 12:55:07 -0500" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="1.0661921386727895" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.1367656765676568" WEIGHT="20.143417366946778"/>
<DICH_DATA CI_END="2.497986273449392" CI_START="0.232879337364642" EFFECT_SIZE="0.7627118644067796" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.3975900475763218" LOG_CI_START="-0.6328690433099229" LOG_EFFECT_SIZE="-0.11763949786680053" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7689" O_E="0.0" SE="0.6052967708413456" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.3663841807909604" WEIGHT="79.85658263305321"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1856429844414441" CI_END="10.192928031970396" CI_START="0.49714899914584854" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.251089507207509" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="100.0" ID="CMP-039.08" LOG_CI_END="1.0082989578499422" LOG_CI_START="-0.30351343056459923" LOG_EFFECT_SIZE="0.35239276364267147" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6665679444475373" P_Q="0.0" P_Z="0.2923354855269963" Q="2.075877872782634E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.0530120484483692">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1856429844414441" CI_END="10.192928031970396" CI_START="0.49714899914584854" DF="1" EFFECT_SIZE="2.251089507207509" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-039.08.01" LOG_CI_END="1.0082989578499422" LOG_CI_START="-0.30351343056459923" LOG_EFFECT_SIZE="0.35239276364267147" MODIFIED="2012-02-17 12:54:44 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6665679444475373" P_Z="0.2923354855269963" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.0530120484483692">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="24.007352802866873" CI_START="0.3674984292149328" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3803442747388461" LOG_CI_START="-0.4347445128648063" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 12:54:44 -0500" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="1.0661921386727895" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.1367656765676568" WEIGHT="50.223488657950604"/>
<DICH_DATA CI_END="14.046305196138265" CI_START="0.16566047226904912" EFFECT_SIZE="1.5254237288135593" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1475621004720362" LOG_CI_START="-0.7807811048776748" LOG_EFFECT_SIZE="0.18339049779718067" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7692" O_E="0.0" SE="1.1327183442752338" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.283050847457627" WEIGHT="49.77651134204939"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.91217071038524" CI_START="0.056962374057853565" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33003300330033003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-039.09" LOG_CI_END="0.2815266616162465" LOG_CI_START="-1.2444119186208566" LOG_EFFECT_SIZE="-0.481442628502305" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.21617606733397843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.2367604105536083">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.91217071038524" CI_START="0.056962374057853565" DF="0" EFFECT_SIZE="0.33003300330033003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-039.09.01" LOG_CI_END="0.2815266616162465" LOG_CI_START="-1.2444119186208566" LOG_EFFECT_SIZE="-0.481442628502305" MODIFIED="2012-02-17 12:53:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21617606733397843" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.2367604105536083">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.91217071038524" CI_START="0.056962374057853565" EFFECT_SIZE="0.33003300330033003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2815266616162465" LOG_CI_START="-1.2444119186208566" LOG_EFFECT_SIZE="-0.481442628502305" MODIFIED="2012-02-17 12:53:59 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.8963438755490681" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.8034323432343233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.623996876843073" CI_START="0.2970738574768003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4752475247524752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="100.00000000000001" ID="CMP-039.10" LOG_CI_END="1.314372834242749" LOG_CI_START="-0.527135564463959" LOG_EFFECT_SIZE="0.393618634889395" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.4021000508271926" Q="1.0534109968284895E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8378765457370111">
<NAME>Flu syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.623996876843073" CI_START="0.2970738574768003" DF="0" EFFECT_SIZE="2.4752475247524752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-039.10.01" LOG_CI_END="1.314372834242749" LOG_CI_START="-0.527135564463959" LOG_EFFECT_SIZE="0.393618634889395" MODIFIED="2012-02-17 13:00:43 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4021000508271926" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8378765457370111">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="20.623996876843073" CI_START="0.2970738574768005" EFFECT_SIZE="2.4752475247524752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.314372834242749" LOG_CI_START="-0.5271355644639587" LOG_EFFECT_SIZE="0.393618634889395" MODIFIED="2012-02-17 13:00:43 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.0817111490139084" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.17009900990099" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.34209060851800116" CI_END="3.037248961430739" CI_START="0.7452072397252257" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5044533608278157" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-039.11" LOG_CI_END="0.48248039222912625" LOG_CI_START="-0.1277229345629084" LOG_EFFECT_SIZE="0.17737872883310896" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.5586251437221886" P_Q="1.0" P_Z="0.2545048324813861" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="99.99999999999999" Z="1.139475662855164">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34209060851800116" CI_END="3.037248961430739" CI_START="0.7452072397252257" DF="1" EFFECT_SIZE="1.5044533608278157" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" I2="0.0" ID="CMP-039.11.01" LOG_CI_END="0.48248039222912625" LOG_CI_START="-0.1277229345629084" LOG_EFFECT_SIZE="0.17737872883310896" MODIFIED="2012-02-21 14:48:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5586251437221886" P_Z="0.2545048324813861" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="99.99999999999999" Z="1.139475662855164">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="5.302768130754942" CI_START="0.64991589556935" EFFECT_SIZE="1.8564356435643565" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.7245026375399812" LOG_CI_START="-0.18714284097779105" LOG_EFFECT_SIZE="0.2686798982810951" MODIFIED="2012-01-31 11:57:28 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.5355050667992384" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.2867656765676567" WEIGHT="44.66528366107253"/>
<DICH_DATA CI_END="3.1434092429423415" CI_START="0.47376180397039486" EFFECT_SIZE="1.2203389830508475" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.4974009258415007" LOG_CI_START="-0.32443995626325206" LOG_EFFECT_SIZE="0.0864804847891243" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7679" O_E="0.0" SE="0.4827534023263089" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.2330508474576271" WEIGHT="55.33471633892746"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.026259055835044846" CI_END="42.509409437560294" CI_START="0.7324880202609556" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.58011049723757" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-039.12" LOG_CI_END="1.62848507156815" LOG_CI_START="-0.13519947374123367" LOG_EFFECT_SIZE="0.7466427989134581" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8712692880650447" P_Q="1.0" P_Z="0.09702061890315015" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.6594724936253868">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.026259055835044846" CI_END="42.509409437560294" CI_START="0.7324880202609556" DF="1" EFFECT_SIZE="5.58011049723757" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-039.12.01" LOG_CI_END="1.62848507156815" LOG_CI_START="-0.13519947374123367" LOG_EFFECT_SIZE="0.7466427989134581" MODIFIED="2012-02-17 12:57:00 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8712692880650447" P_Z="0.09702061890315015" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.6594724936253868">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="113.12980092347722" CI_START="0.3734648134719033" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.053577022890231" LOG_CI_START="-0.4277503096045201" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2012-02-17 12:57:00 -0500" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.4575439578758067" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.1244343891402715" WEIGHT="50.276243093922645"/>
<DICH_DATA CI_END="83.61870998277317" CI_START="0.2585844723561818" EFFECT_SIZE="4.65" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.922303463242084" LOG_CI_START="-0.5873975574621763" LOG_EFFECT_SIZE="0.667452952889954" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7694" O_E="0.0" SE="1.4742108027820942" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.1732974910394267" WEIGHT="49.72375690607735"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5257345685911056" CI_END="1.5207241412551187" CI_START="0.21401540372650438" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.570489606432366" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-039.13" LOG_CI_END="0.1820504403539701" LOG_CI_START="-0.6695549672458146" LOG_EFFECT_SIZE="-0.2437522634459223" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.4684057486135702" P_Q="1.0" P_Z="0.26186742713764544" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="99.99999999999999" Z="1.121988313462296">
<NAME>Increased cough</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5257345685911056" CI_END="1.5207241412551187" CI_START="0.21401540372650438" DF="1" EFFECT_SIZE="0.570489606432366" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-039.13.01" LOG_CI_END="0.1820504403539701" LOG_CI_START="-0.6695549672458146" LOG_EFFECT_SIZE="-0.2437522634459223" MODIFIED="2012-02-17 12:42:05 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4684057486135702" P_Z="0.26186742713764544" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="99.99999999999999" Z="1.121988313462296">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.5125012182533397" CI_START="0.21946915837705785" EFFECT_SIZE="0.7425742574257426" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.40010628100787854" LOG_CI_START="-0.6586265017897636" LOG_EFFECT_SIZE="-0.12926011039094254" MODIFIED="2012-02-17 12:42:05 -0500" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.6219048774271325" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.3867656765676567" WEIGHT="57.361645103138"/>
<DICH_DATA CI_END="1.9204702960519169" CI_START="0.05983404637816052" EFFECT_SIZE="0.3389830508474576" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.28340759431269874" LOG_CI_START="-1.2230516262690247" LOG_EFFECT_SIZE="-0.46982201597816303" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7696" O_E="0.0" SE="0.8849016032631126" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.7830508474576271" WEIGHT="42.63835489686198"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.420562479220028" CI_END="1.3190591456587701" CI_START="0.6944492331680728" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9570891349326176" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="32" I2="29.605348963668348" I2_Q="0.0" ID="CMP-039.14" LOG_CI_END="0.12026426943365776" LOG_CI_START="-0.15835949731417936" LOG_EFFECT_SIZE="-0.01904761394026078" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.23331108692642488" P_Q="1.0" P_Z="0.7887156044927248" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.26797884293999485">
<NAME>Infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.420562479220028" CI_END="1.3190591456587701" CI_START="0.6944492331680728" DF="1" EFFECT_SIZE="0.9570891349326176" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="32" I2="29.605348963668348" ID="CMP-039.14.01" LOG_CI_END="0.12026426943365776" LOG_CI_START="-0.15835949731417936" LOG_EFFECT_SIZE="-0.01904761394026078" MODIFIED="2012-02-17 12:43:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23331108692642488" P_Z="0.7887156044927248" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.26797884293999485">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.0499227856159767" CI_START="0.679823919899884" EFFECT_SIZE="1.1805026656511806" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="13" LOG_CI_END="0.3117375028057763" LOG_CI_START="-0.16760355864415202" LOG_EFFECT_SIZE="0.07206697208081216" MODIFIED="2012-02-17 12:43:47 -0500" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.2815673122722097" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.07928015134019606" WEIGHT="40.84081250349494"/>
<DICH_DATA CI_END="1.162591391517049" CI_START="0.5544299605094174" EFFECT_SIZE="0.8028545941123997" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="19" LOG_CI_END="0.06542710287076965" LOG_CI_START="-0.25615330918206614" LOG_EFFECT_SIZE="-0.09536310315564826" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7700" O_E="0.0" SE="0.18889792588854842" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.03568242640499553" WEIGHT="59.159187496505055"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03204192424040894" CI_END="21.34051530905589" CI_START="2.218482403410804" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="6.880665497817734" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-039.15" LOG_CI_END="1.3292049021164467" LOG_CI_START="0.34605598832329904" LOG_EFFECT_SIZE="0.8376304452198728" METHOD="MH" MODIFIED="2013-03-18 11:46:24 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.8579357187588842" P_Q="1.0" P_Z="8.386015762064051E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.00000000000001" Z="3.3397290724782653">
<NAME>Injection site reaction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03204192424040894" CI_END="21.34051530905589" CI_START="2.218482403410804" DF="1" EFFECT_SIZE="6.880665497817734" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="3" I2="0.0" ID="CMP-039.15.01" LOG_CI_END="1.3292049021164467" LOG_CI_START="0.34605598832329904" LOG_EFFECT_SIZE="0.8376304452198728" MODIFIED="2012-02-21 14:49:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8579357187588842" P_Z="8.386015762064051E-4" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.00000000000001" Z="3.3397290724782653">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="58.04075531139086" CI_START="1.0809464285129662" EFFECT_SIZE="7.920792079207921" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.7637330554789095" LOG_CI_START="0.03380417093969256" LOG_EFFECT_SIZE="0.898768613209301" MODIFIED="2012-01-31 11:50:40 -0500" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="1.0161687900644214" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.03259900990099" WEIGHT="33.53228634311934"/>
<DICH_DATA CI_END="25.052355154862575" CI_START="1.612537979937061" EFFECT_SIZE="6.3559322033898304" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" LOG_CI_END="1.3988485598512297" LOG_CI_START="0.20750995231991978" LOG_EFFECT_SIZE="0.8031792560855746" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7674" O_E="0.0" SE="0.6997981952851078" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.4897175141242939" WEIGHT="66.46771365688068"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3147450031936048" CI_START="0.20537360936228596" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8250825082508251" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-039.16" LOG_CI_END="0.5204501246064153" LOG_CI_START="-0.6874553642669501" LOG_EFFECT_SIZE="-0.08350261983026741" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.7864025782183781" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.27098498846083524">
<NAME>Injection site haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3147450031936048" CI_START="0.20537360936228596" DF="0" EFFECT_SIZE="0.8250825082508251" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-039.16.01" LOG_CI_END="0.5204501246064153" LOG_CI_START="-0.6874553642669501" LOG_EFFECT_SIZE="-0.08350261983026741" MODIFIED="2012-02-17 12:50:23 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7864025782183781" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.27098498846083524">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.3147450031936043" CI_START="0.205373609362286" EFFECT_SIZE="0.8250825082508251" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5204501246064152" LOG_CI_START="-0.6874553642669501" LOG_EFFECT_SIZE="-0.08350261983026741" MODIFIED="2012-02-17 12:50:23 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.7095296633928164" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5034323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="97.53656077231553" CI_START="0.31014011320958995" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-039.17" LOG_CI_END="1.9891674379078073" LOG_CI_START="-0.5084420589193198" LOG_EFFECT_SIZE="0.7403626894942439" METHOD="MH" MODIFIED="2013-03-18 11:46:30 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.2452442383506972" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.1619784507941167">
<NAME>Leukopenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.53656077231553" CI_START="0.31014011320958995" DF="0" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-039.17.01" LOG_CI_END="1.9891674379078073" LOG_CI_START="-0.5084420589193198" LOG_EFFECT_SIZE="0.7403626894942439" MODIFIED="2012-02-17 12:58:08 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2452442383506972" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.1619784507941167">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="97.53656077231553" CI_START="0.3101401132095901" EFFECT_SIZE="5.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9891674379078073" LOG_CI_START="-0.5084420589193196" LOG_EFFECT_SIZE="0.7403626894942439" MODIFIED="2012-02-17 12:58:08 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.4671081818026575" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.1524064171122994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.623996876843073" CI_START="0.2970738574768003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4752475247524752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="100.00000000000001" ID="CMP-039.18" LOG_CI_END="1.314372834242749" LOG_CI_START="-0.527135564463959" LOG_EFFECT_SIZE="0.393618634889395" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.4021000508271926" Q="1.0534109968284895E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8378765457370111">
<NAME>Miscellaneous skin infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.623996876843073" CI_START="0.2970738574768003" DF="0" EFFECT_SIZE="2.4752475247524752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-039.18.01" LOG_CI_END="1.314372834242749" LOG_CI_START="-0.527135564463959" LOG_EFFECT_SIZE="0.393618634889395" MODIFIED="2012-02-17 13:01:21 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4021000508271926" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8378765457370111">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="20.623996876843073" CI_START="0.2970738574768005" EFFECT_SIZE="2.4752475247524752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.314372834242749" LOG_CI_START="-0.5271355644639587" LOG_EFFECT_SIZE="0.393618634889395" MODIFIED="2012-02-17 13:01:21 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.0817111490139084" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.17009900990099" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4339543951769103" CI_START="0.07529115560687076" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-039.19" LOG_CI_END="0.5357945231910793" LOG_CI_START="-1.123256037036043" LOG_EFFECT_SIZE="-0.2937307569224818" METHOD="MH" MODIFIED="2013-03-18 11:46:41 -0400" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.4876737765171083" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6940134538647702">
<NAME>Mouth ulcers</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4339543951769103" CI_START="0.07529115560687076" DF="0" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-039.19.01" LOG_CI_END="0.5357945231910793" LOG_CI_START="-1.123256037036043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4876737765171083" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6940134538647702">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.4339543951769103" CI_START="0.07529115560687076" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5357945231910793" LOG_CI_START="-1.123256037036043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7693" O_E="0.0" SE="0.9745345115101332" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.9497175141242938" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.63951131239763" CI_END="3.9977910278734674" CI_START="0.19886342867714965" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8916358174376264" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="72.52378371256601" I2_Q="0.0" ID="CMP-039.20" LOG_CI_END="0.6018200889783555" LOG_CI_START="-0.7014450770266466" LOG_EFFECT_SIZE="-0.04981249402414549" METHOD="MH" MODIFIED="2012-04-26 16:23:09 -0400" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.05642368808183351" P_Q="1.0" P_Z="0.880902875554434" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8525713924787787" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.14982475832867795">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.63951131239763" CI_END="3.9977910278734674" CI_START="0.19886342867714965" DF="1" EFFECT_SIZE="0.8916358174376264" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="72.52378371256601" ID="CMP-039.20.01" LOG_CI_END="0.6018200889783555" LOG_CI_START="-0.7014450770266466" LOG_EFFECT_SIZE="-0.04981249402414549" MODIFIED="2012-01-31 12:01:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05642368808183351" P_Z="0.880902875554434" STUDIES="2" TAU2="0.8525713924787787" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.14982475832867795">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.700003248675573" CI_START="0.5852510890054876" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.8260750132801598" LOG_CI_START="-0.2326577695174824" LOG_EFFECT_SIZE="0.2967086218813386" MODIFIED="2012-01-31 12:01:47 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.6219048774271325" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.3867656765676567" WEIGHT="47.28804277541695"/>
<DICH_DATA CI_END="1.1822738205105772" CI_START="0.16066705526588743" EFFECT_SIZE="0.4358353510895884" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07271807296201" LOG_CI_START="-0.7940731660681999" LOG_EFFECT_SIZE="-0.360677546553095" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7688" O_E="0.0" SE="0.5091574644921778" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.2592413236481033" WEIGHT="52.71195722458305"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.91217071038524" CI_START="0.056962374057853565" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33003300330033003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-039.21" LOG_CI_END="0.2815266616162465" LOG_CI_START="-1.2444119186208566" LOG_EFFECT_SIZE="-0.481442628502305" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.21617606733397843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.2367604105536083">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.91217071038524" CI_START="0.056962374057853565" DF="0" EFFECT_SIZE="0.33003300330033003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-039.21.01" LOG_CI_END="0.2815266616162465" LOG_CI_START="-1.2444119186208566" LOG_EFFECT_SIZE="-0.481442628502305" MODIFIED="2012-02-17 12:53:28 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21617606733397843" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.2367604105536083">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.91217071038524" CI_START="0.056962374057853565" EFFECT_SIZE="0.33003300330033003" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2815266616162465" LOG_CI_START="-1.2444119186208566" LOG_EFFECT_SIZE="-0.481442628502305" MODIFIED="2012-02-17 12:53:28 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.8963438755490681" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.8034323432343233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="24.007352802866873" CI_START="0.3674984292149328" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-039.22" LOG_CI_END="1.3803442747388461" LOG_CI_START="-0.4347445128648063" LOG_EFFECT_SIZE="0.47279988093701986" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.3072190008008999" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.0210748310057163">
<NAME>Paraesthesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.007352802866873" CI_START="0.3674984292149328" DF="0" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-039.22.01" LOG_CI_END="1.3803442747388461" LOG_CI_START="-0.4347445128648063" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 12:59:00 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3072190008008999" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.0210748310057163">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="24.007352802866873" CI_START="0.3674984292149328" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3803442747388461" LOG_CI_START="-0.4347445128648063" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 12:59:00 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.0661921386727895" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.1367656765676568" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45512685950591336" CI_END="1.6760954828180437" CI_START="0.14832471871598962" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49860444345204863" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-039.23" LOG_CI_END="0.22429875563066456" LOG_CI_START="-0.8287864665887515" LOG_EFFECT_SIZE="-0.3022438554790435" METHOD="MH" MODIFIED="2013-03-20 15:16:38 -0400" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.49991032124904444" P_Q="1.0" P_Z="0.26056761883178337" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.1250505824001151">
<NAME>Pharyngitis (non-infectious)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.45512685950591336" CI_END="1.6760954828180437" CI_START="0.14832471871598962" DF="1" EFFECT_SIZE="0.49860444345204863" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-039.23.01" LOG_CI_END="0.22429875563066456" LOG_CI_START="-0.8287864665887515" LOG_EFFECT_SIZE="-0.3022438554790435" MODIFIED="2013-03-20 15:16:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49991032124904444" P_Z="0.26056761883178337" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="1.1250505824001151">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.8367562233434596" CI_START="0.1535863848590531" EFFECT_SIZE="0.6600660066006601" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4528220163014468" LOG_CI_START="-0.8136472819780945" LOG_EFFECT_SIZE="-0.18041263283832382" MODIFIED="2012-02-17 12:41:20 -0500" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.7439303349335362" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5534323432343233" WEIGHT="60.21435748576532"/>
<DICH_DATA CI_END="2.6922896952753073" CI_START="0.024008039993605172" EFFECT_SIZE="0.2542372881355932" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4301217889436181" LOG_CI_START="-1.619643294116544" LOG_EFFECT_SIZE="-0.594760752586463" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7698" O_E="0.0" SE="1.204042156290341" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.4497175141242937" WEIGHT="39.785642514234674"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3147450031936048" CI_START="0.20537360936228596" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8250825082508251" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-039.24" LOG_CI_END="0.5204501246064153" LOG_CI_START="-0.6874553642669501" LOG_EFFECT_SIZE="-0.08350261983026741" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.7864025782183781" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.27098498846083524">
<NAME>Pharyngitis or laryngitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3147450031936048" CI_START="0.20537360936228596" DF="0" EFFECT_SIZE="0.8250825082508251" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-039.24.01" LOG_CI_END="0.5204501246064153" LOG_CI_START="-0.6874553642669501" LOG_EFFECT_SIZE="-0.08350261983026741" MODIFIED="2012-02-17 13:02:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7864025782183781" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.27098498846083524">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.3147450031936043" CI_START="0.205373609362286" EFFECT_SIZE="0.8250825082508251" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5204501246064152" LOG_CI_START="-0.6874553642669501" LOG_EFFECT_SIZE="-0.08350261983026741" MODIFIED="2012-02-17 13:02:39 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.7095296633928164" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5034323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.037764360357608" CI_START="0.37350642749809676" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7326732673267327" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-039.25" LOG_CI_END="0.9051352700201765" LOG_CI_START="-0.4277019202128728" LOG_EFFECT_SIZE="0.23871667490365187" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.4826321631034749" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.7020753753704985">
<NAME>Pruritus</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.037764360357608" CI_START="0.37350642749809676" DF="0" EFFECT_SIZE="1.7326732673267327" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-039.25.01" LOG_CI_END="0.9051352700201765" LOG_CI_START="-0.4277019202128728" LOG_EFFECT_SIZE="0.23871667490365187" MODIFIED="2012-02-17 12:48:55 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4826321631034749" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.7020753753704985">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.037764360357608" CI_START="0.37350642749809676" EFFECT_SIZE="1.7326732673267327" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9051352700201765" LOG_CI_START="-0.4277019202128728" LOG_EFFECT_SIZE="0.23871667490365187" MODIFIED="2012-02-17 12:48:55 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.7829151631933903" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.6129561527581329" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.98148481953559" CI_START="0.43658529479432306" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-039.26" LOG_CI_END="0.9533481401889927" LOG_CI_START="-0.3599308964263156" LOG_EFFECT_SIZE="0.2967086218813386" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.37581813493543414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8856278012153841">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.98148481953559" CI_START="0.43658529479432306" DF="0" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-039.26.01" LOG_CI_END="0.9533481401889927" LOG_CI_START="-0.3599308964263156" LOG_EFFECT_SIZE="0.2967086218813386" MODIFIED="2012-02-17 12:47:00 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.37581813493543414" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8856278012153841">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.98148481953559" CI_START="0.43658529479432306" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9533481401889927" LOG_CI_START="-0.3599308964263156" LOG_EFFECT_SIZE="0.2967086218813386" MODIFIED="2012-02-17 12:47:00 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.7714266069439075" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5950990099009901" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.546917797075817" CI_END="15.479297273633142" CI_START="0.05759681983548392" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9442236473682202" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="78.0070798587317" I2_Q="0.0" ID="CMP-039.27" LOG_CI_END="1.1897512407712412" LOG_CI_START="-1.2396014951536827" LOG_EFFECT_SIZE="-0.02492512719122094" METHOD="MH" MODIFIED="2012-04-26 16:24:14 -0400" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.03297811340624279" P_Q="1.0" P_Z="0.9679190008242486" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.183033335775517" TOTALS="SUB" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.04021840952320455">
<NAME>Rhinitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.546917797075817" CI_END="15.479297273633142" CI_START="0.05759681983548392" DF="1" EFFECT_SIZE="0.9442236473682202" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="78.0070798587317" ID="CMP-039.27.01" LOG_CI_END="1.1897512407712412" LOG_CI_START="-1.2396014951536827" LOG_EFFECT_SIZE="-0.02492512719122094" MODIFIED="2012-02-21 14:49:04 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03297811340624279" P_Z="0.9679190008242486" STUDIES="2" TAU2="3.183033335775517" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.04021840952320455">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3059806856589598" CI_START="0.04691378958412257" EFFECT_SIZE="0.24752475247524752" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.11593675414138162" LOG_CI_START="-1.3286994843625917" LOG_EFFECT_SIZE="-0.6063813651106049" MODIFIED="2012-02-17 12:45:09 -0500" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.8485864775619454" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.7200990099009901" WEIGHT="52.1726723427161"/>
<DICH_DATA CI_END="31.03043115993122" CI_START="0.5332497372151591" EFFECT_SIZE="4.067796610169491" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.4917878100372126" LOG_CI_START="-0.27306934989828885" LOG_EFFECT_SIZE="0.6093592300694618" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7684" O_E="0.0" SE="1.0366858319299506" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="1.0747175141242937" WEIGHT="47.82732765728391"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2259784954215753" CI_END="4.842442215649716" CI_START="0.2541997650773333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1094808126410836" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="18.432500754743536" I2_Q="0.0" ID="CMP-039.28" LOG_CI_END="0.6850644470319953" LOG_CI_START="-0.5948248551418257" LOG_EFFECT_SIZE="0.04511979594508488" METHOD="MH" MODIFIED="2013-03-18 11:46:49 -0400" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.2681906286195479" P_Q="1.0" P_Z="0.8900912168339012" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.13818878693956407">
<NAME>Trauma/accidental injury</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2259784954215753" CI_END="4.842442215649716" CI_START="0.2541997650773333" DF="1" EFFECT_SIZE="1.1094808126410836" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="18.432500754743536" ID="CMP-039.28.01" LOG_CI_END="0.6850644470319953" LOG_CI_START="-0.5948248551418257" LOG_EFFECT_SIZE="0.04511979594508488" MODIFIED="2012-02-17 12:55:44 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2681906286195479" P_Z="0.8900912168339012" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="80" WEIGHT="100.0" Z="0.13818878693956407">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="66.47484711767984" CI_START="0.18428022825406326" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8226573471916547" LOG_CI_START="-0.7345212584911034" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2012-02-17 12:55:44 -0500" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="1.5020993712162998" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.2563025210084033" WEIGHT="20.090293453724605"/>
<DICH_DATA CI_END="3.4339543951769103" CI_START="0.07529115560687076" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5357945231910793" LOG_CI_START="-1.123256037036043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7697" O_E="0.0" SE="0.9745345115101332" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.9497175141242938" WEIGHT="79.9097065462754"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9644304016547207" CI_START="0.40013023045515617" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0891089108910892" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-039.29" LOG_CI_END="0.4719412585156515" LOG_CI_START="-0.3977986357644865" LOG_EFFECT_SIZE="0.0370713113755825" METHOD="MH" MODIFIED="2013-03-18 11:47:05 -0400" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.8673064432564597" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.16708083792327197">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9644304016547207" CI_START="0.40013023045515617" DF="0" EFFECT_SIZE="1.0891089108910892" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-039.29.01" LOG_CI_END="0.4719412585156515" LOG_CI_START="-0.3977986357644865" LOG_EFFECT_SIZE="0.0370713113755825" MODIFIED="2012-02-21 14:49:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8673064432564597" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.16708083792327197">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.9644304016547207" CI_START="0.40013023045515617" EFFECT_SIZE="1.0891089108910892" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.4719412585156515" LOG_CI_START="-0.3977986357644865" LOG_EFFECT_SIZE="0.0370713113755825" MODIFIED="2012-01-31 11:54:00 -0500" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="0.5108895191820644" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.26100810081008097" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.8198819931752" CI_START="0.19286789350494687" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-039.30" LOG_CI_END="1.8313570297688528" LOG_CI_START="-0.714740062839081" LOG_EFFECT_SIZE="0.5583084834648859" METHOD="MH" MODIFIED="2012-02-22 15:40:52 -0500" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.3900303801512788" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.8595622869460269">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.8198819931752" CI_START="0.19286789350494687" DF="0" EFFECT_SIZE="3.6166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-039.30.01" LOG_CI_END="1.8313570297688528" LOG_CI_START="-0.714740062839081" LOG_EFFECT_SIZE="0.5583084834648859" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3900303801512788" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.8595622869460269">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="67.81988199317513" CI_START="0.19286789350494696" EFFECT_SIZE="3.6166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8313570297688524" LOG_CI_START="-0.7147400628390808" LOG_EFFECT_SIZE="0.5583084834648859" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7695" O_E="0.0" SE="1.4955900355817733" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.23678955453149" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-040" MODIFIED="2013-03-18 11:47:48 -0400" MODIFIED_BY="[Empty name]" NO="40">
<NAME>Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4680203558071832" CI_START="0.732231006646412" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0367883211678832" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-040.01" LOG_CI_END="0.16673207761918166" LOG_CI_START="-0.13535188467283946" LOG_EFFECT_SIZE="0.015690096473171104" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8386667315519011" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.20359918327373278">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4680203558071832" CI_START="0.732231006646412" DF="0" EFFECT_SIZE="1.0367883211678832" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="50" I2="0.0" ID="CMP-040.01.01" LOG_CI_END="0.16673207761918166" LOG_CI_START="-0.13535188467283946" LOG_EFFECT_SIZE="0.015690096473171104" MODIFIED="2012-01-31 14:33:19 -0500" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.8386667315519011" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.20359918327373278">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4680203558071832" CI_START="0.732231006646412" EFFECT_SIZE="1.0367883211678832" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="50" LOG_CI_END="0.16673207761918166" LOG_CI_START="-0.13535188467283946" LOG_EFFECT_SIZE="0.015690096473171104" MODIFIED="2008-10-08 17:33:26 -0400" MODIFIED_BY="Anne Lethaby" ORDER="451" O_E="0.0" SE="0.17744561479006307" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.03148694620822345" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4626117404287107" CI_START="0.6841622095790209" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0003317850033178" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-040.02" LOG_CI_END="0.1651290551971717" LOG_CI_START="-0.16484091820205754" LOG_EFFECT_SIZE="1.4406849755707157E-4" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9986344344830096" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.0017114834032308749">
<NAME>Nasopharyngitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4626117404287107" CI_START="0.6841622095790209" DF="0" EFFECT_SIZE="1.0003317850033178" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" I2="0.0" ID="CMP-040.02.01" LOG_CI_END="0.1651290551971717" LOG_CI_START="-0.16484091820205754" LOG_EFFECT_SIZE="1.4406849755707157E-4" MODIFIED="2012-01-31 14:33:31 -0500" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.9986344344830096" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.0017114834032308749">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4626117404287107" CI_START="0.6841622095790209" EFFECT_SIZE="1.0003317850033178" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" LOG_CI_END="0.1651290551971717" LOG_CI_START="-0.16484091820205754" LOG_EFFECT_SIZE="1.4406849755707157E-4" MODIFIED="2008-10-08 17:38:29 -0400" MODIFIED_BY="Anne Lethaby" ORDER="454" O_E="0.0" SE="0.19382599575241838" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.03756851662941651" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8449383168903932" CI_START="0.20255671560262972" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6113138686131386" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="99.99999999999999" ID="CMP-040.03" LOG_CI_END="0.2659818506674665" LOG_CI_START="-0.6934533535625144" LOG_EFFECT_SIZE="-0.21373575144752396" METHOD="MH" MODIFIED="2012-09-23 00:32:23 -0400" MODIFIED_BY="Anne Lethaby" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.3825257242233181" Q="9.701836794034729E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.8732520407815598">
<NAME>Serious infections</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8449383168903932" CI_START="0.20255671560262972" DF="0" EFFECT_SIZE="0.6113138686131386" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-040.03.01" LOG_CI_END="0.2659818506674665" LOG_CI_START="-0.6934533535625144" LOG_EFFECT_SIZE="-0.21373575144752396" MODIFIED="2008-10-08 17:36:31 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.3825257242233181" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.8732520407815598">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8449383168903932" CI_START="0.20255671560262972" EFFECT_SIZE="0.6113138686131386" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2659818506674665" LOG_CI_START="-0.6934533535625144" LOG_EFFECT_SIZE="-0.21373575144752396" MODIFIED="2008-10-08 17:36:31 -0400" MODIFIED_BY="Anne Lethaby" ORDER="453" O_E="0.0" SE="0.5635769882455471" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.31761902167992156" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9991526033225357" CI_START="0.07656715286782598" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39124087591240875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-040.04" LOG_CI_END="0.3008459468201296" LOG_CI_START="-1.115957501747403" LOG_EFFECT_SIZE="-0.40755577746363675" METHOD="MH" MODIFIED="2013-03-18 11:47:48 -0400" MODIFIED_BY="Anne Lethaby" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2594883915661076" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.1276012157191952">
<NAME>Worsening of rheumatoid arthritis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9991526033225357" CI_START="0.07656715286782598" DF="0" EFFECT_SIZE="0.39124087591240875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-040.04.01" LOG_CI_END="0.3008459468201296" LOG_CI_START="-1.115957501747403" LOG_EFFECT_SIZE="-0.40755577746363675" MODIFIED="2008-10-08 17:39:28 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.2594883915661076" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.1276012157191952">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.9991526033225357" CI_START="0.07656715286782598" EFFECT_SIZE="0.39124087591240875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3008459468201296" LOG_CI_START="-1.115957501747403" LOG_EFFECT_SIZE="-0.40755577746363675" MODIFIED="2008-10-08 17:39:28 -0400" MODIFIED_BY="Anne Lethaby" ORDER="455" O_E="0.0" SE="0.8322373589787481" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.6926190216799215" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6924365797844336" CI_START="0.007252664868280272" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13974025974025975" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-040.05" LOG_CI_END="0.4301454823046351" LOG_CI_START="-2.1395023899888583" LOG_EFFECT_SIZE="-0.8546784538421115" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.19230562096586645" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.3037887454967148">
<NAME>Breast cancer</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6924365797844336" CI_START="0.007252664868280272" DF="0" EFFECT_SIZE="0.13974025974025975" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-040.05.01" LOG_CI_END="0.4301454823046351" LOG_CI_START="-2.1395023899888583" LOG_EFFECT_SIZE="-0.8546784538421115" MODIFIED="2008-10-08 17:40:35 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.19230562096586645" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.3037887454967148">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.692436579784435" CI_START="0.007252664868280272" EFFECT_SIZE="0.13974025974025975" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43014548230463534" LOG_CI_START="-2.1395023899888583" LOG_EFFECT_SIZE="-0.8546784538421115" MODIFIED="2008-10-08 17:40:35 -0400" MODIFIED_BY="Anne Lethaby" ORDER="456" O_E="0.0" SE="1.5094238801473108" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.278360449958963" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.55756681479084" CI_START="0.061493156676974366" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-040.06" LOG_CI_END="1.1919416748168914" LOG_CI_START="-1.2111732124000896" LOG_EFFECT_SIZE="-0.009615768791599127" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.987485606140437" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.01568510986757234">
<NAME>Chest pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.55756681479084" CI_START="0.061493156676974366" DF="0" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-040.06.01" LOG_CI_END="1.1919416748168914" LOG_CI_START="-1.2111732124000896" LOG_EFFECT_SIZE="-0.009615768791599127" MODIFIED="2008-10-08 17:41:42 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.987485606140437" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.01568510986757234">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="15.557566814790848" CI_START="0.06149315667697434" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1919416748168916" LOG_CI_START="-1.2111732124000898" LOG_EFFECT_SIZE="-0.009615768791599127" MODIFIED="2008-10-08 17:41:42 -0400" MODIFIED_BY="Anne Lethaby" ORDER="457" O_E="0.0" SE="1.4116015803617965" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="1.9926190216799216" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.55756681479084" CI_START="0.061493156676974366" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-040.07" LOG_CI_END="1.1919416748168914" LOG_CI_START="-1.2111732124000896" LOG_EFFECT_SIZE="-0.009615768791599127" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.987485606140437" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.01568510986757234">
<NAME>Pneumonia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.55756681479084" CI_START="0.061493156676974366" DF="0" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-040.07.01" LOG_CI_END="1.1919416748168914" LOG_CI_START="-1.2111732124000896" LOG_EFFECT_SIZE="-0.009615768791599127" MODIFIED="2008-10-08 17:42:38 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.987485606140437" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.01568510986757234">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="15.557566814790848" CI_START="0.06149315667697434" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1919416748168916" LOG_CI_START="-1.2111732124000898" LOG_EFFECT_SIZE="-0.009615768791599127" MODIFIED="2008-10-08 17:42:38 -0400" MODIFIED_BY="Anne Lethaby" ORDER="458" O_E="0.0" SE="1.4116015803617965" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="1.9926190216799216" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="101.4013004982983" CI_START="0.235904190754818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.08" LOG_CI_END="2.0060435249737747" LOG_CI_START="-0.6272643439574467" LOG_EFFECT_SIZE="0.6893895905081641" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.30478713455222073" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0262216466631524">
<NAME>Cholelithiasis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.4013004982983" CI_START="0.235904190754818" DF="0" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-040.08.01" LOG_CI_END="2.0060435249737747" LOG_CI_START="-0.6272643439574467" LOG_EFFECT_SIZE="0.6893895905081641" MODIFIED="2008-10-08 17:43:32 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.30478713455222073" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0262216466631524">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="101.40130049829838" CI_START="0.2359041907548179" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006043524973775" LOG_CI_START="-0.6272643439574469" LOG_EFFECT_SIZE="0.6893895905081641" MODIFIED="2008-10-08 17:43:32 -0400" MODIFIED_BY="Anne Lethaby" ORDER="459" O_E="0.0" SE="1.5468180772943783" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.3926461642446775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="101.4013004982983" CI_START="0.235904190754818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.09" LOG_CI_END="2.0060435249737747" LOG_CI_START="-0.6272643439574467" LOG_EFFECT_SIZE="0.6893895905081641" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.30478713455222073" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0262216466631524">
<NAME>Invertebral disc protrusion</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.4013004982983" CI_START="0.235904190754818" DF="0" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-040.09.01" LOG_CI_END="2.0060435249737747" LOG_CI_START="-0.6272643439574467" LOG_EFFECT_SIZE="0.6893895905081641" MODIFIED="2008-10-08 17:44:22 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.30478713455222073" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0262216466631524">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="101.40130049829838" CI_START="0.2359041907548179" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006043524973775" LOG_CI_START="-0.6272643439574469" LOG_EFFECT_SIZE="0.6893895905081641" MODIFIED="2008-10-08 17:44:22 -0400" MODIFIED_BY="Anne Lethaby" ORDER="460" O_E="0.0" SE="1.5468180772943783" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.3926461642446775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.0560520199319345" CI_START="0.009436167630192716" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19563636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-040.10" LOG_CI_END="0.6081035163017375" LOG_CI_START="-2.0252043526294847" LOG_EFFECT_SIZE="-0.7085504181638734" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.2915422769244348" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0547443519360544">
<NAME>Osteoarthritis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.0560520199319345" CI_START="0.009436167630192716" DF="0" EFFECT_SIZE="0.19563636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-040.10.01" LOG_CI_END="0.6081035163017375" LOG_CI_START="-2.0252043526294847" LOG_EFFECT_SIZE="-0.7085504181638734" MODIFIED="2008-10-08 17:45:20 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.2915422769244348" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0547443519360544">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.0560520199319345" CI_START="0.009436167630192716" EFFECT_SIZE="0.19563636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6081035163017375" LOG_CI_START="-2.0252043526294847" LOG_EFFECT_SIZE="-0.7085504181638734" MODIFIED="2008-10-08 17:45:20 -0400" MODIFIED_BY="Anne Lethaby" ORDER="461" O_E="0.0" SE="1.5468180772943783" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.3926461642446775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="101.4013004982983" CI_START="0.235904190754818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-040.11" LOG_CI_END="2.0060435249737747" LOG_CI_START="-0.6272643439574467" LOG_EFFECT_SIZE="0.6893895905081641" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.30478713455222073" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0262216466631524">
<NAME>Interstitial lung disease</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="101.4013004982983" CI_START="0.235904190754818" DF="0" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-040.11.01" LOG_CI_END="2.0060435249737747" LOG_CI_START="-0.6272643439574467" LOG_EFFECT_SIZE="0.6893895905081641" MODIFIED="2008-10-08 17:46:08 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.30478713455222073" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0262216466631524">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="101.40130049829838" CI_START="0.2359041907548179" EFFECT_SIZE="4.890909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006043524973775" LOG_CI_START="-0.6272643439574469" LOG_EFFECT_SIZE="0.6893895905081641" MODIFIED="2008-10-08 17:46:08 -0400" MODIFIED_BY="Anne Lethaby" ORDER="462" O_E="0.0" SE="1.5468180772943783" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.3926461642446775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.0560520199319345" CI_START="0.009436167630192716" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19563636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-040.12" LOG_CI_END="0.6081035163017375" LOG_CI_START="-2.0252043526294847" LOG_EFFECT_SIZE="-0.7085504181638734" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.2915422769244348" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0547443519360544">
<NAME>Hip arthroplasty</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.0560520199319345" CI_START="0.009436167630192716" DF="0" EFFECT_SIZE="0.19563636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-040.12.01" LOG_CI_END="0.6081035163017375" LOG_CI_START="-2.0252043526294847" LOG_EFFECT_SIZE="-0.7085504181638734" MODIFIED="2008-10-08 17:47:03 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.2915422769244348" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="1.0547443519360544">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.0560520199319345" CI_START="0.009436167630192716" EFFECT_SIZE="0.19563636363636364" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6081035163017375" LOG_CI_START="-2.0252043526294847" LOG_EFFECT_SIZE="-0.7085504181638734" MODIFIED="2008-10-08 17:47:03 -0400" MODIFIED_BY="Anne Lethaby" ORDER="463" O_E="0.0" SE="1.5468180772943783" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="2.3926461642446775" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8709321355394826" CI_START="0.24714561251823638" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-040.13" LOG_CI_END="0.5878155574158093" LOG_CI_START="-0.6070470949990076" LOG_EFFECT_SIZE="-0.009615768791599127" METHOD="MH" MODIFIED="2012-02-22 15:40:43 -0500" MODIFIED_BY="Anne Lethaby" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.9748341184995796" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.03154598643971278">
<NAME>Malignancy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8709321355394826" CI_START="0.24714561251823638" DF="0" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-040.13.01" LOG_CI_END="0.5878155574158093" LOG_CI_START="-0.6070470949990076" LOG_EFFECT_SIZE="-0.009615768791599127" MODIFIED="2012-01-31 14:31:57 -0500" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.9748341184995796" STUDIES="1" TAU2="0.0" TOTAL_1="274" TOTAL_2="268" WEIGHT="100.0" Z="0.03154598643971278">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.8709321355394835" CI_START="0.24714561251823633" EFFECT_SIZE="0.9781021897810219" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5878155574158094" LOG_CI_START="-0.6070470949990076" LOG_EFFECT_SIZE="-0.009615768791599127" MODIFIED="2008-10-08 17:49:21 -0400" MODIFIED_BY="Anne Lethaby" ORDER="464" O_E="0.0" SE="0.7018682366939835" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="274" TOTAL_2="268" VAR="0.49261902167992155" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-041" MODIFIED="2013-03-18 11:49:07 -0400" MODIFIED_BY="[Empty name]" NO="41">
<NAME>Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.558689403435996" CI_START="0.9826926222901021" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2376237623762376" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-041.01" LOG_CI_END="0.19275958291648468" LOG_CI_START="-0.007582304465657033" LOG_EFFECT_SIZE="0.09258863922541384" METHOD="MH" MODIFIED="2012-02-22 15:41:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07004691868775342" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.8116071544563048">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.558689403435996" CI_START="0.9826926222901021" DF="0" EFFECT_SIZE="1.2376237623762376" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="32" I2="0.0" ID="CMP-041.01.01" LOG_CI_END="0.19275958291648468" LOG_CI_START="-0.007582304465657033" LOG_EFFECT_SIZE="0.09258863922541384" MODIFIED="2012-02-17 14:54:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07004691868775342" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.8116071544563048">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.558689403435996" CI_START="0.9826926222901021" EFFECT_SIZE="1.2376237623762376" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="32" LOG_CI_END="0.19275958291648468" LOG_CI_START="-0.007582304465657033" LOG_EFFECT_SIZE="0.09258863922541384" MODIFIED="2012-02-17 14:54:39 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.11768181635660666" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.013849009900990094" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9807228654273175" CI_END="21.2219863741403" CI_START="0.24787058084874508" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2935357179085547" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="41" I2="79.9225930247736" I2_Q="0.0" ID="CMP-041.02" LOG_CI_END="1.3267860313539142" LOG_CI_START="-0.6057750155203289" LOG_EFFECT_SIZE="0.3605055079167926" METHOD="MH" MODIFIED="2012-02-23 14:56:34 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02563143519540456" P_Q="1.0" P_Z="0.46463583741617986" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.1327187690904394" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.7312346617852654">
<NAME>Accidental injury</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.9807228654273175" CI_END="21.2219863741403" CI_START="0.24787058084874508" DF="1" EFFECT_SIZE="2.2935357179085547" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="41" I2="79.9225930247736" ID="CMP-041.02.01" LOG_CI_END="1.3267860313539142" LOG_CI_START="-0.6057750155203289" LOG_EFFECT_SIZE="0.3605055079167926" MODIFIED="2012-02-17 14:56:49 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02563143519540456" P_Z="0.46463583741617986" STUDIES="2" TAU2="2.1327187690904394" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.7312346617852654">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="61.44984748679585" CI_START="1.1525885330288084" EFFECT_SIZE="8.415841584158416" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="1.7885208093424863" LOG_CI_START="0.061674294520814014" LOG_EFFECT_SIZE="0.9250975519316502" MODIFIED="2012-02-17 14:56:49 -0500" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="1.0143581908343595" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.0289225393127548" WEIGHT="40.75951896611603"/>
<DICH_DATA CI_END="1.4051871922660695" CI_START="0.6256893489418618" EFFECT_SIZE="0.9376623376623376" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="40" LOG_CI_END="0.14773418271298477" LOG_CI_START="-0.20364123791867025" LOG_EFFECT_SIZE="-0.027953527602842764" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7746" O_E="0.0" SE="0.206399661415418" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.04260082023239918" WEIGHT="59.24048103388397"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1331436992110744" CI_END="10.354591433702367" CI_START="0.3300480225085269" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8486515157209045" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" I2="68.0831747279322" I2_Q="0.0" ID="CMP-041.03" LOG_CI_END="1.0151329673927607" LOG_CI_START="-0.4814228649914979" LOG_EFFECT_SIZE="0.26685505120063135" METHOD="MH" MODIFIED="2013-03-18 11:48:16 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07671597757584425" P_Q="1.0" P_Z="0.48456871771693844" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.15692901587902" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.6989733067460144">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1331436992110744" CI_END="10.354591433702367" CI_START="0.3300480225085269" DF="1" EFFECT_SIZE="1.8486515157209045" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" I2="68.0831747279322" ID="CMP-041.03.01" LOG_CI_END="1.0151329673927607" LOG_CI_START="-0.4814228649914979" LOG_EFFECT_SIZE="0.26685505120063135" MODIFIED="2012-01-31 14:34:33 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07671597757584425" P_Z="0.48456871771693844" STUDIES="2" TAU2="1.15692901587902" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.6989733067460144">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="44.4095473456369" CI_START="0.7946637578623358" EFFECT_SIZE="5.9405940594059405" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.6474763465514295" LOG_CI_START="-0.09981659334942741" LOG_EFFECT_SIZE="0.7738298766010011" MODIFIED="2012-01-31 14:34:33 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.026368522137309" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.0534323432343233" WEIGHT="34.96212102950654"/>
<DICH_DATA CI_END="1.3959818700385995" CI_START="0.6978562239532251" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="50" LOG_CI_END="0.1448797780340461" LOG_CI_START="-0.15623404381742714" LOG_EFFECT_SIZE="-0.005677132891690521" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7745" O_E="0.0" SE="0.17687574949301266" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.03128503075871497" WEIGHT="65.03787897049347"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.582767481720496" CI_END="16.074843603432154" CI_START="0.36962879043794405" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.437565383249391" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" I2="72.08861571112102" I2_Q="0.0" ID="CMP-041.04" LOG_CI_END="1.2061467562465353" LOG_CI_START="-0.432234208876803" LOG_EFFECT_SIZE="0.3869562736848662" METHOD="MH" MODIFIED="2012-02-23 14:57:51 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.05838197742088502" P_Q="1.0" P_Z="0.35454117475582037" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.4205653323261807" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.9258168596423697">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.582767481720496" CI_END="16.074843603432154" CI_START="0.36962879043794405" DF="1" EFFECT_SIZE="2.437565383249391" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" I2="72.08861571112102" ID="CMP-041.04.01" LOG_CI_END="1.2061467562465353" LOG_CI_START="-0.432234208876803" LOG_EFFECT_SIZE="0.3869562736848662" MODIFIED="2012-01-31 14:34:13 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05838197742088502" P_Z="0.35454117475582037" STUDIES="2" TAU2="1.4205653323261807" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.9258168596423697">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="58.04075531139086" CI_START="1.0809464285129662" EFFECT_SIZE="7.920792079207921" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.7637330554789095" LOG_CI_START="0.03380417093969256" LOG_EFFECT_SIZE="0.898768613209301" MODIFIED="2012-01-31 14:34:13 -0500" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="1.0161687900644214" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.03259900990099" WEIGHT="37.755336724480394"/>
<DICH_DATA CI_END="1.984042062873002" CI_START="0.7169161623936389" EFFECT_SIZE="1.1926406926406927" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.2975508752173502" LOG_CI_START="-0.144531628626031" LOG_EFFECT_SIZE="0.07650962329565958" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7744" O_E="0.0" SE="0.25968145110128926" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.06743445604607129" WEIGHT="62.24466327551961"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0386351395154516" CI_END="1.498532688765985" CI_START="0.5682851373130718" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.922818430030255" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-041.05" LOG_CI_END="0.17566622101929832" LOG_CI_START="-0.24543370215925742" LOG_EFFECT_SIZE="-0.034883740569979525" METHOD="MH" MODIFIED="2012-02-22 15:41:24 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8441733418836657" P_Q="1.0" P_Z="0.7453890726303044" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.3247251846883279">
<NAME>Arthralgia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0386351395154516" CI_END="1.498532688765985" CI_START="0.5682851373130718" DF="1" EFFECT_SIZE="0.922818430030255" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" I2="0.0" ID="CMP-041.05.01" LOG_CI_END="0.17566622101929832" LOG_CI_START="-0.24543370215925742" LOG_EFFECT_SIZE="-0.034883740569979525" MODIFIED="2012-01-31 14:35:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8441733418836657" P_Z="0.7453890726303044" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.3247251846883279">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.2971265947241593" CI_START="0.42674881378256635" EFFECT_SIZE="0.9900990099009901" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.361184929838106" LOG_CI_START="-0.3698276774033911" LOG_EFFECT_SIZE="-0.004321373782642578" MODIFIED="2012-01-31 14:35:52 -0500" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.42940042406442075" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.18438472418670437" WEIGHT="30.700917868637504"/>
<DICH_DATA CI_END="1.6157977956368126" CI_START="0.49354565779680293" EFFECT_SIZE="0.8930117501546073" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.20838701130634268" LOG_CI_START="-0.3066726646519043" LOG_EFFECT_SIZE="-0.04914282667278082" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7752" O_E="0.0" SE="0.3025486032443895" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.091535657325131" WEIGHT="69.2990821313625"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7243800506220663" CI_END="2.1172878351533955" CI_START="0.9329050314933613" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4054282174961086" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-041.06" LOG_CI_END="0.32577990229031495" LOG_CI_START="-0.030162564611082292" LOG_EFFECT_SIZE="0.14780866883961633" METHOD="MH" MODIFIED="2012-02-22 15:41:24 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.39471094613263125" P_Q="1.0" P_Z="0.10356957249561699" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.6277892888162067">
<NAME>Back pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7243800506220663" CI_END="2.1172878351533955" CI_START="0.9329050314933613" DF="1" EFFECT_SIZE="1.4054282174961086" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="33" I2="0.0" ID="CMP-041.06.01" LOG_CI_END="0.32577990229031495" LOG_CI_START="-0.030162564611082292" LOG_EFFECT_SIZE="0.14780866883961633" MODIFIED="2012-01-31 14:36:15 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.39471094613263125" P_Z="0.10356957249561699" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.6277892888162067">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.966464838109284" CI_START="0.7895322579431497" EFFECT_SIZE="1.9801980198019802" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.6960473650731945" LOG_CI_START="-0.10263012131051737" LOG_EFFECT_SIZE="0.2967086218813386" MODIFIED="2012-01-31 14:36:15 -0500" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.4691471090191115" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.2200990099009901" WEIGHT="19.18097616559216"/>
<DICH_DATA CI_END="2.0076447169990486" CI_START="0.8021356393997059" EFFECT_SIZE="1.269016697588126" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="28" LOG_CI_END="0.30268686031628267" LOG_CI_START="-0.09575218724952768" LOG_EFFECT_SIZE="0.1034673365333775" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7747" O_E="0.0" SE="0.2340450688452514" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.05477709425077846" WEIGHT="80.81902383440784"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.371713013731302" CI_START="0.5045313139809727" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4851485148514851" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-041.07" LOG_CI_END="0.6406516444387482" LOG_CI_START="-0.29711187389267085" LOG_EFFECT_SIZE="0.17176988527303866" METHOD="MH" MODIFIED="2012-02-22 15:41:24 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4727498153709919" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.7180121260480756">
<NAME>Bronchitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.371713013731302" CI_START="0.5045313139809727" DF="0" EFFECT_SIZE="1.4851485148514851" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-041.07.01" LOG_CI_END="0.6406516444387482" LOG_CI_START="-0.29711187389267085" LOG_EFFECT_SIZE="0.17176988527303866" MODIFIED="2012-02-17 15:19:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4727498153709919" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.7180121260480756">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.371713013731302" CI_START="0.5045313139809727" EFFECT_SIZE="1.4851485148514851" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.6406516444387482" LOG_CI_START="-0.29711187389267085" LOG_EFFECT_SIZE="0.17176988527303866" MODIFIED="2012-02-17 15:19:02 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.5508469326721566" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.3034323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7694517151396365" CI_END="7.683041095380224" CI_START="0.29002970041664394" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4927525271061812" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="43.48531856258735" I2_Q="0.0" ID="CMP-041.08" LOG_CI_END="0.885533156167284" LOG_CI_START="-0.5375575260093517" LOG_EFFECT_SIZE="0.17398781507896616" METHOD="MH" MODIFIED="2013-03-18 11:48:25 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.1834500723356164" P_Q="1.0" P_Z="0.6317590433937219" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8441581508686165" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.47925245463909527">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7694517151396365" CI_END="7.683041095380224" CI_START="0.29002970041664394" DF="1" EFFECT_SIZE="1.4927525271061812" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="43.48531856258735" ID="CMP-041.08.01" LOG_CI_END="0.885533156167284" LOG_CI_START="-0.5375575260093517" LOG_EFFECT_SIZE="0.17398781507896616" MODIFIED="2012-01-31 14:32:40 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1834500723356164" P_Z="0.6317590433937219" STUDIES="2" TAU2="0.8441581508686165" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.47925245463909527">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="113.12980092347722" CI_START="0.3734648134719033" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.053577022890231" LOG_CI_START="-0.4277503096045201" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2012-01-31 14:32:40 -0500" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="1.4575439578758067" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.1244343891402715" WEIGHT="23.539095042809087"/>
<DICH_DATA CI_END="1.5925322808145923" CI_START="0.5655757906733252" EFFECT_SIZE="0.949050949050949" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.20208824429628008" LOG_CI_START="-0.24750918867722188" LOG_EFFECT_SIZE="-0.0227104721904709" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7742" O_E="0.0" SE="0.2640957576718214" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.06974656922025343" WEIGHT="76.46090495719092"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.76540300504557" CI_START="0.691138731865739" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-041.09" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.14336005194521045" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.4633923456182283">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.76540300504557" CI_START="0.691138731865739" DF="0" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-041.09.01" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 14:58:42 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14336005194521045" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.4633923456182283">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="12.76540300504557" CI_START="0.691138731865739" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 14:58:42 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.7439303349335362" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5534323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.76540300504557" CI_START="0.691138731865739" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-041.10" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.14336005194521045" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.4633923456182283">
<NAME>Flu syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.76540300504557" CI_START="0.691138731865739" DF="0" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-041.10.01" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 15:19:36 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14336005194521045" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.4633923456182283">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="12.76540300504557" CI_START="0.691138731865739" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 15:19:36 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.7439303349335362" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5534323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.76540300504557" CI_START="0.691138731865739" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-041.11" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.14336005194521045" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.4633923456182283">
<NAME>Gingival/dental infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.76540300504557" CI_START="0.691138731865739" DF="0" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-041.11.01" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 15:20:14 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14336005194521045" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.4633923456182283">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="12.76540300504557" CI_START="0.691138731865739" EFFECT_SIZE="2.9702970297029703" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.1060345300767906" LOG_CI_START="-0.16043476820275077" LOG_EFFECT_SIZE="0.47279988093701986" MODIFIED="2012-02-17 15:20:14 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.7439303349335362" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5534323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.015813571544161" CI_END="4.729566068693481" CI_START="0.5611788935225088" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6291508994783173" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="41" I2="75.09844562790597" I2_Q="0.0" ID="CMP-041.12" LOG_CI_END="0.6748212966327628" LOG_CI_START="-0.25089867156934365" LOG_EFFECT_SIZE="0.2119613125317096" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.04507555334654034" P_Q="1.0" P_Z="0.36942947949432126" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.45848221475713186" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.8975425678347037">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.015813571544161" CI_END="4.729566068693481" CI_START="0.5611788935225088" DF="1" EFFECT_SIZE="1.6291508994783173" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="41" I2="75.09844562790597" ID="CMP-041.12.01" LOG_CI_END="0.6748212966327628" LOG_CI_START="-0.25089867156934365" LOG_EFFECT_SIZE="0.2119613125317096" MODIFIED="2012-02-17 14:55:03 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04507555334654034" P_Z="0.36942947949432126" STUDIES="2" TAU2="0.45848221475713186" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.8975425678347037">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.406991507147115" CI_START="1.1387193146740906" EFFECT_SIZE="3.094059405940594" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" LOG_CI_END="0.924640608687413" LOG_CI_START="0.05641668710748987" LOG_EFFECT_SIZE="0.4905286478974515" MODIFIED="2012-02-17 14:55:03 -0500" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="0.5099990293137724" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.26009900990099005" WEIGHT="41.148935234261856"/>
<DICH_DATA CI_END="1.5690618902422817" CI_START="0.6898130812715253" EFFECT_SIZE="1.0403650403650404" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" LOG_CI_END="0.19564007428202823" LOG_CI_START="-0.1612685741464008" LOG_EFFECT_SIZE="0.017185750067813706" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7741" O_E="0.0" SE="0.2096499068131623" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.04395308342676764" WEIGHT="58.85106476573814"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.427377778809825" CI_START="0.8704821198368716" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-041.13" LOG_CI_END="0.5349619766825928" LOG_CI_START="-0.06024014509338505" LOG_EFFECT_SIZE="0.23736091579460392" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.11799855370010938" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="1.5632297979944607">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.427377778809825" CI_START="0.8704821198368716" DF="0" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" ID="CMP-041.13.01" LOG_CI_END="0.5349619766825928" LOG_CI_START="-0.06024014509338505" LOG_EFFECT_SIZE="0.23736091579460392" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11799855370010938" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="1.5632297979944607">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.427377778809825" CI_START="0.8704821198368716" EFFECT_SIZE="1.7272727272727273" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.5349619766825928" LOG_CI_START="-0.06024014509338505" LOG_EFFECT_SIZE="0.23736091579460392" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7751" O_E="0.0" SE="0.3496246726292295" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.12223741171109591" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07160845806994576" CI_END="2.035220453470475" CI_START="0.8332748165178434" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3022664665647243" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-041.14" LOG_CI_END="0.3086114585441492" LOG_CI_START="-0.07921174335447952" LOG_EFFECT_SIZE="0.11469985759483484" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7890091094120447" P_Q="1.0" P_Z="0.24632160510269585" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.1593302763588171">
<NAME>Increase in cough</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07160845806994576" CI_END="2.035220453470475" CI_START="0.8332748165178434" DF="1" EFFECT_SIZE="1.3022664665647243" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="29" I2="0.0" ID="CMP-041.14.01" LOG_CI_END="0.3086114585441492" LOG_CI_START="-0.07921174335447952" LOG_EFFECT_SIZE="0.11469985759483484" MODIFIED="2012-01-31 14:35:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7890091094120447" P_Z="0.24632160510269585" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.1593302763588171">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.371713013731302" CI_START="0.5045313139809727" EFFECT_SIZE="1.4851485148514851" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.6406516444387482" LOG_CI_START="-0.29711187389267085" LOG_EFFECT_SIZE="0.17176988527303866" MODIFIED="2012-01-31 14:35:16 -0500" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.5508469326721566" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.3034323432343234" WEIGHT="17.5359658654078"/>
<DICH_DATA CI_END="2.0624947449367945" CI_START="0.7738785741941041" EFFECT_SIZE="1.2633766233766235" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="25" LOG_CI_END="0.3143928506775459" LOG_CI_START="-0.11132717716519006" LOG_EFFECT_SIZE="0.10153283675617789" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7748" O_E="0.0" SE="0.25007005170294777" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.06253503075871497" WEIGHT="82.4640341345922"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4896244626079445" CI_END="1.6100949136057867" CI_START="0.8116771172472319" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1431872978519206" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="193" I2="71.34362133475366" I2_Q="0.0" ID="CMP-041.15" LOG_CI_END="0.20685147804444162" LOG_CI_START="-0.0906166974643843" LOG_EFFECT_SIZE="0.058117390290028666" METHOD="MH" MODIFIED="2012-02-23 15:06:20 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.06175471548738176" P_Q="1.0" P_Z="0.4437656029369563" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04630451809549997" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.7658499377223925">
<NAME>Infections (total)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4896244626079445" CI_END="1.6100949136057867" CI_START="0.8116771172472319" DF="1" EFFECT_SIZE="1.1431872978519206" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="193" I2="71.34362133475366" ID="CMP-041.15.01" LOG_CI_END="0.20685147804444162" LOG_CI_START="-0.0906166974643843" LOG_EFFECT_SIZE="0.058117390290028666" MODIFIED="2012-01-31 14:36:45 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06175471548738176" P_Z="0.4437656029369563" STUDIES="2" TAU2="0.04630451809549997" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.7658499377223925">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.0343229408267396" CI_START="0.9834250709722948" EFFECT_SIZE="1.4144271570014144" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="21" LOG_CI_END="0.3084198966134035" LOG_CI_START="-0.00725872420720232" LOG_EFFECT_SIZE="0.15058058620310058" MODIFIED="2012-01-31 14:36:45 -0500" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.18543118450439877" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.03438472418670438" WEIGHT="37.839081541707785"/>
<DICH_DATA CI_END="1.1142443133834583" CI_START="0.9050748801491721" EFFECT_SIZE="1.0042283298097252" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="172" LOG_CI_END="0.04698042631442955" LOG_CI_START="-0.04331548854031954" LOG_EFFECT_SIZE="0.0018324688870550246" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7754" O_E="0.0" SE="0.053040267357666815" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.002813269961372776" WEIGHT="62.16091845829221"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.670277918244671" CI_START="0.6958245107924002" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.31023102310231" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-041.16" LOG_CI_END="0.8848111000863231" LOG_CI_START="-0.15750027706241942" LOG_EFFECT_SIZE="0.3636554115119518" METHOD="MH" MODIFIED="2013-03-18 11:48:35 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.1714259049989855" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.3676364375802172">
<NAME>Injection site haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.670277918244671" CI_START="0.6958245107924002" DF="0" EFFECT_SIZE="2.31023102310231" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" ID="CMP-041.16.01" LOG_CI_END="0.8848111000863231" LOG_CI_START="-0.15750027706241942" LOG_EFFECT_SIZE="0.3636554115119518" MODIFIED="2012-02-17 14:59:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1714259049989855" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.3676364375802172">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.670277918244667" CI_START="0.6958245107924003" EFFECT_SIZE="2.31023102310231" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.8848111000863229" LOG_CI_START="-0.15750027706241934" LOG_EFFECT_SIZE="0.3636554115119518" MODIFIED="2012-02-17 14:59:31 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.6122588624616999" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.37486091466289484" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.003630874936530296" CI_END="11.043803042688925" CI_START="2.2876227798448685" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.026336182208196" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-041.17" LOG_CI_END="1.0431186527448322" LOG_CI_START="0.3593844125431377" LOG_EFFECT_SIZE="0.701251532643985" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.9519511965221042" P_Q="1.0" P_Z="5.8110101650580434E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="4.020356645237725">
<NAME>Injection Site Reaction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.003630874936530296" CI_END="11.043803042688925" CI_START="2.2876227798448685" DF="1" EFFECT_SIZE="5.026336182208196" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="7" I2="0.0" ID="CMP-041.17.01" LOG_CI_END="1.0431186527448322" LOG_CI_START="0.3593844125431377" LOG_EFFECT_SIZE="0.701251532643985" MODIFIED="2012-01-31 14:30:12 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9519511965221042" P_Z="5.8110101650580434E-5" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="4.020356645237725">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="21.29608657021489" CI_START="1.2687500012123412" EFFECT_SIZE="5.198019801980198" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.328299803574355" LOG_CI_START="0.10337605567227381" LOG_EFFECT_SIZE="0.7158379296233143" MODIFIED="2012-01-31 14:30:12 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.719526272988025" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5177180575200377" WEIGHT="34.70985276445682"/>
<DICH_DATA CI_END="12.666411373867748" CI_START="1.9227913253752635" EFFECT_SIZE="4.935064935064935" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="1.1026535887362672" LOG_CI_START="0.28393215415238954" LOG_EFFECT_SIZE="0.6932928714443283" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7740" O_E="0.0" SE="0.4809210234110326" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.23128503075871498" WEIGHT="65.29014723554317"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.588734579510778" CI_START="0.4836639012341054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4675324675324677" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="100.0" ID="CMP-041.18" LOG_CI_END="1.099982076989833" LOG_CI_START="-0.31545632542913865" LOG_EFFECT_SIZE="0.39226287578034713" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.27733021782661116" Q="1.7830491180389154E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.0863363713852627">
<NAME>Malignancy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.588734579510778" CI_START="0.4836639012341054" DF="0" EFFECT_SIZE="2.4675324675324677" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-041.18.01" LOG_CI_END="1.099982076989833" LOG_CI_START="-0.31545632542913865" LOG_EFFECT_SIZE="0.39226287578034713" MODIFIED="2012-01-31 14:31:57 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27733021782661116" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="1.0863363713852627">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-31 14:31:57 -0500" MODIFIED_BY="[Empty name]" ORDER="534" O_E="0.0" SE="0.0" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.588734579510778" CI_START="0.4836639012341054" EFFECT_SIZE="2.4675324675324677" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.099982076989833" LOG_CI_START="-0.31545632542913865" LOG_EFFECT_SIZE="0.39226287578034713" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7756" O_E="0.0" SE="0.8314355241139958" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.691285030758715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.617495258718588E-32" CI_END="206.92834929342425" CI_START="0.7550922845203657" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.499999999999998" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-041.19" LOG_CI_END="2.3158199933157597" LOG_CI_START="-0.12199996729964724" LOG_EFFECT_SIZE="1.0969100130080565" METHOD="MH" MODIFIED="2012-02-23 15:05:00 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="1.0" P_Z="0.07776694302389099" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.7637923673694327">
<NAME>Miscellaneous skin infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.617495258718588E-32" CI_END="206.92834929342425" CI_START="0.7550922845203657" DF="0" EFFECT_SIZE="12.499999999999998" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="100.0" ID="CMP-041.19.01" LOG_CI_END="2.3158199933157597" LOG_CI_START="-0.12199996729964724" LOG_EFFECT_SIZE="1.0969100130080565" MODIFIED="2012-02-17 15:21:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.07776694302389099" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.7637923673694327">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="206.92834929342442" CI_START="0.755092284520366" EFFECT_SIZE="12.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.31581999331576" LOG_CI_START="-0.12199996729964706" LOG_EFFECT_SIZE="1.0969100130080565" MODIFIED="2012-02-17 15:21:16 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.4319875122689156" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.050588235294118" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8701655937693955" CI_END="2.6397707325299287" CI_START="0.4177960719787698" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0501837186776055" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="95" I2="74.1613123322189" I2_Q="0.0" ID="CMP-041.20" LOG_CI_END="0.42156620947555823" LOG_CI_START="-0.37903564747194857" LOG_EFFECT_SIZE="0.02126528100180487" METHOD="MH" MODIFIED="2012-02-23 15:10:41 -0500" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.04915172521098021" P_Q="1.0" P_Z="0.9170744124067897" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.34481917711323806" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.10411963080768659">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8701655937693955" CI_END="2.6397707325299287" CI_START="0.4177960719787698" DF="1" EFFECT_SIZE="1.0501837186776055" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="95" I2="74.1613123322189" ID="CMP-041.20.01" LOG_CI_END="0.42156620947555823" LOG_CI_START="-0.37903564747194857" LOG_EFFECT_SIZE="0.02126528100180487" MODIFIED="2012-01-31 14:33:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04915172521098021" P_Z="0.9170744124067897" STUDIES="2" TAU2="0.34481917711323806" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.10411963080768659">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.744071130560274" CI_START="0.7459560872859519" EFFECT_SIZE="1.881188118811881" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.6761511920295268" LOG_CI_START="-0.12728673768915402" LOG_EFFECT_SIZE="0.27443222717018634" MODIFIED="2012-01-31 14:33:02 -0500" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.4719434169986467" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.22273058884835853" WEIGHT="38.96767022947024"/>
<DICH_DATA CI_END="0.9383846455525177" CI_START="0.5583000843421718" EFFECT_SIZE="0.7238095238095238" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="90" LOG_CI_END="-0.027619107037422593" LOG_CI_START="-0.2531323065408708" LOG_EFFECT_SIZE="-0.14037570678914674" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7743" O_E="0.0" SE="0.13246756969666665" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.017547657021341236" WEIGHT="61.03232977052976"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6157977956368126" CI_START="0.49354565779680293" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8930117501546073" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-041.21" LOG_CI_END="0.20838701130634268" LOG_CI_START="-0.3066726646519043" LOG_EFFECT_SIZE="-0.04914282667278082" METHOD="MH" MODIFIED="2012-02-23 15:05:01 -0500" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.708398507401965" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.00000000000001" Z="0.3740078086988612">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6157977956368126" CI_START="0.49354565779680293" DF="0" EFFECT_SIZE="0.8930117501546073" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" ID="CMP-041.21.01" LOG_CI_END="0.20838701130634268" LOG_CI_START="-0.3066726646519043" LOG_EFFECT_SIZE="-0.04914282667278082" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.708398507401965" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.00000000000001" Z="0.3740078086988612">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6157977956368126" CI_START="0.49354565779680293" EFFECT_SIZE="0.8930117501546073" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.20838701130634268" LOG_CI_START="-0.3066726646519043" LOG_EFFECT_SIZE="-0.04914282667278082" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7753" O_E="0.0" SE="0.3025486032443895" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.091535657325131" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="41.003749516696985" CI_START="0.7232010692701185" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.445544554455446" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" I2_Q="100.0" ID="CMP-041.22" LOG_CI_END="1.612823571840618" LOG_CI_START="-0.1407409404174154" LOG_EFFECT_SIZE="0.7360413157116013" METHOD="MH" MODIFIED="2013-03-18 11:48:46 -0400" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.09989746980087907" Q="4.646883142425558E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.645350895098334">
<NAME>Paraesthesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="41.003749516696985" CI_START="0.7232010692701185" DF="0" EFFECT_SIZE="5.445544554455446" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-041.22.01" LOG_CI_END="1.612823571840618" LOG_CI_START="-0.1407409404174154" LOG_EFFECT_SIZE="0.7360413157116013" MODIFIED="2012-02-17 15:08:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09989746980087907" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.645350895098334">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="41.00374951669694" CI_START="0.723201069270119" EFFECT_SIZE="5.445544554455446" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="1.6128235718406176" LOG_CI_START="-0.14074094041741514" LOG_EFFECT_SIZE="0.7360413157116013" MODIFIED="2012-02-17 15:08:09 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.030052474784698" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="1.061008100810081" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.730325700434234" CI_START="0.47519891957965743" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6501650165016502" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-041.23" LOG_CI_END="0.7581793071124856" LOG_CI_START="-0.323124555445058" LOG_EFFECT_SIZE="0.2175273758337138" METHOD="MH" MODIFIED="2012-02-23 15:13:38 -0500" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.4303591290035367" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.7885772668511093">
<NAME>Pharyngitis or laryngitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.730325700434234" CI_START="0.47519891957965743" DF="0" EFFECT_SIZE="1.6501650165016502" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-041.23.01" LOG_CI_END="0.7581793071124856" LOG_CI_START="-0.323124555445058" LOG_EFFECT_SIZE="0.2175273758337138" MODIFIED="2012-01-31 14:31:34 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4303591290035367" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.7885772668511093">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="5.730325700434232" CI_START="0.47519891957965754" EFFECT_SIZE="1.6501650165016502" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.7581793071124855" LOG_CI_START="-0.3231245554450579" LOG_EFFECT_SIZE="0.2175273758337138" MODIFIED="2012-01-31 14:31:23 -0500" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="0.6351632414067453" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.4034323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17154515699518313" CI_END="1.6420235000556391" CI_START="0.6459376370095422" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0298760991207037" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-041.24" LOG_CI_END="0.21537936829588009" LOG_CI_START="-0.18980940957460035" LOG_EFFECT_SIZE="0.012784979360639857" METHOD="MH" MODIFIED="2012-02-23 15:13:41 -0500" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.6787424953253933" P_Q="1.0" P_Z="0.9015638598098937" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.12368604689220654">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.17154515699518313" CI_END="1.6420235000556391" CI_START="0.6459376370095422" DF="1" EFFECT_SIZE="1.0298760991207037" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" I2="0.0" ID="CMP-041.24.01" LOG_CI_END="0.21537936829588009" LOG_CI_START="-0.18980940957460035" LOG_EFFECT_SIZE="0.012784979360639857" MODIFIED="2012-02-17 14:57:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6787424953253933" P_Z="0.9015638598098937" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="278" WEIGHT="100.0" Z="0.12368604689220654">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.761778049137844" CI_START="0.36598693057407594" EFFECT_SIZE="1.3201320132013201" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.677769148674675" LOG_CI_START="-0.43653442302336015" LOG_EFFECT_SIZE="0.12061736282565738" MODIFIED="2012-02-17 14:57:26 -0500" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.6545474339070648" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.4284323432343234" WEIGHT="12.867206235011988"/>
<DICH_DATA CI_END="1.6290566037112089" CI_START="0.5980115327564144" EFFECT_SIZE="0.987012987012987" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" LOG_CI_END="0.2119361747028308" LOG_CI_START="-0.22329044048621188" LOG_EFFECT_SIZE="-0.005677132891690521" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7749" O_E="0.0" SE="0.25565426816853465" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.06535910483278903" WEIGHT="87.13279376498801"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7570385508555129" CI_START="0.4164555271299978" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8554112554112554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-041.25" LOG_CI_END="0.2447812903741506" LOG_CI_START="-0.3804313696552206" LOG_EFFECT_SIZE="-0.067825039640535" METHOD="MH" MODIFIED="2012-02-23 15:13:43 -0500" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.6706572537745166" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="0.42524613925509797">
<NAME>Serious infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7570385508555129" CI_START="0.4164555271299978" DF="0" EFFECT_SIZE="0.8554112554112554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-041.25.01" LOG_CI_END="0.2447812903741506" LOG_CI_START="-0.3804313696552206" LOG_EFFECT_SIZE="-0.067825039640535" MODIFIED="2010-05-21 00:43:23 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6706572537745166" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="0.42524613925509797">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7570385508555129" CI_START="0.41645552712999767" EFFECT_SIZE="0.8554112554112554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.2447812903741506" LOG_CI_START="-0.38043136965522073" LOG_EFFECT_SIZE="-0.067825039640535" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7755" O_E="0.0" SE="0.367253011353833" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.13487477434845857" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1851593976094137E-32" CI_END="66.47484711767984" CI_START="0.1842802282540632" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-041.26" LOG_CI_END="1.8226573471916547" LOG_CI_START="-0.7345212584911035" LOG_EFFECT_SIZE="0.5440680443502756" METHOD="MH" MODIFIED="2012-02-23 15:13:46 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.0" P_Q="1.0" P_Z="0.4042764553388859" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8340080506664244">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1851593976094137E-32" CI_END="66.47484711767984" CI_START="0.1842802282540632" DF="0" EFFECT_SIZE="3.4999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" ID="CMP-041.26.01" LOG_CI_END="1.8226573471916547" LOG_CI_START="-0.7345212584911035" LOG_EFFECT_SIZE="0.5440680443502756" MODIFIED="2012-02-17 15:20:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.4042764553388859" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.8340080506664244">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="66.47484711767984" CI_START="0.18428022825406326" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8226573471916547" LOG_CI_START="-0.7345212584911034" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2012-02-17 15:20:46 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.5020993712162998" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="2.2563025210084033" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.705936405894464" CI_START="0.7616854702824216" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4356435643564356" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-041.27" LOG_CI_END="0.43231758572292905" LOG_CI_START="-0.11822432881826452" LOG_EFFECT_SIZE="0.1570466284523323" METHOD="MH" MODIFIED="2013-03-18 11:48:58 -0400" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.26348509068335024" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.1181918307401952">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.705936405894464" CI_START="0.7616854702824216" DF="0" EFFECT_SIZE="1.4356435643564356" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" I2="0.0" ID="CMP-041.27.01" LOG_CI_END="0.43231758572292905" LOG_CI_START="-0.11822432881826452" LOG_EFFECT_SIZE="0.1570466284523323" MODIFIED="2012-02-17 15:10:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.26348509068335024" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="1.1181918307401952">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.705936405894464" CI_START="0.7616854702824216" EFFECT_SIZE="1.4356435643564356" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.43231758572292905" LOG_CI_START="-0.11822432881826452" LOG_EFFECT_SIZE="0.1570466284523323" MODIFIED="2012-02-17 15:10:02 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.323391045827926" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.10458176852167975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0458063598083351" CI_START="0.36387690352654933" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6168831168831169" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-041.28" LOG_CI_END="0.01945127855432489" LOG_CI_START="-0.4390455096495554" LOG_EFFECT_SIZE="-0.20979711554761526" METHOD="MH" MODIFIED="2012-02-23 15:13:51 -0500" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.07286667601622035" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="1.7936648679461096">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0458063598083351" CI_START="0.36387690352654933" DF="0" EFFECT_SIZE="0.6168831168831169" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" I2="0.0" ID="CMP-041.28.01" LOG_CI_END="0.01945127855432489" LOG_CI_START="-0.4390455096495554" LOG_EFFECT_SIZE="-0.20979711554761526" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07286667601622035" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="228" WEIGHT="100.0" Z="1.7936648679461096">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0458063598083351" CI_START="0.36387690352654933" EFFECT_SIZE="0.6168831168831169" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" LOG_CI_END="0.01945127855432489" LOG_CI_START="-0.4390455096495554" LOG_EFFECT_SIZE="-0.20979711554761526" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7750" O_E="0.0" SE="0.26932328298666447" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.07253503075871497" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1869283530975134" CI_START="0.4429425938534029" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.188118811881188" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-041.29" LOG_CI_END="0.5033722999958041" LOG_CI_START="-0.3536525554658397" LOG_EFFECT_SIZE="0.07485987226498224" METHOD="MH" MODIFIED="2013-03-18 11:49:07 -0400" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.7320498921425719" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.34239999596651294">
<NAME>Worsening of rheumatoid arthritis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1869283530975134" CI_START="0.4429425938534029" DF="0" EFFECT_SIZE="1.188118811881188" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-041.29.01" LOG_CI_END="0.5033722999958041" LOG_CI_START="-0.3536525554658397" LOG_EFFECT_SIZE="0.07485987226498224" MODIFIED="2012-02-17 15:06:20 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7320498921425719" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="50" WEIGHT="100.0" Z="0.34239999596651294">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.186928353097513" CI_START="0.44294259385340295" EFFECT_SIZE="1.188118811881188" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.5033722999958041" LOG_CI_START="-0.3536525554658396" LOG_EFFECT_SIZE="0.07485987226498224" MODIFIED="2012-02-17 15:06:20 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.5034206424396236" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.2534323432343234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-042" MODIFIED="2013-03-20 15:15:58 -0400" MODIFIED_BY="[Empty name]" NO="42">
<NAME>Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6146399227017454" CI_START="0.9502925324397749" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2387010378305994" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-042.01" LOG_CI_END="0.2080756864074758" LOG_CI_START="-0.022142683481742347" LOG_EFFECT_SIZE="0.09296650146286674" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.11343501894523733" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.5829405335776605">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6146399227017454" CI_START="0.9502925324397749" DF="0" EFFECT_SIZE="1.2387010378305994" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="29" I2="0.0" ID="CMP-042.01.01" LOG_CI_END="0.2080756864074758" LOG_CI_START="-0.022142683481742347" LOG_EFFECT_SIZE="0.09296650146286674" MODIFIED="2012-02-21 14:49:13 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11343501894523733" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.5829405335776605">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6146399227017454" CI_START="0.9502925324397749" EFFECT_SIZE="1.2387010378305994" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="29" LOG_CI_END="0.2080756864074758" LOG_CI_START="-0.022142683481742347" LOG_EFFECT_SIZE="0.09296650146286674" MODIFIED="2012-02-17 12:04:25 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.13523141007223693" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.018287534270125503" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.129761312576196" CI_START="0.18693117639166396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.02" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" METHOD="MH" MODIFIED="2013-03-18 11:49:53 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5599266138507623" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.5829505184150018">
<NAME>Alopecia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.129761312576196" CI_START="0.18693117639166396" DF="0" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-042.02.01" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2013-03-18 11:49:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5599266138507623" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.5829505184150018">
<NAME>Etanercept/Yisaipu (ET/Y) 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="22.129761312576196" CI_START="0.18693117639166396" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2010-05-20 23:16:02 -0400" MODIFIED_BY="[Empty name]" ORDER="707" O_E="0.0" SE="1.2178637404880237" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="1.4831920903954803" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="110.96829331226084" CI_START="0.3662363706508374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.374999999999999" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-042.03" LOG_CI_END="2.045198906655339" LOG_CI_START="-0.43623852844335326" LOG_EFFECT_SIZE="0.8044801891059927" METHOD="MH" MODIFIED="2013-03-18 11:50:05 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.20378639734601844" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.2708377609053094">
<NAME>Accidental injury</NAME>
<GROUP_LABEL_1>Favours etanercept alone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="110.96829331226084" CI_START="0.3662363706508374" DF="0" EFFECT_SIZE="6.374999999999999" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-042.03.01" LOG_CI_END="2.045198906655339" LOG_CI_START="-0.43623852844335326" LOG_EFFECT_SIZE="0.8044801891059927" MODIFIED="2012-02-21 14:49:15 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.20378639734601844" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.2708377609053094">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="110.96829331226084" CI_START="0.36623637065083725" EFFECT_SIZE="6.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.045198906655339" LOG_CI_START="-0.4362385284433534" LOG_EFFECT_SIZE="0.8044801891059927" MODIFIED="2012-02-17 12:33:05 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.4576086326903783" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.1246229260935143" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.649764248303875" CI_START="0.15537563557659864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4563106796116505" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.04" LOG_CI_END="1.1351251505309947" LOG_CI_START="-0.8086170818299766" LOG_EFFECT_SIZE="0.16325403435050903" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7419795942766296" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.3292329840147659">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.649764248303875" CI_START="0.15537563557659864" DF="0" EFFECT_SIZE="1.4563106796116505" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-042.04.01" LOG_CI_END="1.1351251505309947" LOG_CI_START="-0.8086170818299766" LOG_EFFECT_SIZE="0.16325403435050903" MODIFIED="2012-01-31 12:25:50 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7419795942766296" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.3292329840147659">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="13.649764248303875" CI_START="0.15537563557659864" EFFECT_SIZE="1.4563106796116505" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1351251505309947" LOG_CI_START="-0.8086170818299766" LOG_EFFECT_SIZE="0.16325403435050903" MODIFIED="2012-01-31 12:25:50 -0500" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="1.1417638089680613" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.3036245954692556" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5650876687038873" CI_START="0.08469337045617792" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3640776699029126" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-042.05" LOG_CI_END="0.1945386696575162" LOG_CI_START="-1.072150583612423" LOG_EFFECT_SIZE="-0.43880595697745334" METHOD="MH" MODIFIED="2012-02-23 15:24:01 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.1744827889351019" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.3579397940848568">
<NAME>Arthralgia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5650876687038873" CI_START="0.08469337045617792" DF="0" EFFECT_SIZE="0.3640776699029126" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-042.05.01" LOG_CI_END="0.1945386696575162" LOG_CI_START="-1.072150583612423" LOG_EFFECT_SIZE="-0.43880595697745334" MODIFIED="2012-02-21 14:49:19 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1744827889351019" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.3579397940848568">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5650876687038873" CI_START="0.08469337045617792" EFFECT_SIZE="0.3640776699029126" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.1945386696575162" LOG_CI_START="-1.072150583612423" LOG_EFFECT_SIZE="-0.43880595697745334" MODIFIED="2012-02-17 12:08:33 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.7440595375836907" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5536245954692556" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.501433388609904E-32" CI_END="30.203526133793154" CI_START="0.49933025963038524" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.8834951456310676" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="100.0" I2_Q="0.0" ID="CMP-042.06" LOG_CI_END="1.480057647958947" LOG_CI_START="-0.3016121147133668" LOG_EFFECT_SIZE="0.5892227666227902" METHOD="MH" MODIFIED="2012-02-23 15:24:01 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.19484657894902846" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.2963742503207316">
<NAME>Bronchitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.501433388609904E-32" CI_END="30.203526133793154" CI_START="0.49933025963038524" DF="0" EFFECT_SIZE="3.8834951456310676" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="100.0" ID="CMP-042.06.01" LOG_CI_END="1.480057647958947" LOG_CI_START="-0.3016121147133668" LOG_EFFECT_SIZE="0.5892227666227902" MODIFIED="2012-02-21 14:49:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.19484657894902846" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.2963742503207316">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="30.203526133793183" CI_START="0.49933025963038513" EFFECT_SIZE="3.883495145631068" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.4800576479589473" LOG_CI_START="-0.3016121147133669" LOG_EFFECT_SIZE="0.5892227666227902" MODIFIED="2012-02-17 12:20:43 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.04656163800128" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.0952912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.129761312576196" CI_START="0.18693117639166396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.07" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" METHOD="MH" MODIFIED="2013-03-20 15:15:58 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5599266138507623" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.5829505184150018">
<NAME>Chest discomfort</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.129761312576196" CI_START="0.18693117639166396" DF="0" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-042.07.01" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2013-03-20 15:15:58 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5599266138507623" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.5829505184150018">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="22.129761312576196" CI_START="0.18693117639166396" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2010-05-20 23:16:43 -0400" MODIFIED_BY="[Empty name]" ORDER="708" O_E="0.0" SE="1.2178637404880237" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="1.4831920903954803" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.227053451730313" CI_START="0.2912547023294687" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4271844660194173" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.08" LOG_CI_END="1.3059326221253909" LOG_CI_START="-0.53572705419166" LOG_EFFECT_SIZE="0.38510278396686537" METHOD="MH" MODIFIED="2012-02-23 15:23:30 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.41239745663153604" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.8196819386637042">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.227053451730313" CI_START="0.2912547023294687" DF="0" EFFECT_SIZE="2.4271844660194173" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-042.08.01" LOG_CI_END="1.3059326221253909" LOG_CI_START="-0.53572705419166" LOG_EFFECT_SIZE="0.38510278396686537" MODIFIED="2012-02-21 14:49:22 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.41239745663153604" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.8196819386637042">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="20.227053451730313" CI_START="0.2912547023294687" EFFECT_SIZE="2.4271844660194173" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3059326221253909" LOG_CI_START="-0.53572705419166" LOG_EFFECT_SIZE="0.38510278396686537" MODIFIED="2012-02-17 12:30:04 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.0818000102310603" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.1702912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.426154130752947" CI_END="3.7664030155594714" CI_START="0.17643498888445558" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8151841964762414" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="29.88135164100084" I2_Q="100.0" ID="CMP-042.09" LOG_CI_END="0.5759267888800765" LOG_CI_START="-0.7534152855724702" LOG_EFFECT_SIZE="-0.08874424834619682" METHOD="MH" MODIFIED="2013-03-20 15:15:41 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.23239336384224585" P_Q="0.0" P_Z="0.7935630415309246" Q="1.2634317067814906E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="0.26168664023555355">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.426154130752947" CI_END="3.7664030155594714" CI_START="0.17643498888445558" DF="1" EFFECT_SIZE="0.8151841964762414" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="29.88135164100084" ID="CMP-042.09.01" LOG_CI_END="0.5759267888800765" LOG_CI_START="-0.7534152855724702" LOG_EFFECT_SIZE="-0.08874424834619682" MODIFIED="2013-03-20 15:15:41 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23239336384224585" P_Z="0.7935630415309246" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="0.26168664023555355">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="16.923408122287505" CI_START="0.2227910364916131" EFFECT_SIZE="1.941747572815534" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2284878279497644" LOG_CI_START="-0.6521022860321465" LOG_EFFECT_SIZE="0.288192770958809" MODIFIED="2012-02-17 12:30:34 -0500" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="1.1046679420241734" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.2202912621359223" WEIGHT="35.19487453283503"/>
<DICH_DATA CI_END="4.191380936234114" CI_START="0.009866876115866834" EFFECT_SIZE="0.20336134453781513" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.622357133748713" LOG_CI_START="-2.005820324572912" LOG_EFFECT_SIZE="-0.6917315954120995" MODIFIED="2010-05-20 23:17:55 -0400" MODIFIED_BY="[Empty name]" ORDER="710" O_E="0.0" SE="1.543804448706359" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="2.3833321758455446" WEIGHT="64.80512546716497"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.191380936234114" CI_START="0.009866876115866834" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20336134453781513" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-042.10" LOG_CI_END="0.622357133748713" LOG_CI_START="-2.005820324572912" LOG_EFFECT_SIZE="-0.6917315954120995" METHOD="MH" MODIFIED="2013-03-20 15:15:15 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.3022042505915886" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.00000000000001" Z="1.031718014081098">
<NAME>Oedema</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.191380936234114" CI_START="0.009866876115866834" DF="0" EFFECT_SIZE="0.20336134453781513" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-042.10.01" LOG_CI_END="0.622357133748713" LOG_CI_START="-2.005820324572912" LOG_EFFECT_SIZE="-0.6917315954120995" MODIFIED="2013-03-20 15:15:15 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3022042505915886" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.00000000000001" Z="1.031718014081098">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.191380936234114" CI_START="0.009866876115866834" EFFECT_SIZE="0.20336134453781513" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.622357133748713" LOG_CI_START="-2.005820324572912" LOG_EFFECT_SIZE="-0.6917315954120995" MODIFIED="2010-05-20 23:18:36 -0400" MODIFIED_BY="[Empty name]" ORDER="711" O_E="0.0" SE="1.543804448706359" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="2.3833321758455446" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7360532205379839" CI_START="0.10841372301201552" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2824858757062147" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-042.11" LOG_CI_END="-0.13309078274084324" LOG_CI_START="-0.9649157413107324" LOG_EFFECT_SIZE="-0.5490032620257879" METHOD="MH" MODIFIED="2013-03-18 11:50:54 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.009677436567843162" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="2.587146754566018">
<NAME>Elevation in alanine transaminase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7360532205379839" CI_START="0.10841372301201552" DF="0" EFFECT_SIZE="0.2824858757062147" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" I2="0.0" ID="CMP-042.11.01" LOG_CI_END="-0.13309078274084324" LOG_CI_START="-0.9649157413107324" LOG_EFFECT_SIZE="-0.5490032620257879" MODIFIED="2013-03-18 11:50:54 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.009677436567843162" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="2.587146754566018">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.7360532205379839" CI_START="0.10841372301201552" EFFECT_SIZE="0.2824858757062147" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.13309078274084324" LOG_CI_START="-0.9649157413107324" LOG_EFFECT_SIZE="-0.5490032620257879" MODIFIED="2010-05-20 23:13:25 -0400" MODIFIED_BY="[Empty name]" ORDER="703" O_E="0.0" SE="0.4886180982639057" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.23874764595103576" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.129761312576196" CI_START="0.18693117639166396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.12" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" METHOD="MH" MODIFIED="2013-03-18 11:51:03 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.5599266138507623" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.5829505184150018">
<NAME>Enlargement of lymph nodes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.129761312576196" CI_START="0.18693117639166396" DF="0" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-042.12.01" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2013-03-18 11:51:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5599266138507623" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.5829505184150018">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="22.129761312576196" CI_START="0.18693117639166396" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2010-05-20 23:14:51 -0400" MODIFIED_BY="[Empty name]" ORDER="705" O_E="0.0" SE="1.2178637404880237" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="1.4831920903954803" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3307041707328375" CI_START="0.0036880438451986153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07005494505494506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-042.13" LOG_CI_END="0.12408151806059595" LOG_CI_START="-2.433203924490798" LOG_EFFECT_SIZE="-1.154561203215101" METHOD="MH" MODIFIED="2012-02-23 15:23:43 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.07676613496521469" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.7697659702713073">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3307041707328375" CI_START="0.0036880438451986153" DF="0" EFFECT_SIZE="0.07005494505494506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-042.13.01" LOG_CI_END="0.12408151806059595" LOG_CI_START="-2.433203924490798" LOG_EFFECT_SIZE="-1.154561203215101" MODIFIED="2012-02-21 14:49:23 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07676613496521469" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.7697659702713073">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.3307041707328369" CI_START="0.0036880438451986183" EFFECT_SIZE="0.07005494505494506" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.12408151806059572" LOG_CI_START="-2.4332039244907975" LOG_EFFECT_SIZE="-1.154561203215101" MODIFIED="2012-02-17 12:24:47 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.502162127721787" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.256491057961646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1176484353961023" CI_END="13.182096805866461" CI_START="0.22652790509468398" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.728037260648119" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="52.77780847447646" I2_Q="0.0" ID="CMP-042.14" LOG_CI_END="1.1199844966607952" LOG_CI_START="-0.6448782913016592" LOG_EFFECT_SIZE="0.23755310267956803" METHOD="MH" MODIFIED="2013-03-18 11:51:42 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.14561002296002268" P_Q="1.0" P_Z="0.5977575461756541" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.3161200750777886" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="0.5276280160059716">
<NAME>Gastrointestinal symptoms/abdominal pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1176484353961023" CI_END="13.182096805866461" CI_START="0.22652790509468398" DF="1" EFFECT_SIZE="1.728037260648119" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="52.77780847447646" ID="CMP-042.14.01" LOG_CI_END="1.1199844966607952" LOG_CI_START="-0.6448782913016592" LOG_EFFECT_SIZE="0.23755310267956803" MODIFIED="2013-03-18 11:51:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14561002296002268" P_Z="0.5977575461756541" STUDIES="2" TAU2="1.3161200750777886" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="0.5276280160059716">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="126.28240308275191" CI_START="0.4284630293333524" EFFECT_SIZE="7.355769230769231" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.1013428376773278" LOG_CI_START="-0.3680866459676533" LOG_EFFECT_SIZE="0.8666280958548372" MODIFIED="2012-02-17 12:11:58 -0500" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="1.45055510256615" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.104110105580694" WEIGHT="31.422574265213452"/>
<DICH_DATA CI_END="2.3757472608796206" CI_START="0.33328390896216775" EFFECT_SIZE="0.8898305084745762" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3758002372167299" LOG_CI_START="-0.47718565368910454" LOG_EFFECT_SIZE="-0.05069270823618733" MODIFIED="2010-05-20 23:12:07 -0400" MODIFIED_BY="[Empty name]" ORDER="701" O_E="0.0" SE="0.5010481346663442" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.25104923325262307" WEIGHT="68.57742573478654"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1620995402565915" CI_START="0.1702981385221865" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6067961165048543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-042.15" LOG_CI_END="0.3348756844318281" LOG_CI_START="-0.7687900991540221" LOG_EFFECT_SIZE="-0.21695720736109703" METHOD="MH" MODIFIED="2012-02-23 15:23:50 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.4409592323787258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.7705744237762926">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1620995402565915" CI_START="0.1702981385221865" DF="0" EFFECT_SIZE="0.6067961165048543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-042.15.01" LOG_CI_END="0.3348756844318281" LOG_CI_START="-0.7687900991540221" LOG_EFFECT_SIZE="-0.21695720736109703" MODIFIED="2012-02-21 14:49:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4409592323787258" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.7705744237762926">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.1620995402565915" CI_START="0.1702981385221865" EFFECT_SIZE="0.6067961165048543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.3348756844318281" LOG_CI_START="-0.7687900991540221" LOG_EFFECT_SIZE="-0.21695720736109703" MODIFIED="2012-01-31 11:59:11 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.648298744512067" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.4202912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07481169626163522" CI_END="16.655456665417557" CI_START="0.40537834528101774" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5984151829387594" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.16" LOG_CI_END="1.221556544835781" LOG_CI_START="-0.3921394544001504" LOG_EFFECT_SIZE="0.41470854521781536" METHOD="MH" MODIFIED="2013-03-18 11:51:54 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.7844556267902361" P_Q="1.0" P_Z="0.31374549969060916" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="1.0073939739489688">
<NAME>Increased blood pressure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07481169626163522" CI_END="16.655456665417557" CI_START="0.40537834528101774" DF="1" EFFECT_SIZE="2.5984151829387594" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-042.16.01" LOG_CI_END="1.221556544835781" LOG_CI_START="-0.3921394544001504" LOG_EFFECT_SIZE="0.41470854521781536" MODIFIED="2013-03-18 11:51:54 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7844556267902361" P_Z="0.31374549969060916" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="1.0073939739489688">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="65.20450436590903" CI_START="0.18071414841473227" EFFECT_SIZE="3.4326923076923075" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8142775980891095" LOG_CI_START="-0.7430078444622839" LOG_EFFECT_SIZE="0.5356348768134128" MODIFIED="2012-02-17 12:12:50 -0500" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="1.502162127721787" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.256491057961646" WEIGHT="40.357399073892914"/>
<DICH_DATA CI_END="22.129761312576196" CI_START="0.18693117639166396" EFFECT_SIZE="2.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3449767297343032" LOG_CI_START="-0.728318260923342" LOG_EFFECT_SIZE="0.3083292344054806" MODIFIED="2010-05-20 23:15:24 -0400" MODIFIED_BY="[Empty name]" ORDER="706" O_E="0.0" SE="1.2178637404880237" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="1.4831920903954803" WEIGHT="59.64260092610709"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5650876687038873" CI_START="0.08469337045617792" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3640776699029126" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-042.17" LOG_CI_END="0.1945386696575162" LOG_CI_START="-1.072150583612423" LOG_EFFECT_SIZE="-0.43880595697745334" METHOD="MH" MODIFIED="2012-02-23 15:23:55 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.1744827889351019" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.3579397940848568">
<NAME>Increased cough</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5650876687038873" CI_START="0.08469337045617792" DF="0" EFFECT_SIZE="0.3640776699029126" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-042.17.01" LOG_CI_END="0.1945386696575162" LOG_CI_START="-1.072150583612423" LOG_EFFECT_SIZE="-0.43880595697745334" MODIFIED="2012-02-21 14:49:20 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1744827889351019" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.3579397940848568">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5650876687038873" CI_START="0.08469337045617792" EFFECT_SIZE="0.3640776699029126" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.1945386696575162" LOG_CI_START="-1.072150583612423" LOG_EFFECT_SIZE="-0.43880595697745334" MODIFIED="2012-02-17 12:07:42 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.7440595375836907" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5536245954692556" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8130563644628483" CI_END="4.273383818733316" CI_START="1.1431994907995415" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2102783095273155" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-042.18" LOG_CI_END="0.6307719012122271" LOG_CI_START="0.05812202234082271" LOG_EFFECT_SIZE="0.34444696177652495" METHOD="MH" MODIFIED="2013-03-18 11:52:20 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.3672182340051342" P_Q="1.0" P_Z="0.01838243612349703" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="2.3578233911329836">
<NAME>Infection at another site/pharyngitis or laryngitis, flu syndrome or miscellaneous skin infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8130563644628483" CI_END="4.273383818733316" CI_START="1.1431994907995415" DF="1" EFFECT_SIZE="2.2102783095273155" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="11" I2="0.0" ID="CMP-042.18.01" LOG_CI_END="0.6307719012122271" LOG_CI_START="0.05812202234082271" LOG_EFFECT_SIZE="0.34444696177652495" MODIFIED="2013-03-18 11:52:20 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3672182340051342" P_Z="0.01838243612349703" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="2.3578233911329836">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.835120659180688" CI_START="1.159779320818178" EFFECT_SIZE="2.8155339805825244" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="5" LOG_CI_END="0.8347461854954786" LOG_CI_START="0.06437536089208915" LOG_EFFECT_SIZE="0.4495607731937839" MODIFIED="2012-02-17 12:37:00 -0500" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.45251963576911447" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.20477402075661202" WEIGHT="53.08496539537623"/>
<DICH_DATA CI_END="4.151725139130126" CI_START="0.5604700394292" EFFECT_SIZE="1.5254237288135593" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6182285937540827" LOG_CI_START="-0.25144759815972145" LOG_EFFECT_SIZE="0.18339049779718067" MODIFIED="2010-05-20 23:10:13 -0400" MODIFIED_BY="[Empty name]" ORDER="700" O_E="0.0" SE="0.5108521000967482" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.260969868173258" WEIGHT="46.91503460462376"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2512441390283056" CI_START="0.20133230986757877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8090614886731392" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-042.19" LOG_CI_END="0.5120495823081322" LOG_CI_START="-0.6960865238137263" LOG_EFFECT_SIZE="-0.09201847075279701" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.7652728455727876" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.29856385828393284">
<NAME>Injection site haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2512441390283056" CI_START="0.20133230986757877" DF="0" EFFECT_SIZE="0.8090614886731392" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-042.19.01" LOG_CI_END="0.5120495823081322" LOG_CI_START="-0.6960865238137263" LOG_EFFECT_SIZE="-0.09201847075279701" MODIFIED="2012-02-21 14:49:28 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7652728455727876" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.29856385828393284">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.2512441390283047" CI_START="0.20133230986757883" EFFECT_SIZE="0.8090614886731392" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5120495823081321" LOG_CI_START="-0.6960865238137262" LOG_EFFECT_SIZE="-0.09201847075279701" MODIFIED="2012-02-17 12:22:42 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.709665129106155" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5036245954692556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6100321439401095" CI_END="73.68968063506276" CI_START="4.51668471053342" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="18.24371272105759" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-042.20" LOG_CI_END="1.8674066743307638" LOG_CI_START="0.6548197754729268" LOG_EFFECT_SIZE="1.2611132249018453" METHOD="MH" MODIFIED="2013-03-18 11:52:41 -0400" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.4470809311495544" P_Q="1.0" P_Z="4.565993893395627E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="182" WEIGHT="100.00000000000003" Z="4.076798955296256">
<NAME>Injection site reaction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6100321439401095" CI_END="73.68968063506276" CI_START="4.51668471053342" DF="2" EFFECT_SIZE="18.24371272105759" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="1" I2="0.0" ID="CMP-042.20.01" LOG_CI_END="1.8674066743307638" LOG_CI_START="0.6548197754729268" LOG_EFFECT_SIZE="1.2611132249018453" MODIFIED="2013-03-18 11:52:41 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4470809311495544" P_Z="4.565993893395627E-5" STUDIES="3" TAU2="0.0" TOTAL_1="233" TOTAL_2="182" WEIGHT="100.00000000000003" Z="4.076798955296256">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="113.78922944196505" CI_START="2.2552374905794332" EFFECT_SIZE="16.019417475728154" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="1" LOG_CI_END="2.056101156476538" LOG_CI_START="0.35319228254093005" LOG_EFFECT_SIZE="1.204646719508734" MODIFIED="2012-01-31 11:51:57 -0500" MODIFIED_BY="[Empty name]" ORDER="474" O_E="0.0" SE="1.0002971020846518" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.0005942924389526" WEIGHT="57.4836931877638"/>
<DICH_DATA CI_END="649.3159658845038" CI_START="2.4218651068495114" EFFECT_SIZE="39.65546218487395" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.812456081773557" LOG_CI_START="0.38414995012728015" LOG_EFFECT_SIZE="1.5983030159504186" MODIFIED="2010-05-20 23:01:12 -0400" MODIFIED_BY="[Empty name]" ORDER="697" O_E="0.0" SE="1.4263990420382355" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="2.0346142271275958" WEIGHT="21.169207157556947"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7701" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Marcora-2006" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="21.347099654679273"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1728866028781048E-32" CI_END="136.3111874615749" CI_START="0.3716562125046425" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.11764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-042.21" LOG_CI_END="2.1345315011277113" LOG_CI_START="-0.42985860325135894" LOG_EFFECT_SIZE="0.8523364489381762" METHOD="MH" MODIFIED="2013-03-18 11:52:53 -0400" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="1.0" P_Z="0.19261507970485947" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="1.3028819131511096">
<NAME>Insomnia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1728866028781048E-32" CI_END="136.3111874615749" CI_START="0.3716562125046425" DF="0" EFFECT_SIZE="7.11764705882353" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" ID="CMP-042.21.01" LOG_CI_END="2.1345315011277113" LOG_CI_START="-0.42985860325135894" LOG_EFFECT_SIZE="0.8523364489381762" MODIFIED="2013-03-18 11:52:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.19261507970485947" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="1.3028819131511096">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="136.3111874615749" CI_START="0.3716562125046424" EFFECT_SIZE="7.117647058823529" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1345315011277113" LOG_CI_START="-0.429858603251359" LOG_EFFECT_SIZE="0.8523364489381762" MODIFIED="2010-05-20 23:14:12 -0400" MODIFIED_BY="[Empty name]" ORDER="704" O_E="0.0" SE="1.5063354412480077" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="2.2690464615598303" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08318082983383056" CI_END="2.2761957186047486" CI_START="0.3911847530848946" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9436170092549693" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="100.0" ID="CMP-042.22" LOG_CI_END="0.35720960212356234" LOG_CI_START="-0.4076180807252803" LOG_EFFECT_SIZE="-0.025204239300858973" METHOD="MH" MODIFIED="2013-03-18 11:53:11 -0400" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.7730322594271611" P_Q="0.0" P_Z="0.8972169153905022" Q="2.38549270444722E-34" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="0.12917785900062845">
<NAME>Leukopenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08318082983383056" CI_END="2.2761957186047486" CI_START="0.3911847530848946" DF="1" EFFECT_SIZE="0.9436170092549693" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-042.22.01" LOG_CI_END="0.35720960212356234" LOG_CI_START="-0.4076180807252803" LOG_EFFECT_SIZE="-0.025204239300858973" MODIFIED="2013-03-18 11:53:11 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7730322594271611" P_Z="0.8972169153905022" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="0.12917785900062845">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="35.48355068223175" CI_START="0.06099428037614669" EFFECT_SIZE="1.4711538461538463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5500270712652418" LOG_CI_START="-1.2147108882276048" LOG_EFFECT_SIZE="0.16765809151881847" MODIFIED="2012-02-17 12:33:32 -0500" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="1.6240207630797172" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.637443438914027" WEIGHT="6.9926434859254405"/>
<DICH_DATA CI_END="2.2634080931622074" CI_START="0.36101942331888237" EFFECT_SIZE="0.903954802259887" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.35476286444078353" LOG_CI_START="-0.4424694318525473" LOG_EFFECT_SIZE="-0.043853283705881846" MODIFIED="2010-05-20 23:12:46 -0400" MODIFIED_BY="[Empty name]" ORDER="702" O_E="0.0" SE="0.4682981972062153" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.21930320150659133" WEIGHT="93.00735651407456"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3199237003045674" CI_START="0.1015761756528897" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4854368932038835" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-042.23" LOG_CI_END="0.36547370166607074" LOG_CI_START="-0.9932081424043775" LOG_EFFECT_SIZE="-0.3138672203691534" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.36518089396228026" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.9055371579975869">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3199237003045674" CI_START="0.1015761756528897" DF="0" EFFECT_SIZE="0.4854368932038835" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-042.23.01" LOG_CI_END="0.36547370166607074" LOG_CI_START="-0.9932081424043775" LOG_EFFECT_SIZE="-0.3138672203691534" MODIFIED="2012-01-31 12:03:19 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.36518089396228026" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.9055371579975869">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.3199237003045674" CI_START="0.1015761756528897" EFFECT_SIZE="0.4854368932038835" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.36547370166607074" LOG_CI_START="-0.9932081424043775" LOG_EFFECT_SIZE="-0.3138672203691534" MODIFIED="2012-01-31 12:03:19 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.7980964407905783" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.636957928802589" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7823780776957996" CI_START="0.15056599192209408" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6472491909385113" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-042.24" LOG_CI_END="0.4444161428741161" LOG_CI_START="-0.8222731103958231" LOG_EFFECT_SIZE="-0.18892848376085347" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.5587744950125717" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.5846627700821293">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7823780776957996" CI_START="0.15056599192209408" DF="0" EFFECT_SIZE="0.6472491909385113" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-042.24.01" LOG_CI_END="0.4444161428741161" LOG_CI_START="-0.8222731103958231" LOG_EFFECT_SIZE="-0.18892848376085347" MODIFIED="2012-02-21 14:49:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5587744950125717" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.5846627700821293">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.7823780776957996" CI_START="0.15056599192209408" EFFECT_SIZE="0.6472491909385113" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.4444161428741161" LOG_CI_START="-0.8222731103958231" LOG_EFFECT_SIZE="-0.18892848376085347" MODIFIED="2012-02-17 12:24:09 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.7440595375836907" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5536245954692556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.915485673867666E-33" CI_END="10.454229649963366" CI_START="0.09016407145188907" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9708737864077669" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="99.99999999999999" I2_Q="0.0" ID="CMP-042.25" LOG_CI_END="1.0192920360923607" LOG_CI_START="-1.0449664855027052" LOG_EFFECT_SIZE="-0.012837224705172248" METHOD="MH" MODIFIED="2013-03-18 11:53:24 -0400" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0" P_Q="1.0" P_Z="0.9805516754335747" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.0243772742806882">
<NAME>Paraesthesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.915485673867666E-33" CI_END="10.454229649963366" CI_START="0.09016407145188907" DF="0" EFFECT_SIZE="0.9708737864077669" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="99.99999999999999" ID="CMP-042.25.01" LOG_CI_END="1.0192920360923607" LOG_CI_START="-1.0449664855027052" LOG_EFFECT_SIZE="-0.012837224705172248" MODIFIED="2012-02-21 14:49:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.9805516754335747" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.0243772742806882">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="10.454229649963366" CI_START="0.09016407145188907" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0192920360923607" LOG_CI_START="-1.0449664855027052" LOG_EFFECT_SIZE="-0.0128372247051722" MODIFIED="2012-02-17 12:34:26 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.2125556738294214" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.4702912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2512441390283056" CI_START="0.20133230986757877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8090614886731392" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-042.26" LOG_CI_END="0.5120495823081322" LOG_CI_START="-0.6960865238137263" LOG_EFFECT_SIZE="-0.09201847075279701" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.7652728455727876" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.29856385828393284">
<NAME>Pharyngitis (non-infectious)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2512441390283056" CI_START="0.20133230986757877" DF="0" EFFECT_SIZE="0.8090614886731392" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-042.26.01" LOG_CI_END="0.5120495823081322" LOG_CI_START="-0.6960865238137263" LOG_EFFECT_SIZE="-0.09201847075279701" MODIFIED="2012-02-21 14:49:33 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7652728455727876" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.29856385828393284">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.2512441390283047" CI_START="0.20133230986757883" EFFECT_SIZE="0.8090614886731392" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5120495823081321" LOG_CI_START="-0.6960865238137262" LOG_EFFECT_SIZE="-0.09201847075279701" MODIFIED="2012-02-17 12:23:40 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.709665129106155" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5036245954692556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6135574124908416" CI_START="0.022541017862972273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24271844660194172" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-042.27" LOG_CI_END="0.41723204476439835" LOG_CI_START="-1.6470264768306675" LOG_EFFECT_SIZE="-0.6148972160331346" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.24294382304988182" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.1676603342178686">
<NAME>Pruritus</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6135574124908416" CI_START="0.022541017862972273" DF="0" EFFECT_SIZE="0.24271844660194172" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-042.27.01" LOG_CI_END="0.41723204476439835" LOG_CI_START="-1.6470264768306675" LOG_EFFECT_SIZE="-0.6148972160331346" MODIFIED="2012-02-21 14:49:34 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24294382304988182" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.1676603342178686">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.6135574124908416" CI_START="0.022541017862972273" EFFECT_SIZE="0.24271844660194175" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.41723204476439835" LOG_CI_START="-1.6470264768306675" LOG_EFFECT_SIZE="-0.6148972160331346" MODIFIED="2012-02-17 12:21:58 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.2125556738294214" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.4702912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0577130076429693" CI_START="0.013924439780725821" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12135922330097086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-042.28" LOG_CI_END="0.0243678452938397" LOG_CI_START="-1.8562222686880712" LOG_EFFECT_SIZE="-0.9159272116971159" METHOD="MH" MODIFIED="2012-02-22 15:41:48 -0500" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.056239995822539975" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.9091713117490188">
<NAME>Rhinitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0577130076429693" CI_START="0.013924439780725821" DF="0" EFFECT_SIZE="0.12135922330097086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-042.28.01" LOG_CI_END="0.0243678452938397" LOG_CI_START="-1.8562222686880712" LOG_EFFECT_SIZE="-0.9159272116971159" MODIFIED="2012-02-21 14:49:36 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.056239995822539975" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.9091713117490188">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0577130076429693" CI_START="0.013924439780725821" EFFECT_SIZE="0.12135922330097088" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.0243678452938397" LOG_CI_START="-1.8562222686880712" LOG_EFFECT_SIZE="-0.9159272116971158" MODIFIED="2012-02-17 12:09:19 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.1046679420241734" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.2202912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.691103228006865E-5" CI_END="5.6277784934482025" CI_START="1.0543678605064961" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4359287283378084" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-042.29" LOG_CI_END="0.7503369954851139" LOG_CI_START="0.02299215918334382" LOG_EFFECT_SIZE="0.3866645773342288" METHOD="MH" MODIFIED="2013-03-20 15:14:43 -0400" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.9951525260340262" P_Q="1.0" P_Z="0.03717134246056126" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="2.0838771593562675">
<NAME>Skin rash</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.691103228006865E-5" CI_END="5.6277784934482025" CI_START="1.0543678605064961" DF="1" EFFECT_SIZE="2.4359287283378084" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="7" I2="0.0" ID="CMP-042.29.01" LOG_CI_END="0.7503369954851139" LOG_CI_START="0.02299215918334382" LOG_EFFECT_SIZE="0.3866645773342288" MODIFIED="2013-03-20 15:14:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9951525260340262" P_Z="0.03717134246056126" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="170" WEIGHT="100.0" Z="2.0838771593562675">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="10.663751746709488" CI_START="0.5524532614803058" EFFECT_SIZE="2.4271844660194173" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.0279100261011191" LOG_CI_START="-0.2577044581673883" LOG_EFFECT_SIZE="0.38510278396686537" MODIFIED="2012-02-17 12:05:38 -0500" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.7551763119536539" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5702912621359223" WEIGHT="35.19648523309739"/>
<DICH_DATA CI_END="6.713556424591366" CI_START="0.8872955788968269" EFFECT_SIZE="2.440677966101695" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8269526433289982" LOG_CI_START="-0.05193168242278718" LOG_EFFECT_SIZE="0.3875104804531055" MODIFIED="2010-05-20 23:07:18 -0400" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.5162610034941759" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.26652542372881355" WEIGHT="64.80351476690261"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9312530169868722" CI_START="1.050802901897113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.755041075429425" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-042.30" LOG_CI_END="0.46705330705619946" LOG_CI_START="0.021521263463255204" LOG_EFFECT_SIZE="0.24428728525972732" METHOD="MH" MODIFIED="2013-03-18 11:53:38 -0400" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.03160946355481349" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="2.1493146806184535">
<NAME>Total infectious adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9312530169868722" CI_START="1.050802901897113" DF="0" EFFECT_SIZE="1.755041075429425" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="13" I2="0.0" ID="CMP-042.30.01" LOG_CI_END="0.46705330705619946" LOG_CI_START="0.021521263463255204" LOG_EFFECT_SIZE="0.24428728525972732" MODIFIED="2012-02-21 14:49:37 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03160946355481349" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="2.1493146806184535">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.9312530169868722" CI_START="1.050802901897113" EFFECT_SIZE="1.755041075429425" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="13" LOG_CI_END="0.46705330705619946" LOG_CI_START="0.021521263463255204" LOG_EFFECT_SIZE="0.24428728525972732" MODIFIED="2012-02-17 12:35:33 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.2617077278256798" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.06849093480368011" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0038624806744466398" CI_END="1.7556739389134708" CI_START="0.5099178108078546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9461762052721259" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" I2="0.0" I2_Q="100.0" ID="CMP-042.31" LOG_CI_END="0.24444386254997924" LOG_CI_START="-0.29249981839048195" LOG_EFFECT_SIZE="-0.024027977920251336" METHOD="MH" MODIFIED="2013-03-18 11:53:49 -0400" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.950444337568347" P_Q="0.0" P_Z="0.8607536035405643" Q="4.840027384290842E-34" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="221" TOTAL_2="170" WEIGHT="99.99999999999999" Z="0.17541493835081842">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0038624806744466398" CI_END="1.7556739389134708" CI_START="0.5099178108078546" DF="1" EFFECT_SIZE="0.9461762052721259" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" I2="0.0" ID="CMP-042.31.01" LOG_CI_END="0.24444386254997924" LOG_CI_START="-0.29249981839048195" LOG_EFFECT_SIZE="-0.024027977920251336" MODIFIED="2013-03-18 11:53:49 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.950444337568347" P_Z="0.8607536035405643" STUDIES="2" TAU2="0.0" TOTAL_1="221" TOTAL_2="170" WEIGHT="99.99999999999999" Z="0.17541493835081842">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.689667348844101" CI_START="0.35045073865317955" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.4296985708965389" LOG_CI_START="-0.4553730203068833" LOG_EFFECT_SIZE="-0.0128372247051722" MODIFIED="2012-01-31 11:54:54 -0500" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.5198954338479252" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.27029126213592236" WEIGHT="36.133106144131496"/>
<DICH_DATA CI_END="2.0288530072221063" CI_START="0.4283223855637157" EFFECT_SIZE="0.9322033898305084" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3072505830289904" LOG_CI_START="-0.368229227324791" LOG_EFFECT_SIZE="-0.030489322147900365" MODIFIED="2010-05-20 23:09:31 -0400" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="0.3967801842807986" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.15743451463790448" WEIGHT="63.86689385586849"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.532440328144048" CI_START="0.046732794097915975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-042.32" LOG_CI_END="0.7429167384063408" LOG_CI_START="-1.3303782522513043" LOG_EFFECT_SIZE="-0.2937307569224818" METHOD="MH" MODIFIED="2013-03-18 11:54:01 -0400" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="1.0" P_Q="1.0" P_Z="0.5786556056275756" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.555349535221847">
<NAME>Vision disorder</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.532440328144048" CI_START="0.046732794097915975" DF="0" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-042.32.01" LOG_CI_END="0.7429167384063408" LOG_CI_START="-1.3303782522513043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2013-03-18 11:54:01 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5786556056275756" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="100.0" Z="0.555349535221847">
<NAME>ET/Y 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="5.532440328144048" CI_START="0.046732794097915975" EFFECT_SIZE="0.5084745762711864" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7429167384063408" LOG_CI_START="-1.3303782522513043" LOG_EFFECT_SIZE="-0.2937307569224818" MODIFIED="2010-05-20 23:17:19 -0400" MODIFIED_BY="[Empty name]" ORDER="709" O_E="0.0" SE="1.2178637404880237" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="1.4831920903954803" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-043" MODIFIED="2013-03-18 11:56:49 -0400" MODIFIED_BY="[Empty name]" NO="43">
<NAME>Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="0.10331294269812881" CI_END="0.8565552874391789" CI_START="0.3451900877683481" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5437595009280967" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-043.01" LOG_CI_END="-0.06724459970976528" LOG_CI_START="-0.46194168366747795" LOG_EFFECT_SIZE="-0.26459314168862164" METHOD="MH" MODIFIED="2012-02-23 16:05:50 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7478896521366238" P_Q="0.7479229121007487" P_Z="0.008593834825667815" Q="0.10328472699034322" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="2.6278026838504003">
<NAME>Alopecia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.092579801546437" CI_START="0.31240335143745496" DF="0" EFFECT_SIZE="0.5842307692307692" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" I2="0.0" ID="CMP-043.01.01" LOG_CI_END="0.038453167478207324" LOG_CI_START="-0.5052843156942706" LOG_EFFECT_SIZE="-0.23341557410803163" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09242421477549329" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.682746298869242">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.092579801546437" CI_START="0.31240335143745496" EFFECT_SIZE="0.5842307692307692" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.038453167478207324" LOG_CI_START="-0.5052843156942706" LOG_EFFECT_SIZE="-0.23341557410803163" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7738" O_E="0.0" SE="0.3193940891594639" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.10201258419000356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9749803220450018" CI_START="0.25969608411947176" DF="0" EFFECT_SIZE="0.5031884057971014" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="25" I2="0.0" ID="CMP-043.01.02" LOG_CI_END="-0.011004149546091054" LOG_CI_START="-0.585534598919511" LOG_EFFECT_SIZE="-0.29826937423280103" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04184649518373795" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.0350435101399693">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9749803220450018" CI_START="0.25969608411947176" EFFECT_SIZE="0.5031884057971014" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="25" LOG_CI_END="-0.011004149546091054" LOG_CI_START="-0.585534598919511" LOG_EFFECT_SIZE="-0.29826937423280103" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7739" O_E="0.0" SE="0.33748202993353826" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.11389412052806162" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11000799723094105" CI_END="1.5217776001406493" CI_START="0.6862695376398531" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.021934249371851" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-043.02" LOG_CI_END="0.1823511871985529" LOG_CI_START="-0.1635052782891828" LOG_EFFECT_SIZE="0.009422954454685058" METHOD="MH" MODIFIED="2013-03-18 11:54:30 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7401350704654914" P_Q="0.7401374094806905" P_Z="0.9149480323882896" Q="0.11000594265879965" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.10679951483977039">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8955251515947626" CI_START="0.6275864477197304" DF="0" EFFECT_SIZE="1.0906905594405594" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" I2="0.0" ID="CMP-043.02.01" LOG_CI_END="0.27772955142473066" LOG_CI_START="-0.20232644326242147" LOG_EFFECT_SIZE="0.037701554081154574" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7581930842419976" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.307854454388838">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8955251515947626" CI_START="0.6275864477197303" EFFECT_SIZE="1.0906905594405594" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.27772955142473066" LOG_CI_START="-0.20232644326242155" LOG_EFFECT_SIZE="0.037701554081154574" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7720" O_E="0.0" SE="0.28198726759473164" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.0795168190855428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6933247143649797" CI_START="0.5363560199794377" DF="0" EFFECT_SIZE="0.9530083443126921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" ID="CMP-043.02.02" LOG_CI_END="0.2287402470249328" LOG_CI_START="-0.2705468405581594" LOG_EFFECT_SIZE="-0.020903296766613302" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8696423208062014" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.16411283143346414">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6933247143649797" CI_START="0.5363560199794377" EFFECT_SIZE="0.9530083443126921" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="0.2287402470249328" LOG_CI_START="-0.2705468405581594" LOG_EFFECT_SIZE="-0.020903296766613302" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7721" O_E="0.0" SE="0.29328370675725196" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.08601533264927376" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8761572729195026" CI_END="1.2893013782506648" CI_START="0.6157966686985219" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8910373132900621" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-043.03" LOG_CI_END="0.11035444692083808" LOG_CI_START="-0.21056266484783012" LOG_EFFECT_SIZE="-0.05010410896349604" METHOD="MH" MODIFIED="2012-02-23 16:06:02 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3492564352175199" P_Q="0.3493581083768892" P_Z="0.5405311106752202" Q="0.8757876509723636" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.6120100514721786">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.455761092513076E-31" CI_END="1.2791522127156125" CI_START="0.42135703074294223" DF="0" EFFECT_SIZE="0.7341524216524216" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" I2="100.0" ID="CMP-043.03.01" LOG_CI_END="0.10692222642487703" LOG_CI_START="-0.37534975506565793" LOG_EFFECT_SIZE="-0.13421376432039045" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.27531892618375353" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.0908954050554767">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2791522127156127" CI_START="0.42135703074294234" EFFECT_SIZE="0.7341524216524217" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" LOG_CI_END="0.1069222264248771" LOG_CI_START="-0.3753497550656578" LOG_EFFECT_SIZE="-0.13421376432039037" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7718" O_E="0.0" SE="0.28328894921235026" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.08025262874583758" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7254153282288813" CI_START="0.636920349703222" DF="0" EFFECT_SIZE="1.0483091787439613" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" I2="0.0" ID="CMP-043.03.02" LOG_CI_END="0.23689365190033784" LOG_CI_START="-0.19591487511711436" LOG_EFFECT_SIZE="0.020489388391611754" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8527808068316277" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.1855714978147498">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7254153282288813" CI_START="0.636920349703222" EFFECT_SIZE="1.0483091787439613" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" LOG_CI_END="0.23689365190033784" LOG_CI_START="-0.19591487511711436" LOG_EFFECT_SIZE="0.020489388391611754" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7719" O_E="0.0" SE="0.25423387120681296" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.06463486126880237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.349687631129958" CI_END="2.4552737248235754" CI_START="0.8945858345165388" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.48204355337076" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" I2="25.90878237783061" I2_Q="25.897548932307135" ID="CMP-043.04" LOG_CI_END="0.39009991623646767" LOG_CI_START="-0.04837798302453757" LOG_EFFECT_SIZE="0.17086096660596506" METHOD="MH" MODIFIED="2012-02-23 16:06:22 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.24533289526366275" P_Q="0.24536867708821475" P_Z="0.1266437027080756" Q="1.3494830273380516" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="1.5274719272090536">
<NAME>Back pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2695463582965933" CI_START="0.4795719126384044" DF="0" EFFECT_SIZE="1.0432692307692308" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-043.04.01" LOG_CI_END="0.35593905817240273" LOG_CI_START="-0.31914626040086674" LOG_EFFECT_SIZE="0.018396398885767988" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9149318454415993" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.00000000000001" Z="0.10681991822171354">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.269546358296593" CI_START="0.47957191263840443" EFFECT_SIZE="1.0432692307692308" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3559390581724027" LOG_CI_START="-0.31914626040086674" LOG_EFFECT_SIZE="0.018396398885767988" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7734" O_E="0.0" SE="0.39654845785616005" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.15725067942809876" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7826343938073417" CI_START="0.9764888287952155" DF="0" EFFECT_SIZE="1.921900161030596" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="0.0" ID="CMP-043.04.02" LOG_CI_END="0.5777943670857232" LOG_CI_START="-0.010332720753336806" LOG_EFFECT_SIZE="0.2837308231661932" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05861161977942411" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="1.891095330272623">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.7826343938073417" CI_START="0.9764888287952155" EFFECT_SIZE="1.921900161030596" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5777943670857232" LOG_CI_START="-0.010332720753336806" LOG_EFFECT_SIZE="0.2837308231661932" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7735" O_E="0.0" SE="0.3454687626727011" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.11934866598260709" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1722717365634161" CI_END="1.5371880574673602" CI_START="0.7652799533192629" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0846101626213678" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-043.05" LOG_CI_END="0.18672700173807433" LOG_CI_START="-0.11617966296331318" LOG_EFFECT_SIZE="0.03527366938738058" METHOD="MH" MODIFIED="2013-03-18 11:54:41 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6781009728827095" P_Q="0.6781045393234064" P_Z="0.6480462539412669" Q="0.1722676922859469" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.4564780485764087">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6627248807173773" CI_START="0.6070040235966853" DF="0" EFFECT_SIZE="1.0046296296296295" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" I2="0.0" ID="CMP-043.05.01" LOG_CI_END="0.22082039553897367" LOG_CI_START="-0.21680843014377654" LOG_EFFECT_SIZE="0.002005982697598574" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9856643944537894" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.01796798387203989">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6627248807173776" CI_START="0.6070040235966851" EFFECT_SIZE="1.0046296296296295" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.22082039553897373" LOG_CI_START="-0.21680843014377663" LOG_EFFECT_SIZE="0.002005982697598574" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7712" O_E="0.0" SE="0.2570653385036723" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.06608258826000762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8895547866153939" CI_START="0.7180162435801581" DF="0" EFFECT_SIZE="1.1647879763821793" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" I2="0.0" ID="CMP-043.05.02" LOG_CI_END="0.27635948856835707" LOG_CI_START="-0.14386573066378325" LOG_EFFECT_SIZE="0.06624687895228691" MODIFIED="2012-01-31 14:39:14 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5366007415483858" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.6179614687187064">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8895547866153937" CI_START="0.7180162435801581" EFFECT_SIZE="1.1647879763821793" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.276359488568357" LOG_CI_START="-0.14386573066378325" LOG_EFFECT_SIZE="0.06624687895228691" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7713" O_E="0.0" SE="0.24684237392534258" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.060931157565098655" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7115776802507945" CI_END="1.179647276292033" CI_START="0.5069870841220122" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7733472266063747" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="46" I2="73.05727951428922" I2_Q="72.92991455038373" ID="CMP-043.06" LOG_CI_END="0.07175216928949754" LOG_CI_START="-0.29500310450490647" LOG_EFFECT_SIZE="-0.11162546760770449" METHOD="MH" MODIFIED="2012-02-23 16:06:28 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.05403653291619537" P_Q="0.054604982044391015" P_Z="0.23284296543087413" Q="3.6941146782164136" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="1.193067486147115">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9296765634249823" CI_START="0.22131214269265453" DF="0" EFFECT_SIZE="0.4535953177257525" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" I2="0.0" ID="CMP-043.06.01" LOG_CI_END="-0.03166811720013717" LOG_CI_START="-0.6549947570635126" LOG_EFFECT_SIZE="-0.3433314371318249" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.030841170932044488" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="2.1591159706771035">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9296765634249822" CI_START="0.2213121426926546" EFFECT_SIZE="0.4535953177257525" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.03166811720013723" LOG_CI_START="-0.6549947570635125" LOG_EFFECT_SIZE="-0.3433314371318249" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7716" O_E="0.0" SE="0.3661451537723766" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.13406227363099732" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8757635935284722" CI_START="0.63792186166785" DF="0" EFFECT_SIZE="1.093887838689351" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" ID="CMP-043.06.02" LOG_CI_END="0.27317810243555113" LOG_CI_START="-0.1952325142643014" LOG_EFFECT_SIZE="0.03897279408562487" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7443134166421296" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.32614663315228154">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8757635935284722" CI_START="0.63792186166785" EFFECT_SIZE="1.093887838689351" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.27317810243555113" LOG_CI_START="-0.1952325142643014" LOG_EFFECT_SIZE="0.03897279408562487" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7717" O_E="0.0" SE="0.2751467149194411" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.07570571473096017" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19574862568198598" CI_END="1.7021326763100062" CI_START="0.770900562668333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1455020898730561" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-043.07" LOG_CI_END="0.23099340906441962" LOG_CI_START="-0.11300163734399601" LOG_EFFECT_SIZE="0.058995885860211796" METHOD="MH" MODIFIED="2012-02-23 16:06:42 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6581745502513614" P_Q="0.6581760855623902" P_Z="0.5014079929954334" Q="0.19574674791877847" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.6722760268167752">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8525049865459997" CI_START="0.5875345522816471" DF="0" EFFECT_SIZE="1.0432692307692308" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" I2="0.0" ID="CMP-043.07.01" LOG_CI_END="0.26775938568051383" LOG_CI_START="-0.23096658790897784" LOG_EFFECT_SIZE="0.018396398885767988" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8850317908611025" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.14459354904589936">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8525049865459997" CI_START="0.5875345522816471" EFFECT_SIZE="1.0432692307692308" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.26775938568051383" LOG_CI_START="-0.23096658790897784" LOG_EFFECT_SIZE="0.018396398885767988" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7722" O_E="0.0" SE="0.2929541056198519" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.08582210799952736" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.158796212594783" CI_START="0.7214538530733151" DF="0" EFFECT_SIZE="1.247987117552335" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" I2="0.0" ID="CMP-043.07.02" LOG_CI_END="0.33421164746496174" LOG_CI_START="-0.1417914428055015" LOG_EFFECT_SIZE="0.0962101023297301" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.428186485830683" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.7922987870017413">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.158796212594783" CI_START="0.7214538530733151" EFFECT_SIZE="1.247987117552335" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.33421164746496174" LOG_CI_START="-0.1417914428055015" LOG_EFFECT_SIZE="0.0962101023297301" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7723" O_E="0.0" SE="0.2796065714781681" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.07817983481377593" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02060407795363991" CI_END="1.2699558747799358" CI_START="0.5449505124141296" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8319033024965463" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-043.08" LOG_CI_END="0.1037886314500494" LOG_CI_START="-0.26364293471657185" LOG_EFFECT_SIZE="-0.07992715163326121" METHOD="MH" MODIFIED="2012-02-23 16:06:49 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8858627795867077" P_Q="0.8858634322820219" P_Z="0.39382603058615484" Q="0.02060384067965887" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.852699403170085">
<NAME>Ecchymosis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4743142803778944" CI_START="0.4408138251073418" DF="0" EFFECT_SIZE="0.8061625874125874" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" I2="0.0" ID="CMP-043.08.01" LOG_CI_END="0.16859007218314626" LOG_CI_START="-0.35574479329947495" LOG_EFFECT_SIZE="-0.09357736055816436" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4841868679788972" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.6995844393963923">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4743142803778944" CI_START="0.4408138251073418" EFFECT_SIZE="0.8061625874125874" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.16859007218314626" LOG_CI_START="-0.35574479329947495" LOG_EFFECT_SIZE="-0.09357736055816436" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7736" O_E="0.0" SE="0.3079968954839355" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.09486208762774229" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5520960934664623" CI_START="0.4739797848881626" DF="0" EFFECT_SIZE="0.857707509881423" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" I2="0.0" ID="CMP-043.08.02" LOG_CI_END="0.1909186058205724" LOG_CI_START="-0.3242401804751492" LOG_EFFECT_SIZE="-0.06666078732728839" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6119914157173725" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.5072328991301313">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5520960934664623" CI_START="0.4739797848881626" EFFECT_SIZE="0.857707509881423" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.1909186058205724" LOG_CI_START="-0.3242401804751492" LOG_EFFECT_SIZE="-0.06666078732728839" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7737" O_E="0.0" SE="0.30260682114722615" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.09157088820482931" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.24771846388047428" CI_END="1.0948371722672336" CI_START="0.6889087390052937" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.86847158604225" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-043.09" LOG_CI_END="0.03934953429570208" LOG_CI_START="-0.16183830606262353" LOG_EFFECT_SIZE="-0.061244385883460754" METHOD="MH" MODIFIED="2012-02-23 16:06:54 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6186862106462043" P_Q="0.6187192360400042" P_Z="0.23275945238075113" Q="0.24767183194572373" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="1.1932807705780317">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2670729969338272" CI_START="0.6672580564592443" DF="0" EFFECT_SIZE="0.9194915254237288" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="59" I2="0.0" ID="CMP-043.09.01" LOG_CI_END="0.10280163560352648" LOG_CI_START="-0.1757061738466807" LOG_EFFECT_SIZE="-0.03645226912157708" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6079117323532022" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.5130565981190258">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2670729969338272" CI_START="0.6672580564592443" EFFECT_SIZE="0.9194915254237288" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="59" LOG_CI_END="0.10280163560352648" LOG_CI_START="-0.1757061738466807" LOG_EFFECT_SIZE="-0.03645226912157708" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7706" O_E="0.0" SE="0.1635968659069428" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.02676393453457423" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1428013815405857" CI_START="0.5845473017024032" DF="0" EFFECT_SIZE="0.8173258003766478" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="59" I2="0.0" ID="CMP-043.09.02" LOG_CI_END="0.05797075673266046" LOG_CI_START="-0.23318033987057718" LOG_EFFECT_SIZE="-0.08760479156895837" MODIFIED="2012-01-31 14:38:07 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2382104284738722" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="1.1794716788051913">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1428013815405857" CI_START="0.5845473017024032" EFFECT_SIZE="0.8173258003766478" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="59" LOG_CI_END="0.05797075673266046" LOG_CI_START="-0.23318033987057718" LOG_EFFECT_SIZE="-0.08760479156895837" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7707" O_E="0.0" SE="0.1710235953659137" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.029249070171883773" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.47723400482904765" CI_END="1.40304215872611" CI_START="0.6599698544317332" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9622710269233172" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-043.10" LOG_CI_END="0.14707072094071283" LOG_CI_START="-0.18047590135654298" LOG_EFFECT_SIZE="-0.01670259020791505" METHOD="MH" MODIFIED="2013-03-18 11:54:50 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.48967791646347447" P_Q="0.48970887828666343" P_Z="0.8415674325337268" Q="0.47716594516242616" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.19988895032070153">
<NAME>Influenza-like syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.455860357085313" CI_START="0.47846816959235794" DF="0" EFFECT_SIZE="0.8346153846153846" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="0.0" ID="CMP-043.10.01" LOG_CI_END="0.16311972040578568" LOG_CI_START="-0.32014694865036264" LOG_EFFECT_SIZE="-0.07851361412228844" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5242234557528113" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.6368486213887089">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.455860357085313" CI_START="0.47846816959235794" EFFECT_SIZE="0.8346153846153846" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.16311972040578568" LOG_CI_START="-0.32014694865036264" LOG_EFFECT_SIZE="-0.07851361412228844" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7730" O_E="0.0" SE="0.28387323361217437" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.08058401276143212" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8245310191127704" CI_START="0.6514696740923216" DF="0" EFFECT_SIZE="1.0902415458937198" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" I2="0.0" ID="CMP-043.10.02" LOG_CI_END="0.2611512512660243" LOG_CI_START="-0.18610579588524007" LOG_EFFECT_SIZE="0.03752272769039211" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7422590810911697" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.32886321341740515">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8245310191127706" CI_START="0.6514696740923215" EFFECT_SIZE="1.0902415458937198" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.26115125126602434" LOG_CI_START="-0.18610579588524015" LOG_EFFECT_SIZE="0.03752272769039211" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7731" O_E="0.0" SE="0.2627210034547424" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.06902232565626677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005865357123443724" CI_END="2.131294389217981" CI_START="1.012582439142085" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4690511465446612" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-043.11" LOG_CI_END="0.32864344163471676" LOG_CI_START="0.005430391301047146" LOG_EFFECT_SIZE="0.16703691646788196" METHOD="MH" MODIFIED="2013-03-18 11:55:00 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9389531993964874" P_Q="0.9389532139836443" P_Z="0.04278284697889919" Q="0.005865354314898507" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="2.0258237718291157">
<NAME>Injection site haemorrhagia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5174634708270744" CI_START="0.8823350676247911" DF="0" EFFECT_SIZE="1.4903846153846154" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="0.0" ID="CMP-043.11.01" LOG_CI_END="0.40096317752423427" LOG_CI_START="-0.05436645978121197" LOG_EFFECT_SIZE="0.17329835887151113" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.13571914494548068" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.4919237147754916">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.5174634708270744" CI_START="0.8823350676247911" EFFECT_SIZE="1.4903846153846154" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.40096317752423427" LOG_CI_START="-0.05436645978121197" LOG_EFFECT_SIZE="0.17329835887151113" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7726" O_E="0.0" SE="0.26746288287127445" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.07153639371381307" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4553758459668398" CI_START="0.8535288472639625" DF="0" EFFECT_SIZE="1.4476650563607085" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" I2="0.0" ID="CMP-043.11.02" LOG_CI_END="0.3901179792842875" LOG_CI_START="-0.06878179617099031" LOG_EFFECT_SIZE="0.16066809155664857" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.16992993699246234" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="1.3724289692815694">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.4553758459668398" CI_START="0.8535288472639625" EFFECT_SIZE="1.4476650563607085" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="21" LOG_CI_END="0.3901179792842875" LOG_CI_START="-0.06878179617099031" LOG_EFFECT_SIZE="0.16066809155664857" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7727" O_E="0.0" SE="0.2695599996929544" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.07266259343446557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3130292522194811" CI_END="6.556504355680094" CI_START="3.1935358275402583" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.5758530967774895" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-043.12" LOG_CI_END="0.8166723540601208" LOG_CI_START="0.504271792770739" LOG_EFFECT_SIZE="0.6604720734154299" METHOD="MH" MODIFIED="2013-03-18 11:55:44 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.5758273500108972" P_Q="0.5759824305070829" P_Z="1.1570557058989455E-16" Q="0.31277498020439587" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="8.287446548405004">
<NAME>Injection site reaction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.872894616868928" CI_START="2.4552416713642673" DF="0" EFFECT_SIZE="4.107872596153846" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="16" I2="0.0" ID="CMP-043.12.01" LOG_CI_END="0.8371396848572359" LOG_CI_START="0.390094246509614" LOG_EFFECT_SIZE="0.6136169656834248" MODIFIED="2013-03-18 11:55:44 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.42734010303892E-8" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="5.380514148573287">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.872894616868928" CI_START="2.4552416713642673" EFFECT_SIZE="4.107872596153846" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="16" LOG_CI_END="0.8371396848572359" LOG_CI_START="0.390094246509614" LOG_EFFECT_SIZE="0.6136169656834248" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7702" O_E="0.0" SE="0.2625967033960023" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.068957028634448" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.348663187969038" CI_START="3.0486201883099455" DF="0" EFFECT_SIZE="5.044987922705314" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="16" I2="0.0" ID="CMP-043.12.02" LOG_CI_END="0.9216169405653761" LOG_CI_START="0.48410332125096156" LOG_EFFECT_SIZE="0.7028601309081688" MODIFIED="2012-01-31 14:37:23 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.0284542743057793E-10" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="6.297315018022948">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.348663187969038" CI_START="3.0486201883099455" EFFECT_SIZE="5.044987922705314" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="16" LOG_CI_END="0.9216169405653761" LOG_CI_START="0.48410332125096156" LOG_EFFECT_SIZE="0.7028601309081688" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7703" O_E="0.0" SE="0.2569976657126311" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.06604780018174129" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2955572403910241" CI_END="0.6358794971350776" CI_START="0.2526565871417746" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.40082308264317384" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-043.13" LOG_CI_END="-0.19662517788578301" LOG_CI_START="-0.5974693745600008" LOG_EFFECT_SIZE="-0.3970472762228919" METHOD="MH" MODIFIED="2013-03-18 11:56:01 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5866812146662438" P_Q="0.5869418923888202" P_Z="1.0326168886874651E-4" Q="0.29514561785967364" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="3.88279719658293">
<NAME>Mouth ulcers</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8424047182432117" CI_START="0.2426141922661586" DF="0" EFFECT_SIZE="0.45208333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="30" I2="0.0" ID="CMP-043.13.01" LOG_CI_END="-0.07447920936619208" LOG_CI_START="-0.6150837976879234" LOG_EFFECT_SIZE="-0.3447815035270577" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.012418864532364602" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="2.500013296396354">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8424047182432117" CI_START="0.2426141922661586" EFFECT_SIZE="0.45208333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="30" LOG_CI_END="-0.07447920936619208" LOG_CI_START="-0.6150837976879234" LOG_EFFECT_SIZE="-0.3447815035270577" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7724" O_E="0.0" SE="0.31755381121605575" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.10084042301784238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6965930408784575" CI_START="0.1752899979293785" DF="0" EFFECT_SIZE="0.3494363929146538" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" I2="0.0" ID="CMP-043.13.02" LOG_CI_END="-0.157020868555907" LOG_CI_START="-0.7562428641001944" LOG_EFFECT_SIZE="-0.4566318663280507" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0028159453426935097" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.987146729763665">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.6965930408784575" CI_START="0.17528999792937847" EFFECT_SIZE="0.3494363929146538" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" LOG_CI_END="-0.157020868555907" LOG_CI_START="-0.7562428641001945" LOG_EFFECT_SIZE="-0.4566318663280507" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7725" O_E="0.0" SE="0.3519859663794306" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.12389412052806163" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4870015760733244" CI_END="0.7071244413426299" CI_START="0.41209976573505763" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5398201706335465" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="124" I2="0.0" I2_Q="0.0" ID="CMP-043.14" LOG_CI_END="-0.15050415136188822" LOG_CI_START="-0.3849976323572382" LOG_EFFECT_SIZE="-0.26775089185956324" METHOD="MH" MODIFIED="2012-02-23 16:07:55 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.4852679346877804" P_Q="0.4854747986258956" P_Z="7.609793643231755E-6" Q="0.48654011137298553" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="4.475877987274446">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7263884858103048" CI_START="0.327820767799504" DF="0" EFFECT_SIZE="0.4879807692307692" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="62" I2="0.0" ID="CMP-043.14.01" LOG_CI_END="-0.13883104855729148" LOG_CI_START="-0.48436353686976824" LOG_EFFECT_SIZE="-0.3115972927135298" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.078573579391201E-4" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="3.534946739054009">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.7263884858103048" CI_START="0.327820767799504" EFFECT_SIZE="0.4879807692307692" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="62" LOG_CI_END="-0.13883104855729148" LOG_CI_START="-0.48436353686976824" LOG_EFFECT_SIZE="-0.3115972927135298" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7714" O_E="0.0" SE="0.2029674940481512" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.04119580364018629" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8550749562775056" CI_START="0.409569209240968" DF="0" EFFECT_SIZE="0.5917874396135265" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="62" I2="0.0" ID="CMP-043.14.02" LOG_CI_END="-0.06799581314217473" LOG_CI_START="-0.38767270037055834" LOG_EFFECT_SIZE="-0.2278342567563665" MODIFIED="2012-01-31 14:39:24 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0052102467500040085" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.7937392756699846">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8550749562775056" CI_START="0.40956920924096807" EFFECT_SIZE="0.5917874396135265" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="62" LOG_CI_END="-0.06799581314217473" LOG_CI_START="-0.3876727003705583" LOG_EFFECT_SIZE="-0.2278342567563665" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7715" O_E="0.0" SE="0.1877797859840653" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.03526124802422137" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8149704725783132" CI_END="0.8139007073893861" CI_START="0.4518862918601033" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6064573955394598" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-043.15" LOG_CI_END="-0.08942857405815238" LOG_CI_START="-0.34497083295472925" LOG_EFFECT_SIZE="-0.21719970350644077" METHOD="MH" MODIFIED="2012-02-23 16:07:58 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.366654856695261" P_Q="0.36697865144650677" P_Z="8.629656266534715E-4" Q="0.8138698616755207" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="3.3317667157172077">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0234294819027228" CI_START="0.463257805271198" DF="0" EFFECT_SIZE="0.6885576923076923" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="50" I2="0.0" ID="CMP-043.15.01" LOG_CI_END="0.010057923524555576" LOG_CI_START="-0.3341772546692824" LOG_EFFECT_SIZE="-0.1620596655723634" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06497488966871522" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="1.8454308448951187">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0234294819027228" CI_START="0.463257805271198" EFFECT_SIZE="0.6885576923076923" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="50" LOG_CI_END="0.010057923524555576" LOG_CI_START="-0.3341772546692824" LOG_EFFECT_SIZE="-0.1620596655723634" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7732" O_E="0.0" SE="0.2022054476626741" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.040887043064462426" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8144383944728648" CI_START="0.33733433421631664" DF="0" EFFECT_SIZE="0.5241545893719807" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="50" I2="0.0" ID="CMP-043.15.02" LOG_CI_END="-0.08914176089796291" LOG_CI_START="-0.4719394536467759" LOG_EFFECT_SIZE="-0.28054060727236946" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.004068591219228779" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.8727941514299773">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8144383944728648" CI_START="0.33733433421631664" EFFECT_SIZE="0.5241545893719807" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="50" LOG_CI_END="-0.08914176089796291" LOG_CI_START="-0.4719394536467759" LOG_EFFECT_SIZE="-0.28054060727236946" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7733" O_E="0.0" SE="0.22485725959979208" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.050560787194728285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19418212847254646" CI_END="1.6102246851522282" CI_START="0.8467788521057766" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1676918302898198" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-043.16" LOG_CI_END="0.2068864802017305" LOG_CI_START="-0.07222999681281962" LOG_EFFECT_SIZE="0.06732824169445543" METHOD="MH" MODIFIED="2012-02-23 16:08:00 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.6594584337656311" P_Q="0.6594609287907727" P_Z="0.3443721851453124" Q="0.19417909155010007" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.9455617258787746">
<NAME>Rhinitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9548417651418502" CI_START="0.8017586990826414" DF="0" EFFECT_SIZE="1.251923076923077" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" I2="0.0" ID="CMP-043.16.01" LOG_CI_END="0.2911116091452058" LOG_CI_START="-0.09595631927842027" LOG_EFFECT_SIZE="0.09757764493339278" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3230587532391943" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.9881917654328376">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.9548417651418502" CI_START="0.8017586990826414" EFFECT_SIZE="1.251923076923077" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.2911116091452058" LOG_CI_START="-0.09595631927842027" LOG_EFFECT_SIZE="0.09757764493339278" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7710" O_E="0.0" SE="0.2273656171731848" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.05169512387254322" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.723591703558854" CI_START="0.6808089557165969" DF="0" EFFECT_SIZE="1.0832528180354268" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" I2="0.0" ID="CMP-043.16.02" LOG_CI_END="0.23643439496188548" LOG_CI_START="-0.16697473994944134" LOG_EFFECT_SIZE="0.03472982750622204" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7357627336184187" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="0.33746985484821007">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7235917035588537" CI_START="0.6808089557165969" EFFECT_SIZE="1.0832528180354268" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" LOG_CI_END="0.23643439496188542" LOG_CI_START="-0.16697473994944134" LOG_EFFECT_SIZE="0.03472982750622204" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7711" O_E="0.0" SE="0.23696452275433688" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.056152185044190644" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8995108752882672" CI_END="0.9788956918679836" CI_START="0.4963594179837829" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.697053868709173" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-043.17" LOG_CI_END="-0.009263582823629424" LOG_CI_START="-0.30420373335012796" LOG_EFFECT_SIZE="-0.15673365808687864" METHOD="MH" MODIFIED="2013-03-18 11:56:49 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.3429130170595144" P_Q="0.3431753058792152" P_Z="0.03724370920254716" Q="0.8985336906189112" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="2.0830824454868373">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2799487415831563" CI_START="0.5144122252129545" DF="0" EFFECT_SIZE="0.8114316239316239" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" I2="0.0" ID="CMP-043.17.01" LOG_CI_END="0.10719257769995341" LOG_CI_START="-0.2886887187785536" LOG_EFFECT_SIZE="-0.09074807053930008" MODIFIED="2013-03-18 11:56:49 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.36888331110911365" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.8985670780897068">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2799487415831563" CI_START="0.5144122252129545" EFFECT_SIZE="0.8114316239316239" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" LOG_CI_END="0.10719257769995341" LOG_CI_START="-0.2886887187785536" LOG_EFFECT_SIZE="-0.09074807053930008" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7708" O_E="0.0" SE="0.2325426331954973" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.05407607625349561" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.972153796428999" CI_START="0.348898249152592" DF="0" EFFECT_SIZE="0.5823939881910897" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="36" I2="0.0" ID="CMP-043.17.02" LOG_CI_END="-0.012265023492663563" LOG_CI_START="-0.45730120993072504" LOG_EFFECT_SIZE="-0.2347831167116943" MODIFIED="2012-01-31 14:38:33 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03864043041022871" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="2.0679956684692167">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9721537964289991" CI_START="0.348898249152592" EFFECT_SIZE="0.5823939881910897" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="36" LOG_CI_END="-0.012265023492663514" LOG_CI_START="-0.45730120993072504" LOG_EFFECT_SIZE="-0.2347831167116943" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7709" O_E="0.0" SE="0.2614164588783692" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.06833856497250608" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3948997267886416" CI_END="1.7416748912521627" CI_START="0.8111030896510878" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1885612670209103" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-043.18" LOG_CI_END="0.24096709090572382" LOG_CI_START="-0.09092394428290433" LOG_EFFECT_SIZE="0.07502157331140975" METHOD="MH" MODIFIED="2012-02-23 16:08:00 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.5297354679739954" P_Q="0.5297381541168633" P_Z="0.3755790479182002" Q="0.39489457193568833" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="415" TOTAL_2="434" WEIGHT="200.0" Z="0.8860714280536408">
<NAME>Skin infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8255295938687972" CI_START="0.5962164029141714" DF="0" EFFECT_SIZE="1.0432692307692308" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-043.18.01" LOG_CI_END="0.2613888777402737" LOG_CI_START="-0.2245960799687378" LOG_EFFECT_SIZE="0.018396398885767988" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8820394560226922" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="100.0" Z="0.14838434272250506">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8255295938687974" CI_START="0.5962164029141714" EFFECT_SIZE="1.0432692307692308" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.26138887774027375" LOG_CI_START="-0.2245960799687378" LOG_EFFECT_SIZE="0.018396398885767988" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7728" O_E="0.0" SE="0.2854699698226121" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.08149310367052304" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.255261049407556" CI_START="0.7893191845590029" DF="0" EFFECT_SIZE="1.334211682037769" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" I2="0.0" ID="CMP-043.18.02" LOG_CI_END="0.35319681927626567" LOG_CI_START="-0.10274734145301612" LOG_EFFECT_SIZE="0.12522473891162472" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2816565963871901" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="217" WEIGHT="100.0" Z="1.0766054239959633">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.255261049407556" CI_START="0.7893191845590026" EFFECT_SIZE="1.334211682037769" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.35319681927626567" LOG_CI_START="-0.10274734145301624" LOG_EFFECT_SIZE="0.12522473891162472" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7729" O_E="0.0" SE="0.26782385697237554" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.07172961836355947" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.285674633805658" CI_END="1.0015540971958048" CI_START="0.6351744844101843" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7975973967455341" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="178" I2="53.332901564111275" I2_Q="54.0466632907894" ID="CMP-043.19" LOG_CI_END="6.7441192127379E-4" LOG_CI_START="-0.1971069562711829" LOG_EFFECT_SIZE="-0.09821627217495456" METHOD="MH" MODIFIED="2013-03-18 11:56:32 -0400" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.11732155954086199" P_Q="0.140167465931054" P_Z="0.051583011335974406" Q="2.1761205422969123" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03351769798779336" TOTALS="SUB" TOTAL_1="518" TOTAL_2="484" WEIGHT="200.0" Z="1.946597476981517">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9342609926883672" CI_START="0.5364332887279047" DF="0" EFFECT_SIZE="0.7079326923076923" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="84" I2="0.0" ID="CMP-043.19.01" LOG_CI_END="-0.02953178345872325" LOG_CI_START="-0.27048427954852133" LOG_EFFECT_SIZE="-0.1500080315036223" MODIFIED="2013-03-18 11:56:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.014670972296294875" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="217" WEIGHT="99.99999999999999" Z="2.4404008583441095">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9342609926883672" CI_START="0.5364332887279047" EFFECT_SIZE="0.7079326923076923" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="84" LOG_CI_END="-0.02953178345872325" LOG_CI_START="-0.27048427954852133" LOG_EFFECT_SIZE="-0.1500080315036223" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7704" O_E="0.0" SE="0.14153668893723925" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="208" TOTAL_2="217" VAR="0.020032634315316825" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6828740010933192" CI_END="1.5201428361807223" CI_START="0.6848739996005889" DF="1" EFFECT_SIZE="1.0203461687972735" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="94" I2="40.57784484457385" ID="CMP-043.19.02" LOG_CI_END="0.18188439718860888" LOG_CI_START="-0.16438932093323125" LOG_EFFECT_SIZE="0.008747538127688801" MODIFIED="2012-01-31 14:25:42 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19454308285260546" P_Z="0.9211185020943858" STUDIES="2" TAU2="0.04135773763472957" TOTAL_1="310" TOTAL_2="267" WEIGHT="100.0" Z="0.09902489727868057">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1545109545007015" CI_START="0.6993380197904491" EFFECT_SIZE="0.8985507246376812" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="84" LOG_CI_END="0.062398058047163175" LOG_CI_START="-0.1553128605251661" LOG_EFFECT_SIZE="-0.046457401239001446" MODIFIED="2008-07-17 15:41:43 -0400" MODIFIED_BY="[Empty name]" ORDER="7705" O_E="0.0" SE="0.12788447125581384" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="207" TOTAL_2="217" VAR="0.01635443798837908" WEIGHT="71.68805836576058"/>
<DICH_DATA CI_END="2.654939526961294" CI_START="0.7464606552534148" EFFECT_SIZE="1.4077669902912622" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.4240546333624534" LOG_CI_START="-0.12699307830284806" LOG_EFFECT_SIZE="0.1485307775298027" MODIFIED="2012-01-31 14:25:42 -0500" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.32368815356236313" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.10477402075661198" WEIGHT="28.31194163423942"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-044" MODIFIED="2013-03-18 11:58:10 -0400" MODIFIED_BY="[Empty name]" NO="44">
<NAME>Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7020441335119825" CI_START="1.0951656268856538" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3652912621359223" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-044.01" LOG_CI_END="0.23097081702484534" LOG_CI_START="0.039479804475685616" LOG_EFFECT_SIZE="0.1352253107502655" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.005637764190404009" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="2.7681376304876646">
<NAME>Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7020441335119825" CI_START="1.0951656268856538" DF="0" EFFECT_SIZE="1.3652912621359223" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="32" I2="0.0" ID="CMP-044.01.01" LOG_CI_END="0.23097081702484534" LOG_CI_START="0.039479804475685616" LOG_EFFECT_SIZE="0.1352253107502655" MODIFIED="2012-02-21 14:50:10 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005637764190404009" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="2.7681376304876646">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7020441335119827" CI_START="1.0951656268856538" EFFECT_SIZE="1.3652912621359223" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="32" LOG_CI_END="0.2309708170248454" LOG_CI_START="0.039479804475685616" LOG_EFFECT_SIZE="0.1352253107502655" MODIFIED="2012-02-17 15:27:07 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.11248276866717608" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.012652373247033447" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.701904345400215" CI_END="16.139352009030443" CI_START="0.21301659972598053" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.854170943236987" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" I2="78.73202161208827" I2_Q="0.0" ID="CMP-044.02" LOG_CI_END="1.207886093920638" LOG_CI_START="-0.6715865520143468" LOG_EFFECT_SIZE="0.2681497709531456" METHOD="MH" MODIFIED="2012-02-23 16:19:32 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03012929691930566" P_Q="1.0" P_Z="0.5759792404998982" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.9974834551955578" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.5592674037236408">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.701904345400215" CI_END="16.139352009030443" CI_START="0.21301659972598053" DF="1" EFFECT_SIZE="1.854170943236987" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" I2="78.73202161208827" ID="CMP-044.02.01" LOG_CI_END="1.207886093920638" LOG_CI_START="-0.6715865520143468" LOG_EFFECT_SIZE="0.2681497709531456" MODIFIED="2012-02-21 14:50:12 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03012929691930566" P_Z="0.5759792404998982" STUDIES="2" TAU2="1.9974834551955578" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.5592674037236408">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="50.238529952213725" CI_START="0.9193581020680078" EFFECT_SIZE="6.796116504854369" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.70103692286723" LOG_CI_START="-0.03651529224906071" LOG_EFFECT_SIZE="0.8322608153090846" MODIFIED="2012-01-31 14:40:25 -0500" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="1.0206467721814896" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.0417198335644937" WEIGHT="40.10397973715388"/>
<DICH_DATA CI_END="1.1354245132559422" CI_START="0.5317761877328022" EFFECT_SIZE="0.7770403587443946" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="50" LOG_CI_END="0.0551582661945444" LOG_CI_START="-0.2742711137283755" LOG_EFFECT_SIZE="-0.10955642376691554" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7762" O_E="0.0" SE="0.19350844846845341" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.037445519628668086" WEIGHT="59.89602026284612"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5506677034886845" CI_END="1.8988121040328472" CI_START="0.6822063309991856" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.138148337761424" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-044.03" LOG_CI_END="0.2784819914779212" LOG_CI_START="-0.16608425457791332" LOG_EFFECT_SIZE="0.056198868450003964" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4580450954321802" P_Q="1.0" P_Z="0.6202266807383241" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.49552911005339034">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5506677034886845" CI_END="1.8988121040328472" CI_START="0.6822063309991856" DF="1" EFFECT_SIZE="1.138148337761424" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="25" I2="0.0" ID="CMP-044.03.01" LOG_CI_END="0.2784819914779212" LOG_CI_START="-0.16608425457791332" LOG_EFFECT_SIZE="0.056198868450003964" MODIFIED="2012-02-21 14:50:14 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4580450954321802" P_Z="0.6202266807383241" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.49552911005339034">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="20.227053451730313" CI_START="0.2912547023294687" EFFECT_SIZE="2.4271844660194173" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3059326221253909" LOG_CI_START="-0.53572705419166" LOG_EFFECT_SIZE="0.38510278396686537" MODIFIED="2012-01-31 14:39:58 -0500" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="1.0818000102310603" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.1702912621359223" WEIGHT="5.368371298576578"/>
<DICH_DATA CI_END="1.8072565187427772" CI_START="0.6276213401843578" EFFECT_SIZE="1.0650224215246638" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.25701979991446205" LOG_CI_START="-0.20230229808901257" LOG_EFFECT_SIZE="0.027358750912724734" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7761" O_E="0.0" SE="0.26980807404829554" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.07279639682165054" WEIGHT="94.63162870142342"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.32077854805631" CI_END="20.678261547674914" CI_START="0.20138899561514306" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.04067986812079" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="41" I2="81.20575793620839" I2_Q="0.0" ID="CMP-044.04" LOG_CI_END="1.315514024171037" LOG_CI_START="-0.6959642640415356" LOG_EFFECT_SIZE="0.30977488006475074" METHOD="MH" MODIFIED="2012-02-23 16:21:13 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.02107265624127408" P_Q="1.0" P_Z="0.5460544320931731" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.3357676376297944" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="99.99999999999999" Z="0.6036829845989995">
<NAME>Accidental injury</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.32077854805631" CI_END="20.678261547674914" CI_START="0.20138899561514306" DF="1" EFFECT_SIZE="2.04067986812079" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="41" I2="81.20575793620839" ID="CMP-044.04.01" LOG_CI_END="1.315514024171037" LOG_CI_START="-0.6959642640415356" LOG_EFFECT_SIZE="0.30977488006475074" MODIFIED="2012-02-21 14:50:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02107265624127408" P_Z="0.5460544320931731" STUDIES="2" TAU2="2.3357676376297944" TOTAL_1="326" TOTAL_2="278" WEIGHT="99.99999999999999" Z="0.6036829845989995">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="56.92430298825997" CI_START="1.0597606824804153" EFFECT_SIZE="7.766990291262136" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.7552977215848393" LOG_CI_START="0.025207802988703905" LOG_EFFECT_SIZE="0.8902527622867714" MODIFIED="2012-02-17 15:28:13 -0500" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="1.0162633822665865" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.0327912621359223" WEIGHT="41.444008770107224"/>
<DICH_DATA CI_END="1.2194736275845202" CI_START="0.5148621432755441" EFFECT_SIZE="0.7923766816143498" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="40" LOG_CI_END="0.08617241267077246" LOG_CI_START="-0.28830903975356553" LOG_EFFECT_SIZE="-0.10106831354139657" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7763" O_E="0.0" SE="0.21997225886714195" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.048387794671112906" WEIGHT="58.55599122989276"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.022277229268912" CI_END="2.495469762085841" CI_START="0.3854482167171305" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9807519409450635" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="66.91236692929391" I2_Q="0.0" ID="CMP-044.05" LOG_CI_END="0.3971523118343491" LOG_CI_START="-0.41403395925919767" LOG_EFFECT_SIZE="-0.008440823712424305" METHOD="MH" MODIFIED="2012-02-23 16:21:29 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0821282790738811" P_Q="1.0" P_Z="0.9674641636856747" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.31368605426712115" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.04078893113883936">
<NAME>Arthralgia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.022277229268912" CI_END="2.495469762085841" CI_START="0.3854482167171305" DF="1" EFFECT_SIZE="0.9807519409450635" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" I2="66.91236692929391" ID="CMP-044.05.01" LOG_CI_END="0.3971523118343491" LOG_CI_START="-0.41403395925919767" LOG_EFFECT_SIZE="-0.008440823712424305" MODIFIED="2012-01-31 14:42:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0821282790738811" P_Z="0.9674641636856747" STUDIES="2" TAU2="0.31368605426712115" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.04078893113883936">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.44382621018155" CI_START="0.21317414598691845" EFFECT_SIZE="0.5547850208044383" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.15951492141823972" LOG_CI_START="-0.6712654682011732" LOG_EFFECT_SIZE="-0.25587527339146665" MODIFIED="2012-01-31 14:42:59 -0500" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.4880045132916961" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.2381484049930652" WEIGHT="41.144100415119546"/>
<DICH_DATA CI_END="2.4720854957253486" CI_START="0.8629793453070347" EFFECT_SIZE="1.4606021780909673" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.39306348651373285" LOG_CI_START="-0.06399959863766035" LOG_EFFECT_SIZE="0.16453194393803627" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7769" O_E="0.0" SE="0.26848111871668895" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.07208211110736482" WEIGHT="58.855899584880454"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6393559028230232" CI_END="1.9451469573574216" CI_START="0.8516558833518386" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2870881283802504" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-044.06" LOG_CI_END="0.28895241818533207" LOG_CI_START="-0.06973584907136646" LOG_EFFECT_SIZE="0.10960828455698281" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.42394437495653003" P_Q="1.0" P_Z="0.23097344293920308" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.1978551279747343">
<NAME>Back pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6393559028230232" CI_END="1.9451469573574216" CI_START="0.8516558833518386" DF="1" EFFECT_SIZE="1.2870881283802504" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="33" I2="0.0" ID="CMP-044.06.01" LOG_CI_END="0.28895241818533207" LOG_CI_START="-0.06973584907136646" LOG_EFFECT_SIZE="0.10960828455698281" MODIFIED="2012-02-21 14:50:22 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.42394437495653003" P_Z="0.23097344293920308" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.1978551279747343">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.4714130657583517" CI_START="0.3089336610608476" EFFECT_SIZE="0.8737864077669902" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.39294533835517587" LOG_CI_START="-0.5101347688868707" LOG_EFFECT_SIZE="-0.05859471526584736" MODIFIED="2012-01-31 14:41:00 -0500" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.5304737253126053" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.28140237324703343" WEIGHT="19.55756035085976"/>
<DICH_DATA CI_END="2.1802789863307446" CI_START="0.8830779268420687" EFFECT_SIZE="1.387572069186419" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.3385120690503568" LOG_CI_START="-0.054000970596588566" LOG_EFFECT_SIZE="0.14225554922688408" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7764" O_E="0.0" SE="0.2305641024594978" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.053159805342953795" WEIGHT="80.44243964914024"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.028691046162251" CI_START="0.9240803008294359" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5485436893203883" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-044.07" LOG_CI_END="0.8468744538450359" LOG_CI_START="-0.03429028777142892" LOG_EFFECT_SIZE="0.4062920830368035" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.07069665475479284" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.8074210470452454">
<NAME>Bronchitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.028691046162251" CI_START="0.9240803008294359" DF="0" EFFECT_SIZE="2.5485436893203883" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" ID="CMP-044.07.01" LOG_CI_END="0.8468744538450359" LOG_CI_START="-0.03429028777142892" LOG_EFFECT_SIZE="0.4062920830368035" MODIFIED="2012-02-21 14:50:24 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07069665475479284" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.8074210470452454">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.028691046162251" CI_START="0.924080300829436" EFFECT_SIZE="2.5485436893203883" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" LOG_CI_END="0.8468744538450359" LOG_CI_START="-0.034290287771428875" LOG_EFFECT_SIZE="0.4062920830368035" MODIFIED="2012-02-17 15:43:49 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.5176005310613291" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.26791030975496993" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1615651322264307" CI_END="26.316736600570067" CI_START="0.20482657468149892" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.321716394112339" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" I2="68.37009651305895" I2_Q="0.0" ID="CMP-044.08" LOG_CI_END="1.4202320337171646" LOG_CI_START="-0.6886136976532025" LOG_EFFECT_SIZE="0.36580916803198105" METHOD="MH" MODIFIED="2013-03-18 11:57:35 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.07539120453034753" P_Q="1.0" P_Z="0.49652533568249346" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.2991752997257566" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.6799670396860575">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1615651322264307" CI_END="26.316736600570067" CI_START="0.20482657468149892" DF="1" EFFECT_SIZE="2.321716394112339" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="26" I2="68.37009651305895" ID="CMP-044.08.01" LOG_CI_END="1.4202320337171646" LOG_CI_START="-0.6886136976532025" LOG_EFFECT_SIZE="0.36580916803198105" MODIFIED="2012-02-21 14:50:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07539120453034753" P_Z="0.49652533568249346" STUDIES="2" TAU2="2.2991752997257566" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.6799670396860575">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="187.62745517917432" CI_START="0.6780050949401254" EFFECT_SIZE="11.278846153846153" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.273296388202912" LOG_CI_START="-0.16876704256941413" LOG_EFFECT_SIZE="1.0522646728167488" MODIFIED="2012-01-31 14:39:14 -0500" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.434480147644606" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.057733293986491" WEIGHT="35.21975877911236"/>
<DICH_DATA CI_END="1.6487125682017094" CI_START="0.5862034103652769" EFFECT_SIZE="0.9830976198689203" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.21714494859506825" LOG_CI_START="-0.23195165928804268" LOG_EFFECT_SIZE="-0.0074033553464872455" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7759" O_E="0.0" SE="0.2638015705346015" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.06959126861652234" WEIGHT="64.78024122088765"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.101347877905128E-32" CI_END="14.379008397435554" CI_START="0.8030317228932016" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.398058252427184" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="100.0" I2_Q="0.0" ID="CMP-044.09" LOG_CI_END="1.1577289373423605" LOG_CI_START="-0.09526729805215386" LOG_EFFECT_SIZE="0.5312308196451033" METHOD="MH" MODIFIED="2012-02-23 16:32:52 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.0965276885885685" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.6619256220738268">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.101347877905128E-32" CI_END="14.379008397435554" CI_START="0.8030317228932016" DF="0" EFFECT_SIZE="3.398058252427184" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="100.0" ID="CMP-044.09.01" LOG_CI_END="1.1577289373423605" LOG_CI_START="-0.09526729805215386" LOG_EFFECT_SIZE="0.5312308196451033" MODIFIED="2012-02-21 14:50:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0965276885885685" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="1.6619256220738268">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="14.379008397435554" CI_START="0.8030317228932017" EFFECT_SIZE="3.3980582524271843" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.1577289373423605" LOG_CI_START="-0.09526729805215381" LOG_EFFECT_SIZE="0.5312308196451034" MODIFIED="2012-02-17 15:29:34 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.7360161911021345" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5417198335644937" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.09783436043304" CI_START="1.0546879134715321" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.368932038834951" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-044.10" LOG_CI_END="1.257626609035788" LOG_CI_START="0.023123969104554876" LOG_EFFECT_SIZE="0.6403752890701715" METHOD="MH" MODIFIED="2013-03-13 04:36:10 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.04201316274089301" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="2.033389743479005">
<NAME>Flu syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.09783436043304" CI_START="1.0546879134715321" DF="0" EFFECT_SIZE="4.368932038834951" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" I2="0.0" ID="CMP-044.10.01" LOG_CI_END="1.257626609035788" LOG_CI_START="0.023123969104554876" LOG_EFFECT_SIZE="0.6403752890701715" MODIFIED="2012-02-21 14:50:33 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04201316274089301" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="2.033389743479005">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="18.097834360433048" CI_START="1.054687913471532" EFFECT_SIZE="4.368932038834951" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.2576266090357882" LOG_CI_START="0.023123969104554786" LOG_EFFECT_SIZE="0.6403752890701715" MODIFIED="2012-02-17 15:44:53 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.7251529615822292" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.5258468176914779" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.041088613264986E-32" CI_END="7.883588026100005" CI_START="0.3661657562730566" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.699029126213592" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="100.0" I2_Q="0.0" ID="CMP-044.11" LOG_CI_END="0.8967239212052941" LOG_CI_START="-0.43632227324304973" LOG_EFFECT_SIZE="0.23020082398112215" METHOD="MH" MODIFIED="2012-02-23 16:32:57 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="0.4984543295784788" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.676923764672924">
<NAME>Gingival/dental infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.041088613264986E-32" CI_END="7.883588026100005" CI_START="0.3661657562730566" DF="0" EFFECT_SIZE="1.699029126213592" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="100.0" ID="CMP-044.11.01" LOG_CI_END="0.8967239212052941" LOG_CI_START="-0.43632227324304973" LOG_EFFECT_SIZE="0.23020082398112215" MODIFIED="2012-02-21 14:50:36 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.4984543295784788" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.676923764672924">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.883588026100005" CI_START="0.36616575627305675" EFFECT_SIZE="1.6990291262135921" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.8967239212052941" LOG_CI_START="-0.43632227324304956" LOG_EFFECT_SIZE="0.2302008239811222" MODIFIED="2012-02-17 15:45:30 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.7830379333040418" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.6131484049930651" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20016540862530557" CI_END="1.5683906395971348" CI_START="0.7198140563116591" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0625204130602155" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-044.12" LOG_CI_END="0.195454241697894" LOG_CI_START="-0.14277967682872458" LOG_EFFECT_SIZE="0.026337282434584698" METHOD="MH" MODIFIED="2012-02-23 16:32:59 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6545873762043791" P_Q="1.0" P_Z="0.7601884839121552" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.3052332849840012">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.20016540862530557" CI_END="1.5683906395971348" CI_START="0.7198140563116591" DF="1" EFFECT_SIZE="1.0625204130602155" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="41" I2="0.0" ID="CMP-044.12.01" LOG_CI_END="0.195454241697894" LOG_CI_START="-0.14277967682872458" LOG_EFFECT_SIZE="0.026337282434584698" MODIFIED="2012-02-21 14:50:38 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6545873762043791" P_Z="0.7601884839121552" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.3052332849840012">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.9839245095136047" CI_START="0.44732157611178713" EFFECT_SIZE="1.3349514563106797" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.6003111004815069" LOG_CI_START="-0.3493801535592884" LOG_EFFECT_SIZE="0.12546547346110928" MODIFIED="2012-01-31 14:38:07 -0500" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.5578533436710882" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.31120035304501326" WEIGHT="12.830415373407956"/>
<DICH_DATA CI_END="1.5508344855292204" CI_START="0.6740537329093989" EFFECT_SIZE="1.0224215246636772" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.1905654497433012" LOG_CI_START="-0.171305481838715" LOG_EFFECT_SIZE="0.009629983952293144" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7758" O_E="0.0" SE="0.2125647765012772" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.04518378420903793" WEIGHT="87.16958462659204"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.718482357931396" CI_START="1.2938714678634378" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4708520179372195" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-044.13" LOG_CI_END="0.6738023355915383" LOG_CI_START="0.11189113601571042" LOG_EFFECT_SIZE="0.39284673580362434" METHOD="MH" MODIFIED="2012-02-23 16:33:02 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.006134137532788154" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.00000000000001" Z="2.7405236065785927">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.718482357931396" CI_START="1.2938714678634378" DF="0" EFFECT_SIZE="2.4708520179372195" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" I2="0.0" ID="CMP-044.13.01" LOG_CI_END="0.6738023355915383" LOG_CI_START="0.11189113601571042" LOG_EFFECT_SIZE="0.39284673580362434" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.006134137532788154" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.00000000000001" Z="2.7405236065785927">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.718482357931396" CI_START="1.2938714678634378" EFFECT_SIZE="2.4708520179372195" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.6738023355915383" LOG_CI_START="0.11189113601571042" LOG_EFFECT_SIZE="0.39284673580362434" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7768" O_E="0.0" SE="0.3300694201361387" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.10894582210900686" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01779323741222389" CI_END="1.3172457778959035" CI_START="0.47379654213373323" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7900041105635708" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-044.14" LOG_CI_END="0.11966681522398717" LOG_CI_START="-0.32440811317365637" LOG_EFFECT_SIZE="-0.10237064897483462" METHOD="MH" MODIFIED="2012-02-23 16:33:09 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.8938839356446105" P_Q="1.0" P_Z="0.36618430124002843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.9036438323084255">
<NAME>Increased cough</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01779323741222389" CI_END="1.3172457778959035" CI_START="0.47379654213373323" DF="1" EFFECT_SIZE="0.7900041105635708" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-044.14.01" LOG_CI_END="0.11966681522398717" LOG_CI_START="-0.32440811317365637" LOG_EFFECT_SIZE="-0.10237064897483462" MODIFIED="2012-02-21 14:50:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8938839356446105" P_Z="0.36618430124002843" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.9036438323084255">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.76770733889507" CI_START="0.2607483034021362" EFFECT_SIZE="0.8495145631067961" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.4421201653285703" LOG_CI_START="-0.5837785086942883" LOG_EFFECT_SIZE="-0.07082917168285899" MODIFIED="2012-01-31 14:41:29 -0500" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.602617959401365" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.36314840499306517" WEIGHT="17.887401363320876"/>
<DICH_DATA CI_END="1.3702331283542266" CI_START="0.44064889880660363" EFFECT_SIZE="0.7770403587443946" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.136794463320213" LOG_CI_START="-0.35590731085404403" LOG_EFFECT_SIZE="-0.10955642376691554" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7765" O_E="0.0" SE="0.28941546106307503" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0837613091023523" WEIGHT="82.11259863667912"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.315091230090449" CI_END="2.3837266672746367" CI_START="0.6686959207553809" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2625324940778233" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="193" I2="91.87988151028375" I2_Q="0.0" ID="CMP-044.15" LOG_CI_END="0.37725645505313204" LOG_CI_START="-0.1747713261179285" LOG_EFFECT_SIZE="0.10124256446760183" METHOD="MH" MODIFIED="2012-02-23 16:33:09 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="4.493154603413263E-4" P_Q="1.0" P_Z="0.4721904997236157" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19406058278162344" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.7189195429187457">
<NAME>Infections (total)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.315091230090449" CI_END="2.3837266672746367" CI_START="0.6686959207553809" DF="1" EFFECT_SIZE="1.2625324940778233" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="193" I2="91.87988151028375" ID="CMP-044.15.01" LOG_CI_END="0.37725645505313204" LOG_CI_START="-0.1747713261179285" LOG_EFFECT_SIZE="0.10124256446760183" MODIFIED="2012-01-31 15:01:35 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.493154603413263E-4" P_Z="0.4721904997236157" STUDIES="2" TAU2="0.19406058278162344" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.7189195429187457">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.481768973070083" CI_START="1.2436346208447966" EFFECT_SIZE="1.756819232547388" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="21" LOG_CI_END="0.3947613507361586" LOG_CI_START="0.09469280361927873" LOG_EFFECT_SIZE="0.2447270771777187" MODIFIED="2012-01-31 15:01:35 -0500" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.17626174993971908" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.031068204491812055" WEIGHT="46.70528655859557"/>
<DICH_DATA CI_END="1.0565680500722208" CI_START="0.8454732061806307" EFFECT_SIZE="0.9451454791949109" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="172" LOG_CI_END="0.02389747376798914" LOG_CI_START="-0.07290015103759777" LOG_EFFECT_SIZE="-0.0245013386348043" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7771" O_E="0.0" SE="0.05685940396677224" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0032329918194565948" WEIGHT="53.294713441404426"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6896673488441003" CI_START="0.35045073865317966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="100.00000000000001" ID="CMP-044.16" LOG_CI_END="0.4296985708965388" LOG_CI_START="-0.45537302030688315" LOG_EFFECT_SIZE="-0.0128372247051722" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.9546604753148594" Q="4.4533671038048966E-35" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.05685528342260965">
<NAME>Injection site haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6896673488441003" CI_START="0.35045073865317966" DF="0" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-044.16.01" LOG_CI_END="0.4296985708965388" LOG_CI_START="-0.45537302030688315" LOG_EFFECT_SIZE="-0.0128372247051722" MODIFIED="2012-02-21 14:50:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9546604753148594" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="0.05685528342260965">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.689667348844101" CI_START="0.35045073865317955" EFFECT_SIZE="0.970873786407767" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.4296985708965389" LOG_CI_START="-0.4553730203068833" LOG_EFFECT_SIZE="-0.0128372247051722" MODIFIED="2012-02-17 15:31:27 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.5198954338479252" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.27029126213592236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.024210921164258034" CI_END="19.23657899554728" CI_START="4.210213013229045" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="8.999449717458377" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-044.17" LOG_CI_END="1.2841278402871392" LOG_CI_START="0.6243040692631389" LOG_EFFECT_SIZE="0.954215954775139" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.8763494531612169" P_Q="1.0" P_Z="1.4373903332584367E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="5.6688739841255185">
<NAME>Injection site reaction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.024210921164258034" CI_END="19.23657899554728" CI_START="4.210213013229045" DF="1" EFFECT_SIZE="8.999449717458377" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="7" I2="0.0" ID="CMP-044.17.01" LOG_CI_END="1.2841278402871392" LOG_CI_START="0.6243040692631389" LOG_EFFECT_SIZE="0.954215954775139" MODIFIED="2012-02-21 14:50:41 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8763494531612169" P_Z="1.4373903332584367E-8" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="5.6688739841255185">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="32.98323982098489" CI_START="2.064762430996391" EFFECT_SIZE="8.25242718446602" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" LOG_CI_END="1.5182933125356028" LOG_CI_START="0.314870089482638" LOG_EFFECT_SIZE="0.9165817010091206" MODIFIED="2012-01-31 14:37:23 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.7068967582623397" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.4997030268418047" WEIGHT="35.2583102151415"/>
<DICH_DATA CI_END="23.235003407803188" CI_START="3.807964421891895" EFFECT_SIZE="9.406278026905829" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="5" LOG_CI_END="1.3661427405114661" LOG_CI_START="0.5806928820842309" LOG_EFFECT_SIZE="0.9734178112978483" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7757" O_E="0.0" SE="0.4613771348796627" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.21286886058976645" WEIGHT="64.7416897848585"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.667849591250164E-4" CI_END="10.63439790827673" CI_START="0.6017512903421055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5296763949795853" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-044.18" LOG_CI_END="1.0267129063200664" LOG_CI_START="-0.22058296978935887" LOG_EFFECT_SIZE="0.40306496826535376" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.9810063606731891" P_Q="1.0" P_Z="0.20525229375114562" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.2667288273156563">
<NAME>Malignancy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.667849591250164E-4" CI_END="10.63439790827673" CI_START="0.6017512903421055" DF="1" EFFECT_SIZE="2.5296763949795853" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-044.18.01" LOG_CI_END="1.0267129063200664" LOG_CI_START="-0.22058296978935887" LOG_EFFECT_SIZE="0.40306496826535376" MODIFIED="2012-01-31 15:01:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9810063606731891" P_Z="0.20525229375114562" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="1.2667288273156563">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="50.13369185375276" CI_START="0.11991789459044006" EFFECT_SIZE="2.451923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7001296873115541" LOG_CI_START="-0.9211160050412046" LOG_EFFECT_SIZE="0.38950684113517486" MODIFIED="2012-01-31 15:01:52 -0500" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="1.5397326950634518" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.3707767722473605" WEIGHT="25.331057873020676"/>
<DICH_DATA CI_END="13.037961463574433" CI_START="0.5011067954411881" EFFECT_SIZE="2.5560538116591927" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1152096930577724" LOG_CI_START="-0.30006970780911096" LOG_EFFECT_SIZE="0.4075699926243307" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7773" O_E="0.0" SE="0.8313421258152288" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.6911297301549838" WEIGHT="74.66894212697933"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="310.457748093462" CI_START="1.1781494494699742" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="19.125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-044.19" LOG_CI_END="2.49200250300386" LOG_CI_START="0.0712003846474504" LOG_EFFECT_SIZE="1.281601443825655" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.03796276819046468" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="2.0752565055901835">
<NAME>Miscellaneous skin infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="310.457748093462" CI_START="1.1781494494699742" DF="0" EFFECT_SIZE="19.125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" I2="0.0" ID="CMP-044.19.01" LOG_CI_END="2.49200250300386" LOG_CI_START="0.0712003846474504" LOG_EFFECT_SIZE="1.281601443825655" MODIFIED="2012-02-21 14:50:45 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03796276819046468" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="2.0752565055901835">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="310.457748093462" CI_START="1.1781494494699742" EFFECT_SIZE="19.125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.49200250300386" LOG_CI_START="0.0712003846474504" LOG_EFFECT_SIZE="1.281601443825655" MODIFIED="2012-02-17 15:45:53 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="1.4219911474863027" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.0220588235294117" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.642419759509642" CI_END="0.49158143583583824" CI_START="0.24003857654040814" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34350910921214967" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="95" I2="39.114224959241945" I2_Q="0.0" ID="CMP-044.20" LOG_CI_END="-0.30840452624589265" LOG_CI_START="-0.6197189573203677" LOG_EFFECT_SIZE="-0.46406174178313025" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.19999385534156955" P_Q="1.0" P_Z="5.119155713550507E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="99.99999999999999" Z="5.843251771905643">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.642419759509642" CI_END="0.49158143583583824" CI_START="0.24003857654040814" DF="1" EFFECT_SIZE="0.34350910921214967" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="95" I2="39.114224959241945" ID="CMP-044.20.01" LOG_CI_END="-0.30840452624589265" LOG_CI_START="-0.6197189573203677" LOG_EFFECT_SIZE="-0.46406174178313025" MODIFIED="2012-02-21 14:50:43 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19999385534156955" P_Z="5.119155713550507E-9" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="278" WEIGHT="99.99999999999999" Z="5.843251771905643">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.03512150292697" CI_START="0.22695057509404828" EFFECT_SIZE="0.6796116504854369" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.3085903430332194" LOG_CI_START="-0.6440687124150501" LOG_EFFECT_SIZE="-0.16773918469091537" MODIFIED="2012-01-31 14:39:24 -0500" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.5595966449086924" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.3131484049930652" WEIGHT="7.031993884301274"/>
<DICH_DATA CI_END="0.46599068356801016" CI_START="0.217126972915071" EFFECT_SIZE="0.31808669656203287" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="90" LOG_CI_END="-0.3316227659611801" LOG_CI_START="-0.663286222328445" LOG_EFFECT_SIZE="-0.4974544941448126" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7760" O_E="0.0" SE="0.1948207560307184" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0379551269803807" WEIGHT="92.96800611569871"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.964367583450777" CI_START="0.6383432814523412" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.119795003203075" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-044.21" LOG_CI_END="0.2932227586683773" LOG_CI_START="-0.19494570819644386" LOG_EFFECT_SIZE="0.04913852523596675" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.6931559527858859" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.39457583294734416">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.964367583450777" CI_START="0.6383432814523412" DF="0" EFFECT_SIZE="1.119795003203075" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" ID="CMP-044.21.01" LOG_CI_END="0.2932227586683773" LOG_CI_START="-0.19494570819644386" LOG_EFFECT_SIZE="0.04913852523596675" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6931559527858859" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.39457583294734416">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.964367583450777" CI_START="0.6383432814523412" EFFECT_SIZE="1.119795003203075" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2932227586683773" LOG_CI_START="-0.19494570819644386" LOG_EFFECT_SIZE="0.04913852523596675" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7770" O_E="0.0" SE="0.28675257390927933" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0822270386435967" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.010082758644336E-32" CI_END="16.923408122287505" CI_START="0.2227910364916131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9417475728155338" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="100.0" I2_Q="0.0" ID="CMP-044.22" LOG_CI_END="1.2284878279497644" LOG_CI_START="-0.6521022860321465" LOG_EFFECT_SIZE="0.28819277095880896" METHOD="MH" MODIFIED="2013-03-18 11:57:45 -0400" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.0" P_Q="1.0" P_Z="0.5480311711870542" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.6007129862956406">
<NAME>Paraesthesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.010082758644336E-32" CI_END="16.923408122287505" CI_START="0.2227910364916131" DF="0" EFFECT_SIZE="1.9417475728155338" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="100.0" ID="CMP-044.22.01" LOG_CI_END="1.2284878279497644" LOG_CI_START="-0.6521022860321465" LOG_EFFECT_SIZE="0.28819277095880896" MODIFIED="2012-02-21 14:50:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5480311711870542" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.6007129862956406">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="16.923408122287505" CI_START="0.2227910364916131" EFFECT_SIZE="1.941747572815534" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2284878279497644" LOG_CI_START="-0.6521022860321465" LOG_EFFECT_SIZE="0.288192770958809" MODIFIED="2012-02-17 15:32:23 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="1.1046679420241734" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="1.2202912621359223" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.285744240451969" CI_START="1.2275637723665695" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.883495145631068" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-044.23" LOG_CI_END="1.089401470114543" LOG_CI_START="0.08904406313103747" LOG_EFFECT_SIZE="0.5892227666227902" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.020949930763343363" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="2.3088855910690733">
<NAME>Pharyngitis or laryngitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.285744240451969" CI_START="1.2275637723665695" DF="0" EFFECT_SIZE="3.883495145631068" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" I2="0.0" ID="CMP-044.23.01" LOG_CI_END="1.089401470114543" LOG_CI_START="0.08904406313103747" LOG_EFFECT_SIZE="0.5892227666227902" MODIFIED="2012-02-21 14:50:48 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.020949930763343363" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="2.3088855910690733">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="12.285744240451969" CI_START="1.2275637723665695" EFFECT_SIZE="3.883495145631068" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" LOG_CI_END="1.089401470114543" LOG_CI_START="0.08904406313103747" LOG_EFFECT_SIZE="0.5892227666227902" MODIFIED="2012-02-17 15:43:18 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.5876148927111381" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.3452912621359223" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5983644059011293" CI_END="3.949112764980879" CI_START="0.3352678805817959" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1506566242340306" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="72.20959616096546" I2_Q="0.0" ID="CMP-044.24" LOG_CI_END="0.5964995349798305" LOG_CI_START="-0.4746080509679982" LOG_EFFECT_SIZE="0.06094574200591618" METHOD="MH" MODIFIED="2012-04-26 16:30:59 -0400" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.05783661934531037" P_Q="1.0" P_Z="0.8235021352523858" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.589846369378427" TOTALS="YES" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.22304287806338793">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5983644059011293" CI_END="3.949112764980879" CI_START="0.3352678805817959" DF="1" EFFECT_SIZE="1.1506566242340306" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="72.20959616096546" ID="CMP-044.24.01" LOG_CI_END="0.5964995349798305" LOG_CI_START="-0.4746080509679982" LOG_EFFECT_SIZE="0.06094574200591618" MODIFIED="2012-02-21 14:50:49 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05783661934531037" P_Z="0.8235021352523858" STUDIES="2" TAU2="0.589846369378427" TOTAL_1="326" TOTAL_2="278" WEIGHT="100.0" Z="0.22304287806338793">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.999672734458156" CI_START="0.7364331801612125" EFFECT_SIZE="2.4271844660194173" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.9030722204261745" LOG_CI_START="-0.13286665249244392" LOG_EFFECT_SIZE="0.38510278396686537" MODIFIED="2012-01-31 14:42:27 -0500" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.6085156219325205" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.3702912621359223" WEIGHT="41.22948429465002"/>
<DICH_DATA CI_END="1.2018002051448942" CI_START="0.3865851576920407" EFFECT_SIZE="0.6816143497757847" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" LOG_CI_END="0.07983227381042665" LOG_CI_START="-0.4127548240172029" LOG_EFFECT_SIZE="-0.16646127510338815" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7766" O_E="0.0" SE="0.289348099609409" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.08372232274757646" WEIGHT="58.77051570534997"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="32.98323982098489" CI_START="2.064762430996391" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.25242718446602" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-044.25" LOG_CI_END="1.5182933125356028" LOG_CI_START="0.314870089482638" LOG_EFFECT_SIZE="0.9165817010091206" METHOD="MH" MODIFIED="2013-03-18 11:57:56 -0400" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.0028302729691580203" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="2.9855949070167984">
<NAME>Rheumatoid arthritis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="32.98323982098489" CI_START="2.064762430996391" DF="0" EFFECT_SIZE="8.25242718446602" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" I2="0.0" ID="CMP-044.25.01" LOG_CI_END="1.5182933125356028" LOG_CI_START="0.314870089482638" LOG_EFFECT_SIZE="0.9165817010091206" MODIFIED="2012-02-21 14:50:51 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0028302729691580203" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="99.99999999999999" Z="2.9855949070167984">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="32.98323982098489" CI_START="2.064762430996391" EFFECT_SIZE="8.25242718446602" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="2" LOG_CI_END="1.5182933125356028" LOG_CI_START="0.314870089482638" LOG_EFFECT_SIZE="0.9165817010091206" MODIFIED="2012-02-17 15:30:51 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.7068967582623397" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.4997030268418047" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9304369568529265" CI_START="0.47171305726152113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9542600896860987" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-044.26" LOG_CI_END="0.28565562324162197" LOG_CI_START="-0.32632210209192214" LOG_EFFECT_SIZE="-0.0203332394251501" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.8963754433907714" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.13024139707242935">
<NAME>Serious infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9304369568529265" CI_START="0.47171305726152113" DF="0" EFFECT_SIZE="0.9542600896860987" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-044.26.01" LOG_CI_END="0.28565562324162197" LOG_CI_START="-0.32632210209192214" LOG_EFFECT_SIZE="-0.0203332394251501" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8963754433907714" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="0.13024139707242935">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.930436956852926" CI_START="0.4717130572615212" EFFECT_SIZE="0.9542600896860987" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.2856556232416219" LOG_CI_START="-0.32632210209192214" LOG_EFFECT_SIZE="-0.0203332394251501" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7772" O_E="0.0" SE="0.3594787451995207" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.12922496825022195" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="202.97514462691782" CI_START="0.7404757348736293" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.259615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-044.27" LOG_CI_END="2.3074428595276313" LOG_CI_START="-0.13048916858524442" LOG_EFFECT_SIZE="1.0884768454711937" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.0800921444300257" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.7501516781669144">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="202.97514462691782" CI_START="0.7404757348736293" DF="0" EFFECT_SIZE="12.259615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="0.0" ID="CMP-044.27.01" LOG_CI_END="2.3074428595276313" LOG_CI_START="-0.13048916858524442" LOG_EFFECT_SIZE="1.0884768454711937" MODIFIED="2012-02-21 14:50:53 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0800921444300257" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.7501516781669144">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="202.975144626918" CI_START="0.7404757348736288" EFFECT_SIZE="12.259615384615385" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.3074428595276317" LOG_CI_START="-0.1304891685852447" LOG_EFFECT_SIZE="1.0884768454711937" MODIFIED="2012-01-31 14:38:27 -0500" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="1.4320533412716723" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="2.0507767722473607" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.654939526961294" CI_START="0.7464606552534148" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4077669902912622" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-044.28" LOG_CI_END="0.4240546333624534" LOG_CI_START="-0.12699307830284806" LOG_EFFECT_SIZE="0.1485307775298027" METHOD="MH" MODIFIED="2013-03-18 11:58:10 -0400" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.2907000482975557" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.0565871825304431">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.654939526961294" CI_START="0.7464606552534148" DF="0" EFFECT_SIZE="1.4077669902912622" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" I2="0.0" ID="CMP-044.28.01" LOG_CI_END="0.4240546333624534" LOG_CI_START="-0.12699307830284806" LOG_EFFECT_SIZE="0.1485307775298027" MODIFIED="2012-02-21 14:50:57 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2907000482975557" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="50" WEIGHT="100.0" Z="1.0565871825304431">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.654939526961294" CI_START="0.7464606552534148" EFFECT_SIZE="1.4077669902912622" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.4240546333624534" LOG_CI_START="-0.12699307830284806" LOG_EFFECT_SIZE="0.1485307775298027" MODIFIED="2012-01-31 14:37:37 -0500" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.32368815356236313" STUDY_ID="STD-Combe-2006" TOTAL_1="103" TOTAL_2="50" VAR="0.10477402075661198" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6342409243958722" CI_START="0.1609554734248045" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3195067264573991" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-044.29" LOG_CI_END="-0.19774573855320468" LOG_CI_START="-0.793294250182021" LOG_EFFECT_SIZE="-0.4955199943676129" METHOD="MH" MODIFIED="2012-02-22 15:42:18 -0500" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.0011081050895270779" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="3.261535621754106">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DMARD alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6342409243958722" CI_START="0.1609554734248045" DF="0" EFFECT_SIZE="0.3195067264573991" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="32" I2="0.0" ID="CMP-044.29.01" LOG_CI_END="-0.19774573855320468" LOG_CI_START="-0.793294250182021" LOG_EFFECT_SIZE="-0.4955199943676129" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0011081050895270779" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="100.0" Z="3.261535621754106">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.6342409243958722" CI_START="0.1609554734248045" EFFECT_SIZE="0.3195067264573991" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="32" LOG_CI_END="-0.19774573855320468" LOG_CI_START="-0.793294250182021" LOG_EFFECT_SIZE="-0.4955199943676129" MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]" ORDER="7767" O_E="0.0" SE="0.34982814374344423" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.12237973015498387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-045" MODIFIED="2013-03-18 12:03:43 -0400" MODIFIED_BY="[Empty name]" NO="45">
<NAME>Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="2.3675743511753833" CI_END="1.1118215396241622" CI_START="0.7270753830979696" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8990984772864494" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="129" I2="57.762678096949756" I2_Q="0.0" ID="CMP-045.01" LOG_CI_END="0.04603508349036391" LOG_CI_START="-0.1384205592011298" LOG_EFFECT_SIZE="-0.046192737855382984" METHOD="MH" MODIFIED="2013-03-18 12:03:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12387957313361875" P_Q="1.0" P_Z="0.32626878269218207" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013681683288351388" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="99.99999999999999" Z="0.9816571748393113">
<NAME>Total</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3675743511753833" CI_END="1.1118215396241622" CI_START="0.7270753830979696" DF="1" EFFECT_SIZE="0.8990984772864494" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="129" I2="57.762678096949756" ID="CMP-045.01.01" LOG_CI_END="0.04603508349036391" LOG_CI_START="-0.1384205592011298" LOG_EFFECT_SIZE="-0.046192737855382984" MODIFIED="2013-03-18 12:03:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12387957313361875" P_Z="0.32626878269218207" STUDIES="2" TAU2="0.013681683288351388" TOTAL_1="177" TOTAL_2="174" WEIGHT="99.99999999999999" Z="0.9816571748393113">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1796614907215697" CI_START="0.8345951427866969" EFFECT_SIZE="0.9922397645169923" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="74" LOG_CI_END="0.07175740238861335" LOG_CI_START="-0.07852414714296958" LOG_EFFECT_SIZE="-0.003383372377178096" MODIFIED="2012-02-17 11:22:34 -0500" MODIFIED_BY="[Empty name]" ORDER="534" O_E="0.0" SE="0.08827612610051956" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.0077926744393148305" WEIGHT="54.66872070419792"/>
<DICH_DATA CI_END="0.9914250462143006" CI_START="0.6428356647022765" EFFECT_SIZE="0.7983253588516747" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="55" LOG_CI_END="-0.0037401137794005317" LOG_CI_START="-0.19190003646108433" LOG_EFFECT_SIZE="-0.09782007512024243" MODIFIED="2012-01-31 08:33:18 -0500" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="0.11052606998985987" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.012216012147403402" WEIGHT="45.33127929580206"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.992201556483053" CI_START="0.963585537852745" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.399339933993399" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-045.02" LOG_CI_END="1.0788989192175384" LOG_CI_START="-0.016109726811803983" LOG_EFFECT_SIZE="0.5313945962028671" METHOD="MH" MODIFIED="2012-02-22 15:42:58 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.05713271020715851" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.9022941488425762">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.992201556483053" CI_START="0.963585537852745" DF="0" EFFECT_SIZE="3.399339933993399" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-045.02.01" LOG_CI_END="1.0788989192175384" LOG_CI_START="-0.016109726811803983" LOG_EFFECT_SIZE="0.5313945962028671" MODIFIED="2012-01-31 12:26:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05713271020715851" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.9022941488425762">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="11.992201556483053" CI_START="0.963585537852745" EFFECT_SIZE="3.3993399339933994" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0788989192175384" LOG_CI_START="-0.016109726811803983" LOG_EFFECT_SIZE="0.5313945962028672" MODIFIED="2012-01-31 12:26:31 -0500" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="0.6432134990578523" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.4137236053702458" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.086262364345818" CI_END="29.432593164296485" CI_START="0.04641523158875761" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1688116306653118" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="67.59834771169996" I2_Q="0.0" ID="CMP-045.03" LOG_CI_END="1.4688285273843977" LOG_CI_START="-1.3333394782933232" LOG_EFFECT_SIZE="0.06774452454553721" METHOD="MH" MODIFIED="2013-03-18 12:03:32 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07895623669322238" P_Q="1.0" P_Z="0.9244997286653307" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.706781645814474" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.09476721452105068">
<NAME>Blood and lymphatic system disorders/leukopenia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.086262364345818" CI_END="29.432593164296485" CI_START="0.04641523158875761" DF="1" EFFECT_SIZE="1.1688116306653118" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="67.59834771169996" ID="CMP-045.03.01" LOG_CI_END="1.4688285273843977" LOG_CI_START="-1.3333394782933232" LOG_EFFECT_SIZE="0.06774452454553721" MODIFIED="2013-03-18 12:03:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07895623669322238" P_Z="0.9244997286653307" STUDIES="2" TAU2="3.706781645814474" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.09476721452105068">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="42.88252030298918" CI_START="0.6063053614081237" EFFECT_SIZE="5.099009900990099" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6322803019066257" LOG_CI_START="-0.2173085913895289" LOG_EFFECT_SIZE="0.7074858552585485" MODIFIED="2012-02-17 11:56:24 -0500" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="1.0864576715348429" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="1.1803902720369124" WEIGHT="55.43779237673656"/>
<DICH_DATA CI_END="3.8295106520970106" CI_START="0.009132722295045251" EFFECT_SIZE="0.18701298701298702" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5831432818872245" LOG_CI_START="-2.039399748041689" LOG_EFFECT_SIZE="-0.7281282330772322" MODIFIED="2012-01-31 08:35:55 -0500" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="1.5404947575776096" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="2.373124098124098" WEIGHT="44.56220762326344"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.259810439675414" CI_START="0.44488127550846823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5297029702970297" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-045.04" LOG_CI_END="0.7209700927304674" LOG_CI_START="-0.3517558727740457" LOG_EFFECT_SIZE="0.1846071099782109" METHOD="MH" MODIFIED="2012-02-23 17:14:46 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4999384462029203" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.6745866110869224">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.259810439675414" CI_START="0.44488127550846823" DF="0" EFFECT_SIZE="1.5297029702970297" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-045.04.01" LOG_CI_END="0.7209700927304674" LOG_CI_START="-0.3517558727740457" LOG_EFFECT_SIZE="0.1846071099782109" MODIFIED="2012-02-17 11:51:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4999384462029203" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.6745866110869224">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="5.259810439675414" CI_START="0.44488127550846823" EFFECT_SIZE="1.5297029702970297" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7209700927304674" LOG_CI_START="-0.3517558727740457" LOG_EFFECT_SIZE="0.1846071099782109" MODIFIED="2012-02-17 11:51:26 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.6301245422165201" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.39705693870357905" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="104.88977285659773" CI_START="0.24778396536531633" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.098039215686274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-045.05" LOG_CI_END="2.0207331449287906" LOG_CI_START="-0.6059268011830278" LOG_EFFECT_SIZE="0.7074031718728816" METHOD="MH" MODIFIED="2012-02-23 17:14:49 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.291104516902711" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.0557017412723149">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="104.88977285659773" CI_START="0.24778396536531633" DF="0" EFFECT_SIZE="5.098039215686274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-045.05.01" LOG_CI_END="2.0207331449287906" LOG_CI_START="-0.6059268011830278" LOG_EFFECT_SIZE="0.7074031718728816" MODIFIED="2012-02-17 11:49:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.291104516902711" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.0557017412723149">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="104.88977285659783" CI_START="0.24778396536531622" EFFECT_SIZE="5.098039215686274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.020733144928791" LOG_CI_START="-0.605926801183028" LOG_EFFECT_SIZE="0.7074031718728816" MODIFIED="2012-02-17 11:49:29 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.542913054522512" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="2.380580693815988" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.882729593911261" CI_START="0.21577632263349367" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6373762376237624" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-045.06" LOG_CI_END="0.27478794916953647" LOG_CI_START="-0.6659962126363268" LOG_EFFECT_SIZE="-0.19560413173339514" METHOD="MH" MODIFIED="2013-03-13 04:36:21 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.4150631820807942" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.8150159600662901">
<NAME>Flu syndrome</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.882729593911261" CI_START="0.21577632263349367" DF="0" EFFECT_SIZE="0.6373762376237624" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-045.06.01" LOG_CI_END="0.27478794916953647" LOG_CI_START="-0.6659962126363268" LOG_EFFECT_SIZE="-0.19560413173339514" MODIFIED="2012-02-17 11:58:28 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4150631820807942" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.8150159600662901">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.882729593911261" CI_START="0.21577632263349367" EFFECT_SIZE="0.6373762376237624" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27478794916953647" LOG_CI_START="-0.6659962126363268" LOG_EFFECT_SIZE="-0.19560413173339514" MODIFIED="2012-02-17 11:58:28 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.5526212736014715" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.30539027203691244" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.003048329820637268" CI_END="2.293675420098175" CI_START="0.629205663632586" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.201329915077712" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-045.07" LOG_CI_END="0.36053196054269326" LOG_CI_START="-0.20120737684132944" LOG_EFFECT_SIZE="0.0796622918506819" METHOD="MH" MODIFIED="2013-03-18 11:59:06 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9559698495651422" P_Q="1.0" P_Z="0.5782797705677466" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.5558991958098041">
<NAME>Gastrointestinal symptoms/abdominal pain/dyspepsia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.003048329820637268" CI_END="2.293675420098175" CI_START="0.629205663632586" DF="1" EFFECT_SIZE="1.201329915077712" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" ID="CMP-045.07.01" LOG_CI_END="0.36053196054269326" LOG_CI_START="-0.20120737684132944" LOG_EFFECT_SIZE="0.0796622918506819" MODIFIED="2013-03-18 11:59:06 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9559698495651422" P_Z="0.5782797705677466" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.5558991958098041">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.4456273386106795" CI_START="0.5788086336949138" EFFECT_SIZE="1.1897689768976898" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3883902805354184" LOG_CI_START="-0.23746499942913268" LOG_EFFECT_SIZE="0.07546264055314283" MODIFIED="2012-02-17 11:52:01 -0500" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="0.3676304894847776" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.1351521767988172" WEIGHT="79.29818939272552"/>
<DICH_DATA CI_END="5.372015931765553" CI_START="0.2888216163382785" EFFECT_SIZE="1.2456140350877194" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7301372919839463" LOG_CI_START="-0.5393703058907784" LOG_EFFECT_SIZE="0.09538349304658392" MODIFIED="2012-01-31 08:38:26 -0500" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.7457150471555725" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.5560909315542376" WEIGHT="20.701810607274474"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.104483127268258" CI_START="1.1549119866570865" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0594059405940595" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-045.08" LOG_CI_END="0.9087253224376906" LOG_CI_START="0.06254888884669361" LOG_EFFECT_SIZE="0.4856371056421921" METHOD="MH" MODIFIED="2012-02-23 17:14:57 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.02446654292575196" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="2.249722868257146">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.104483127268258" CI_START="1.1549119866570865" DF="0" EFFECT_SIZE="3.0594059405940595" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-045.08.01" LOG_CI_END="0.9087253224376906" LOG_CI_START="0.06254888884669361" LOG_EFFECT_SIZE="0.4856371056421921" MODIFIED="2012-02-21 14:49:45 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02446654292575196" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="2.249722868257146">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.104483127268255" CI_START="1.1549119866570865" EFFECT_SIZE="3.0594059405940595" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9087253224376903" LOG_CI_START="0.06254888884669361" LOG_EFFECT_SIZE="0.4856371056421921" MODIFIED="2012-01-31 12:00:44 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.4970482257322513" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.2470569387035791" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.159015621140444" CI_START="0.17317300088085374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-045.09" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" METHOD="MH" MODIFIED="2013-03-18 11:59:17 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.6064931329171046" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.5150857058238162">
<NAME>Hepatobiliary disorders</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.159015621140444" CI_START="0.17317300088085374" DF="0" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-045.09.01" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" MODIFIED="2013-03-18 11:59:17 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6064931329171046" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.5150857058238162">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="20.159015621140444" CI_START="0.17317300088085374" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" MODIFIED="2012-01-31 08:39:21 -0500" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="1.2135722468072943" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="1.4727575982209045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.934421555885284" CI_START="0.5242958526923213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-045.10" LOG_CI_END="0.8995152708206628" LOG_CI_START="-0.28042357764764114" LOG_EFFECT_SIZE="0.30954584658651085" METHOD="MH" MODIFIED="2012-02-23 17:15:02 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.30378232173064457" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.02835619262996">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.934421555885284" CI_START="0.5242958526923213" DF="0" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-045.10.01" LOG_CI_END="0.8995152708206628" LOG_CI_START="-0.28042357764764114" LOG_EFFECT_SIZE="0.30954584658651085" MODIFIED="2012-02-17 11:55:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30378232173064457" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.02835619262996">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.934421555885284" CI_START="0.5242958526923213" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8995152708206628" LOG_CI_START="-0.28042357764764114" LOG_EFFECT_SIZE="0.30954584658651085" MODIFIED="2012-02-17 11:55:31 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.6931019203817808" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.4803902720369124" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.934421555885284" CI_START="0.5242958526923213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-045.11" LOG_CI_END="0.8995152708206628" LOG_CI_START="-0.28042357764764114" LOG_EFFECT_SIZE="0.30954584658651085" METHOD="MH" MODIFIED="2012-02-23 17:15:02 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.30378232173064457" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.02835619262996">
<NAME>Increased cough</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.934421555885284" CI_START="0.5242958526923213" DF="0" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-045.11.01" LOG_CI_END="0.8995152708206628" LOG_CI_START="-0.28042357764764114" LOG_EFFECT_SIZE="0.30954584658651085" MODIFIED="2012-02-17 11:31:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30378232173064457" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.02835619262996">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.934421555885284" CI_START="0.5242958526923213" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8995152708206628" LOG_CI_START="-0.28042357764764114" LOG_EFFECT_SIZE="0.30954584658651085" MODIFIED="2012-02-17 11:31:26 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.6931019203817808" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.4803902720369124" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4563734042122796" CI_END="1.0312553727733411" CI_START="0.5786049179180673" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7724567498029161" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" I2="31.336290740568824" I2_Q="0.0" ID="CMP-045.12" LOG_CI_END="0.013366224209846919" LOG_CI_START="-0.23761787933718517" LOG_EFFECT_SIZE="-0.11212582756366914" METHOD="MH" MODIFIED="2013-03-18 11:59:38 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.2275083281793544" P_Q="1.0" P_Z="0.07991022686275842" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="1.751207193250457">
<NAME>Infection and infestations/total infectious adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4563734042122796" CI_END="1.0312553727733411" CI_START="0.5786049179180673" DF="1" EFFECT_SIZE="0.7724567498029161" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" I2="31.336290740568824" ID="CMP-045.12.01" LOG_CI_END="0.013366224209846919" LOG_CI_START="-0.23761787933718517" LOG_EFFECT_SIZE="-0.11212582756366914" MODIFIED="2013-03-18 11:59:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2275083281793544" P_Z="0.07991022686275842" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="1.751207193250457">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9650729287155589" CI_START="0.468812562014245" EFFECT_SIZE="0.6726353486412471" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="47" LOG_CI_END="-0.015439866612691575" LOG_CI_START="-0.32900075974513876" LOG_EFFECT_SIZE="-0.17222031317891517" MODIFIED="2012-02-17 11:34:57 -0500" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.18418722077745325" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.03392493229772231" WEIGHT="67.16825633339975"/>
<DICH_DATA CI_END="1.589159714834968" CI_START="0.600250148400767" EFFECT_SIZE="0.9766746411483254" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.20116754716697055" LOG_CI_START="-0.22166772389962938" LOG_EFFECT_SIZE="-0.010250088366329421" MODIFIED="2012-01-31 08:40:05 -0500" MODIFIED_BY="[Empty name]" ORDER="427" O_E="0.0" SE="0.24837553129286918" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.061690404545015044" WEIGHT="32.831743666600254"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05262884714571507" CI_END="0.8207002477232015" CI_START="0.3654317348157279" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.547640315617091" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-045.13" LOG_CI_END="-0.08581543548767946" LOG_CI_START="-0.43719374035267" LOG_EFFECT_SIZE="-0.2615045879201748" METHOD="MH" MODIFIED="2013-03-18 11:59:58 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.8185504369819327" P_Q="1.0" P_Z="0.0035306562688374806" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.00000000000001" Z="2.917309162342637">
<NAME>Injection site reaction/injection site haemorrhage/general disorders and administration site conditions</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05262884714571507" CI_END="0.8207002477232015" CI_START="0.3654317348157279" DF="1" EFFECT_SIZE="0.547640315617091" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="51" I2="0.0" ID="CMP-045.13.01" LOG_CI_END="-0.08581543548767946" LOG_CI_START="-0.43719374035267" LOG_EFFECT_SIZE="-0.2615045879201748" MODIFIED="2013-03-18 11:59:58 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8185504369819327" P_Z="0.0035306562688374806" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.00000000000001" Z="2.917309162342637">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8899128032398345" CI_START="0.3569074743495809" EFFECT_SIZE="0.5635747785304847" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="38" LOG_CI_END="-0.0506525449584479" LOG_CI_START="-0.4474443569622745" LOG_EFFECT_SIZE="-0.24904845096036124" MODIFIED="2012-02-17 11:38:00 -0500" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.23307747452219457" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.054325109129644264" WEIGHT="73.67872562155725"/>
<DICH_DATA CI_END="1.1887739741624754" CI_START="0.2128627162925535" EFFECT_SIZE="0.5030364372469636" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.0750992885082313" LOG_CI_START="-0.6719004002168233" LOG_EFFECT_SIZE="-0.298400555854296" MODIFIED="2012-01-31 08:38:14 -0500" MODIFIED_BY="[Empty name]" ORDER="425" O_E="0.0" SE="0.43879131486519213" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.19253781800112416" WEIGHT="26.321274378442762"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8639502090243593" CI_END="2.2111134098040957" CI_START="0.22881403962417335" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7112902300499111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-045.14" LOG_CI_END="0.3446110184669867" LOG_CI_START="-0.6405173315213126" LOG_EFFECT_SIZE="-0.14795315652716293" METHOD="MH" MODIFIED="2013-03-18 12:00:17 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.3526356994924841" P_Q="1.0" P_Z="0.5560484723215773" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.5887209685838416">
<NAME>Injury, poisoning and procedural complications/accidental Injury</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8639502090243593" CI_END="2.2111134098040957" CI_START="0.22881403962417335" DF="1" EFFECT_SIZE="0.7112902300499111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-045.14.01" LOG_CI_END="0.3446110184669867" LOG_CI_START="-0.6405173315213126" LOG_EFFECT_SIZE="-0.14795315652716293" MODIFIED="2013-03-18 12:00:17 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3526356994924841" P_Z="0.5560484723215773" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.5887209685838416">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.983605388971321" CI_START="0.1310739631730803" EFFECT_SIZE="0.5099009900990099" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2974552794927004" LOG_CI_START="-0.8824835689756036" LOG_EFFECT_SIZE="-0.29251414474145154" MODIFIED="2012-02-17 11:54:37 -0500" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="0.6931019203817808" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.4803902720369124" WEIGHT="85.17583615397854"/>
<DICH_DATA CI_END="20.159015621140444" CI_START="0.17317300088085374" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" MODIFIED="2012-01-31 08:40:48 -0500" MODIFIED_BY="[Empty name]" ORDER="428" O_E="0.0" SE="1.2135722468072943" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="1.4727575982209045" WEIGHT="14.824163846021456"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-045.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-03-18 12:00:28 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Malignancy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-045.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-03-18 12:00:28 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-31 08:48:03 -0500" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.0" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.75588518647855" CI_START="0.11613925304694112" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8051948051948052" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-045.16" LOG_CI_END="1.8309470234284828" LOG_CI_START="-0.9350209714715847" LOG_EFFECT_SIZE="0.44796302597844906" METHOD="MH" MODIFIED="2013-03-18 12:00:57 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.5255243637778134" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.6348528970271488">
<NAME>Metabolism and nutrition disorders</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.75588518647855" CI_START="0.11613925304694112" DF="0" EFFECT_SIZE="2.8051948051948052" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-045.16.01" LOG_CI_END="1.8309470234284828" LOG_CI_START="-0.9350209714715847" LOG_EFFECT_SIZE="0.44796302597844906" MODIFIED="2013-03-18 12:00:57 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5255243637778134" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.6348528970271488">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="67.75588518647855" CI_START="0.11613925304694112" EFFECT_SIZE="2.8051948051948052" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8309470234284828" LOG_CI_START="-0.9350209714715847" LOG_EFFECT_SIZE="0.44796302597844906" MODIFIED="2012-01-31 08:41:16 -0500" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="1.6247432919666924" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="2.6397907647907646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.632354375741727" CI_START="0.1966401713066123" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5665566556655666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-045.17" LOG_CI_END="0.21281444775247577" LOG_CI_START="-0.7063277561140286" LOG_EFFECT_SIZE="-0.24675665418077644" METHOD="MH" MODIFIED="2012-02-22 15:42:58 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.2926345182054305" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.0523598048385765">
<NAME>Miscellaneous skin infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.632354375741727" CI_START="0.1966401713066123" DF="0" EFFECT_SIZE="0.5665566556655666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-045.17.01" LOG_CI_END="0.21281444775247577" LOG_CI_START="-0.7063277561140286" LOG_EFFECT_SIZE="-0.24675665418077644" MODIFIED="2012-02-17 12:00:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2926345182054305" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.0523598048385765">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.632354375741727" CI_START="0.1966401713066123" EFFECT_SIZE="0.5665566556655666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21281444775247577" LOG_CI_START="-0.7063277561140286" LOG_EFFECT_SIZE="-0.24675665418077644" MODIFIED="2012-02-17 12:00:06 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.5399086803784725" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.29150138314802354" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9186761018727134" CI_END="4.142831176544647" CI_START="0.3614519599504508" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.223697041144537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-045.18" LOG_CI_END="0.617297235835354" LOG_CI_START="-0.4419494159761962" LOG_EFFECT_SIZE="0.08767390992957885" METHOD="MH" MODIFIED="2013-03-18 12:01:25 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.337822964030441" P_Q="1.0" P_Z="0.7455953448595594" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.32445267691316665">
<NAME>Musculoskeletal and connective tissue disorders/arthralgia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9186761018727134" CI_END="4.142831176544647" CI_START="0.3614519599504508" DF="1" EFFECT_SIZE="1.223697041144537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-045.18.01" LOG_CI_END="0.617297235835354" LOG_CI_START="-0.4419494159761962" LOG_EFFECT_SIZE="0.08767390992957885" MODIFIED="2013-03-18 12:01:25 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.337822964030441" P_Z="0.7455953448595594" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.32445267691316665">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.9256282421851445" CI_START="0.4171286554357523" EFFECT_SIZE="1.6996699669966997" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.840459175532705" LOG_CI_START="-0.37972997445493306" LOG_EFFECT_SIZE="0.230364600538886" MODIFIED="2012-02-17 11:32:13 -0500" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.7167451467364434" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.5137236053702458" WEIGHT="65.7075492293586"/>
<DICH_DATA CI_END="7.528431687386508" CI_START="0.012904361449660126" EFFECT_SIZE="0.3116883116883117" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.876704513989158" LOG_CI_START="-1.8892634809109095" LOG_EFFECT_SIZE="-0.5062794834608758" MODIFIED="2012-01-31 08:42:44 -0500" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="1.6247432919666924" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="2.6397907647907646" WEIGHT="34.2924507706414"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.026161172467772" CI_START="1.186350068022582" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.079207920792079" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-045.19" LOG_CI_END="1.1469388250027486" LOG_CI_START="0.07421285949823549" LOG_EFFECT_SIZE="0.610575842250492" METHOD="MH" MODIFIED="2012-02-22 15:42:58 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.02567114633281889" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="2.2311507302395754">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.026161172467772" CI_START="1.186350068022582" DF="0" EFFECT_SIZE="4.079207920792079" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-045.19.01" LOG_CI_END="1.1469388250027486" LOG_CI_START="0.07421285949823549" LOG_EFFECT_SIZE="0.610575842250492" MODIFIED="2012-01-31 12:04:19 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02567114633281889" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="2.2311507302395754">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="14.026161172467772" CI_START="1.186350068022582" EFFECT_SIZE="4.079207920792079" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.1469388250027486" LOG_CI_START="0.07421285949823549" LOG_EFFECT_SIZE="0.610575842250492" MODIFIED="2012-01-31 12:04:19 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.6301245422165201" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.39705693870357905" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8720346888863162" CI_END="6.399155384788685" CI_START="0.6088165897701894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.973806464366907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-045.20" LOG_CI_END="0.80612265586951" LOG_CI_START="-0.21551352189535936" LOG_EFFECT_SIZE="0.2953045669870753" METHOD="MH" MODIFIED="2013-03-18 12:01:45 -0400" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.35039273203991794" P_Q="1.0" P_Z="0.2571900858274603" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="99.99999999999999" Z="1.1330575959655802">
<NAME>Nervous system disorders/paraesthesia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8720346888863162" CI_END="6.399155384788685" CI_START="0.6088165897701894" DF="1" EFFECT_SIZE="1.973806464366907" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-045.20.01" LOG_CI_END="0.80612265586951" LOG_CI_START="-0.21551352189535936" LOG_EFFECT_SIZE="0.2953045669870753" MODIFIED="2013-03-18 12:01:45 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35039273203991794" P_Z="0.2571900858274603" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="99.99999999999999" Z="1.1330575959655802">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="14.802748002929992" CI_START="0.6323126427261714" EFFECT_SIZE="3.0594059405940595" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1703423459169657" LOG_CI_START="-0.19906813463258163" LOG_EFFECT_SIZE="0.4856371056421921" MODIFIED="2012-02-17 11:57:16 -0500" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.8043984949660081" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.647056938703579" WEIGHT="48.91766333893446"/>
<DICH_DATA CI_END="6.4561238562541385" CI_START="0.13518162397609204" EFFECT_SIZE="0.9342105263157895" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8099718534320678" LOG_CI_START="-0.8690823405555" LOG_EFFECT_SIZE="-0.029555243561716057" MODIFIED="2012-01-31 08:43:26 -0500" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.9862847450006029" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.9727575982209044" WEIGHT="51.082336661065526"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7223700111250513" CI_START="0.09550465904394198" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5099009900990099" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-045.21" LOG_CI_END="0.43494715204622975" LOG_CI_START="-1.0199754415291329" LOG_EFFECT_SIZE="-0.29251414474145154" METHOD="MH" MODIFIED="2012-02-22 15:42:58 -0500" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.4306342498028196" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.7881067916512284">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7223700111250513" CI_START="0.09550465904394198" DF="0" EFFECT_SIZE="0.5099009900990099" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-045.21.01" LOG_CI_END="0.43494715204622975" LOG_CI_START="-1.0199754415291329" LOG_EFFECT_SIZE="-0.29251414474145154" MODIFIED="2012-02-17 11:48:52 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4306342498028196" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.7881067916512284">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.7223700111250513" CI_START="0.09550465904394198" EFFECT_SIZE="0.5099009900990099" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43494715204622975" LOG_CI_START="-1.0199754415291329" LOG_EFFECT_SIZE="-0.29251414474145154" MODIFIED="2012-02-17 11:48:52 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.8546287334491582" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.7303902720369124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.951408066091805" CI_START="0.22551862552963886" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8158415841584158" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-045.22" LOG_CI_END="0.4700292598557535" LOG_CI_START="-0.6468175840268071" LOG_EFFECT_SIZE="-0.0883941620855268" METHOD="MH" MODIFIED="2012-02-22 15:42:58 -0500" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.7563728833460651" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.3102473272502637">
<NAME>Pharyngitis (non-infectious)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.951408066091805" CI_START="0.22551862552963886" DF="0" EFFECT_SIZE="0.8158415841584158" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-045.22.01" LOG_CI_END="0.4700292598557535" LOG_CI_START="-0.6468175840268071" LOG_EFFECT_SIZE="-0.0883941620855268" MODIFIED="2012-02-17 11:44:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7563728833460651" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.3102473272502637">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.951408066091805" CI_START="0.22551862552963886" EFFECT_SIZE="0.8158415841584158" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4700292598557535" LOG_CI_START="-0.6468175840268071" LOG_EFFECT_SIZE="-0.0883941620855268" MODIFIED="2012-02-17 11:44:25 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.6560413645776556" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.43039027203691244" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.869525729678041E-31" CI_END="1.162601493712091" CI_START="0.15530246242666798" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42491749174917487" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="100.0" I2_Q="0.0" ID="CMP-045.23" LOG_CI_END="0.06543087660291012" LOG_CI_START="-0.808821658181063" LOG_EFFECT_SIZE="-0.37169539078907643" METHOD="MH" MODIFIED="2012-02-23 17:22:08 -0500" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="1.0" P_Z="0.09559627131366814" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.6665884288139807">
<NAME>Pharyngitis or laryngitis (infectious)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.869525729678041E-31" CI_END="1.162601493712091" CI_START="0.15530246242666798" DF="0" EFFECT_SIZE="0.42491749174917487" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="100.0" ID="CMP-045.23.01" LOG_CI_END="0.06543087660291012" LOG_CI_START="-0.808821658181063" LOG_EFFECT_SIZE="-0.37169539078907643" MODIFIED="2012-02-17 12:01:27 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.09559627131366814" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="1.6665884288139807">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1626014937120912" CI_START="0.15530246242666798" EFFECT_SIZE="0.4249174917491749" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.0654308766029102" LOG_CI_START="-0.808821658181063" LOG_EFFECT_SIZE="-0.3716953907890764" MODIFIED="2012-02-17 12:01:27 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.513540266551948" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.26372360537024575" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.75588518647855" CI_START="0.11613925304694112" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8051948051948052" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-045.24" LOG_CI_END="1.8309470234284828" LOG_CI_START="-0.9350209714715847" LOG_EFFECT_SIZE="0.44796302597844906" METHOD="MH" MODIFIED="2013-03-18 12:03:43 -0400" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.5255243637778134" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.6348528970271488">
<NAME>Reproductive system and breast disorders</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.75588518647855" CI_START="0.11613925304694112" DF="0" EFFECT_SIZE="2.8051948051948052" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-045.24.01" LOG_CI_END="1.8309470234284828" LOG_CI_START="-0.9350209714715847" LOG_EFFECT_SIZE="0.44796302597844906" MODIFIED="2013-03-18 12:03:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5255243637778134" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.6348528970271488">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="67.75588518647855" CI_START="0.11613925304694112" EFFECT_SIZE="2.8051948051948052" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8309470234284828" LOG_CI_START="-0.9350209714715847" LOG_EFFECT_SIZE="0.44796302597844906" MODIFIED="2012-01-31 08:44:13 -0500" MODIFIED_BY="[Empty name]" ORDER="432" O_E="0.0" SE="1.6247432919666924" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="2.6397907647907646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2760691849693052" CI_END="1.6107029931504886" CI_START="0.22182488128179578" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5977407466752123" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-045.25" LOG_CI_END="0.20701546572799423" LOG_CI_START="-0.6539897422385256" LOG_EFFECT_SIZE="-0.22348713825526564" METHOD="MH" MODIFIED="2013-03-18 12:02:05 -0400" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.5992893209180588" P_Q="1.0" P_Z="0.3089263128401425" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="1.017477566768161">
<NAME>Respiratory, thoracic and mediastinal disorders/bronchitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2760691849693052" CI_END="1.6107029931504886" CI_START="0.22182488128179578" DF="1" EFFECT_SIZE="0.5977407466752123" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-045.25.01" LOG_CI_END="0.20701546572799423" LOG_CI_START="-0.6539897422385256" LOG_EFFECT_SIZE="-0.22348713825526564" MODIFIED="2013-03-18 12:02:05 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5992893209180588" P_Z="0.3089263128401425" STUDIES="2" TAU2="0.0" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="1.017477566768161">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.6403117904642697" CI_START="0.15850585310391577" EFFECT_SIZE="0.5099009900990099" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21492640658920226" LOG_CI_START="-0.7999546960721053" LOG_EFFECT_SIZE="-0.29251414474145154" MODIFIED="2012-02-17 11:36:32 -0500" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.5961461834457321" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.3553902720369124" WEIGHT="79.29818939272552"/>
<DICH_DATA CI_END="6.4561238562541385" CI_START="0.13518162397609204" EFFECT_SIZE="0.9342105263157895" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8099718534320678" LOG_CI_START="-0.8690823405555" LOG_EFFECT_SIZE="-0.029555243561716057" MODIFIED="2012-01-31 08:45:14 -0500" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.9862847450006029" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.9727575982209044" WEIGHT="20.701810607274474"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.141841702888307" CI_START="0.18787887525727173" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-045.26" LOG_CI_END="1.3452137415714471" LOG_CI_START="-0.7261220483984255" LOG_EFFECT_SIZE="0.30954584658651085" METHOD="MH" MODIFIED="2012-02-22 15:42:58 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.5580070337349203" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.5858043044603083">
<NAME>Rhinitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.141841702888307" CI_START="0.18787887525727173" DF="0" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-045.26.01" LOG_CI_END="1.3452137415714471" LOG_CI_START="-0.7261220483984255" LOG_EFFECT_SIZE="0.30954584658651085" MODIFIED="2012-02-17 11:32:42 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5580070337349203" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.5858043044603083">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="22.141841702888307" CI_START="0.18787887525727173" EFFECT_SIZE="2.0396039603960396" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3452137415714471" LOG_CI_START="-0.7261220483984255" LOG_EFFECT_SIZE="0.30954584658651085" MODIFIED="2012-02-17 11:32:42 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.2167128963058262" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="1.4803902720369124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3697026596738624" CI_END="2.9650720154736865" CI_START="0.20285269720182547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.775546810796415" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="70.32379111761792" I2_Q="0.0" ID="CMP-045.27" LOG_CI_END="0.47203524594413193" LOG_CI_START="-0.6928192133869077" LOG_EFFECT_SIZE="-0.11039198372138778" METHOD="MH" MODIFIED="2013-03-18 12:02:27 -0400" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.06640582340218093" P_Q="1.0" P_Z="0.7102746228089593" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6742478971915734" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.37148728846367157">
<NAME>Skin and subcutaneous tissue disorders/rash/pruritus</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.3697026596738624" CI_END="2.9650720154736865" CI_START="0.20285269720182547" DF="1" EFFECT_SIZE="0.775546810796415" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="70.32379111761792" ID="CMP-045.27.01" LOG_CI_END="0.47203524594413193" LOG_CI_START="-0.6928192133869077" LOG_EFFECT_SIZE="-0.11039198372138778" MODIFIED="2013-03-18 12:02:27 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06640582340218093" P_Z="0.7102746228089593" STUDIES="2" TAU2="0.6742478971915734" TOTAL_1="177" TOTAL_2="174" WEIGHT="100.0" Z="0.37148728846367157">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.8799360375369707" CI_START="0.6714999850192389" EFFECT_SIZE="1.3906390639063906" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.4593828423240862" LOG_CI_START="-0.1729539926841146" LOG_EFFECT_SIZE="0.1432144248199858" MODIFIED="2012-02-17 11:28:23 -0500" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.3714377870016324" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.13796602961267002" WEIGHT="57.643203064248524"/>
<DICH_DATA CI_END="1.2686850073893479" CI_START="0.09673825311202808" EFFECT_SIZE="0.3503289473684211" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.10335380764732399" LOG_CI_START="-1.0144017593153183" LOG_EFFECT_SIZE="-0.4555239758339972" MODIFIED="2012-01-31 08:46:02 -0500" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.6565751530131473" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="0.4310909315542377" WEIGHT="42.35679693575147"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.159015621140444" CI_START="0.17317300088085374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-045.28" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" METHOD="MH" MODIFIED="2013-03-18 12:02:34 -0400" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.6064931329171046" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.5150857058238162">
<NAME>Total serious adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.159015621140444" CI_START="0.17317300088085374" DF="0" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-045.28.01" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" MODIFIED="2013-03-18 12:02:34 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6064931329171046" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="0.5150857058238162">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="20.159015621140444" CI_START="0.17317300088085374" EFFECT_SIZE="1.868421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3044693213873542" LOG_CI_START="-0.7615198171828238" LOG_EFFECT_SIZE="0.2714747521022651" MODIFIED="2012-01-31 08:34:08 -0500" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="1.2135722468072943" STUDY_ID="STD-Kameda-2010" TOTAL_1="76" TOTAL_2="71" VAR="1.4727575982209045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5246816065582096" CI_START="0.49843720970528144" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.121782178217822" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-045.29" LOG_CI_END="0.4022066160255067" LOG_CI_START="-0.3023895438639973" LOG_EFFECT_SIZE="0.04990853608075471" METHOD="MH" MODIFIED="2013-03-18 12:02:47 -0400" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.7812736997267159" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.27765956957454097">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5246816065582096" CI_START="0.49843720970528144" DF="0" EFFECT_SIZE="1.121782178217822" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-045.29.01" LOG_CI_END="0.4022066160255067" LOG_CI_START="-0.3023895438639973" LOG_EFFECT_SIZE="0.04990853608075471" MODIFIED="2012-02-21 14:49:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7812736997267159" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.27765956957454097">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.5246816065582096" CI_START="0.49843720970528144" EFFECT_SIZE="1.121782178217822" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.4022066160255067" LOG_CI_START="-0.3023895438639973" LOG_EFFECT_SIZE="0.04990853608075471" MODIFIED="2012-01-31 11:56:42 -0500" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="0.4138832721263368" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.17129936294600334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-046" MODIFIED="2013-03-18 12:09:57 -0400" MODIFIED_BY="[Empty name]" NO="46">
<NAME>Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0261417263443346" CI_START="0.8007912316065152" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9064906490649065" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-046.01" LOG_CI_END="0.011207347830875155" LOG_CI_START="-0.09648069088057848" LOG_EFFECT_SIZE="-0.04263667152485165" METHOD="MH" MODIFIED="2013-03-18 12:04:36 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12066034578135806" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="99.99999999999999" Z="1.5520078480264055">
<NAME>Total</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0261417263443346" CI_START="0.8007912316065152" DF="0" EFFECT_SIZE="0.9064906490649065" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="90" I2="0.0" ID="CMP-046.01.01" LOG_CI_END="0.011207347830875155" LOG_CI_START="-0.09648069088057848" LOG_EFFECT_SIZE="-0.04263667152485165" MODIFIED="2013-03-18 12:04:36 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12066034578135806" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="99.99999999999999" Z="1.5520078480264055">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0261417263443346" CI_START="0.8007912316065152" EFFECT_SIZE="0.9064906490649065" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="90" LOG_CI_END="0.011207347830875155" LOG_CI_START="-0.09648069088057848" LOG_EFFECT_SIZE="-0.04263667152485165" MODIFIED="2012-02-17 15:53:25 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.06325648700349665" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.00400138314802354" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8097444591778525" CI_END="1.6294440353607746" CI_START="0.8339286801448137" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1656929757780348" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-046.02" LOG_CI_END="0.21203944884449977" LOG_CI_START="-0.07887108982269601" LOG_EFFECT_SIZE="0.06658417951090188" METHOD="MH" MODIFIED="2013-03-18 12:04:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36819586881162125" P_Q="1.0" P_Z="0.3696117525145194" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="0.897200867176652">
<NAME>Abdominal pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8097444591778525" CI_END="1.6294440353607746" CI_START="0.8339286801448137" DF="1" EFFECT_SIZE="1.1656929757780348" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="52" I2="0.0" ID="CMP-046.02.01" LOG_CI_END="0.21203944884449977" LOG_CI_START="-0.07887108982269601" LOG_EFFECT_SIZE="0.06658417951090188" MODIFIED="2013-03-18 12:04:47 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.36819586881162125" P_Z="0.3696117525145194" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="0.897200867176652">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7967874324486626" CI_START="0.42524715944932434" EFFECT_SIZE="0.8741159830268741" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.254496701274192" LOG_CI_START="-0.37135857869035915" LOG_EFFECT_SIZE="-0.05843093870808357" MODIFIED="2012-02-17 15:56:39 -0500" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.3676304894847776" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.1351521767988172" WEIGHT="26.38896881941967"/>
<DICH_DATA CI_END="1.8566037009258864" CI_START="0.869039206363639" EFFECT_SIZE="1.2702210070631124" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="38" LOG_CI_END="0.2687192118342433" LOG_CI_START="-0.06096063008379329" LOG_EFFECT_SIZE="0.10387929087522503" MODIFIED="2008-07-11 13:38:12 -0400" MODIFIED_BY="Anne Lethaby" ORDER="731" O_E="0.0" SE="0.1936555710841918" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.03750248021194446" WEIGHT="73.61103118058034"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05126713434804893" CI_END="1.6453533467189387" CI_START="0.8037569309078031" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.149984415641228" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-046.03" LOG_CI_END="0.21625917891294055" LOG_CI_START="-0.09487526906985481" LOG_EFFECT_SIZE="0.060691954921542876" METHOD="MH" MODIFIED="2013-03-18 12:04:57 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8208728554266681" P_Q="1.0" P_Z="0.44448164759003006" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.7646472228888667">
<NAME>Accidental injury</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05126713434804893" CI_END="1.6453533467189387" CI_START="0.8037569309078031" DF="1" EFFECT_SIZE="1.149984415641228" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="47" I2="0.0" ID="CMP-046.03.01" LOG_CI_END="0.21625917891294055" LOG_CI_START="-0.09487526906985481" LOG_EFFECT_SIZE="0.060691954921542876" MODIFIED="2013-03-18 12:04:57 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.8208728554266681" P_Z="0.44448164759003006" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.7646472228888667">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.0244875188871565" CI_START="0.5799285312443029" EFFECT_SIZE="1.083539603960396" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.30631510365560793" LOG_CI_START="-0.2366255243658505" LOG_EFFECT_SIZE="0.03484478964487874" MODIFIED="2012-02-17 15:55:07 -0500" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="0.31892601249925845" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.10171380144867714" WEIGHT="33.43182162015358"/>
<DICH_DATA CI_END="1.8322845701938604" CI_START="0.7642521118595789" EFFECT_SIZE="1.1833542801284738" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="31" LOG_CI_END="0.26299292439040506" LOG_CI_START="-0.11676335251329725" LOG_EFFECT_SIZE="0.07311478593855388" MODIFIED="2008-07-11 13:39:00 -0400" MODIFIED_BY="Anne Lethaby" ORDER="732" O_E="0.0" SE="0.22307071687712282" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.04976054472807349" WEIGHT="66.56817837984642"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.519473849722505" CI_END="2.8378578782725383" CI_START="0.3503415162364286" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9971055269817208" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" I2="77.87353056459438" I2_Q="0.0" ID="CMP-046.04" LOG_CI_END="0.45299064192218635" LOG_CI_START="-0.45550839478611926" LOG_EFFECT_SIZE="-0.0012588764319664857" METHOD="MH" MODIFIED="2013-03-18 12:05:05 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.033511185191235415" P_Q="1.0" P_Z="0.9956661423286244" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.446921172502178" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="99.99999999999999" Z="0.005431711797032468">
<NAME>Arthralgia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.519473849722505" CI_END="2.8378578782725383" CI_START="0.3503415162364286" DF="1" EFFECT_SIZE="0.9971055269817208" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="38" I2="77.87353056459438" ID="CMP-046.04.01" LOG_CI_END="0.45299064192218635" LOG_CI_START="-0.45550839478611926" LOG_EFFECT_SIZE="-0.0012588764319664857" MODIFIED="2013-03-18 12:05:05 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.033511185191235415" P_Z="0.9956661423286244" STUDIES="2" TAU2="0.446921172502178" TOTAL_1="332" TOTAL_2="326" WEIGHT="99.99999999999999" Z="0.005431711797032468">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.068953482829554" CI_START="0.7827536010951278" EFFECT_SIZE="1.7846534653465347" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6094827249317035" LOG_CI_START="-0.10637492571405534" LOG_EFFECT_SIZE="0.25155389960882407" MODIFIED="2012-01-31 15:05:16 -0500" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.42049832754183913" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.17681884346548385" WEIGHT="45.658384312077324"/>
<DICH_DATA CI_END="1.0537958403445562" CI_START="0.35472678178102035" EFFECT_SIZE="0.6113997113997114" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="0.02275647994660881" LOG_CI_START="-0.45010602116824305" LOG_EFFECT_SIZE="-0.21367477061081713" MODIFIED="2008-07-11 13:43:17 -0400" MODIFIED_BY="Anne Lethaby" ORDER="738" O_E="0.0" SE="0.2777617738619949" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.07715160301896198" WEIGHT="54.34161568792266"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.744681610120052" CI_END="4.987236888050036" CI_START="0.62188593112528" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7611054641523718" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="30" I2="73.29545995853195" I2_Q="0.0" ID="CMP-046.05" LOG_CI_END="0.6978599971996342" LOG_CI_START="-0.20628926808400103" LOG_EFFECT_SIZE="0.2457853645578166" METHOD="MH" MODIFIED="2013-03-18 12:05:14 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.052976083802573015" P_Q="1.0" P_Z="0.2866047813106245" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4234490964694951" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="1.0655994114185279">
<NAME>Asthenia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.744681610120052" CI_END="4.987236888050036" CI_START="0.62188593112528" DF="1" EFFECT_SIZE="1.7611054641523718" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="30" I2="73.29545995853195" ID="CMP-046.05.01" LOG_CI_END="0.6978599971996342" LOG_CI_START="-0.20628926808400103" LOG_EFFECT_SIZE="0.2457853645578166" MODIFIED="2013-03-18 12:05:14 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.052976083802573015" P_Z="0.2866047813106245" STUDIES="2" TAU2="0.4234490964694951" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="1.0655994114185279">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.573756394839656" CI_START="1.242111316981613" EFFECT_SIZE="3.263366336633663" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.9331711397904435" LOG_CI_START="0.09416051869442747" LOG_EFFECT_SIZE="0.5136658292424355" MODIFIED="2012-02-17 15:55:32 -0500" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="0.4928389920013558" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.24289027203691244" WEIGHT="42.33114332944004"/>
<DICH_DATA CI_END="1.8504621852350787" CI_START="0.6776751025783647" EFFECT_SIZE="1.1198268398268398" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.2672802145802575" LOG_CI_START="-0.16897846981438783" LOG_EFFECT_SIZE="0.04915087238293485" MODIFIED="2008-07-11 13:37:24 -0400" MODIFIED_BY="Anne Lethaby" ORDER="730" O_E="0.0" SE="0.2562605107287307" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.06566944935894989" WEIGHT="57.668856670559954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.425839221853536" CI_END="3.30866611791265" CI_START="0.5636262746035247" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3655955323396503" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="47" I2="77.40541511173103" I2_Q="0.0" ID="CMP-046.06" LOG_CI_END="0.5196529441123672" LOG_CI_START="-0.24900876955602907" LOG_EFFECT_SIZE="0.135322087278169" METHOD="MH" MODIFIED="2013-03-18 12:05:24 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.03539873963217299" P_Q="1.0" P_Z="0.4901318100922103" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.31994193606593074" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.6900992014086885">
<NAME>Back pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.425839221853536" CI_END="3.30866611791265" CI_START="0.5636262746035247" DF="1" EFFECT_SIZE="1.3655955323396503" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="47" I2="77.40541511173103" ID="CMP-046.06.01" LOG_CI_END="0.5196529441123672" LOG_CI_START="-0.24900876955602907" LOG_EFFECT_SIZE="0.135322087278169" MODIFIED="2013-03-18 12:05:24 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.03539873963217299" P_Z="0.4901318100922103" STUDIES="2" TAU2="0.31994193606593074" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.6900992014086885">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.73693046099899" CI_START="1.084200654315731" EFFECT_SIZE="2.2662266226622663" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6754970092527428" LOG_CI_START="0.0351096650416292" LOG_EFFECT_SIZE="0.355303337147186" MODIFIED="2012-02-17 15:54:01 -0500" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.37616669595808655" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.14150138314802352" WEIGHT="44.18016576149827"/>
<DICH_DATA CI_END="1.3878429114002637" CI_START="0.602675120077634" EFFECT_SIZE="0.9145591250854409" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.14234031152739435" LOG_CI_START="-0.21991673691440738" LOG_EFFECT_SIZE="-0.03878821269350651" MODIFIED="2008-07-11 13:39:42 -0400" MODIFIED_BY="Anne Lethaby" ORDER="733" O_E="0.0" SE="0.21279158345602447" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.04528025798972223" WEIGHT="55.81983423850173"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1207458240118249" CI_START="0.303004079134034" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5827439886845828" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-046.07" LOG_CI_END="0.04950712932502576" LOG_CI_START="-0.5185515248525554" LOG_EFFECT_SIZE="-0.2345221977637648" METHOD="MH" MODIFIED="2013-03-18 12:05:35 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.10559007282191164" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.618336620036656">
<NAME>Bronchitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1207458240118249" CI_START="0.303004079134034" DF="0" EFFECT_SIZE="0.5827439886845828" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" I2="0.0" ID="CMP-046.07.01" LOG_CI_END="0.04950712932502576" LOG_CI_START="-0.5185515248525554" LOG_EFFECT_SIZE="-0.2345221977637648" MODIFIED="2013-03-18 12:05:35 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10559007282191164" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.618336620036656">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1207458240118247" CI_START="0.303004079134034" EFFECT_SIZE="0.5827439886845828" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="0.04950712932502567" LOG_CI_START="-0.5185515248525554" LOG_EFFECT_SIZE="-0.2345221977637648" MODIFIED="2012-02-17 16:04:26 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.33368046539959956" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.11134265298929337" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9845020692880238" CI_END="1.329431713747553" CI_START="0.5341964152994519" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8427203900875723" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-046.08" LOG_CI_END="0.12366603470687623" LOG_CI_START="-0.27229903061807303" LOG_EFFECT_SIZE="-0.07431649795559842" METHOD="MH" MODIFIED="2013-03-18 12:05:42 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3210900666647767" P_Q="1.0" P_Z="0.4619074224684284" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="99.99999999999999" Z="0.735709648176075">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9845020692880238" CI_END="1.329431713747553" CI_START="0.5341964152994519" DF="1" EFFECT_SIZE="0.8427203900875723" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" I2="0.0" ID="CMP-046.08.01" LOG_CI_END="0.12366603470687623" LOG_CI_START="-0.27229903061807303" LOG_EFFECT_SIZE="-0.07431649795559842" MODIFIED="2013-03-18 12:05:42 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.3210900666647767" P_Z="0.4619074224684284" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="99.99999999999999" Z="0.735709648176075">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4471232677228096" CI_START="0.2138175287975944" EFFECT_SIZE="0.5562556255625563" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.16050552642773247" LOG_CI_START="-0.6699566941318361" LOG_EFFECT_SIZE="-0.2547255838520518" MODIFIED="2012-01-31 15:04:06 -0500" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.4878176192109813" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.23796602961267" WEIGHT="29.978947918982175"/>
<DICH_DATA CI_END="1.6285479665657296" CI_START="0.5722492230449581" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.21180055461598338" LOG_CI_START="-0.24241478830395066" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2008-07-11 13:35:49 -0400" MODIFIED_BY="Anne Lethaby" ORDER="728" O_E="0.0" SE="0.26680834083337845" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.07118669073826024" WEIGHT="70.02105208101781"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7967874324486626" CI_START="0.42524715944932434" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8741159830268741" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-046.09" LOG_CI_END="0.254496701274192" LOG_CI_START="-0.37135857869035915" LOG_EFFECT_SIZE="-0.05843093870808357" METHOD="MH" MODIFIED="2013-03-18 12:05:56 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.7143864916317435" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.36597130076843903">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7967874324486626" CI_START="0.42524715944932434" DF="0" EFFECT_SIZE="0.8741159830268741" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" ID="CMP-046.09.01" LOG_CI_END="0.254496701274192" LOG_CI_START="-0.37135857869035915" LOG_EFFECT_SIZE="-0.05843093870808357" MODIFIED="2013-03-18 12:05:56 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7143864916317435" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.36597130076843903">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.7967874324486626" CI_START="0.42524715944932434" EFFECT_SIZE="0.8741159830268741" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.254496701274192" LOG_CI_START="-0.37135857869035915" LOG_EFFECT_SIZE="-0.05843093870808357" MODIFIED="2012-02-17 15:56:18 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.3676304894847776" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.1351521767988172" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.337834823858216" CI_START="0.34549891453765613" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6798679867986799" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-046.10" LOG_CI_END="0.12640249645487409" LOG_CI_START="-0.4615533127211772" LOG_EFFECT_SIZE="-0.1675754081331516" METHOD="MH" MODIFIED="2013-03-18 12:06:05 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.2638948073582529" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.1172328243370837">
<NAME>Flu syndrome</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.337834823858216" CI_START="0.34549891453765613" DF="0" EFFECT_SIZE="0.6798679867986799" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-046.10.01" LOG_CI_END="0.12640249645487409" LOG_CI_START="-0.4615533127211772" LOG_EFFECT_SIZE="-0.1675754081331516" MODIFIED="2013-03-18 12:06:05 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2638948073582529" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.1172328243370837">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.337834823858216" CI_START="0.34549891453765613" EFFECT_SIZE="0.6798679867986799" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.12640249645487409" LOG_CI_START="-0.4615533127211772" LOG_EFFECT_SIZE="-0.1675754081331516" MODIFIED="2012-02-17 16:04:56 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.34536815273820676" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.11927916092580132" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.260690510586742" CI_START="0.717328564357815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7482319660537482" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-046.11" LOG_CI_END="0.6294799889233096" LOG_CI_START="-0.14428187501151438" LOG_EFFECT_SIZE="0.24259905695589762" METHOD="MH" MODIFIED="2013-03-18 12:06:15 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.21906335066095273" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.2290226140092944">
<NAME>Gingival/dental infection</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.260690510586742" CI_START="0.717328564357815" DF="0" EFFECT_SIZE="1.7482319660537482" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-046.11.01" LOG_CI_END="0.6294799889233096" LOG_CI_START="-0.14428187501151438" LOG_EFFECT_SIZE="0.24259905695589762" MODIFIED="2013-03-18 12:06:15 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21906335066095273" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.2290226140092944">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.260690510586742" CI_START="0.717328564357815" EFFECT_SIZE="1.7482319660537482" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6294799889233096" LOG_CI_START="-0.14428187501151438" LOG_EFFECT_SIZE="0.24259905695589762" MODIFIED="2012-02-17 16:05:30 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.4545115490583145" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.2065807482273886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.379519432381977" CI_END="3.293556149508386" CI_START="0.6598862018323992" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4742361608713952" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="48" I2="77.16644450516549" I2_Q="0.0" ID="CMP-046.12" LOG_CI_END="0.517665071819976" LOG_CI_START="-0.18053095260575128" LOG_EFFECT_SIZE="0.16856705960711235" METHOD="MH" MODIFIED="2013-03-18 12:06:24 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.03637328479787216" P_Q="1.0" P_Z="0.3439460671275131" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.26217315871575636" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.9463971556741584">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.379519432381977" CI_END="3.293556149508386" CI_START="0.6598862018323992" DF="1" EFFECT_SIZE="1.4742361608713952" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="48" I2="77.16644450516549" ID="CMP-046.12.01" LOG_CI_END="0.517665071819976" LOG_CI_START="-0.18053095260575128" LOG_EFFECT_SIZE="0.16856705960711235" MODIFIED="2013-03-18 12:06:24 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.03637328479787216" P_Z="0.3439460671275131" STUDIES="2" TAU2="0.26217315871575636" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.9463971556741584">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.456945061902526" CI_START="1.2052831026152684" EFFECT_SIZE="2.317731773177318" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.6490372808307067" LOG_CI_START="0.08108906804197792" LOG_EFFECT_SIZE="0.36506317443634223" MODIFIED="2012-01-31 15:03:43 -0500" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.33361559158109405" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.11129936294600336" WEIGHT="45.03719076699599"/>
<DICH_DATA CI_END="1.5339469594778687" CI_START="0.6749959845863756" EFFECT_SIZE="1.0175500175500176" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="37" LOG_CI_END="0.1858103429217446" LOG_CI_START="-0.1706988106907034" LOG_EFFECT_SIZE="0.007555766115520603" MODIFIED="2008-07-11 13:35:03 -0400" MODIFIED_BY="Anne Lethaby" ORDER="727" O_E="0.0" SE="0.2094152415807238" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.043854743406312915" WEIGHT="54.96280923300401"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1883658702145734" CI_START="0.41122375040691006" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6990595611285266" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-046.13" LOG_CI_END="0.07495017040331434" LOG_CI_START="-0.3859218104213553" LOG_EFFECT_SIZE="-0.15548582000902048" METHOD="MH" MODIFIED="2013-03-18 12:06:36 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.18600891553430318" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="1.3224783454140718">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1883658702145734" CI_START="0.41122375040691006" DF="0" EFFECT_SIZE="0.6990595611285266" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" I2="0.0" ID="CMP-046.13.01" LOG_CI_END="0.07495017040331434" LOG_CI_START="-0.3859218104213553" LOG_EFFECT_SIZE="-0.15548582000902048" MODIFIED="2013-03-18 12:06:36 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.18600891553430318" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="1.3224783454140718">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.1883658702145734" CI_START="0.41122375040691006" EFFECT_SIZE="0.6990595611285266" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" LOG_CI_END="0.07495017040331434" LOG_CI_START="-0.3859218104213553" LOG_EFFECT_SIZE="-0.15548582000902048" MODIFIED="2008-07-11 13:42:32 -0400" MODIFIED_BY="Anne Lethaby" ORDER="737" O_E="0.0" SE="0.2707184828895092" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.07328849697799751" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.018692139791182734" CI_END="2.626315431803527" CI_START="1.0469139461899988" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.658169548824583" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-046.14" LOG_CI_END="0.41934688552527966" LOG_CI_START="0.01991098518336856" LOG_EFFECT_SIZE="0.21962893535432407" METHOD="MH" MODIFIED="2013-03-18 12:06:55 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.891252758961859" P_Q="1.0" P_Z="0.031133391202309024" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="2.1553636159838394">
<NAME>Increased cough</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.018692139791182734" CI_END="2.626315431803527" CI_START="1.0469139461899988" DF="1" EFFECT_SIZE="1.658169548824583" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="26" I2="0.0" ID="CMP-046.14.01" LOG_CI_END="0.41934688552527966" LOG_CI_START="0.01991098518336856" LOG_EFFECT_SIZE="0.21962893535432407" MODIFIED="2013-03-18 12:06:55 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.891252758961859" P_Z="0.031133391202309024" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="2.1553636159838394">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.260690510586742" CI_START="0.717328564357815" EFFECT_SIZE="1.7482319660537482" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.6294799889233096" LOG_CI_START="-0.14428187501151438" LOG_EFFECT_SIZE="0.24259905695589762" MODIFIED="2012-01-31 15:04:31 -0500" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.4545115490583145" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.2065807482273886" WEIGHT="26.38896881941967"/>
<DICH_DATA CI_END="2.7816755655567826" CI_START="0.9503247616680564" EFFECT_SIZE="1.6258828890407837" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="19" LOG_CI_END="0.44430647565426956" LOG_CI_START="-0.022127954608082836" LOG_EFFECT_SIZE="0.21108926052309335" MODIFIED="2008-07-11 13:40:22 -0400" MODIFIED_BY="Anne Lethaby" ORDER="734" O_E="0.0" SE="0.27398589322377287" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.07506826968562866" WEIGHT="73.61103118058034"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.8217286480457275" CI_END="1.2300658081468434" CI_START="0.7130229819671234" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9365175868827353" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="235" I2="82.82297131221178" I2_Q="0.0" ID="CMP-046.15" LOG_CI_END="0.08992834668371583" LOG_CI_START="-0.14689647185830032" LOG_EFFECT_SIZE="-0.02848406258729227" METHOD="MH" MODIFIED="2013-03-18 12:07:04 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.01582941482832778" P_Q="1.0" P_Z="0.6373061153062549" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03231792091202982" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.47146863363539687">
<NAME>Infections (total)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.8217286480457275" CI_END="1.2300658081468434" CI_START="0.7130229819671234" DF="1" EFFECT_SIZE="0.9365175868827353" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="235" I2="82.82297131221178" ID="CMP-046.15.01" LOG_CI_END="0.08992834668371583" LOG_CI_START="-0.14689647185830032" LOG_EFFECT_SIZE="-0.02848406258729227" MODIFIED="2013-03-18 12:07:04 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.01582941482832778" P_Z="0.6373061153062549" STUDIES="2" TAU2="0.03231792091202982" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.47146863363539687">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.9814838039601839" CI_START="0.6604255713814158" EFFECT_SIZE="0.805106826472121" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="76" LOG_CI_END="-0.008116862552773116" LOG_CI_START="-0.180176119396463" LOG_EFFECT_SIZE="-0.09414649097461805" MODIFIED="2012-01-31 15:05:43 -0500" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.10106845917704099" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.010214833440421203" WEIGHT="45.49944745592934"/>
<DICH_DATA CI_END="1.1868938725717884" CI_START="0.9511647067305068" EFFECT_SIZE="1.0625119115685153" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="159" LOG_CI_END="0.07441188776924285" LOG_CI_START="-0.021744272725524198" LOG_EFFECT_SIZE="0.026333807521859313" MODIFIED="2008-07-11 13:44:47 -0400" MODIFIED_BY="Anne Lethaby" ORDER="740" O_E="0.0" SE="0.0564826046552971" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.0031902846286465895" WEIGHT="54.50055254407066"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.49933345641873" CI_START="0.7191465897492482" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5863586358635864" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-046.16" LOG_CI_END="0.5439853289883141" LOG_CI_START="-0.14318257466542844" LOG_EFFECT_SIZE="0.2004013771614428" METHOD="MH" MODIFIED="2013-03-18 12:07:14 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.25296245831992303" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.143183433336181">
<NAME>Injection site haemorrhage</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.49933345641873" CI_START="0.7191465897492482" DF="0" EFFECT_SIZE="1.5863586358635864" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-046.16.01" LOG_CI_END="0.5439853289883141" LOG_CI_START="-0.14318257466542844" LOG_EFFECT_SIZE="0.2004013771614428" MODIFIED="2013-03-18 12:07:14 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.25296245831992303" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.143183433336181">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.49933345641873" CI_START="0.7191465897492482" EFFECT_SIZE="1.5863586358635864" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5439853289883141" LOG_CI_START="-0.14318257466542844" LOG_EFFECT_SIZE="0.2004013771614428" MODIFIED="2012-02-17 15:57:41 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.4036458281421907" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.16292995457659495" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.30459751613970065" CI_END="0.787782879317516" CI_START="0.41050737908854334" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5686744983551308" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-046.17" LOG_CI_END="-0.10359346183447368" LOG_CI_START="-0.386679031800003" LOG_EFFECT_SIZE="-0.24513624681723836" METHOD="MH" MODIFIED="2013-03-18 12:07:23 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.581014541375011" P_Q="1.0" P_Z="6.876959678049208E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="99.99999999999999" Z="3.394438050131718">
<NAME>Injection site reaction</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.30459751613970065" CI_END="0.787782879317516" CI_START="0.41050737908854334" DF="1" EFFECT_SIZE="0.5686744983551308" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="80" I2="0.0" ID="CMP-046.17.01" LOG_CI_END="-0.10359346183447368" LOG_CI_START="-0.386679031800003" LOG_EFFECT_SIZE="-0.24513624681723836" MODIFIED="2013-03-18 12:07:23 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.581014541375011" P_Z="6.876959678049208E-4" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="99.99999999999999" Z="3.394438050131718">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.0074582893441848" CI_START="0.3938087692129402" EFFECT_SIZE="0.6298776936517181" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="34" LOG_CI_END="0.0032270745822355878" LOG_CI_START="-0.40471461735384806" LOG_EFFECT_SIZE="-0.20074377138580624" MODIFIED="2012-01-31 15:03:18 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.23962696918719817" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.057421084361842414" WEIGHT="41.8337742906669"/>
<DICH_DATA CI_END="0.8235674806286202" CI_START="0.33423423402218433" EFFECT_SIZE="0.5246565029173725" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="46" LOG_CI_END="-0.08430081025989683" LOG_CI_START="-0.4759490694471432" LOG_EFFECT_SIZE="-0.28012493985352005" MODIFIED="2008-07-11 13:33:51 -0400" MODIFIED_BY="Anne Lethaby" ORDER="726" O_E="0.0" SE="0.23005612613673831" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.052925821173042856" WEIGHT="58.166225709333084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8907961469823676" CI_END="2.137347857739538" CI_START="0.23994858406560873" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7161379700310998" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="100.0" ID="CMP-046.18" LOG_CI_END="0.32987521023257965" LOG_CI_START="-0.6198818084917482" LOG_EFFECT_SIZE="-0.14500329912958423" METHOD="MH" MODIFIED="2013-03-18 12:07:30 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.3452617625542145" P_Q="0.0" P_Z="0.5495253869894581" Q="9.900570961570332E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="0.598471479189909">
<NAME>Malignancy</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8907961469823676" CI_END="2.137347857739538" CI_START="0.23994858406560873" DF="1" EFFECT_SIZE="0.7161379700310998" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-046.18.01" LOG_CI_END="0.32987521023257965" LOG_CI_START="-0.6198818084917482" LOG_EFFECT_SIZE="-0.14500329912958423" MODIFIED="2013-03-18 12:07:30 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.3452617625542145" P_Z="0.5495253869894581" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.00000000000001" Z="0.598471479189909">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.195590914263914" CI_START="0.009911358614612646" EFFECT_SIZE="0.20392156862745098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6227931362567535" LOG_CI_START="-2.0038668098550656" LOG_EFFECT_SIZE="-0.690536836799156" MODIFIED="2012-01-31 15:06:09 -0500" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.542913054522512" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="2.380580693815988" WEIGHT="32.73112807463953"/>
<DICH_DATA CI_END="3.2890933516603122" CI_START="0.2833410940094633" EFFECT_SIZE="0.9653679653679653" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5170761998844813" LOG_CI_START="-0.5476904335724486" LOG_EFFECT_SIZE="-0.015307116843983656" MODIFIED="2008-07-11 13:46:17 -0400" MODIFIED_BY="Anne Lethaby" ORDER="742" O_E="0.0" SE="0.6254491911724407" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.39118669073826023" WEIGHT="67.26887192536049"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2568857332751637" CI_START="0.3300587080573267" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6440854611776967" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-046.19" LOG_CI_END="0.09929579664874205" LOG_CI_START="-0.4814088046140911" LOG_EFFECT_SIZE="-0.1910565039826745" METHOD="MH" MODIFIED="2013-03-18 12:07:38 -0400" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.19715902095270527" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.2896879618444388">
<NAME>Miscellaneous skin infections</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2568857332751637" CI_START="0.3300587080573267" DF="0" EFFECT_SIZE="0.6440854611776967" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" ID="CMP-046.19.01" LOG_CI_END="0.09929579664874205" LOG_CI_START="-0.4814088046140911" LOG_EFFECT_SIZE="-0.1910565039826745" MODIFIED="2013-03-18 12:07:38 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19715902095270527" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.2896879618444388">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2568857332751637" CI_START="0.3300587080573267" EFFECT_SIZE="0.6440854611776967" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.09929579664874205" LOG_CI_START="-0.4814088046140911" LOG_EFFECT_SIZE="-0.1910565039826745" MODIFIED="2012-02-17 16:06:48 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.3411087573159243" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.11635518431761416" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17655215474107216" CI_END="3.4037004789583962" CI_START="1.652852003367225" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3718796671644977" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-046.20" LOG_CI_END="0.5319513357665863" LOG_CI_START="0.21823396851492835" LOG_EFFECT_SIZE="0.3750926521407573" METHOD="MH" MODIFIED="2013-03-18 12:07:52 -0400" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.6743531675103669" P_Q="1.0" P_Z="2.7748563218602096E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="4.686817918319185">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.17655215474107216" CI_END="3.4037004789583962" CI_START="1.652852003367225" DF="1" EFFECT_SIZE="2.3718796671644977" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="35" I2="0.0" ID="CMP-046.20.01" LOG_CI_END="0.5319513357665863" LOG_CI_START="0.21823396851492835" LOG_EFFECT_SIZE="0.3750926521407573" MODIFIED="2013-03-18 12:07:52 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.6743531675103669" P_Z="2.7748563218602096E-6" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="4.686817918319185">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.297203319850768" CI_START="1.2167324982900045" EFFECT_SIZE="2.768033946251768" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.7991477157355611" LOG_CI_START="0.08519510798664244" LOG_EFFECT_SIZE="0.44217141186110176" MODIFIED="2012-02-17 15:54:37 -0500" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.41937929591412076" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.1758789938414237" WEIGHT="19.56646042244506"/>
<DICH_DATA CI_END="3.4011999947887483" CI_START="1.5223881855854353" EFFECT_SIZE="2.2755102040816326" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="28" LOG_CI_END="0.5316321697390949" LOG_CI_START="0.18252540497223685" LOG_EFFECT_SIZE="0.35707878735566584" MODIFIED="2008-07-11 13:36:36 -0400" MODIFIED_BY="Anne Lethaby" ORDER="729" O_E="0.0" SE="0.20506704173040852" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.04205249160406111" WEIGHT="80.43353957755494"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4230315840212873" CI_START="0.44691276237510585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7974778844344061" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-046.21" LOG_CI_END="0.15321453930701043" LOG_CI_START="-0.3497772431245056" LOG_EFFECT_SIZE="-0.09828135190874757" METHOD="MH" MODIFIED="2013-03-18 12:08:00 -0400" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.44371876010118705" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.7659286565751362">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4230315840212873" CI_START="0.44691276237510585" DF="0" EFFECT_SIZE="0.7974778844344061" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-046.21.01" LOG_CI_END="0.15321453930701043" LOG_CI_START="-0.3497772431245056" LOG_EFFECT_SIZE="-0.09828135190874757" MODIFIED="2013-03-18 12:08:00 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.44371876010118705" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.7659286565751362">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.4230315840212873" CI_START="0.44691276237510585" EFFECT_SIZE="0.7974778844344061" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.15321453930701043" LOG_CI_START="-0.3497772431245056" LOG_EFFECT_SIZE="-0.09828135190874757" MODIFIED="2008-07-11 13:44:08 -0400" MODIFIED_BY="Anne Lethaby" ORDER="739" O_E="0.0" SE="0.29545986284975134" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.08729653055519387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.517996428630413" CI_START="0.923335717729233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8044554455445545" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-046.22" LOG_CI_END="0.9303374536496308" LOG_CI_START="-0.03464036414404621" LOG_EFFECT_SIZE="0.4478485447527923" METHOD="MH" MODIFIED="2013-03-18 12:08:23 -0400" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.06887359148287084" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.8192480740149488">
<NAME>Paraesthesia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.517996428630413" CI_START="0.923335717729233" DF="0" EFFECT_SIZE="2.8044554455445545" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-046.22.01" LOG_CI_END="0.9303374536496308" LOG_CI_START="-0.03464036414404621" LOG_EFFECT_SIZE="0.4478485447527923" MODIFIED="2013-03-18 12:08:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06887359148287084" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="1.8192480740149488">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="8.517996428630413" CI_START="0.923335717729233" EFFECT_SIZE="2.8044554455445545" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9303374536496308" LOG_CI_START="-0.03464036414404621" LOG_EFFECT_SIZE="0.4478485447527923" MODIFIED="2012-02-17 16:00:51 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.5668327468892419" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.32129936294600336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.039410385021192E-31" CI_END="0.8427250388828815" CI_START="0.21425122841223998" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42491749174917487" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="100.0" I2_Q="0.0" ID="CMP-046.23" LOG_CI_END="-0.0743141022136591" LOG_CI_START="-0.6690766793644939" LOG_EFFECT_SIZE="-0.37169539078907643" METHOD="MH" MODIFIED="2013-03-18 12:08:36 -0400" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="1.0" P_Z="0.014295574225928191" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="2.449749218103133">
<NAME>Pharyngitis or laryngitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.039410385021192E-31" CI_END="0.8427250388828815" CI_START="0.21425122841223998" DF="0" EFFECT_SIZE="0.42491749174917487" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="100.0" ID="CMP-046.23.01" LOG_CI_END="-0.0743141022136591" LOG_CI_START="-0.6690766793644939" LOG_EFFECT_SIZE="-0.37169539078907643" MODIFIED="2013-03-18 12:08:36 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.014295574225928191" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="2.449749218103133">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8427250388828816" CI_START="0.21425122841224004" EFFECT_SIZE="0.4249174917491749" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.07431410221365904" LOG_CI_START="-0.6690766793644938" LOG_EFFECT_SIZE="-0.3716953907890764" MODIFIED="2012-02-17 16:03:55 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.34936648194063935" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.12205693870357909" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7489241544712075" CI_END="2.41412593149915" CI_START="0.3570105956439941" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.928368750424164" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="33" I2="73.32568068075382" I2_Q="0.0" ID="CMP-046.24" LOG_CI_END="0.3827599210756147" LOG_CI_START="-0.4473188943599839" LOG_EFFECT_SIZE="-0.032279486642184614" METHOD="MH" MODIFIED="2013-03-18 12:08:50 -0400" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.05284178017122432" P_Q="1.0" P_Z="0.8788436652700972" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3516371851695545" TOTALS="YES" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.15243523887529475">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7489241544712075" CI_END="2.41412593149915" CI_START="0.3570105956439941" DF="1" EFFECT_SIZE="0.928368750424164" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="33" I2="73.32568068075382" ID="CMP-046.24.01" LOG_CI_END="0.3827599210756147" LOG_CI_START="-0.4473188943599839" LOG_EFFECT_SIZE="-0.032279486642184614" MODIFIED="2013-03-18 12:08:50 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="0.05284178017122432" P_Z="0.8788436652700972" STUDIES="2" TAU2="0.3516371851695545" TOTAL_1="332" TOTAL_2="326" WEIGHT="100.0" Z="0.15243523887529475">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.2262833255645287" CI_START="0.2412338981507215" EFFECT_SIZE="0.5438943894389439" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.0885908229666946" LOG_CI_START="-0.6175616652491106" LOG_EFFECT_SIZE="-0.26448542114120804" MODIFIED="2012-01-31 15:04:51 -0500" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.41479746708915555" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.17205693870357908" WEIGHT="45.39794179760527"/>
<DICH_DATA CI_END="2.5536505102427327" CI_START="0.8211203670379033" EFFECT_SIZE="1.448051948051948" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.407161459936437" LOG_CI_START="-0.08559317551304178" LOG_EFFECT_SIZE="0.1607841422116976" MODIFIED="2008-07-11 13:41:09 -0400" MODIFIED_BY="Anne Lethaby" ORDER="735" O_E="0.0" SE="0.2894465120378078" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.08377928333085283" WEIGHT="54.60205820239472"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.704685986974051" CI_START="0.5537035946898348" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2237623762376237" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-046.25" LOG_CI_END="0.43211685094329016" LOG_CI_START="-0.2567226570029812" LOG_EFFECT_SIZE="0.08769709697015445" METHOD="MH" MODIFIED="2013-03-18 12:09:03 -0400" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.6177431939653397" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.4990513744563737">
<NAME>Rheumatoid arthritis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.704685986974051" CI_START="0.5537035946898348" DF="0" EFFECT_SIZE="1.2237623762376237" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-046.25.01" LOG_CI_END="0.43211685094329016" LOG_CI_START="-0.2567226570029812" LOG_EFFECT_SIZE="0.08769709697015445" MODIFIED="2013-03-18 12:09:03 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6177431939653397" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.4990513744563737">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.704685986974051" CI_START="0.5537035946898348" EFFECT_SIZE="1.2237623762376237" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.43211685094329016" LOG_CI_START="-0.2567226570029812" LOG_EFFECT_SIZE="0.08769709697015445" MODIFIED="2012-02-17 15:59:00 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.40462773677819686" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.16372360537024577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8641166983880642" CI_START="0.4310655366842612" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.896413110698825" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-046.26" LOG_CI_END="0.27047309679454873" LOG_CI_START="-0.3654566972253185" LOG_EFFECT_SIZE="-0.04749180021538488" METHOD="MH" MODIFIED="2013-03-18 12:09:12 -0400" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.7697180708634401" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.2927436923334904">
<NAME>Serious infections</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8641166983880642" CI_START="0.4310655366842612" DF="0" EFFECT_SIZE="0.896413110698825" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" ID="CMP-046.26.01" LOG_CI_END="0.27047309679454873" LOG_CI_START="-0.3654566972253185" LOG_EFFECT_SIZE="-0.04749180021538488" MODIFIED="2013-03-18 12:09:12 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.7697180708634401" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="100.0" Z="0.2927436923334904">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.8641166983880642" CI_START="0.4310655366842612" EFFECT_SIZE="0.896413110698825" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.27047309679454873" LOG_CI_START="-0.3654566972253185" LOG_EFFECT_SIZE="-0.04749180021538488" MODIFIED="2008-07-11 13:45:34 -0400" MODIFIED_BY="Anne Lethaby" ORDER="741" O_E="0.0" SE="0.3735483089105191" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.1395383390899086" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8766350732792356" CI_START="0.07414687925141135" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25495049504950495" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-046.27" LOG_CI_END="-0.05718115765317623" LOG_CI_START="-1.1299071231576894" LOG_EFFECT_SIZE="-0.5935441404054328" METHOD="MH" MODIFIED="2013-03-18 12:09:19 -0400" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.030089219879213955" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="2.1689139180709787">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8766350732792356" CI_START="0.07414687925141135" DF="0" EFFECT_SIZE="0.25495049504950495" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-046.27.01" LOG_CI_END="-0.05718115765317623" LOG_CI_START="-1.1299071231576894" LOG_EFFECT_SIZE="-0.5935441404054328" MODIFIED="2013-03-18 12:09:19 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.030089219879213955" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.00000000000001" Z="2.1689139180709787">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="0.8766350732792356" CI_START="0.07414687925141135" EFFECT_SIZE="0.25495049504950495" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.05718115765317623" LOG_CI_START="-1.1299071231576894" LOG_EFFECT_SIZE="-0.5935441404054328" MODIFIED="2012-02-17 16:06:06 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.6301245422165201" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.39705693870357905" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5762321161920816" CI_START="0.6597988127080309" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0198019801980198" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-046.28" LOG_CI_END="0.1976201721374234" LOG_CI_START="-0.18058847029236413" LOG_EFFECT_SIZE="0.008515850922529638" METHOD="MH" MODIFIED="2013-03-18 12:09:37 -0400" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="1.0" P_Z="0.9296682914251185" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.08826218776303527">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5762321161920816" CI_START="0.6597988127080309" DF="0" EFFECT_SIZE="1.0198019801980198" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" ID="CMP-046.28.01" LOG_CI_END="0.1976201721374234" LOG_CI_START="-0.18058847029236413" LOG_EFFECT_SIZE="0.008515850922529638" MODIFIED="2013-03-18 12:09:37 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9296682914251185" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="103" WEIGHT="100.0" Z="0.08826218776303527">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="1.5762321161920814" CI_START="0.659798812708031" EFFECT_SIZE="1.0198019801980198" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.19762017213742333" LOG_CI_START="-0.18058847029236405" LOG_EFFECT_SIZE="0.008515850922529638" MODIFIED="2012-02-17 16:03:16 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.22216162872623105" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.049355789278291734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.032369349172086" CI_START="0.9244543124503487" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9307359307359306" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-046.29" LOG_CI_END="0.6055603049257662" LOG_CI_START="-0.034114547285771055" LOG_EFFECT_SIZE="0.28572287881999753" METHOD="MH" MODIFIED="2013-03-18 12:09:57 -0400" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.0799614116757007" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="223" WEIGHT="99.99999999999999" Z="1.750910013455105">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept+DMARD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.032369349172086" CI_START="0.9244543124503487" DF="0" EFFECT_SIZE="1.9307359307359306" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" I2="0.0" ID="CMP-046.29.01" LOG_CI_END="0.6055603049257662" LOG_CI_START="-0.034114547285771055" LOG_EFFECT_SIZE="0.28572287881999753" MODIFIED="2013-03-18 12:09:57 -0400" MODIFIED_BY="Anne Lethaby" NO="1" P_CHI2="1.0" P_Z="0.0799614116757007" STUDIES="1" TAU2="0.0" TOTAL_1="231" TOTAL_2="223" WEIGHT="99.99999999999999" Z="1.750910013455105">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.032369349172086" CI_START="0.9244543124503487" EFFECT_SIZE="1.9307359307359306" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.6055603049257662" LOG_CI_START="-0.034114547285771055" LOG_EFFECT_SIZE="0.28572287881999753" MODIFIED="2008-07-11 13:41:48 -0400" MODIFIED_BY="Anne Lethaby" ORDER="736" O_E="0.0" SE="0.3757481746306431" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.14118669073826026" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-047" MODIFIED="2013-03-18 12:10:50 -0400" MODIFIED_BY="[Empty name]" NO="47">
<NAME>Adverse events within six months: etanercept vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.7142655596841178" CI_END="2.804708350628121" CI_START="0.556656575703298" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2495036399735275" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-047.01" LOG_CI_END="0.4478877075536317" LOG_CI_START="-0.25441265630758214" LOG_EFFECT_SIZE="0.09673752562302482" METHOD="MH" MODIFIED="2013-03-18 12:10:27 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3980318627016364" P_Q="0.3980347264359153" P_Z="0.5892344130467806" Q="0.7142568889355883" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="0.5399458007745468">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.921609752233099" CI_START="0.5763490483303484" DF="0" EFFECT_SIZE="1.6842105263157894" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-047.01.01" LOG_CI_END="0.6921071743462791" LOG_CI_START="-0.23931441961212507" LOG_EFFECT_SIZE="0.226396377367077" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3406919717526813" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="0.952798923168677">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.921609752233099" CI_START="0.5763490483303484" EFFECT_SIZE="1.6842105263157894" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6921071743462791" LOG_CI_START="-0.23931441961212507" LOG_EFFECT_SIZE="0.226396377367077" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7685" O_E="0.0" SE="0.5471216549024156" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.2993421052631579" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9430090829171047" CI_START="0.22875950078909998" DF="0" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-047.01.02" LOG_CI_END="0.4687916024511879" LOG_CI_START="-0.6406208598643744" LOG_EFFECT_SIZE="-0.08591462870659325" MODIFIED="2012-02-20 09:08:12 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7614590717502165" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.3035653262062545">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.9430090829171047" CI_START="0.22875950078909998" EFFECT_SIZE="0.8205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4687916024511879" LOG_CI_START="-0.6406208598643744" LOG_EFFECT_SIZE="-0.08591462870659325" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7686" O_E="0.0" SE="0.6516743720444185" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.42467948717948717" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3168593321919815" CI_END="3.0239998093755647" CI_START="0.9445959325216741" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6901058901389807" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-047.02" LOG_CI_END="0.4805817594524682" LOG_CI_START="-0.024753928849511005" LOG_EFFECT_SIZE="0.22791391530147861" METHOD="MH" MODIFIED="2012-02-22 15:45:44 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5735013333362895" P_Q="0.5735141276442935" P_Z="0.07706995733160167" Q="0.3168381808932018" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="1.7679458463241131">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.386243171231082" CI_START="0.8881015508740158" DF="0" EFFECT_SIZE="1.9736842105263157" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-047.02.01" LOG_CI_END="0.6420927050880467" LOG_CI_START="-0.05153737153826709" LOG_EFFECT_SIZE="0.29527766677488987" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09517494083749951" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="1.6687096243941866">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="4.386243171231082" CI_START="0.8881015508740158" EFFECT_SIZE="1.9736842105263157" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6420927050880467" LOG_CI_START="-0.05153737153826709" LOG_EFFECT_SIZE="0.29527766677488987" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7677" O_E="0.0" SE="0.40744174053455123" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.16600877192982455" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.31819934776577" CI_START="0.5993681916695038" DF="0" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-047.02.02" LOG_CI_END="0.5209024736214327" LOG_CI_START="-0.22230630868594342" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2012-02-20 09:08:47 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4310200894713775" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.7874472734006235">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.31819934776577" CI_START="0.5993681916695038" EFFECT_SIZE="1.4102564102564104" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5209024736214327" LOG_CI_START="-0.22230630868594342" LOG_EFFECT_SIZE="0.14929808246774467" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7678" O_E="0.0" SE="0.4365645176701584" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.19058857808857807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06444667717290188" CI_END="5.74894580084089" CI_START="2.3645536591009875" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.686962276637989" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-047.03" LOG_CI_END="0.7595882142805754" LOG_CI_START="0.3737491739602597" LOG_EFFECT_SIZE="0.5666686941204175" METHOD="MH" MODIFIED="2013-03-18 12:10:36 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7996010167505646" P_Q="0.7996314677895888" P_Z="8.55889236077386E-9" Q="0.0644266669965178" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="5.757065074183906">
<NAME>Injection site reaction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.548542852705836" CI_START="1.842620910615864" DF="0" EFFECT_SIZE="3.4736842105263164" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" I2="0.0" ID="CMP-047.03.01" LOG_CI_END="0.8161446738191007" LOG_CI_START="0.2654359953589787" LOG_EFFECT_SIZE="0.5407903345890398" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.1844159673096449E-4" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="3.8493294928477693">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="6.548542852705836" CI_START="1.842620910615864" EFFECT_SIZE="3.473684210526316" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="0.8161446738191007" LOG_CI_START="0.2654359953589787" LOG_EFFECT_SIZE="0.5407903345890397" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7672" O_E="0.0" SE="0.32348900377939926" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.10464513556618821" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.881793308574993E-31" CI_END="7.265888644906183" CI_START="2.0905917110732295" DF="0" EFFECT_SIZE="3.897435897435898" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" I2="100.0" ID="CMP-047.03.02" LOG_CI_END="0.8612887376949648" LOG_CI_START="0.32026922414158204" LOG_EFFECT_SIZE="0.5907789809182734" MODIFIED="2012-02-20 09:09:18 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="1.8650947823379417E-5" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="4.280457530332094">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="7.265888644906181" CI_START="2.090591711073229" EFFECT_SIZE="3.8974358974358974" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="10" LOG_CI_END="0.8612887376949647" LOG_CI_START="0.320269224141582" LOG_EFFECT_SIZE="0.5907789809182733" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7673" O_E="0.0" SE="0.3177975403510408" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.1009952766531714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.050735036259012836" CI_END="1.8334740413307054" CI_START="0.5256223436303412" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9816898301345688" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-047.04" LOG_CI_END="0.26327476551743445" LOG_CI_START="-0.27932618167294687" LOG_EFFECT_SIZE="-0.008025708077756188" METHOD="MH" MODIFIED="2012-02-22 15:45:44 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8217891578009424" P_Q="0.8217919312694897" P_Z="0.9537642736639791" Q="0.05073343012952439" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="0.057980358730612865">
<NAME>Rhinitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.509929364045268" CI_START="0.44145992985691285" DF="0" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-047.04.01" LOG_CI_END="0.39966149947425617" LOG_CI_START="-0.35510871005195177" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9078956097196956" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="0.1156933084750766">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.509929364045268" CI_START="0.44145992985691285" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.39966149947425617" LOG_CI_START="-0.35510871005195177" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7682" O_E="0.0" SE="0.44335575724848786" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.1965643274853801" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.400725020966178E-32" CI_END="2.2420535453517325" CI_START="0.3707146452619381" DF="0" EFFECT_SIZE="0.9116809116809116" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="100.0" ID="CMP-047.04.02" LOG_CI_END="0.3506459803254584" LOG_CI_START="-0.4309602566172947" LOG_EFFECT_SIZE="-0.04015713814591815" MODIFIED="2012-02-20 09:10:31 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.8403882232732649" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.2013969202601535">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.2420535453517325" CI_START="0.3707146452619382" EFFECT_SIZE="0.9116809116809117" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3506459803254584" LOG_CI_START="-0.4309602566172946" LOG_EFFECT_SIZE="-0.0401571381459181" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7683" O_E="0.0" SE="0.45911937259344465" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.21079059829059826" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02069139650708476" CI_END="1.8325925606135827" CI_START="0.5250876361356169" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.980954481947202" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-047.05" LOG_CI_END="0.26306591921959316" LOG_CI_START="-0.27976820761523336" LOG_EFFECT_SIZE="-0.00835114419782007" METHOD="MH" MODIFIED="2012-02-22 15:45:44 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8856228428444222" P_Q="0.8856236257573329" P_Z="0.951912321143538" Q="0.02069111128043606" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="0.06030550051400293">
<NAME>Sinusitis</NAME>
<GROUP_LABEL_1>Treeatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.856860663111888E-32" CI_END="2.299397816264444" CI_START="0.38074449250255776" DF="0" EFFECT_SIZE="0.9356725146198831" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="100.0" ID="CMP-047.05.01" LOG_CI_END="0.36161411457605397" LOG_CI_START="-0.41936637004851207" LOG_EFFECT_SIZE="-0.028876127736229027" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.88476124775715" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="0.14493619620519457">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.2993978162644435" CI_START="0.3807444925025577" EFFECT_SIZE="0.935672514619883" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3616141145760539" LOG_CI_START="-0.4193663700485121" LOG_EFFECT_SIZE="-0.02887612773622908" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7680" O_E="0.0" SE="0.45875180258421766" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.210453216374269" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4473958600289474" CI_START="0.4298199284628734" DF="0" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-047.05.02" LOG_CI_END="0.3887042210565836" LOG_CI_START="-0.36671345245365733" LOG_EFFECT_SIZE="0.010995384301463145" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.954500582328597" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="0.05705600486391775">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="2.4473958600289474" CI_START="0.4298199284628734" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3887042210565836" LOG_CI_START="-0.36671345245365733" LOG_EFFECT_SIZE="0.010995384301463145" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7681" O_E="0.0" SE="0.44373608079770727" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.19690170940170937" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10656136673187225" CI_END="2.9267352247275813" CI_START="1.255918805863932" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.91722242020058" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-047.06" LOG_CI_END="0.46638343454822156" LOG_CI_START="0.09896156352134614" LOG_EFFECT_SIZE="0.2826724990347838" METHOD="MH" MODIFIED="2013-03-18 12:10:50 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7440934897009808" P_Q="0.7440982623065753" P_Z="0.002563368639971739" Q="0.10655724783643247" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="160" WEIGHT="200.0" Z="3.015759056365943">
<NAME>Upper respiratory tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.277009209879347" CI_START="0.9683531831689726" DF="0" EFFECT_SIZE="1.7813765182186234" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="0.0" ID="CMP-047.06.01" LOG_CI_END="0.5154776619481856" LOG_CI_START="-0.013966215495142285" LOG_EFFECT_SIZE="0.2507557232265217" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06337376641417312" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="1.856560090238777">
<NAME>Etanercept 10 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.277009209879347" CI_START="0.9683531831689726" EFFECT_SIZE="1.7813765182186234" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.5154776619481856" LOG_CI_START="-0.013966215495142285" LOG_EFFECT_SIZE="0.2507557232265217" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7675" O_E="0.0" SE="0.3109979543996717" STUDY_ID="STD-Moreland-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.09671972764078028" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.693828834046477" CI_START="1.1391318447483199" DF="0" EFFECT_SIZE="2.051282051282051" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" I2="0.0" ID="CMP-047.06.02" LOG_CI_END="0.5674767670783991" LOG_CI_START="0.05657399285248954" LOG_EFFECT_SIZE="0.3120253799654443" MODIFIED="2012-02-20 09:10:50 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.016664346093344155" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="80" WEIGHT="100.0" Z="2.394030871808418">
<NAME>Etanercept 25 mg SC twice weekly</NAME>
<DICH_DATA CI_END="3.693828834046478" CI_START="1.1391318447483199" EFFECT_SIZE="2.051282051282051" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.5674767670783992" LOG_CI_START="0.05657399285248954" LOG_EFFECT_SIZE="0.3120253799654443" MODIFIED="2012-02-20 09:02:11 -0500" MODIFIED_BY="[Empty name]" ORDER="7676" O_E="0.0" SE="0.3001068185898191" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.09006410256410258" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-048" MODIFIED="2013-03-18 12:12:27 -0400" MODIFIED_BY="[Empty name]" NO="48">
<NAME>Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD</NAME>
<DICH_OUTCOME CHI2="43.77166266963751" CI_END="2.883891470620908" CI_START="1.3841030331719029" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9978996300677814" ESTIMABLE="YES" EVENTS_1="479" EVENTS_2="274" I2="90.86166767255422" I2_Q="73.94617055544059" ID="CMP-048.01" LOG_CI_END="0.4599789125670365" LOG_CI_START="0.14116842037542593" LOG_EFFECT_SIZE="0.3005736664712312" METHOD="MH" MODIFIED="2013-03-18 12:11:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.156083059456364E-9" P_Q="0.02153219354007585" P_Z="2.1928398509312038E-4" Q="7.6764147253510275" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13446827870876205" TOTALS="YES" TOTAL_1="600" TOTAL_2="518" WEIGHT="100.0" Z="3.6956974466869195">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6559572702546386" CI_START="1.21673973629983" DF="0" EFFECT_SIZE="1.419460817470287" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="79" I2="0.0" ID="CMP-048.01.01" LOG_CI_END="0.21904912620970404" LOG_CI_START="0.08519769147839755" LOG_EFFECT_SIZE="0.1521234088440508" MODIFIED="2012-05-07 16:57:31 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="8.387957231731484E-6" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="130" WEIGHT="24.934470980427456" Z="4.455034839758287">
<NAME>DMARD naive</NAME>
<DICH_DATA CI_END="1.6559572702546386" CI_START="1.21673973629983" EFFECT_SIZE="1.419460817470287" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="79" LOG_CI_END="0.21904912620970404" LOG_CI_START="0.08519769147839755" LOG_EFFECT_SIZE="0.1521234088440508" MODIFIED="2012-01-31 17:12:02 -0500" MODIFIED_BY="[Empty name]" ORDER="712" O_E="0.0" SE="0.07862499533645725" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.006181889891657924" WEIGHT="24.934470980427456"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2436494308116246" CI_END="7.23509766524237" CI_START="1.9089198668325786" DF="1" EFFECT_SIZE="3.716345203510455" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="17" I2="55.42975715068566" ID="CMP-048.01.02" LOG_CI_END="0.8594443979553402" LOG_CI_START="0.2807876978421374" LOG_EFFECT_SIZE="0.5701160478987388" MODIFIED="2013-03-18 12:11:30 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1341641039310395" P_Z="1.1242941685846458E-4" STUDIES="2" TAU2="0.12813119028529796" TOTAL_1="137" TOTAL_2="110" WEIGHT="29.543975856667643" Z="3.862072004596998">
<NAME>Methotrexate (MTX)-inadequate response</NAME>
<DICH_DATA CI_END="9.968604902184852" CI_START="2.7566842798777613" EFFECT_SIZE="5.2421652421652425" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="9" LOG_CI_END="0.9986343834192503" LOG_CI_START="0.4403870296681745" LOG_EFFECT_SIZE="0.7195107065437124" MODIFIED="2012-01-31 17:13:22 -0500" MODIFIED_BY="[Empty name]" ORDER="7530" O_E="0.0" SE="0.32791725896234997" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.10752972872538089" WEIGHT="14.492010015056847"/>
<DICH_DATA CI_END="4.9386965489029695" CI_START="1.4429282977290927" EFFECT_SIZE="2.669491525423729" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="8" LOG_CI_END="0.6936123423823175" LOG_CI_START="0.15924475058463272" LOG_EFFECT_SIZE="0.4264285464834751" MODIFIED="2012-01-31 17:13:22 -0500" MODIFIED_BY="[Empty name]" ORDER="7531" O_E="0.0" SE="0.31389016858420016" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.09852703793381759" WEIGHT="15.051965841610798"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.022517360829992" CI_END="3.227002005635793" CI_START="0.8265004239873371" DF="1" EFFECT_SIZE="1.6331315090542984" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="178" I2="90.92766228199707" ID="CMP-048.01.03" LOG_CI_END="0.508799235325283" LOG_CI_START="-0.08275691930328545" LOG_EFFECT_SIZE="0.21302115801099875" MODIFIED="2013-03-18 12:11:39 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="9.001283268582627E-4" P_Z="0.15807428301927734" STUDIES="2" TAU2="0.22100704985054784" TOTAL_1="332" TOTAL_2="278" WEIGHT="45.521553162904894" Z="1.4115779013700769">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="3.430823642361403" CI_START="1.5426066766306414" EFFECT_SIZE="2.3005241700640653" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="17" LOG_CI_END="0.5353983942095422" LOG_CI_START="0.18825520672154525" LOG_EFFECT_SIZE="0.3618268004655437" MODIFIED="2012-01-31 17:11:39 -0500" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.20391362671694127" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.04158076716085607" WEIGHT="19.920798377724307"/>
<DICH_DATA CI_END="1.346143552672601" CI_START="1.1056273146955957" EFFECT_SIZE="1.219972574009841" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="161" LOG_CI_END="0.12909137549662633" LOG_CI_START="0.04360875947570651" LOG_EFFECT_SIZE="0.0863500674861664" MODIFIED="2012-01-31 17:11:39 -0500" MODIFIED_BY="[Empty name]" ORDER="7578" O_E="0.0" SE="0.05021291179646201" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.0025213365110792743" WEIGHT="25.60075478518059"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.971149811416836" CI_END="4.675426086294366" CI_START="1.7051004732921782" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.823485652979862" ESTIMABLE="YES" EVENTS_1="369" EVENTS_2="165" I2="85.16933824487228" I2_Q="86.30023489365506" ID="CMP-048.02" LOG_CI_END="0.6698211956351136" LOG_CI_START="0.23174997494772306" LOG_EFFECT_SIZE="0.4507855852914182" METHOD="MH" MODIFIED="2013-03-18 12:12:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.014780348014167E-5" P_Q="6.759518348101734E-4" P_Z="5.490586564143211E-5" Q="14.598790449872133" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20052807058630664" TOTALS="YES" TOTAL_1="600" TOTAL_2="518" WEIGHT="100.0" Z="4.03369803902948">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8895863235173307" CI_START="1.2253228441188946" DF="0" EFFECT_SIZE="1.5216284987277353" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="60" I2="0.0" ID="CMP-048.02.01" LOG_CI_END="0.2763667369362209" LOG_CI_START="0.0882505302897473" LOG_EFFECT_SIZE="0.18230863361298413" MODIFIED="2012-05-07 16:57:55 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.453333117464707E-4" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="130" WEIGHT="31.12567274643376" Z="3.798910921307965">
<NAME>DMARD naive</NAME>
<DICH_DATA CI_END="1.8895863235173307" CI_START="1.2253228441188946" EFFECT_SIZE="1.5216284987277353" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="60" LOG_CI_END="0.2763667369362209" LOG_CI_START="0.0882505302897473" LOG_EFFECT_SIZE="0.18230863361298413" MODIFIED="2012-01-31 17:15:08 -0500" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.11050039097437953" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.012210336405490737" WEIGHT="31.12567274643376"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12447361579921942" CI_END="20.861381037567284" CI_START="3.549647653416388" DF="1" EFFECT_SIZE="8.605263055074252" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="5" I2="0.0" ID="CMP-048.02.02" LOG_CI_END="1.3193430556313324" LOG_CI_START="0.5501852460772338" LOG_EFFECT_SIZE="0.9347641508542831" MODIFIED="2013-03-12 17:16:53 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7242323146784717" P_Z="1.89865519846772E-6" STUDIES="2" TAU2="0.0" TOTAL_1="137" TOTAL_2="110" WEIGHT="20.02162058669895" Z="4.763922427767278">
<NAME>MTX-inadequate response</NAME>
<DICH_DATA CI_END="21.466572319046385" CI_START="2.943279257127233" EFFECT_SIZE="7.948717948717949" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" LOG_CI_END="1.331762703878927" LOG_CI_START="0.4688314697366198" LOG_EFFECT_SIZE="0.9002970868077734" MODIFIED="2012-01-31 17:14:27 -0500" MODIFIED_BY="[Empty name]" ORDER="7533" O_E="0.0" SE="0.5068900785136913" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="0.25693755169561616" WEIGHT="14.474587191042753"/>
<DICH_DATA CI_END="82.47034208424034" CI_START="1.6584270096040779" EFFECT_SIZE="11.694915254237289" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="1.9162977960059562" LOG_CI_START="0.2196963621842661" LOG_EFFECT_SIZE="1.0679970790951112" MODIFIED="2012-01-31 17:14:27 -0500" MODIFIED_BY="[Empty name]" ORDER="7534" O_E="0.0" SE="0.9965920805394045" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="0.993195774993859" WEIGHT="5.5470333956561975"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.035905677152668" CI_END="10.807716627012223" CI_START="0.8125058892011248" DF="1" EFFECT_SIZE="2.9633314712101217" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="100" I2="88.93304074069182" ID="CMP-048.02.03" LOG_CI_END="1.0337339491766055" LOG_CI_START="-0.09017348248658695" LOG_EFFECT_SIZE="0.47178023334500924" MODIFIED="2013-03-18 12:12:03 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.002647285583806447" P_Z="0.09987501995240598" STUDIES="2" TAU2="0.7833283126750806" TOTAL_1="332" TOTAL_2="278" WEIGHT="48.852706666867284" Z="1.6454598304519845">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="13.635383171399639" CI_START="2.5026143417392626" EFFECT_SIZE="5.841584158415841" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="5" LOG_CI_END="1.1346673466697506" LOG_CI_START="0.3983939290492527" LOG_EFFECT_SIZE="0.7665306378595016" MODIFIED="2012-01-31 17:14:51 -0500" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.4324906501224772" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.187048162443363" WEIGHT="17.084706110236187"/>
<DICH_DATA CI_END="2.0283467406407505" CI_START="1.431343997898105" EFFECT_SIZE="1.7038961038961038" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="95" LOG_CI_END="0.3071421985286158" LOG_CI_START="0.1557440212057034" LOG_EFFECT_SIZE="0.23144310986715957" MODIFIED="2012-01-31 17:14:51 -0500" MODIFIED_BY="[Empty name]" ORDER="7579" O_E="0.0" SE="0.08893203879254322" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.00790890752379841" WEIGHT="31.768000556631097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.774445337096218" CI_END="4.12133839090474" CI_START="1.627704598301556" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5900427506186805" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="92" I2="59.07696179118112" I2_Q="66.07626127648619" ID="CMP-048.03" LOG_CI_END="0.6150382746238872" LOG_CI_START="0.21157559037611778" LOG_EFFECT_SIZE="0.41330693250000244" METHOD="MH" MODIFIED="2013-03-18 12:12:27 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.044403496732252856" P_Q="0.0524556922970546" P_Z="5.9301823897506494E-5" Q="5.895576594020061" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11282333441501816" TOTALS="YES" TOTAL_1="600" TOTAL_2="518" WEIGHT="99.99999999999999" Z="4.015571867673712">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01650553845061932" CI_END="58.648476902501116" CI_START="2.2149637439698746" DF="1" EFFECT_SIZE="11.397554561312464" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" I2="0.0" ID="CMP-048.03.01" LOG_CI_END="1.7682567379958225" LOG_CI_START="0.34536662179038075" LOG_EFFECT_SIZE="1.0568116798931015" MODIFIED="2012-05-07 16:58:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8977739701367332" P_Z="0.003597941404182851" STUDIES="2" TAU2="0.0" TOTAL_1="137" TOTAL_2="110" WEIGHT="7.386523473465223" Z="2.911416429759905">
<NAME>DMARD naive</NAME>
<DICH_DATA CI_END="92.41030659850975" CI_START="1.63920341265561" EFFECT_SIZE="12.307692307692308" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.9657204111469375" LOG_CI_START="0.21463284955123846" LOG_EFFECT_SIZE="1.090176630349088" MODIFIED="2012-01-31 17:17:48 -0500" MODIFIED_BY="[Empty name]" ORDER="7536" O_E="0.0" SE="1.0285975017045397" STUDY_ID="STD-Moreland-1999" TOTAL_1="78" TOTAL_2="80" VAR="1.0580128205128205" WEIGHT="4.797177923162684"/>
<DICH_DATA CI_END="163.14803287586722" CI_START="0.5906718134797626" EFFECT_SIZE="9.816666666666666" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.2125818417383196" LOG_CI_START="-0.22865375293140375" LOG_EFFECT_SIZE="0.991964044403458" MODIFIED="2012-01-31 17:17:48 -0500" MODIFIED_BY="[Empty name]" ORDER="7537" O_E="0.0" SE="1.4339938726200825" STUDY_ID="STD-Weinblatt-1999" TOTAL_1="59" TOTAL_2="30" VAR="2.056338426711941" WEIGHT="2.5893455503025393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3670711618173215" CI_START="1.3266511715126401" DF="0" EFFECT_SIZE="1.772082878953108" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="42" I2="0.0" ID="CMP-048.03.02" LOG_CI_END="0.37421131442254507" LOG_CI_START="0.12275674486719913" LOG_EFFECT_SIZE="0.2484840296448721" MODIFIED="2012-05-07 16:58:13 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0723048518266352E-4" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="130" WEIGHT="41.716406734222154" Z="3.873620190705167">
<NAME>MTX-inadequate response</NAME>
<DICH_DATA CI_END="2.3670711618173215" CI_START="1.3266511715126401" EFFECT_SIZE="1.772082878953108" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="42" LOG_CI_END="0.37421131442254507" LOG_CI_START="0.12275674486719913" LOG_EFFECT_SIZE="0.2484840296448721" MODIFIED="2012-01-31 17:17:25 -0500" MODIFIED_BY="[Empty name]" ORDER="714" O_E="0.0" SE="0.14770565887700413" STUDY_ID="STD-Emery-2008-_x0028_COMET_x0029_" TOTAL_1="131" TOTAL_2="130" VAR="0.02181696166428991" WEIGHT="41.716406734222154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3619717072611164" CI_END="8.962868938433948" CI_START="1.1947163695895826" DF="1" EFFECT_SIZE="3.2723212310580148" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="49" I2="57.662490328490215" ID="CMP-048.03.03" LOG_CI_END="0.9524470459007659" LOG_CI_START="0.07726481428617016" LOG_EFFECT_SIZE="0.514855930093468" MODIFIED="2013-03-18 12:12:27 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.12432512793384021" P_Z="0.021108848915253352" STUDIES="2" TAU2="0.3590862196756456" TOTAL_1="332" TOTAL_2="278" WEIGHT="50.89706979231261" Z="2.3060319182861253">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="27.935464996518842" CI_START="1.719481183754231" EFFECT_SIZE="6.930693069306931" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="2" LOG_CI_END="1.4461559047544077" LOG_CI_START="0.2353974277088207" LOG_EFFECT_SIZE="0.8407766662316143" MODIFIED="2012-01-31 17:17:01 -0500" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.7112055227676988" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="50" VAR="0.5058132956152758" WEIGHT="9.079173591427116"/>
<DICH_DATA CI_END="3.1349110577369492" CI_START="1.7646591808852898" EFFECT_SIZE="2.3520309477756287" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="47" LOG_CI_END="0.49622522373706973" LOG_CI_START="0.2466608399484776" LOG_EFFECT_SIZE="0.37144303184277366" MODIFIED="2012-01-31 17:17:01 -0500" MODIFIED_BY="[Empty name]" ORDER="7580" O_E="0.0" SE="0.1465953544010425" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.02149019793196725" WEIGHT="41.81789620088549"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-049" MODIFIED="2013-03-18 12:13:56 -0400" MODIFIED_BY="[Empty name]" NO="49">
<NAME>Sensitivity analysis: etanercept vs. disease-modifying anti-rheumatic drug (DMARD)</NAME>
<DICH_OUTCOME CHI2="1.3736629656366466" CI_END="1.1507732200021146" CI_START="0.9885827408792386" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.06659952370143" ESTIMABLE="YES" EVENTS_1="397" EVENTS_2="384" I2="0.0" I2_Q="0.0" ID="CMP-049.01" LOG_CI_END="0.06098974673529108" LOG_CI_START="-0.004986975916855475" LOG_EFFECT_SIZE="0.028001385409217813" METHOD="MH" MODIFIED="2013-03-18 12:13:13 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5031678925236922" P_Q="0.5135626141946983" P_Z="0.09617863809161056" Q="1.3327667948116155" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="547" TOTAL_2="565" WEIGHT="100.0" Z="1.663668782356734">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.30380591998439" CI_START="0.9739817750455153" DF="0" EFFECT_SIZE="1.1268909460374803" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="129" I2="0.0" ID="CMP-049.01.01" LOG_CI_END="0.11521294864059758" LOG_CI_START="-0.01144916947787021" LOG_EFFECT_SIZE="0.05188188958136368" MODIFIED="2012-05-07 16:58:34 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10835388755644178" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="33.23567704780891" Z="1.605636105567864">
<NAME>DMARD naive</NAME>
<DICH_DATA CI_END="1.30380591998439" CI_START="0.9739817750455153" EFFECT_SIZE="1.1268909460374803" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="129" LOG_CI_END="0.11521294864059758" LOG_CI_START="-0.01144916947787021" LOG_EFFECT_SIZE="0.05188188958136368" MODIFIED="2012-01-31 17:21:52 -0500" MODIFIED_BY="[Empty name]" ORDER="7559" O_E="0.0" SE="0.07440195517038459" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.005535650933175917" WEIGHT="33.23567704780891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.259353559642424" CI_START="0.921875439234755" DF="0" EFFECT_SIZE="1.0774818401937045" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="84" I2="0.0" ID="CMP-049.01.02" LOG_CI_END="0.100147674067756" LOG_CI_START="-0.035327755418694935" LOG_EFFECT_SIZE="0.032409959324530536" MODIFIED="2013-03-18 12:13:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34836296455951143" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="22.032932466023855" Z="0.9377693542996428">
<NAME>Methotrexate (MTX)-inadequate response</NAME>
<DICH_DATA CI_END="1.259353559642424" CI_START="0.921875439234755" EFFECT_SIZE="1.0774818401937045" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="84" LOG_CI_END="0.100147674067756" LOG_CI_START="-0.035327755418694935" LOG_EFFECT_SIZE="0.032409959324530536" MODIFIED="2012-01-31 17:27:01 -0500" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.07957893789453278" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.006332807356421905" WEIGHT="22.032932466023855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.12876741514234" CI_START="0.9152950760174777" DF="0" EFFECT_SIZE="1.0164424514200299" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="171" I2="0.0" ID="CMP-049.01.03" LOG_CI_END="0.052604463868073346" LOG_CI_START="-0.03843887399124692" LOG_EFFECT_SIZE="0.007082794938413197" MODIFIED="2013-03-18 12:13:13 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7604010544264631" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="44.731390486167236" Z="0.3049541749144324">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="1.12876741514234" CI_START="0.9152950760174777" EFFECT_SIZE="1.0164424514200299" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="171" LOG_CI_END="0.052604463868073346" LOG_CI_START="-0.03843887399124692" LOG_EFFECT_SIZE="0.007082794938413197" MODIFIED="2012-01-31 17:27:03 -0500" MODIFIED_BY="[Empty name]" ORDER="7560" O_E="0.0" SE="0.05347930733035546" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.0028600363125346117" WEIGHT="44.731390486167236"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6767708281641327" CI_END="1.3471536762663172" CI_START="1.0232281082316559" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1740721901413491" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="220" I2="0.0" I2_Q="0.0" ID="CMP-049.02" LOG_CI_END="0.12941714059870774" LOG_CI_START="0.009972461769889113" LOG_EFFECT_SIZE="0.0696948011842984" METHOD="MH" MODIFIED="2013-03-18 12:13:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7129205403733475" P_Q="0.7139107839091924" P_Z="0.022181841284308702" Q="0.6739947583645389" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="547" TOTAL_2="565" WEIGHT="100.0" Z="2.28723960866722">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4699625559664824" CI_START="0.9429488037851276" DF="0" EFFECT_SIZE="1.1773272415762421" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="85" I2="0.0" ID="CMP-049.02.01" LOG_CI_END="0.16730627220106659" LOG_CI_START="-0.025511886093204317" LOG_EFFECT_SIZE="0.07089719305393113" MODIFIED="2012-05-07 16:58:59 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14949543885950478" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="38.259049263477564" Z="1.4413159654664849">
<NAME>DMARD naive</NAME>
<DICH_DATA CI_END="1.4699625559664824" CI_START="0.9429488037851276" EFFECT_SIZE="1.1773272415762421" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="85" LOG_CI_END="0.16730627220106659" LOG_CI_START="-0.025511886093204317" LOG_EFFECT_SIZE="0.07089719305393113" MODIFIED="2012-01-31 17:24:27 -0500" MODIFIED_BY="[Empty name]" ORDER="7562" O_E="0.0" SE="0.11326234064733173" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.012828357808912214" WEIGHT="38.259049263477564"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8635239637917635" CI_START="0.9339906362280546" DF="0" EFFECT_SIZE="1.3192853870819972" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="37" I2="0.0" ID="CMP-049.02.02" LOG_CI_END="0.2703349818902942" LOG_CI_START="-0.029657477790110888" LOG_EFFECT_SIZE="0.12033875205009163" MODIFIED="2012-05-07 16:59:10 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1158492416859405" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="16.954897523786432" Z="1.5724369886759595">
<NAME>MTX-inadequate response</NAME>
<DICH_DATA CI_END="1.8635239637917635" CI_START="0.9339906362280546" EFFECT_SIZE="1.3192853870819972" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="37" LOG_CI_END="0.2703349818902942" LOG_CI_START="-0.029657477790110888" LOG_EFFECT_SIZE="0.12033875205009163" MODIFIED="2012-01-31 17:26:48 -0500" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.17621705580289493" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.031052450755840587" WEIGHT="16.954897523786432"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.366950251060561" CI_START="0.9116385103426713" DF="0" EFFECT_SIZE="1.116317378969525" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="98" I2="0.0" ID="CMP-049.02.03" LOG_CI_END="0.1357527090937666" LOG_CI_START="-0.04017733720375077" LOG_EFFECT_SIZE="0.04778768594500793" MODIFIED="2013-03-18 12:13:33 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.28698196625258043" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="44.786053212736" Z="1.0647657444292753">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="1.366950251060561" CI_START="0.9116385103426713" EFFECT_SIZE="1.116317378969525" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="98" LOG_CI_END="0.1357527090937666" LOG_CI_START="-0.04017733720375077" LOG_EFFECT_SIZE="0.04778768594500793" MODIFIED="2012-01-31 17:26:51 -0500" MODIFIED_BY="[Empty name]" ORDER="7563" O_E="0.0" SE="0.10334218006293605" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.010679606180160298" WEIGHT="44.786053212736"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6488846971257505" CI_END="1.6596506924503613" CI_START="1.0394996672451569" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3134711045719067" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-049.03" LOG_CI_END="0.22001669147101238" LOG_CI_START="0.016824354645251016" LOG_EFFECT_SIZE="0.11842052305813171" METHOD="MH" MODIFIED="2013-03-18 12:13:56 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4384796745636793" P_Q="0.43938481409731733" P_Z="0.02234013254587671" Q="1.6447603928275527" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="547" TOTAL_2="565" WEIGHT="100.0" Z="2.284534582850536">
<NAME>ACR-70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours DMARD alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6808641371582018" CI_START="0.8187272074548836" DF="0" EFFECT_SIZE="1.1731023830538394" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" I2="0.0" ID="CMP-049.03.01" LOG_CI_END="0.2255326111985038" LOG_CI_START="-0.08686077715509906" LOG_EFFECT_SIZE="0.06933591702170236" MODIFIED="2012-05-07 16:59:29 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3842837027389189" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="217" WEIGHT="43.6103247789567" Z="0.8700305785202578">
<NAME>DMARD naive</NAME>
<DICH_DATA CI_END="1.6808641371582018" CI_START="0.8187272074548835" EFFECT_SIZE="1.1731023830538394" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" LOG_CI_END="0.2255326111985038" LOG_CI_START="-0.08686077715509911" LOG_EFFECT_SIZE="0.06933591702170236" MODIFIED="2012-01-31 17:24:52 -0500" MODIFIED_BY="[Empty name]" ORDER="7565" O_E="0.0" SE="0.18350142269111824" STUDY_ID="STD-Bathon-2000-_x0028_ERA_x0029_" TOTAL_1="206" TOTAL_2="217" VAR="0.03367277212966444" WEIGHT="43.6103247789567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.508554403930611" CI_START="1.0046297648902969" DF="0" EFFECT_SIZE="1.8774445893089962" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" I2="0.0" ID="CMP-049.03.02" LOG_CI_END="0.5451282151226863" LOG_CI_START="0.0020060411698511874" LOG_EFFECT_SIZE="0.2735671281462687" MODIFIED="2012-05-07 16:59:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04833146330648108" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="13.117715091941424" Z="1.97444237865826">
<NAME>MTX-inadequate response</NAME>
<DICH_DATA CI_END="3.508554403930611" CI_START="1.0046297648902969" EFFECT_SIZE="1.8774445893089962" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5451282151226863" LOG_CI_START="0.0020060411698511874" LOG_EFFECT_SIZE="0.2735671281462687" MODIFIED="2012-01-31 17:26:38 -0500" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.31903265347801596" STUDY_ID="STD-Hu-2009" TOTAL_1="118" TOTAL_2="120" VAR="0.10178183398522381" WEIGHT="13.117715091941424"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8321405903863246" CI_START="0.8998119984814703" DF="0" EFFECT_SIZE="1.2839712170195015" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" I2="0.0" ID="CMP-049.03.03" LOG_CI_END="0.26295879645316506" LOG_CI_START="-0.04584822006181494" LOG_EFFECT_SIZE="0.10855528819567507" MODIFIED="2013-03-18 12:13:56 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1682104452373615" STUDIES="1" TAU2="0.0" TOTAL_1="223" TOTAL_2="228" WEIGHT="43.27196012910187" Z="1.3779768192836268">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="1.8321405903863246" CI_START="0.8998119984814703" EFFECT_SIZE="1.2839712170195015" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="43" LOG_CI_END="0.26295879645316506" LOG_CI_START="-0.04584822006181494" LOG_EFFECT_SIZE="0.10855528819567507" MODIFIED="2012-01-31 17:26:40 -0500" MODIFIED_BY="[Empty name]" ORDER="7566" O_E="0.0" SE="0.18139477012028424" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="223" TOTAL_2="228" VAR="0.03290406262699076" WEIGHT="43.27196012910187"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-050" MODIFIED="2013-03-18 12:15:36 -0400" MODIFIED_BY="[Empty name]" NO="50">
<NAME>Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept</NAME>
<DICH_OUTCOME CHI2="4.043785923147224" CI_END="1.360420164398597" CI_START="1.0705700517442245" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2068243806760337" ESTIMABLE="YES" EVENTS_1="344" EVENTS_2="282" I2="50.54139764047087" I2_Q="75.09158309208745" ID="CMP-050.01" LOG_CI_END="0.13367306050130504" LOG_CI_START="0.02961509021111073" LOG_EFFECT_SIZE="0.08164407535620789" METHOD="MH" MODIFIED="2013-03-18 12:14:43 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13240482501984197" P_Q="0.0451051374678737" P_Z="0.0021009164786367123" Q="4.014707171865004" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.005746412838286207" TOTALS="YES" TOTAL_1="405" TOTAL_2="395" WEIGHT="100.0" Z="3.075582712270541">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-050.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-05-07 16:59:51 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DMARD naive</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7194781867288078" CI_START="1.1690640578541782" DF="0" EFFECT_SIZE="1.417808219178082" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="44" I2="0.0" ID="CMP-050.01.02" LOG_CI_END="0.23539667074052698" LOG_CI_START="0.06783830860443427" LOG_EFFECT_SIZE="0.15161748967248062" MODIFIED="2013-03-18 12:14:35 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.8964346262353666E-4" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="24.20764599432934" Z="3.5470007631499185">
<NAME>Methotrexate (MTX)-inadequate response</NAME>
<DICH_DATA CI_END="1.7194781867288078" CI_START="1.1690640578541782" EFFECT_SIZE="1.417808219178082" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="44" LOG_CI_END="0.23539667074052698" LOG_CI_START="0.06783830860443427" LOG_EFFECT_SIZE="0.15161748967248062" MODIFIED="2012-01-31 17:26:25 -0500" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.09842461134601027" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.009687404118613173" WEIGHT="24.20764599432934"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004495938456848627" CI_END="1.240717055682532" CI_START="1.0570129348034916" DF="1" EFFECT_SIZE="1.1451873105687733" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="238" I2="0.0" ID="CMP-050.01.03" LOG_CI_END="0.09367275235597296" LOG_CI_START="0.02408030185748268" LOG_EFFECT_SIZE="0.058876527106727805" MODIFIED="2013-03-18 12:14:43 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9465404977747593" P_Z="9.120705561160871E-4" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="75.79235400567066" Z="3.316333074562048">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="1.3612623254667457" CI_START="0.9730787292602137" EFFECT_SIZE="1.150919377652051" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="70" LOG_CI_END="0.13394182507454638" LOG_CI_START="-0.011852020677117887" LOG_EFFECT_SIZE="0.06104490219871425" MODIFIED="2012-01-31 17:28:54 -0500" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.08564002668570335" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.0073342141707279825" WEIGHT="28.562574024657156"/>
<DICH_DATA CI_END="1.2526662275999534" CI_START="1.043849738750274" EFFECT_SIZE="1.1435013399299114" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="168" LOG_CI_END="0.09783536882215875" LOG_CI_START="0.018637986857561586" LOG_EFFECT_SIZE="0.05823667783986019" MODIFIED="2012-01-31 17:28:54 -0500" MODIFIED_BY="[Empty name]" ORDER="765" O_E="0.0" SE="0.046520934199367724" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.0021641973187819016" WEIGHT="47.22977998101351"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.813171641378819" CI_END="1.790953269611866" CI_START="1.1628218528546015" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4431076187679408" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="177" I2="58.447357604993606" I2_Q="0.0" ID="CMP-050.02" LOG_CI_END="0.2530842541826599" LOG_CI_START="0.06551318485018646" LOG_EFFECT_SIZE="0.15929871951642316" METHOD="MH" MODIFIED="2013-03-18 12:15:03 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09012250675721456" P_Q="0.6977171958279083" P_Z="8.713268764580979E-4" Q="0.15085771806015805" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02123511017070647" TOTALS="YES" TOTAL_1="405" TOTAL_2="400" WEIGHT="99.99999999999999" Z="3.329082188918181">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-050.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-05-07 17:00:21 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DMARD naive</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8167126078027573" CI_START="0.9975486085782341" DF="0" EFFECT_SIZE="1.3462017434620175" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="33" I2="0.0" ID="CMP-050.02.02" LOG_CI_END="0.2592862301604411" LOG_CI_START="-0.001065932811182198" LOG_EFFECT_SIZE="0.12911014867462942" MODIFIED="2012-05-07 17:00:27 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.051905698388429185" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="27.204748657417742" Z="1.9439150307229556">
<NAME>MTX-inadequate response</NAME>
<DICH_DATA CI_END="1.8167126078027573" CI_START="0.9975486085782341" EFFECT_SIZE="1.3462017434620175" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="33" LOG_CI_END="0.2592862301604411" LOG_CI_START="-0.001065932811182198" LOG_EFFECT_SIZE="0.12911014867462942" MODIFIED="2012-01-31 17:27:47 -0500" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.15293214929352314" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.02338824228753645" WEIGHT="27.204748657417742"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.183728948645247" CI_END="2.021525633810603" CI_START="1.0665374584506546" DF="1" EFFECT_SIZE="1.4683435605052413" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="144" I2="76.09787793915726" ID="CMP-050.02.03" LOG_CI_END="0.3056792527445937" LOG_CI_START="0.02797611314947748" LOG_EFFECT_SIZE="0.16682768294703557" MODIFIED="2013-03-18 12:15:03 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.040813939101780106" P_Z="0.01852959827766238" STUDIES="2" TAU2="0.04084166351256272" TOTAL_1="332" TOTAL_2="331" WEIGHT="72.79525134258225" Z="2.3548617468076114">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="1.5942958449557016" CI_START="0.9457462998505676" EFFECT_SIZE="1.2279248332996564" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="49" LOG_CI_END="0.20256891424327664" LOG_CI_START="-0.02422534917095637" LOG_EFFECT_SIZE="0.08917178253616012" MODIFIED="2012-01-31 17:29:17 -0500" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.13322007297923025" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.01774758784459143" WEIGHT="31.141176719001546"/>
<DICH_DATA CI_END="2.0283467406407505" CI_START="1.431343997898105" EFFECT_SIZE="1.7038961038961038" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="95" LOG_CI_END="0.3071421985286158" LOG_CI_START="0.1557440212057034" LOG_EFFECT_SIZE="0.23144310986715957" MODIFIED="2012-01-31 17:29:17 -0500" MODIFIED_BY="[Empty name]" ORDER="766" O_E="0.0" SE="0.08893203879254322" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="228" VAR="0.00790890752379841" WEIGHT="41.654074623580705"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.302719184243633" CI_END="1.9023042763135658" CI_START="1.2737749948626538" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5566334249875649" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="105" I2="39.44383738280108" I2_Q="0.0" ID="CMP-050.03" LOG_CI_END="0.27927998418654676" LOG_CI_START="0.10509271911412753" LOG_EFFECT_SIZE="0.19218635165033715" METHOD="MH" MODIFIED="2013-03-18 12:15:36 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19178916484432273" P_Q="0.8028409368463718" P_Z="1.5254483790624493E-5" Q="0.06233615895879237" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="405" TOTAL_2="395" WEIGHT="100.0" Z="4.324981248177988">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept+DMARD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-050.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-05-07 17:00:40 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DMARD naive</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4054406305387426" CI_START="0.8987292393533559" DF="0" EFFECT_SIZE="1.4703196347031964" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" I2="0.0" ID="CMP-050.03.02" LOG_CI_END="0.3811946424077351" LOG_CI_START="-0.04637112869630991" LOG_EFFECT_SIZE="0.16741175685571258" MODIFIED="2012-05-07 17:00:45 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12482487010912917" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="69" WEIGHT="17.405773701730638" Z="1.534832936595981">
<NAME>MTX-inadequate response</NAME>
<DICH_DATA CI_END="2.4054406305387426" CI_START="0.8987292393533559" EFFECT_SIZE="1.4703196347031964" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" LOG_CI_END="0.3811946424077351" LOG_CI_START="-0.04637112869630991" LOG_EFFECT_SIZE="0.16741175685571258" MODIFIED="2012-01-31 17:27:59 -0500" MODIFIED_BY="[Empty name]" ORDER="386" O_E="0.0" SE="0.2511542504312172" STUDY_ID="STD-Kameda-2010" TOTAL_1="73" TOTAL_2="69" VAR="0.06307845750966656" WEIGHT="17.405773701730638"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.227544936346395" CI_END="1.9615681744114992" CI_START="1.2643290620582004" DF="1" EFFECT_SIZE="1.574823053589484" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="87" I2="69.01669783931786" ID="CMP-050.03.03" LOG_CI_END="0.2926034066568396" LOG_CI_START="0.10186012081121594" LOG_EFFECT_SIZE="0.19723176373402773" MODIFIED="2013-03-18 12:15:36 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07240921736708972" P_Z="5.050634948218246E-5" STUDIES="2" TAU2="0.0" TOTAL_1="332" TOTAL_2="326" WEIGHT="82.59422629826936" Z="4.053271409394427">
<NAME>Non-MTX inadequate response</NAME>
<DICH_DATA CI_END="1.7359451432313495" CI_START="0.6948084178876175" EFFECT_SIZE="1.0982482863670981" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.2395359971259908" LOG_CI_START="-0.15813492853812916" LOG_EFFECT_SIZE="0.04070053429393085" MODIFIED="2012-01-31 17:29:36 -0500" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.2335938702379337" STUDY_ID="STD-Combe-2006" TOTAL_1="101" TOTAL_2="103" VAR="0.054566096212736614" WEIGHT="24.213126239240086"/>
<DICH_DATA CI_END="2.2800728671182866" CI_START="1.3778864048574713" EFFECT_SIZE="1.7724788872329855" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="61" LOG_CI_END="0.35794872650997434" LOG_CI_START="0.13921341512088753" LOG_EFFECT_SIZE="0.24858107081543093" MODIFIED="2012-01-31 17:29:36 -0500" MODIFIED_BY="[Empty name]" ORDER="767" O_E="0.0" SE="0.12848620466720345" STUDY_ID="STD-Klareskog-2004-_x0028_TEMPO_x0029_" TOTAL_1="231" TOTAL_2="223" VAR="0.016508704789782495" WEIGHT="58.38110005902927"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-03-14 18:53:09 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-03-14 18:53:09 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzcAAAZ8CAYAAAA3dnvSAACAAElEQVR42uydD2RX3//HP8wkk0SS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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-03-14 15:57:30 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVgAAAIoCAIAAACjxGRLAAAbu0lEQVR42u3dsY4dtxnF8QUCBClU
qNAT5BlUBYtUSZV3isotBMSl3iLIIxiRXSqq0gVxJMNW4WKddLZjTK6ygbHZnZnLe4cfL7/h72AR
OCvp6IpL/vmRw+G5uiIiOmgiooEFBEQEBEQEBEQEBEQEBEQEBEQEBEQEBEQEBEQEBJS2szoOCwQ0
5qCa/ZC6LhDQQINq/YPpvUBABhUBAY1KMZ0WCGjQQXX/A6tfgIAGHVRAAARkUAEBEJBB9WgVo9MC
ARlUBAREBAQ0emd1yhgIaNhB9WAho9MCAY04qDw1AAIyqIAACMigevRpdVogIIOKgICIgIDGLF5k
dgIBGVQEBEQEBET/11mVMEBAww6q2XsW/RyBgMYaVEAABGRQPfyQOi0Q0FiD6mpZfo5AQAYVAQER
AQERAQERAQERAQEN3VltcAIBDTuo9FIgIIMKCICADCosAAIyqCZ3KAABGVQEBEQEBEQLhYwGAQIa
blC5jwAIyKCK/cxqDSAAgqFBMNv/BxwUQAAEaWbX6s7rJkONCyCwR1CtA5hdgYD0pMSzqyRIIKAc
iIk7BCVwHQgMqvqL+XSzKxAAAaUZVHEbnEAABNbzCQZVg5uX77vZI6Bhft4J19t6KRBQeEVQvUsZ
vUBAFM6v0KNK9gjIoEpTxQQtZ+wR0LhLg7gjxp4aAAGZXbt+1wAIgAALDKr5j21pQGR2HXti0BDU
/+x6v37RaYGARhxUQWcWJ3c6A4FJO1EBb9EBBGR2BQIgILPr/y9n+r8EDQgo2R6BDuCidCCgNIhp
cAgKCICA+h2ube4jGJkCQDD6dJ3xjYBErQEEpCgYd3YFAlJrhF8o5mQhENA07KByjgAIyKBy9gEI
yKBK+JlzBcABARCYXevfqpQuAA4IRt8j0AH0fyCgcMQkWnREF1/2CMjsWpMsDc4vj7YEAwLbBAlG
1GPz0GuXB3x1GghGp0DEuGpTa3jSAQTUaQfN+BZDgwHW/wcGAiBINqhcTAIENNxM1RKLuWoNIKBB
5+2MIMjyMBUIRp/96g6A1Ft61T9zonhVIBh6UbD+zXHKbAFwQKCAz3GzYOr6CwgIYuovszNuQDhi
TFS/3Ki4kHFnIRBQSgpYdAABdT1Q93E/8oDxqkBAdh8sDYDAoBr+jQD9HwistwPJ4vqjyeWlNOYc
GH0fQcTNgt6YBAIs8IGbfmYgoK43CPoPFM1bxaRgGRBQmjkwEQvS7ZgAAeUAQehK3gYnEFgduO2H
gMC83f3yVWsAAen6azX8aCt5IKA0IAgKXI+77Uf/BwJ7BGnu5GngXB0NicoNIKCQWiMFCBqHqfV8
TxEQUA4QTAlj2pZqDSCgLgZq9Bzo8SEQEKUcsS2xCATU9UxlOTNsUwDB6FOfZ/JJkyCBgOpXBFpj
Ctvg9NIRUdSIrf5+RIRzopEFBNYIUdtjU+TJwsltiEBAdQfVsCcLoyNhE7EACICg9+Ea6hwdCWuP
gICg8pQY9yjeISggwAIXkxAQEIVx1tKAcpQDKWct5QYQUP8siH4mn+ggsFwDSja1DvvUoGULWxrQ
cIVGxucRDSLPLA0ICIZbdAABpVkdTDHP5BONhDbwAgIaq+trjfWdAiCgPXf9uHP7ba5Xi1h05KsQ
jQ0gqLsoWP8mAQH1tUfgiHGbuJfOWwMIaFx4RT/td6CIKM283T7XAAio09k1420/PjMQUKdzYLOP
HbqvYY+AgKC7ObDZSl6uARBgwdT5cG3QFHINgGD0DYIBX7NpAwJLA6KULAh90cBmIY1bbuALEFDv
w3Ua9cXb9iywNKBRVsWhfak6vBo8j8iygQoEQFB5AAd1p2af2eNDAoKQOTBdFePxIQ23R5DuHcFc
IIi7CQoICLxyvDqd6KgSEFDUcJ2Gf4gABJRpaq37hn+Wrg8EQEDz++QVby60tx+9nAECqjmi7n+n
ZxDY2wcCSgOCKX7jLREIBJxQypK1857Q4KnBFHDlCRAQZaqPBJwAAUXN2y4mURGQ3YcEiMmV+wQE
NDQIWiKmomfJN4GAsKALEORCDBBQ/Q46pboa3A8OCKj+7JroYpLoNOTBr1cDAiDIAYKM+xpAQIOC
IOO40v+BwB5BeI2dooA3BICAUlYxKTY4E0U/AQGNvpyJPqGw8k8AAupoYZzlavB0IAh9yxMIKKqD
JioKUrwjCAQEBJlao9kGp6UBdd37Q8eV1k7THzQERazkIQYICAhqlsHp3j7MBS8gsDSwtx+1Y+LO
Qsoxb0cXBan39oGAgGDEKiaifVxeSliQqYpJ9+YFEFDXHTToyhO9FAgo37ztBWcgICBIlhEQ8eaF
pQFlWh0ETdqJMgIcuAYC83ZIAZ/r7pCWjw9VBDQKCFpO3d3CK/qlbCCgcQv4vGFqlgaUY1wF9f6k
hYaThUSjrIrbFPBOFhIQVB4JGbch7RHQoOvtZsNVvwUCip3GR1vJu/IECCgHC5pVBKEXkwABjQKC
dIuOuNZwoIiS7RH0XFm0759AQNQpCFru7adbzgABjcKCpFt69ggo09KgVk9tEHlGQEAh8/bgbxwl
mreBgGIH1cgsyHgaEgho0K7fctHhqQENuk0wcq0BBEBAFh2xBXyWvRggoHyLjqR86XmzAAhGXxpM
SU7XJ71eLVl/0BBjztsZ7xoGAiAgIMh34WqK5QwQAEH9lXzEBsGU8NhPIngBweh7BB4fTuJegICC
5sBEIAiNaQMCUmtceR7hiDGlmQbdWZhl3gYCylEMJ110ZAw1qItyIACCNHNgulenp/g3Jmv9BIEA
CNJUBHGXqcQtOqLfmAQCqtBHh10SR8MlHcqBgMJHV2h1He0/CMqBgHIsiWcLeF23Mr41BPUMgtla
I8J52IUSEFAmFqRYb2dcggEBxfbOwd9rbPMWgz0C6mI+2UcJk+hdA08NaMTqvTEWB0QMEABBjkGl
1lgxtzSgvljQ+JReugORvX9OA8MeQecgmBbeNdjin/dkIRBQ10uD9mEh/U+zES1cHV5AAAQ5iuGM
IHjQICoCGosFLRFT5R/SZl3Q81gDAhsEzhHE3rMY1MLV3+wCAup37ZoaBHH//OqfGQgocSETMa7G
vMERCAyqHLkG0Uv3urVMg/qoLryAwKq4ak+Kv5zLzy6inYEACHLM21PmF5z7/ycAARDkGGPRZXbI
JnyerVMgUGHG5hFlfGowYAkDBBTS9RNd+6X/AwHFgmCqd8twsx34OMr0/IGBYOgVQf/BG5dqlqDh
2i0LgGD0qTuiS93vWyMvDRJlKAHB6BTof95OfULBxSQEBPmqmNHXjMbG4JsF/Q/XjFGlbX6CkyPG
NE6tkbeKaZBrMHnpiMZZdGSctOsOVyCg2KXByMN1kmsABOZtarCcCQ1Tc0MRjQWCpMd+PD6kEVmQ
+hTwsBUTENggyDG7OvYTWh8BAaWZXfO91ZvnNCQQUA4QuIIdCKj3wnIHZXa6usPbh1StDyW6PiTv
cqbuyUKXl1IUCKbu3z6ckm9w9t/OQAAEdTpo6ojxvCcLa8ELCLBABwBcIKBs07VaY/LUgAzXNh9+
0B+ffjzgiA2dYTIW8HmxCwR0fqe/vxsf2l/rwivLWwz3P2T/jzmAYGgQhI6BiH6fKCYg6DMvOdgs
pAodtPr4b5D/3fPhZSCgQUEQt+nQoCJo1s5AQCoCIKh2ytgeAdUvg+MCkTv/zKGt8cCq8ze7gIDC
uaMd0swQGoIICICACAiAgAgIgIAICICACAiAYJc/UaJTHosCwQ5BwJnzqc5AAAScOQMBEHDmDARA
wJkzEAABZ85AAAScOQPBmCD48cfbb7+9+fDh+v37p//4x9W7d0++/vr57e2LH3/8plvn2x9ub97d
XL+9fvrZ06tPr568fvL8zfMXX7z45vsRnSPaGQjGAsG//vXq/ftnh97z+OvQq/75z086dH711atn
nz87jKXHX4cx9smXYzkHtTMQDASCw6Qx24Hufx1+T1fOhyl0djjd/zr8nkGc49oZCEYBwWEmOdqH
7r6WZpX2zod59eiIuvtammP35BzXzn2B4KRLVyJSJZcu/N/yzcefeenU59HToIU3Xs3+0mFVeb+e
/POfr37966tf/OLj1+9+d/WXvzysMP/97w8Xdz6ssZeq69l6+8N3e3aOa+ceQVC+UgpNlZw1P+Ob
J33gkpFfwoLZ73/77c39jvLLX378of/pT1d//OPH//jVr4rKy8bON+9uCkfUSrG9G+e4ds4EgqXJ
c1pO6Xg8r5bneewPBB8+XM/WkH/728fW+PnPH37/66+fX9z5+u31zOC509ygev5mz85x7ZwGBOsD
7wEg1v9IYR1RHQTnDeB1EBwlzn3dPWd68PXXv1795jcf2+QPf3j4S+/ePbm4891Tt/JB9eT1np3j
2jnlHkH5mD9j0l7/bRVBcOoewUl3Y89+c3Yy+e1vP/4tv//9/IbTxZ3nh9N9PRpXO3aOa+eUS4N9
gOCkv3cFkRsrgp/97KPb3/8+04c2VgRVnFUEbdp5P0uDiiBYh1HLpUHdimBphbn0tX2PYLuzPYI2
7ZwPBNEVQeEAbgyCFbdyEDzYc777ulP5oZTGzp4atGnnTHsEj4O0ZqO1Vh40lIzVpfK7yjmCo3sB
SwO+/PsrP+wHT6HXu9GWcwQVnZ0jaNPO3YFg3woN3i75vpOF2Z1HOVmIBVWsvGuwY2fvGlAd3Pz3
3bWny++uvezQ+TDHzu/G/7e6fvl+LOegdgaC4eqOpbfZZ1eVnTgvvds/u8bevXNEOwOBBQhnzkAA
BJw5AwEQcOYMBEDAmTMQAAFnzkAABJw5A8FuQUAkDRkIzIGcVQRAoOtzBgLS9TkDAen6nIGAdH3O
QEC6PmcgoKJulCulN/ozZ2wNaci0FQTpUnonmcVNnIFgIBBkvDnHPUJtnIFgFBBkvEvPzYJtnAcF
QWHgcty+Tmjs8m5SemUWt3EeFASFeUdxIGgWu3xfGVN6ZRa3cR4RBIWphA9+9XFC4cpvOKno2AiC
cjZlTOmVWdzGGQiKJuqjOUuF4Ut1QXDq0iBjSq/M4jbOQHBmxT5dOm31jMizjCm9MovbOANBIAgK
3wCPoMxuUnplFrdxBoLzR93GZfwUFrs87SilV2ZxG2dPDc4c59v3COJil6cdpfTKLG7jPCgIVrb0
ywOUj27drawLmsUu31fGlF6ZxW2cxwXBmPsgThZmbw0nC6nOhqh3DbK3hncNqAIIpoQpvZPM4ibO
QDAWCKZsKb3Rnzlja0hDpgog4MwZCICAM2cgAALOnIEACDhzBgIg4MwZCICAM2cgGAcERNKQgcAc
yFlFAAS6PmcgIF2fMxCQrs8ZCEjX5wwEpOtzBgIq6kaShbUGEIwOAsnCWgMIRgeB2360BhCMDgL3
/2mNS4Kg/JBjxF9a8ZtLDVpyYfH6D2MpGeX+FcknnRWdXa9KFtYaFwbBBafE6Ljhld+88tuW/m9h
UOL6b5YsrDV6zDVY768rQcNTWTzxVBZkFgGCwtyk2Wm/MQgkC2uNfkFwRl7Q/YL5IiA4I+B01v/x
/54KgqmP7EM5y9lb48J7BLUiQKunjB5d9oeCYGUjYAsIJAtrja6XBkcn/6P4aBw3rCK47BwoZzlr
GvIWEJT8qcKlchsQlG8fNAaBZGGtsQcQLA2V8g2zCBCc/dTg6H9UB4FkYa2RdY9gOhZPvDISWsYN
n32OYPY/yvcIOklDlrOcvTUagSBUF/nknTTXSSCYnKXTGnsFwQU/9sVb7NSThXdyul5r7LMioFMh
JVlYawABEPxvHStZWGsAwegg4MwZCICAM2cgAALOnIEACDhzBgIg4MwZCICAM2cgGAcERNKQgcAc
yFlFAAS6PmcgIF2fMxCQrs8ZCEjX5wwEpOtzBgIq6kZxycIyi9s4S0OmrSCISxaWWdzGWRoybQVB
3P027hFq4+yGItoKgrgb79ws2MbZnYU5xlt5M4aGNTfO0pVZ3MY5fRoyEKz8tuiw5p8Ul6Urs7iN
c/o05AFBUBiL1hIEcVm6MovbOKdPQwaCHkAQl6Urs7iNc/o05B2D4NQQp5I1QjkISvKaf1Jclq7M
4jbO6dOQVQR1QXAfARsrgipZujKLL1gRZEpDBoKSP15xFdA4S1dm8WX3CNKkIY8MgvLqvfFTg4pZ
ujKLL/LUIF8a8oAgWK/eG4c13ykuS1dmcRtnaci0lVB3crIwu7OThVQBBJN3DfI7e9eAKoBgikwW
llncxlkaMlUAwRSZLCyzuI2zNGSqAALOnIEACDhzBgIg4MwZCICAM2cgAALOnIEACDhzBoJxQEAk
DRkIzIGcVQRAoOtzBgLS9TkDAen6nIGAdH3OQEC6PmcgoKJulCul904/3N6+u7l5e3392dOnn15d
vX7y5M3z51+8ePH9N9KQpSHT6d0oXUrvQV+9evX5s2ezF3wcuPDlJ9KQpSHTKT/sjDfnHKb9o7d+
HX5PV63hhiLqFwQZ79I71AKFFwIv1QXuLASCTYHFoXs8J91NvHIPcvnHyJjS+8Pt7dKKYHaN8N0H
achuMS4YEtH/zOppyNNcMsJ5uQYZU3rf3dyc8pHnFwjSkIFgbczMxgo8GHgnpQzMDuCjDVuSZVIF
BBlTet9eX58EgjfPpSFLOioeZiujbum/S2byM0JQp7L8oiogyJjSe/eksPzr9RNpyLIPl4fZxqEY
EUBW+DdWBEHGlN7HA+fZkY8sDVka8vK/bTqWO1YOgpP+VMkb4M1AkDGlV0XQpp3H3SM4dbuucNRV
T0OuCIKMKb32CNq087hPDU5a2G/ZI9iYhlwRBBlTej01aNPOw4FgdoiWg+CMpwbT5jTkKds5goop
vc4RtGnn/YNgTDlZeNnWcLKQugbB5F2DVq3hXQPqGgRTwpTeu7pg6QnC4fvvX0pDloZMJ3ajKVtK
70/7BbP3EczuC3TSGtKQqWsQcOYMBEDAmTMQAAFnzkAABJw5AwEQcOYMBEDAmTMQjAMCImnIQGAO
5KwiAAJdnzMQkK7PGQhI1+cMBKTrcwYC0vU5AwEVdaO4zOKMycLSkIFgRBDEZRZnTBaWhgwEI4Ig
7n6bjLf9uKEICEYEQdyNdxnv/3Nn4TkgWLpaN4IgtTzLE4dXTl8eb7i5I5xL5zqP3qq8cpHxbFJj
eQPGZelmvBFYGnIdEKxnfvQAgiqZZeVXhhfGLs/eX37UoTAQaf37cVm6GTMCpCFXAEH5nf+PgwNK
ZuP1uLHZcbUl3bBzEKwXEeUgiMvSzZgaJA15KwhK+mt5jtDR7KDC3xYBghXEHM0gWR+ij//3PBBM
pyQdxWXpZswRlIa8CQQlITxTpTTBs6MKT61lgkCwskewBIKl+KMqIIjL0s2YLCwN+XwQzA6M9fzf
pV89uqAoXCzEgaA8+DSoIqgOgrgsXfP2BSuC1mnIG4dTyRbg2UuDaVvicHkCemoQxGXpWslfdo+g
aRpySaxw4b5Asz2CwiFUXofXAkF56VGynXnennPFLF17+xd5anCZNOSScwTr+cKNnxqclDh8xjmC
o08N1s8RnASClY999jmCilm6nvZf5ByBNOSoowed/41nQ+onOVmY3Vka8tokeakPf9lGO/Vk4f/m
K+8aJHf2rgHVIVRcZnHGZGFpyEAwKAimyMzijMnC0pCBYFAQcOYMBEDAmTMQAAFnzkAABJw5AwEQ
cOYMBEDAmTMQjAMCImnIQGAO5KwiAAJdnzMQkK7PGQhI1+cMBKTrcwYC0vU5AwEVdaNcKb13+uH2
9t3Nzdvr68+ePv306ur1kydvnj//4sWL77/5ZsDWkIZMW0GQLqX3oK9evfr82bPZCz4OXPjyk0+G
ag1pyLQVBBlvzjlM+0dv/Tr8nkFaww1FtBUEGe/SO9QChRcCL9UFe2oNdxbWHxsXv3FwS1Lz+nHR
3aT0/nB7u7QimF0jfPdhz5nFXaQh7wAES+mjl6XSlmzI6ZRcg4wpve9ubk75yPMLhN20RhdpyPsG
QWGO8/qcXBL9vPKDOQ8E5RVBxpTet9fXJ4HgzfM9ZxZ3kYa8j6XB0ayx9bymjdHPdUFw6tIgY0rv
3ZPC8q/XT/acWdxFGvKOQVA+LMtr+/KmP2+9cGpG65QzpffxkHx25CPvuTW6SEPeNwiO5jifAYLC
N8BrbRz0NgdWSendTUVQpTW6SEMecGmwBQTRSc1ngCBjSu+e9gi2t0YXaci7eXy4Jcf5vPV89aTm
zp8aVEzp3cFTg4qt0UUa8o5BMBXnOJc8NVjxnF01nJfU3PM5goopvTs4R1CxNaQh05nUeyAnC7O3
hpOFVAEEk3cN8reGdw2oAgimhCm9d3XB0hOEw/ffv3w5VGtIQ6YKIJiypfT+tF8wex/B7L7A7ltD
GjJVAAFnzkAABJw5AwEQcOYMBEDAmTMQAAFnzkAABJw5A8E4ICCShgwE5kDOKgIg0PU5AwHp+pyB
gHR9zkBAuj5nICBdnzMQUFE3isv/5dzGWRoybQVBXP4v5zbO0pBpKwji7uTh3MbZDUW0FQRxt/Rx
buPszsJNw2Djvy7oj6/cbnzeN9f/xrh7ezm3cZaGfPLAqxt8HPHHZ8f24/9OkWvAuY2zNOSaIDgj
xbjwj5+UazDtKOmIcxtnacjnzMAbg4+nbSHIR5OO2oMgLu2PcxtnacjhICgfjbXG6goIlshSTpnG
+b+c2zhLQ24KgqPJyCW5yWeAYGk1Uf5Ns+uAFYE05PCKYMvkfx4Izij47RHYI5CGfGQUbUkxnurl
JneyR2AHfmdPDaQhnw+CqTjFeP2pQSFHVqr3yTkCzt3kLO8TBOSU3l6dnSykCiCYnNvP7+xdA6oA
giky/5dzG2dpyFQBBFNk/i/nNs7SkKkCCDhzBgIg4MwZCICAM2cgAALOnIEACDhzBgIg4MwZCMYB
AZE0ZCAwB3JWEQCBrs8ZCEjX5wwEpOtzBgLS9TkDAen6nIGAirpRRJZutLM05Oh2BoKxQBCUpRvq
LA25QTsDwUAgiLvfJs7ZDUVt2hkIRgFB3I13cc7uLGzTznsDwcod4dPpUQLrv1r4Rzq5xTguSzfO
2S3Gbdp55yCYDQiqOMduAUH7NOS4LN04Z7kGbdp5LBAUphvMphuvfHPWcP1Nj4ukIcdl6cY5Szpq
08773CN4PKRPGl0nZZAWGp66iokAQVyWbpyz7MM27bxnEJSXBmePvcKgxE7SkOOydOOcpSG3aedx
QbASanz2zFxiWLJZOMWkIcdl6cY5qwjatLOKYNpSjdddGpy3N7l9j2B7lm6csz2CNu28TxAsTbaF
q/GlXy3ZI9hSETR+alAxSzfO2VODNu08KAhKnhqUP0pYqtXvf6dwuLY8R1AxSzfO2TmCNu28WxAM
LicL9+rsZCFVAMHkXYP8zt41oAogmMKydEOdpSE3aGcgGAsEU0yWbrSzNOTodgaC4UDAmTMQAAFn
zkAABJw5AwEQcOYMBEDAmTMQAAFnzkAwDgiIpCET0bnzh4YgAgIgIAICICACAiAgAgIgIAICICAC
AiAgIicsiOij/gNkTwLw2dm3rwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-03-14 15:57:30 -0400" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-03-14 18:53:40 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-03-14 18:53:40 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-14 18:53:40 -0400" MODIFIED_BY="Anne Lethaby">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-14 17:27:28 -0400" MODIFIED_BY="[Empty name]">
<P>The original search strategy was modified in 2007. The following search was undertaken in MEDLINE. This strategy was modified for other databases.</P>
<P>1. exp arthritis, rheumatoid/<BR/>2. (felty$ adj2 syndrome).tw.<BR/>3. (caplan$ adj2 syndrome).tw.<BR/>4. rheumatoid nodule.tw.<BR/>5. (sjogren$ adj2 syndrome).tw.<BR/>6. (sicca adj2 syndrome).tw.<BR/>7. still$ disease.tw.<BR/>8. bechterew$ disease.tw.9. (arthritis adj2 rheumat$).tw.<BR/>10. or/1-9<BR/>11. etanercept.tw.<BR/>12. enbrel.tw.<BR/>13. exp Tumor Necrosis Factor-alpha/<BR/>14. anti-tumo?r necrosis factor$.tw.<BR/>15. anti-tnf.tw.<BR/>16. or/11-15<BR/>17. 10 and 16<BR/>18. clinical trial.pt.<BR/>19. randomized.ab.<BR/>20. placebo.ab.<BR/>21. dt.fs.<BR/>22. clinical trials/<BR/>23. randomly.ab.<BR/>24. trial.ti.<BR/>25. groups.ab.<BR/>26. or/18-25<BR/>27. animals/<BR/>28. humans/<BR/>29. 27 and 28<BR/>30. 27 not 29<BR/>31. 26 not 30<BR/>32. 17 and 31</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2008-07-10 13:19:47 -0400" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_5474_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="5474">
<ADDRESS>
<DEPARTMENT>Ottawa Hospital Research Institute</DEPARTMENT>
<ORGANISATION>Clinical Epidemiology Program</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_5474_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="5474">
<ADDRESS>
<DEPARTMENT>Institute of Population Health &amp; Department of Epidemiology and Community Medicine</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in quantitative synthesis (meta-analysis)&lt;br&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies (8 publications) included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;a link_type=&quot;STUDY&quot; protected=&quot;true&quot; href=&quot;Combe 2006&quot;&gt;Combe 2006&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; protected=&quot;true&quot; href=&quot;Hu 2009&quot;&gt;Hu 2009&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; protected=&quot;true&quot; href=&quot;Kameda 2010&quot;&gt;Kameda 2010&lt;/a&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;77 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1604 records after duplicates removed&lt;br&gt;&amp;#8226;781 MEDLINE&lt;br&gt;&amp;#8226;19 CINAHL&lt;br&gt;&amp;#8226;128 EMBASE&lt;br&gt;&amp;#8226;4 &lt;i&gt;The Cochrane Library&lt;/i&gt; (2 CENTRAL, 1 DARE, 1 HTA database, 0 NHS EED)&lt;br&gt;&amp;#8226;554 Web of Science&lt;br&gt;&amp;#8226;32 Weblinks&lt;br&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;From 2008 to 2012:&lt;br&gt;2363 records identified through database searching&lt;br&gt;&amp;#8226;1211 MEDLINE&lt;br&gt;&amp;#8226;74 CINAHL&lt;br&gt;&amp;#8226;128 EMBASE&lt;br&gt;&amp;#8226;104 &lt;i&gt;The Cochrane Library&lt;/i&gt; (79 CENTRAL, 9 DARE, 1 HTA database, 15 NHS EED)&lt;br&gt;&amp;#8226;814 Web of Science&lt;br&gt;&amp;#8226;32 Weblinks&lt;br&gt;&lt;/p&gt;" WIDTH="163"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1527 records excluded:&lt;br&gt;&amp;#8226;137 basic science&lt;br&gt;&amp;#8226;269 other drug&lt;br&gt;&amp;#8226;244 other disease&lt;br&gt;&amp;#8226;26 comment&lt;br&gt;&amp;#8226;762 other study design&lt;br&gt;&amp;#8226;23 methods&lt;br&gt;&amp;#8226;26 unrealted&lt;br&gt;&amp;#8226;40 other outcomes&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;69 full-text articles excluded:&lt;br&gt;&amp;#8226;5 different route (intra-articular)&lt;br&gt;&amp;#8226;7 active control (etanercept vs. abatacept, vs. anakinra, vs. adalimumab, vs. CCR5 antagonists, etc.)&lt;br&gt;&amp;#8226;3 dose ranging&lt;br&gt;&amp;#8226;5 pooled analysis of participants (&amp;#8805; 2 trials)&lt;br&gt;&amp;#8226;10 &amp;lt; 24 weeks' follow-up&lt;br&gt;&amp;#8226;39 sub-analysis/pos-hoc analysis of included studies&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;From 2003 to 2008:&lt;br&gt;3 studies (5 publications) included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;a link_type=&quot;STUDY&quot; href=&quot;Emery 2008 (COMET)&quot; protected=&quot;true&quot;&gt;Emery 2008 (COMET)&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Klareskog 2004 (TEMPO)&quot; protected=&quot;true&quot;&gt;Klareskog 2004 (TEMPO)&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Marcora 2006&quot; protected=&quot;true&quot;&gt;Marcora 2006&lt;/a&gt;&lt;br&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;From inception to 2003:&lt;br&gt;3 studies (5 publications) included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;a link_type=&quot;STUDY&quot; href=&quot;Bathon 2000 (ERA)&quot; protected=&quot;true&quot;&gt;Bathon 2000 (ERA)&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Moreland 1999&quot; protected=&quot;true&quot;&gt;Moreland 1999&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Weinblatt 1999&quot; protected=&quot;true&quot;&gt;Weinblatt 1999&lt;/a&gt;&lt;br&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>